

=> b reg

FILE "REGISTRY" ENTERED AT 08:20:25 ON 09 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUN 2005 HIGHEST RN 851931-88-9
DICTIONARY FILE UPDATES: 8 JUN 2005 HIGHEST RN 851931-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide l2 tot

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 141760-45-4 REGISTRY
ED Entered STN: 12 Jun 1992
CN Furin (enzyme) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Furin
CN PACE
CN PACE-furin protease
CN Paired basic amino acid cleaving enzyme
CN Paired basic amino acid converting enzyme
CN Saccharomyces cerevisiae gene QDS1 proteinase
CN Serine proteinase PACE
DR 144131-39-5
MF Unspecified
CI MAN
SR CA
LC STN Files: ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CEN,
CIN, IPA, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
704 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
705 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 550-23-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 2,4,5-tri-2-furanyl-4,5-dihydro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN 2-Imidazoline, 2,4,5-tri-2-furyl- (6CI, 7CI, 8CI)

OTHER NAMES:

CN Furfurin

CN Furin

CN NSC 66440


FS 3D CONCORD

MF C15 H12 N2 O3

CI COM

LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CIN, HODOC*, PROMT, TOXCENTER, USPATFULL

(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1907 TO DATE)

15 REFERENCES IN FILE CAPLUS (1907 TO DATE)

2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d, here, full

(FILE 'HOME' ENTERED AT 06:43:26 ON 09 JUN 2005)

FILE 'REGISTRY' ENTERED AT 06:44:25 ON 09 JUN 2005

L1 896 SEA ABB=ON PLU=ON (PROPROTEIN OR PROHORMONE OR NEUROENDOCRINE OR NEURO? (1A)ENDOCRIN?) (1A)CONVERTAS? OR (NEC OR PC OR SPC) (1A) (I OR 1 OR 2 OR II OR 3 OR III) OR NEC1 OR NECI OR PC1 OR PC1 OR PCI O RPC2 OR PCII OR PC3 OR PCIII OR SPC1 OR SPC2 OR E FURIN/CN

L2 2 SEA ABB=ON PLU=ON FURIN/CN

L3 158 SEA ABB=ON PLU=ON FURIN

L4 29 SEA ABB=ON PLU=ON RXXR/SQEP PDX Derivative Analog. limited b/c can not

L5 1 SEA ABB=ON PLU=ON RIPR/SQEP PDX search all w/o

L6 0 SEA ABB=ON PLU=ON L5 AND L4 overloading

L7 30 SEA ABB=ON PLU=ON (L4 OR L5) system

L8 86 SEA ABB=ON PLU=ON (TACE OR ((TUMOUR OR TUMOR) (1A)NECRO? (1A)FACTOR? OR TNF#) (1A) (?PROTEINASE? OR ?PROTEASE?))/CNS

L9 455 SEA ABB=ON PLU=ON AGGRECAN? OR ADAMTS#

L10 305 SEA ABB=ON PLU=ON ((A1 OR ALPHA (1A) 1) (1A) ((PROTEASE? OR PROTEINASE?) (1A) (INHIB? OR ANTAGON?) OR ANTIPROTEAS? OR ANTIPROTEINAS? OR AT OR TRYPSIN OR SERPIN?) OR PROLASTIN# OR RESPITIN# OR SERPIN(1A) (A1 OR A(1A)1) OR SERPINA1)/CNS mutant PDX

L11 392 SEA ABB=ON PLU=ON PDGF?/CNS

FILE 'HCAPLUS' ENTERED AT 07:38:46 ON 09 JUN 2005

E INFLAMMATION/CT

E E3+ALL

L12 QUE ABB=ON PLU=ON INFLAMMATION+NT/CT

E E275

E E3+ALL

L13 QUE ABB=ON PLU=ON ANTI-INFLAMMATORY AGENTS+OLD,NT/CT

E E21

```

E E3+ALL
L14      QUE ABB=ON  PLU=ON  INFECTION+OLD,NT/CT
E E237
E E3+ALL
L15      QUE ABB=ON  PLU=ON  ANTI-INFECTIVE AGENTS+NT/CT
E ARTHRITIS/CT
E E3+ALL
L16      30230 SEA ABB=ON  PLU=ON  ARTHRITIS+OLD,NT/CT
E E29
E E3+ALL
L17      6780 SEA ABB=ON  PLU=ON  ANTIARTHRITICS+OLD/CT
L18      QUE ABB=ON  PLU=ON  L1 OR (PROPROTEIN OR PROHORMONE OR
NEUROENDOCRINE OR NEURO?(1A)ENDOCRIN?) (1A)CONVERTAS? OR (NEC
OR PC OR SPC) (1A) (I OR 1 OR 2 OR II OR 3 OR III) OR NEC1 OR
NECI OR PC1 OR PC1 OR PCI O RPC2 OR PCII OR PC3 OR PCIII OR
SPC1 OR SPC2 OR SPC3 OR SPCI OR SPCII OR SPCIII
L19      QUE ABB=ON  PLU=ON  "E.C.3.4.21.61" OR "E.C.3.4.21.94" OR
"E.C.3.4.21.93" OR "E.C.3.4.21.75"
L20      QUE ABB=ON  PLU=ON  KEXIN OR KEX2 OR KEX (1A) 2 OR PAIRED
(1A)BASIC (1A) (PEPTIDASE OR ?PROTEASE? OR ?PROTEINASE?)
L21      QUE ABB=ON  PLU=ON  "EC3.4.21.61" OR "EC3.4.21.94" OR "EC3.4.21
.93" OR "EC3.4.21.75" OR (EC OR E(1A)C) (1A) ("3.4.21.61" OR
L22      QUE ABB=ON  PLU=ON  (PROPROTEIN OR PROHORMONE OR NEUROENDOCRINE
OR NEURO?(1A)ENDOCRIN? OR YEAST (1A) CYS?) (1A) (?PROTEAS? OR
?PROTEINAS? OR ?PEPTIDAS?) OR DIBASIC (1A)PROCESS? (1A)ENZYM?
OR PAIRED (1A)BAS? (1A) AMINO (1A) ACID? (1A)ENZYM? OR PACE

FILE 'REGISTRY' ENTERED AT 07:56:46 ON 09 JUN 2005
L23      62 SEA ABB=ON  PLU=ON  DIBASIC (1A)PROCESS? (1A)ENZYM? OR PAIRED
(1A)BAS? (1A) AMINO (1A) ACID? (1A)ENZYM? OR PACE

FILE 'HCAPLUS' ENTERED AT 07:57:07 ON 09 JUN 2005
L24      QUE ABB=ON  PLU=ON  L23
L25      6822 SEA ABB=ON  PLU=ON  L7 OR L10 OR (A1 OR ALPHA (1A)
1) (1A) ((PROTEASE? OR PROTEINASE?) (1A) (INHIB? OR ANTAGON?) OR
ANTIPROTEAS? OR ANTIPROTEINAS? OR AT OR TRYPSIN OR SERPIN?) OR
PROLASTIN# OR RESPITIN# OR SERPIN(1A) (A1 OR A(1A)1) OR SERPINAL
E PIPTIDOMIMETICS/CT
E PEPTIDOMIMETICS/CT
E E3+ALL
L26      2 SEA ABB=ON  PLU=ON  PEPTIDOMIMETICS/CT (L) ( (A1 OR ALPHA
(1A) 1) (1A) ((PROTEASE? OR PROTEINASE?) (1A) (INHIB? OR ANTAGON?)
OR ANTIPROTEAS? OR ANTIPROTEINAS? OR AT OR TRYPSIN OR
SERPIN?) OR PROLASTIN# OR RESPITIN# OR SERPIN(1A) (A1 OR
A(1A)1) OR SERPINAL OR PDX)
L27      165 SEA ABB=ON  PLU=ON  (PEPTIDES+NT/CT OR (PROTEIN# OR POLYPEPTIDE
# OR PEPTIDE#)/CW) (L) ((A1 OR ALPHA (1A) 1) (1A) ((PROTEAS
E? OR PROTEINASE?) (1A) (INHIB? OR ANTAGON?) OR ANTIPROTEAS? OR
ANTIPROTEINAS? OR AT OR TRYPSIN OR SERPIN?) OR PROLASTIN# OR
RESPITIN# OR SERPIN(1A) (A1 OR A(1A)1) OR SERPINAL OR PDX)
L28      QUE ABB=ON  PLU=ON  L8 OR TACE## OR ((TUMOUR OR TUMOR)
(1A)NECRO? (1A)FACTOR? OR TNF#) (2A) (?PROTEINASE? OR ?PROTEASE
? OR (CLEAV? OR PROCESS?) (1A)ENZYME? OR CONVERT?)

FILE 'HCAPLUS' ENTERED AT 08:23:23 ON 09 JUN 2005
L29      5291 SEA ABB=ON  PLU=ON  L2 OR L3 OR FURIN# OR FURFURIN# OR
SACCHAROMYCES(1A)CEREVISIAE (2A) (?PROTEASE? OR ?PROTEINAS? OR
?PEPTIDASE?) OR NSC6640 OR NSC (1A) (66440 OR 66 (1A)440)
L30      142 SEA ABB=ON  PLU=ON  PACE# OR PAIRED(2A)AMINO(1A)ACID?(1A) (CONVE
RT? OR CLEAV?) (1A)ENZYM?
L31      17647 SEA ABB=ON  PLU=ON  L30 OR PACE# OR PAIRED(2A)AMINO(1A)ACID?(1A
) (CONVERT? OR CLEAV?) (1A)ENZYM?
E TGF/CT
E E4+ALL
E E2+ALL
L32      23414 SEA ABB=ON  PLU=ON  TRANSFORMING GROWTH FACTORS+OLD,NT/CT (L)

```

B

```

FILE 'REGISTRY' ENTERED AT 08:32:31 ON 09 JUN 2005
L33      149 SEA ABB=ON  PLU=ON  (TGFB OR (TGF OR TRANSFORM? (1A)GROW?
        (1A)FACTOR?) (1A)B)/CNS

FILE 'HCAPLUS' ENTERED AT 08:33:41 ON 09 JUN 2005
L34      QUE ABB=ON  PLU=ON  L33

FILE 'REGISTRY' ENTERED AT 08:34:47 ON 09 JUN 2005
L35      923 SEA ABB=ON  PLU=ON  (PLATELET? (1A)DERIV? (1A)GROW? (1A)FACTOR?
        )/CNS

FILE 'HCAPLUS' ENTERED AT 08:35:15 ON 09 JUN 2005
L36      759 SEA ABB=ON  PLU=ON  L35
L37      1443 SEA ABB=ON  PLU=ON  L11
        E PLATELET DERIVED/CT
        E E4+ALL
        E PLATELET-DERIVED GROWTH FACTORS/CT
        E E3+ALL
L38      9648 SEA ABB=ON  PLU=ON  PLATELET-DERIVED GROWTH FACTORS+OLD,NT/CT
L39      1916 SEA ABB=ON  PLU=ON  L9 OR AGGREGAN? OR ADAMTS### OR AGGREGAN?
        (1A) DEGRAD? (1A) (?PROTEINASE? OR ?PEPTIDASE? OR ?PROTEASE?)
        E DUBOIS C/AU
L40      180 SEA ABB=ON  PLU=ON  ("DUBOIS C"/AU OR "DUBOIS C A"/AU OR
        "DUBOIS C G B"/AU OR "DUBOIS C H"/AU OR "DUBOIS C J"/AU OR
        "DUBOIS C J JR"/AU OR "DUBOIS C M"/AU OR "DUBOIS C W"/AU)
        E DUBOIS CLAIR/AU
L41      38 SEA ABB=ON  PLU=ON  ("DUBOIS CLAIRE"/AU OR "DUBOIS CLAIRE
        M"/AU)
        E DU BOIS C/AU
L42      7 SEA ABB=ON  PLU=ON  ("DU BOIS C"/AU OR "DU BOIS C G B"/AU OR
        "DU BOIS C J"/AU OR "DU BOIS C W"/AU)
        E DU BOIS CLAIR/AU
L43      6912 SEA ABB=ON  PLU=ON  SHERBROOKE/CS, PA
L44      6652 SEA ABB=ON  PLU=ON  (L12 OR L13 OR L14 OR L15 OR L16 OR L17)
        AND (L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L29 OR
        L31)
L45      2182 SEA ABB=ON  PLU=ON  L44 AND (INHIB? OR BLOCK? OR ?ANTAGON?)
L46      1 SEA ABB=ON  PLU=ON  L45 AND (L40 OR L41 OR L42 OR L43)
L47      2181 SEA ABB=ON  PLU=ON  L45 NOT L46
L48      32 SEA ABB=ON  PLU=ON  L47 AND (L25 OR L26 OR L27)
L49      QUE ABB=ON  PLU=ON  PY<=2000 OR AY<=2000 OR PRY<=2000 OR
        PD<20000623 OR AD<20000623 OR PRD<20000623
L50      18 SEA ABB=ON  PLU=ON  L48 AND L49
        D TI L50 TOT
        SEL AN 2-4 9 12-16
L51      9 SEA ABB=ON  PLU=ON  ("122:255627"/AN OR "122:96045"/AN OR
        "125:104639"/AN OR "131:225365"/AN OR "131:281544"/AN OR
        "132:329471"/AN OR "136:355482"/AN OR "137:109489"/AN OR
        "138:343889"/AN OR "1995:295611"/AN OR "1995:502187"/AN OR
        "1996:460684"/AN OR "1999:396712"/AN OR "1999:659407"/AN OR
        "2000:202240"/AN OR "2002:332011"/AN OR "2002:556104"/AN OR
        "2003:334829"/AN) AND L50
        E PRODRUG/CT
        E E4+ALL
        E GENE THERAPY/CT
        E E3+ALL
L52      33883 SEA ABB=ON  PLU=ON  GENE THERAPY+OLD/CT
        E GENE/CT
        E E3+OLD,NT1
L53      24299 SEA ABB=ON  PLU=ON  (GENE+OLD,NT1/CT OR GENE#/CW) (L) (THU OR
        PAC OR DMA)/RL
L54      QUE ABB=ON  PLU=ON  DRUG DELIVERY SYSTEMS+OLD,NT/CT (L)
        (PRODRUG? OR INTRACELL? OR INTRA? (1A)CELL?)
L55      10976 SEA ABB=ON  PLU=ON  (L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR

```

Search done by Noble Jarrell

L24 OR L20 OR L31) (L) (INHIB? OR BLOCK? OR PREVENT? OR ANTAGON?)

L56 11 SEA ABB=ON PLU=ON (L52 OR L53 OR L54) AND (L40 OR L41 OR L42 OR L43)

L57 134 SEA ABB=ON PLU=ON L55 NOT L56 AND (L52 OR L53 OR L54)

L58 52 SEA ABB=ON PLU=ON L57 AND L49

L59 25 SEA ABB=ON PLU=ON L58 AND P/DT
SEL AN 2 4 17-18 22 24-25

L60 7 SEA ABB=ON PLU=ON ("124:197110"/AN OR "124:76521"/AN OR "126:208952"/AN OR "129:225725"/AN OR "130:33011"/AN OR "136:305218"/AN OR "139:2062"/AN OR "1996:155643"/AN OR "1996:34652"/AN OR "1997:220655"/AN OR "1998:612193"/AN OR "1998:785606"/AN OR "2002:293830"/AN OR "2003:450955"/AN) AND L59

L61 7 SEA ABB=ON PLU=ON L28 AND L47
SEL AN 1 7

L62 2 SEA ABB=ON PLU=ON ("115:278159"/AN OR "140:139544"/AN OR "1991:678159"/AN OR "2004:80524"/AN) AND L61
D BIB TOT

L63 143 SEA ABB=ON PLU=ON L55 NOT L56 AND (L32 OR L34 OR L36 OR L37 OR L38 OR L39)

L64 79 SEA ABB=ON PLU=ON L63 AND L49

L65 17 SEA ABB=ON PLU=ON L64 AND P/DT
SEL AN 1 6 11 L65

L66 3 SEA ABB=ON PLU=ON ("132:189689"/AN OR "135:71268"/AN OR "136:352301"/AN OR "2000:144772"/AN OR "2001:489619"/AN OR "2002:332578"/AN) AND L65

L67 62 SEA ABB=ON PLU=ON L64 NOT L65
SEL AN 18 27 40 L67

L68 3 SEA ABB=ON PLU=ON ("122:158051"/AN OR "127:13736"/AN OR "129:170182"/AN OR "1995:373643"/AN OR "1997:299996"/AN OR "1998:404607"/AN) AND L67

~~L69~~ 11 SEA ABB=ON PLU=ON L46 OR L56

~~L70~~ 38 SEA ABB=ON PLU=ON L51 OR L60 OR L62 OR L65 OR L68

=> b hcap

FILE 'HCAPLUS' ENTERED AT 10:24:44 ON 09 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Jun 2005 VOL 142 ISS 24
FILE LAST UPDATED: 8 Jun 2005 (20050608/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

~~L69~~ 11 SEA ABB=ON PLU=ON L46 OR L56

L69 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:226519 HCAPLUS
DN 142:442537

Search done by Noble Jarrell

ED Entered STN: 15 Mar 2005
 TI Target-dependent on/off switch increases ribozyme fidelity
 AU Bergeron, Lucien Junior; Perreault, Jean-Pierre
 CS RNA Group/Groupe ARN, Departement de Biochimie, Faculte de Medecine,
 Universite de Sherbrooke, Sherbrooke, QC, J1H 5N4,
 Can.
 SO Nucleic Acids Research (2005), 33(4), 1240-1248
 CODEN: NARHAD; ISSN: 0305-1048
 PB Oxford University Press
 DT Journal
 LA English
 CC 3-1 (Biochemical Genetics)
 Section cross-reference(s): 6
 AB Ribozymes, RNA mols. that catalyze the cleavage of RNA substrates, provide
 an interesting alternative to the RNA interference (RNAi) approach to gene
 inactivation, especially given the fact that RNAi seems to trigger an immunol.
 response. Unfortunately, the limited substrate specificity of ribozymes
 is considered to be a significant hurdle in their development as mol.
 tools. Here, authors report the mol. engineering of a ribozyme possessing
 a new biosensor module that switches the cleavage activity from 'off' (a
 'safety lock') to on' solely in the presence of the appropriate RNA target
 substrate. Both proof-of-concept and the mechanism of action of this
 man-made riboswitch are demonstrated using hepatitis delta virus ribozymes
 that cleave RNA transcripts derived from the hepatitis B and C viruses.
 To our knowledge, this is the first report of a ribozyme bearing a
 target-dependent module that is activated by its RNA substrate, an
 arrangement which greatly diminishes non-specific effects. This new
 approach provides a highly specific and improved tool with significant
 potential for application in the fields of both functional genomics and
 gene therapy.
 ST specific on off adapter ribozyme RNA cleavage riboswitch
 IT Hepatitis B virus
 Hepatitis C virus
 (RNA transcripts cleavage, derived from; target-dependent on/off switch
 increases ribozyme fidelity)
 IT Hepatitis delta virus
 (ribozymes; target-dependent on/off switch increases ribozyme fidelity)
 IT Gene therapy
 Genomics
 Molecular modeling
 Structure-activity relationship
 (target-dependent on/off switch increases ribozyme fidelity)
 IT RNA
 RL: BCP (Biochemical process); BIOL (Biological study); PROC (Process)
 (target-dependent on/off switch increases ribozyme fidelity)
 IT Ribozymes
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (target-dependent on/off switch increases ribozyme fidelity)
 RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Alaoui-Ismaili, M; Antiviral Res 2000, V46, P181
 (2) Bergeron, L; Curr Med Chem 2003, V10, P2589 HCAPLUS
 (3) Bergeron, L; Nucleic Acids Res 2002, V30, P4682 HCAPLUS
 (4) Breaker, R; Curr Opin Biotechnol 2002, V13, P31 HCAPLUS
 (5) Burke, D; Biochemistry 2002, V41, P6588 HCAPLUS
 (6) Carlson, C; Biopolymers 2003, V70, P86 HCAPLUS
 (7) Deschenes, P; Antisense Nucleic Acid Drug Dev 2000, V10, P53 HCAPLUS
 (8) D'Anjou, F; J Biol Chem 2004, V279, P14232 HCAPLUS
 (9) Fersht, A; Structure and Mechanism in Protein Science: A Guide to Enzyme
 Catalysis and Protein Folding, Chapters 3, 10 and 13 1999
 (10) Janeway, C; Immunobiologie, Chapter 7 1997
 (11) Jankowsky, E; Biochemistry 1996, V35, P15313 HCAPLUS
 (12) Jankowsky, E; Nucleic Acids Res 1996, V24, P423 HCAPLUS
 (13) Kieft, J; J Mol Biol 1999, V292, P513 HCAPLUS
 (14) Kuwabara, T; Mol Cell 1998, V2, P617 HCAPLUS

- (15) Levesque, D; RNA 2002, V8, P464 HCAPLUS
- (16) Lewin, A; Trends Mol Med 2001, V7, P221 HCAPLUS
- (17) Michienzi, A; Methods Enzymol 2001, V341, P581 HCAPLUS
- (18) Nassal, M; J Virol 1992, V66, P4107 HCAPLUS
- (19) Nishikawa, F; Nucleic Acids Res 1999, V27, P403 HCAPLUS
- (20) Odreman-Macchioli, F; J Biol Chem 2001, V276, P41648 HCAPLUS
- (21) Pebernard, S; Differentiation 2004, V72, P103 HCAPLUS
- (22) Perrotta, A; Nature 1991, V350, P434 HCAPLUS
- (23) Robertson, M; Nat Biotechnol 1999, V17, P62 HCAPLUS
- (24) Roy, G; Nucleic Acids Res 1999, V27, P942 HCAPLUS
- (25) Shih, I; Annu Rev Biochem 2002, V71, P887 HCAPLUS
- (26) Sledz, C; Nature Cell Biol 2003, V5, P834 HCAPLUS
- (27) Soukup, G; Proc Natl Acad Sci USA 1999, V96, P3584 HCAPLUS
- (28) Tang, J; Chem Biol 1997, V4, P453 HCAPLUS
- (29) Wang, D; Comb Chem High Throughput Screen 2002, V5, P301 HCAPLUS
- (30) Wang, D; Nucleic Acids Res 2002, V30, P1735 HCAPLUS

L69 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:921185 HCAPLUS

DN 142:132567

ED Entered STN: 03 Nov 2004

TI Immune responses to a DNA/protein vaccination strategy against
Staphylococcus aureus induced mastitis in dairy cows

AU Shkreta, Lulzim; Talbot, Brian G.; Diarra, Moussa S.; Lacasse, Pierre

CS Departement de Biologie, Faculte des Sciences, Universite de
Sherbrooke, Sherbrooke, QC, J1K 2R1, Can.

SO Vaccine (2004), 23(1), 114-126

CODEN: VACCDE; ISSN: 0264-410X

PB Elsevier B.V.

DT Journal

LA English

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3

AB The fibronectin binding protein (FnBP) and clumping factor A (ClfA) of *S. aureus* are important proteins involved in the pathogenesis of staphylococcal bovine mastitis. These antigens were the targets of a DNA and protein vaccination strategy against *S. aureus*-induced mastitis in dairy cows. The DNA vaccine comprised the bicistronic plasmid (pCI-D1D3-IRES-ClfA) that encoded the fusion of 2 sequences, (D121-34; D320-33) from the fibronectin-binding motifs of FnBP and a fragment from ClfA (aa 221-550) of *S. aureus* 8325-4 separated by an internal ribosomal entry site (IRES) sequence. In addition, the vaccine contained the plasmid encoding the bovine granulocyte-macrophage colony-stimulatory factor gene (pCI-bGM-CSF). Four 7-mo pregnant heifers were immunized twice with the DNA vaccine and boosted once with recombinant D1D3 and ClfA proteins while 4 others were not immunized. The immunization induced lymphoproliferative responses and functional antibodies against D1D3 and ClfA antigens. Three weeks after calving, 3 mammary quarters of each vaccinated and non-vaccinated cow were challenged with 900 CFU/each of *S. aureus* Newbould 305. The fourth quarter received saline only. Serum haptoglobin levels, cardiac rhythm, and the body temperature of vaccinated cows during the 24-72 h post-challenge were lower than in non-vaccinated animals. At 21 days post-challenge, bacteria were present in 5 of the vaccinated and 11 of the control challenged quarters. The bacteria averaged 1.4 and 3.3 log₁₀ CFU/mL of milk from vaccinated and control cows resp. Thus, DNA-protein vaccination against FnBP and ClfA of *S. aureus* caused both lymphoproliferative and humoral immune responses that provided partial protection of mammary gland from staphylococcal mastitis and better post-challenge conditions in vaccinated cows.

ST DNA protein vaccine Staphylococcus mastitis dairy cattle

IT Mastitis

Plasmid vectors

Staphylococcus aureus

Vaccines

(DNA/protein vaccine against Staphylococcus aureus induced mastitis in dairy cows)

- IT DNA
Fusion proteins (chimeric proteins)
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(DNA/protein vaccine against Staphylococcus aureus induced mastitis in dairy cows)
- IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IRES (internal ribosomal entry site) element; as part of DNA/protein vaccine against Staphylococcus aureus induced mastitis in dairy cows)
- IT Gene, microbial
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric; DNA/protein vaccine against Staphylococcus aureus induced mastitis in dairy cows)
- IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(clumping factor A (ClfA); DNA/protein vaccine against Staphylococcus aureus induced mastitis in dairy cows)
- IT Bos taurus
(dairy cattle; DNA/protein vaccine against Staphylococcus aureus induced mastitis in dairy cows)
- IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fibronectin-binding, FnBP; DNA/protein vaccine against Staphylococcus aureus induced mastitis in dairy cows)
- IT Chimeric gene
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microbial; DNA/protein vaccine against Staphylococcus aureus induced mastitis in dairy cows)
- IT 83869-56-1, Granulocyte-macrophage colony-stimulating factor
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DNA/protein vaccine against Staphylococcus aureus induced mastitis in dairy cows)

RE.CNT 91 THERE ARE 91 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adlam, C; J Comp Pathol 1981, V91, P105 MEDLINE
- (2) Alsemgeest, S; Vet Q 1994, V16, P21 MEDLINE
- (3) An, L; J Virol 1997, V71, P2292 HCAPLUS
- (4) Babiuk, L; Vaccine 2003, V21, P649 HCAPLUS
- (5) Barouch, D; J Immunol 2002, V168, P562 HCAPLUS
- (6) Berry, D; J Dairy Sci 2002, V85, P2030 HCAPLUS
- (7) Bowne, W; Cytokines Cell Mol Ther 1999, V5, P217 HCAPLUS
- (8) Brennan, F; Vaccine 1999, V17, P1846 HCAPLUS
- (9) Brouillette, E; Infect Immun 2003, V71, P2292 HCAPLUS
- (10) Brouillette, E; Microb Pathogen 2003, V35, P159 HCAPLUS
- (11) Brouillette, E; Vaccine 2002, V20, P2348 HCAPLUS
- (12) Cai, T; Am J Vet Res 1994, V55, P934 HCAPLUS
- (13) Casolini, F; Infect Immun 1998, V66, P5433 HCAPLUS
- (14) Chaplin, P; Infect Immun 1999, V67, P6434 HCAPLUS
- (15) Ciborowski, P; J Med Microbiol 1992, V37, P376 HCAPLUS
- (16) Daley, M; J Dairy Sci 1991, V74, P4413 HCAPLUS
- (17) Dirks, W; Gene 1993, V128, P247 HCAPLUS
- (18) Dosogne, H; J Dairy Res 2001, V68, P539 HCAPLUS
- (19) Dziekanowska, K; Infect Immun 1999, V67, P4673 HCAPLUS
- (20) Eckersall, P; Vet Rec 2001, V148, P35 MEDLINE
- (21) Eckersall, P; Vet Res Commun 1988, V12, P169 MEDLINE
- (22) Erskine, R; Am J Vet Res 1990, V51, P1107 HCAPLUS
- (23) Giraudo, J; J Dairy Sci 1997, V80, P845 HCAPLUS
- (24) Gomez, M; Infect Immun 2002, V70, P4254 HCAPLUS
- (25) Gresham, H; J Immunol 2000, V164, P3713 HCAPLUS
- (26) Gudding, R; Am J Vet Res 1984, V45, P2525 MEDLINE

Search done by Noble Jarrell

- (27) Gurunathan, S; Annu Rev Immunol 2000, V18, P927 HCAPLUS
- (28) Haddad, D; J Immunol 2000, V165, P3772 HCAPLUS
- (29) Heald, C; Am J Vet Res 1979, V40, P1294 MEDLINE
- (30) Hensen, S; J Dairy Sci 2000, V83, P418 HCAPLUS
- (31) Horadagoda, N; Vet Rec 1999, V144, P437 MEDLINE
- (32) House-Pompeo, K; J Biol Chem 1996, V271, P1379 HCAPLUS
- (33) Huesca, M; Infect Immun 2000, V68, P1156 HCAPLUS
- (34) Huynh, H; Exp Cell Res 1991, V197, P191 HCAPLUS
- (35) Iwasaki, A; J Immunol 1997, V158, P4591 HCAPLUS
- (36) Johnson, P; J Gen Virol 2000, V81, P1737 HCAPLUS
- (37) Kamath, A; Immunology 1999, V96, P511 HCAPLUS
- (38) Kehrl, M; Adv Vet Med 1999, V41, P61 MEDLINE
- (39) Kim, J; Hum Gene Ther 2000, V11, P305 HCAPLUS
- (40) Kimura, K; J Dairy Sci 1999, V82, P315 HCAPLUS
- (41) Kitchen, B; J Dairy Res 1978, V45, P15 HCAPLUS
- (42) Kozak, M; Nucleic Acids Res 1984, V12, P857 HCAPLUS
- (43) Lammers, A; FEMS Microbiol Lett 1999, V180, P103 HCAPLUS
- (44) Lee, J; Trends Microbiol 1996, V4, P162 MEDLINE
- (45) Leitner, G; Res Vet Sci 2000, V69, P181 MEDLINE
- (46) Loehr, B; J Gen Virol 2001, V82, P3035 HCAPLUS
- (47) Mallard, B; J Dairy Sci 1998, V81, P585 HCAPLUS
- (48) Mamo, W; FEMS Immunol Med Microbiol 1994, V10, P47 HCAPLUS
- (49) Mamo, W; Microb Pathogen 1995, V19, P49 HCAPLUS
- (50) Mamo, W; Vaccine 1994, V12, P988 HCAPLUS
- (51) McDevitt, D; Mol Microbiol 1995, V16, P895 HCAPLUS
- (52) Michie, C; Trends Immunol 2002, V23, P461
- (53) Mombaerts, P; Nature 1993, V365, P53 MEDLINE
- (54) Nickerson, S; J Dairy Sci 1982, V65, P105 MEDLINE
- (55) Nordhaug, M; J Dairy Sci 1994, V77, P1276 HCAPLUS
- (56) Ohwada, A; J Antimicrob Chemother 1999, V44, P767 HCAPLUS
- (57) Operschall, E; J Clin Virol 1999, V13, P17 HCAPLUS
- (58) Paape, M; Adv Exp Med Biol 2000, V480, P259 HCAPLUS
- (59) Pankey, J; J Dairy Sci 1985, V68, P726 MEDLINE
- (60) Park, Y; Vet Immunol Immunopathol 1993, V36, P137 MEDLINE
- (61) Parker, S; Gene Ther 2001, V8, P1011 HCAPLUS
- (62) Pasquini, S; Gene Ther 2002, V9, P503 HCAPLUS
- (63) Penkett, C; J Mol Biol 1997, V274, P152 HCAPLUS
- (64) Preisler, M; J Dairy Sci 2000, V83, P38 HCAPLUS
- (65) Scheerlinck, J; Vaccine 2001, V19, P4053 HCAPLUS
- (66) Schennings, T; Microb Pathogen 1993, V15, P227 HCAPLUS
- (67) Schneider, J; Immunol Rev 1999, V170, P29 HCAPLUS
- (68) Schrijver, R; Vaccine 1997, V15, P1908 HCAPLUS
- (69) Schukken, Y; J Dairy Sci 1999, V82, P2393 HCAPLUS
- (70) Schultze, W; Am J Vet Res 1984, V45, P420 MEDLINE
- (71) Seder, R; Nature 2000, V406, P793 HCAPLUS
- (72) Shafer-Weaver, K; J Dairy Sci 1996, V79, P1347 HCAPLUS
- (73) Shafer-Weaver, K; Proc Soc Exp Biol Med 1996, V212, P271 HCAPLUS
- (74) Shafer-Weaver, K; Vet Immunol Immunopathol 1997, V56, P53 MEDLINE
- (75) Sharma, A; Immunol Cell Biol 2001, V79, P537 HCAPLUS
- (76) Shinefield, H; N Engl J Med 2002, V346, P491
- (77) Shkreta, L; Vaccine 2003, V21, P2372 HCAPLUS
- (78) Sordillo, L; J Mammary Gland Biol Neoplasia 2002, V7, P135
- (79) Sun, Q; Infect Immun 1997, V65, P537 HCAPLUS
- (80) Sun, X; Vaccine 2002, V20, P1466 HCAPLUS
- (81) Sutra, L; J Med Microbiol 1994, V40, P79 MEDLINE
- (82) Tanghe, A; Infect Immun 2001, V69, P5403 HCAPLUS
- (83) Tenhagen, B; J Vet Med A Physiol Pathol Clin Med 2001, V48, P601 MEDLINE
- (84) Thomson, S; J Immunol 1996, V157, P822 HCAPLUS
- (85) Vordermeier, H; Vet Microbiol 2003, V93, P349 HCAPLUS
- (86) Waller, K; Adv Exp Med Biol 2000, V480, P231 HCAPLUS
- (87) Warren, T; Curr Opin Hematol 2000, V7, P168 MEDLINE
- (88) White, D; Curr Opin Microbiol 2001, V4, P313 HCAPLUS
- (89) Wild, J; Vaccine 1998, V16, P353 HCAPLUS
- (90) Wilson, D; J Dairy Sci 1997, V80, P2592 HCAPLUS
- (91) Yancey, R; Adv Vet Med 1999, V41, P257

L69 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:533954 HCAPLUS
 DN 141:82318
 ED Entered STN: 02 Jul 2004
 TI Use of furin and furin-like protease
 inhibitors in the treatment of inflammatory or matrix remodelling
 diseases
 IN Dubois, Claire
 PA Can.
 SO U.S. Pat. Appl. Publ., 22 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K038-17
 INCL 514002000
 CC 1-7 (Pharmacology)
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 2004127396 | A1 | 20040701 | US 2001-885914 | 20010622 |
| | CA 2312109 | AA | 20011223 | CA 2000-2312109 | 20000623 |
| PRAI | CA 2000-2312109 | A | 20000623 | | |
| | US 2000-213995P | P | 20000626 | | |

CLASS

| | PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|----|---|-------|------------------------------------|
| | US 2004127396 | ICM | A61K038-17 |
| | | INCL | 514002000 |
| | US 2004127396 | NCL | 514/002.000 |
| | | ECLA | A61K038/57 |
| | CA 2312109 | ECLA | A61K038/57 |
| AB | The present invention provides methods, uses and compns. of an α 1-antitrypsin variant called PDX or a construct, variant, analog, peptide, peptidomimetic, salt, complex or derivative thereof for the treatment of inflammatory or erosive diseases such as rheumatoid arthritis. PDX inhibited collagen-induced arthritis in female Lewis rats. | | |
| ST | furin protease inhibitor treatment inflammation; matrix remodelling disease treatment furin protease inhibitor; PDX treatment rheumatoid arthritis | | |
| IT | Peptidomimetics (PDX-related; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases) | | |
| IT | Peptides, biological studies RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (PDX-related; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases) | | |
| IT | Cell proliferation (blocking of proprotein convertase -mediated; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases) | | |
| IT | Drug delivery systems (carriers, intracellular; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases) | | |
| IT | Disease, animal (erosive, treatment of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases) | | |
| IT | Gene RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | |

- (for PDX; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT Adenoviral vectors
 Anti-inflammatory agents
 Antiarthritics
 Antirheumatic agents
 Drug delivery systems
 Gene therapy
 Human
 Mammalia
 Transformation, genetic
 (furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT Drug delivery systems
 (prodrugs; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT Platelet-derived growth factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (proprotein convertase-mediated endoproteolytic activation of mature, blocking of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT Extracellular matrix
 (remodelling diseases, treatment of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT Synovial membrane
 (synoviocyte, recombinant PDX production in rat; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT Inflammation
 Rheumatoid arthritis
 (treatment of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT Transforming growth factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β -, proprotein convertase-mediated endoproteolytic activation of, blocking of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT Transforming growth factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β 1-, PDX inhibition of furin-mediated processing of human; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT 146480-35-5, Gelatinase A
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PDX inhibition of furin-mediated processing of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT 9041-92-3DP, α 1-Antitrypsin, PDX mutant
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (furin inhibitor; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT 9041-92-3D, PDX mutant, analogs, salts, complexes, derivs.
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (furin inhibitor; furin and furin-like protease inhibitors in treatment of inflammatory or

matrix remodelling diseases)
 IT 99676-46-7, Proprotein convertase
 141760-45-4, Furin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; furin and furin-like
 protease inhibitors in treatment of inflammatory or matrix
 remodelling diseases)
 IT 147172-61-0, AggreCANase-1 151769-16-3, TACE
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (proprotein convertase-mediated endoproteolytic
 activation of, blocking of; furin and furin
 -like protease inhibitors in treatment of inflammatory or
 matrix remodelling diseases)
 IT 257637-28-8 257904-58-8 476616-83-8 714399-15-2
 RL: PRP (Properties)
 (unclaimed sequence; use of furin and furin-like
 protease inhibitors in the treatment of inflammatory or
 matrix remodelling diseases)
 IT 99676-46-7, Proprotein convertase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; furin and furin-like
 protease inhibitors in treatment of inflammatory or matrix
 remodelling diseases)
 RN 99676-46-7 HCAPLUS
 CN Kexin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L69 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:87104 HCAPLUS
 DN 141:99165
 ED Entered STN: 03 Feb 2004
 TI Delivery of herpes simplex thymidine kinase bystander effect by engineered
 human mesothelial cells for the treatment of ovarian cancer
 AU Rancourt, C.; Bergeron, C.; Lane, D.; Garon, G.; Piche, A.
 CS Departement de Microbiologie et Infectiologie, Faculte de Medecine,
 Universite de Sherbrooke, Sherbrooke, QC, J1H 5N4,
 Can.
 SO Cytotherapy (2003), 5(6), 509-522
 CODEN: CYTRF3; ISSN: 1465-3249
 PB Taylor & Francis Ltd.
 DT Journal
 LA English
 CC 1-6 (Pharmacology)
 Section cross-reference(s): 3
 AB Background: Resistance to conventional chemotherapy is a major clin.
 problem for ovarian cancer, and long-term survival for patients with
 advanced-stage disease is rare. Other therapeutic strategies, such as
 gene therapy, have been explored but several limitations exist, which
 include low viral vector transduction efficiency, host immune response to
 the vector, and vector toxicity. Methods: We developed a cell-based
 therapy that exploits human mesothelial cells to deliver anticancer
 modalities for treatment of ovarian cancer. As a proof of concept, we
 genetically engineered mesothelial with the herpes simplex virus thymidine
 kinase/ganciclovir (HSVTK/GCV) system to deliver cytotoxicity to human
 ovarian cancer cells. This system is well characterized, and has been
 widely used in different gene-therapy based strategies. Results: Our
 results demonstrate that HSVTK-modified mesothelial cells are sensitive to
 GCV killing in vitro and support the HSVTK bystander effect. Engineered
 mesothelial cells can deliver the HSVTK bystander effect to human ovarian
 cancer cell-lines, as well as to primary ovarian cancer cells. A
 significant reduction of tumor growth and prolongation of survival in s.c. and
 i.p. xenograft mouse models of ovarian cancer are obtained with as little
 as 1% of HSVTK-expressing mesothelial cells. I.p. administration of
 HSVTK-expressing mesothelial cells in an established mouse model of
 ovarian cancer results in a statistically significant prolonged survival

of treated animals. Importantly, distribution studies showed that mesothelial cells localize preferentially to tumor sites. Discussion: Our study demonstrates the feasibility of using a mesothelial cell-based therapy for treatment of ovarian cancer, and suggests that this strategy should be further explored.

- ST antitumor gene therapy mesothelial cell ovarian carcinoma; herpes simplex virus thymidine kinase gancyclovir cytotoxicity adenoviral vector
- IT Connexins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(43; delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for treatment of ovarian cancer in human ovarian carcinoma cell line and mouse ovarian tumor xenograft)
- IT Ovary, neoplasm
(carcinoma; delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for treatment of ovarian cancer in human ovarian carcinoma cell line and mouse ovarian tumor xenograft)
- IT Adenoviral vectors
Cytotoxicity
Gene therapy
Human
Human herpesvirus
Mesothelium
(delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for treatment of ovarian cancer in human ovarian carcinoma cell line and mouse ovarian tumor xenograft)
- IT Antitumor agents
(ovarian carcinoma; delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for treatment of ovarian cancer in human ovarian carcinoma cell line and mouse ovarian tumor xenograft)
- IT Carcinoma
(ovarian; delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for treatment of ovarian cancer in human ovarian carcinoma cell line and mouse ovarian tumor xenograft)
- IT 9002-06-6, Thymidine kinase
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for treatment of ovarian cancer in human ovarian carcinoma cell line and mouse ovarian tumor xenograft)
- IT 82410-32-0, Ganciclovir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for treatment of ovarian cancer in human ovarian carcinoma cell line and mouse ovarian tumor xenograft)

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Barnes, M; Curr Opin Obstet Gynecol 2001, V13, P47 MEDLINE
- (2) Bett, A; Proc Natl Acad Sci USA 1994, V91, P8802 HCAPLUS
- (3) Blackwell, J; Hum Gene Ther 2000, V11, P1657 HCAPLUS
- (4) Brand, K; Cancer Gene Ther 1997, V4, P9 HCAPLUS
- (5) Cannistra, S; Cancer Res 1993, V53, P3830 HCAPLUS
- (6) Cannistra, S; N Engl J Med 1993, V329, P1550 MEDLINE
- (7) Goldman, C; Cancer Res 1997, V57, P1447 HCAPLUS
- (8) Goodman, J; Hum Gene Ther 1996, V7, P1241 HCAPLUS
- (9) Graham, F; Methods in molecular biology, Gene transfer and expression techniques 1991, V7, P109 HCAPLUS
- (10) He, T; Proc Natl Acad Sci USA 1998, V95, P2509 HCAPLUS
- (11) Hinshaw, V; J Virol 1994, V68, P3667 HCAPLUS
- (12) Hollon, T; Nat Med 2000, V6, P6 HCAPLUS
- (13) Kanerva, A; Clin Cancer Res 2002, V8, P275 HCAPLUS
- (14) Kanerva, A; Mol Ther 2002, V6, P695
- (15) Kelly, F; Clin Cancer Res 2000, V6, P4323 HCAPLUS
- (16) Murphy, J; Hum Gene Ther 1997, V8, P1867 HCAPLUS

Search done by Noble Jarrell

- (17) Nagy, J; Gene Ther 1995, V2, P393 HCAPLUS
 (18) Nagy, J; Gene Ther 1995, V2, P402 HCAPLUS
 (19) Ozols, R; Principles and practice of gynaecologic oncology 2000, P981
 (20) Piche, A; Tumor Target 1998, V3, P147 HCAPLUS
 (21) Rancourt, C; Clin Cancer Res 1998, V4, P265 HCAPLUS
 (22) Robertson, M; Sem Oncol 1998, V25, P397
 (23) Sterman, D; Gene therapy for cancer V 1996, PS29
 (24) Strobel, T; Cancer Res 1997, V57, P1228 HCAPLUS
 (25) Vanderkwaak, T; Gynecol Oncol 1999, V74, P227 HCAPLUS
 (26) Wersto, R; J Virol 1998, V72, P9491 HCAPLUS
 (27) Yang, Y; J Virol 1995, V69, P2004 HCAPLUS
 (28) Yang, Y; Proc Natl Acad Sci USA 1994, V91, P4407 HCAPLUS
 (29) Yee, D; Hum Gene Ther 1996, V7, P1251 HCAPLUS
 (30) Zang, Y; Mol Ther 2001, V3, P697

L69 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:595007 HCAPLUS

DN 137:151133

ED Entered STN: 09 Aug 2002

TI Mammalian Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses

IN Day, Robert

PA Universite De Sherbrooke, Can.

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N015-12

ICS C07K014-47; A61K038-17; A61K031-7088

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 2, 6, 13

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2002061082 | A2 | 20020808 | WO 2002-CA101 | 20020129 |
| | WO 2002061082 | A3 | 20030410 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2472051 | AA | 20020808 | CA 2002-2472051 | 20020129 |
| | EP 1409678 | A2 | 20040421 | EP 2002-710719 | 20020129 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | US 2004116668 | A1 | 20040617 | US 2004-470283 | 20040216 |
| PRAI | US 2001-264296P | P | 20010129 | | |
| | WO 2002-CA101 | W | 20020129 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|--|
| WO 2002061082 | ICM | C12N015-12 |
| | ICS | C07K014-47; A61K038-17; A61K031-7088 |
| WO 2002061082 | ECLA | C07K014/47 |
| US 2004116668 | NCL | 530/350.000; 514/012.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000 |
| | ECLA | C07K014/47 |

AB The present invention relates to genes and protein encoded thereby that regulate the secretory pathway and/or the neuroendocrine phenotype (NEP) in cells and method of isolating same. More particularly, the present

invention relates to long-term therapies for diseases or conditions associated with a loss function. More particularly, the present invention relates to the treatment of such diseases using a cell replacement therapy. In particular, the invention relates to genes involved in cellular differentiation and genes that modulate the formation of the regulated secretory pathway. The invention thus also concerns a method to identify such genes, the genes, variants or fragments thereof, vectors comprising same, the products of these genes, variants or fragments thereof and to cells expressing same. In a particular, the invention relates to the characterization of Zis-SR gene, a novel sequence involved in the secretory pathway in cells. The invention further claims use of the Zis-SR protein, its activities, and its gene for measuring the effects of test compds. and for screening assays which can identify therapeutic compds. for the secretory pathway. The 6T3 cell line undergoes morphol. changes and forms functional dense core secretory granules when stimulated by cAMP. CDNA encoding a murine Zis-SR (ZInc finger Splicing with extended Ser-Arg domain) protein was identified using differential display PCR with mRNA from cAMP-stimulated and non-stimulated 6T3 cells. Zis-SR mRNA was expressed in brain neurons and preferentially in all endocrine tissues. Antisense regulation of Zis-SR expression resulted in reduced levels of the secretory granule marker protein CPE (carboxypeptidase E), absence of regulated secretion of CPE, and no dense core secretory granules.

- ST cDNA sequence mouse protein Zis SR; endocrine protein ZisSR gene expression cell differentiation therapy
- IT Animal cell line
 - (6T3; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Animal cell line
 - (AtT-20; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT PCR (polymerase chain reaction)
 - (DD- (differential display); murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Protein motifs
 - (SR (serine and arginine rich), C-terminal; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Brain
 - Pancreas
 - Pituitary gland, intermediate lobe
 - (Zis-SR mRNA expression; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Transcription, genetic
 - (Zis-SR mRNA levels; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Proteins
 - RL: BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (Zis-SR; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Peptides, biological studies
 - RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (antisense, regulation of ZisSR; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Signal transduction, biological
 - (cAMP-related; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and

- polypeptide sequences and their uses)
- IT Nervous system
 - (central, Zis-SR mRNA expression; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT mRNA
 - RL: BSU (Biological study, unclassified); BIOL (Biological study) (for Zis-SR; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Gene, animal
 - RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (for Zis-SR; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Genetic methods
 - (mol. comparison of secretion defective cells; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Drug screening
 - Gene therapy
 - High throughput screening
 - Molecular association
 - Molecular cloning
 - Mus
 - Protein sequences
 - cDNA sequences
 - (murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Fusion proteins (chimeric proteins)
 - Nucleic acids
 - Peptides, biological studies
 - RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Cell differentiation
 - (neuroendocrine; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Phosphorylation, biological
 - (protein, regulation of ZisSR; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Secretion (process)
 - (protein; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Drugs
 - (regulation of ZisSR; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Antibodies and Immunoglobulins
 - Antisense DNA
 - Antisense RNA
 - RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (regulation of ZisSR; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)
- IT Organelle
 - (secretory granule, formation; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation,

nucleic acid and polypeptide sequences and their uses)

IT Human
Rattus
(sequence homolog; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)

IT Nucleic acid hybridization
(sequence homologs; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)

IT 445506-30-9, Protein Zis-SR (mouse)
RL: BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)

IT 445506-00-3
RL: BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)

IT 81876-95-1, Carboxypeptidase E
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protein expression, effect of Zis-SR; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)

IT 60-92-4, CAMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(signaling; murine Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)

IT 445474-65-7 445474-67-9 445507-51-7 445507-52-8 445507-53-9
445507-54-0 445507-55-1 445507-56-2 445507-57-3 445507-58-4
445507-59-5 445507-60-8 445507-61-9 445507-62-0 445507-63-1
445507-64-2 445507-65-3 445507-66-4 445507-67-5 445507-68-6
445507-69-7 445507-70-0 445507-71-1
RL: PRP (Properties)
(unclaimed sequence; mammalian Zis-SR cDNA involved in the regulated secretory pathway or neuroendocrine cell differentiation, nucleic acid and polypeptide sequences and their uses)

L69 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:352830 HCAPLUS
DN 138:21290
ED Entered STN: 12 May 2002
TI Delta ribozyme benefits from a good stability in vitro that becomes outstanding in vivo
AU Levesque, Dominique; Choufani, Sanaa; Perreault, Jean-Pierre
CS Departement de biochimie, Universite de Sherbrooke, Sherbrooke, QC, J1H 5N4, Can.
SO RNA (2002), 8(4), 464-477
CODEN: RNARFU; ISSN: 1355-8382
PB Cambridge University Press
DT Journal
LA English
CC 7-5 (Enzymes)
Section cross-reference(s): 1, 3
AB The stability of a trans-acting delta ribozyme was studied under various conditions. Although in vitro (i.e., in the presence of protein exts.) this delta ribozyme appears to be only slightly more stable than a hammerhead ribozyme, in vivo (i.e., after cell transfection) it exhibits an outstanding stability that manifests itself in the calculated half-life of over 100 h regardless of the means of transfection. The P2 stem, which includes both the 5' and 3' ends, is shown to play a critical role in this stability. Direct mutagenesis of the most nuclease susceptible

nucleotides failed to generate a more stable ribozyme that retained the same catalytic potential. Clearly, delta ribozyme appears to be well adapted to the human cell environment, and is therefore ideal for the development of a gene-inactivation system.

ST delta ribozyme conformation stability therapeutics

IT Gene therapy

(Delta ribozymes for; extremely high stability of delta ribozymes in vivo)

IT Ribozymes

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Delta; extremely high stability of delta ribozymes in vivo)

IT Conformation

(RNA, of Delta ribozymes, in stability; extremely high stability of delta ribozymes in vivo)

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ananvoranich, S; Biochem Biophys Res Comm 2000, V270, P600 HCAPLUS
- (2) Ananvoranich, S; J Biol Chem 1998, V273, P13182 HCAPLUS
- (3) Beaudry, D; Nucleic Acids Res 1995, V23, P745 HCAPLUS
- (4) Been, M; Eur J Biochem 1997, V247, P741 HCAPLUS
- (5) Bkaily, G; Methods Enzymol 1999, V307, P119 HCAPLUS
- (6) Bramlage, B; Nucleic Acids Res 1999, V27, P3159 HCAPLUS
- (7) Chowrira, B; J Biol Chem 1994, V269, P25856 HCAPLUS
- (8) Doherty, E; Annu Rev Biochem 2000, V69, P597 HCAPLUS
- (9) Elroy-Stein, O; Proc Natl Acad Sci 1990, V87, P6743 HCAPLUS
- (10) Felgner, P; Proc Natl Acad Sci 1987, V84, P7413 HCAPLUS
- (11) Ferre-D'Amare, A; Nature 1998, V395, P567 HCAPLUS
- (12) Gagnon, L; Antisense Nucleic Acids Drug Dev 2000, V10, P251
- (13) Gao, X; Nucleic Acids Res 1993, V21, P2867 HCAPLUS
- (14) Guhaniyogi, J; Gene 2001, V265, P11 HCAPLUS
- (15) Kariko, K; FEBS Lett 1994, V352, P41 HCAPLUS
- (16) Kato, Y; J Biol Chem 2001, V276, P15378 HCAPLUS
- (17) Lafontaine, D; Nucleic Acids Res 1997, V25, P123 HCAPLUS
- (18) Malone, R; Proc Natl Acad Sci 1989, V86, P6077 HCAPLUS
- (19) Mercure, S; Biochemistry 1998, V37, P16975 HCAPLUS
- (20) Nakano, S; Science 2000, V287, P1493 HCAPLUS
- (21) Nicholson, A; FEMS Microbiol Rev 1999, V23, P371 HCAPLUS
- (22) Nishikawa, F; Nucleic Acids Res 2000, V28, P925 HCAPLUS
- (23) Pattnaik, A; Cell 1992, V69, P1011 HCAPLUS
- (24) Prasmickaite, L; Nucleic Acids Res 1998, V26, P4241 HCAPLUS
- (25) Rossi, J; Adv Drug Deliv Rev 2000, V44, P71 HCAPLUS
- (26) Roy, G; Nucleic Acids Res 1999, V27, P942 HCAPLUS
- (27) Sioud, M; Nucleic Acids Res 1994, V22, P5571 HCAPLUS
- (28) Sorrentino, S; Cell Mol Life Sci 1998, V54, P785 HCAPLUS
- (29) Verma, S; Annu Rev Biochem 1998, V67, P99 HCAPLUS
- (30) Wadkins, T; RNA 1999, V5, P720 HCAPLUS

L69 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:920262 HCAPLUS

DN 136:177384

ED Entered STN: 21 Dec 2001

TI Gene therapy to overcome drug resistance in cancer: targeting key regulators of the apoptotic pathway

AU Piche, Alain; Rancourt, Claudine

CS Departement de Microbiologie et Infectiologie, Faculte de Medecine, Universite de Sherbrooke, Sherbrooke, QC, J1H 5N1, Can.

SO Current Gene Therapy (2001), 1(4), 317-324

CODEN: CGTUAH; ISSN: 1566-5232

PB Bentham Science Publishers Ltd.

DT Journal; General Review

LA English

CC 1-0 (Pharmacology)

AB A review. A better understanding of the mol. events responsible for the development of drug resistance in cancer cells has emerged in recent years. It is now established that tumor cells can acquire drug resistance

by alterations of pathways involved in the regulation of apoptosis and that failure to activate this pathway in cancer cells may confer resistance to chemotherapy. This resistance to drug-induced apoptosis is likely to play an important role in tumors that are refractory to chemotherapy. The identification of points in the apoptotic pathway at which dysregulation occurs opens up new therapeutic opportunities in situations where conventional cytotoxic chemotherapy approaches fail. Although these gene therapy-based strategies are still in their infancy they will likely lead to more effective treatments for human cancers. This review will focus on gene therapy strategies developed to specifically target the apoptotic pathway and how these strategies can affect the sensitivity of tumor cells to chemotherapy.

ST review gene therapy antitumor drug resistance apoptosis pathway
 IT Drug resistance
 (antitumor; gene therapy to overcome drug resistance in cancer by
 targeting key regulators of apoptotic pathway)
 IT Apoptosis
 Gene therapy
 Neoplasm
 (gene therapy to overcome drug resistance in cancer by targeting key
 regulators of apoptotic pathway)
 IT Antitumor agents
 (resistance to; gene therapy to overcome drug resistance in cancer by
 targeting key regulators of apoptotic pathway)

RE.CNT 85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Alvarez, R; Clin Cancer Res 2000, V6, P3081 HCAPLUS
- (2) Amundson, S; Cancer Res 2000, V60, P6101 HCAPLUS
- (3) Anon; <http://www.nih.gov/od/oba/protocol/>
- (4) Aslaro, F; New Engl J Med 1995, V334, P316
- (5) Baker, S; Science 1990, V249, P912 MEDLINE
- (6) Barnes, M; Clin Cancer Res 1996, V2, P1089 HCAPLUS
- (7) Boxhorn, H; Hematology/Oncology Clin North Am 1998, V12, P665 MEDLINE
- (8) Bunnell, B; Mol Cell 1996, V1, P1
- (9) Casey, G; Oncogene 1991, V6, P1791 HCAPLUS
- (10) Chen, S; Semin Oncol 1997, V23, P148
- (11) Chen, Y; Oncogene 1991, V6, P1799 HCAPLUS
- (12) Cirielli, C; Inter J Cancer 1995, V63, P673 HCAPLUS
- (13) Datta, S; Cell 1997, V91, P231 HCAPLUS
- (14) Delpeso, L; Science 1996, V278, P687
- (15) Deshane, J; Cancer Gene Therapy 1996, V3, P89 HCAPLUS
- (16) Deshane, J; Gene Therapy 1994, V1, P332 MEDLINE
- (17) Deveraux, Q; Nature (London) 1997, V388, P300 MEDLINE
- (18) Dorai, T; Anticancer Res 1997, V17, P3307 HCAPLUS
- (19) Dorai, T; Prostate 1997, V32, P246 HCAPLUS
- (20) Douglas, J; Nature Biotechnology 1996, V14, P1574 HCAPLUS
- (21) Eliopoulos, A; Oncogene 1995, V11, P1217 HCAPLUS
- (22) Fiedman, E; Cancer Res 1986, V46, P5189
- (23) Fox, S; Breast Cancer Res Treat 1994, V29, P41 MEDLINE
- (24) Frank, D; Clin Cancer Res 1998, V4, P2521 HCAPLUS
- (25) Funato, T; Cancer Gene Therapy 2000, V7, P495 HCAPLUS
- (26) Gill, J; Cancer Res 1999, V59, P2034
- (27) Gleave, M; Clin Cancer Res 1999, V5, P2891 HCAPLUS
- (28) Goldman, C; Cancer Res 1997, V57, P1447 HCAPLUS
- (29) Graus-Porta, D; Mol Cell Biol 1995, V15, P1182 HCAPLUS
- (30) Gross, A; Gene & Development 1999, V13, P1899 HCAPLUS
- (31) Hamada, K; Cancer Res 1996, V56, P3047 HCAPLUS
- (32) Hoogenboom, H; Immunol Rev 1992, V130, P41 HCAPLUS
- (33) James, H; Blood 1997, V91, P371
- (34) Jansen, B; Lancet 2000, V356, P1728 HCAPLUS
- (35) Kay, M; Nature Medecine 2001, V7, P33 HCAPLUS
- (36) Keith, F; Leukemia 1995, V9, P131 MEDLINE
- (37) Kimura, M; Anticancer Res 1997, V17, P879 HCAPLUS
- (38) Kirsch, D; J Clin Oncol 1998, V16, P3158 HCAPLUS
- (39) Kolata, G; Science 1987, V235, P160 MEDLINE
- (40) Koumenis, C; Apoptosis and Cancer Chemotherapy 1999, P223 HCAPLUS

- (41) Krajewski, S; Cancer Res 1995, V55, P4471 HCAPLUS
- (42) Krasnyckh, V; Molecular Therapy 2000, V1, P391
- (43) Krasnykh, V; Molecular Therapy 2000, V1, P391 MEDLINE
- (44) Lebedeva, I; Cancer Res 2000, V60, P6052 HCAPLUS
- (45) Liu, T; Cancer Res 1994, V54, P3662 HCAPLUS
- (46) Lowe, S; Cold Spring Harbor Symposia on Quantitative Biology 1994, V59, P419 HCAPLUS
- (47) Marasco, W; Gene Therapy 1997, V4, P11 HCAPLUS
- (48) Meijerink, J; Blood 1998, V91, P2991 HCAPLUS
- (49) Mensil, M; Cancer Res 2000, V60, P3989
- (50) Nishizaki, M; Clin Cancer Res 1999, V5, P1015 HCAPLUS
- (51) Page, C; Anticancer Res 2000, V20, P407 HCAPLUS
- (52) Perego, P; Cancer Res 1996, V56, P556 HCAPLUS
- (53) Piche, A; Cancer Res 1998, V58, P2134 HCAPLUS
- (54) Piche, A; Gene Therapy 1998, V5, P1171 HCAPLUS
- (55) Piche, A; Gene Therapy 1999, V6, P1202 HCAPLUS
- (56) Piche, A; Tumor Targeting 1998, V3, P147 HCAPLUS
- (57) Pollman, M; Nature Med 1998, V4, P222 HCAPLUS
- (58) Putzer, B; Human Gene Therapy 1998, V9, P707 HCAPLUS
- (59) Rancourt, C; Clin Cancer Res 1998, V4, P2455 HCAPLUS
- (60) Reed, J; Curr Opin Oncol 1995, V7, P541 HCAPLUS
- (61) Reed, J; Journal of the National Cancer Institute 1997, V89, P988 MEDLINE
- (62) Roemer, K; Ann NY Acad Sci 1994, V716, P265 HCAPLUS
- (63) Ryan, P; Clin Cancer Res 2000, V6, P4607 MEDLINE
- (64) Sasaki, H; Cancer Res 2000, V60, P5659 HCAPLUS
- (65) Stiff, P; Ann Intern Med 2000, V133, P504 HCAPLUS
- (66) Strobel, T; Cancer Res 1998, V58, P4776 HCAPLUS
- (67) Strobel, T; Oncogene 1998, V15, P2419
- (68) Strobel, T; Proc Natl Acad Sci USA 1996, V93, P14094 HCAPLUS
- (69) Sumantran, V; Cancer Res 1995, V55, P2507 HCAPLUS
- (70) Tai, Y; Cancer Res 1999, V59, P2121 HCAPLUS
- (71) Tai, Y; J Clin Oncol 1998, V16, P2583 HCAPLUS
- (72) Toulme, J; Nature Biotechnology 2001, V19, P17 HCAPLUS
- (73) Uhlman, D; Clin Cancer Res 1995, V1, P913 HCAPLUS
- (74) Wagener, C; Int J Cancer 1995, V60, P854
- (75) Webb, A; Lancet 1997, V349, P1137 MEDLINE
- (76) Wickham, T; J Virol 1996, V70, P6831 HCAPLUS
- (77) Winter, G; Nature 1991, V349, P293 HCAPLUS
- (78) Xiang, J; Tumor Targeting 1999, V4, P84 HCAPLUS
- (79) Xie, Y; Clin Cancer Res 1999, V5, P4224 HCAPLUS
- (80) Yamasaki, H; Carcinogenesis 1990, V11, P1051 HCAPLUS
- (81) Yang, C; Cancer Res 1995, V55, P4210 HCAPLUS
- (82) Yang, E; Blood 1996, V88, P386 HCAPLUS
- (83) Yang, E; Cell 1995, V80, P285 HCAPLUS
- (84) Zha, J; Cell 1996, V87, P619 HCAPLUS
- (85) Zhang, Y; Gene Therapy 2000, V7, P2041 HCAPLUS

L69 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:586520 HCAPLUS

DN 132:117181

ED Entered STN: 20 Sep 1999

TI An inducible recombinant adenoviral vector encoding Bax selectively induces apoptosis in ovarian cancer cells

AU Xiang, J.; Piche, A.; Rancourt, C.; Gomez-Navarro, J.; Siegal, G. P.; Alvarez, R. D.; Curiel, D. T.

CS Gene Therapy Program, Sherbrooke, QC, Can.

SO Tumor Targeting (1999), 4(2), 84-91

CODEN: TUTAF9; ISSN: 1351-8488

PB Stockton Press

DT Journal

LA English

CC 1-6 (Pharmacology)

Section cross-reference(s): 3

AB A variety of strategies have been developed to accomplish gene therapy for cancer. One of these approaches is mutation compensation, whereby gene transfer is used for abrogating the function of dysregulated dominant

oncogenes or for restoration of the function of deficient tumor suppressor genes. Bax, a member of the Bcl-2 family that can act as a tumor suppressor, potently induces apoptosis by caspase-dependent and -independent mechanisms. The authors were able to generate a recombinant adenoviral vector encoding bax by using the inducible Cre-loxP system. Bax expression was tightly induced specifically by Cre recombinase, therefore allowing viral production. Furthermore, expression of Bax resulted in apoptotic cell death in human ovarian cancer cells. In contrast, Bax-mediated cell death was not observed in normal human peritoneal mesothelial cells. Thus, production and delivery of Bax via recombinant adenovirus vector is feasible, and its preferential killing effect in human ovarian cancer cells might allow its use for gene therapy of ovarian cancer.

ST inducible adenoviral vector Bax antitumor apoptosis ovary cancer
 IT Proteins, specific or class
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Bax; inducible recombinant adenoviral vector encoding Bax selectively induces apoptosis in ovarian cancer cells)
 IT Virus vectors
 (adenovirus; inducible recombinant adenoviral vector encoding Bax selectively induces apoptosis in ovarian cancer cells)
 IT Apoptosis
 Gene therapy
 Transduction, genetic
 (inducible recombinant adenoviral vector encoding Bax selectively induces apoptosis in ovarian cancer cells)
 IT Ovary, neoplasm
 Ovary, neoplasm
 (inhibitors; inducible recombinant adenoviral vector encoding Bax selectively induces apoptosis in ovarian cancer cells)
 IT Antitumor agents
 Antitumor agents
 (ovary; inducible recombinant adenoviral vector encoding Bax selectively induces apoptosis in ovarian cancer cells)
 IT Human adenovirus
 (recombinant; inducible recombinant adenoviral vector encoding Bax selectively induces apoptosis in ovarian cancer cells)

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anderson, W; Nature 1998, V392, P25 HCAPLUS
- (2) Baker, S; Science 1990, V249, P912 MEDLINE
- (3) Bilbao, G; Tumor Targeting 1998, V3, P59 HCAPLUS
- (4) Boente, M; Curr Opin Oncol 1993, V5, P900 MEDLINE
- (5) Brimmell, M; Oncogene 1998, V16, P1803 HCAPLUS
- (6) Cai, D; Hum Gene Ther 1993, V4, P617 HCAPLUS
- (7) Casey, G; Oncogene 1991, V6, P1791 HCAPLUS
- (8) Chen, Y; Oncogene 1991, V6, P1799 HCAPLUS
- (9) Cirielli, C; Int J Cancer 1995, V63, P673 HCAPLUS
- (10) Connell, N; Cell 1983, V34, P245 HCAPLUS
- (11) Danen-Van Oorschot, A; Proc Natl Acad Sci USA 1997, V94, P5843 HCAPLUS
- (12) Degli-Esposti, M; J Exp Med 1997, V186, P1165 HCAPLUS
- (13) Deshane, J; Cancer Gene Ther 1996, V3, P89 HCAPLUS
- (14) Douglas, J; Targeted Gene Therapy 1995, V1, P67 HCAPLUS
- (15) Favrot, M; Gene Ther 1998, V5, P728 HCAPLUS
- (16) Fujiwara, T; Cancer Res 1994, V54, P2287 HCAPLUS
- (17) Graham, F; Virology 1973, V52, P456 MEDLINE
- (18) Gura, T; Science 1997, V277, P768 HCAPLUS
- (19) Hamada, K; Cancer Res 1996, V56, P3047 HCAPLUS
- (20) Ishibashi, Y; Biochem Biophys Res Commun 1998, V243, P609 HCAPLUS
- (21) Jurgensmeier, J; Proc Natl Acad Sci USA 1998, V95, P4997 HCAPLUS
- (22) Kanegae, Y; Gene 1996, V181, P207 HCAPLUS
- (23) Kimura, M; Anticancer Res 1997, V17, P879 HCAPLUS
- (24) Kitada, S; Oncogene 1996, V12, P187 HCAPLUS
- (25) Knudson, C; Nat Genet 1997, V16, P358 HCAPLUS

Search done by Noble Jarrell

- (26) Liu, T; Cancer Res 1994, V54, P3662 HCAPLUS
- (27) Marzo, I; Science 1998, V281, P2027 HCAPLUS
- (28) Murphy, J; Hum Gene Ther 1997, V8, P1867 HCAPLUS
- (29) Nielsen, L; Cancer Gene Ther 1998, V5, P52 HCAPLUS
- (30) Noteborn, M; Mutat Res 1998, V400, P447 HCAPLUS
- (31) Ouyang, H; Clin Cancer Res 1998, V4, P1071 HCAPLUS
- (32) Parks, R; J Virol 1997, V71, P3293 HCAPLUS
- (33) Roemer, K; Ann NY Acad Sci 1994, V716, P265 HCAPLUS
- (34) Sakakura, C; Int J Cancer 1996, V67, P101 HCAPLUS
- (35) Santoso, J; Gynecol Oncol 1995, V59, P171 HCAPLUS
- (36) Shaw, P; Proc Natl Acad Sci USA 1992, V89, P4495 HCAPLUS
- (37) Shinoura, N; Hum Gene Ther 1998, V9, P2683 HCAPLUS
- (38) Whartenby, K; Lab Invest 1995, V72, P131 MEDLINE
- (39) Xiang, H; J Neurosci 1998, V18, P1363 HCAPLUS
- (40) Xiang, J; Proc Natl Acad Sci USA 1996, V93, P14559 HCAPLUS
- (41) Yagi, O; Gastroenterology 1998, V114, P268 HCAPLUS
- (42) Yang, B; Clin Cancer Res 1996, V2, P1649 HCAPLUS
- (43) Yang, C; Cancer Res 1995, V55, P4210 HCAPLUS
- (44) Yin, C; Nature 1997, V385, P637 HCAPLUS
- (45) Yin, X; Curr Top Microbiol Immunol 1995, V194, P331 HCAPLUS
- (46) Yin, X; Nature 1994, V369, P321 HCAPLUS
- (47) Zhang, H; J Virol 1998, V72, P2483 HCAPLUS

L69 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:446244 HCAPLUS

DN 131:212651

ED Entered STN: 21 Jul 1999

TI A role for intracellular immunization in chemosensitization of tumor cells?

AU Piche, A.; Rancourt, C.

CS Departement de Microbiologie, Faculte de Medecine, Universite de Sherbrooke, Sherbrooke, QC, J1H 5N4, Can.

SO Gene Therapy (1999), 6(7), 1202-1209

CODEN: GETHEC; ISSN: 0969-7128

PB Stockton Press

DT Journal; General Review

LA English

CC 15-0 (Immunochemistry)

AB A review with 119 refs. Acquired drug resistance represents a major cause of chemotherapy failure in patients with cancer. The characterization of the mol. pathways involved in drug resistance has provided us with new targets to overcome this problem. Many of these target proteins are often overexpressed in human cancers. A number of gene therapy strategies, including antisense oligonucleotides, ribozymes and single-chain antibodies, have been developed to achieve the selective modulation and inhibition of various cellular proteins. Thus, these approaches can be exploited to modulate the resistance phenotype of tumor cells. These gene therapy strategies represent a novel and unique way to enhance the sensitivity of tumor cells to chemotherapeutic drugs. This review will focus on the use of intracellular immunization as a means to modulate the expression of specific genetic determinants involved in the drug resistance phenotype.

ST review chemotherapy oligonucleotide ribozyme antibody

IT Chemotherapy

Drug resistance

Gene therapy

Immunization

(intracellular immunization in chemosensitization of tumor cells)

IT Antisense oligonucleotides

Ribozymes

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(intracellular immunization in chemosensitization of tumor cells using)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(single chain; intracellular immunization in chemosensitization of tumor cells using)

RE.CNT 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aboud-Pirak, E; J Natl Cancer Inst 1988, V80, P1605 HCAPLUS
- (2) Alderson, L; Cancer Res 1995, V55, P999 HCAPLUS
- (3) Andrews, P; Cancer Cells 1990, V2, P35 HCAPLUS
- (4) Aoki, K; Cancer Res 1995, V55, P3810 HCAPLUS
- (5) Arber, N; Cancer Res 1997, V57, P1569 HCAPLUS
- (6) Arnold, A; J Clin Invest 1989, V83, P2034 HCAPLUS
- (7) Arteaga, C; Cancer Res 1996, V56, P1098 HCAPLUS
- (8) Aslaro, F; New Engl J Med 1995, V334, P316
- (9) Baltimore, D; Nature 1988, V335, P395 MEDLINE
- (10) Barnes, M; Clin Cancer Res 1996, V2, P1089 HCAPLUS
- (11) Baselga, J; J Natl Cancer Inst 1993, V85, P1327 HCAPLUS
- (12) Baserga, R; Cell 1994, V79, P927 HCAPLUS
- (13) Beerli, R; Biochem Biophys Res Commun 1994, V204, P666 HCAPLUS
- (14) Bellacosa, A; Clin Cancer Res 1996, V2, P175 HCAPLUS
- (15) Berchuck, A; Cancer Res 1990, V50, P4087 MEDLINE
- (16) Berchuck, A; Cancer Res 1990, V50, P4087 MEDLINE
- (17) Bergmann, C; Nature 1986, V319, P226
- (18) Bergmann, C; Nature 1986, V319, P226
- (19) Bi, W; Hum Gene Ther 1993, V4, P725 HCAPLUS
- (20) Bos, J; Cancer Res 1989, V49, P4682 HCAPLUS
- (21) Brader, K; Oncol Res 1998, V5, P1269 HCAPLUS
- (22) Bronner, M; Am J Pathol 1995, V146, P20 MEDLINE
- (23) Bunnell, B; Mol Cell 1996, V1, P1
- (24) Campos, L; Blood 1992, V79, P473 MEDLINE
- (25) Chan, H; Lab Invest 1989, V59, P870
- (26) Chan, H; New Engl J Med 1991, V325, P1608 MEDLINE
- (27) Chang, F; J Clin Oncol 1995, V13, P1009 MEDLINE
- (28) Chen, C; Hum Gene Ther 1995, V6, P1467 HCAPLUS
- (29) Chen, S; Semin Oncol 1996, V23, P148 HCAPLUS
- (30) Cochet, O; Cancer Res 1998, V58, P1170 HCAPLUS
- (31) Deshane, J; Cancer Gene Ther 1996, V3, P89 HCAPLUS
- (32) Deshane, J; Gene Therapy 1994, V1, P332 MEDLINE
- (33) Deshane, J; Gynecol Oncol 1995, V59, P8 HCAPLUS
- (34) Deshane, J; J Clin Invest 1995, V96, P2980 HCAPLUS
- (35) Dickstein, B; J Cell Physiol 1993, V157, P110 HCAPLUS
- (36) Dixit, M; J Natl Cancer Inst 1997, V89, P365 HCAPLUS
- (37) Doglioni, C; Virchows Arch 1994, V424, P47 MEDLINE
- (38) Dorai, T; Anticancer Res 1997, V17, P3307 HCAPLUS
- (39) Dorai, T; Prostate 1997, V32, P246 HCAPLUS
- (40) Drilca, K; Biochemistry 1988, V27, P2253
- (41) Driscoll, B; Am J Physiol-Lung Cell & Mol Physiol 1997, V17, P941
- (42) Eliopoulos, A; Oncogene 1995, V11, P1217 HCAPLUS
- (43) Fan, Z; Cancer Res 1993, V53, P4637 HCAPLUS
- (44) Fantl, W; Ann Rev Biochem 1993, V62, P453 HCAPLUS
- (45) Felipe, E; Cancer 1995, V75, P2147 MEDLINE
- (46) Feng, M; Nature Biotechnol 1997, V15, P866 HCAPLUS
- (47) Fisher, D; Cell 1994, V78, P539 MEDLINE
- (48) Fojo, A; Cancer 1987, V60(Suppl. 8), P2075
- (49) Frank, D; Clin Cancer Res 1998, V4, P2521 HCAPLUS
- (50) Fujiwara, T; J Natl Cancer Inst 1994, V86, P1458 HCAPLUS
- (51) Goasguen, J; Blood 1993, V81, P2394 HCAPLUS
- (52) Godwin, A; Proc Natl Acad Sci USA 1992, V89, P3070 HCAPLUS
- (53) Goldstein, L; J Natl Cancer Inst 1989, V81, P116 HCAPLUS
- (54) Grandis, J; Oncogene 1997, V15, P409 HCAPLUS
- (55) Graus-Porta, D; Molec Cell Biol 1995, V15, P1182 HCAPLUS
- (56) Grim, J; Gene Submitted
- (57) Gu, D; Proc Am Assoc Cancer Res 1998, V39, P512
- (58) Gusterson, B; J Clin Oncol 1992, V10, P1049 MEDLINE
- (59) Hall, M; Adv Cancer Res 1996, V68, P67 HCAPLUS
- (60) Hamel, W; Cancer Res 1996, V56, P2697 HCAPLUS

Search done by Noble Jarrell

- (61) Hancock, M; Cancer Res 1991, V51, P4575 HCAPLUS
- (62) Hartmann, A; Trends Genet 1997, V13, P27 HCAPLUS
- (63) He, Y; J Natl Cancer Inst 1998, V90, P1080 HCAPLUS
- (64) Hochhauser, D; J Natl Cancer Inst 1996, V88, P1269 HCAPLUS
- (65) Hoedemaeker, F; J Biol Chem 1997, V47, P29784
- (66) Holt, J; Hum Gene Ther 1996, V7, P1367 MEDLINE
- (67) Holzmayer, T; J Natl Cancer Inst 1992, V84, P1486 MEDLINE
- (68) Hoogenboom, H; Immunol Rev 1992, V130, P41 HCAPLUS
- (69) James, H; Blood 1997, V91, P371
- (70) Jannot, C; Oncogene 1996, V13, P275 HCAPLUS
- (71) Jansen, B; Nature Med 1998, V4, P232 HCAPLUS
- (72) Johnston, K; Hum Gene Ther 1997, V8, P359 HCAPLUS
- (73) Keith, F; Leukemia 1995, V9, P131 MEDLINE
- (74) Kiehnopf, M; EMBO J 1994, V13, P4645 HCAPLUS
- (75) Kobayashi, H; Cancer Res 1994, V54, P1271 HCAPLUS
- (76) Kornmann, M; J Clin Invest 1998, V101, P344 HCAPLUS
- (77) Krajewski, M; Am J Pathol 1996, V148, P1567
- (78) Krajewski, M; Cancer Res 1996, V56, P2422
- (79) Krajewski, S; Am J Pathol 1997, V150, P805 MEDLINE
- (80) Krajewski, S; Clin Cancer Res 1997, V3, P199 HCAPLUS
- (81) Marasco, W; Gene Therapy 1997, V4, P11 HCAPLUS
- (82) Marie, J; Blood 1991, V78, P586 MEDLINE
- (83) Meyn, R; Cancer Metast Rev 1996, V15, P119 MEDLINE
- (84) Mills, N; Cancer Res 1995, V55, P1444 HCAPLUS
- (85) Minagawa, Y; Jpn J Cancer Res 1997, V88, P1218 HCAPLUS
- (86) Motokura, T; Biochem Biophys Acta 1993, V1155, P63 HCAPLUS
- (87) Murphy, L; Semin Cancer Biol 1990, V1, P305 MEDLINE
- (88) Murray, P; Br J Cancer 1993, V67, P1408 MEDLINE
- (89) Nakasu, S; Acta Neuropathol 1994, V88, P520 MEDLINE
- (90) Nguyen, D; J Thorac Cardiovasc Surg 1996, V112, P1372 HCAPLUS
- (91) Nooter, K; Br J Cancer 1995, V71, P556 HCAPLUS
- (92) Paik, S; Cancer Invest 1992, V10, P575 MEDLINE
- (93) Peng, D; Cancer Res 1996, V56, P3666 HCAPLUS
- (94) Piche, A; Cancer Res 1998, V58, P2134 HCAPLUS
- (95) Piche, A; Tumor Targeting 1998, V3, P147 HCAPLUS
- (96) Pines, J; Semin Cell Biol 1994, V5, P399 HCAPLUS
- (97) Pirker, R; J Natl Cancer Inst 1991, V83, P708 MEDLINE
- (98) Pirollo, K; Oncogene 1997, V14, P1735 HCAPLUS
- (99) Pirollo, K; Oncogene 1997, V14, P1735 HCAPLUS
- (100) Poul, M; Exploring and exploiting antibody and Ig superfamily combining sites 1996, P22
- (101) Rancourt, C; Clin Cancer Res 1998, V4, P2455 HCAPLUS
- (102) Reed, J; Curr Opin Oncol 1995, V7, P541 HCAPLUS
- (103) Reed, J; Hematol/Oncol Clin North Am 1995, V9, P451 MEDLINE
- (104) Reed, J; Nature 1997, V387, P773 HCAPLUS
- (105) Roth, J; J Natl Cancer Inst 1997, V89, P21 MEDLINE
- (106) Salomon, D; Crit Rev Oncol/Hematol 1995, V19, P183 MEDLINE
- (107) Scanlon, K; Anticancer Res 1989, V9, P1311
- (108) Schlaifer, D; Blood 1995, V85, P2671
- (109) Sullivan, G; Clin Cancer Res 1998, V4, P1393 HCAPLUS
- (110) Tsai, C; J Natl Cancer Inst 1993, V85, P897 HCAPLUS
- (111) Tsai, C; J Natl Cancer Inst 1995, V87, P682 HCAPLUS
- (112) Tu, Y; Cancer Res 1998, V58, P256 HCAPLUS
- (113) Vicker, P; Mol Endocrinol 1988, V2, P886
- (114) Warenus, H; Int J Cancer 1996, V67, P224 HCAPLUS
- (115) Werge, T; FEBS Lett 1990, V274, P193 HCAPLUS
- (116) Winter, G; Nature 1991, V349, P293 HCAPLUS
- (117) Wu, L; Chung Hua Fu Can Ko Tsa Chih 1996, V31, P169 MEDLINE
- (118) Xerri, L; Br J Haematol 1996, V92, P900 MEDLINE
- (119) Zhou, P; Oncogene 1995, V11, P571 HCAPLUS

L69 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:98860 HCAPLUS

DN 130:320466

ED Entered STN: 15 Feb 1999

TI Modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain

antibody in ovarian cancer cells

AU Piche, Alain; Rancourt, Claudine; Xiang, Jialing; Siegal, Gene P.;
Alvarez, Ronald D.; Reed, John C.; Curiel, David T.

CS Departement de Microbiologie, Universite de Sherbrooke, QC, Can.

SO Tumor Targeting (1998), 3(3), 147-155
CODEN: TUTAF9; ISSN: 1351-8488

PB Stockton Press

DT Journal

LA English

CC 1-6 (Pharmacology)
Section cross-reference(s): 14, 15

AB Bcl-2 overexpression has been correlated with poor response to chemotherapy and protection from drug-induced apoptosis in ovarian cancer. Gene therapy strategies that can modulate Bcl-2 protein levels may therefore increase the chemosensitivity of ovarian cancer cells. To this end, we have previously reported the construction of a single-chain antibody (sFv) directed against the Bcl-2 protein. In this study, we examined the effect of this sFv on ovarian cancer cells overexpressing Bcl-2. PA-1 cells were stably transfected with the anti-Bcl-2 sFv and were subsequently analyzed for Bcl-2 protein levels. In PA-1 clones expressing the anti-Bcl-2 sFv, there was a reduction in Bcl-2 protein levels compared to control transfectant cells. Cell growth rates were not affected by expression of the anti-Bcl-2 sFv expression. However, the survival rates were reduced by 40-50% in anti-Bcl-2 sFv transfectants after treatment with cisplatin. In addition, there was an enhancement in sensitivity to cisplatin and taxol-mediated cytotoxicity as demonstrated by a reduction in the IC50 in the anti-Bcl-2 sFv clones. Drug-mediated apoptosis was also increased in anti-Bcl-2 sFv transfectants after drug treatment. These clones displayed numerous apoptotic cells, whereas control clones did not display the features of dying cells. The enzyme activity of caspase 3/apopain was also increased in anti-Bcl-2 sFv clones. Taken together, these results suggest that intracellular expression of the anti-Bcl-2 sFv reduces Bcl-2 levels and enhances drug-induced apoptosis in ovarian cancer cells.

ST apoptosis ovarian cancer Bcl2 antibody gene therapy; antitumor antiBcl2 antibody ovarian cancer resistance

IT Drug resistance
(antitumor; modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain antibody in ovarian cancer cells)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(bcl-2; modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain antibody in ovarian cancer cells)

IT Ovary, neoplasm
(inhibitors; modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain antibody in ovarian cancer cells)

IT Apoptosis
Gene therapy
Ovary, neoplasm
(modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain antibody in ovarian cancer cells)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, anti-Bcl-2 sFv; modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain antibody in ovarian cancer cells)

IT Antitumor agents
(ovary; modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain antibody in ovarian cancer cells)

IT Antitumor agents
(resistance to; modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain antibody in ovarian cancer cells)

IT 15663-27-1, Cisplatin 33069-62-4, Taxol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain antibody in ovarian cancer cells)

IT 169592-56-7, Caspase 3

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(modulation of drug-induced apoptosis by an anti-Bcl-2 single-chain antibody in ovarian cancer cells)

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Alderson, L; Cancer Res 1995, V55, P999 HCAPLUS
- (2) Andrews, P; Cancer Cells 1990, V2, P35 HCAPLUS
- (3) Barnes, M; Clin Cancer Res 1996, V2, P1089 HCAPLUS
- (4) Baserga, R; Cell 1994, V79, P927 HCAPLUS
- (5) Berchuck, A; Cancer Res 1990, V50, P4087 MEDLINE
- (6) Biocca, S; Trends Cell Biol 1995, V5, P248 HCAPLUS
- (7) Boring, C; Cancer J Clin 1994, V44, P7 MEDLINE
- (8) Bronner, M; Am J Pathol 1995, V146, P20 MEDLINE
- (9) Curiel, D; Nat Immun 1994, V13, P141 HCAPLUS
- (10) Darmon, A; Nature 1995, V377, P446 HCAPLUS
- (11) Dickstein, B; J Cell Physiol 1993, V157, P110 HCAPLUS
- (12) Doglioni, C; Virchows Arch 1994, V424, P47 MEDLINE
- (13) Drlica, K; Biochemistry 1988, V27, P2253 HCAPLUS
- (14) Eliopoulos, A; Oncogene 1995, V11, P1217 HCAPLUS
- (15) Felip, E; Cancer 1995, V75, P2147 MEDLINE
- (16) Fernandes-Alnemri, T; Biol Chem 1994, V267, P30761
- (17) Fojo, A; Proc Natl Acad Sci USA 1987, V84, P265 HCAPLUS
- (18) Godwin, A; Proc Natl Acad Sci USA 1992, V89, P3070 HCAPLUS
- (19) Goldstein, L; J Natl Cancer Inst 1989, V81, P116 HCAPLUS
- (20) Grim, J; Am J Respir Cell Mol Biol 1996, V15, P348 HCAPLUS
- (21) Gusterson, B; J Clin Oncol 1992, V10, P1049 MEDLINE
- (22) Haldar, S; Cancer Res 1996, V56, P1253 HCAPLUS
- (23) Henkels, K; Cancer Res 1997, V57, P4488 HCAPLUS
- (24) Hockenbery, D; Cell 1993, V75, P241 HCAPLUS
- (25) Jansen, B; Nat Med 1998, V4, P232 HCAPLUS
- (26) Krajewski, S; Clin Cancer Res 1997, V3, P199 HCAPLUS
- (27) Liu, Y; Biochem Pharmacol 1994, V48, P1265 HCAPLUS
- (28) Minagawa, Y; Jpn J Cancer Res 1997, V88, P1218 HCAPLUS
- (29) Nakasu, S; Acta Neuropathol 1994, V88, P520 MEDLINE
- (30) Piche, A; Cancer Res 1998, V58, P2134 HCAPLUS
- (31) Reed, J; Analyt Biochem 1992, V205, P70 HCAPLUS
- (32) Reed, J; Hematol Oncol Clin North Am 1995, V9, P451 MEDLINE
- (33) Reed, J; J Cell Biol 1994, V12, P1
- (34) Salvesen, G; Cell 1997, V91, P443 HCAPLUS
- (35) Scanlon, K; Anticancer Res 1989, V9, P1311
- (36) Tsai, C; J Natl Cancer Inst 1993, V85, P897 HCAPLUS
- (37) Tsai, C; J Natl Cancer Inst 1995, V87, P682 HCAPLUS
- (38) Webb, A; Lancet 1997, V349, P1137 MEDLINE
- (39) Werner, E; Proc Natl Acad Sci USA 1996, V93, P13797 HCAPLUS
- (40) Yang, E; Blood 1996, V88, P386 HCAPLUS
- (41) Ziegler, A; J Nat Cancer Inst 1997, V89, P1027 HCAPLUS

L69 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:585284 HCAPLUS

DN 127:288536

ED Entered STN: 13 Sep 1997

TI DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors

AU D'Orleans-Juste, P.; Sirois, M. G.; Edelman, E. R.; Regoli, D.; Pheng, L. H.; Bkaily, G.; Lindsey, C. J.

CS Department of Pharmacology, Faculty of Medicine, Universite de Sherbrooke, Sherbrooke, QC, J1H 5N4, Can.

SO Molecular and Cellular Biochemistry (1997), 172(1&2), 199-211
CODEN: MCBIB8; ISSN: 0300-8177

PB Kluwer

DT Journal
 LA English
 CC 2-10 (Mammalian Hormones)
 Section cross-reference(s): 1, 15

AB Antisense oligodeoxynucleotide technol. has contributed greatly to the overall understanding of both mRNA stability as well as translational processes leading to protein synthesis. Arrest of translational processes by DNA antisense strands usually reduces maximal effects of agonists without affecting their apparent affinities in treated isolated vascular or nonvascular prepns. In the present study, examples are given of DNA antisense oligonucleotide-induced repression of receptors for endothelins, kinins as well as of the platelet-derived growth factor. Furthermore, the efficiency of this technol. illustrates the roles of protooncogenes (c-myc and c-myb) in wound-healing mechanisms. The overall mechanism of action of these oligomers is described and the relevance of size, chemical alterations and mode of delivery are illustrated. Release of oligophosphorothioates from polymer matrixes and gels can produce a prolonged effect in vivo. Antisense oligonucleotides remain essential in exptl. models for which receptor antagonists or selective inhibitors of intracellular components are currently unavailable.

ST DNA antisense receptor study wound healing

IT Bradykinin receptors
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
 (B1; DNA antisense strategies in study of receptors for vasoactive peptides, and of growth and wound-healing factors)

IT Gene therapy
 Wound healing
 Wound healing promoters
 (DNA antisense strategies in study of receptors for vasoactive peptides, and of growth and wound-healing factors)

IT Antisense DNA
 Antisense oligonucleotides
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (DNA antisense strategies in study of receptors for vasoactive peptides, and of growth and wound-healing factors)

IT Endothelin receptors
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
 (ETA; DNA antisense strategies in study of receptors for vasoactive peptides, and of growth and wound-healing factors)

IT Endothelin receptors
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
 (ETB; DNA antisense strategies in study of receptors for vasoactive peptides, and of growth and wound-healing factors)

IT Gene, animal
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (c-myb; DNA antisense strategies in study of receptors for vasoactive peptides, and of growth and wound-healing factors)

IT Gene, animal
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (c-myc; DNA antisense strategies in study of receptors for vasoactive peptides, and of growth and wound-healing factors)

IT Blood vessel, disease
 (injury; DNA antisense strategies in study of receptors for vasoactive peptides, and of growth and wound-healing factors)

IT Platelet-derived growth factor receptors
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
 (β ; DNA antisense strategies in study of receptors for vasoactive peptides, and of growth and wound-healing factors)

IT 157911-20-1 186162-52-7 196825-16-8 196825-17-9 196825-18-0
 196825-19-1 196825-20-4 196825-21-5 196825-22-6 196889-23-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)

(DNA antisense strategies in study of receptors for vasoactive
 peptides, and of growth and wound-healing factors)

RE.CNT 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adner, M; Eur J Pharmacol 1994, V261, P281 HCAPLUS
- (2) Agrawal, S; Clin Pharma 1995, V28, P7 HCAPLUS
- (3) Anderson, K; Antimicrob Agents Chemother 1996, V40, P2004 HCAPLUS
- (4) Arai, H; Nature 1990, V348, P730 HCAPLUS
- (5) Ariens, E; Molecular Pharmacology 1964
- (6) Baird, P; Leukemia & Lymphoma 1995, V18, P373 MEDLINE
- (7) Bennett, M; Circulation 1995, V92, P1981 MEDLINE
- (8) Bennett, M; J Clin Invest 1994, V93, P820 HCAPLUS
- (9) Betsholtz, C; Int J Develop Biol 1995, V39, P817 HCAPLUS
- (10) Blake, K; Biochemistry 1985, V24, P6132 HCAPLUS
- (11) Blake, K; Biochemistry 1985, V24, P6139 HCAPLUS
- (12) Burgess, T; Proc Natl Acad USA 1995, V92, P4051 HCAPLUS
- (13) Cazenave, C; Nucleic Acids Res 1989, V17, P4255 HCAPLUS
- (14) Chai, K; Genomics 1996, V31, P51 HCAPLUS
- (15) Chonn, A; Curr Opin Biotechnol 1995, V6, P698 HCAPLUS
- (16) Clozel, M; J Cardiovasc Pharmacol 1994, V26(supp 3), P262
- (17) Crooke, S; Ann Rev Pharmacol Toxicol 1992, V32, P329 HCAPLUS
- (18) Daaka, Y; Oncogene Res 1990, V5, P267 HCAPLUS
- (19) Dargemont, C; J Cell Biol 1992, V118, P1 HCAPLUS
- (20) Drapeau, G; Meth Enzymol 1988, V163, P263 HCAPLUS
- (21) Edelman, E; Circ Res 1995, V76, P176 HCAPLUS
- (22) Flynn, D; J Cardiovasc Pharmacol 1995, V26, PS219 HCAPLUS
- (23) Gadeau, A; J Cell Physiol 1991, V146, P356 HCAPLUS
- (24) Gao, W; J Biol Chem 1989, V264, P11521 HCAPLUS
- (25) Gobeil, F; Br J Pharmacol 1996, V118, P289 HCAPLUS
- (26) Green, P; Ann Rev Biochem 1986, V55, P596
- (27) Gurthie, C; Science 1991, V253, P157
- (28) Guvakova, M; J Biol Chem 1995, V270, P2620 HCAPLUS
- (29) Helene, C; Genome 1989, V31, P413 MEDLINE
- (30) Hess, J; Biochem Biophys Res Comm 1992, V184, P260 HCAPLUS
- (31) Holt, J; Mol Cell Biol 1988, V8, P963 HCAPLUS
- (32) Ihara, M; Life Sciences 1992, V50, P247 HCAPLUS
- (33) Ishikawa, K; Proc Natl Acad Sci (USA) 1994, V91, P4892 HCAPLUS
- (34) Jawien, A; J Clin Invest 1992, V89, P507 HCAPLUS
- (35) Koyama, N; Circ Res 1994, V75, P682 HCAPLUS
- (36) Kurihara, Y; Nature 1994, V368, P703 HCAPLUS
- (37) Langer, R; Meth Enzymol 1985, V112, P399 HCAPLUS
- (38) Liebhaver, S; J Mol Biol 1992, V226, P609 HCAPLUS
- (39) Loke, S; Proc Natl Acad Sci USA 1989, V86, P3474 HCAPLUS
- (40) Lu, X; J Hucl Med 1994, V35, P269 HCAPLUS
- (41) Luscher, B; Genes Dev 1990, V4, P2025 HCAPLUS
- (42) Majesky, M; J Cell Biol 1990, V111, P2149 HCAPLUS
- (43) Marceau, F; Immunopharmacology 1995, V30, P1 HCAPLUS
- (44) Marcus-Sekura, C; Nucleic Acids Res 1987, V15, P5749 HCAPLUS
- (45) Masaki, T; Ann Rev Pharmacol Toxicol 1995, V35, P235 HCAPLUS
- (46) McCarthy, J; Trends Biochem Sci 1995, V20, P191 HCAPLUS
- (47) Menke, J; J Biol Chem 1994, V269, P21583 HCAPLUS
- (48) Mishra, R; Biochim Ciphys Acta 1995, V1264, P229 HCAPLUS
- (49) Morishita, R; J Clin Invest 1994, V93, P1458 HCAPLUS
- (50) Morishita, R; Proc Natl Acad Sci USA 1993, V90, P8474 HCAPLUS
- (51) Nicolau, M; Can J Physiol Pharmacol 1996, V74, P337 HCAPLUS
- (52) Pardridge, W; Proc Natl Acad Sci USA 1995, V92, P5592 HCAPLUS
- (53) Rabbitts, T; EMBO J 1985, V4, P2009
- (54) Regoli, D; Eur J Pharmacol 1981, V71, P105 HCAPLUS
- (55) Regoli, D; Pharmacol Rev 1994, V46, P450
- (56) Rosbash, M; Cell 1993, V75, P399 HCAPLUS
- (57) Sakurai, T; Nature 1990, V348, P732 HCAPLUS

- (58) Schinke, M; Hypertension 1996, V29, P508
 (59) Seifert, R; J Biol Chem 1989, V264, P8771 HCAPLUS
 (60) Shakin-Eshleman, S; Biochemistry 1988, V27, P3975 HCAPLUS
 (61) Simons, M; Circ Res 1992, V70, P835 HCAPLUS
 (62) Simons, M; J Clin Invest 1994, V93, P2351 HCAPLUS
 (63) Sirois, M; Circulation 1994, V90, PI
 (64) Stein, C; Nature Med 1995, V1, P1119 HCAPLUS
 (65) Thompson, C; Nature 1985, V314, P363 HCAPLUS
 (66) Tullis, R; J Cell Biochem Suppl 1984, V8A, P58
 (67) Uhlmann, E; Chem Rev 1990, V90, P544
 (68) Verspieren, P; Gene 1987, V61, P307 HCAPLUS
 (69) Wagner, R; Mol Cell Biol 1988, V8, P770 HCAPLUS
 (70) Wahlestedt, C; Trends Pharmacol Sci 1994, V15, P42 HCAPLUS
 (71) Walker, I; Pharm Res 1995, V12, P1548 HCAPLUS
 (72) Wang, A; Science 1985, V228, P149 HCAPLUS
 (73) Wang, S; Proc Natl Acad Sci USA 1995, V92, P3318 HCAPLUS
 (74) Wickstrom, E; Fed Proc 1986, V45, P1708
 (75) Wu, D; J Pharmacol Exp Ther 1996, V276, P206 HCAPLUS
 (76) Yakubov, L; Proc Natl Acad Sci USA 1989, V86, P6454 HCAPLUS
 (77) Zamecnik, P; Proc Natl Acad Sci USA 1978, V75, P280 HCAPLUS

=> d all hitstr 170 tot

L70 ANSWER 1 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:80524 HCAPLUS
 DN 140:139544
 ED Entered STN: 01 Feb 2004
 TI Use of convertase inhibitors in the treatment of fibrosis and
 scarring
 IN Ferguson, Mark William James; Brunner, Georg
 PA Renovo Limited, UK
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K038-55
 ICS A61K038-08; A61K038-07; A61P017-02
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 2004009113 | A1 | 20040129 | WO 2003-GB3159 | 20030723 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2492331 | AA | 20040129 | CA 2003-2492331 | 20030723 |
| PRAI GB 2002-17136 | A | 20020724 | | |
| WO 2003-GB3159 | W | 20030723 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|--|------------------------------------|
| WO 2004009113 | ICM | A61K038-55 |
| | ICS | A61K038-08; A61K038-07; A61P017-02 |
| WO 2004009113 | ECLA | A61K038/07; A61K038/08; A61K038/55 |
| AB | The invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions. | |

ST convertase inhibitor fibrosis scarring wound healing promoter
cytoprotectant

IT Insulin-like growth factor II receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(M6P/IGF-II receptor inhibitor; use of convertase
inhibitors in treatment of fibrosis and scarring)

IT Cytoprotective agents
(anti-scarring and anti-fibrotic agents; use of convertase
inhibitors in treatment of fibrosis and scarring)

IT Inflammation
Kidney, disease
(glomerulonephritis; use of convertase inhibitors
in treatment of fibrosis and scarring)

IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(monoclonal, PG19, specific for plasmin; use of convertase
inhibitors in treatment of fibrosis and scarring)

IT Drug delivery systems
(of DNA mol. encoding convertase inhibitor protein; use of
convertase inhibitors in treatment of fibrosis and scarring)

IT Artery, disease
(restenosis; use of convertase inhibitors in treatment of
fibrosis and scarring)

IT Burn
Eye
Intestine
Nerve
Skin, disease
(scar; use of convertase inhibitors in treatment of fibrosis
and scarring)

IT Drug delivery systems
(topical; use of convertase inhibitors in treatment of
fibrosis and scarring)

IT Nerve
(toxicity, scar; use of convertase inhibitors in treatment of
fibrosis and scarring)

IT Cirrhosis
Cystic fibrosis
Fibrosis
Gene therapy
Human
Wound healing
Wound healing promoters
(use of convertase inhibitors in treatment of fibrosis and
scarring)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(use of convertase inhibitors in treatment of
fibrosis and scarring)

IT 9001-90-5, Plasmin 37259-58-8, Serine protease 78990-62-2, Calpain
141760-45-4, Furin (enzyme) 151662-24-7,
PACE4 169592-56-7, Caspase-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; use of convertase inhibitors in
treatment of fibrosis and scarring)

IT 257904-60-2 439598-42-2 439598-43-3
RL: PRP (Properties)
(unclaimed sequence; use of convertase inhibitors in the
treatment of fibrosis and scarring)

IT 9041-92-3 9087-70-1, Aprotinin 39324-30-6, Pepstatin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(use of convertase inhibitors in treatment of fibrosis and
scarring)

IT 96337-25-6 150113-99-8 162559-45-7

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of convertase inhibitors in treatment of fibrosis and scarring)

IT 3672-15-9, Mannose-6-phosphate 30827-99-7, Pefabloc 55123-66-5, Leupeptin 66701-25-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of convertase inhibitors in treatment of fibrosis and scarring)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Brantly, M; US 5439824 A 1995 HCAPLUS
- (2) Cameron, A; JOURNAL OF BIOLOGICAL CHEMISTRY 2000, V275(47), P36741 HCAPLUS
- (3) Dubois, C; JOURNAL OF BIOLOGICAL CHEMISTRY 1995, V270(18), P10618 HCAPLUS
- (4) Lezdey, J; US 6262020 B1 2001 HCAPLUS
- (5) Shah, M; JOURNAL OF CELL SCIENCE 1995, V108(Pt 3), P985
- (6) Sharon, O; INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY 1997, V29(1), P63
- (7) Tomlinson, A; METHODS IN MOLECULAR BIOLOGY 2003, V225, P249
- (8) Univ Manchester; GB 2324960 A 1998 HCAPLUS
- (9) Univ Manchester; EP 0968723 A 2000 HCAPLUS
- (10) Zeneca Ltd; WO 9502579 A 1995 HCAPLUS

IT 141760-45-4, Furin (enzyme) 151662-24-7, PACE4

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; use of convertase inhibitors in treatment of fibrosis and scarring)

RN 141760-45-4 HCAPLUS

CN Furin (enzyme) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 151662-24-7 HCAPLUS

CN Proteinase, PACE4 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 2 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:450955 HCAPLUS

DN 139:2062

ED Entered STN: 13 Jun 2003

TI cDNA and protein sequences of a novel human 10.89 kDa protein showing a similar gene distribution pattern to that for lymphoma proprotein convertase and their uses

IN Mao, Yumin; Xie, Yi

PA Fudan Univ., Peop. Rep. China; Bodao Gene Technology Co., Ltd.

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 31 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

IC ICM C12N009-00

ICS C12N015-52; C12N015-63; C07K016-40; C12Q001-25; C12Q001-68; A61K038-43

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 13

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------|------|--------------|-----------------|--------------|
| PI CN 1355296 | A | 20020626 | CN 2000-127551 | 20001124 <-- |
| PRAI CN 2000-127551 | | 20001124 <-- | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|--|
| CN 1355296 | ICM | C12N009-00 |
| | ICS | C12N015-52; C12N015-63; C07K016-40; C12Q001-25; C12Q001-68; A61K038-43 |

AB This invention provides the cDNA' and protein sequence of a novel human 10.89 kDa protein cloned from fetal brain. The mol. weight of protein is 10.89 kDa determined on SDS PAGE and the gene distribution pattern for 10.89 kDa protein was similar to that for lymphoma proprotein convertase. The invention discloses the process of screening the agonists and antagonists against the polypeptide. The 10.89 kDa protein can be used to diagnosis and treatment for many diseases.

ST cDNA sequence human 11 kilodalton protein

IT AIDS (disease)
Blood, disease
Inflammation
Neoplasm
(10.89 kDa protein associated with, treatment of; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT Human
(10.89 kDa protein gene cloned from; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT Anti-AIDS agents
Anti-inflammatory agents
Antitumor agents
(10.89 kDa protein gene used as; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(10.89 kDa protein of human; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT Immunity
(disorder, 10.89 kDa protein associated with, treatment of; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT Therapy
(for 10.89 kDa protein associated disorders; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT Probes (nucleic acid)
RL: ARG (Analytical reagent use); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(for 10.89 kDa protein gene; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT Molecular cloning
cDNA sequences
(for 10.89 kDa protein of human; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT Gene, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for 10.89 kDa protein of human; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT mRNA
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for 10.89 kDa protein, tissue distribution of; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

- IT Drug screening
(for identification of agonist and antagonist; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT Diagnosis
(mol., for 10.89 kDa protein associated disorders; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT Primers (nucleic acid)
RL: ARG (Analytical reagent use); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(of 10.89 kDa protein gene; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT Antisense oligonucleotides
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(of 10.89 kDa protein gene; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT Protein sequences
(of 10.89 kDa protein of human; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT Brain
(of fetal, 10.89 kDa protein gene cloned from; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT Microarray technology
(preparation of; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(to 10.89 kDa protein; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT 532755-64-9
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT 99676-46-7, Proprotein convertase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lymphoma, LPC family, gene distribution pattern of; cDNA and protein sequences of novel human 10.89 kDa protein showing similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT 532755-63-8 532755-65-0
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; cDNA and protein sequences of a novel human 10.89 kDa protein showing a similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)
- IT 532770-92-6 532770-93-7 532770-94-8 532770-95-9 532770-96-0
532770-97-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; cDNA and protein sequences of a novel human 10.89 kDa protein showing a similar gene distribution pattern to that for lymphoma proprotein convertase and their uses)

IT 532414-31-6
 RL: PRP (Properties)
 (unclaimed sequence; cDNA and protein sequences of a novel human 10.89
 kDa protein showing a similar gene distribution pattern to that for
 lymphoma proprotein convertase and their uses)

L70 ANSWER 3 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:334829 HCAPLUS

DN 138:343889

ED Entered STN: 02 May 2003

TI Novel pharmaceutical compounds containing drugs bound to polypeptides

IN Picariello, Thomas

PA New River Pharmaceuticals Inc., USA

SO PCT Int. Appl., 4662 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 2, 15

FAN.CNT 12

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|------|-----------------|------|----------|--|--------------|--|
| PI | WO 2003034980 | A2 | 20030501 | WO 2001-US43089 | 20011114 <-- | |
| | WO 2003034980 | C1 | 20031120 | | | |
| | W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | |
| | RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| | CA 2428971 | AA | 20030501 | CA 2001-2428971 | 20011114 <-- | |
| | EP 1401374 | A1 | 20040331 | EP 2001-274606 | 20011114 <-- | |
| | R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | |
| PRAI | US 2000-274622P | P | 20001114 | <-- | | |
| | US 2000-247622P | P | 20001114 | <-- | | |
| | WO 2001-US43089 | W | 20011114 | | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|--|
| WO 2003034980 | ICM | A61K |
| WO 2003034980 | ECLA | A61K031/506; A61K031/52; A61K047/48R2T <-- |

AB Compns. comprising polypeptides and drugs covalently attached to the polypeptide are disclosed. Also provided is a method for delivery of these drugs to a patient comprising administering to the patient a composition comprising a polypeptide and a drug covalently attached to the polypeptide. Also provided is a method for protecting drugs from degradation comprising covalently attaching them to a polypeptide. Also provided is a method for controlling release of drugs from a composition comprising covalently attaching them to the polypeptide.

ST drug delivery polypeptide conjugation

IT Enzymes, uses

RL: CAT (Catalyst use); USES (Uses)

(-catalyzed drug release; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT pH

(-dependent drug release; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Drug delivery systems

(carriers; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Drug delivery systems
(controlled-release, pH-dependent; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Proteins
RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug conjugates; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Drug delivery systems
(injections, i.v.; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(intestinal; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Polyoxyalkylenes, biological studies
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microencapsulation agent; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Amino acids, biological studies
Carbohydrates, biological studies
Salts, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microencapsulation agent; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Encapsulation
(microencapsulation; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Peptides, biological studies
RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oligopeptides, drug conjugates; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Drug delivery systems
(oral; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Polyamides, biological studies
RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(poly(amino acids), drug conjugates; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Drug delivery systems
(prodrugs; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Drugs
(protein conjugates; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Antisense oligonucleotides
Estrogens
Interleukin 2
RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein conjugates; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Drug delivery systems
(suspensions; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Drug delivery systems
(tablets; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Intestine
(transport proteins of; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT Interferons
RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(β , 1A, protein conjugates; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT 25322-68-3, Polyethylene glycol
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (microencapsulation agent; novel pharmaceutical compds. containing drugs bound to polypeptides)

IT 50-18-0DP, Cyclophosphamide, protein conjugates 50-48-6DP, Amitriptyline, protein conjugates 50-49-7DP, Imipramine, protein conjugates 50-78-2DP, Aspirin, protein conjugates 51-61-6DP, Dopamine, protein conjugates, biological studies 51-64-9DP, Dextroamphetamine, protein conjugates 51-98-9DP, Norethindrone acetate, protein conjugates 52-86-8DP, Haloperidol, protein conjugates 53-16-7DP, Estrone, protein conjugates, biological studies 54-31-9DP, Furosemide, protein conjugates 57-63-6DP, Ethinyl estradiol, protein conjugates 58-08-2DP, Caffeine, protein conjugates, biological studies 58-18-4DP, Methyltestosterone, protein conjugates 58-25-3DP, Chlordiazepoxide, protein conjugates 58-32-2DP, Dipyridamole, protein conjugates 58-61-7DP, Adenosine, protein conjugates, biological studies 58-93-5DP, Hydrochlorothiazide, protein conjugates 59-92-7DP, Levodopa, protein conjugates 68-22-4DP, Norethindrone, protein conjugates 71-58-9DP, Medroxyprogesterone acetate, protein conjugates 77-19-0DP, Dicyclomine, protein conjugates 78-44-4DP, Carisoprodol, protein conjugates 86-13-5DP, Benztropine, protein conjugates 87-33-2DP, Isosorbide dinitrate, protein conjugates 103-90-2DP, Acetaminophen, protein conjugates 113-15-5DP, Ergotamine, protein conjugates 114-07-8DP, Erythromycin, protein conjugates 118-42-3DP, Hydroxychloroquine, protein conjugates 125-71-3DP, Dextromethorphan, protein conjugates 127-31-1DP, Fludrocortisone, protein conjugates 132-22-9DP, Chlorpheniramine, protein conjugates 297-76-7DP, Ethynodiol diacetate, protein conjugates 298-46-4DP, Carbamazepine, protein conjugates 303-49-1DP, Clomipramine, protein conjugates 303-53-7DP, Cyclobenzaprine, protein conjugates 315-30-0DP, Allopurinol, protein conjugates 378-44-9DP, Betamethasone, protein conjugates 396-01-0DP, Triamterene, protein conjugates 437-38-7DP, Fentanyl, protein conjugates 439-14-5DP, Diazepam, protein conjugates 446-86-6DP, Azathioprine, protein conjugates 466-99-9DP, Hydromorphone, protein conjugates 469-62-5DP, Propoxyphene, protein conjugates 745-65-3DP, Alprostadil, protein conjugates 797-63-7DP, Levonorgestrel, protein conjugates 1134-47-0DP, Baclofen, protein conjugates 1403-66-3DP, Gentamicin, protein conjugates 1622-61-3DP, Clonazepam, protein conjugates 1951-25-3DP, Amiodarone, protein conjugates 4205-90-7DP, Clonidine, protein conjugates 4759-48-2DP, Isotretinoin, protein conjugates 5786-21-0DP, Clozapine, protein conjugates 5991-71-9DP, Clorazepate depot, protein conjugates 6533-00-2DP, Norgestrel, protein conjugates 7280-37-7DP, Estropipate, protein conjugates 9002-60-2DP, Adrenocorticotropin, protein conjugates 9002-68-0DP, Follitropin, protein conjugates 9007-92-5DP, Glucagon, protein conjugates 9041-92-3DP, α 1-Proteinase inhibitor, protein conjugates 10238-21-8DP, Glyburide, protein conjugates 11061-68-0DP, Human insulin, protein conjugates 13311-84-7DP, Flutamide, protein conjugates 15307-86-5DP, Diclofenac, protein conjugates 15663-27-1DP, Cisplatin, protein conjugates 15686-71-2DP, Cephalexin, protein conjugates 15687-27-1DP, Ibuprofen, protein conjugates 16679-58-6DP, Desmopressin, protein conjugates 18559-94-9DP, Albuterol, protein conjugates 20537-88-6DP, Amifostine, protein conjugates 20830-75-5DP, Digoxin, protein conjugates 22071-15-4DP, Ketoprofen, protein conjugates 23214-92-8DP, Doxorubicin, protein conjugates 25614-03-3DP, Bromocriptine, protein conjugates 25812-30-0DP, Gemfibrozil, protein conjugates 25953-19-9DP, Cefazolin, protein conjugates 26787-78-0DP, Amoxicillin, protein conjugates 28860-95-9DP, Carbidopa, protein conjugates 28981-97-7DP, Alprazolam, protein conjugates 29094-61-9DP, Glipizide, protein conjugates 29122-68-7DP, Atenolol, protein conjugates 30516-87-1DP, Zidovudine, protein conjugates 32222-06-3DP, Calcitriol, protein conjugates 34580-13-7DP, Ketotifen, protein conjugates 34911-55-2DP, Bupropion, protein

conjugates 35189-28-7DP, Norgestimate, protein conjugates
 35607-66-0DP, Cefoxitin, protein conjugates 36505-84-7DP,
 Buspirone, protein conjugates 36894-69-6DP, Labetalol, protein
 conjugates 38398-32-2DP, Ganaxolone, protein conjugates 40431-64-9DP,
 protein conjugates 41575-94-4DP, Carboplatin, protein conjugates
 42399-41-7DP, Diltiazem, protein conjugates 42408-82-2DP, Butorphanol,
 protein conjugates 42617-41-4DP, Activated protein C, protein conjugates
 49562-28-9DP, Fenofibrate, protein conjugates 50370-12-2DP,
 Cefadroxil, protein conjugates 50925-79-6DP, Colestipol, protein
 conjugates 51481-61-9DP, Cimetidine, protein conjugates
 53994-73-3DP, Cefaclor, protein conjugates 54024-22-5DP,
 Desogestrel, protein conjugates 54143-56-5DP, Flecainide acetate,
 protein conjugates 54910-89-3DP, Fluoxetine, protein conjugates
 55079-83-9DP, Acitretin, protein conjugates 55268-75-2DP,
 Cefuroxime, protein conjugates 56180-94-0DP, Acarbose, protein
 conjugates 58001-44-8DP, protein conjugates 58581-89-8DP, Azelastine,
 protein conjugates 58957-92-9DP, Idarubicin, protein conjugates
 59017-64-0DP, protein conjugates 59122-46-2DP, Misoprostol, protein
 conjugates 59277-89-3DP, Acyclovir, protein conjugates 59729-33-8DP,
 Citalopram, protein conjugates 59865-13-3DP, Cyclosporine, protein
 conjugates 59989-18-3DP, Eniluracil, protein conjugates 60142-96-3DP,
 Gabapentin, protein conjugates 60205-81-4DP, Ipratropium, protein
 conjugates 61718-82-9DP, Fluvoxamine maleate, protein conjugates
 62571-86-2DP, Captopril, protein conjugates 63527-52-6DP,
 Cefotaxime, protein conjugates 64221-86-9DP, Imipenem, protein
 conjugates 64544-07-6DP, Cefuroxime axetil, protein conjugates
 65277-42-1DP, Ketoconazole, protein conjugates 65646-68-6DP,
 Fenretinide, protein conjugates 66376-36-1DP, Alendronate, protein
 conjugates 66722-44-9DP, Bisoprolol, protein conjugates 68475-42-3DP,
 Anagrelide, protein conjugates 68844-77-9DP, Astemizole, protein
 conjugates 69655-05-6DP, Didanosine, protein conjugates
 69712-56-7DP, Cefotetan, protein conjugates 72509-76-3DP,
 Felodipine, protein conjugates 72558-82-8DP, Ceftazidime,
 protein conjugates 72956-09-3DP, Carvedilol, protein conjugates
 73334-07-3DP, Iopromide, protein conjugates 73573-87-2DP, Formoterol,
 protein conjugates 74103-06-3DP, Ketorolac, protein conjugates
 74191-85-8DP, Doxazosin, protein conjugates 75695-93-1DP, Isradipine,
 protein conjugates 75706-12-6DP, Leflunomide, protein conjugates
 75847-73-3DP, Enalapril, protein conjugates 76584-70-8DP, protein
 conjugates 76824-35-6DP, Famotidine, protein conjugates 78755-81-4DP,
 Flumazenil, protein conjugates 79350-37-1DP, Cefixime, protein
 conjugates 81098-60-4DP, Cisapride, protein conjugates 81103-11-9DP,
 Clarithromycin, protein conjugates 81409-90-7DP, Cabergoline, protein
 conjugates 82009-34-5DP, Cilastatin, protein conjugates 82410-32-0DP,
 Ganciclovir, protein conjugates 83799-24-0DP, Fexofenadine, protein
 conjugates 83881-51-0DP, Cetirizine, protein conjugates 83905-01-5DP,
 Azithromycin, protein conjugates 84057-84-1DP, Lamotrigine, protein
 conjugates 84625-61-6DP, Itraconazole, protein conjugates
 85721-33-1DP, Ciprofloxacin, protein conjugates 86050-77-3DP,
 Gadopentetate dimeglumine, protein conjugates 86386-73-4DP, Fluconazole,
 protein conjugates 86541-75-5DP, Benazepril, protein conjugates
 87239-81-4DP, Cefpodoxime proxetil, protein conjugates 88150-42-9DP,
 Amlodipine, protein conjugates 90357-06-5DP, Bicalutamide, protein
 conjugates 91832-40-5DP, Cefdinir, protein conjugates 92339-11-2DP,
 Iodixanol, protein conjugates 92665-29-7DP, Cefprozil, protein
 conjugates 93379-54-5DP, Esatenolol, protein conjugates 93390-81-9DP,
 Fosphenytoin, protein conjugates 93479-97-1DP, Glimepiride, protein
 conjugates 93957-54-1DP, Fluvastatin, protein conjugates 95058-81-4DP,
 Gemcitabine, protein conjugates 95233-18-4DP, Atovaquone, protein
 conjugates 95896-08-5DP, Anaritide, protein conjugates 96946-42-8DP,
 Cisatracurium besylate, protein conjugates 97519-39-6DP, Ceftibuten,
 protein conjugates 97682-44-5DP, Irinotecan, protein conjugates
 98048-97-6DP, Fosinopril, protein conjugates 98319-26-7DP, Finasteride,
 protein conjugates 103577-45-3DP, Lansoprazole, protein conjugates
 104227-87-4DP, Famciclovir, protein conjugates 109889-09-0DP,
 Granisetron, protein conjugates 111470-99-6DP, Amlodipine besylate,

protein conjugates 112108-01-7DP, Ecopipam, protein conjugates
 112573-73-6DP, Ecadotril, protein conjugates 113427-24-0DP, Epoetin
 alfa, protein conjugates 113665-84-2DP, Clopidogrel, protein conjugates
 115956-13-3DP, Dolasetron mesylate, protein conjugates 116539-59-4DP,
 Duloxetine, protein conjugates 118390-30-0DP, Interferon alfacon-1,
 protein conjugates 120014-06-4DP, Donepezil, protein conjugates
 120066-54-8DP, Gadoteridol, protein conjugates 120511-73-1DP,
 Anastrozole, protein conjugates 120635-74-7DP, Cilansetron, protein
 conjugates 121181-53-1DP, Filgrastim, protein conjugates
 123122-55-4DP, Candoxatril, protein conjugates 123258-84-4DP, Itasetron,
 protein conjugates 126544-47-6DP, Ciclesonide, protein conjugates
 129722-12-9DP, Aripiprazole, protein conjugates 130801-33-1DP, protein
 conjugates 131410-48-5DP, Gadodiamide, protein conjugates
 132449-46-8DP, Lesopitron, protein conjugates 134523-00-5DP,
 Atorvastatin, protein conjugates 134564-82-2DP, Befloxatone, protein
 conjugates 134678-17-4DP, Lamivudine, protein conjugates
 135306-42-2DP, protein conjugates 138402-11-6DP, Irbesartan, protein
 conjugates 139481-59-7DP, Candesartan, protein conjugates
 141732-76-5DP, Exendin-4, protein conjugates 142340-99-6DP, Adefovir
 dipivoxil, protein conjugates 145599-86-6DP, Cerivastatin, protein
 conjugates 147245-92-9DP, Glatiramer acetate, protein conjugates
 147536-97-8DP, Bosentan, protein conjugates 149824-15-7DP, Ilodecakin,
 protein conjugates 149950-60-7DP, Emivirine, protein conjugates
 150378-17-9DP, Indinavir, protein conjugates 153259-65-5DP, Cilomilast,
 protein conjugates 153438-49-4DP, Dapitant, protein conjugates
 154248-97-2DP, Imiglucerase, protein conjugates 154361-50-9DP,
 Capecitabine, protein conjugates 154598-52-4DP, Efavirenz, protein
 conjugates 160135-92-2DP, protein conjugates 161814-49-9DP,
 Amprenavir, protein conjugates 162808-62-0DP, Caspofungin, protein
 conjugates 164656-23-9DP, Dutasteride, protein conjugates
 166518-60-1DP, Avasimibe, protein conjugates 169590-42-5DP, Celecoxib,
 protein conjugates 170277-31-3DP, Infliximab, protein conjugates
 178961-24-5DP, protein conjugates 179120-92-4DP, Altinicine, protein
 conjugates 183547-57-1DP, Gantofiban, protein conjugates
 183552-38-7DP, Abarelix, protein conjugates 185243-69-0DP, Etanercept,
 protein conjugates 187348-17-0DP, Edodekin alfa, protein conjugates
 188062-50-2DP, Abacavir sulfate, protein conjugates 188627-80-7DP,
 Eptifibatide, protein conjugates 194804-75-6DP, protein conjugates
 198283-73-7DP, protein conjugates 205110-48-1DP, protein conjugates
 RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (novel pharmaceutical compds. containing drugs bound to polypeptides)
 IT 210101-16-9DP, Conivaptan, protein conjugates 679809-58-6DP, Enoxaparin
 sodium, protein conjugates
 RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (novel pharmaceutical compds. containing drugs bound to polypeptides)
 IT 103-90-2DP, Acetaminophen, protein conjugates 9041-92-3DP
 , α 1-Proteinase inhibitor,
 protein conjugates 15686-71-2DP, Cephalixin, protein conjugates
 25953-19-9DP, Cefazolin, protein conjugates 26787-78-0DP
 , Amoxicillin, protein conjugates 35607-66-0DP, Cefoxitin,
 protein conjugates 50370-12-2DP, Cefadroxil, protein conjugates
 53994-73-3DP, Cefaclor, protein conjugates 55268-75-2DP,
 Cefuroxime, protein conjugates 63527-52-6DP, Cefotaxime, protein
 conjugates 69712-56-7DP, Cefotetan, protein conjugates
 72558-82-8DP, Ceftazidime, protein conjugates 79350-37-1DP
 , Cefixime, protein conjugates
 RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (novel pharmaceutical compds. containing drugs bound to polypeptides)
 RN 103-90-2 HCAPLUS
 CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 15686-71-2 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[(2R)-aminophenylacetyl]amino]-3-methyl-8-oxo-, (6R,7R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 25953-19-9 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[(1H-tetrazol-1-ylacetyl)amino]-, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26787-78-0 HCAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 35607-66-0 HCAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-
, (6R,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50370-12-2 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, (6R,7R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 53994-73-3 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R,7R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 55268-75-2 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[[[(aminocarbonyl)oxy]methyl]-7-[[[(2Z)-2-furanyl(methoxyimino)acetyl]amin
o]-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 63527-52-6 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(acetyloxy)methyl]-7-[[{(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]a
mino]-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 69712-56-7 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-
yl]carbonyl]amino]-7-methoxy-3-[[{(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-
oxo-, (6R,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 72558-82-8 HCAPLUS

CN Pyridinium, 1-[[{(6R,7R)-7-[[{(2Z)-(2-amino-4-thiazolyl)[{(1-carboxy-1-
methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-


azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 79350-37-1 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(2-amino-4-thiazolyl)[(carboxymethoxy)imino]acetyl]amino]-3-
ethenyl-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L70 ANSWER 4 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:556104 HCAPLUS
DN 137:109489
ED Entered STN: 26 Jul 2002
TI Compositions comprising a polypeptide and an active agent
IN Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randal J.
PA USA
SO U.S. Pat. Appl. Publ., 34 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K038-17
INCL 514012000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
FAN.CNT 12

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|-------|-----------------|-------|
| ----- | ---- | ----- | ----- | ----- |

| | | | | | |
|------|-----------------|----|----------|----------------|--------------|
| PI | US 2002099013 | A1 | 20020725 | US 2001-933708 | 20010822 <-- |
| | US 2004087483 | A1 | 20040506 | US 2002-136433 | 20020502 <-- |
| PRAI | US 2000-247556P | P | 20001114 | <-- | |
| | US 2000-247558P | P | 20001114 | <-- | |
| | US 2000-247559P | P | 20001114 | <-- | |
| | US 2000-247560P | P | 20001114 | <-- | |
| | US 2000-247561P | P | 20001114 | <-- | |
| | US 2000-247594P | P | 20001114 | <-- | |
| | US 2000-247595P | P | 20001114 | <-- | |
| | US 2000-247606P | P | 20001114 | <-- | |
| | US 2000-247607P | P | 20001114 | <-- | |
| | US 2000-247608P | P | 20001114 | <-- | |
| | US 2000-247609P | P | 20001114 | <-- | |
| | US 2000-247610P | P | 20001114 | <-- | |
| | US 2000-247611P | P | 20001114 | <-- | |
| | US 2000-247612P | P | 20001114 | <-- | |
| | US 2000-247620P | P | 20001114 | <-- | |
| | US 2000-247621P | P | 20001114 | <-- | |
| | US 2000-247634P | P | 20001114 | <-- | |
| | US 2000-247635P | P | 20001114 | <-- | |
| | US 2000-247698P | P | 20001114 | <-- | |
| | US 2000-247699P | P | 20001114 | <-- | |
| | US 2000-247700P | P | 20001114 | <-- | |
| | US 2000-247701P | P | 20001114 | <-- | |
| | US 2000-247702P | P | 20001114 | <-- | |
| | US 2000-247797P | P | 20001114 | <-- | |
| | US 2000-247798P | P | 20001114 | <-- | |
| | US 2000-247799P | P | 20001114 | <-- | |
| | US 2000-247800P | P | 20001114 | <-- | |
| | US 2000-247801P | P | 20001114 | <-- | |
| | US 2000-247802P | P | 20001114 | <-- | |
| | US 2000-247803P | P | 20001114 | <-- | |
| | US 2000-247804P | P | 20001114 | <-- | |
| | US 2000-247805P | P | 20001114 | <-- | |
| | US 2000-247807P | P | 20001114 | <-- | |
| | US 2000-247832P | P | 20001114 | <-- | |
| | US 2000-247833P | P | 20001114 | <-- | |
| | US 2000-247926P | P | 20001114 | <-- | |
| | US 2000-247927P | P | 20001114 | <-- | |
| | US 2000-247928P | P | 20001114 | <-- | |
| | US 2000-247929P | P | 20001114 | <-- | |
| | US 2000-247930P | P | 20001114 | <-- | |
| | US 2000-642820 | A2 | 20000822 | <-- | |
| | US 2000-248607P | P | 20001116 | <-- | |
| | US 2001-933708 | A2 | 20010822 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES | |
|---------------|-------|--|-----|
| US 2002099013 | ICM | A61K038-17 | |
| | INCL | 514012000 | |
| US 2002099013 | NCL | 514/012.000 | |
| | ECLA | A61K047/48R2T | <-- |
| US 2004087483 | NCL | 514/002.000 | |
| | ECLA | A61K047/48R; A61K047/48R2; A61K047/48R2T; A61K047/48T4B28; A61K047/48T4B10D; A61K047/48T4B10; A61K047/48T4B30B; A61K047/48T4B30M | <-- |

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalixin hydrochloride.

ST peptide conjugate drug prodrug

IT CD22 (antigen)

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(LYM-1; compns. comprising a polypeptide and an active agent)

IT Oligonucleotides
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antisense; compns. comprising a polypeptide and an active agent)

IT Drugs
 Human
 Vaccines
 (compns. comprising a polypeptide and an active agent)

IT Peptides, preparation
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (compns. comprising a polypeptide and an active agent)

IT Estrogens
 Interleukin 2
 Polyoxyalkylenes, biological studies
 Vitamins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. comprising a polypeptide and an active agent)

IT Drug delivery systems
 (prodrugs; compns. comprising a polypeptide and an active agent)

IT 330600-85-6, BCX 1812
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (BCX 1812; compns. comprising a polypeptide and an active agent)

IT 176960-47-7, BMS 193884
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (BMS 193884; compns. comprising a polypeptide and an active agent)

IT 154802-96-7, GM 611
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (GM 611; compns. comprising a polypeptide and an active agent)

IT 222535-22-0, LFA 3TIP
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (LFA 3TIP; compns. comprising a polypeptide and an active agent)

IT 106463-17-6, Tamsulosin hydrochloride
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Tamsulosin hydrochloride; compns. comprising a polypeptide and an
 active agent)

IT 61512-21-8, Thymosin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (alpha; compns. comprising a polypeptide and an active agent)

IT 56-84-8P, L-Aspartic acid, preparation 59-92-7DP, polyglutamic acid
 derivs. 443-48-1DP, polyglutamic acid derivs. 3056-17-5DP,
 polyglutamic acid derivs. 7481-89-2DP, polyglutamic acid derivs.
 22204-53-1DP, polylysine derivs. 24991-23-9DP, drug conjugate derivs.
 25812-30-0DP, polylysine derivs. 29122-68-7DP, polyglutamic derivs.
 31631-78-4DP, reaction products with cephalixin 31724-47-7DP, reaction
 products with cephalixin 59277-89-3DP, polyglutamic acid derivs.
 73573-88-3DP, acetylated polyglutamic derivs. 76584-70-8DP, polylysine
 derivs. 83799-24-0DP, polyglutamic acid derivs. 104400-30-8P
 420824-33-5P 420824-50-6P 420824-76-6P 420824-81-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (compns. comprising a polypeptide and an active agent)

IT 51-48-9, Thyroxine, reactions 61-90-5, Leucine, reactions 63-68-3,
 L-Methionine, reactions 63-91-2, L-Phenylalanine, reactions 73-32-5,
 L-Isoleucine, reactions 99-66-1, Valproic acid 492-62-6, α -D
 Glucose 1676-73-9 2418-95-3 3057-74-7 4125-79-5 4378-13-6
 6893-02-3 13726-84-6 16590-41-3, Naltrexone 18822-58-7 25718-94-9
 25734-27-4, Poly[imino(1-oxo-1,2-ethanediyl)] 25812-30-0, Gemfibrozil
 25988-63-0 26386-88-9, Diphenylphosphoryl azide 34582-32-6
 51219-19-3 81659-82-7 104400-52-4 146645-63-8 340816-48-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (compns. comprising a polypeptide and an active agent)

IT 56-41-7P, L-Alanine, preparation 72-18-4P, L-Valine, preparation
 3190-71-4P 14825-82-2P 16617-07-5P 20700-95-2P 22204-53-1P,

Naproxen 24937-47-1P 24991-23-9P 25014-27-1P, .gamma.-Benzyl glutamate homopolymer 25038-53-3P, .gamma.-Benzyl L-glutamate homopolymer, SRU 25212-18-4P 25248-59-3DP, iodotyrosine-capped derivs. 25249-36-9P 25322-63-8DP, iodotyrosine-capped derivs. 25513-46-6P, Polyglutamic acid 25608-40-6P, Polyaspartic acid 25667-19-0DP, iodotyrosine-capped derivs. 25821-52-7P, Polyserine 25821-94-7P, Polyserine 26063-13-8P 26588-20-5P 26854-80-8DP, iodotyrosine-capped derivs. 29435-39-0P 31764-54-2P 33043-60-6P 33540-31-7DP, iodotyrosine-capped derivs. 38000-06-5DP, Ibuprofen derivs. 38000-06-5DP, iodotyrosine-capped derivs. 56210-05-0P 56218-11-2P, Polythreonine 82822-12-6P, Polythreonine 86409-29-2P 114994-77-3P 119739-55-8DP, iodotyrosine-capped derivs. 125780-85-0P 125780-86-1P 129288-31-9P 137132-61-7P 137132-62-8P 148085-06-7P 148230-67-5P 340816-48-0DP, polyglycine derivs. 420824-10-8P 420824-13-1P 420824-15-3P 420824-17-5P 420824-18-6P 420824-20-0P 420824-28-8P 420824-30-2P 420824-36-8P 420824-38-0P 420824-40-4P 420824-43-7P 420824-56-2P 420824-64-2P 420824-72-2DP, iodotyrosine-capped derivs. 420824-74-4P 420824-79-9P 420824-83-5P 420824-85-7P 421555-53-5P 421555-54-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(compsns. comprising a polypeptide and an active agent)

IT 53-03-2, Prednisone 58-32-2, Dipyrindamole 59-92-7, reactions 103-90-2, Acetaminophen 443-48-1, Metronidazole 3056-17-5, Stavudine 7481-89-2, Zalcitabine 15687-27-1, Ibuprofen 29122-68-7, Atenolol 30516-87-1, Azt 59277-89-3, Acyclovir 59695-59-9, Cephalixin hydrochloride 73573-88-3, Mevastatin 79559-97-0, Sertraline hydrochloride 83799-24-0, Fexofenadine

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(compsns. comprising a polypeptide and an active agent)

IT 420824-87-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(compsns. comprising a polypeptide and an active agent)

IT 50-06-6, Phenobarbital, biological studies 50-18-0, Cyclophosphamide 50-35-1, Thalidomide 50-44-2, Mercaptopurine 50-78-2, Acetylsalicylic acid 50-81-7, Vitamin C, biological studies 51-21-8, Fluorouracil 51-61-6, Dopamine, biological studies 51-63-8, Dextroamphetamine sulfate 51-98-9, Norethindrone acetate 52-01-7, Spironolactone 52-24-4, Thiotepa 52-86-8, Haloperidol 53-36-1, Methylprednisolone Acetate 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-63-6, Ethinyl estradiol 58-08-2, Caffeine, biological studies 58-18-4, Methyltestosterone 58-25-3, Chlordiazepoxide 58-33-3, Promethazine hydrochloride 58-55-9, Theophylline, biological studies 58-61-7, Adenosine, biological studies 58-93-5, Hydrochlorothiazide 59-42-7, Phenylephrine 60-54-8, Tetracycline 60-87-7, Promethazine 64-31-3, Morphine Sulfate 67-20-9, Nitrofurantoin 67-92-5, Dicyclomine hydrochloride 68-19-9, Vitamin B12 68-22-4, Norethindrone 71-58-9, Medroxyprogesterone acetate 71-68-1, Hydromorphone hydrochloride 74-79-3, Arginine, biological studies 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-58-4, Ethylmorphine 78-44-4, Carisoprodol 84-02-6, Prochlorperazine maleate 87-08-1, Penicillin V 87-33-2, Isosorbide Dinitrate 89-57-6, Mesalamine 90-82-4, Pseudoephedrine 93-14-1, Guaifenesin 113-45-1, Methylphenidate 113-52-0 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 124-90-3, Oxycodone hydrochloride 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone 125-33-7, Primidone 125-71-3, Dextromethorphan 128-13-2, Ursodiol 129-06-6, Warfarin Sodium 132-17-2, Benzatropine methanesulfonate 143-52-2, Methyldihydromorphine 143-71-5, Hydrocodone bitartrate 152-11-4, Verapamil hydrochloride 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-59-9, Methylphenidate hydrochloride 303-49-1, Clomipramine 315-30-0, Allopurinol 318-98-9, Propranolol Hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine Tartrate 437-38-7, Fentanyl 439-14-5, Diazepam 446-86-6, Azathioprine 466-99-9, Hydromorphone 469-62-5, Propoxyphene 509-60-4, Dihydromorphone 514-36-3, Fludrocortisone acetate 541-15-1,

Levocarnitine 549-18-8, Amitriptyline hydrochloride 554-13-2, Lithium Carbonate 561-27-3, Diacetylmorphine 595-33-5, Megestrol acetate 604-75-1, Oxazepam 630-93-3, Sodium phenytoin 657-24-9, Metformin 745-65-3, Alprostadil 747-36-4, Hydroxychloroquine sulfate 797-63-7, Levonorgestrel 846-49-1, Lorazepam 846-50-4, Temazepam 894-71-3, Nortriptyline hydrochloride 959-24-0, Sotalol hydrochloride 1134-47-0, Baclofen 1403-66-3, Gentamicin 1404-93-9, Vancomycin hydrochloride 1501-84-4, Rimantadine hydrochloride 1508-65-2, Oxybutynin chloride 1622-61-3, Clonazepam 1665-48-1, Metaxalone 1744-22-5, Riluzole 1951-25-3, Amiodarone 2078-54-8, Propofol 2152-34-3, Pemoline 2375-03-3, Methylprednisolone sodium succinate 4205-91-8 4682-36-4, Orphenadrine citrate 4759-48-2, Isotretinoin 5786-21-0, Clozapine 6202-23-9, Cyclobenzaprine hydrochloride 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 7280-37-7, Estropipate 7414-83-7, Etidronate disodium 9002-60-2, Adrenocorticotrophic hormone, biological studies 9002-69-1, Relaxin 9005-49-6, Heparin, biological studies 9014-42-0, Thrombopoietin 9039-53-6, Urokinase 9041-08-1, Dalteparin sodium 9041-92-3, α .1-Protease inhibitor 9080-79-9, Sodium polystyrene sulfonate 10238-21-8, Glyburide 11005-12-2, β -Phytosterol 11056-06-7, Bleomycin 11140-85-5, Glucagon hydrochloride 13311-84-7, Flutamide 13614-98-7, Minocycline hydrochloride 14124-50-6, Hydrochlorothiazide-triamterene mixture 14611-52-0, Selegiline hydrochloride 14838-15-4, Phenylpropanolamine 15307-79-6, Diclofenac sodium 15663-27-1, Cisplatin 15686-71-2, Cephalixin 17140-78-2, Propoxyphene napsylate 17560-51-9, Metolazone 18559-94-9, Albuterol 19767-45-4, Mesna 20537-88-6, Amifostine 20830-75-5, Digoxin 21062-37-3D, analogs 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 23031-32-5, Terbutaline sulfate 25316-40-9, Doxorubicin hydrochloride 25322-68-3, Polyethylene glycol 25332-39-2, Trazodone hydrochloride 25614-03-3, Bromocriptine 26159-34-2, Naproxen sodium 26787-78-0, Amoxicillin 27164-46-1, Cefazolin sodium 27314-97-2, Tirapazamine 28860-95-9, Carbidopa 28981-97-7, Alprazolam 29094-61-9, Glipizide 29354-16-3, Thyronine, iodo- 31677-93-7, Bupropion hydrochloride 32222-06-3, Calcitriol 32780-64-6, Labetalol hydrochloride 33069-62-4, Paclitaxel 33286-22-5, Diltiazem hydrochloride 33419-42-0, Etoposide 33564-30-6, Cefoxitin sodium 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen 35189-28-7, Norgestimate 36282-47-0, Tramadol hydrochloride 36505-84-7, Buspirone 36791-04-5, Ribavirin 37296-80-3, Colestipol hydrochloride 38398-32-2, Ganaxolone 41340-25-4, Etodolac 41575-94-4, Carboplatin 42200-33-9, Nadolol 42617-41-4, Activated protein C 42924-53-8, Nabumetone 49562-28-9, Fenofibrate 49842-07-1, Tobramycin sulfate 50370-12-2, Cefadroxil 50700-72-6, Vecuronium bromide 51321-79-0, Sparfosic acid 51481-61-9, Cimetidine 51773-92-3, Mefloquine hydrochloride 52232-67-4, Teriparatide 53885-35-1, Ticlopidine hydrochloride 53994-73-3, Cefaclor 54024-22-5, Desogestrel 54143-56-5, Flecainide acetate 54182-58-0, Sucralfate 54910-89-3, Fluoxetine 54965-24-1, Tamoxifen citrate 55079-83-9, Acitretin 56180-94-0, Acarbose 56238-63-2, Cefuroxime sodium 57109-90-7, Clorazepate dipotassium 57248-88-1, Pamidronate disodium 57852-57-0, Idarubicin hydrochloride 58579-51-4, Anagrelide hydrochloride 58786-99-5, Butorphanol tartrate 59122-46-2, Misoprostol 59703-84-3, Piperacillin sodium 59729-32-7, Citalopram hydrobromide 59865-13-3, Cyclosporin 59989-18-3, Eniluracil 60142-96-3, Gabapentin 60205-81-4, Ipratropium 60748-06-3, Gastrin 17 61718-82-9, Fluvoxamine maleate 62288-83-9, Desmopressin acetate 62571-86-2, Captopril 63074-08-8, Terazosin hydrochloride 63675-72-9, Nisoldipine 64221-86-9, Imipenem 64461-82-1, Tizanidine hydrochloride 64485-93-4, Cefotaxime sodium 64544-07-6, Cefuroxime axetil 65277-42-1, Ketoconazole 65646-68-6, Fenretinide 65807-02-5, Goserelin 66085-59-4, Nimodipine 66104-22-1, Pergolide 66357-35-5, Ranitidine 66722-44-9, Bisoprolol 67889-72-9, Acetaminophen-codeine phosphate mixture 67992-58-9, Sodium ioxaglate 68562-41-4, Mecasermin 68693-11-8, Modafinil 68844-77-9, Astemizole 69655-05-6, Didanosine 70458-96-7, Norfloxacin 70476-82-3, Mitoxantrone hydrochloride 72509-76-3,

Felodipine 72558-82-8, Ceftazidime 72956-09-3, Carvedilol
 73334-07-3, Iopromide 73573-87-2, Formoterol 73590-58-6, Omeprazole
 74103-06-3, Ketorolac 74191-85-8, Doxazosin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. comprising a polypeptide and an active agent)

IT 74356-00-6, Cefotetan disodium 74381-53-6, Leuprolide acetate 74469-00-4, Amoxicillin-potassium clavulanate mixture 75330-75-5, Lovastatin 75695-93-1, Isradipine 75706-12-6, Leflunomide 75847-73-3, Enalapril 75970-99-9, Norastemizole 76470-66-1, Loracarbef 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium 76820-74-1, Sodium meglumine ioxaglate 76824-35-6, Famotidine 76963-41-2, Nizatidine 78246-49-8, Paroxetine hydrochloride 78628-80-5, Terbinafine hydrochloride 78755-81-4, Flumazenil 79307-93-0, Azelastine hydrochloride 79350-37-1, Cefixime 79517-01-4, Octreotide acetate 79794-75-5, Loratadine 79902-63-9, Simvastatin 81098-60-4, Cisapride 81103-11-9, Clarithromycin 81129-83-1, Cilastatin sodium 81131-70-6, Pravastatin sodium 81409-90-7, Cabergoline 81627-83-0, M-CSF 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 82586-52-5, Moexipril hydrochloride 82586-55-8, Quinapril hydrochloride 82626-48-0, Zolpidem 82640-04-8, Raloxifene hydrochloride 82657-92-9, Prourokinase 82752-99-6, Nefazodone hydrochloride 83015-26-3, Tomoxetine 83881-52-1, Cetirizine hydrochloride 83905-01-5, Azithromycin 83928-66-9, Gepirone hydrochloride 84057-84-1, Lamotrigine 84485-00-7, Sibutramine hydrochloride 84625-61-6, Itraconazole 85650-52-8, Mirtazapine 85721-33-1, Ciprofloxacin 86050-77-3, Gadopentetate dimeglumine 86386-73-4, Fluconazole 86541-74-4, Benazepril hydrochloride 87239-81-4, Cefpodoxime proxetil 87333-19-5, Ramipril 87679-37-6, Trandolapril 90357-06-5, Bicalutamide 90566-53-3, Fluticasone 91374-20-8, Ropinirole hydrochloride 91421-42-0, Rubitecan 91832-40-5, Cefdinir 92134-98-0, Fosphenytoin sodium 92339-11-2, Iodixanol 92665-29-7, Cefprozil 93379-54-5, Esatenolol 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 95233-18-4, Atovaquone 95635-56-6, Ranolazine hydrochloride 95896-08-5, Anaritide 96036-03-2, Meropenem 96829-58-2, Orlistat 96946-42-8, Cisatracurium besylate 97240-79-4, Topiramate 97322-87-7, Troglitazone 97519-39-6, Ceftibuten 98048-97-6, Fosinopril 98319-26-7, Finasteride 98418-47-4, Metoprolol succinate 99300-78-4, Venlafaxine hydrochloride 99614-01-4, Ondansetron hydrochloride 100286-90-6, Irinotecan hydrochloride 100286-97-3, Milrinone lactate 100986-85-4, Levofloxacin 103475-41-8, Tepoxalin 103577-45-3, Lansoprazole 104227-87-4, Famciclovir 104632-25-9, Pramipexole dihydrochloride 106266-06-2, Risperidone 106392-12-5, Poloxamer 188 106861-44-3, Mivacurium chloride 107007-99-8, Granisetron hydrochloride 107753-78-6, Zafirlukast 111470-99-6, Amlodipine besylate 111974-72-2, Quetiapine fumarate 112108-01-7, Ecopipam 112529-15-4, Pioglitazone hydrochloride 112573-73-6, Ecadotril 112733-06-9, Zenarestat 113427-24-0, Epoetin alfa 114977-28-5, Docetaxel 115956-13-3, Dolasetron mesylate 116539-59-4, Duloxetine 117976-90-6, Rabeprazole sodium 118390-30-0, Interferon alfacon-1 119302-91-9, Rocuronium bromide 119413-54-6, Topotecan hydrochloride 120011-70-3, Donepezil hydrochloride 120066-54-8, Gadoteridol 120202-66-6, Clopidogrel bisulfate 120511-73-1, Anastrozole 120635-74-7, Cilansetron 121032-29-9, Nelarabine 121181-53-1D, PEGylated 121584-18-7, Valspodar 122111-03-9, Gemcitabine hydrochloride 123122-55-4, Candoxatril 123258-84-4, Itasetron 124584-08-3, Nesiritide 124750-99-8, Losartan potassium 124832-27-5, Valacyclovir hydrochloride 124937-52-6, Tolterodine tartrate 125317-39-7, Vinorelbine tartrate 126544-47-6, Ciclesonide 127254-12-0, Sitafloxacin 127779-20-8, Saquinavir 128298-28-2, Remacemide 128794-94-5, Mycophenolate mofetil 129318-43-0, Alendronate sodium 129580-63-8, Satraplatin 129618-40-2, Nevirapine 129722-12-9, Aripiprazole 130018-77-8, Levocetirizine 130325-35-8, PD 135158 131918-61-1, Paricalcitol 132449-46-8, Lesopitron 132539-06-1, Olanzapine 133107-64-9, Insulin lispro 133737-32-3, Pagoclone 134523-03-8, Atorvastatin calcium 134564-82-2, Befloxatone 134678-17-4, Lamivudine 135062-02-1, Repaglinide 135306-42-2, BW 1555U88 135354-02-8, Xaliproden 137234-62-9,

Voriconazole 137281-23-3, Pemetrexed 137862-53-4, Valsartan 138402-11-6, Irbesartan 138531-07-4, Sinapultide 138660-96-5, Sevirumab 139264-17-8, Zolmitriptan 140207-93-8, Pentosan polysulfate sodium 141579-67-1, A 78773 141732-76-5, Exendin-4 142340-99-6, Adefovir dipivoxil 142373-60-2, Tirofiban hydrochloride 142880-36-2, Ilomastat 143201-11-0, Cerivastatin sodium 143388-64-1, Naratriptan hydrochloride 144980-29-0, Repinotan 145040-37-5, Candesartan cilexetil 145202-66-0, Rizatriptan benzoate 145258-61-3, Interferon β 1 (human fibroblast protein moiety) 145375-43-5, Mitiglinide 145821-59-6, Tiagabine hydrochloride 145941-26-0, Oprelvekin 146479-72-3 147059-75-4, Trovafloxacin mesylate 147245-92-9, Glatiramer acetate 147536-97-8, Bosentan 148553-50-8, Pregabalin 148883-56-1, Tifacogin 149824-15-7, Ilodecakin 149845-06-7, Saquinavir mesylate 149950-60-7, Emivirine 151035-56-2 151063-30-8, Lisinopril-hydrochlorothiazide mixture 151319-34-5, Zaleplon 151767-02-1, Montelukast sodium 152751-57-0, Sevelamer hydrochloride 153168-05-9, Pleconaril 153259-65-5, Cilomilast 153438-49-4, Dapitant 153439-40-8, Fexofenadine hydrochloride 153773-82-1, MK 826 154039-60-8, Marimastat 154248-97-2, Imiglucerase 154361-50-9, Capecitabine 154598-52-4, Efavirenz 155141-29-0, Rosiglitazone maleate 155213-67-5, Ritonavir 156154-37-9, Losartan-hydrochlorothiazide mixture 157263-00-8, L 159282 157542-49-9, CS 834 157810-81-6, Indinavir sulfate 159989-65-8, Nelfinavir mesylate 160135-92-2 161814-49-9, Amprenavir 162011-90-7, Rofecoxib 162808-62-0, Caspofungin 164656-23-9, Dutasteride 166089-32-3, Lintuzumab 166374-48-7, CVT 124 166518-60-1, Avasimibe 169148-63-4, NN 304 169590-42-5, Celecoxib 170277-31-3, Infliximab 171228-49-2, Posaconazole 171599-83-0, Sildenafil citrate 178961-24-5, 264W94 179120-92-4, Altinicine 180288-69-1, Trastuzumab 181069-80-7, ALT 711 181695-72-7, Valdecocixib 182167-03-9, EM 800 183547-57-1, Gantofiban 183552-38-7, Abarelix 185243-69-0, Etanercept 187348-17-0, Edodekin alfa 187523-35-9, BMS 204352 188039-54-5, Palivizumab 188062-50-2, Abacavir sulfate 188627-80-7, Eptifibatide 189013-61-4, 4030W92 192329-42-3, Prinomastat 193079-69-5, Tabimorelin 198153-51-4, Peginterferon alfa-2a 198283-73-7, ABT 594 202138-50-9, Tenofovir disoproxil fumarate 202409-33-4, Etoricoxib 205110-48-1, ABT 773 208538-73-2, FK 463 210101-16-9, Conivaptan 223652-82-2, BMS 284756 332348-12-6, BMS 188667


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a polypeptide and an active agent)

IT 103-90-2, Acetaminophen

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT
(Reactant or reagent); USES (Uses)
(compns. comprising a polypeptide and an active agent)

RN 103-90-2 HCAPLUS

CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



IT 60-54-8, Tetracycline 67-20-9, Nitrofurantoin

87-08-1, Penicillin V 9041-92-3, . α .

1-Protease inhibitor 15686-71-2,

Cephalexin 26787-78-0, Amoxicillin 50370-12-2,

Cefadroxil 53994-73-3, Cefaclor 56238-63-2, Cefuroxime


sodium 72558-82-8, Ceftazidime 79350-37-1, Cefixime

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a polypeptide and an active agent)

RN 60-54-8 HCAPLUS


CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 67-20-9 HCAPLUS


CN 2,4-Imidazolidinedione, 1-[[[(5-nitro-2-furanyl)methylene]amino]- (9CI)
(CA INDEX NAME)



RN 87-08-1 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-
[(phenoxyacetyl)amino]-, (2S,5R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9041-92-3 HCAPLUS


CN Trypsin inhibitor, α1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 15686-71-2 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2R)-aminophenylacetyl]amino]-3-methyl-8-oxo-, (6R,7R)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 26787-78-0 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50370-12-2 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53994-73-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 56238-63-2 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[[[(aminocarbonyl)oxy]methyl]-7-[[[(2Z)-2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, monosodium salt, (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● Na


RN 72558-82-8 HCAPLUS
CN Pyridinium, 1-[[[(6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 79350-37-1 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(2-amino-4-thiazolyl)[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L70 ANSWER 5 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:332578 HCAPLUS
 DN 136:352301
 ED Entered STN: 03 May 2002
 TI HER-2/neu overexpression abrogates growth inhibitory pathways
 IN Slamon, Dennis J.; Wilson, Cindy A.; Calzone, Frank J.
 PA The Regents of the University of California, USA; Amgen Inc.
 SO U.S. Pat. Appl. Publ., 37 pp.
 CODEN: USXXCO

DT Patent

LA English

IC ICM A61K039-395

ICS A61K048-00

INCL 424145100

CC 9-10 (Biochemical Methods)

Section cross-reference(s): 1, 14, 15

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------|------|----------|-----------------|--------------|
| US 2002051785 | A1 | 20020502 | US 2001-813517 | 20010320 <-- |
| US 6767541 | B2 | 20040727 | | |
| PRAI US 2000-190598P | P | 20000320 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|--|
| US 2002051785 | ICM | A61K039-395 |
| | ICS | A61K048-00 |
| | INCL | 424145100 |
| US 2002051785 | NCL | 424/143.100; 424/130.100; 424/133.100; 424/141.100; 424/142.100; 424/152.100; 424/155.100; 424/156.100; 424/172.100; 424/174.100; 514/002.000; 530/387.100; 530/387.300; 530/387.700; 530/388.100; 530/388.150; 530/388.200; 530/388.220; 530/388.800; 530/388.850 |
| | ECLA | A61K039/395C3+M; C07K016/32; C12Q001/68M6B <-- |

AB The invention concerns immunol. methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods for inhibiting the growth of cancer cells that exhibit certain genetic profiles. These methods identify an important link between HER-2/neu overexpression and loss of growth inhibition by the TGF- β signaling pathway in cancer cells. Comps. as well as therapeutic and diagnostic methodologies based on this disclosure are provided.

ST breast cancer diagnosis immunoassay HER2 neu TGF expression array

IT Animal cell line

(BT20, (/H2); HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Affinity

DNA microarray technology
 Drug screening
 Human
 Mammalia
 Molecular association
 Molecular recognition
 Neoplasm
 Northern blot hybridization
 Nucleic acid hybridization
 (HER-2/neu overexpression abrogates growth inhibitory pathways)

IT mRNA
 RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Antibodies and Immunoglobulins
 RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Animal cell line
 (MCF-7, (/H2); HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Animal cell line
 (ZR-75-1, (/H2); HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Mammary gland
 (epithelium; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT neu (receptor)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (expression of; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Immunoassay
 (immunoblotting; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Cell proliferation
 Signal transduction, biological
 (inhibition of; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Mammary gland, neoplasm
 (malignant; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Epithelium
 (mammary; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Mammary gland
 (mesenchyme; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Antibodies and Immunoglobulins
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
 (monoclonal, 4D5; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Transforming growth factors
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (β 1-; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Transforming growth factors
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (β 2-; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT Transforming growth factors
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(β 3-; HER-2/neu overexpression abrogates growth inhibitory pathways)

IT 180288-69-1, Herceptin

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(HER-2/neu overexpression abrogates growth inhibitory pathways)

IT 140035-99-0, Genbank M19154 140770-05-4, Genbank M62826
182939-79-3, Genbank U29343 384421-02-7, Genbank M60316
384425-63-2, Genbank M65062 384430-35-7, Genbank M92934 384537-64-8,
Genbank L22548 385135-88-6, Genbank U83508 389190-15-2, Genbank X53587
391522-25-1, Genbank M29870 391523-97-0, Genbank J03241 391528-33-9,
Genbank X04434 391528-40-8, Genbank X51521 391528-52-2, Genbank X56807
391528-58-8, Genbank M59040 391532-29-9, Genbank M15990 391532-31-3,
Genbank K00650 391536-09-7, Genbank L03840 391538-48-0, Genbank Z18951
391545-64-5, Genbank Z29083 392009-79-9, Genbank AF000974 392209-70-0,
Genbank M81934

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(nucleotide sequence; HER-2/neu overexpression abrogates growth inhibitory pathways)

RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ala-Kokka, L; Biochem. J. 1989, V260, P509
- (2) Bae, S; Breast Cancer Res. Treat. 1993, V24, P241 MEDLINE
- (3) Barbara, N; J. Biol. Chem. 1999, V274(2), P584 HCAPLUS
- (4) Bartholomew, C; Oncogene 1997, V14, P569 HCAPLUS
- (5) Bellon, T; Eur. J. Immunol. 1993, V23, P2340 HCAPLUS
- (6) Bookman; Seminars in Oncology 1998, V25(3), P381 MEDLINE
- (7) Bork, P; FEBS Lett 1993, V327(2), P125 HCAPLUS
- (8) Bradham, D; J Cell Biol 1991, V114(6), P1285 HCAPLUS
- (9) Brunner, A; DNA Cell Biol 1991, V10(4), P293 HCAPLUS
- (10) Celeste, A; Proc Natl Acad Sci USA 1990, V87, P9843 HCAPLUS
- (11) Chen, N; J Biol Chem 2000, V275(32), P24953 HCAPLUS
- (12) Davis, S; Cell 1996, V87, P1161 HCAPLUS
- (13) Didsbury, J; J Biol Chem 1989, V264(28), P16378 HCAPLUS
- (14) Dijke, P; Proc Natl Acad Sci 1988, V85, P4715
- (15) Galaktionov, K; Cell 1991, V67, P1181 HCAPLUS
- (16) Glenney, J; FEBS Lett 1992, V314(1), P45 HCAPLUS
- (17) Gould, K; EMBO J 1989, V8(13), P4133 HCAPLUS
- (18) Graves, M; Proc Natl Acad Sci USA 1985, V82, P1653 HCAPLUS
- (19) Greenspan, D; J Biol Chem 1991, V266(36), P24727 HCAPLUS
- (20) Grotendorst, G; Cytokine Growth Factor Rev 1997, V8(3), P171 HCAPLUS
- (21) Harn, H; Biochem Biophys Res Commun 1991, V178(3), P1127 HCAPLUS
- (22) Hirai, H; Int J Biochem Cell Bio 1999, V31, P1367 HCAPLUS
- (23) Hudziak; US 5720954 A 1998 HCAPLUS
- (24) Inoue, A; J Biol Chem 1989, V264(25), P14954 HCAPLUS
- (25) Kiefer, M; Biochem Biophys Res Commun 1991, V176(1), P219 HCAPLUS
- (26) Kireeva, M; Mol Cell Biol 1996, V16(4), P1326 HCAPLUS
- (27) Kornblihtt, A; Proc Natl Acad Sci USA 1983, V80, P3218 HCAPLUS
- (28) Kretzschmar, M; Genes and Dev 1999, V13, P804 HCAPLUS
- (29) Kurokawa, M; Nature 1998, V394, P92 HCAPLUS
- (30) Letamendia, A; J. Biol. Chem. 1998, V273(49), P33011 HCAPLUS
- (31) Lewis, G; Cancer Immunol. Immunother. 1993, V37, P255 HCAPLUS
- (32) Lin, H; Cell 1992, V68, P775 HCAPLUS
- (33) Lin, H; Mol Reprod Dev 1992, V32, P105 HCAPLUS
- (34) Madisen, L; DNA 1988, V7(1), P1 HCAPLUS
- (35) Marquardt; US 5120535 A 1992 HCAPLUS
- (36) Massague, J; Cell 1992, V69, P1067 HCAPLUS
- (37) Murthy, K; J Bio Chem 1999, V274(29), P20679 HCAPLUS
- (38) Myers, K; J Biol Chem 1999, V274(12), P9319 HCAPLUS
- (39) Newman; US 5147854 A 1992 HCAPLUS
- (40) Nucifora, G; Leukemia 1997, V11, P2022 HCAPLUS
- (41) Ny, T; Proc Natl Acad Sci USA 1986, V83, P6776 HCAPLUS
- (42) Ogasa, H; Gene 1996, V181, P185 HCAPLUS
- (43) Ogawa, S; Oncogene 1996, V13, P183 HCAPLUS
- (44) Oh, S; Genomics 1994, V19, P494 HCAPLUS

(45) Park, B; Nat Biotechnol 2000, V18, P194 HCAPLUS
 (46) Parker, A; J Biol Chem 1991, V266(16), P10438 HCAPLUS
 (47) Perrella, M; Miner Electrolyte Metal 1998, V24, P136 HCAPLUS
 (48) Piek, E; J. Cell Science 1999, V112, P4557 HCAPLUS
 (49) Ralph, D; Proc Natl Acad Sci USA 1993, V90, P10710 HCAPLUS
 (50) Roberts, A; Microbes Infect 1999, V1, P1265 HCAPLUS
 (51) Ron, D; J Biol Chem 1993, V268(8), P5386
 (52) Shimizu, N; J Biochem 1992, V111, P272 HCAPLUS
 (53) Skonier, J; DNA Cell Biol 1992, V11(7), P511 HCAPLUS
 (54) Stetler-Stevenson, W; J Biol Chem 1990, V265(23), P13933 HCAPLUS
 (55) Straaten, F; Proc Natl Acad Sci USA 1983, V80, P3183
 (56) Sukegawa, J; Mol Cell Biol 1987, V7(1), P41 HCAPLUS
 (57) Tamura, R; J Cell Biol 1990, V111, P1593 HCAPLUS
 (58) Ullrich, A; EMBO J 1986, V5(10), P2503 HCAPLUS
 (59) Wang, C; Gene 1996, V174, P299 HCAPLUS
 (60) Wiener, J; Current Opinion in Oncology 1992, V4, P946 MEDLINE
 (61) Wozney, J; Science 1988, V242, P1528 HCAPLUS
 (62) Yamashita, H; J. Biol. Chem. 1994, V269(3), P1995 HCAPLUS
 IT 140035-99-0, Genbank M19154 384421-02-7, Genbank M60316
 RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL
 (Biological study); USES (Uses)
 (nucleotide sequence; HER-2/neu overexpression abrogates growth
 inhibitory pathways)
 RN 140035-99-0 HCAPLUS
 CN DNA (human PC-3 cell clone λ -PC21 transforming growth factor
 β 2 cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 384421-02-7 HCAPLUS
 CN DNA (human gene $\text{tgf-}\beta$ transforming growth factor β cDNA plus
 flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 6 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:332011 HCAPLUS
 DN 136:355482
 ED Entered STN: 03 May 2002
 TI Compositions comprising a polypeptide and an active agent
 IN Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall J.
 PA New River Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K009-14
 ICS A61K009-22; A61K009-50; A61K047-42; C07K001-02; C07K001-13
 CC 34-3 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 1, 63
 FAN.CNT 12

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|--|--------------|
| WO 2002034237 | A1 | 20020502 | WO 2001-US26142 | 20010822 <-- |
| W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | |
| US 6716452 | B1 | 20040406 | US 2000-642820 | 20000822 <-- |
| CA 2420590 | AA | 20020502 | CA 2001-2420590 | 20010822 <-- |
| AU 2001086599 | A5 | 20020506 | AU 2001-86599 | 20010822 <-- |
| EP 1311242 | A1 | 20030521 | EP 2001-966056 | 20010822 <-- |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | |
|---------------------|----|----------|----------------|--------------|
| JP 2004523480 | T2 | 20040805 | JP 2002-537291 | 20010822 <-- |
| US 2004127397 | A1 | 20040701 | US 2003-727565 | 20031205 <-- |
| PRAI US 2000-642820 | A | 20000822 | <-- | |
| US 2000-247613P | P | 20001114 | <-- | |
| US 2000-247614P | P | 20001114 | <-- | |
| US 2000-247615P | P | 20001114 | <-- | |
| US 2000-247616P | P | 20001114 | <-- | |
| US 2000-247617P | P | 20001114 | <-- | |
| US 2000-247622P | P | 20001114 | <-- | |
| US 2000-247630P | P | 20001114 | <-- | |
| US 2000-247631P | P | 20001114 | <-- | |
| US 2000-247632P | P | 20001114 | <-- | |
| US 2000-247633P | P | 20001114 | <-- | |
| US 2000-247556P | P | 20001114 | <-- | |
| US 2000-247558P | P | 20001114 | <-- | |
| US 2000-247559P | P | 20001114 | <-- | |
| US 2000-247560P | P | 20001114 | <-- | |
| US 2000-247561P | P | 20001114 | <-- | |
| US 2000-247594P | P | 20001114 | <-- | |
| US 2000-247595P | P | 20001114 | <-- | |
| US 2000-247606P | P | 20001114 | <-- | |
| US 2000-247607P | P | 20001114 | <-- | |
| US 2000-247608P | P | 20001114 | <-- | |
| US 2000-247609P | P | 20001114 | <-- | |
| US 2000-247610P | P | 20001114 | <-- | |
| US 2000-247611P | P | 20001114 | <-- | |
| US 2000-247612P | P | 20001114 | <-- | |
| US 2000-247620P | P | 20001114 | <-- | |
| US 2000-247621P | P | 20001114 | <-- | |
| US 2000-247634P | P | 20001114 | <-- | |
| US 2000-247635P | P | 20001114 | <-- | |
| US 2000-247698P | P | 20001114 | <-- | |
| US 2000-247699P | P | 20001114 | <-- | |
| US 2000-247701P | P | 20001114 | <-- | |
| US 2000-247702P | P | 20001114 | <-- | |
| US 2000-247797P | P | 20001114 | <-- | |
| US 2000-247798P | P | 20001114 | <-- | |
| US 2000-247799P | P | 20001114 | <-- | |
| US 2000-247800P | P | 20001114 | <-- | |
| US 2000-247801P | P | 20001114 | <-- | |
| US 2000-247802P | P | 20001114 | <-- | |
| US 2000-247803P | P | 20001114 | <-- | |
| US 2000-247804P | P | 20001114 | <-- | |
| WO 2001-US26142 | W | 20010822 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES | |
|---------------|-------|--|-----|
| WO 2002034237 | ICM | A61K009-14 | |
| | ICS | A61K009-22; A61K009-50; A61K047-42; C07K001-02; C07K001-13 | |
| WO 2002034237 | ECLA | A61K047/48R | <-- |
| US 6716452 | NCL | 424/457.000; 424/468.000; 514/002.000; 530/300.000; 530/345.000 | |
| | ECLA | A61K047/48R | <-- |
| JP 2004523480 | FTERM | 4C076/AA12; 4C076/AA22; 4C076/AA36; 4C076/AA95; 4C076/BB01; 4C076/BB11; 4C076/CC01; 4C076/CC05; 4C076/CC11; 4C076/CC15; 4C076/CC27; 4C076/CC30; 4C076/CC32; 4C076/CC41; 4C076/EE41; 4C076/EE59; 4C076/FF63 | <-- |
| US 2004127397 | NCL | 514/002.000 | |
| | ECLA | A61K047/48R | <-- |

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The

peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalixin hydrochloride.

- ST peptide conjugate drug prodrug
- IT CD22 (antigen)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LYM-1; compns. comprising a polypeptide and an active agent)
- IT Oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antisense; compns. comprising a polypeptide and an active agent)
- IT Drugs
Human
Vaccines
(compns. comprising a polypeptide and an active agent)
- IT Peptides, preparation
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. comprising a polypeptide and an active agent)
- IT Estrogens
Interleukin 2
Polyoxyalkylenes, biological studies
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a polypeptide and an active agent)
- IT Drug delivery systems
(prodrugs; compns. comprising a polypeptide and an active agent)
- IT 330600-85-6, BCX 1812
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BCX 1812; compns. comprising a polypeptide and an active agent)
- IT 176960-47-7, BMS 193884
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BMS 193884; compns. comprising a polypeptide and an active agent)
- IT 154802-96-7, GM 611
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GM 611; compns. comprising a polypeptide and an active agent)
- IT 222535-22-0, LFA 3TIP
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LFA 3TIP; compns. comprising a polypeptide and an active agent)
- IT 106463-17-6, Tamsulosin hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Tamsulosin hydrochloride; compns. comprising a polypeptide and an active agent)
- IT 61512-21-8, Thymosin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alpha; compns. comprising a polypeptide and an active agent)
- IT 56-84-8P, L-Aspartic acid, preparation 59-92-7DP, polyglutamic acid derivs. 443-48-1DP, polyglutamic acid derivs. 3056-17-5DP, polyglutamic acid derivs. 7481-89-2DP, polyglutamic acid derivs. 22204-53-1DP, polylysine derivs. 24991-23-9DP, drug conjugate derivs. 25812-30-0DP, polylysine derivs. 29122-68-7DP, polyglutamic derivs. 31631-78-4DP, reaction products with cephalixin 31724-47-7DP, reaction products with cephalixin 59277-89-3DP, polyglutamic acid derivs. 73573-88-3DP, acetylated polyglutamic derivs. 76584-70-8DP, polylysine derivs. 83799-24-0DP, polyglutamic acid derivs. 104400-30-8P 420824-33-5P 420824-50-6P 420824-76-6P 420824-81-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. comprising a polypeptide and an active agent)
- IT 51-48-9, Thyroxine, reactions 61-90-5, Leucine, reactions 63-68-3, L-Methionine, reactions 63-91-2, L-Phenylalanine, reactions 73-32-5, L-Isoleucine, reactions 99-66-1, Valproic acid 492-62-6, α -D Glucose 1676-73-9 2418-95-3 3057-74-7 4125-79-5 4378-13-6 6893-02-3 13726-84-6 16590-41-3, Naltrexone 18822-58-7 25718-94-9

25734-27-4, Poly[imino(1-oxo-1,2-ethanediyl)] 25812-30-0, Gemfibrozil

25988-63-0 26386-88-9, Diphenylphosphoryl azide 34582-32-6

51219-19-3 81659-82-7 104400-52-4 146645-63-8 340816-48-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(compns. comprising a polypeptide and an active agent)

IT 56-41-7P, L-Alanine, preparation 72-18-4P, L-Valine, preparation
3190-71-4P 14825-82-2P 16617-07-5P 20700-95-2P 22204-53-1P,
Naproxen 24937-47-1P 24991-23-9P 25014-27-1P, .γ.-Benzyl
glutamate homopolymer 25038-53-3P, .γ.-Benzyl L-glutamate
homopolymer, SRU 25212-18-4P 25248-59-3DP, iodotyrosine-capped derivs.
25249-36-9P 25322-63-8DP, iodotyrosine-capped derivs. 25513-46-6P,
Polyglutamic acid 25608-40-6P, Polyaspartic acid 25667-19-ODP,
iodotyrosine-capped derivs. 25821-52-7P, Polyserine 25821-94-7P,
Polyserine 26063-13-8P 26588-20-5P 26854-80-8DP, iodotyrosine-capped
derivs. 29435-39-OP 31764-54-2P 33043-60-6P 33540-31-7DP,
iodotyrosine-capped derivs. 38000-06-5DP, Ibuprofen derivs.
38000-06-5DP, iodotyrosine-capped derivs. 56210-05-OP 56218-11-2P,
Polythreonine 82822-12-6P, Polythreonine 86409-29-2P 114994-77-3P
119739-55-8DP, iodotyrosine-capped derivs. 125780-85-OP 125780-86-1P
129288-31-9P 137132-61-7P 137132-62-8P 148085-06-7P 148230-67-5P
340816-48-ODP, polyglycine derivs. 420824-10-8P 420824-13-1P
420824-15-3P 420824-17-5P 420824-18-6P 420824-20-OP 420824-28-8P
420824-30-2P 420824-36-8P 420824-38-OP 420824-40-4P 420824-43-7P
420824-56-2P 420824-64-2P 420824-72-2DP, iodotyrosine-capped derivs.
420824-74-4P 420824-79-9P 420824-83-5P 420824-85-7P 421555-53-5P
421555-54-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(compns. comprising a polypeptide and an active agent)

IT 53-03-2, Prednisone 58-32-2, Dipyridamole 59-92-7, reactions
103-90-2, Acetaminophen 443-48-1, Metronidazole 3056-17-5,
Stavudine 7481-89-2, Zalcitabine 15687-27-1, Ibuprofen 29122-68-7,
Atenolol 30516-87-1, Azt 59277-89-3, Acyclovir 59695-59-9,
Cephalexin hydrochloride 73573-88-3, Mevastatin 79559-97-0, Sertraline
hydrochloride 83799-24-0, Fexofenadine

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT
(Reactant or reagent); USES (Uses)

(compns. comprising a polypeptide and an active agent)

IT 420824-87-9P
RL: SPN (Synthetic preparation); PREP (Preparation)

(compns. comprising a polypeptide and an active agent)

IT 50-06-6, Phenobarbital, biological studies 50-18-0, Cyclophosphamide
50-35-1, Thalidomide 50-44-2, Mercaptopurine 50-78-2, Acetylsalicylic
acid 50-81-7, Vitamin C, biological studies 51-21-8, Fluorouracil
51-61-6, Dopamine, biological studies 51-63-8, Dextroamphetamine sulfate
51-98-9, Norethindrone acetate 52-01-7, Spironolactone 52-24-4,
Thiotepa 52-86-8, Haloperidol 53-36-1, Methylprednisolone Acetate
54-31-9, Furosemide 55-63-0, Nitroglycerin 57-63-6, Ethinyl estradiol
58-08-2, Caffeine, biological studies 58-18-4, Methyltestosterone
58-25-3, Chlordiazepoxide 58-33-3, Promethazine hydrochloride 58-55-9,
Theophylline, biological studies 58-61-7, Adenosine, biological studies
58-93-5, Hydrochlorothiazide 59-42-7, Phenylephrine 60-54-8,
Tetracycline 60-87-7, Promethazine 64-31-3, Morphine Sulfate
67-20-9, Nitrofurantoin 67-92-5, Dicyclomine hydrochloride
68-19-9, Vitamin B12 68-22-4, Norethindrone 71-58-9,
Medroxyprogesterone acetate 71-68-1, Hydromorphone hydrochloride
74-79-3, Arginine, biological studies 76-41-5, Oxymorphone 76-42-6,
Oxycodone 76-58-4, Ethylmorphine 78-44-4, Carisoprodol 84-02-6,
Prochlorperazine maleate 87-08-1, Penicillin V 87-33-2,
Isosorbide Dinitrate 89-57-6, Mesalamine 90-82-4, Pseudoephedrine
93-14-1, Guaifenesin 113-45-1, Methylphenidate 113-52-0 113-92-8,
Chlorpheniramine maleate 114-07-8, Erythromycin 124-90-3, Oxycodone
hydrochloride 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone
125-33-7, Primidone 125-71-3, Dextromethorphan 128-13-2, Ursodiol
129-06-6, Warfarin Sodium 132-17-2, Benztropine methanesulfonate
132-22-9, Chlorpheniramine 143-52-2, Methyldihydromorphinone 143-71-5,

Hydrocodone bitartrate 152-11-4, Verapamil hydrochloride 297-76-7,
 Ethynodiol diacetate 298-46-4, Carbamazepine 298-59-9, Methylphenidate
 hydrochloride 303-49-1, Clomipramine 315-30-0, Allopurinol 318-98-9,
 Propranolol Hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine
 Tartrate 437-38-7, Fentanyl 439-14-5, Diazepam 446-86-6,
 Azathioprine 466-99-9, Hydromorphone 469-62-5, Propoxyphene
 509-60-4, Dihydromorphone 514-36-3, Fludrocortisone acetate 541-15-1,
 Levocarnitine 549-18-8, Amitriptyline hydrochloride 554-13-2, Lithium
 Carbonate 561-27-3, Diacetylmorphine 595-33-5, Megestrol acetate
 604-75-1, Oxazepam 630-93-3, Sodium phenytoin 657-24-9, Metformin
 745-65-3, Alprostadil 747-36-4, Hydroxychloroquine sulfate 797-63-7,
 Levonorgestrel 846-49-1, Lorazepam 846-50-4, Temazepam 894-71-3,
 Nortriptyline hydrochloride 959-24-0, Sotalol hydrochloride 1134-47-0,
 Baclofen 1403-66-3, Gentamicin 1404-93-9, Vancomycin hydrochloride
 1501-84-4, Rimantadine hydrochloride 1508-65-2, Oxybutynin chloride
 1622-61-3, Clonazepam 1665-48-1, Metaxalone 1744-22-5, Riluzole
 1951-25-3, Amiodarone 2078-54-8, Propofol 2152-34-3, Pemoline
 2375-03-3, Methylprednisolone sodium succinate 4205-91-8 4682-36-4,
 Orphenadrine citrate 4759-48-2, Isotretinoin 5786-21-0, Clozapine
 6202-23-9, Cyclobenzaprine hydrochloride 6493-05-6, Pentoxifylline
 6533-00-2, Norgestrel 7280-37-7, Estropipate 7414-83-7, Etidronate
 disodium 9002-60-2, Adrenocorticotrophic hormone, biological studies
 9002-69-1, Relaxin 9005-49-6, Heparin, biological studies 9014-42-0,
 Thrombopoietin 9039-53-6, Urokinase 9041-08-1, Dalteparin sodium
 9041-92-3, α 1-Protease
 inhibitor 9080-79-9, Sodium polystyrene sulfonate 10238-21-8,
 Glyburide 11005-12-2, β -Phytosterol 11056-06-7, Bleomycin
 11140-85-5, Glucagon hydrochloride 13311-84-7, Flutamide 13614-98-7,
 Minocycline hydrochloride 14124-50-6, Hydrochlorothiazide-triamterene
 mixture 14611-52-0, Selegiline hydrochloride 14838-15-4,
 Phenylpropanolamine 15307-79-6, Diclofenac sodium 15663-27-1,
 Cisplatin 15686-71-2, Cephalixin 17140-78-2, Propoxyphene
 napsylate 17560-51-9, Metolazone 18559-94-9, Albuterol 19767-45-4,
 Mesna 20537-88-6, Amifostine 20830-75-5, Digoxin 21062-37-3D,
 analogs 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22071-15-4,
 Ketoprofen 23031-32-5, Terbutaline sulfate 25316-40-9, Doxorubicin
 hydrochloride 25322-68-3, Polyethylene glycol 25332-39-2, Trazodone
 hydrochloride 25614-03-3, Bromocriptine 26159-34-2, Naproxen sodium
 26787-78-0, Amoxicillin 27164-46-1, Cefazolin sodium
 27314-97-2, Tirapazamine 28860-95-9, Carbidopa 28981-97-7, Alprazolam
 29094-61-9, Glipizide 29354-16-3, Thyronine, iodo- 31677-93-7,
 Bupropion hydrochloride 32222-06-3, Calcitriol 32780-64-6, Labetalol
 hydrochloride 33069-62-4, Paclitaxel 33286-22-5, Diltiazem
 hydrochloride 33419-42-0, Etoposide 33564-30-6, Cefoxitin sodium
 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen 35189-28-7,
 Norgestimate 36282-47-0, Tramadol hydrochloride 36505-84-7, Buspirone
 36791-04-5, Ribavirin 37296-80-3, Colestipol hydrochloride 38398-32-2,
 Ganaxolone 41340-25-4, Etodolac 41575-94-4, Carboplatin 42200-33-9,
 Nadolol 42617-41-4, Activated protein C 42924-53-8, Nabumetone
 49562-28-9, Fenofibrate 49842-07-1, Tobramycin sulfate
 50370-12-2, Cefadroxil 50700-72-6, Vecuronium bromide
 51321-79-0, Sparfosic acid 51481-61-9, Cimetidine 51773-92-3,
 Mefloquine hydrochloride 52232-67-4, Teriparatide 53885-35-1,
 Ticlopidine hydrochloride 53994-73-3, Cefaclor 54024-22-5,
 Desogestrel 54143-56-5, Flecainide acetate 54182-58-0, Sucralfate
 54910-89-3, Fluoxetine 54965-24-1, Tamoxifen citrate 55079-83-9,
 Acitretin 56180-94-0, Acarbose 56238-63-2, Cefuroxime sodium
 57109-90-7, Clorazepate dipotassium 57248-88-1, Pamidronate disodium
 57852-57-0, Idarubicin hydrochloride 58579-51-4, Anagrelide
 hydrochloride 58786-99-5, Butorphanol tartrate 59122-46-2, Misoprostol
 59703-84-3, Piperacillin sodium 59729-32-7, Citalopram hydrobromide
 59865-13-3, Cyclosporin 59989-18-3, Eniluracil 60142-96-3, Gabapentin
 60205-81-4, Ipratropium 60748-06-3, Gastrin 17 61718-82-9, Fluvoxamine
 maleate 62288-83-9, Desmopressin acetate 62571-86-2, Captopril
 63074-08-8, Terazosin hydrochloride 63675-72-9, Nisoldipine
 64221-86-9, Imipenem 64461-82-1, Tizanidine hydrochloride 64485-93-4,

Cefotaxime sodium 64544-07-6, Cefuroxime axetil 65277-42-1,
 Ketoconazole 65646-68-6, Fenretinide 65807-02-5, Goserelin
 66085-59-4, Nimodipine 66104-22-1, Pergolide 66357-35-5, Ranitidine
 66722-44-9, Bisoprolol 67889-72-9, Acetaminophen-codeine phosphate mixture
 67992-58-9, Sodium ioxaglate 68562-41-4, Mecasermin 68693-11-8,
 Modafinil 68844-77-9, Astemizole 69655-05-6, Didanosine 70458-96-7,
 Norfloxacin 70476-82-3, Mitoxantrone hydrochloride 72509-76-3,
 Felodipine 72558-82-8, Ceftazidime 72956-09-3, Carvedilol
 73334-07-3, Iopromide 73573-87-2, Formoterol 73590-58-6, Omeprazole
 74103-06-3, Ketorolac

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comps. comprising a polypeptide and an active agent)

IT 74191-85-8, Doxazosin 74356-00-6, Cefotetan disodium 74381-53-6,
 Leuprolide acetate 74469-00-4, Amoxicillin-potassium clavulanate mixture
 75330-75-5, Lovastatin 75695-93-1, Isradipine 75706-12-6, Leflunomide
 75847-73-3, Enalapril 75970-99-9, Norastemizole 76470-66-1, Loracarbef
 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium 76820-74-1,
 Sodium meglumine ioxaglate 76824-35-6, Famotidine 76963-41-2,
 Nizatidine 78246-49-8, Paroxetine hydrochloride 78628-80-5,
 Terbinafine hydrochloride 78755-81-4, Flumazenil 79307-93-0,
 Azelastine hydrochloride 79350-37-1, Cefixime 79517-01-4,
 Octeotide acetate 79794-75-5, Loratadine 79902-63-9, Simvastatin
 81098-60-4, Cisapride 81103-11-9, Clarithromycin 81129-83-1,
 Cilastatin sodium 81131-70-6, Pravastatin sodium 81409-90-7,
 Cabergoline 81627-83-0, M-CSF 82410-32-0, Ganciclovir 82419-36-1,
 Ofloxacin 82586-52-5, Moexipril hydrochloride 82586-55-8, Quinapril
 hydrochloride 82626-48-0, Zolpidem 82640-04-8, Raloxifene
 hydrochloride 82657-92-9, Prourokinase 82752-99-6, Nefazodone
 hydrochloride 83015-26-3, Tomoxetine 83881-52-1, Cetirizine
 hydrochloride 83905-01-5, Azithromycin 83928-66-9, Gepirone
 hydrochloride 84057-84-1, Lamotrigine 84485-00-7, Sibutramine
 hydrochloride 84625-61-6, Itraconazole 85650-52-8, Mirtazapine
 85721-33-1, Ciprofloxacin 86050-77-3, Gadopentetate dimeglumine
 86386-73-4, Fluconazole 86541-74-4, Benazepril hydrochloride
 87239-81-4, Cefpodoxime proxetil 87333-19-5, Ramipril 87679-37-6,
 Trandolapril 90357-06-5, Bicalutamide 90566-53-3, Fluticasone
 91374-20-8, Ropinirole hydrochloride 91421-42-0, Rubitecan 91832-40-5,
 Cefdinir 92134-98-0, Fosphenytoin sodium 92339-11-2, Iodixanol
 92665-29-7, Cefprozil 93379-54-5, Esatenolol 93479-97-1, Glimepiride
 93957-54-1, Fluvastatin 95233-18-4, Atovaquone 95635-56-6, Ranolazine
 hydrochloride 95896-08-5, Anaritide 96036-03-2, Meropenem
 96829-58-2, Orlistat 96946-42-8, Cisatracurium besylate 97240-79-4,
 Topiramate 97322-87-7, Troglitazone 97519-39-6, Ceftibuten
 98048-97-6, Fosinopril 98319-26-7, Finasteride 98418-47-4, Metoprolol
 succinate 99300-78-4, Venlafaxine hydrochloride 99614-01-4,
 Ondansetron hydrochloride 100286-90-6, Irinotecan hydrochloride
 100286-97-3, Milrinone lactate 100986-85-4, Levofloxacin 103475-41-8,
 Tepoxalin 103577-45-3, Lansoprazole 104227-87-4, Famciclovir
 104632-25-9, Pramipexole dihydrochloride 106266-06-2, Risperidone
 106392-12-5, Poloxamer 188 106861-44-3, Mivacurium chloride
 107007-99-8, Granisetron hydrochloride 107753-78-6, Zafirlukast
 111470-99-6, Amlodipine besylate 111974-72-2, Quetiapine fumarate
 112108-01-7, Ecopipam 112529-15-4, Pioglitazone hydrochloride
 112573-73-6, Ecadotril 112733-06-9, Zenarestat 113427-24-0, Epoetin
 alfa 114977-28-5, Docetaxel 115956-13-3, Dolasetron mesylate
 116539-59-4, Duloxetine 117976-90-6, Rabeprazole sodium 118390-30-0,
 Interferon alfacon-1 119302-91-9, Rocuronium bromide 119413-54-6,
 Topotecan hydrochloride 120011-70-3, Donepezil hydrochloride
 120066-54-8, Gadoteridol 120202-66-6, Clopidogrel bisulfate
 120511-73-1, Anastrozole 120635-74-7, Cilansetron 121032-29-9,
 Nelarabine 121181-53-1D, PEGylated 121584-18-7, Valspodar
 122111-03-9, Gemcitabine hydrochloride 123122-55-4, Candoxatril
 123258-84-4, Itasetron 124584-08-3, Nesiritide 124750-99-8, Losartan
 potassium 124832-27-5, Valacyclovir hydrochloride 124937-52-6,
 Tolterodine tartrate 125317-39-7, Vinorelbine tartrate 126544-47-6,
 Ciclesonide 127254-12-0, Sitafloxacin 127779-20-8, Saquinavir

128298-28-2, Remacemide 128794-94-5, Mycophenolate mofetil
 129318-43-0, Alendronate sodium 129580-63-8, Satraplatin 129618-40-2,
 Nevirapine 129722-12-9, Aripiprazole 130018-77-8, Levocetirizine
 130325-35-8, PD 135158 131918-61-1, Paricalcitol 132449-46-8,
 Lesopitron 132539-06-1, Olanzapine 133107-64-9, Insulin lispro
 133737-32-3, Pagoclone 134523-03-8, Atorvastatin calcium 134564-82-2,
 Befloxatone 134678-17-4, Lamivudine 135062-02-1, Repaglinide
 135306-42-2, BW 1555U88 135354-02-8, Xaliproden 137234-62-9,
 Voriconazole 137281-23-3, Pemetrexed 137862-53-4, Valsartan
 138402-11-6, Irbesartan 138531-07-4, Sinapultide 138660-96-5,
 Sevirumab 139264-17-8, Zolmitriptan 140207-93-8, Pentosan polysulfate
 sodium 141579-67-1, A 78773 141732-76-5, Exendin-4 142340-99-6,
 Adefovir dipivoxil 142373-60-2, Tirofiban hydrochloride 142880-36-2,
 Ilomastat 143201-11-0, Cerivastatin sodium 143388-64-1, Naratriptan
 hydrochloride 144980-29-0, Repinotan 145040-37-5, Candesartan
 cilexetil 145202-66-0, Rizatriptan benzoate 145258-61-3, Interferon
 β 1 (human fibroblast protein moiety) 145375-43-5, Mitiglinide
 145821-59-6, Tiagabine hydrochloride 145941-26-0, Oprelvekin
 146479-72-3 147059-75-4, Trovafloxacin mesylate 147245-92-9,
 Glatiramer acetate 147536-97-8, Bosentan 148553-50-8, Pregabalin
 148883-56-1, Tifacogin 149824-15-7, Ilodecakin 149845-06-7, Saquinavir
 mesylate 149950-60-7, Emivirine 151035-56-2 151063-30-8,
 Lisinopril-hydrochlorothiazide mixture 151319-34-5, Zaleplon
 151767-02-1, Montelukast sodium 152751-57-0, Sevelamer hydrochloride
 153168-05-9, Pleconaril 153259-65-5, Cilomilast 153438-49-4, Dapitant
 153439-40-8, Fexofenadine hydrochloride 153773-82-1, MK 826
 154039-60-8, Marimastat 154248-97-2, Imiglucerase 154361-50-9,
 Capecitabine 154598-52-4, Efavirenz 155141-29-0, Rosiglitazone maleate
 155213-67-5, Ritonavir 156154-37-9, Losartan-hydrochlorothiazide mixture
 157263-00-8, L 159282 157542-49-9, CS 834 157810-81-6, Indinavir
 sulfate 159989-65-8, Nelfinavir mesylate 160135-92-2 161814-49-9,
 Amprenavir 162011-90-7, Rofecoxib 162808-62-0, Caspofungin
 164656-23-9, Dutasteride 166089-32-3, Lintuzumab 166374-48-7, CVT 124
 166518-60-1, Avasimibe 169148-63-4, NN 304 169590-42-5, Celecoxib
 170277-31-3, Infliximab 171228-49-2, Posaconazole 171599-83-0,
 Sildenafil citrate 178961-24-5, 264W94 179120-92-4, Altinicine
 180288-69-1, Trastuzumab 181069-80-7, ALT 711 181695-72-7, Valdecocixib
 182167-03-9, EM 800 183547-57-1, Gantofiban 183552-38-7, Abarelix
 185243-69-0, Etanercept 187348-17-0, Edodekin alfa 187523-35-9, BMS
 204352 188039-54-5, Palivizumab 188062-50-2, Abacavir sulfate
 188627-80-7, Eptifibatide 189013-61-4, 4030W92 192329-42-3,
 Prinomastat 193079-69-5, Tabimorelin 198153-51-4, Peginterferon
 alfa-2a 198283-73-7, ABT 594 202138-50-9, Tenofovir disoproxil
 fumarate 202409-33-4, Etoricoxib 205110-48-1, ABT 773 208538-73-2,
 FK 463 210101-16-9, Conivaptan 223652-82-2, BMS 284756 332348-12-6,
 BMS 188667

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. comprising a polypeptide and an active agent)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Garsky; US 5948750 A 1999 HCAPLUS
- (2) Hirschmann; US 3846399 A 1974 HCAPLUS
- (3) Katz; US 6005004 A 1999 HCAPLUS
- (4) Myers; US 5087616 A 1992 HCAPLUS
- (5) Peterson; US 4356166 A 1982 HCAPLUS
- (6) Schmidt; Journal Of Medicinal Chemistry 1994, V37(22), P3812 HCAPLUS
- (7) Summerton; US 6030941 A 2000 HCAPLUS
- (8) Swadesh; US 5898033 A 1999 HCAPLUS
- (9) The University Of Birmingham; WO 9736616 A2 1997 HCAPLUS
- (10) Toth; US 5882645 A 1999 HCAPLUS
- (11) Wallace; US 5238714 A 1993 HCAPLUS

IT 103-90-2, Acetaminophen

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT
 (Reactant or reagent); USES (Uses)
 (compns. comprising a polypeptide and an active agent)


RN 103-90-2 HCAPLUS

CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




IT 60-54-8, Tetracycline 67-20-9, Nitrofurantoin
 87-08-1, Penicillin V 9041-92-3, .α.
 1-Protease inhibitor 15686-71-2,
 Cephalexin 26787-78-0, Amoxicillin 50370-12-2,
 Cefadroxil 53994-73-3, Cefaclor 56238-63-2, Cefuroxime
 sodium 72558-82-8, Ceftazidime 79350-37-1, Cefixime
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. comprising a polypeptide and an active agent)
 RN 60-54-8 HCAPLUS
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
 3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 67-20-9 HCAPLUS
 CN 2,4-Imidazolidinedione, 1-[[[(5-nitro-2-furanyl)methylene]amino]- (9CI)
 (CA INDEX NAME)



RN 87-08-1 HCAPLUS
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-
 [(phenoxyacetyl)amino]-, (2S,5R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 15686-71-2 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2R)-aminophenylacetyl]amino]-3-methyl-8-oxo-, (6R,7R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 26787-78-0 HCAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(2R)-amino(4-
hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 50370-12-2 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, (6R,7R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 53994-73-3 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R,7R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 56238-63-2 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[[[(aminocarbonyl)oxy]methyl]-7-[[[(2Z)-2-furanyl(methoxyimino)acetyl]amin
 o]-8-oxo-, monosodium salt, (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



● Na

RN 72558-82-8 HCAPLUS
 CN Pyridinium, 1-[[[(6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)[(1-carboxy-1-
 methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-
 azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 79350-37-1 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(2-amino-4-thiazolyl)[(carboxymethoxy)imino]acetyl]amino]-3-
ethenyl-8-oxo-, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L70 ANSWER 7 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:293830 HCAPLUS

DN 136:305218

ED Entered STN: 19 Apr 2002

TI Novel serine protease genes related to DPPIV and use thereof in screening
for inhibitors and therapy

IN Qi, Steve; Akinsanya, Karen O.; Riviere, Pierre J.-M.; Junien, Jean-Louis
PA Ferring BV, Neth.

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N009-64

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 7, 13

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|---|----------|-----------------|--------------|
| PI | WO 2002031134 | A2 | 20020418 | WO 2001-US31874 | 20011012 <-- |
| | WO 2002031134 | A3 | 20030717 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, | | | |
| | | CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, | | | |

Search done by Noble Jarrell

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2425001 AA 20020418 CA 2001-2425001 20011012 <--
 AU 2002013138 A5 20020422 AU 2002-13138 20011012 <--
 US 2002115843 A1 20020822 US 2001-976674 20011012 <--
 US 6844180 B2 20050118
 EP 1346033 A2 20030924 EP 2001-981501 20011012 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004528812 T2 20040924 JP 2002-534503 20011012 <--
 NO 2003001702 A 20030515 NO 2003-1702 20030411 <--
 ZA 2003003306 A 20040812 ZA 2003-3306 20030429 <--
 US 2005059081 A1 20050317 US 2004-982512 20041105 <--
 PRAI US 2000-240117P P 20001012 <--
 US 2001-976674 A3 20011012
 WO 2001-US31874 W 20011012

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|--|
| WO 2002031134 | ICM | C12N009-64 |
| WO 2002031134 | ECLA | C12N009/48 |
| US 2002115843 | NCL | 435/226.000; 435/219.000; 435/252.300; 435/320.100; 435/325.000; 435/348.000; 536/023.200; 536/024.500 |
| | ECLA | C12N009/48 |
| JP 2004528812 | FTERM | 2G045/AA34; 2G045/AA35; 2G045/AA40; 2G045/BA11; 2G045/BB50; 2G045/DA12; 2G045/DA13; 2G045/DA14; 2G045/DA36; 2G045/FB02; 4B024/AA01; 4B024/AA11; 4B024/BA14; 4B024/BA41; 4B024/CA01; 4B024/CA09; 4B024/CA11; 4B024/DA02; 4B024/DA05; 4B024/EA04; 4B024/GA11; 4B024/HA12; 4B050/CC01; 4B050/CC04; 4B050/DD11; 4B050/EE10; 4B050/LL01; 4B050/LL03; 4B063/QA01; 4B063/QA18; 4B063/QQ36; 4B063/QQ95; 4B063/QR41; 4B063/QR57; 4B063/QR67; 4B065/AA26X; 4B065/AA50X; 4B065/AA90X; 4B065/AA91X; 4B065/AA93Y; 4B065/AB02; 4B065/BA02; 4B065/BA08; 4B065/CA25; 4B065/CA33; 4B065/CA44; 4B065/CA46; 4C084/AA17; 4C084/NA14; 4C084/ZA221; 4C084/ZA291; 4C084/ZA421; 4C084/ZA451; 4C084/ZA541; 4C084/ZA891; 4C084/ZA941; 4C084/ZB211; 4C084/ZB212; 4C084/ZB271; 4C084/ZB331; 4C084/ZC201; 4C084/ZC211; 4H045/AA10; 4H045/AA20; 4H045/AA30; 4H045/BA10; 4H045/CA40; 4H045/DA75; 4H045/DA89; 4H045/EA20; 4H045/EA23; 4H045/EA29; 4H045/EA50; 4H045/FA72; 4H045/FA73; 4H045/FA74 |
| US 2005059081 | NCL | 435/006.000; 435/069.100; 435/212.000; 435/320.100; 435/325.000; 435/235.100; 435/456.000; 536/023.200; 435/226.000 |
| | ECLA | C12N009/48 |

AB The invention provides protein and cDNA sequences for three novel human dipeptidyl peptidase IV-related protein-1, 2, & 3 (DPRP-1, DPRP-2, and DPRP-3, alternative splicing variants). Sequence homol. of these proteins to DPPIV are provided as well as their chromosome locations. The mRNA and protein tissue distribution profiles are provided too. The invention also relates to the recombinant expression and purification of these proteins in mammalian or insect cells. Screening methods for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins or of related proteins, and therapeutic agents discovered by such screening methods, as well as new therapeutic treatments, are all provided. The methods are exemplified by testing the effects of various tetrapeptide amide inhibitors on the dipeptidyl peptidase enzyme activity and effects of DPRP inhibitors on the proliferation of human cancer cells.

ST dipeptidyl peptidase IV related protein cDNA sequence human; DPRP1 DPRP2
DPRP3 serine proteinase inhibitor screening therapy

IT Northern blot hybridization
(DPRP expression assay; novel serine protease genes related to DPPIV
and use thereof in screening for inhibitors and therapy)

IT Animal cell line
Animal tissue
(DPRP mRNA or protein expression in; novel serine protease genes
related to DPPIV and use thereof in screening for inhibitors and
therapy)

IT Animal cell line
(DU-145, for DPRP inhibitor screening and testing inhibitor's
antiproliferative activity; novel serine protease genes related to
DPPIV and use thereof in screening for inhibitors and therapy)

IT Animal cell line
(LNCaP, for DPRP inhibitor screening and testing inhibitor's
antiproliferative activity; novel serine protease genes related to
DPPIV and use thereof in screening for inhibitors and therapy)

IT Animal cell line
(MDA-MB-231, for DPRP inhibitor screening and testing inhibitor's
antiproliferative activity; novel serine protease genes related to
DPPIV and use thereof in screening for inhibitors and therapy)

IT Animal cell line
(MLTC-1, for DPRP inhibitor screening and testing inhibitor's
antiproliferative activity; novel serine protease genes related to
DPPIV and use thereof in screening for inhibitors and therapy)

IT Animal cell line
(PC-3, for DPRP inhibitor screening and
testing inhibitor's antiproliferative activity; novel serine
protease genes related to DPPIV and use thereof in screening for
inhibitors and therapy)

IT RNA splicing
(alternative, resulted in DPRP variants; novel serine protease genes
related to DPPIV and use thereof in screening for inhibitors and
therapy)

IT Drug screening
(for DPRPs serine proteinase inhibitors; novel serine protease genes
related to DPPIV and use thereof in screening for inhibitors and
therapy)

IT Gene, animal
RL: BSU (Biological study, unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(for serine proteinase DPPIVs (dipeptidyl peptidase IV-related
proteins), of human; novel serine protease genes related to DPPIV and
use thereof in screening for inhibitors and therapy)

IT Immunoassay
(immunoblotting, DPRP expression assay; novel serine protease genes
related to DPPIV and use thereof in screening for inhibitors and
therapy)

IT Immunoassay
(immunohistochem., DPRP expression assay; novel serine protease genes
related to DPPIV and use thereof in screening for inhibitors and
therapy)

IT Promoter (genetic element)
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)
(in regulation of DPRP gene recombinant expression; novel serine
protease genes related to DPPIV and use thereof in screening for
inhibitors and therapy)

IT Antitumor agents
Gene therapy
Genetic vectors
Human
Molecular cloning
Nucleic acid hybridization
Protein sequences

cDNA sequences

(novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT Primers (nucleic acid)

Probes (nucleic acid)

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT mRNA

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(of DPRP, tissue expression pattern of; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT Glycosylation

(of DPRPs; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT Leupeptins

RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(tested for dipeptidyl peptidase inhibitory activity; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT Antibodies and Immunoglobulins

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(to DPRPs; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT 37259-58-8P, Serine proteinase

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(DPPIVs (dipeptidyl peptidase IV-related proteins), of human; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT 411500-27-1P 411500-29-3P 411500-31-7P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT 411500-26-0 411500-28-2 411500-30-6

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nucleotide sequence; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT 139691-92-2, Serine proteinase inhibitor

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(screening for, specific for DPRP; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT 60-00-4, EDTA, biological studies 60-24-2, β -Mercaptoethanol

3483-12-3, DTT 9087-70-1, Aprotinin 26305-03-3, Pepstatin 34284-75-8, AEBSF

RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(tested for dipeptidyl peptidase inhibitory activity; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT 411500-98-6, 8: PN: WO0231134 SEQID: 8 unclaimed DNA 411501-00-3

411501-02-5 411501-04-7 411501-06-9 411501-08-1 411501-10-5

411501-12-7 411501-14-9 411501-16-1 411501-17-2 411501-19-4

411501-20-7 411501-22-9 411501-23-0 411501-25-2 411501-26-3

411501-28-5 411501-30-9 411501-31-0 411501-32-1 411501-33-2

411501-34-3 411501-35-4 411501-36-5 411501-37-6 411501-38-7

411501-39-8 411501-40-1 411501-41-2 411501-42-3 411501-43-4

411501-44-5

RL: PRP (Properties)

(unclaimed nucleotide sequence; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT 411500-97-5 411500-99-7 411501-01-4 411501-03-6 411501-05-8
 411501-07-0 411501-09-2 411501-11-6 411501-13-8 411501-15-0
 411501-18-3 411501-21-8 411501-24-1 411501-27-4 411501-29-6
 411501-45-6

RL: PRP (Properties)

(unclaimed protein sequence; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

IT 411231-21-5 411231-22-6 411231-23-7

RL: PRP (Properties)

(unclaimed sequence; novel serine protease genes related to DPPIV and use thereof in screening for inhibitors and therapy)

L70 ANSWER 8 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:116539 HCAPLUS

DN 136:146231

ED Entered STN: 14 Feb 2002

TI Nucleic acid compositions, kits, and methods for identification, assessment, prevention, and therapy of human breast cancer

IN Lillie, James; Palermo, Adam; Wang, Youzhen; Steinmann, Kathleen; Elias, Josh

PA Millennium Predictive Medicine, Inc., USA

SO PCT Int. Appl., 2674 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM G01N033-574

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 9, 14

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|--------------|
| PI | WO 2001046697 | A2 | 20010628 | WO 2000-US35214 | 20001221 <-- |
| | WO 2001046697 | A3 | 20020110 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI | US 1999-171406P | P | 19991221 | <-- | |
| | US 2000-176423P | P | 20000114 | <-- | |
| | US 2000-190471P | P | 20000317 | <-- | |
| | US 2000-193482P | P | 20000329 | <-- | |
| | US 2000-205231P | P | 20000515 | <-- | |
| | US 2000-213236P | P | 20000620 | <-- | |
| | US 2000-219865P | P | 20000720 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|------------------------------------|
| WO 2001046697 | ICM | G01N033-574 |
| WO 2001046697 | ECLA | G01N033/574C4 <-- |

AB The invention relates to nucleic acid marker compns., kits and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the nucleic acid markers is correlated with the presence of breast cancer. The level of expression of numerous potential markers was measured in cells obtained from breast cancer tissue samples obtained from fifteen patients afflicted with breast cancer and from eleven breast cancer cell cultures, based on comparison with expression levels of each marker in corresponding non-cancerous breast

tissue and cell cultures. The 15 cancer tissue samples include (i) five invasive lobular carcinomas (ILC), (ii) five invasive ductal carcinomas (IDC), and (iii) five samples of ductal carcinoma in situ (DCIS). As an addnl. evaluation of ability to indicate breast cancer, individual markers that were identified by transcriptional profiling criteria were also tested in six different subtracted library expts. In addition, protein profiling expts. were undertaken to assess whether the proteins associated with the expression of individual markers of the invention are secreted. Table 21 lists approx. 43,500 GenBank Accession Nos. from the present invention. [This abstract record is one of 8 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

- ST nucleic acid marker breast cancer treatment diagnosis
- IT Hybridoma
 - (antibody production with; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT Nucleic acid amplification (method)
 - Nucleic acid hybridization
 - (assay; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT Diagnosis
 - (cancer; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT Drug screening
 - (for breast cancer inhibitors and their carcinogenic potential; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT Computer application
 - (for identifying selected polynucleotides that identify a breast cancer cell; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT Milk
 - (human, sample anal. in; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT Antitumor agents
 - (mammary gland; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT Mammary gland
 - (neoplasm, inhibitors; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT Blood analysis
 - Gene therapy
 - Immunoassay
 - Mammary gland, neoplasm
 - Prognosis
 - Test kits
 - Tumor markers
 - Urine
 - cDNA sequences
 - (nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT cDNA
 - mRNA
 - RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)
- IT Antibodies and Immunoglobulins
 - RL: ARG (Analytical reagent use); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (nucleic acid compns., kits, and methods for identification,

assessment, prevention, and therapy of human breast cancer)

IT Antisense oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

IT Uterus
(sample anal. in body fluid from; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

IT Mammary gland
(sample anal. in body fluids from; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

IT Ascitic fluid
Body fluid
Lymph
(sample anal. in; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

IT Drug toxicity
(screening for breast cancer inhibitors; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

IT Proteins
RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(secretory; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

IT 108727-61-3, DNA (silkworm actin gene A1) 133021-20-2, DNA (Trypanosoma cruzi strain Y U2II RNA gene plus flanks) 134093-84-8, DNA (human cannabinoid receptor cDNA plus flanks) 137800-17-0, DNA (human clone YMH801 collagen type VIII α 1-chain gene coding region) 137878-05-8
139803-04-6 139803-98-8 139804-09-4 139804-26-5 139805-65-5,
GenBank X02486 139809-79-3 139810-50-7 139812-90-1 139838-52-1,
GenBank X06269 139840-60-1, DNA (human chorionic gonadotropin)
139843-95-1 139844-06-7 139868-79-4 140027-00-5 140027-24-3
140027-81-2 140028-24-6 140029-83-0 140030-78-0 140036-26-6
140067-53-4 140070-32-2, GenBank X52947 140072-53-3 140072-72-6
140072-78-2 140077-48-1 140081-63-6 140090-57-9 140093-06-7
140107-31-9 140274-25-5 140274-57-3, GenBank X04350 140274-68-6
140276-00-2 140277-47-0 140280-01-9 140280-02-0, GenBank X03069
140281-60-3 140283-40-5 140284-47-5 140285-23-0 140285-46-7
140286-56-2 140286-85-7 140323-52-0 140324-74-9 140330-33-2
140333-22-8 140333-23-9 140333-66-0, GenBank X15505 140336-39-6
140345-33-1 140493-23-8 140506-65-6, GenBank X07428 140507-59-1
140510-92-5, GenBank X15987 140512-43-2, GenBank X00700 140513-96-8
140554-79-6 140556-57-6 140557-23-9 140561-07-5 140561-24-6,
GenBank V00528 140610-87-3 140796-26-5 140800-69-7 140804-52-0
140879-44-3 140971-99-9 140997-59-7 140997-61-1 141003-09-0
141011-07-6 141015-21-6 142318-67-0 142432-97-1 142433-00-9
142433-06-5 142433-09-8 142433-10-1 142433-12-3 142433-14-5
142433-16-7 142789-00-2, DNA (human laminin-binding protein cDNA)
142862-70-2 143368-94-9 143609-85-2 143761-93-7 144014-52-8, DNA
(human chromosome X 1872-nucleotide fragment) 145043-79-4 145044-79-7
145211-09-2 145885-88-7 147053-02-9 147191-78-4 147476-07-1
147845-50-9 148086-85-5 148086-87-7 148087-00-7, GenBank V00496
148087-60-9, GenBank Z18923 148087-64-3 148087-68-7 148107-34-0
148107-97-5 148142-69-2 148634-78-0, GenBank Z20412 148634-80-4,
GenBank Z20414 148784-58-1 149165-56-0 150219-26-4 150246-60-9
150247-47-5 150248-06-9 150426-76-9 150510-91-1 150756-20-0
150888-11-2 150888-20-3 151033-61-3 151119-65-2 151279-87-7
151279-88-8 151350-69-5 151428-90-9 151429-23-1 151429-25-3
151430-21-6 151470-24-5 151569-92-5 151631-75-3 151682-02-9
152057-44-8 152514-62-0 153350-19-7 153420-63-4 153518-69-5
153662-57-8 153962-40-4 153962-52-8 154301-45-8 154332-70-4

154449-49-7 154680-58-7 154683-02-0 154683-04-2 154688-58-1
 154688-65-0 154688-68-3 154688-71-8 154688-89-8 154945-64-9
 155037-77-7 155119-11-2 155316-13-5 155461-93-1 155483-98-0
 155484-03-0 155484-35-8 155745-93-0 155747-69-6 156555-33-8
 156583-08-3 156797-90-9 156924-25-3 157417-00-0, DNA (potato gene
 ST-ACS1A plus flanks) 157417-40-8 157417-50-0, DNA (potato gene
 ST-ACS2 plus flanks) 158162-51-7 158184-34-0 158245-55-7
 158246-39-0 158279-26-6 158338-26-2 158448-22-7 158646-24-3
 158765-45-8 158998-02-8 159069-09-7 159127-16-9
 159127-65-8 159128-16-2 159128-57-1 159164-96-2 159199-32-3
 159230-97-4 159231-74-0 159232-13-0 159286-25-6 159314-21-3
 159340-60-0 159743-40-5 159773-76-9 159774-08-0 159775-72-1
 159776-38-2 159807-98-4 159866-45-2 159905-52-9 159907-07-0
 159939-40-9 159961-38-3 159963-84-5 159987-20-9 160020-24-6
 160020-62-2 160864-76-6 160900-79-8 160930-43-8 161100-76-1
 162159-76-4 162525-98-6 163239-69-8 163331-57-5 163366-58-3
 163370-08-9, DNA (human clone mk17f1) 163576-79-2 164127-05-3
 164127-42-8 164127-60-0 164128-07-8 164128-69-2 164129-23-1
 164129-42-4 164130-03-4 164130-14-7 164130-22-7 164130-23-8
 164130-31-8 164130-53-4 164187-38-6 164187-42-2

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human
 breast cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 164187-80-8 | 164188-20-9 | 164188-22-1 | 164188-31-2 | 164188-39-0 |
| | 164188-52-7 | 164188-64-1 | 164188-76-5 | 164188-97-0 | 164189-39-3 |
| | 164189-45-1 | 164189-53-1 | 164189-58-6 | 164189-67-7 | 164189-73-5 |
| | 164189-98-4 | 164190-15-2 | 164190-45-8 | 164191-00-8 | 164191-01-9 |
| | 164191-50-8 | 164191-84-8 | 164192-33-0 | 164192-39-6 | 164192-87-4 |
| | 164192-88-5 | 164192-99-8 | 164193-12-8 | 164193-36-6 | 164193-74-2 |
| | 164194-50-7 | 164194-77-8 | 164195-35-1 | 164195-39-5 | 164195-40-8 |
| | 164195-42-0 | 164195-45-3 | 164195-74-8 | 164195-89-5 | 164196-16-1 |
| | 164196-32-1 | 164197-50-6 | 164197-63-1 | 164197-72-2 | 164197-97-1 |
| | 164197-98-2 | 164477-40-1 | 164478-77-7 | 164572-77-4 | 164573-77-7 |
| | 164573-78-8 | 164573-92-6 | 164574-00-9 | 164574-35-0 | 164574-58-7 |
| | 164574-78-1 | 164575-17-1 | 164575-18-2 | 164600-50-4 | 164601-56-3 |
| | 164601-69-8 | 164603-23-0 | 164603-42-3 | 164604-29-9 | 164605-39-4 |
| | 164605-46-3 | 164605-49-6 | 164605-78-1 | 164605-96-3 | 164606-18-2 |
| | 164608-28-0 | 164690-37-3 | 164690-39-5 | 164690-46-4 | 164690-68-0 |
| | 164690-90-8 | 164691-04-7 | 164691-13-8 | 164691-16-1 | 164691-25-2 |
| | 164691-38-7 | 164691-81-0 | 164691-85-4 | 164695-65-2 | 164695-90-3 |
| | 164696-19-9 | 164696-23-5 | 164696-38-2 | 164697-41-0 | 164697-58-9 |
| | 164697-88-5 | 164698-08-2 | 164698-94-6 | 164699-30-3 | 164699-45-0 |
| | 164700-49-6 | 164700-52-1 | 164702-53-8 | 164702-62-9 | 164703-26-8 |
| | 164703-89-3 | 164704-33-0 | 164704-38-5 | 164704-91-0 | 164705-18-4 |
| | 164705-48-0 | 164706-08-5 | 164706-13-2 | 164707-71-5 | 164708-50-3 |
| | 164708-54-7 | 164708-63-8 | 164709-10-8 | 164709-14-2 | 164709-23-3 |
| | 164709-60-8 | 164709-71-1 | 164709-75-5 | 164709-86-8 | 164710-00-3 |
| | 164710-13-8 | 164710-75-2 | 164711-55-1 | 164711-56-2 | 164711-65-3 |
| | 164711-66-4 | 164712-18-9 | 164712-19-0 | 164712-62-3 | 164740-92-5 |
| | 164741-94-0 | 164742-31-8 | 164742-82-9 | 164742-93-2 | 164742-97-6 |
| | 164743-91-3 | 164744-69-8 | 164745-31-7 | 164745-34-0 | 164745-47-5 |
| | 164747-10-8 | 164747-15-3 | 164747-64-2 | 164752-12-9 | 164752-79-8 |
| | 164753-77-9 | 164754-06-7 | 164754-12-5 | 164754-36-3 | 164754-53-4 |
| | 164754-66-9 | 164754-77-2 | 164755-24-2 | 164755-37-7 | 164755-45-7 |
| | 164755-72-0 | 164760-82-1 | 164761-41-5 | 164761-96-0 | 164762-51-0 |
| | 164762-77-0 | 164763-28-4 | 164764-12-9 | 164765-10-0 | 164765-31-5 |
| | 164765-44-0 | 164765-68-8 | 164765-94-0 | 164766-02-3 | 164766-08-9 |
| | 164766-33-0 | 164766-69-2 | 164767-69-5 | 164767-84-4 | 164769-52-2 |
| | 164769-67-9 | 164770-39-2 | 164771-47-5 | 164772-67-2 | 164772-68-3 |
| | 164775-11-5 | 164775-35-3 | 164775-91-1 | 164777-37-1 | 164777-50-8 |
| | 164777-67-7 | 164777-93-9 | 164779-37-7 | 164780-34-1 | 164803-89-8 |
| | 164804-95-9 | 164804-99-3 | 164811-14-7 | 164813-00-7 | 164814-08-8 |
| | 164814-09-9 | 164816-57-3 | 164816-82-4 | 164818-83-1 | 164818-94-4 |
| | 164819-13-0 | 164819-73-2 | 164819-88-9 | 164821-56-1 | 164821-63-0 |

| | | | | |
|-------------|-------------|-------------|-------------|-------------|
| 164821-64-1 | 164821-73-2 | 164821-99-2 | 164822-16-6 | 164822-67-7 |
| 164822-74-6 | 164822-81-5 | 164823-14-7 | 164823-65-8 | 164823-70-5 |
| 164823-77-2 | 164824-00-4 | 164824-94-6 | 164825-82-5 | 164829-03-2 |
| 164829-23-6 | 164830-74-4 | 164830-82-4 | 164830-90-4 | 164837-15-4 |
| 164837-18-7 | 164865-34-3 | 164865-53-6 | 164866-41-5 | 164866-42-6 |
| 164866-56-2 | 164866-83-5 | 164866-97-1 | 164867-03-2 | 164867-57-6 |
| 164868-28-4 | 164868-53-5 | | | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

| | | | | | |
|----|--|---|---|--|--|
| IT | 164868-99-9 | 164869-08-3 | 164869-09-4 | 164869-17-4 | 164869-29-8 |
| | 164869-52-7 | 164869-88-9 | 164870-01-3 | 164870-15-9 | 164870-18-2 |
| | 164870-27-3 | 164870-51-3 | 164870-93-3 | 164871-00-5 | 164871-09-4 |
| | 164871-82-3 | 164872-68-8 | 164872-95-1 | 164874-73-1 | 164875-28-9 |
| | 164875-34-7 | 164876-97-5 | 164877-02-5 | 164877-15-0 | 164878-17-5 |
| | 164878-30-2 | 164879-40-7 | 164879-41-8 | 164879-42-9 | 164879-65-6 |
| | 164879-66-7 | 164879-83-8 | 164879-99-6 | 164880-06-2 | 164880-07-3 |
| | 164880-33-5 | 164880-39-1 | 164880-42-6 | 164880-51-7 | 164880-81-3 |
| | 164881-22-5 | 164881-31-6 | 164881-40-7 | 164881-56-5 | 164881-57-6 |
| | 164881-93-0 | 164881-94-1 | 164881-95-2 | 164882-83-1 | 164890-53-3 |
| | 164892-90-4 | 164893-98-5 | 164894-30-8 | 164896-26-8 | 164896-40-6 |
| | 164897-03-4 | 164897-19-2 | 164897-35-2 | 164899-54-1 | 164901-63-7 |
| | 164901-75-1 | 164901-87-5 | 164902-03-8 | 164902-19-6 | 164902-42-5 |
| | 164902-43-6 | 164902-78-7 | 164902-93-6 | 164903-06-4 | 164903-15-5 |
| | 164903-16-6 | 164903-21-3 | 164903-37-1 | 164903-45-1 | 164904-25-0 |
| | 164904-30-7 | 164904-70-5 | 164937-78-4 | 164938-35-6 | 164938-62-9 |
| | 164938-72-1 | 164938-85-6 | 164939-18-8 | 164939-24-6 | 164939-49-5 |
| | 164939-75-7 | 164939-77-9 | 164940-37-8 | 164940-70-9 | 164940-76-5 |
| | 164940-77-6 | 164940-90-3 | 164940-91-4 | 164941-03-1 | 164941-09-7 |
| | 164941-16-6 | 164941-31-5 | 164941-45-1 | 164941-52-0 | 164941-80-4 |
| | 164941-97-3 | 164941-98-4 | 164942-02-3 | 164942-20-5 | 164942-30-7 |
| | 164942-50-1 | 164942-52-3 | 164942-57-8 | 164942-63-6 | 164943-22-0 |
| | 164943-25-3 | 164943-38-8 | 164943-42-4 | 164943-48-0 | 164943-65-1 |
| | 164943-73-1 | 164944-14-3 | 164944-26-7 | 164944-27-8 | 164944-47-2 |
| | 164944-51-8 | 164944-70-1 | 164945-46-4 | 164945-58-8 | 164946-73-0 |
| | 164946-89-8 | 164947-19-7 | 164947-20-0 | 164947-21-1 | 164947-26-6 |
| | 164952-76-5 | 164952-79-8 | 165500-22-1, DNA (human gene LMO4 autoantigen cDNA) | 165757-17-5 | 165998-16-3, DNA (human granzyme E cDNA plus flanks) |
| | 166088-73-9, GenBank U11036 | 166088-95-5, DNA (human cathepsin X cDNA plus flanks) | 166217-93-2 | 166357-76-2 | 166848-09-5, GenBank Z30564 |
| | 166848-12-0, GenBank Z30567 | 166853-03-8, DNA (Aix sponsa clone pMM33) | 167201-57-2 | 167246-71-1 | 167712-54-1 |
| | 167201-57-2 | 167246-71-1 | 167712-54-1 | 167712-57-4 | 167723-48-0, DNA (stealth virus 1 clone 3B534 T7) |
| | 168513-82-4 | 168605-07-0 | 168665-23-4, DNA (human RIG cDNA plus flanks) | 168309-24-8, DNA (human clone A1 cDNA) | 168513-82-4 |
| | 168854-91-9 | 168855-03-6 | 169279-19-0 | 169714-83-4 | 169909-84-6, DNA (human clone 17f12) |
| | 170003-96-0, DNA (human clone 76b4) | 170322-31-3 | 170403-72-2 | 170613-81-7 | 170896-07-8 |
| | 171166-38-4 | 171167-07-0 | 171639-11-5 | 171693-30-4 | 172179-20-3 |
| | 172179-52-1 | 172203-32-6 | 172249-69-3 | 172444-63-2 | 172627-94-0 |
| | 172632-78-9, DNA (human clone LLOXNC01-177E8) | 173714-82-4 | 173760-69-5, GenBank U47918 | 173826-44-3 | 173889-20-8 |
| | 173760-69-5 | 173826-44-3 | 173889-20-8 | 173893-01-1 | 173893-05-5 |
| | 173893-05-5 | 174054-91-2 | 174121-27-8 | 174518-29-7 | 174957-29-0 |
| | 174983-56-3 | 175004-94-1 | 175007-03-1 | 175107-65-0 | 175635-64-0 |
| | 175636-42-7 | 175636-66-5 | 175636-77-8 | 175636-87-0 | 175637-30-6 |
| | 175637-43-1 | 175637-46-4 | 175637-53-3 | 175637-66-8 | 175637-78-2 |
| | 175638-06-9 | 175638-10-5 | 175638-32-1 | 175638-80-9 | 175639-09-5 |
| | 175639-40-4 | 175639-62-0 | 175639-83-5 | 175639-91-5 | 175640-20-7 |
| | 175740-46-2 | 175740-80-4 | 175741-06-7 | 175741-23-8 | 175741-31-8 |
| | 175741-84-1 | 175742-11-7 | 175742-39-9 | 175742-49-1 | 175742-66-2 |
| | 175742-70-8 | 175742-86-6 | 175742-94-6 | 175743-21-2 | 175744-71-5 |
| | 175745-16-1 | 175745-57-0 | 175745-79-6 | 175746-06-2 | 175746-12-0 |
| | 175746-20-0 | 175746-32-4 | 175746-39-1 | 175746-41-5 | 175747-37-2 |
| | 175747-54-3 | 175747-55-4 | 175747-56-5 | | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 175747-58-7 | 175747-80-5 | 175748-24-0 | 175748-99-9 | 175749-00-5 |
| | 175749-09-4 | 175750-07-9 | 175750-14-8 | 175750-15-9 | 175750-30-8 |
| | 175750-32-0 | 175750-38-6 | 175750-42-2 | 175750-47-7 | 175751-16-3 |
| | 175751-17-4 | 175751-29-8 | 175751-39-0 | 175751-68-5 | 175751-77-6 |
| | 175751-78-7 | 175751-85-6 | 175751-91-4 | 175752-01-9 | 175752-16-6 |
| | 175752-47-3 | 175752-50-8 | 175752-83-7 | 175752-87-1 | 175752-92-8 |
| | 175753-41-0 | 175753-49-8 | 175754-23-1 | 175754-50-4 | 175754-61-7 |
| | 175754-66-2 | 175754-89-9 | 175755-02-9 | 175755-13-2 | 175755-29-0 |
| | 175755-39-2 | 175755-41-6 | 175755-78-9 | 175756-00-0 | 175756-48-6 |
| | 175757-40-1 | 175757-78-5 | 175758-15-3 | 175758-34-6 | 175758-49-3 |
| | 175758-50-6 | 175758-52-8 | 175758-61-9 | 175758-64-2 | 175758-68-6 |
| | 175758-77-7 | 175758-94-8 | 175759-10-1 | 175759-16-7 | 175759-45-2 |
| | 175759-82-7 | 175759-92-9 | 175759-96-3 | 175760-02-8 | 175760-12-0 |
| | 175760-62-0 | 175760-66-4 | 175760-81-3 | 175760-99-3 | 175761-02-1 |
| | 175761-11-2 | 175761-26-9 | 175761-29-2 | 175761-39-4 | 175761-49-6 |
| | 175761-66-7 | 175761-75-8 | 175762-09-1 | 175762-22-8 | 175762-31-9 |
| | 175762-33-1 | 175762-48-8 | 175762-55-7 | 175762-60-4 | 175762-69-3 |
| | 175762-83-1 | 175762-84-2 | 175762-94-4 | 175763-20-9 | 175763-21-0 |
| | 175763-24-3 | 175763-30-1 | 175763-33-4 | 175763-41-4 | 175764-81-5 |
| | 175764-92-8 | 175764-94-0 | 175764-96-2 | 175765-03-4 | 175765-09-0 |
| | 175765-19-2 | 175765-26-1 | 175765-43-2 | 175765-44-3 | 175765-72-7 |
| | 175766-24-2 | 175766-43-5 | 175766-45-7 | 175766-93-5 | 175766-97-9 |
| | 175767-30-3 | 175767-37-0 | 175767-67-6 | 175768-11-3 | 175768-67-9 |
| | 175768-80-6 | 175768-81-7 | 175769-07-0 | 175769-27-4 | 175769-95-6 |
| | 175770-22-6 | 175770-39-5 | 175770-42-0 | 175770-43-1 | 175770-44-2 |
| | 175770-65-7 | 175772-99-3 | 175801-68-0 | 175801-86-2 | 175802-02-5 |
| | 175802-13-8 | 175802-26-3 | 175802-52-5 | 175802-92-3 | 175803-32-4 |
| | 175803-56-2 | 175803-67-5 | 175804-18-9 | 175804-96-3 | 175805-52-4 |
| | 175805-61-5 | 175805-70-6 | 175805-95-5 | 175806-44-7 | 175806-87-8 |
| | 175807-70-2 | 175808-20-5 | 175809-11-7 | 175809-15-1 | 175809-88-8 |
| | 175809-96-8 | 175809-97-9 | 175810-12-5 | 175810-20-5 | 175811-09-3 |
| | 175811-20-8 | 175811-24-2 | 175811-70-8 | 175812-37-0 | 175812-91-6 |
| | 175813-60-2 | 175813-75-9 | 175814-21-8 | 175814-58-1 | 175814-69-4 |
| | 175814-70-7 | 175814-88-7 | 175815-00-6 | 175815-08-4 | 175815-21-1 |
| | 175815-42-6 | 175815-46-0 | 175815-85-7 | 175816-16-7 | 175816-66-7 |
| | 175816-75-8 | 175817-07-9 | 175817-63-7 | 175827-80-2 | 175926-47-3 |
| | 175926-65-5 | 175927-59-0 | 175928-29-7 | 175928-34-4 | 175928-43-5 |
| | 175928-90-2 | 175929-00-7 | 175929-31-4 | 175930-48-0 | 175930-53-7 |
| | 175930-57-1 | 175930-60-6 | 175931-39-2 | 175932-76-0 | 175932-80-6 |
| | 175933-12-7 | 175935-04-3 | 175935-83-8 | 175936-49-9 | 175936-57-9 |
| | 175936-63-7 | 175936-67-1 | 175936-81-9 | 176080-12-9 | 176080-17-4 |
| | 176081-49-5 | 176081-92-8 | 176081-96-2 | 176119-51-0 | 176119-62-3 |
| | 176120-04-0 | 176120-41-5 | 176122-39-7 | 176122-60-4 | 176123-34-5 |
| | 176125-02-3 | 176125-60-3 | 176125-75-0 | 176126-23-1 | 176126-62-8 |
| | 176126-77-5 | 176127-47-2 | 176127-55-2 | 176127-58-5 | 176144-61-9 |
| | 176145-34-9 | 176155-31-0 | 176156-14-2 | 176157-09-8 | 176157-24-7 |
| | 176157-55-4 | 176157-74-7 | 176158-16-0 | 176158-20-6 | 176158-29-5 |
| | 176158-46-6 | 176158-47-7 | | | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 176158-57-9 | 176182-63-1 | 176182-66-4 | 176182-68-6 | 176182-86-8 |
| | 176184-62-6 | 176185-55-0 | 176185-76-5 | 176186-63-3 | 176188-49-1 |
| | 176188-92-4 | 176188-94-6 | 176189-26-7 | 176189-72-3 | 176189-93-8 |
| | 176189-95-0 | 176190-34-4 | 176190-38-8 | 176190-93-5 | 176191-20-1 |
| | 176191-89-2 | 176191-90-5 | 176192-32-8 | 176192-55-5 | 176192-62-4 |
| | 176192-63-5 | 176192-75-9 | 176194-36-8 | 176194-49-3 | 176194-87-9 |
| | 176267-25-7 | 176267-41-7 | 176267-69-9 | 176268-06-7 | 176268-12-5 |
| | 176268-23-8 | 176268-55-6 | 176268-70-5 | 176269-22-0 | 176269-34-4 |
| | 176269-80-0 | 176270-34-1 | 176270-47-6 | 176271-04-8 | 176271-13-9 |

| | | | |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| 176271-21-9 | 176272-09-6 | 176273-17-9 | 176277-33-1, GenBank W21979 |
| 176279-01-9, GenBank W22059 | 176283-56-0, GenBank W22634 | 176291-28-4 | |
| 176292-07-2 | 176292-54-9 | 176294-93-2 | 176295-36-6 176295-41-3 |
| 176295-83-3 | 176295-90-2 | 176296-16-5 | 176296-86-9 176297-01-1 |
| 176330-63-5 | 176330-64-6 | 176331-78-5 | 176331-94-5 176332-07-3 |
| 176332-60-8 | 176332-80-2 | 176332-98-2 | 176333-35-0 176333-52-1 |
| 176333-92-9 | 176334-08-0 | 176334-11-5 | 176334-37-5 176334-63-7 |
| 176334-84-2 | 176335-29-8 | 176335-48-1 | 176336-56-4 176337-29-4 |
| 176338-07-1 | 176338-12-8 | 176338-48-0 | 176338-52-6 176339-03-0 |
| 176339-38-1 | 176339-57-4 | 176339-62-1 | 176339-89-2 176340-00-4 |
| 176340-14-0 | 176340-68-4 | 176341-08-5 | 176343-65-0 176343-96-7 |
| 176344-67-5 | 176345-64-5 | 176345-69-0 | 176345-76-9 176345-78-1 |
| 176345-91-8 | 176345-97-4 | 176346-00-2 | 176347-21-0 176347-26-5 |
| 176347-58-3 | 176347-70-9 | 176358-19-3 | 176361-18-5, GenBank W27056 |
| 176364-24-2 | 176364-62-8, GenBank W26185 | 176394-85-7, GenBank W26373 | |
| 176396-73-9 | 176400-89-8, GenBank W26608 | 176406-42-1, GenBank W28226 | |
| 176460-98-3 | 176461-11-3 | 176461-16-8 | 176461-18-0 176461-53-3 |
| 176461-59-9 | 176462-28-5 | 176462-67-2 | 176463-11-9 176463-37-9 |
| 176463-71-1 | 176465-71-7 | 176466-08-3 | 176467-02-0 176467-34-8 |
| 176467-58-6 | 176468-07-8 | 176468-22-7 | 176468-29-4 176468-67-0 |
| 176469-36-6 | 176469-80-0 | 176470-00-1 | 176470-11-4 176470-62-5 |
| 176470-65-8 | 176470-75-0 | 176471-17-3 | 176471-28-6 176471-37-7 |
| 176471-45-7 | 176471-53-7 | 176471-64-0 | 176471-70-8 176471-92-4 |
| 176471-98-0 | 176472-04-1 | 176472-13-2 | 176472-25-6 176473-05-5 |
| 176473-34-0 | 176473-82-8 | 176473-88-4 | 176474-24-1 176475-03-9 |
| 176475-05-1 | 176475-19-7 | 176475-27-7 | 176476-25-8 176476-49-6 |
| 176476-58-7 | 176476-73-6 | 176477-02-4 | 176477-03-5 176478-28-7 |
| 176478-38-9 | 176478-64-1 | 176478-66-3 | 176479-18-8 176479-50-8 |
| 176479-54-2 | 176479-71-3 | 176479-75-7 | 176479-83-7 176480-12-9 |
| 176480-14-1 | 176480-26-5 | 176480-82-3 | 176481-12-2 176481-13-3 |
| 176481-27-9 | 176481-71-3 | 176481-72-4 | 176552-10-6 176552-14-0 |
| 176552-48-0 | 176552-67-3 | 176553-19-8 | 176553-38-1 176554-26-0 |
| 176554-27-1 | 176554-55-5 | 176555-26-3 | 176573-25-4 176573-84-5 |
| 176574-09-7 | 176574-10-0 | 176574-37-1 | 176574-79-1 176574-96-2 |
| 176575-18-1 | 176575-73-8 | 176575-89-6 | 176576-22-0 176602-94-1 |
| 176603-49-9 | 176603-66-0 | 176603-75-1 | 176604-13-0 176604-22-1 |
| 176604-37-8 | 176604-68-5 | 176604-69-6 | 176604-70-9 176605-15-5 |
| 176605-51-9 | 176605-95-1 | 176606-21-6 | 176606-30-7 176606-67-0 |
| 176606-84-1 | 176607-22-0 | 176607-23-1 | 176607-34-4 176607-65-1 |
| 176607-73-1 | 176607-76-4 | 176607-99-1 | 176608-11-0 176608-14-3 |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 176608-30-3 | 176608-65-4 | 176609-08-8 | 176609-11-3 | 176610-30-3 |
| | 176610-41-6 | 176610-45-0 | 176610-58-5 | 176610-91-6 | 176610-92-7 |
| | 176610-95-0 | 176610-96-1 | 176610-97-2 | 176614-56-5 | 176614-62-3 |
| | 176615-45-5 | 176616-11-8 | 176617-05-3 | 176618-49-8 | 176618-51-2 |
| | 176619-23-1 | 176619-68-4 | 176619-99-1 | 176621-05-9 | 176621-10-6 |
| | 176621-66-2 | 176621-72-0 | 176622-63-2 | 176623-64-6 | 176623-71-5 |
| | 176623-91-9 | 176624-12-7 | 176624-69-4 | 176624-77-4 | 176624-94-5 |
| | 176625-37-9 | 176625-44-8 | 176625-99-3 | 176626-16-7 | 176626-56-5 |
| | 176626-86-1 | 176628-26-5 | 176628-50-5 | 176628-79-8 | 176629-24-6 |
| | 176629-28-0 | 176629-40-6 | 176629-84-8 | 176632-98-7 | 176808-03-0 |
| | 176808-13-2 | 176808-25-6 | 176808-70-1 | 176808-95-0 | 176809-24-8 |
| | 176809-78-2 | 176810-97-2 | 176811-09-9 | 176811-65-7 | 176811-87-3 |
| | 176832-67-0 | 176833-84-4 | 176863-93-7 | 176878-73-2 | 176878-79-8 |
| | 176879-17-7 | 176879-95-1 | 176882-29-4 | 176883-06-0 | 176883-35-5 |
| | 176883-59-3 | 176886-39-8 | 176886-60-5 | 176886-90-1 | 176887-25-5 |
| | 176887-26-6 | 176888-02-1 | 176888-45-2 | 176888-50-9 | 176888-64-5 |
| | 176888-78-1 | 176889-02-4 | 176889-09-1 | 176889-20-6 | 176889-68-2 |
| | 176889-82-0 | 176890-35-0 | 176890-46-3 | 176890-91-8 | 176891-58-0 |
| | 176892-20-9 | 176921-96-3 | 176923-08-3 | 176923-52-7 | 176924-23-5 |
| | 176924-48-4 | 176926-07-1 | 176926-18-4 | 176926-19-5 | 176928-19-1 |
| | 176929-26-3 | 176929-60-5 | 176929-64-9 | 176929-65-0 | 176929-74-1 |

| | | | | |
|-------------|-------------|-------------|-------------|-------------|
| 176929-76-3 | 176929-77-4 | 176929-95-6 | 176929-98-9 | 176929-99-0 |
| 176930-04-4 | 176930-06-6 | 176930-10-2 | 176930-27-1 | 176930-61-3 |
| 176930-76-0 | 176930-86-2 | 176930-87-3 | 176931-10-5 | 176931-11-6 |
| 176931-62-7 | 176931-65-0 | 176931-66-1 | 176931-67-2 | 176931-71-8 |
| 176931-82-1 | 176931-92-3 | 176932-18-6 | 176932-20-0 | 176932-21-1 |
| 176932-28-8 | 176932-58-4 | 176932-59-5 | 176932-68-6 | 176932-69-7 |
| 176932-78-8 | 176933-52-1 | 176934-19-3 | 176934-23-9 | 176934-63-7 |
| 176934-64-8 | 176935-73-2 | 176935-91-4 | 176936-09-7 | 176936-15-5 |
| 176936-33-7 | 176936-34-8 | 176936-88-2 | 176936-89-3 | 176937-25-0 |
| 176983-69-0 | 176983-70-3 | 176983-85-0 | 176984-26-2 | 176985-26-5 |
| 176985-36-7 | 176985-37-8 | 176985-38-9 | 176985-57-2 | 176985-58-3 |
| 176985-68-5 | 176986-24-6 | 176986-63-3 | 176992-54-4 | 176992-55-5 |
| 176992-71-5 | 176992-72-6 | 176993-12-7 | 176993-35-4 | 176993-45-6 |
| 176993-62-7 | 176993-67-2 | 176993-71-8 | 176993-96-7 | 176994-71-1 |
| 176994-72-2 | 176995-03-2 | 176995-32-7 | 176995-45-2 | 176995-46-3 |
| 176995-94-1 | 176996-08-0 | 177116-61-9 | 177118-44-4 | 177118-68-2 |
| 177119-26-5 | 177119-31-2 | 177119-32-3 | 177119-39-0 | 177120-30-8 |
| 177121-58-3 | 177121-81-2 | 177121-82-3 | 177121-98-1 | 177122-94-0 |
| 177123-05-6 | 177123-06-7 | 177123-09-0 | 177123-36-3 | 177123-57-8 |
| 177124-56-0 | 177124-70-8 | 177125-08-5 | 177125-29-0 | 177126-20-4 |
| 177127-26-3 | 177127-43-4 | 177127-92-3 | 177128-28-8 | 177129-83-8 |
| 177129-86-1 | 177130-08-4 | 177131-33-8 | 177131-34-9 | 177131-50-9 |
| 177248-41-8 | 177248-65-6 | 177248-66-7 | 177249-06-8 | 177249-52-4 |
| 177252-36-7 | 177252-49-2 | 177252-86-7 | 177253-10-0 | 177254-72-7 |
| 177254-87-4 | 177255-00-4 | 177289-49-5 | 177289-91-7 | 177290-26-5 |
| 177290-27-6 | 177290-33-4 | 177290-42-5 | 177291-05-3 | 177291-48-4 |
| 177292-15-8 | 177292-26-1 | | | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human breast
cancer)

| | | | | | |
|----|-------------|-------------|-------------------------------------|-------------|-------------|
| IT | 177292-39-6 | 177305-13-4 | 177305-78-1 | 177305-90-7 | 177305-95-2 |
| | 177308-61-1 | 177309-09-0 | 177309-16-9 | 177309-27-2 | 177367-92-9 |
| | 177369-34-5 | 177369-38-9 | 177370-02-4 | 177370-33-1 | 177370-64-8 |
| | 177370-74-0 | 177372-14-4 | 177372-20-2 | 177372-67-7 | 177374-02-6 |
| | 177374-74-2 | 177374-75-3 | 177375-06-3 | 177375-21-2 | 177375-31-4 |
| | 177375-42-7 | 177375-49-4 | 177376-05-5 | 177376-31-7 | 177376-68-0 |
| | 177377-28-5 | 177377-46-7 | 177391-89-8 | 177393-10-1 | 177393-27-0 |
| | 177393-44-1 | 177394-69-3 | 177394-70-6 | 177395-54-9 | 177396-13-3 |
| | 177396-38-2 | 177396-48-4 | 177398-93-5 | 177398-94-6 | 177398-95-7 |
| | 177400-15-6 | 177400-57-6 | 177400-78-1 | 177400-79-2 | 177452-05-0 |
| | 177458-92-3 | 177458-96-7 | 177459-58-4 | 177460-97-8 | 177460-98-9 |
| | 177461-83-5 | 177462-15-6 | 177513-99-4 | 177514-09-9 | 177514-70-4 |
| | 177515-26-3 | 177527-95-6 | DNA (synthetic construct clone 31) | | |
| | 177622-61-6 | 177623-27-7 | 177623-34-6 | 177623-48-2 | 177623-62-0 |
| | 177623-63-1 | 177623-71-1 | 177623-84-6 | 177624-01-0 | 177624-15-6 |
| | 177624-41-8 | 177625-13-7 | 177625-61-5 | 177625-75-1 | 177625-76-2 |
| | 177626-19-6 | 177626-20-9 | 177627-20-2 | 177627-63-3 | 177627-72-4 |
| | 177628-04-5 | 177628-23-8 | 177628-46-5 | 177628-52-3 | 177628-59-0 |
| | 177628-68-1 | 177628-69-2 | 177632-67-6 | 177632-87-0 | 177633-35-1 |
| | 177633-58-8 | 177633-73-7 | 177633-74-8 | 177633-80-6 | 177634-36-5 |
| | 177635-72-2 | 177635-90-4 | 177636-75-8 | 177637-02-4 | 177637-03-5 |
| | 177637-55-7 | 177638-00-5 | 177639-16-6 | 177639-31-5 | 177643-37-7 |
| | 177644-20-1 | 177667-98-0 | 177668-19-8 | 177668-26-7 | 177669-02-2 |
| | 177669-23-7 | 177669-29-3 | 177669-58-8 | 177669-87-3 | 177669-89-5 |
| | 177669-92-0 | 177670-49-4 | 177670-50-7 | 177670-70-1 | 177670-76-7 |
| | 177670-91-6 | 177670-98-3 | 177671-55-5 | 177671-90-8 | 177671-92-0 |
| | 177672-47-8 | 177672-49-0 | 177673-22-2 | 177673-23-3 | 177673-28-8 |
| | 177673-40-4 | 177673-41-5 | 177673-46-0 | 177673-47-1 | 177674-11-2 |
| | 177674-69-0 | 177674-90-7 | 177675-20-6 | 177675-52-4 | 177675-79-5 |
| | 177675-93-3 | 177676-00-5 | 177676-06-1 | 177676-66-3 | 177676-67-4 |
| | 177676-68-5 | 177676-69-6 | 177677-39-3 | 177677-56-4 | 177677-69-9 |
| | 177678-03-4 | 177678-06-7 | 177678-43-2 | 177678-50-1 | 177678-64-7 |
| | 177678-77-2 | 177678-89-6 | 177678-90-9 | 177679-01-5 | 177679-02-6 |
| | 177679-13-9 | 177679-21-9 | 177679-34-4 | 177679-35-5 | 177679-72-0 |

| | | | | |
|-------------|-------------|-------------|-------------|-------------|
| 177679-93-5 | 177680-47-6 | 177802-76-5 | 177802-84-5 | 177802-86-7 |
| 177803-01-9 | 177803-27-9 | 177803-29-1 | 177803-54-2 | 177803-81-5 |
| 177804-13-6 | 177804-65-8 | 177804-66-9 | 177804-71-6 | 177804-82-9 |
| 177805-17-3 | 177805-25-3 | 177805-88-8 | 177806-04-1 | 177806-13-2 |
| 177806-46-1 | 177806-49-4 | 177806-58-5 | 177806-60-9 | 177806-64-3 |
| 177806-79-0 | 177806-96-1 | 177808-08-1 | 177808-64-9 | 177808-82-1 |
| 177808-87-6 | 177808-96-7 | 177809-22-2 | 177809-23-3 | 177809-46-0 |
| 177809-68-6 | 177809-70-0 | 177810-07-0 | 177810-51-4 | 177811-07-3 |
| 177811-41-5 | 177811-49-3 | 177811-60-8 | 177811-75-5 | 177811-79-9 |
| 177811-97-1 | 177812-10-1 | 177812-45-2 | 177812-77-0 | 177812-89-4 |
| 177813-24-0 | 177814-27-6 | 177814-29-8 | 177814-63-0 | 177814-75-4 |
| 177814-77-6 | 177815-16-6 | 177815-54-2 | 177816-89-6 | 177817-90-2 |
| 177818-33-6 | 177818-44-9 | 177819-23-7 | 177819-32-8 | 177819-60-2 |
| 177819-93-1 | 177820-02-9 | 177820-29-0 | 177820-35-8 | 177820-55-2 |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 177820-79-0 | 177821-21-5 | 177821-50-0 | 177821-55-5 | 177827-96-2 |
| | 177828-07-8 | 177828-20-5 | 177828-22-7 | 177829-12-8 | 177829-24-2 |
| | 177830-27-2 | 177831-48-0 | 177831-96-8 | 177832-26-7 | 177832-46-1 |
| | 177832-70-1 | 177833-17-9 | 177833-74-8 | 177834-15-0 | 177834-19-4 |
| | 177861-76-6 | 177861-90-4 | 177862-04-3 | 177862-31-6 | 177874-10-1 |
| | 177874-31-6 | 177874-55-4 | 177874-66-7 | 177874-84-9 | 177875-15-9 |
| | 177875-26-2 | 177875-33-1 | 177875-41-1 | 177875-53-5 | 177875-70-6 |
| | 177876-05-0 | 177876-10-7 | 177876-23-2 | 177876-64-1 | 177876-69-6 |
| | 177876-82-3 | 177877-60-0 | 177877-65-5 | 177877-82-6 | 177877-83-7 |
| | 177878-11-4 | 177878-19-2 | 177878-29-4 | 177878-30-7 | 177878-36-3 |
| | 177878-47-6 | 177878-56-7 | 177878-65-8 | 177878-67-0 | 177878-97-6 |
| | 177879-35-5 | 177879-53-7 | 177879-81-1 | 177879-84-4 | 177879-99-1 |
| | 177880-01-2 | 177880-20-5 | 177880-28-3 | 177880-50-1 | 177880-59-0 |
| | 177880-66-9 | 177915-97-8 | 177916-24-4 | 177916-29-9 | 177916-30-2 |
| | 177916-38-0 | 177916-40-4 | 177916-44-8 | 177916-61-9 | 177916-86-8 |
| | 177916-94-8 | 177917-08-7 | 177917-39-4 | 177917-44-1 | 177917-81-6 |
| | 177918-52-4 | 177920-21-7 | 177925-94-9 | 177926-14-6 | 177926-18-0 |
| | 177926-34-0 | 177926-49-7 | 177926-55-5 | 177926-62-4 | 177926-69-1 |
| | 177926-75-9 | 177926-77-1 | 177927-07-0 | 177927-10-5 | 177927-15-0 |
| | 177927-22-9 | 177927-31-0 | 177927-34-3 | 177927-60-5 | 177927-90-1 |
| | 177927-93-4 | 177928-07-3 | 177928-12-0 | 177928-16-4 | 177928-60-8 |
| | 177929-43-0 | 177997-81-8 | 177998-08-2 | 177998-11-7 | 177998-21-9 |
| | 177998-30-0 | 177998-39-9 | 177998-52-6 | 177998-94-6 | 177999-92-7 |
| | 178000-20-9 | 178000-44-7 | 178000-93-6 | 178000-94-7 | 178001-11-1 |
| | 178001-35-9 | 178001-73-5 | 178001-74-6 | 178001-83-7 | 178001-91-7 |
| | 178002-02-3 | 178002-07-8 | 178002-09-0 | 178002-24-9 | 178002-31-8 |
| | 178002-57-8 | 178002-62-5 | 178002-63-6 | 178002-68-1 | 178002-70-5 |
| | 178003-02-6 | 178003-32-2 | 178003-93-5 | 178004-01-8 | 178004-12-1 |
| | 178004-21-2 | 178004-28-9 | 178004-40-5 | 178004-83-6 | 178005-14-6 |
| | 178005-30-6 | 178005-34-0 | 178005-77-1 | 178005-81-7 | 178006-11-6 |
| | 178006-22-9 | 178010-85-0 | 178010-89-4 | 178010-90-7 | 178010-95-2 |
| | 178010-96-3 | 178011-27-3 | 178012-17-4 | 178012-48-1 | 178012-65-2 |
| | 178012-77-6 | 178012-84-5 | 178012-85-6 | 178013-17-7 | 178013-19-9 |
| | 178013-70-2 | 178013-96-2 | 178014-22-7 | 178014-31-8 | 178014-44-3 |
| | 178014-79-4 | 178015-13-9 | 178016-01-8 | 178016-11-0 | 178016-21-2 |
| | 178016-37-0 | 178016-41-6 | 178016-63-2 | 178017-15-7 | 178017-16-8 |
| | 178018-06-9 | 178018-13-8 | 178018-26-3 | 178018-33-2 | 178018-38-7 |
| | 178018-39-8 | 178018-58-1 | 178018-93-4 | 178019-11-9 | 178019-12-0 |
| | 178019-15-3 | 178019-20-0 | 178019-21-1 | 178019-51-7 | 178019-59-5 |
| | 178019-60-8 | 178019-81-3 | 178019-95-9 | 178019-96-0 | 178020-03-6 |
| | 178020-04-7 | 178020-16-1 | 178020-17-2 | 178021-45-9 | 178021-92-6 |
| | 178022-03-2 | 178022-21-4 | 178022-22-5 | 178022-35-0 | 178022-48-5 |
| | 178023-11-5 | 178023-26-2 | 178023-54-6 | 178023-79-5 | 178023-98-8 |
| | 178024-06-1 | 178024-07-2 | 178024-27-6 | 178024-75-4 | 178024-82-3 |
| | 178088-71-6 | 178088-79-4 | 178088-97-6 | 178088-98-7 | 178089-97-9 |
| | 178089-98-0 | 178090-42-1 | 178090-45-4 | 178090-80-7 | 178090-99-8 |
| | 178091-02-6 | 178091-54-8 | 178092-33-6 | 178092-36-9 | 178092-56-3 |

178092-92-7 178092-95-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human breast
cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 178093-14-6 | 178093-24-8 | 178093-39-5 | 178093-56-6 | 178093-57-7 |
| | 178093-60-2 | 178093-61-3 | 178093-79-3 | 178093-80-6 | 178093-84-0 |
| | 178094-01-4 | 178094-05-8 | 178094-16-1 | 178094-17-2 | 178094-57-0 |
| | 178129-35-6 | 178129-64-1 | 178130-65-9 | 178130-66-0 | 178130-76-2 |
| | 178130-88-6 | 178130-96-6 | 178131-06-1 | 178131-27-6 | 178131-49-2 |
| | 178131-50-5 | 178131-59-4 | 178131-71-0 | 178131-74-3 | 178131-79-8 |
| | 178131-86-7 | 178131-89-0 | 178131-98-1 | 178132-30-4 | 178132-31-5 |
| | 178133-07-8 | 178133-47-6 | 178133-54-5 | 178133-67-0 | 178133-75-0 |
| | 178133-91-0 | 178133-96-5 | 178134-25-3 | 178134-58-2 | 178134-59-3 |
| | 178135-59-6 | 178135-89-2 | 178136-27-1 | 178186-02-2 | 178186-07-7 |
| | 178186-16-8 | 178186-17-9 | 178186-88-4 | 178186-93-1 | 178186-95-3 |
| | 178187-37-6 | 178187-88-7 | 178188-01-7 | 178188-38-0 | 178188-43-7 |
| | 178188-92-6 | 178188-93-7 | 178189-24-7 | 178189-87-2 | 178190-04-0 |
| | 178190-10-8 | 178190-12-0 | 178190-16-4 | 178190-17-5 | 178190-71-1 |
| | 178191-40-7 | 178218-53-6 | 178218-62-7 | 178219-01-7 | 178219-63-1 |
| | 178219-71-1 | 178219-72-2 | 178220-23-0 | 178221-90-4 | 178221-91-5 |
| | 178222-56-5 | 178222-93-0 | 178223-15-9 | 178223-82-0 | 178223-88-6 |
| | 178224-03-8 | 178224-19-6 | 178224-26-5 | 178224-38-9 | 178224-72-1 |
| | 178224-80-1 | 178224-82-3 | 178224-93-6 | 178224-94-7 | 178279-37-3 |
| | 178279-46-4 | 178279-59-9 | 178279-70-4 | 178279-93-1 | 178280-11-0 |
| | 178280-17-6 | 178280-31-4 | 178280-54-1 | 178280-64-3 | 178281-16-8 |
| | 178281-45-3 | 178281-48-6 | 178281-93-1 | 178282-06-9 | 178282-07-0 |
| | 178282-11-6 | 178282-15-0 | 178282-75-2 | 178282-82-1 | 178282-84-3 |
| | 178282-89-8 | 178282-98-9 | 178283-39-1 | 178283-57-3 | 178283-96-0 |
| | 178283-97-1 | 178284-20-3 | 178284-26-9 | 178284-27-0 | 178284-32-7 |
| | 178285-13-7 | 178285-25-1 | 178285-28-4 | 178285-34-2 | 178285-35-3 |
| | 178285-42-2 | 178285-80-8 | 178286-17-4 | 178286-28-7 | 178286-56-1 |
| | 178286-57-2 | 178286-84-5 | 178286-97-0 | 178300-56-6 | 178335-51-8 |
| | 178335-52-9 | 178335-92-7 | 178336-32-8 | 178336-53-3 | 178336-55-5 |
| | 178336-99-7 | 178337-30-9 | 178337-42-3 | 178337-51-4 | 178337-84-3 |
| | 178337-98-9 | 178338-22-2 | 178338-40-4 | 178338-51-7 | 178338-76-6 |
| | 178339-08-7 | 178339-59-8 | 178340-00-6 | 178340-44-8 | 178340-61-9 |
| | 178341-44-1 | 178341-45-2 | 178341-70-3 | 178341-71-4 | 178341-99-6 |
| | 178342-26-2 | 178342-90-0 | 178343-19-6 | 178343-20-9 | 178343-34-5 |
| | 178656-80-9 | 178705-68-5 | 178705-69-6 | 178705-80-1 | 178706-54-2 |
| | 178706-62-2 | 178706-81-5 | 178707-07-8 | 178707-15-8 | 178707-52-3 |
| | 178707-59-0 | 178707-75-0 | 178708-47-9 | 178708-48-0 | 178708-54-8 |
| | 178708-88-8 | 178709-18-7 | 178709-84-7 | 178710-03-7 | 178710-36-6 |
| | 178710-56-0 | 178710-78-6 | 178710-86-6 | 178710-91-3 | 178710-99-1 |
| | 178711-49-4 | 178711-73-4 | 178711-74-5 | 178711-91-6 | 178712-59-9 |
| | 178712-61-3 | 178712-72-6 | 178713-33-2 | 178713-34-3 | 178713-62-7 |
| | 178714-04-0 | 178714-97-1 | 178714-98-2 | 178715-08-7 | 178715-47-4 |
| | 178715-55-4 | 178716-21-7 | 178716-98-8 | 178717-22-1 | 178717-40-3 |
| | 178718-25-7 | 178718-26-8 | 178718-82-6 | 178719-52-3 | 178719-82-9 |
| | 178720-28-0 | 178720-38-2 | 178720-63-3 | 178720-67-7 | 178720-82-6 |
| | 178721-76-1 | 178721-86-3 | 178722-33-3 | 178722-41-3 | 178722-52-6 |
| | 178722-82-2 | 178723-09-6 | 178723-33-6 | 178723-46-1 | 178723-83-6 |
| | 178724-66-8 | 178725-04-7 | | | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human breast
cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 178725-25-2 | 178725-36-5 | 178725-72-9 | 178726-43-7 | 178727-34-9 |
| | 178728-18-2 | 178728-19-3 | 178728-31-9 | 178728-33-1 | 178728-34-2 |
| | 178728-41-1 | 178728-52-4 | 178728-60-4 | 178728-81-9 | 178728-84-2 |
| | 178729-10-7 | 178729-40-3 | 178729-78-7 | 178729-93-6 | 178730-05-7 |
| | 178730-19-3 | 178730-21-7 | 178730-28-4 | 178730-30-8 | 178730-33-1 |
| | 178730-56-8 | 178730-57-9 | 178730-83-1 | 178731-16-3 | 178731-53-8 |
| | 178731-85-6 | 178732-03-1 | 178732-10-0 | 178732-16-6 | 178732-17-7 |

178732-37-1 178732-38-2 178732-67-7 178733-11-4 178733-41-0
 178768-11-1 178768-39-3 178768-43-9 178768-94-0 178769-04-5
 178770-08-6 178770-58-6 178771-17-0 178771-40-9 178772-03-7
 178772-90-2 178774-42-0 178774-69-1 178774-88-4 178774-93-1
 178775-04-7 178775-18-3 178775-60-5 178775-61-6 178777-40-7
 178777-60-1 178777-69-0 178778-38-6 178778-99-9 178779-02-7
 178779-88-9 178780-78-4 178780-87-5 178781-08-3 178781-67-4
 178781-85-6 178781-87-8 178781-94-7 178781-96-9 178782-03-1
 178782-15-5 178782-39-3 178782-71-3 178782-97-3 178782-98-4
 178784-08-2 178784-51-5 178785-09-6 178785-25-6 178785-51-8
 179300-08-4, DNA (human clone EST 257753 cDNA) 179345-13-2 179345-50-7
 179345-52-9 179345-66-5 179346-00-0 179346-01-1 179379-04-5
 179576-58-0 179576-94-4 179706-62-8 179709-47-8 179726-18-2, DNA
 (*Nasturtium officinale*) 179956-41-3 180107-44-2 180109-29-9
 180169-09-9 180500-98-5 180563-65-9 180564-21-0 180711-28-8
 180770-06-3, DNA (*Arabidopsis thaliana* cDNA) 180924-48-5 181109-06-8,
 DNA (human imogen 38 cDNA) 181692-67-1 182214-99-9 182762-21-6
 182848-69-7 182995-77-3 183104-39-4, DNA (human clone RP1-274L7)
 183104-88-3, GenBank Z82141 183105-03-5, GenBank Z82156 183390-81-0
 183391-99-3, GenBank U76622 183392-10-1 183640-35-9 183779-11-5
 183818-00-0, DNA (human gene msg1 cDNA) 183976-04-7, DNA (human cell
 line KLE cDNA) 183984-21-6 183984-43-2 184265-55-2 184753-67-1
 184860-63-7 185083-76-5 185230-97-1 185235-73-8 185241-83-2, DNA
 (human zyginII cDNA) 185242-26-6 185243-36-1, DNA (human cell line
 CD34+ cDNA) 185655-64-5 185770-65-4 185773-19-7 185928-35-2
 186220-72-4, GenBank Y09530 186222-17-3 186285-09-6 186336-09-4
 186362-21-0, DNA (*Escherichia coli* strain QC871) 186363-70-2, DNA
 (human clone cosmid W12A) 186637-50-3 186999-71-3 187002-82-0
 187261-14-9, DNA (human clone pJ555 cDNA) 187261-15-0 187261-43-4
 187501-51-5, DNA (human gene CLDN10 cDNA) 187764-90-5 187765-05-5
 187790-51-8 187790-83-6 187824-20-0 187824-32-4 188089-64-7, DNA
 (human clone 23587 cDNA) 188101-37-3 188219-78-5, DNA (human gene
 GCP-2 plus flanks) 188226-04-2 188227-84-1 188228-17-3 188230-28-6
 188379-53-5 188379-60-4 189520-93-2, DNA (human blue cone rhodopsin
 gene) 189718-46-5, DNA (human clone RP3-465G10) 189868-36-8
 189922-93-8 189923-57-7 190045-74-0 190113-43-0 191452-47-8
 192856-33-0 192982-14-2, DNA (human β 3A-adaptin cDNA plus flanks)
 193234-21-8 193263-88-6 193310-28-0, DNA (human Wip1 cDNA)
 193311-89-6 194129-22-1, GenBank U80765 194129-28-7, GenBank U80771
 194130-22-8, GenBank U83583 194134-31-1 194194-51-9, DNA (human
 thioesterase II cDNA) 194381-44-7 194617-16-8, GenBank U66064
 194978-53-5 194979-16-3 195018-87-2 195124-29-9, DNA (human clone
 P1/1898RN4.5) 195268-57-6, DNA (human gene CTG4a cDNA) 195412-61-4,
 DNA (human clone RP3-340N1) 195808-69-6 196384-03-9, DNA (human clone
 RP3-376D21) 196384-39-1 196384-40-4 196972-66-4 197262-66-1
 197530-10-2 197624-04-7 197624-57-0 198087-91-1 200473-15-0,
 GenBank U68139 200594-90-7 200668-81-1, DNA (human strain Jurkat cDNA)
 201899-22-1, GenBank U70668 202080-85-1 202251-85-2 202378-36-7, DNA
 (human clone cos4) 202960-25-6 207317-78-0, DNA (human clone hl2-274
 cDNA) 208164-46-9 210001-93-7 210442-58-3 213076-75-6
 216125-97-2, DNA (human gene NIFIE 14 cDNA) 219232-50-5 221210-43-1
 222254-68-4 224290-49-7, GenBank U41724 224290-66-8, GenBank U42455
 224290-67-9, GenBank U42456 224290-70-4, GenBank U42592 224336-65-6,
 GenBank U87571 224340-93-6 225396-58-7 225396-94-1, GenBank U60259
 225468-53-1 225469-94-3, GenBank X95583 225547-35-3 242223-15-0
 246184-00-9, DNA (human clone 29354 gene HTcD37 cDNA) 248236-83-1
 382735-91-3, DNA (human clone pKH18 cDNA) 382735-93-5
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human breast
 cancer)
 IT 382753-53-9 384423-47-6 384423-89-6 384426-73-7 384430-03-9, DNA
 (human 760-amino acid protein cDNA) 384431-28-1, GenBank X04701
 384432-21-7, DNA (human lipocortin cDNA plus flanks) 384439-55-8
 384439-99-0 384440-36-2 384440-39-5 384443-47-4 384448-06-0

384449-48-3, DNA (human gene RSRFR2 cDNA) 384450-79-7 384450-81-1,
 GenBank X03559 384451-01-8 384451-79-0 384455-63-4, DNA (human gene
 G7a cDNA) 384457-48-1, DNA (human clone Zn133, Zn102 cDNA)
 384463-43-8, DNA (human strain cell line MKN-7 cDNA) 384463-51-8
 384463-53-0, DNA (human integrin $\alpha 5$ cDNA) 384463-79-0
 384465-73-0 384466-28-8 384467-82-7 384473-36-3 384480-41-5
 384484-07-5 384485-18-1, GenBank X61969 384485-21-6, DNA (human
 macropain subunit zeta) 384487-17-6 384490-13-5, DNA (human clone FR2,
 FR7 cDNA) 384494-76-2, DNA (human PC1/PC3)
 384497-75-0 384498-37-7, DNA (human gene CD24) 384501-15-9
 384503-10-0 384503-12-2, GenBank X67001 384512-40-7, DNA (human clone
 G9a-4C7 cDNA) 384515-84-8 384518-00-7, DNA (human cell line IARC 171
 cDNA) 384522-48-9 384529-99-1 384534-03-6 384535-02-8, DNA (human
 clone R32 cDNA) 384543-53-7, DNA (human gene trkE cDNA) 384555-10-6,
 DNA (human cell line HL-60 cDNA) 384559-61-9 384563-26-2, DNA (human
 beta2-chimaerin cDNA) 384565-73-5, GenBank U07343 384567-37-7
 384568-31-4, DNA (human clone JL13 cDNA) 384568-33-6, DNA (human clone
 JL14 cDNA) 384574-79-2 384576-96-9 384577-05-3 384583-67-9, DNA
 (human clone E2) 384587-72-8, DNA (human clone LUCA-1 cDNA)
 384591-16-6 384608-99-5, DNA (human nuclear protein SA-1 cDNA)
 384609-28-3 384614-14-6 384615-26-3, DNA (human gene hPAK65 cDNA)
 384648-64-0, DNA (human clone 126 cDNA) 384649-76-7, DNA (Canine
 herpesvirus isolate Milou) 384653-31-0 384655-21-4, DNA (human gene
 MIHB cDNA) 384655-55-4 384657-95-8 384658-61-1, DNA (human gene
 TRP-185 cDNA) 384665-79-6, DNA (human gene FRP1 cDNA) 384675-48-3
 384675-52-9 384676-63-5, DNA (human strain Caucasian cDNA)
 384681-00-9, DNA (human gene h-SmLIM cDNA) 384683-54-9, DNA (human gene
 PKD2 protein cDNA) 384683-57-2, DNA (human ribosomal protein S27 cDNA)
 384686-54-8 384696-39-3 384724-32-7, DNA (human gene hGH cDNA)
 384726-68-5, DNA (human hGATA-6 cDNA) 384727-47-3 384731-98-0, GenBank
 U66894 384737-44-4, DNA (human ABPP-1) 384747-18-6, DNA (human p97
 cDNA) 384747-89-1, DNA (human UCP2 cDNA) 384747-91-5 384748-92-9
 384753-40-6 384762-33-8 384763-90-0, DNA (human cell line U937 cDNA)
 384767-18-4 384770-18-7 384771-37-3, DNA (human gene HMG2a cDNA)
 384781-28-6 384976-50-5 384976-75-4 384976-77-6 384976-79-8, DNA
 (human clone pAH12 cDNA) 384976-87-8, DNA (human cell line HL60 clone c5
) 384978-99-8 385009-16-5, GenBank Z20410 385093-03-8 385093-79-8
 385096-20-8, DNA (human cell line IARC-EW11 cDNA) 385097-49-4, DNA
 (human TAFII32 precursor cDNA) 385098-08-8 385102-00-1 385102-02-3,
 GenBank X80197 385102-04-5, DNA (human gene MLN 64 cDNA) 385109-98-8
 385128-67-6 385128-93-8 385130-48-3 385130-50-7 385131-24-8
 385133-15-3 385133-17-5 385133-24-4 385133-95-9 385134-64-5
 385136-01-6 385136-39-0 385137-18-8 385137-52-0 385141-58-2
 385141-62-8 385163-36-0 385216-19-3 385246-24-2, DNA (human clone
 PDG37 cDNA) 389179-87-7 389180-12-5, GenBank X02990 389180-98-7,
 GenBank X03963 389181-02-6 389181-03-7 389181-35-5 389182-18-7
 389182-36-9 389182-67-6 389182-81-4 389183-67-9 389183-71-5,
 GenBank V00503 389183-88-4 389183-89-5, DNA (human tubulin cDNA plus
 flanks) 389183-97-5, GenBank X16455 389184-00-3, DNA (human calretinin
 cDNA) 389184-05-8 389185-04-0, DNA (human clone pGPI2 cDNA)
 389185-14-2, DNA (human 130-amino acid protein cDNA) 389185-45-9
 389186-95-2, GenBank X13923 389187-39-7, GenBank X13482 389189-84-8,
 GenBank X04011 389190-79-8, DNA (human cystatin S cDNA plus flanks)
 389191-53-1, DNA (human cell line U105MG cDNA) 389191-62-2 389191-63-3
 389192-44-3 389192-45-4 389192-48-7, DNA (human cell line L1)
 389193-19-5, DNA (Escherichia coli) 389195-70-4, DNA (human cell line
 CEPH 134702) 389196-98-9, DNA (human clone pHCAL2 cDNA) 389197-74-0
 389200-08-2 389200-11-7, DNA (human clone CENPE cDNA) 389200-12-8, DNA
 (human clone 5s2 cDNA) 389200-14-0 389200-15-1, DNA (human cell line
 Hep-2 clone H2-14) 389200-20-8, GenBank X12660 389200-21-9
 389200-77-5 389200-79-7, GenBank Z19054 389202-39-5, DNA (human M130
 antigen cDNA) 389202-77-1 389203-07-0 389207-77-6 389208-38-2
 389208-39-3 389209-67-0, DNA (human cell line U937 Lymphoma cDNA)
 389211-78-3 389211-86-3 389212-46-8 389214-12-4 389214-43-1, DNA
 (human gene LMP7 cDNA) 389217-81-6 389231-40-7, DNA (human
 acylphosphatase) 389231-41-8 389232-87-5 389236-62-8 389236-63-9

389236-64-0 389236-97-9 389236-98-0 389236-99-1 389237-00-7
 389237-01-8 389237-02-9 389237-03-0 389237-04-1 389237-05-2
 389237-07-4 389237-08-5 389237-09-6 389237-10-9 389237-11-0
 389237-13-2 389237-14-3 389237-15-4 389237-16-5 389237-19-8
 389237-20-1 389237-21-2 389237-22-3 389237-23-4 389237-26-7
 389237-28-9 389237-31-4 389239-77-4 389239-78-5 389239-79-6
 389239-83-2 389239-84-3 389239-85-4 389239-86-5 389239-88-7
 389239-91-2 389239-92-3 389239-94-5 389239-96-7 389239-97-8
 389239-99-0 389240-00-0 389240-01-1 389240-35-1

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human
 breast cancer)

IT 389240-36-2 389240-37-3 389240-41-9 389240-42-0 389240-43-1
 389240-46-4 389240-47-5 389240-48-6 389240-49-7 389240-51-1
 389240-54-4 389240-57-7 389240-58-8 389240-59-9 389240-61-3
 389240-62-4 389240-66-8 389240-74-8 389240-78-2 389240-79-3
 389240-80-6 389240-82-8 389240-90-8 389240-92-0 389240-93-1
 389240-94-2 389240-99-7 389241-00-3 389241-03-6 389241-04-7
 389241-05-8 389241-06-9 389241-07-0 389241-08-1 389241-17-2
 389241-19-4 389241-35-4 389241-37-6 389241-39-8 389241-40-1
 389241-41-2 389241-42-3 389241-45-6 389241-47-8 389241-52-5
 389241-53-6 389241-54-7 389241-55-8 389241-60-5 389241-61-6
 389241-71-8 389241-72-9 389241-76-3 389241-77-4 389241-89-8
 389241-90-1 389241-91-2 389241-97-8 389241-99-0 389242-00-6
 389242-02-8 389242-03-9 389242-05-1 389242-06-2 389242-07-3
 389242-08-4 389242-13-1 389242-16-4 389242-17-5 389242-18-6
 389242-19-7 389242-20-0 389242-21-1 389242-22-2 389242-25-5
 389242-26-6 389242-27-7 389242-28-8 389242-29-9 389242-30-2
 389242-31-3 389242-33-5 389242-35-7 389242-40-4 389242-52-8
 389242-54-0 389242-56-2 389242-58-4 389242-60-8 389242-62-0
 389242-65-3 389242-70-0 389242-71-1 389242-72-2 389242-73-3
 389242-74-4 389242-76-6 389242-77-7 389242-78-8 389242-79-9
 389242-83-5 389242-84-6 389242-85-7 389242-86-8 389242-87-9
 389242-88-0 389242-89-1 389242-90-4 389242-91-5 389242-92-6
 389242-93-7 389242-94-8 389242-95-9 389242-97-1 389242-98-2
 389243-00-9 389243-01-0 389243-03-2 389243-04-3 389243-06-5
 389243-07-6 389243-09-8 389247-63-6, DNA (human cell line Jurkat cDNA)
 389255-81-6, DNA (human clone SB-8 cDNA) 389259-07-8 389259-08-9
 389267-26-9, GenBank Z30570 389273-50-1 389280-71-1, GenBank U31657
 389283-39-0, DNA (human clone pSURSLAM1 cDNA) 389324-25-8, DNA (human
 cell line HL60 cDNA) 389324-96-3, DNA (human clone I-14 cDNA)
 389329-10-6 389338-30-1 389338-32-3 389338-34-5 389338-35-6
 389338-36-7 389338-38-9 389338-44-7 389338-45-8 389338-46-9
 389338-47-0 389338-49-2 389338-50-5 389338-51-6 389338-52-7
 389338-54-9 389338-55-0 389338-57-2 389338-59-4 389338-61-8
 389338-63-0 389338-68-5 389338-69-6 389338-70-9 389338-71-0
 389338-72-1 389338-73-2 389338-74-3 389338-75-4 389338-76-5
 389338-78-7 389338-80-1 389338-81-2 389338-82-3 389338-83-4
 389338-86-7 389338-87-8 389338-89-0 389338-92-5 389338-93-6
 389338-95-8 389338-96-9 389338-99-2 389339-00-8 389339-01-9
 389339-02-0 389339-03-1 389339-04-2 389339-05-3 389339-09-7
 389339-12-2 389339-14-4 389339-15-5 389339-16-6 389339-19-9
 389339-22-4 389339-28-0 389339-29-1 389339-31-5 389339-33-7
 389339-34-8 389339-35-9 389339-36-0 389339-37-1 389339-40-6
 389339-42-8 389339-44-0 389339-49-5 389339-50-8 389339-53-1
 389339-54-2 389339-58-6 389339-59-7 389339-76-8 389339-77-9
 389339-78-0 389339-85-9 389339-91-7 389339-95-1 389340-32-3
 389340-38-9 389340-39-0 389340-40-3 389340-41-4 389340-42-5
 389340-43-6 389340-48-1 389340-51-6 389340-53-8 389340-54-9
 389340-67-4 389340-69-6 389340-71-0 389340-73-2 389340-74-3
 389340-76-5 389340-78-7 389340-80-1 389340-81-2 389340-83-4
 389340-87-8 389340-89-0 389341-32-6 389341-34-8 389341-35-9

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human breast
cancer)

| | | | | | |
|----|-------------|-----------------------------|-------------|-------------|-------------|
| IT | 389341-36-0 | 389341-40-6 | 389341-41-7 | 389341-43-9 | 389341-60-0 |
| | 389341-62-2 | 389341-63-3 | 389341-64-4 | 389341-65-5 | 389341-66-6 |
| | 389341-69-9 | 389341-71-3 | 389341-72-4 | 389341-73-5 | 389341-76-8 |
| | 389341-77-9 | 389341-78-0 | 389341-80-4 | 389341-81-5 | 389341-83-7 |
| | 389341-84-8 | 389341-85-9 | 389341-87-1 | 389341-88-2 | 389341-89-3 |
| | 389341-95-1 | 389341-97-3 | 389341-98-4 | 389341-99-5 | 389342-47-6 |
| | 389342-48-7 | 389342-49-8 | 389342-51-2 | 389342-52-3 | 389342-63-6 |
| | 389342-69-2 | 389342-70-5 | 389342-71-6 | 389342-72-7 | 389342-74-9 |
| | 389342-78-3 | 389342-87-4 | 389342-90-9 | 389342-91-0 | 389342-98-7 |
| | 389342-99-8 | 389343-03-7 | 389343-04-8 | 389343-05-9 | 389343-09-3 |
| | 389343-10-6 | 389343-11-7 | 389343-12-8 | 389343-13-9 | 389343-17-3 |
| | 389343-18-4 | 389343-19-5 | 389343-20-8 | 389343-21-9 | 389343-22-0 |
| | 389343-25-3 | 389343-26-4 | 389343-27-5 | 389343-28-6 | 389343-35-5 |
| | 389343-38-8 | 389343-44-6 | 389343-48-0 | 389343-51-5 | 389343-54-8 |
| | 389343-84-4 | 389343-85-5 | 389343-96-8 | 389343-97-9 | 389343-98-0 |
| | 389344-01-8 | 389344-02-9 | 389344-05-2 | 389344-06-3 | 389344-08-5 |
| | 389344-11-0 | 389344-12-1 | 389344-15-4 | 389344-16-5 | 389344-17-6 |
| | 389344-20-1 | 389344-27-8 | 389344-34-7 | 389344-36-9 | 389344-37-0 |
| | 389344-39-2 | 389344-41-6 | 389344-42-7 | 389344-43-8 | 389344-44-9 |
| | 389344-45-0 | 389344-46-1 | 389344-47-2 | 389344-50-7 | 389344-58-5 |
| | 389344-59-6 | 389344-61-0 | 389344-62-1 | 389344-63-2 | 389344-65-4 |
| | 389344-66-5 | 389344-67-6 | 389344-69-8 | 389344-70-1 | 389344-71-2 |
| | 389344-72-3 | 389344-73-4 | 389344-74-5 | 389344-75-6 | 389344-79-0 |
| | 389344-80-3 | 389344-84-7 | 389344-85-8 | 389344-86-9 | 389344-88-1 |
| | 389344-92-7 | 389344-93-8 | 389344-94-9 | 389344-95-0 | 389344-96-1 |
| | 389344-98-3 | 389344-99-4 | 389345-00-0 | 389345-01-1 | 389345-02-2 |
| | 389345-03-3 | 389345-05-5 | 389345-06-6 | 389345-07-7 | 389345-08-8 |
| | 389345-09-9 | 389345-11-3 | 389345-13-5 | 389345-27-1 | 389345-31-7 |
| | 389345-32-8 | 389345-33-9 | 389345-34-0 | 389345-35-1 | 389345-36-2 |
| | 389345-38-4 | 389345-46-4 | 389345-51-1 | 389345-69-1 | 389345-71-5 |
| | 389345-72-6 | 389345-80-6 | 389345-81-7 | 389345-96-4 | 389345-97-5 |
| | 389345-99-7 | 389346-00-3 | 389346-05-8 | 389346-13-8 | 389346-14-9 |
| | 389346-16-1 | 389346-19-4 | 389346-20-7 | 389346-21-8 | 389346-22-9 |
| | 389346-23-0 | 389346-27-4 | 389346-29-6 | 389346-30-9 | 389346-31-0 |
| | 389346-33-2 | 389346-40-1 | 389346-43-4 | 389346-45-6 | 389346-46-7 |
| | 389346-47-8 | 389346-48-9 | 389346-50-3 | 389346-51-4 | 389346-53-6 |
| | 389346-55-8 | 389346-56-9 | 389346-58-1 | 389346-67-2 | 389346-69-4 |
| | 389346-72-9 | 389346-74-1 | 389346-75-2 | 389346-78-5 | 389346-79-6 |
| | 389346-83-2 | 389346-90-1 | 389346-91-2 | 389346-93-4 | 389346-94-5 |
| | 389346-96-7 | 389346-97-8, GenBank U57846 | 389347-09-5 | 389347-10-8 | |
| | 389347-11-9 | 389347-12-0 | 389347-26-6 | 389347-28-8 | 389347-30-2 |
| | 389347-37-9 | 389347-41-5 | 389347-42-6 | 389347-43-7 | 389347-44-8 |
| | 389347-46-0 | 389347-48-2 | 389347-49-3 | 389347-51-7 | 389347-53-9 |
| | 389347-56-2 | 389347-59-5 | 389347-60-8 | 389347-61-9 | 389347-63-1 |
| | 389347-65-3 | 389347-67-5 | 389347-69-7 | 389347-70-0 | 389347-71-1 |
| | 389347-72-2 | 389347-73-3 | 389347-74-4 | 389347-75-5 | 389347-76-6 |
| | 389347-77-7 | 389347-78-8 | 389347-79-9 | 389347-80-2 | 389347-81-3 |
| | 389347-83-5 | 389348-35-0 | 389348-36-1 | | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human breast
cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 389348-37-2 | 389348-41-8 | 389348-43-0 | 389348-45-2 | 389348-48-5 |
| | 389348-50-9 | 389348-51-0 | 389348-52-1 | 389348-53-2 | 389348-55-4 |
| | 389348-58-7 | 389348-61-2 | 389348-62-3 | 389348-64-5 | 389348-66-7 |
| | 389348-69-0 | 389348-75-8 | 389348-76-9 | 389348-77-0 | 389348-78-1 |
| | 389348-79-2 | 389348-80-5 | 389348-81-6 | 389348-82-7 | 389348-83-8 |
| | 389348-85-0 | 389348-86-1 | 389348-88-3 | 389348-89-4 | 389348-93-0 |
| | 389348-97-4 | 389348-98-5 | 389348-99-6 | 389349-01-3 | 389349-02-4 |
| | 389349-08-0 | 389349-12-6 | 389349-14-8 | 389349-21-7 | 389349-28-4 |
| | 389349-29-5 | 389349-30-8 | 389349-34-2 | 389349-35-3 | 389349-36-4 |
| | 389349-38-6 | 389349-40-0 | 389349-41-1 | 389349-43-3 | 389349-44-4 |

389349-45-5 389349-46-6 389349-47-7 389349-48-8 389349-54-6
 389349-55-7 389349-59-1 389349-62-6 389349-63-7 389349-65-9
 389349-66-0 389349-67-1 389349-70-6 389349-73-9 389350-00-9
 389350-02-1 389350-05-4 389350-06-5 389350-09-8 389350-12-3
 389350-14-5 389350-15-6 389350-18-9 389350-19-0 389350-21-4
 389350-25-8 389350-28-1 389350-29-2 389350-30-5 389350-32-7
 389350-33-8 389350-34-9 389350-38-3 389350-41-8 389350-44-1
 389350-47-4 389350-48-5 389350-49-6 389350-50-9 389350-52-1
 389350-53-2 389350-54-3 389350-55-4 389350-56-5 389350-73-6, DNA
 (human gene TSLRP) 389350-80-5 389350-81-6 389350-83-8 389350-88-3
 389350-92-9 389350-93-0 389350-94-1 389351-02-4 389351-03-5
 389351-04-6 389351-05-7 389351-07-9 389351-08-0 389351-09-1
 389351-11-5 389351-14-8 389351-15-9 389351-16-0 389351-17-1
 389351-18-2 389351-19-3 389351-24-0 389351-25-1 389351-27-3
 389351-28-4 389351-29-5 389351-31-9 389351-32-0 389351-34-2
 389351-36-4 389351-38-6 389351-44-4 389351-45-5 389351-47-7
 389351-48-8 389351-50-2 389351-51-3 389351-52-4 389351-55-7
 389351-61-5 389351-62-6 389351-63-7 389351-64-8 389351-65-9
 389351-66-0 389351-69-3 389351-70-6 389351-72-8 389351-74-0
 389351-75-1 389351-76-2 389351-79-5 389351-81-9 389351-82-0
 389351-95-5 389351-97-7 389351-98-8 389351-99-9 389352-00-5
 389352-01-6 389352-02-7 389352-06-1 389352-07-2 389352-08-3
 389352-09-4 389352-11-8 389352-13-0 389352-14-1 389353-11-1
 389353-17-7 389353-18-8 389353-21-3 389353-22-4 389353-23-5
 389353-24-6 389353-25-7 389353-26-8 389353-29-1 389353-30-4
 389353-31-5 389353-33-7 389353-34-8 389353-35-9 389353-36-0
 389353-38-2 389353-40-6 389353-41-7 389353-42-8 389353-43-9
 389353-44-0 389353-45-1 389353-49-5 389353-50-8 389353-51-9
 389353-54-2 389353-56-4 389353-57-5 389353-58-6 389353-60-0
 389353-61-1 389353-63-3 389353-65-5 389353-66-6 389353-67-7
 389353-68-8 389353-69-9 389353-72-4 389353-74-6 389353-76-8
 389353-78-0 389353-79-1 389353-80-4 389353-81-5 389353-82-6
 389353-83-7 389353-85-9 389353-88-2 389353-89-3 389353-90-6
 389353-91-7 389353-93-9 389354-02-3 389354-03-4 389354-05-6
 389354-06-7 389354-07-8 389354-08-9 389354-09-0 389354-12-5
 389354-13-6 389354-17-0 389354-22-7 389354-24-9 389354-25-0
 389354-26-1 389354-27-2 389354-30-7 389354-31-8 389354-32-9
 389354-33-0 389354-34-1 389354-36-3

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human breast
 cancer)

IT 389354-37-4 389354-39-6 389354-40-9 389354-41-0 389357-25-9
 389365-02-0 389386-88-3 389387-99-9 389397-11-9 389398-09-8
 389399-94-4 389448-82-2, DNA (human clone 23667 and 23775 cDNA)
 389473-43-2 389475-49-4, DNA (human gene NHC cDNA) 389713-60-4, DNA
 (human clone RP3-467L1) 389720-72-3, GenBank U75330 389750-65-6,
 GenBank U58855 389788-87-8, DNA (human clone hl2-129 cDNA)
 390091-27-7, DNA (human eRFS cDNA) 390108-68-6, GenBank U42593
 390108-83-5, DNA (human gene CKA-3 cDNA) 390108-89-1, GenBank U97251
 390115-78-3, GenBank U60067 390293-65-9, GenBank Y17957 391521-30-5
 391523-90-3 391524-69-9, DNA (human α -actin cDNA plus flanks)
 391524-72-4, DNA (human apolipoprotein CI cDNA) 391524-81-5, GenBank
 X05231 391524-82-6 391524-95-1 391525-13-6 391525-15-8
 391525-21-6 391525-32-9 391525-64-7 391525-65-8 391525-67-0
 391525-71-6 391525-72-7, GenBank X54304 391525-74-9 391525-76-1
 391525-77-2 391525-78-3 391525-91-0 391525-93-2, DNA (human gene
 Hcox6b cDNA) 391526-02-6 391526-40-2 391526-50-4 391526-60-6
 391526-70-8, GenBank X03558 391526-83-3, GenBank X04526 391526-94-6,
 DNA (human clone (lambda)a7 cDNA) 391527-25-6 391527-39-2, DNA (human
 clone Op-30 cDNA) 391527-47-2 391527-56-3, DNA (human gelsolin cDNA
 plus flanks) 391527-62-1 391527-72-3 391527-74-5, DNA (human clone
 pRP15) 391527-87-0 391527-88-1, GenBank X04588 391527-91-6, DNA
 (human gene β 2 plus flanks) 391528-28-2 391528-32-8
 391528-40-8, DNA (human cell line HeLa clone F6 cDNA) 391528-42-0

391528-46-4 391528-48-6 391528-50-0, DNA (human clone p8h cDNA)
 391528-52-2 391528-76-0 391528-98-6, DNA (human cell line BC-10 cDNA)
 391529-03-6, DNA (human clone p-lambda-H6-7 cDNA) 391529-05-8, DNA
 (human β -actin cDNA plus flanks) 391529-22-9, DNA (human clone
 pBS.CYC5 cDNA) 391529-44-5, GenBank X05857 391529-48-9, DNA (human
 clone HP3A-1 cDNA) 391529-58-1 391529-68-3 391529-97-8, GenBank
 X12791 391530-12-4, GenBank X16064 391530-35-1, GenBank V00478
 391530-37-3 391530-50-0, DNA (human clone ADUb2 cDNA) 391530-69-1, DNA
 (human clone pHGP34 cDNA) 391530-72-6, DNA (human cell line A2058 (ATCC)
 cDNA) 391531-05-8, DNA (human clone pCOX6a.24 cDNA) 391531-16-1, DNA
 (human clone hmGLA9-3 cDNA) 391531-25-2, GenBank X06617 391531-30-9
 391531-33-2, DNA (human clone PLUb5 cDNA) 391532-37-9 391532-52-8,
 GenBank X04665 391532-74-4 391533-15-6, DNA (human cell line TT cells
 cDNA) 391533-18-9 391533-19-0 391533-20-3 391533-34-9
 391533-48-5, DNA (human clone hhmg2 cDNA) 391533-75-8 391534-12-6
 391534-53-5 391534-85-3, DNA (human clone pC14 cDNA) 391534-95-5, DNA
 (human clone C328-10 cDNA) 391535-27-6, DNA (human E-cadherin cDNA)
 391535-29-8 391535-52-7 391538-40-2 391538-48-0, DNA (human clone
 cav lambda c cDNA) 391538-55-9 391538-57-1, DNA (human HL23 ribosomal
 protein cDNA) 391538-89-9 391538-91-3 391538-96-8 391539-25-6, DNA
 (human cell line Hela clone HL-27) 391539-26-7 391539-31-4
 391539-32-5 391540-40-2, DNA (human clone KOX2 cDNA) 391540-45-7
 391540-55-9 391540-56-0 391540-59-3 391541-01-8, DNA (human testican
 cDNA plus flanks) 391541-65-4 391542-15-7 391542-17-9 391542-19-1
 391542-35-1 391543-11-6, DNA (human clone H8 and H8PPCR cDNA)
 391543-89-8 391543-99-0, DNA (human clone HP53 cDNA) 391544-11-9
 391544-26-6, DNA (human 165kD protein) 391544-31-3 391544-33-5, DNA
 (human gene GPAT cDNA) 391544-35-7, DNA (human cell line U188-MG cDNA)
 391544-36-8 391544-83-5 391544-85-7 391545-60-1 391545-96-3
 391545-97-4, DNA (human gene Cctg cDNA) 391546-18-2 391546-29-5, DNA
 (human caltractin cDNA) 391546-58-0 391546-76-2 391546-94-4
 391546-95-5 391547-32-3, DNA (human gene TEGT) 391547-83-4, DNA (human
 clone Lambda GS2-1 cDNA) 391547-94-7 391547-97-0, DNA (human FUSE
 binding protein cDNA) 391548-04-2, DNA (human gene ARL3 cDNA)
 391548-10-0 391548-22-4 391548-23-5 391548-30-4, DNA (human gene
 HLF2 cDNA) 391548-39-3 391548-40-6 391548-45-1 391548-46-2
 391548-61-1 391548-76-8, DNA (human clone Z16 cDNA) 391549-04-5, DNA
 (human DNA topoisomerase I cDNA) 391549-31-8, DNA (human clone CDM cDNA)
 391549-70-5 391549-84-1, DNA (human gene rpl11) 391550-19-9
 391550-44-0, DNA (human gene mig-2 plus 3'-flank) 391550-45-1, DNA
 (human cell line WI-38 clone mig-1) 391550-60-0, DNA (human clone
 mNTK1.2 cDNA) 391550-68-8, DNA (human cell line HeLa S3 cDNA)
 391550-70-2 391550-73-5 391550-75-7 391551-06-7 391551-14-7, DNA
 (human clone pPAP12 cDNA) 391551-26-1, DNA (human clone cPINCH 1 cDNA)
 391551-43-2, DNA (human cell line Hela S3 cDNA) 391551-83-0
 391552-21-9, DNA (human gene Eps8 cDNA) 391552-24-2, DNA (human gene
 SYT) 391552-27-5, DNA (human Csa-19 cDNA) 391552-39-9 391552-46-8
 391552-47-9 391553-28-9 391553-30-3, DNA (human fibrinogen-like
 protein cDNA) 391553-41-6 391553-42-7 391553-43-8, DNA (human
 ribosomal protein L27a cDNA) 391553-44-9 391553-45-0, DNA (human
 ribosomal protein S5 cDNA) 391553-46-1 391553-48-3, DNA (human
 ribosomal protein L5 cDNA) 391553-49-4, DNA (human ribosomal protein S10
 cDNA) 391553-60-9 391553-74-5 391553-76-7, DNA (human gene GTF2A2
 cDNA) 391553-82-5, DNA (human gene alpha NAC cDNA) 391553-90-5, DNA
 (human HLA-DMB cDNA) 391554-21-5, DNA (human gene BNIP3 cDNA)
 391554-66-8 391554-90-8 391555-24-1 391555-32-1, DNA (human clone
 201, 213, R cDNA) 391555-39-8 391555-65-0 391556-17-5 391556-18-6
 391556-45-9 391556-61-9, DNA (human clone phACL33 cDNA) 391556-73-3,
 DNA (human clone pG77-12 cDNA) 391556-76-6, DNA (human gene RAD54L cDNA)
 391556-82-4 391556-92-6, DNA (human gene ANK-3 cDNA) 391556-93-7
 391556-94-8, DNA (human clone G to O cDNA) 391557-02-1, GenBank U16826
 391557-03-2 391557-48-5, DNA (human SURF-1 cDNA) 391557-52-1
 391558-00-2 391558-12-6, DNA (human clone 7-21 cDNA) 391560-41-1
 391560-67-1 391561-72-1 391561-73-2 391562-44-0 391562-45-1
 391562-46-2 391562-47-3 391562-48-4 391562-49-5
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human breast cancer)

IT 391562-76-8 391562-78-0 391562-79-1 391562-80-4 391562-81-5
 391562-82-6 391562-83-7 391562-84-8 391562-86-0 391562-88-2
 391562-91-7 391562-94-0 391562-95-1 391562-97-3 391562-98-4
 391563-01-2 391563-07-8, DNA (human clone RORg cDNA)
 391563-77-2 391563-98-7, DNA (human cell line T47D cDNA) 391564-20-8,
 GenBank X84939 391564-41-3 391564-43-5 391564-44-6 391564-46-8
 391564-51-5 391564-67-3 391564-68-4 391564-69-5 391564-70-8
 391564-73-1 391564-74-2 391564-75-3 391564-77-5 391564-79-7
 391564-80-0 391564-81-1 391564-83-3 391564-88-8 391564-90-2
 391564-91-3 391564-92-4 391564-93-5 391564-94-6 391564-95-7
 391564-96-8 391565-02-9 391565-08-5 391565-09-6 391565-10-9
 391565-11-0 391565-13-2 391565-16-5 391565-17-6 391565-18-7
 391565-20-1 391565-21-2 391565-22-3 391565-24-5 391565-26-7
 391565-27-8 391565-28-9 391565-29-0 391565-30-3 391565-31-4
 391565-36-9 391565-43-8 391565-44-9 391565-47-2 391565-48-3
 391565-49-4 391565-50-7 391565-51-8 391565-52-9 391565-53-0
 391565-54-1 391565-56-3 391565-58-5 391565-59-6 391565-61-0
 391565-62-1 391565-63-2 391565-64-3 391565-66-5 391565-67-6
 391565-70-1 391565-71-2 391565-72-3 391565-76-7 391565-78-9
 391565-80-3 391565-81-4 391565-83-6 391565-86-9 391565-87-0
 391565-88-1 391565-89-2 391565-92-7 391565-93-8 391565-96-1
 391565-97-2 391565-98-3 391565-99-4 391566-00-0 391566-01-1
 391566-03-3 391566-05-5 391566-07-7 391566-08-8 391566-11-3
 391566-12-4 391566-16-8 391567-29-6, DNA (human clone p5 cDNA)
 391567-40-1 391568-60-8, DNA (human gene CYP51) 391570-76-6
 391571-52-1, DNA (human cell line HeLa S3 cDNA) 391571-53-2
 391571-59-8 391571-60-1, DNA (human clone B1-T1 cDNA) 391571-64-5, DNA
 (human clone 975:8 cDNA) 391574-77-9, DNA (human clone HTH55 cDNA)
 391574-78-0, DNA (human gene TIAM1 cDNA) 391575-76-1 391581-46-7
 391581-54-7, DNA (human RNPL cDNA) 391581-67-2, DNA (human clone cl19
 cDNA) 391581-69-4, DNA (human gene EF-Tu cDNA) 391583-56-5
 391583-61-2, DNA (human cell line MZ2-MEL.43 cDNA) 391584-74-0
 391584-75-1 391584-82-0 391584-83-1 391585-04-9 391588-40-2
 391588-43-5 391588-50-4, DNA (human FXR1) 391588-56-0 391590-46-8,
 DNA (human isolate patient RIC) 391590-47-9, DNA (human isolate patient
 THR) 391590-91-3, GenBank U25657 391590-99-1 391591-13-2
 391591-14-3 391591-62-1 391591-66-5 391592-28-2 391592-29-3
 391592-80-6 391758-89-7, DNA (human clone pHTO3 cDNA) 391759-21-0
 391759-23-2 391759-28-7 391759-29-8 391759-77-6 391759-87-8, DNA
 (human clone pHCC-1 cDNA) 391759-90-3 391763-23-8, DNA (human gene
 CYP2A6V2) 391763-26-1, DNA (human cell line HL60 cells cDNA)
 391763-27-2, DNA (human gene RbAp46 cDNA) 391763-31-8, DNA (human clone
 CM1 cDNA) 391763-48-7 391763-60-3 391765-26-7 391765-30-3
 391765-32-5 391765-35-8 391768-19-7, DNA (human gene hPMSR6 cDNA)
 391768-53-9, DNA (human gene DOC-2 cDNA) 391768-57-3 391769-36-1, DNA
 (human clone pYes-33 cDNA) 391770-18-6, DNA (human cell line SKBR-3
 cDNA) 391770-94-8 391770-95-9 391772-00-2, DNA (human gene DSCR1
 cDNA) 391772-31-9 391772-56-8 391772-79-5 391772-90-0
 391773-73-2 391773-74-3 391773-77-6 391774-04-2, DNA (human cell
 line BL41/B95-8 cDNA) 391774-10-0 391775-32-9 391776-00-4
 391776-51-5 391776-90-2, DNA (human clone 5.21 cDNA) 391777-01-8
 391777-02-9 391780-20-4, GenBank U40580 391780-23-7 391780-95-3
 391781-92-3, DNA (human cell line MGR-1 cDNA) 391782-13-1 391782-15-3,
 DNA (human SGP28 protein cDNA) 391782-25-5, DNA (human RGP4 cDNA)
 391783-13-4, DNA (human dynamitin cDNA) 391784-18-2, DNA (human gene N33
 cDNA) 391785-91-4 391785-95-8 391785-98-1, DNA (human gene CRISP-3
 protein cDNA) 391786-02-0, DNA (human clone ICRFp507M243) 391786-93-9
 391786-98-4 391786-99-5 391787-02-3 391787-03-4 391787-04-5
 391787-06-7 391787-08-9 391787-09-0 391787-10-3 391787-13-6
 391787-17-0 391787-18-1 391787-19-2 391787-20-5 391787-22-7
 391787-23-8 391787-26-1 391787-27-2 391787-28-3 391787-29-4
 391787-32-9 391787-35-2 391787-36-3 391787-39-6 391787-46-5

391787-47-6 391787-48-7 391787-49-8 391787-50-1 391787-51-2
 391787-54-5 391787-57-8 391787-58-9

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human
 breast cancer)

IT 391787-60-3 391787-63-6 391787-66-9, DNA (human gene UHX1 cDNA)
 391787-70-5, DNA (human protein XMP cDNA plus flanks) 391787-71-6, DNA
 (human protein YMP cDNA plus flanks) 391787-78-3 391787-86-3
 391787-89-6 391787-98-7 391787-99-8 391788-00-4 391788-01-5
 391788-02-6 391788-04-8 391788-05-9 391788-06-0 391788-13-9
 391788-28-6 391788-37-7 391788-40-2 391788-43-5 391788-50-4, DNA
 (human cell line Hela, IMR90 cDNA) 391788-51-5, DNA (human gene sec23
 cDNA) 391788-52-6, DNA (human gene sec23 cDNA) 391788-55-9
 391788-56-0 391788-59-3 391788-61-7 391788-62-8 391788-63-9
 391788-64-0 391788-65-1 391788-66-2 391788-67-3 391788-83-3
 391788-85-5 391788-87-7, DNA (human clone QLLD9139) 391789-01-8
 391789-03-0 391789-04-1 391789-06-3 391789-08-5 391789-11-0
 391789-12-1 391789-13-2 391789-14-3 391789-16-5 391789-17-6
 391789-19-8 391789-20-1 391789-21-2 391789-22-3 391789-26-7
 391789-31-4 391789-32-5 391789-33-6 391789-34-7 391789-37-0
 391789-38-1 391789-39-2 391789-40-5 391789-41-6 391789-42-7
 391789-43-8 391789-44-9 391789-45-0 391789-47-2 391789-48-3
 391789-50-7 391789-51-8 391789-52-9 391789-53-0 391789-54-1
 391789-55-2 391789-64-3 391789-65-4 391789-66-5 391789-67-6
 391789-71-2 391789-86-9 391789-89-2 391789-90-5 391789-91-6
 391789-93-8 391789-94-9 391789-95-0 391789-96-1 391789-97-2
 391789-98-3 391789-99-4 391790-00-4 391790-02-6 391790-03-7
 391790-04-8 391790-06-0 391790-07-1 391790-14-0 391790-15-1
 391790-16-2 391790-17-3 391790-19-5 391790-21-9 391790-22-0
 391790-23-1 391790-24-2 391790-25-3 391790-27-5 391790-28-6
 391790-30-0 391790-31-1 391790-32-2 391790-33-3 391790-34-4
 391790-35-5 391790-36-6 391790-38-8 391790-39-9 391790-40-2
 391790-42-4 391790-51-5 391790-53-7 391790-56-0 391790-57-1
 391790-59-3 391790-62-8 391790-64-0 391790-65-1 391790-66-2
 391790-78-6 391790-79-7 391790-80-0 391790-81-1 391790-82-2
 391790-85-5 391790-86-6 391790-87-7 391790-88-8 391790-89-9
 391790-90-2 391790-91-3 391790-97-9 391790-98-0 391791-00-7
 391791-06-3 391791-07-4 391791-08-5 391791-31-4, DNA (human isolate
 individual La cDNA) 391791-49-4 391791-50-7 391791-51-8
 391791-52-9 391791-53-0 391791-54-1 391791-55-2 391791-57-4
 391791-59-6 391791-60-9 391791-61-0 391791-62-1 391791-63-2
 391791-64-3 391791-66-5 391791-72-3 391791-74-5 391791-75-6
 391791-76-7 391791-80-3, DNA (human gene CALM cDNA) 391791-87-0, DNA
 (human gene NKCC2 cDNA) 391791-91-6, DNA (synthetic construct clone 5)
 391791-93-8, DNA (synthetic construct clone 14) 391791-95-0
 391791-97-2 391791-98-3 391792-00-0 391792-02-2 391792-04-4
 391792-06-6 391792-24-8 391792-25-9 391792-26-0 391792-27-1
 391792-28-2 391792-29-3 391792-30-6 391792-31-7 391792-32-8
 391792-33-9 391792-34-0 391792-35-1 391792-36-2 391792-37-3
 391792-39-5 391792-40-8 391792-42-0 391792-44-2 391792-45-3
 391792-46-4 391792-47-5 391792-48-6 391792-49-7 391792-50-0
 391792-51-1 391792-52-2 391792-54-4 391792-56-6 391792-57-7
 391792-58-8 391792-59-9 391792-60-2 391792-62-4 391792-63-5
 391792-67-9 391792-68-0 391792-69-1 391792-70-4 391792-71-5
 391792-72-6 391792-73-7 391792-74-8 391792-75-9 391792-76-0
 391792-77-1 391792-86-2 391792-87-3 391792-89-5 391792-90-8
 391792-91-9 391792-92-0 391792-93-1 391792-95-3 391792-97-5
 391792-98-6 391792-99-7 391793-00-3 391793-01-4 391793-02-5
 391793-03-6

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human breast
 cancer)

IT 391793-04-7 391793-08-1 391793-11-6 391793-12-7 391793-14-9
 391793-15-0 391793-18-3 391793-19-4 391793-21-8 391793-22-9
 391793-23-0 391793-24-1 391793-25-2 391793-27-4 391793-28-5
 391793-29-6 391793-31-0 391793-32-1 391793-34-3 391793-35-4
 391793-36-5 391793-37-6 391793-38-7 391793-48-9 391793-49-0
 391793-51-4 391793-52-5 391793-54-7 391793-55-8 391793-56-9
 391793-57-0 391793-58-1 391793-59-2 391793-60-5 391793-61-6
 391793-62-7 391793-63-8 391793-64-9 391793-65-0 391793-66-1
 391793-67-2 391793-68-3 391793-72-9 391793-74-1 391793-75-2
 391793-76-3 391793-77-4 391793-78-5 391793-79-6 391793-80-9
 391793-81-0 391793-82-1 391793-83-2 391793-84-3 391793-85-4
 391793-89-8, DNA (human cell line HeLa cell R19 cDNA) 391793-92-3
 391793-96-7 391794-00-6 391794-01-7 391794-02-8 391794-03-9
 391794-04-0 391794-05-1 391794-06-2 391794-14-2 391794-15-3
 391794-16-4 391794-17-5 391794-18-6 391794-19-7 391794-20-0
 391794-22-2 391794-27-7, DNA (human gene SUPT4H cDNA) 391794-44-8
 391794-46-0 391794-47-1 391794-48-2 391794-49-3 391794-50-6
 391794-51-7 391794-52-8 391794-53-9 391794-54-0 391794-55-1
 391794-56-2 391794-57-3 391794-58-4 391794-59-5 391794-60-8
 391794-61-9 391794-62-0 391794-63-1 391794-66-4, DNA (human gene
 S3111125 cDNA) 391794-94-8 391795-01-0 391795-04-3 391795-05-4
 391795-06-5 391795-08-7 391795-09-8 391795-10-1 391795-11-2
 391795-12-3 391795-13-4 391795-14-5 391795-16-7 391795-17-8
 391795-19-0 391795-20-3 391795-21-4 391795-22-5 391795-23-6
 391795-24-7 391795-25-8 391795-26-9 391795-27-0 391795-28-1
 391795-29-2 391795-30-5 391795-31-6 391795-32-7 391795-33-8
 391795-34-9 391795-36-1 391795-37-2 391795-38-3 391795-39-4
 391795-40-7 391795-41-8 391795-42-9 391795-45-2 391795-46-3
 391795-47-4 391795-51-0 391795-52-1 391795-53-2 391795-54-3
 391795-57-6 391795-58-7 391795-59-8 391795-60-1 391795-61-2
 391795-62-3 391795-63-4 391795-64-5 391795-65-6 391795-66-7
 391795-67-8 391795-68-9 391795-76-9, DNA (human clone FA146-1C4 cDNA)
 391797-51-6, DNA (human Rab22b cDNA) 391799-35-2 391799-36-3
 391800-21-8, GenBank U54804 391801-57-3 391802-06-5 391804-84-5, DNA
 (human gp330 precursor cDNA) 391805-53-1, DNA (human gene EXT2 cDNA)
 391805-54-2 391805-55-3 391806-12-5 391806-64-7, DNA (human gene LPP
 cDNA) 391809-05-5, DNA (human gene BAF155) 391809-06-6 391809-08-8,
 DNA (human gene BAF60b cDNA) 391809-09-9 391809-36-2, GenBank Y07968
 391810-34-7, GenBank U38784 391810-36-9 391810-50-7, DNA (human zinc
 finger protein cDNA) 391810-58-5 391811-20-4 391811-21-5
 391812-62-7, DNA (human gene tpr2 cDNA) 391813-21-1 391813-34-6, DNA
 (human gene HEAB cDNA) 391813-80-2 391813-81-3 391814-64-5, DNA
 (human gastricsin cDNA) 391814-69-0 391815-23-9, DNA (human gene DFFRX
 cDNA) 391815-89-7 391815-90-0, DNA (human gene C3f cDNA)
 391816-47-0, DNA (human gene CL-20 cDNA) 391816-49-2 391816-92-5, DNA
 (human gene chs cDNA) 391816-93-6, DNA (human CD97 cDNA) 391819-70-8
 391819-84-4 391819-90-2 391820-02-3 391820-10-3, DNA (human clone
 23733 cDNA) 391820-11-4, DNA (human clone 23761 cDNA) 391820-12-5, DNA
 (human clone 23801 cDNA) 391822-82-5 391822-88-1 391822-90-5, DNA
 (human gene MCP-4 cDNA) 391823-41-9, GenBank U63542 391824-85-4
 391824-86-5, DNA (human clone PIP5KIa1 cDNA) 391826-32-7 391826-67-8
 391827-22-8 391827-23-9, DNA (human clone F2 cDNA) 391827-35-3
 391828-30-1 391828-31-2, DNA (human cell line NB4 cDNA) 391828-32-3,
 GenBank U62583 391829-01-9, DNA (human clone 119777 cDNA) 391830-45-8,
 DNA (human gene MIP-3 β cDNA) 391831-22-4, DNA (human cell line
 Molt-4) 391831-82-6 391831-92-8, DNA (human cell line U937 clone 3
 cDNA) 391832-47-6, DNA (human gene Sort1 cDNA) 391832-75-0, DNA (human
 nucleolar protein p40 cDNA) 391832-90-9 391832-97-6, DNA (human clone
 RP1-94G16) 391832-99-8 391833-40-2, DNA (human gene tpr cDNA)
 391833-97-9, DNA (human gene IL13RA1 cDNA) 391834-23-4, DNA (human gene
 UCP2 cDNA) 391834-24-5 391834-26-7, DNA (human cell line IMR-32 cDNA)
 391834-29-0 391834-39-2 391835-19-1 391835-20-4 391836-19-4, DNA
 (human clone 23773 cDNA) 391836-20-7, DNA (human clone 23907 cDNA)
 391836-22-9, DNA (human clone 23600 cDNA) 391836-23-0, DNA (human clone
 23815 cDNA) 391836-74-1 391836-81-0, DNA (human HS1 binding protein
 cDNA) 391837-44-8, DNA (human myosin I beta cDNA) 391839-11-5

391839-14-8

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human breast
cancer)

IT 391840-26-9, DNA (human gene DPP-I) 391840-95-2, DNA (human isolate
Korean cDNA) 391841-60-4, DNA (human gene UCPH cDNA) 391842-52-7
391842-53-8, DNA (human clone 323380 cDNA) 391843-44-0 391844-54-5
391844-55-6, DNA (human gene BTF5 cDNA) 391845-63-9, DNA (human bikunin
cDNA) 391845-65-1, DNA (human gene OPG cDNA) 391847-56-6, DNA (human
Hlark cDNA) 391847-74-8 391849-07-3, DNA (human karyopherin beta 3
cDNA) 391850-64-9, DNA (human gene SAP18 cDNA) 391853-22-8, DNA (human
gene fb19) 391853-26-2 391854-60-7, DNA (human gene GPP130 cDNA)
391854-61-8 391995-75-8 391996-11-5, DNA (human tyrosyl-tRNA
synthetase cDNA) 391996-17-1, DNA (human gene RETL1 cDNA) 391997-17-4
391998-11-1 392000-38-3, DNA (human clone RP3-434P1) 392007-47-5, DNA
(human gene hCTR1 cDNA) 392009-65-3 392009-82-4, DNA (human clone
hsalg7 cDNA) 392011-03-9, DNA (human gene OB-RGRP cDNA) 392011-10-8,
DNA (human gene selW cDNA) 392011-64-2 392013-07-9 392013-40-0
392013-44-4, GenBank U80747 392014-80-1 392014-81-2, DNA (human gene
Int-6 cDNA) 392015-14-4 392015-54-2, DNA (human disintegrin-protease)
392015-93-9, DNA (human gene NVL.2 cDNA) 392020-55-2, GenBank Y12653
392022-63-8 392025-01-3 392027-37-1 392037-22-8 392037-62-6
392037-63-7 392037-64-8 392039-00-8 392042-82-9, DNA (human gene
Dell cDNA) 392049-34-2 392053-41-7, DNA (human clone pCDL-1 cDNA)
392060-73-0 392076-97-0, DNA (human clone pHCC3-1 cDNA) 392077-73-5
392077-74-6, GenBank U41850 392077-75-7, GenBank U42404 392077-76-8,
GenBank U42457 392077-77-9, GenBank U42458 392077-78-0, GenBank U42594
392077-86-0, GenBank U61083 392077-87-1 392077-88-2, DNA (human gene
P5Cs cDNA) 392077-92-8, DNA (human gene MYO5A cDNA) 392089-90-6, DNA
(human gene AFG3L2 cDNA) 392185-63-6, DNA (human glutaminyl-tRNA
synthetase) 392194-19-3 392198-72-0 392204-55-6, DNA (human gene RR2
cDNA) 392204-89-6 392207-56-6 392207-63-5 392209-03-9
392209-04-0 392209-91-5 392210-60-5, DNA (human clone EHB8/pB8.3)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human breast
cancer)

IT 159127-16-9 172627-94-0 384494-76-2, DNA
(human PC1/PC3) 391563-01-2
391763-60-3

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human
breast cancer)

RN 159127-16-9 HCAPLUS

CN DNA (human testis clone PC3 centractin β -isoform cDNA plus flanks)
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 172627-94-0 HCAPLUS

CN DNA (human osteoblast gene TIEG transforming growth factor β -induced
protein cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 384494-76-2 HCAPLUS

CN DNA (human PC1/PC3) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 391563-01-2 HCAPLUS

CN DNA (human strain NCI-H69 cell line NEC clone 1 cDNA) (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 391763-60-3 HCAPLUS

CN DNA (human TGF- β receptor interacting protein isoform 1 cDNA plus
flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 9 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:785622 HCAPLUS

DN 135:314495

ED Entered STN: 30 Oct 2001

TI Differentially expressed nucleic acids encoding tumor-associated proteins,
kits, and methods for identification, assessment, prevention, and therapy
of human prostate cancer

IN Schlegel, Robert; Endege, Wilson; Monahan, John E.

PA Millennium Predictive Medicine, Inc., USA

SO PCT Int. Appl., 975 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM G01N033-574

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 9, 13, 14, 63

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|--|--------------|
| PI | WO 2001053836 | A2 | 20010726 | WO 2001-XC2318 | 20010124 <-- |
| | W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| | RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | |
| | WO 2001053836 | A2 | 20010726 | WO 2001-US2318 | 20010124 <-- |
| | WO 2001053836 | A3 | 20020606 | | |
| | WO 2001053836 | C2 | 20021107 | | |
| | W: | | | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | |
| | RW: | | | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | |
| PRAI | US 2000-178525P | P | 20000124 | <-- | |
| | US 2000-183245P | P | 20000217 | <-- | |
| | US 2000-190139P | P | 20000316 | <-- | |
| | US 2000-208126P | P | 20000531 | <-- | |
| | US 2000-219705P | P | 20000718 | <-- | |
| | US 2000-255160P | P | 20001213 | <-- | |
| | WO 2001-US2318 | A | 20010124 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|------------------------------------|
| WO 2001053836 | ICM | G01N033-574 |
| WO 2001053836 | ECLA | G01N033/574C14 |

AB This invention relates to newly discovered correlations between expression of certain nucleic acid markers and the cancerous state of human prostate cells. The levels of expression of individual markers and combinations of markers described herein correlates with the presence of prostate cancer or a pre-malignant condition in a patient. Methods are provided for detecting the presence of prostate cancer in a sample, the absence of

prostate cancer in a sample, the stage of a prostate cancer, the metastatic potential of a prostate cancer, the indolence or aggressiveness of the cancer, and other characteristics of prostate cancer that are relevant to prevention, diagnosis, characterization and therapy of prostate cancer in a patient. Thousands of differentially-expressed cDNA markers are identified in subtracted cDNA libraries and by transcript profiling. [This abstract record is the fourth of four records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

- ST tumor assocd protein cDNA prostate cancer; diagnosis prostate cancer tumor assocd protein cDNA; antitumor agent prostate tumor assocd protein cDNA
- IT Carcinogens
 - (assessment of test compound potential; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)
- IT Diagnosis
 - (cancer; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)
- IT Blood analysis
 - Computer application
 - Drug screening
 - Immunoassay
 - Nucleic acid amplification (method)
 - Nucleic acid hybridization
 - Test kits
 - Tumor markers
 - Urine analysis
 - cDNA sequences
 - (differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)
- IT cDNA
 - mRNA
 - RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 - (differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)
- IT Antibodies
 - RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)
- IT Antisense oligonucleotides
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)
- IT Hybridoma
 - (for antibody production; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)
- IT Androgens
 - RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 - (markers with sensitivity to; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)
- IT Prostate gland
 - (neoplasm, inhibitors; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Prostate gland
(neoplasm; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Antitumor agents
(prostate gland; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Lymph
Semen
(sample anal. in; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Proteins, specific or class
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(secretory; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Proteins, specific or class
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(tumor-associated; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT 78849-82-8, DNA (human mitochondria 16569-nucleotide fragment)
85496-43-1, DNA (human relaxin cDNA) 99576-76-8, RNA (human 18 S ribosomal) 99674-67-6, DNA (human 28 S rRNA gene) 115536-85-1
121630-81-7 124586-01-2 126466-74-8, DNA (human clone LP211 lipocortin I cDNA plus flanks) 132749-27-0 132892-47-8 134010-88-1
134546-96-6 135373-53-4 135433-70-4 135542-32-4 136046-25-8
137925-72-5, DNA (human proteinase C5-subunit cDNA plus flanks)
139804-18-5, GenBank J05480 139804-75-4 139804-76-5 139804-77-6
139805-28-0, 1335: PN: WO0153836 TABLE: 6 claimed DNA 139806-30-7
139806-48-7 139806-77-2 139808-59-6 139809-47-5 139809-48-6
139810-76-7 139810-88-1 139811-01-1 139811-02-2, DNA (human gene rps24 cDNA) 139812-70-7, GenBank M29960 139825-25-5 139848-18-3
139852-34-9 139858-26-7 139859-64-6 139862-15-0 139866-58-3
139898-87-6 140026-00-2 140026-28-4, GenBank J04205 140026-51-3
140027-77-6 140028-18-8 140028-23-5, GenBank M30448 140028-69-9
140028-71-3 140028-85-9 140028-86-0 140029-63-6 140029-85-2
140030-55-3 140030-60-0 140030-70-2 140031-50-1 140032-05-9
140033-36-9 140033-55-2 140033-67-6, GenBank M21895 140033-76-7, GenBank M24902 140033-83-6 140034-30-6 140034-31-7, DNA (human clone p3.32 prothymosin α pseudogene plus flanks) 140034-40-8, DNA (human prothymosin α pseudogene plus flanks) 140034-43-1
140034-55-5 140034-69-1 140034-99-7 140035-01-4 140035-08-1
140036-18-6 140036-36-8 140036-42-6 140036-49-3, DNA (human α -tubulin cDNA) 140048-87-9 140050-69-7 140051-24-7
140061-49-0 140061-68-3 140063-51-0 140064-33-1 140064-70-6
140066-85-9 140067-35-2 140069-99-4 140070-33-3 140078-69-9
140078-78-0 140079-02-3 140087-32-7 140091-95-8 140093-26-1
140094-05-9 140095-12-1 140095-38-1 140106-55-4 140110-18-5
140274-41-5 140274-63-1 140274-96-0 140275-68-9 140275-84-9
140276-84-2 140276-85-3, GenBank M19961 140277-27-6 140277-28-7
140278-33-7 140278-35-9 140278-60-0, GenBank J00139 140278-77-9
140279-68-1 140279-85-2 140280-05-3 140280-40-6 140284-11-3, GenBank M22919 140284-33-9, GenBank M16650 140284-36-2 140284-54-4
140284-66-8 140286-10-8 140286-11-9 140287-63-4
140287-71-4 140288-10-4 140321-66-0 140324-70-5 140325-13-9
140331-92-6, DNA (human ribosomal protein L 17 cDNA plus flanks)
140336-55-6 140337-45-7 140345-29-5 140507-63-7 140509-73-5

140513-90-2 140513-91-3 140538-77-8 140559-42-8 140561-17-7
 140568-75-8 140740-51-8, GenBank J03779 140747-52-0 140750-33-0
 140774-52-3, GenBank M24543 140775-47-9 140775-61-7 140794-51-0
 140801-66-7 140801-95-2 140832-58-2, GenBank M90357 140961-32-6
 140962-80-7 140962-96-5 141004-90-2 141015-35-2, DNA (human
 β -actin cDNA plus flanks) 141015-40-9 141155-71-7 141161-60-6,
 DNA (human gene RPS6 plus flanks) 141370-75-4 141490-77-9
 141878-69-5 142101-50-6 142101-96-0 142318-55-6 142432-43-7
 142480-42-0 142579-00-8 142693-75-2 142830-35-1 143001-94-9
 143283-41-4, DNA (human rps8 gene for ribosomal protein S8) 143297-30-7
 143342-11-4 143368-89-2, DNA (human clone hEc10 cadherin E cDNA plus
 flanks) 144014-49-3 144014-66-4 144560-33-8 144560-34-9
 144560-36-1 144713-92-8, DNA (human clone λ KB3 basigin cDNA plus
 flanks) 144725-55-3, DNA (human T-plastin gene, last exon (16))
 144966-66-5 145001-51-0 145113-52-6 145171-97-7 145280-63-3, DNA
 (human clone λ 21726 antigen GA 733 isoform 2 gene exon 9 plus
 flanks) 145347-70-2 145405-57-8, DNA (human ribosome protein S20 cDNA
 plus flanks) 145710-46-9 145710-47-0 145711-51-9 145734-32-3
 145885-53-6, DNA (human non-histone chromosomal protein (HMG-1)
 retropseudogene) 145971-93-3 145972-45-8, DNA (human clone
 λ KM-A gene c-myc plus flanks) 145975-45-7 145977-29-3
 146003-70-5 146193-40-0, DNA (human clone plac-1 calnexin cDNA plus
 flanks) 146210-04-0 146316-77-0 146883-04-7 147351-38-0
 147371-77-5 147565-03-5 147748-67-2 147825-15-8, DNA (human antigen
 tum- cDNA plus flanks) 148141-28-0 148142-00-1 148284-09-7
 148286-00-4 148286-03-7, DNA (human gene RING1 protein cDNA plus flanks)
 148311-39-1 148311-87-9, DNA (human gene Rb plus flanks) 148391-16-6
 148391-57-5 148426-48-6 148450-07-1 148450-37-7 148450-41-3
 148450-44-6 148450-46-8 148450-48-0 148450-56-0 148512-85-0
 148664-96-4 148783-33-9 148784-15-0 148784-16-1 148954-98-7
 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 148958-72-9 148984-44-5, DNA (human antigen CD 9 gene exon 8 plus
 flanks) 149162-41-4 149448-51-1 149482-88-2 149583-64-2
 149768-39-8 149956-88-7 150001-21-1, DNA (human gene PRAD1 exon 1 plus
 flanks) 150003-53-5 150090-65-6 150121-85-0 150247-01-1
 150249-62-0 150353-61-0, GenBank D16234 150383-62-3 150425-12-0
 150471-65-1 150490-72-5 150575-53-4 150735-27-6 150820-40-9
 150886-88-7 151002-40-3 151208-88-7 151212-17-8 151280-19-2
 151346-89-3 151494-35-8 151548-43-5 151548-67-3 151549-93-8
 151875-72-8 151875-74-0 151973-87-4 152054-72-3
 152057-23-3 152115-63-4 152282-50-3 152282-55-8, DNA (human clone
 PO2ST9 cDNA) 152283-37-9 152283-58-4 152283-61-9 152395-06-7
 152410-77-0 152472-34-9 153016-44-5 153056-13-4 153269-93-3
 153320-43-5 153418-26-9 153420-53-2 153608-67-4 153663-93-5
 153792-68-8 153793-54-5 153961-36-5 153962-35-7 153962-36-8
 154298-47-2 154332-50-0 154449-83-9 154513-28-7 154527-62-5
 154980-07-1 154980-79-7 154980-81-1 154980-84-4 154982-58-8
 154983-27-4 155570-90-4 155571-92-9 155610-75-6 155712-28-0
 155714-34-4 155715-45-0 156104-30-2 156225-32-0 156552-53-3
 156552-89-5 156584-19-9, GenBank U10362 156613-27-3 156650-88-3
 156797-76-1 156887-92-2 156924-17-3 157083-97-1 157152-28-8
 157153-51-0 158058-75-4 158085-71-3 158106-95-7 158125-26-9
 158162-53-9 158184-31-7 158206-09-8 158245-35-3 158317-99-8
 158339-28-7 158340-05-7 158340-06-8 158448-63-6 158481-10-8
 158645-17-1 158681-71-1 158764-13-7 158765-60-7 158929-86-3
 158929-87-4 159200-90-5 159287-92-0 159409-46-8 159447-26-4
 160075-35-4 160165-32-2 160166-16-5 160263-66-1 160364-88-5
 160613-31-0 160830-99-9 160865-22-5 160899-13-8, DNA (human clone
 30B, 17A, 13) 160932-08-1 161046-66-8 161048-67-5 161049-54-3
 161274-01-7 161310-01-6 161381-56-2 162454-40-2 162527-29-9

162528-37-2, DNA (human isolate sample K1) 162528-42-9, DNA (human isolate sample K3) 162528-48-5 162528-58-7 162765-83-5
 162775-37-3 162983-89-3 163174-72-9 163204-94-2 163249-48-7
 163377-49-9 163568-17-0 163695-58-7 163870-31-3 163998-88-7
 164056-24-0 164100-04-3 164316-17-0 164372-42-3 164442-68-6
 164476-73-7 164479-08-7 164574-28-1 164598-52-1 164598-64-5, DNA (human cell line Hela) 164600-32-2 164696-32-6 164704-73-8
 164741-68-8 164806-49-9 164821-84-5 164952-69-6, DNA (human clone 5G7 cDNA) 164954-10-3 165018-30-4 165094-05-3 165146-46-3
 165228-08-0 165244-91-7 165647-97-2 165719-62-0 165755-95-3
 165757-12-0 165758-39-4, DNA (human clone XX-HW2) 165764-85-2
 165868-20-2 166415-72-1 166513-74-2 166690-01-3 166779-33-5
 166841-06-1 166845-86-9 166848-08-4 166856-20-8 166857-87-0
 166870-30-0 166915-46-4 166920-79-2 166933-28-4 166933-29-5
 167034-57-3 167039-88-5 167189-93-7 167205-99-4 167229-60-9
 167436-89-7 167438-33-7 167712-50-7 167712-74-5, DNA (human FXR1 gene plus flanks) 167713-02-2 167713-53-3 167714-30-9 168314-09-8
 168355-89-3 168373-43-1 168384-39-2 168384-40-5 168437-67-0
 168515-03-5 168515-04-6 168515-57-9 168519-75-3 168522-62-1
 168522-88-1 168532-98-7 168582-28-3 168584-68-7 168604-40-8
 168654-85-1 168858-55-7 168957-25-3 168987-50-6 169006-16-0
 169011-99-8 169014-90-8 169073-83-0 169075-13-2, DNA (human clone plck13-1 cDNA) 169079-58-7 169146-75-2 169278-10-8 169570-90-5
 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, **prevention**, and therapy of human prostate cancer)

IT 169641-26-3 169641-47-8 169651-08-5 169711-70-0 169725-05-7
 169733-50-0, DNA (human clone HLC-21 cDNA) 169861-54-5, DNA (human clone 151e9) 169914-99-2, DNA (human clone 27d10) 170036-62-1, DNA (human clone 79a12) 170046-84-1, DNA (human clone 97c6) 170193-47-2
 170248-70-1 170273-84-4 170315-86-3 170318-73-7 170336-90-0
 170404-41-8 170406-48-1 170421-14-4 170475-23-7 170522-00-6
 170535-74-7 170618-54-9 170816-65-6, DNA (human clone B9 cDNA)
 170896-44-3 171122-43-3 171129-01-4 171138-14-0 171166-37-3
 171175-13-6 171305-38-7 171449-27-7 171449-31-3 171635-73-7
 171716-06-6 171750-24-6 171786-63-3 171793-53-6
 171840-12-3 171845-13-9, DNA (human cell line KG-1 cDNA) 171845-27-5
 171845-40-2 171870-36-3 171941-48-3 171941-55-2 172013-52-4
 172013-56-8 172013-65-9 172014-16-3 172047-20-0 172047-21-1
 172055-85-5 172110-16-6 172119-51-6 172126-92-0 172137-43-8, 9:
 PN: WO0021995 PAGE: 25 unclaimed DNA 172183-31-2 172191-78-5
 172387-00-7 172445-63-5 172631-11-7 172773-12-5 172855-91-3
 172866-18-1 173003-48-0 173005-06-6 173005-18-0 173112-13-5
 173125-02-5 173138-09-5 173182-69-9 173229-17-9 173487-92-8
 173488-82-9 173573-20-1 173706-41-7 173707-30-7 173795-20-5
 173826-70-5 173827-31-1 174029-18-6 174031-26-6 174053-40-8
 174057-08-0 174098-53-4 174170-67-3 174242-50-3 174286-77-2
 174286-79-4 174387-66-7, DNA (human transposon MER37) 174444-87-2
 174445-99-9 174477-86-2 175000-59-6, DNA (human clone GHc-870H8)
 175001-40-8 175004-25-8 175006-21-0 175064-82-1 175115-00-1, DNA (human gene FRG1 cDNA plus flanks) 175196-66-4 175581-12-1
 175581-79-0 175582-67-9 175748-25-1 175750-24-0 175757-27-4
 175801-56-6 175815-72-2 175895-64-4 176156-91-5 176188-04-8
 176270-87-4 176291-24-0 176348-56-4 176349-40-9 176358-29-5
 176365-18-7 176553-02-9 176630-37-8 176800-79-6, DNA (human clone LLOXNC01-131B10) 176937-26-1 177116-99-3, DNA (human clone LLOXNC01-85H7) 177149-83-6 177368-39-7 177397-05-6 177459-01-7
 177527-67-2 177527-68-3 177527-90-1 177589-54-7 177669-72-6
 177823-32-4 177998-42-4 178003-56-0 178186-32-8 178298-58-3
 178639-19-5 178847-33-1 178923-06-3 179225-07-1 179228-73-0
 179290-96-1 179294-75-8 179297-20-2 179298-77-2 179423-16-6
 179442-92-3 179501-26-9 179501-99-6 179503-60-7 179565-73-2

| | | | | |
|-------------|-------------|-------------|-------------|-------------|
| 179566-72-4 | 179567-02-3 | 179582-23-1 | 179583-61-0 | 179587-03-2 |
| 179588-64-8 | 179589-53-8 | 179591-49-2 | 179594-48-0 | 179645-13-7 |
| 179698-50-1 | 179708-98-6 | 179709-04-7 | 179719-48-3 | 179776-64-8 |
| 179778-57-5 | 179779-53-4 | 179780-31-5 | 179782-97-9 | 179837-30-0 |
| 179840-71-2 | 179843-60-8 | 179844-08-7 | 179854-84-3 | 179964-15-9 |
| 179965-41-4 | 179966-47-3 | 179970-01-5 | 179970-76-4 | 179973-99-0 |
| 179980-51-9 | 180010-17-7 | 180011-21-6 | 180011-91-0 | 180012-23-1 |
| 180014-24-8 | 180015-42-3 | 180016-46-0 | 180017-04-3 | 180096-57-5 |
| 180098-35-5 | 180113-92-2 | 180123-08-4 | 180218-50-2 | 180245-65-2 |
| 180245-76-5 | 180245-79-8 | 180246-36-0 | 180309-39-1 | 180369-99-7 |
| 180374-65-6 | 180378-12-5 | 180447-24-9 | 180454-21-1 | 180499-98-3 |
| 180544-42-7 | 180544-53-0 | 180544-72-3 | 180546-19-4 | 180546-36-5 |
| 180546-77-4 | 180547-02-8 | 180547-32-4 | 180551-33-1 | 180552-05-0 |
| 180552-23-2 | 180554-50-1 | 180556-17-6 | 180563-66-0 | 180655-52-1 |
| 180658-65-5 | 180665-04-7 | 180669-74-3 | 180671-04-9 | 180673-59-0 |
| 180701-59-1 | 180703-22-4 | 180703-89-3 | 180703-94-0 | 180704-15-8 |

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

| | | | | | |
|----|------------------------------|--------------------------------------|--------------------------------------|-------------------------|------------------|
| IT | 180707-94-2 | 180709-80-2 | 180749-62-6 | 180752-61-8 | 180753-65-5 |
| | 180753-82-6 | 180754-37-4 | 180754-66-9 | 180755-99-1 | 180758-99-0 |
| | 180762-58-7 | 180806-61-5 | 181092-10-4 | 181093-80-1 | 181094-58-6 |
| | 181096-71-9 | 181098-38-4 | 181099-74-1 | 181099-75-2 | 181110-09-8 |
| | 181159-43-3 | 181163-43-9 | 181164-88-5 | 181198-15-2 | 181199-29-1 |
| | 181200-23-7 | 181200-70-4 | 181249-63-8 | 181252-58-4 | 181290-35-7, DNA |
| | (human clone 10E6) | 181290-43-7 | 181353-24-2, DNA | (human protein FAN | |
| | cDNA plus flanks) | 181354-00-7 | 181382-08-1 | 181384-06-5 | 181385-33-1 |
| | 181391-76-4 | 181392-89-2 | 181462-81-7 | 181547-98-8 | 181598-58-3 |
| | 181615-78-1 | 181666-45-5 | 181670-25-7 | 181671-76-1 | 181673-22-3 |
| | 181678-19-3 | 181680-93-3 | 181685-70-1 | 181687-30-9 | 181689-36-1 |
| | 181690-46-0 | 181691-50-9 | 181692-15-9 | 181694-22-4 | 181726-24-9 |
| | 181745-04-0 | 181860-27-5 | 181897-01-8 | 181897-16-5 | 181901-36-0 |
| | 181902-52-3 | 181903-21-9 | 181905-19-1 | 181907-13-1 | 181910-07-6 |
| | 181911-86-4 | 181914-93-2 | 181915-46-8 | 181922-96-3 | 182098-23-3 |
| | 182105-92-6 | 182179-71-1 | 182341-90-8 | 182341-91-9, DNA | (human clone |
| | p91c10) | 182341-96-4, DNA | (human clone p130c12) | 182375-12-8 | |
| | 182380-99-0 | 182387-76-4 | 182391-42-0 | 182394-82-7 | 182399-77-5 |
| | 182400-82-4 | 182403-20-9 | 182445-77-8 | 182448-29-9 | 182450-11-9 |
| | 182462-50-6 | 182463-67-8 | 182521-84-2 | 182538-03-0 | 182538-22-3 |
| | 182539-14-6 | 182543-37-9 | 182544-13-4 | 182591-58-8 | 182596-12-9 |
| | 182599-20-8 | 182603-91-4 | 182605-53-4 | 182605-67-0 | 182612-63-1 |
| | 182646-88-4, DNA | (human EST (expressed sequence tag)) | 182659-54-7 | | |
| | 182660-03-3 | 182662-54-0, DNA | (human EST (expressed sequence tag)) | | |
| | 182668-69-5 | 182730-17-2 | 182730-51-4 | 182735-63-3 | 182736-77-2 |
| | 182764-56-3 | 182766-30-9 | 182775-34-4 | 182778-63-8 | 182779-20-0 |
| | 182779-50-6 | 182782-66-7 | 182782-86-1 | 182783-21-7 | 182791-45-3 |
| | 182791-63-5 | 182793-46-0 | 182793-68-6 | 182795-08-0 | 182848-66-4, DNA |
| | (human gene ATR plus flanks) | 182862-08-4, DNA | (human clone c86) | | |
| | 183050-30-8 | 183080-66-2 | 183094-89-5 | 183100-41-6 | 183100-59-6 |
| | 183104-38-3 | 183104-50-9 | 183104-55-4, DNA | (human clone RP1-96A9) | |
| | 183215-32-9 | 183217-48-3 | 183266-02-6 | 183291-66-9 | 183330-05-4 |
| | 183331-99-9 | 183332-59-4 | 183334-31-8 | 183338-52-5 | 183338-72-9 |
| | 183391-25-5, DNA | (human clone 68a1) | 183391-28-8 | 183391-41-5 | |
| | 183391-51-7, DNA | (human clone RP1-36J3) | 183391-98-2 | 183453-19-2 | |
| | 183455-63-2 | 183456-04-4 | 183461-08-7 | 183629-83-6 | 183629-97-2 |
| | 183631-41-6 | 183639-78-3 | 183645-77-4 | 183648-88-6 | 183650-87-5 |
| | 183651-06-1 | 183656-26-0 | 183656-39-5 | 183687-24-3 | 183690-61-1 |
| | 183693-72-3 | 183695-62-7 | 183703-62-0 | 183703-84-6 | 183706-85-6 |
| | 183707-75-7 | 183716-95-2 | 183717-87-5 | 183761-06-0 | 183762-20-1 |
| | 183763-31-7 | 183768-31-2 | 183769-15-5 | 183770-97-0 | 183777-48-2 |
| | 183777-82-4 | 183780-18-9 | 183784-70-5 | 183822-48-2 | 183823-21-4 |
| | 183824-77-3 | 183826-43-9 | 183828-23-1 | 183829-38-1 | 183831-25-6 |

183834-16-4 183836-57-9 183840-51-9 183841-26-1 183843-04-1
 183982-06-1, DNA (human gene STP2 plus 3'-flank) 183984-23-8
 183984-24-9 183984-53-4 184077-49-4 184081-23-0 184081-53-6
 184082-41-5 184137-27-7 184141-66-0 184184-72-3 184187-76-6
 184195-58-2 184199-34-6 184202-89-9 184204-28-2 184205-24-1
 184207-34-9 184209-19-6 184209-31-2 184210-16-0 184210-30-8
 184210-37-5 184213-71-6 184214-48-0 184215-10-9 184217-45-6
 184252-95-7 184257-49-6 184258-71-7 184259-45-8 184324-78-5
 184326-53-2 184333-90-2 184333-93-5

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT 184341-63-7 184342-41-4 184380-25-4 184382-13-6, DNA (human clone RP1-106C24) 184389-98-8 184394-44-3 184394-96-5 184399-20-0
 184400-77-9 184413-14-7 184440-33-3 184442-87-3 184443-26-3
 184444-24-4 184507-69-5 184507-78-6 184511-55-5, DNA (human clone 46b2) 184512-64-9 184517-37-1 184541-21-7 184542-16-3
 184542-52-7 184544-18-1 184544-27-2 184544-82-9 184549-41-5
 184549-81-3 184565-93-3 184569-94-6 184570-35-2 184570-74-9
 184571-46-8 184613-87-4 184616-42-0 184618-52-8 184663-28-3
 184663-44-3 184666-61-3 184668-46-0 184672-19-3 184695-27-0, DNA (human clone RP3-453A3) 184743-37-1 184745-80-0 184746-88-1
 184751-40-4 184752-72-5 184754-38-9 184802-72-0 184804-35-1
 184805-02-5 184805-36-5 184805-83-2 184811-76-5 184814-94-6
 184815-94-9 184927-67-1 184935-28-2 184975-47-1 184980-42-5
 185077-28-5 185083-77-6 185128-25-0, DNA (human clone RP3-368A4)
 185128-94-3 185171-19-1 185177-48-4 185178-90-9 185180-28-3
 185187-71-7 185266-39-1 185268-81-9 185276-10-2 185277-03-6
 185282-68-2 185282-76-2 185283-09-4, DNA (human clone RP1-57A13)
 185284-55-3 185288-47-5 185289-21-8 185295-15-2 185296-32-6
 185297-15-8 185362-45-2 185368-10-9 185368-77-8 185646-89-3
 185648-58-2 185650-15-1 185650-35-5 185666-78-8 185706-86-9
 185710-08-1 185715-36-0 185717-41-3 185772-83-2 185772-87-6, DNA (human clone RP1-230G1) 185782-87-0 185862-71-9 185872-47-3
 185922-77-4 185925-34-2 185925-38-6, DNA (human clone RG161K23)
 185938-83-4 185974-16-7 185975-08-0 185975-17-1 185977-98-4
 185978-09-0 186017-40-3 186017-55-0 186173-08-0 186286-66-8
 186364-62-5 186404-30-8 186472-04-8 186476-22-2 186479-81-2
 186485-10-9 186487-51-4 186516-67-6 186560-28-1 186564-89-6
 186565-92-4 186567-03-3 186569-33-5 186570-18-3 186577-40-2
 186621-26-1 186621-51-2 186624-77-1 186679-73-2, DNA (human clone 92E23) 186721-91-5 186816-96-6 186817-00-5 186848-84-0, DNA (human gene STP1 plus flanks) 186854-79-5 186860-56-0 186861-93-8
 186864-94-8 186866-07-9 186871-48-7 186881-97-0 186920-47-8
 186925-67-7 186999-95-1 187125-49-1, DNA (human clone LA16-313D11)
 187132-49-6 187132-50-9 187132-53-2 187139-65-7 187194-15-6
 187198-99-8 187199-24-2 187201-93-0 187203-01-6 187209-11-6
 187261-85-4, DNA (human clone LA16-443D9) 187301-93-5 187307-58-0
 187307-89-7 187312-92-1 187363-42-4 187365-41-9 187372-12-9
 187372-23-2 187373-33-7 187374-47-6 187378-90-1 187379-00-6
 187383-73-9 187439-33-4 187440-66-0 187504-27-4 187504-37-6
 187512-42-1 187519-12-6 187519-85-3 187556-31-6 187557-14-8
 187560-69-6 187564-14-3 187566-55-8 187566-56-9 187638-02-4
 187639-95-8 187641-69-6 187642-02-0 187643-29-4 187645-26-7
 187646-66-8 187649-12-3 187766-19-4 187766-21-8, DNA (human clone LA16-366D3) 187791-05-5, DNA (human clone RP3-389A20) 187821-66-5
 187958-71-0, DNA (human clone pDJ1173a5) 188089-54-5 188089-57-8, DNA (human clone 23907 cDNA) 188089-59-0, DNA (human clone 23722 cDNA)
 188089-65-8 188162-70-1 188162-79-0 188163-34-0 188167-35-3
 188170-77-6 188212-15-9 188215-25-0 188221-33-2 188221-37-6
 188222-50-6 188233-46-7 188234-78-8 188267-81-4 188277-14-7
 188277-28-3 188287-81-2, DNA (human gene hsRBP7 plus flanks)

188317-32-0 188321-02-0 188321-86-0 188325-66-8 188334-62-5
 188340-28-5 188379-57-9 188421-50-3 188454-18-4 188458-20-0
 188459-36-1 188459-56-5 188469-64-9, DNA (human clone RP1-127B14)
 188963-19-1 188963-34-0 189123-41-9

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT 189409-51-6 189416-37-3 189417-12-7 189419-33-8 189429-19-4
 189433-99-6 189465-14-3 189472-65-9 189473-35-6 189478-86-2, DNA (human clone cSRL7f12) 189598-43-4 189598-97-8 189599-70-0
 189601-85-2 189607-09-8 189612-11-1 189675-74-9 189711-80-6
 189713-39-1 189714-37-2 189715-38-6 189729-74-6 189737-99-3
 189738-26-9 189738-71-4 189739-07-9 189739-19-3 189780-47-0
 189783-53-7 189784-10-9 189785-60-2 189790-67-8 189792-82-3
 189836-17-7 189838-70-8 189841-79-0 189841-80-3 189849-56-7
 189861-10-7 189904-07-2 189905-38-2 189908-67-6 189911-74-8
 189913-62-0 189917-25-7 189920-78-3 189925-62-0, DNA (human chromosome 16 clone A-17E1) 189925-63-1 189925-64-2 189925-65-3
 189971-36-6 190023-87-1 190026-72-3 190027-25-9 190033-88-6
 190038-32-5 190048-49-8 190117-94-3 190118-14-0 190119-45-0
 190146-48-6 190147-81-0, DNA (human clone RG326K09) 190147-86-5
 190153-13-0 190159-13-8 190165-15-2 190166-83-7 190169-04-1
 190170-35-5 190180-25-7, DNA (human clone CTA-331C24) 190180-74-6
 190212-68-1 190213-51-5 190213-57-1 190213-92-4 190214-18-7
 190305-87-4 190416-94-5 190416-96-7 190470-11-2 190474-05-6
 190478-09-2 190496-22-1 190496-51-6, DNA (human clone 113F3)
 190496-59-4, DNA (human clone 26a1) 190498-71-6 190499-29-7
 190502-31-9 190550-95-9 190550-97-1 190556-61-7 190558-11-3
 190559-13-8 190559-65-0 190565-46-9 190566-66-6 190622-80-1
 190631-70-0 190632-21-4 190633-51-3 190633-76-2 190634-69-6
 190640-41-6 190641-07-7 190641-12-4 190645-51-3 190646-00-5
 190693-30-2 190696-68-5 190696-88-9 190696-90-3 190699-48-0
 190701-79-2 190742-77-9, DNA (human clone 4PTEL) 190823-98-4
 190827-01-1 190867-88-0 190872-17-4 190872-77-6 190881-07-3
 190882-82-7 190883-40-0 190920-78-6 190987-30-5 190987-93-0
 190990-37-5 191004-34-9 191005-26-2 191009-45-7 191049-44-2
 191077-62-0 191078-94-1 191079-51-3 191080-51-0 191081-34-2
 191116-76-4 191120-57-7 191124-68-2 191125-71-0 191127-48-7
 191128-89-9 191129-60-9 191140-41-7 191148-04-6 191150-70-6
 191189-94-3 191191-64-7 191192-71-9 191203-93-7 191206-51-6
 191209-57-1 191211-53-7 191240-04-7 191249-36-2 191258-03-4
 191261-27-5 191262-21-2 191265-85-7 191267-39-7 191310-24-4
 191313-12-9 191322-06-2 191362-64-8 191363-92-5 191365-10-3
 191372-75-5 191377-21-6 191377-57-8 191395-86-5 191397-18-9
 191431-44-4 191438-88-7 191440-19-4 191442-44-1 191443-10-4
 191443-72-8 191447-15-1 191454-61-2 191458-06-7 191458-74-9
 191504-45-7 191507-04-7 191508-84-6 191510-37-9 191514-33-7
 191559-52-1 191565-96-5 191619-62-2 191621-78-0 191629-48-8
 191635-00-4 191636-79-0 191652-23-0 191718-18-0 191818-98-1
 191829-20-6 191834-50-1 191839-12-0 191887-20-4 191900-07-9
 191900-61-5 191915-32-9 191944-09-9 191957-22-9 191964-11-1
 191970-11-3 192111-96-9 192143-36-5 192143-41-2 192143-54-7
 192143-55-8 192143-56-9 192143-70-7 192143-92-3 192143-95-6
 192143-96-7 192143-98-9 192144-00-6 192144-15-3 192144-19-7
 192144-22-2 192144-23-3 192236-92-3 192260-44-9 192263-22-2
 192266-31-2 192274-40-1, DNA (human gene OXA1L plus flanks)
 192277-15-9 192286-56-9 192288-39-4 192291-91-1

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding

tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

IT 192293-09-7, DNA (human EST (expressed sequence tag)) 192302-37-7
192392-34-0 192404-38-9 192409-89-5 192412-07-0, DNA (human EST
(expressed sequence tag)) 192412-89-8 192414-73-6 192429-00-8
192502-04-8 192535-04-9 192549-51-2 192550-54-2 192559-71-0
192593-08-1 192608-88-1 192615-86-4 192616-16-3 192673-81-7
192695-23-1 192730-01-1 192734-18-2 192737-26-1 192844-38-5
192846-03-0 192961-88-9 192962-42-8 192966-78-2 192983-47-4
192984-51-3 193030-04-5 193033-70-4 193035-91-5 193036-17-8
193036-23-6 193043-64-0 193045-32-8 193053-69-9 193105-74-7
193114-23-7 193119-78-7 193121-41-4 193122-79-1 193125-40-5
193129-96-3 193134-69-9, DNA (human clone RP1-179M20) 193134-70-2,
DNA (human clone RP3-339A18) 193134-72-4 193135-60-3 193163-05-2
193167-97-4 193175-29-0 193185-15-8 193194-45-5 193231-12-8
193231-55-9 193231-78-6 193234-12-7 193234-84-3 193235-80-2
193238-66-3 193254-67-0 193258-60-5 193298-18-9 193300-01-5
193301-02-9 193302-26-0 193303-81-0 193311-88-5 193315-30-9
193315-48-9 193316-57-3 193317-88-3 193318-42-2 193319-87-8
193323-42-1 193325-96-1 193365-54-7 193368-69-3 193376-87-3
193379-32-7, DNA (human EST (expressed sequence tag)) 193380-04-0, DNA
(human EST (expressed sequence tag)) 193384-14-4, DNA (human EST
(expressed sequence tag)) 193385-01-2, DNA (human EST (expressed
sequence tag)) 193386-40-2 193432-69-8 193434-73-0 193452-17-4
193460-42-3 193514-29-3 193518-73-9 193522-61-1 193522-89-3
193571-45-8 193575-99-4 193578-55-1 193580-53-9 193582-55-7
193584-02-0 193588-73-7 193590-86-2 193593-03-2 193595-43-6
193596-60-0 193597-49-8 193640-44-7 193642-33-0 193643-89-9
193648-20-3 193656-29-0 193661-48-2 193671-52-2 193702-33-9
193704-41-5 193713-93-8 193719-43-6 193720-27-3 193722-94-0
193724-73-1 193726-24-8 193730-35-7 193730-44-8 193731-46-3
193733-19-6 193734-89-3 193737-08-5 193769-13-0 193769-72-1
193770-07-9 193778-02-8 193779-22-5 193781-08-7 193782-53-5
193783-55-0 193784-97-3 193785-15-8 193785-50-1 193786-77-5
193792-73-3 193794-65-9 193802-12-9 193803-37-1 193848-40-7
193853-88-2 193860-10-5 193933-83-4 193943-69-0 194004-22-3
194080-37-0 194109-90-5 194111-40-5 194112-91-9 194117-57-2
194118-93-9 194119-58-9 194121-78-3 194125-76-3 194127-11-2
194129-20-9 194135-21-2 194169-47-6 194169-62-5 194171-29-4
194172-76-4 194175-24-1 194178-32-0 194196-90-2 194202-66-9
194247-47-7 194253-62-8 194255-22-6 194257-38-0 194260-75-8
194260-76-9, DNA (human clone HEC-1-B) 194260-77-0 194260-79-2
194336-30-6 194338-48-2 194338-58-4 194339-14-5 194381-43-6
194382-88-2 194385-07-4 194385-63-2 194387-45-6 194387-91-2
194388-08-4 194390-85-7 194392-43-3 194399-84-3 194402-42-1
194406-18-3 194511-13-2 194512-58-8 194514-49-3 194517-94-7
194527-56-5 194528-40-0 194556-07-5 194556-80-4 194558-47-9
194562-05-5 194562-41-9, DNA (human clone 297N7) 194566-49-9
194569-44-3 194569-47-6 194575-80-9 194581-27-6 194583-45-4, DNA
(human clone LA16-395F10) 194584-60-6, DNA (human clone RPCI3-424M6)
194590-11-9 194617-84-0 194619-17-5 194619-45-9 194622-18-9
194623-78-4 194625-35-9 194626-42-1 194627-39-9 194628-45-0
194628-76-7 194631-64-6 194633-92-6 194636-61-8 194637-72-4
194638-47-6 194644-72-9 194695-20-0 194695-97-1 194698-42-5
194698-87-8

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
(Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

IT 194745-84-1 194745-85-2, DNA (human clone U177G4) 194745-93-2, DNA
(human clone U151G1, RPCI1-93D11) 194750-76-0 194755-38-9
194755-45-8 194756-14-4 194757-42-1 194763-16-1 194765-44-1
194765-46-3 194767-56-1 194775-14-9 194779-87-8 194817-44-2

194826-46-5, DNA (human clone RP3-427A4) 194832-54-7 194832-59-2
 194832-73-0 194882-60-5 194916-11-5 194948-02-2 194949-31-0
 194950-49-7 194958-41-3 194964-21-1 194978-95-5 194979-18-5
 195018-93-0 195037-32-2 195038-28-9, GenBank A36460 195038-74-5, 2:
 PN: WO0153836 TABLE: 3-5 claimed DNA 195369-27-8, DNA (human gene
 survivin plus flanks) 195410-77-6 195428-47-8 195432-09-8
 195432-12-3 195467-82-4 195472-91-4 195496-70-9 195498-86-3
 195499-13-9 195501-09-8 195541-01-6 195541-19-6 195541-24-3
 195541-61-8 195545-46-1 195547-35-4 195564-16-0 195571-00-7
 195571-08-5 195572-55-5 195575-72-5 195577-03-8 195589-16-3
 195589-30-1 195589-87-8 195593-94-3 195595-20-1 195595-28-9
 195652-89-2 195691-49-7 195693-32-4 195695-15-9 195747-23-0
 195751-72-5 195753-57-2 195754-04-2 195768-34-4 195770-08-2
 195770-27-5 195778-08-6, DNA (human clone cos14) 195779-37-4
 195781-47-6 195783-69-8 195792-26-8 195792-58-6, DNA (human clone
 CTA-369K23) 195797-87-6 195800-43-2 195801-12-8 195805-89-1
 195806-45-2 195808-90-3 195863-04-8 195899-23-1 195900-04-0
 195902-06-8 195903-62-9 195925-71-4 195932-38-8 195938-92-2
 195943-90-9 195944-32-2 195949-93-0 195950-82-4 195953-16-3
 195961-44-5 196011-82-2 196012-93-8 196014-23-0 196014-96-7
 196016-83-8 196042-45-2 196043-63-7 196053-14-2 196056-32-3
 196056-59-4 196056-64-1, DNA (human clone 46a9) 196157-99-0
 196161-00-9 196168-66-8 196384-02-8, DNA (human clone LA16-356B8)
 196384-05-1, DNA (human clone RP3-467L1) 196384-06-2, DNA (human clone
 RP3-507I15) 196384-48-2 196481-49-9, DNA (human clone 486-O-8)
 196481-54-6, DNA (human clone GS1-542D18) 196532-10-2 196536-13-7
 196538-89-3 196594-91-9 196595-63-8 196595-66-1 196629-71-7
 196635-90-2 196678-52-1 196680-51-0 196690-14-9 196693-76-2
 196731-44-9 196734-67-5 196771-89-8 197003-76-2 197061-33-9, DNA
 (human clone hCIT529I10) 197065-92-2 197107-81-6 197109-07-2
 197112-57-5 197113-75-0 197117-86-5 197119-52-1 197124-06-4
 197136-65-5 197185-60-7 197187-89-6 197203-33-1 197332-22-2
 197333-91-8 197336-73-5 197337-28-3 197351-38-5 197416-24-3
 197419-36-6 197420-34-1 197423-05-5 197425-23-3 197429-52-0
 197468-66-9 197472-69-8 197625-57-3, DNA (human gene C7orf1 plus
 flanks) 197627-83-1 197670-39-6 197670-50-1 197675-55-1
 197675-92-6 197676-42-9 197677-95-5 197682-58-9, DNA (human clone
 RP3-388N15) 197690-14-5 197734-28-4 197736-62-2 197737-79-4
 197813-32-4 197815-65-9 197827-57-9 197829-80-4 198006-55-2
 198123-02-3 198158-03-1 198158-07-5 198383-26-5 198384-71-3
 198392-05-1 198440-85-6 198463-67-1 198466-99-8, DNA (human clone
 C36) 198507-03-8 198511-12-5 198519-85-6 198521-43-6
 198522-43-9 198522-50-8 198522-66-6 198524-41-3 198531-17-8
 198532-13-7 198534-43-9 198534-91-7 198540-00-0 198541-19-4
 198588-54-4 198622-28-5 198734-21-3 198844-01-8 198850-02-1
 198851-34-2 198854-10-3 198857-52-2 198860-62-7 198861-31-3
 198862-98-5 198863-04-6 198865-17-7 198867-54-8 198867-92-4
 198869-48-6 198869-83-9 199029-03-3, DNA (human clone RP1-169K13)
 199030-35-8 199031-05-5 199032-11-6 199033-40-4 199033-73-3
 199034-18-9 199036-33-4 199037-58-6 199044-16-1 199046-92-9
 199047-28-4 199050-09-4

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 199050-41-4 199050-42-5 199052-48-7 199068-40-1 199068-48-9
 199072-58-7 199072-72-5 199076-67-0 199139-77-0 199143-86-7
 199148-98-6 199149-09-2 199150-13-5 199157-85-2 199159-47-2
 199159-65-4 199162-63-5 199206-14-9 199218-11-6 199221-08-4
 199225-57-5 199227-65-1 199229-59-9 199231-67-9 199239-46-8
 199308-02-6 199317-27-6 199352-11-9 199352-60-8 199376-83-5, DNA
 (human clone RP1-9E21 cDNA) 199409-65-9 199409-68-2 199409-89-7
 199417-41-9 199418-59-2 199425-34-8 199426-26-1 199429-67-9

199490-42-1 199490-77-2 199490-99-8, DNA (human clone U152D7)
 199491-00-4 199499-13-3 199510-36-6, DNA (human clone HCIT39G8)
 199511-49-4 199517-13-0 199552-90-4 199554-31-9 199577-59-8
 199624-19-6 199636-90-3 199637-30-4 199640-25-0 199647-76-2, DNA
 (human clone RP1-148E22) 199648-03-8 199648-86-7 199650-66-3
 199769-17-0, DNA (human gene HUMP68 plus flanks) 199770-89-3
 199879-85-1, DNA (human isolate sample EW24) 199899-69-9 199908-01-5
 199913-53-6 199913-69-4 199946-89-9 199957-12-5 200034-60-2
 200044-22-0 200047-59-2, DNA (human clone HCIT48C15) 200047-60-5, DNA
 (human clone HCIT268N12) 200160-57-2, DNA (human gene UbC(8u) plus
 flanks) 200168-15-6 200174-76-1 200175-07-1 200176-60-9
 200219-98-3 200320-90-7 200323-30-4 200361-95-1 200369-02-4, DNA
 (human clone RP4-747L4) 200385-49-5 200466-15-5 200473-61-6
 200475-34-9 200475-37-2 200516-22-9, DNA (human clone hg004891 cDNA)
 200516-36-5, DNA (human clone HG1666 cDNA) 200518-75-8 200518-76-9
 200521-52-4, DNA (human cell line HepG2 cDNA) 200521-72-8, DNA (human
 clone RP1-97D16) 200521-73-9, DNA (human clone RP1-212P9)
 200534-41-4 200540-34-7 200542-39-8 200545-94-4 200547-13-3
 200547-84-8 200579-20-0 200586-93-2 200593-47-1 200593-56-2, DNA
 (human clone 23623 cDNA) 200593-57-3, DNA (human clone 23837 cDNA)
 200593-94-8, DNA (human clone 23956 cDNA fragment) 200594-01-0
 200597-32-6 200597-75-7 200613-48-5 200762-08-9 200762-09-0, DNA
 (human clone HG0135 cDNA) 200762-22-7, DNA (human clone HG0960 cDNA)
 200762-30-7, DNA (human clone HG0106 cDNA) 200771-04-6 200775-26-4
 200783-87-5 200851-68-9 200853-08-3 200853-44-7 200891-18-5
 201120-96-9 201120-98-1, DNA (human clone RP1-117O3) 201121-00-8, DNA
 (human clone RP3-426I6) 201172-79-4 201205-32-5 201250-68-2
 201264-29-1 201264-34-8 201368-88-9 201369-24-6 201370-07-2
 201373-46-8 201391-94-8 201392-48-5 201393-03-5 201394-58-3
 201397-10-6 201400-67-1 201400-88-6 201401-66-3 201435-69-0, DNA
 (human clone RP5-970D1) 201444-68-0 201452-57-5 201461-64-5
 201499-92-5 201500-46-1 201514-32-1 201515-53-9 201515-62-0
 201515-64-2 201525-66-8 201526-58-1 201726-01-4 201755-17-1
 201762-11-0 201773-64-0 201776-06-9 201897-98-5 201900-00-7
 201901-56-6, DNA (human clone pDJ306b4) 201901-59-9, DNA (human clone
 HRP1169K15) 201903-71-1 201905-67-1 201913-62-4 201920-27-6
 201927-65-3, DNA (human chromosome 16 clone A-911E12) 201952-35-4
 201967-50-2 201977-29-9 201980-52-1 202019-10-1 202030-74-8
 202034-20-6 202081-16-1 202096-38-6 202101-26-6 202154-26-5
 202156-18-1 202156-74-9 202161-43-1 202166-19-6 202168-39-6
 202176-64-5 202307-11-7 202437-99-8 202442-60-2 202492-57-7
 202498-05-3, DNA (human clone CTB-7J15) 202498-12-2, DNA (human clone
 RP5-1139P1) 202504-43-6 202517-45-1 202517-85-9 202543-80-4
 202550-10-5 202563-28-8 202576-26-9 202610-27-3 202615-39-2
 202618-32-4 202624-06-4 202627-95-0 202628-10-2 202631-18-3
 202633-83-8, DNA (human clone GS1-541B18) 202633-88-3, DNA (human clone
 RP5-899B21) 202633-90-7, DNA (human clone RP4-740B21) 202636-20-2
 202774-16-1, DNA (human clone 23912 cDNA) 202774-34-3, DNA (human clone
 23701 cDNA) 202774-38-7, DNA (human clone 23954 cDNA) 202838-02-6
 202841-96-1 202943-33-7 202943-40-6 202943-43-9, DNA (human clone
 RP1-69E11) 202952-74-7 202953-50-2 203030-22-2, DNA (human clone
 282d12) 203030-24-4, DNA (human clone 876h9) 203030-26-6, DNA (human
 clone 400D1) 203030-71-1 203030-97-1 203041-43-4 203090-61-3
 203099-82-5 203101-83-1 203104-44-3 203104-98-7 203105-97-9
 203137-99-9 203140-27-6 203144-24-5

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 203145-48-6, DNA (human gene NHRPD plus flanks) 203147-71-1, DNA (human
 clone B207D4) 203155-42-4 203161-48-2 203166-64-7 203214-03-3,
 DNA (human clone B366O24) 203214-05-5, DNA (human clone B203C23)
 203222-08-6 203224-68-4 203224-75-3, DNA (human clone CTB-158O17)

203227-42-3 203231-87-2 203232-79-5, DNA (human clone HCIT305D20)
 203235-10-3 203235-17-0, DNA (human clone CTB-103H13) 203269-67-4
 203289-02-5 203291-46-7 203292-22-2 203293-15-6 203349-97-7
 203353-84-8 203358-00-3 203361-01-7 203363-10-4 203364-51-6
 203365-20-2 203366-69-2 203371-15-7 203373-42-6 203406-18-2
 203423-37-4 203429-35-0 203429-54-3 203546-06-9 203547-60-8
 203609-93-2 203610-58-6 203611-10-3 203611-16-9 203611-22-7
 203626-14-6 203782-09-6 203843-79-2 203848-80-0 203848-83-3
 203848-84-4 204025-36-5 204031-66-3 204031-70-9 204036-48-6
 204046-88-8 204051-50-3 204055-74-3 204085-02-9 204089-57-6
 204093-12-9 204102-58-9 204104-40-5 204104-94-9 204107-62-0
 204108-46-3 204110-95-2 204112-57-2 204113-88-2 204150-58-3
 204154-44-9 204160-99-6 204164-83-0 204166-18-7 204177-90-2
 204180-86-9 204209-77-8 204212-07-7 204214-15-3 204214-90-4
 204215-01-0 204216-61-5 204222-01-5 204281-08-3, DNA (human clone
 CTB-118D7) 204314-80-7 204339-77-5 204372-88-3 204406-16-6
 204410-81-1 204414-80-2 204421-13-6 204421-14-7 204421-17-0, DNA
 (human chromosome 16 clone A-10F4) 204426-94-8 204429-48-1
 204431-01-6 204438-74-4 204465-49-6 204468-91-7 204477-23-6
 204477-34-9 204479-19-6 204479-20-9 204488-75-5 204489-80-5
 204492-66-0 204531-07-7 204535-06-8 204535-76-2 204550-26-5
 204557-58-4 204557-73-3 204613-50-3 204622-93-5 204629-91-4, DNA
 (human clone RP1-163M9) 204629-93-6 204631-31-2 204631-39-0
 204660-64-0 204662-15-7 204662-20-4 204664-66-4 204665-29-2
 204665-30-5, DNA (human clone 356a8) 204667-47-0 204678-04-6
 204685-64-3, GenBank AC004228 204721-58-4, DNA (human clone HRPC837J1)
 204721-59-5 204828-52-4 204828-55-7, DNA (human clone 380H5)
 204882-37-1, DNA (human gene XRCC3 plus flanks) 204884-40-2
 204888-97-1 204889-90-7 204892-92-2 204895-41-0 204938-06-7
 204945-71-1 204947-10-4 204948-93-6 204952-99-8 204953-58-2
 204953-77-5 204957-41-5 204967-54-4 205083-01-8 205157-09-1
 205203-74-3 205209-48-9 205230-21-3 205280-63-3 205290-88-6, DNA
 (human clone 278C19) 205291-30-1 205291-33-4 205291-35-6
 205291-39-0 205342-48-9 205349-97-9 205400-61-9 205403-19-6
 205423-31-0 205423-40-1 205423-60-5 205424-73-3 205457-42-7
 205465-98-1 205468-19-5 205468-36-6 205471-37-0 205474-21-1
 205477-98-1 205478-74-6 205484-71-5, DNA (human clone hRPC.906-A-24)
 205544-05-4 205574-67-0 205576-26-7 205605-98-7 205606-12-8
 205607-73-4 205660-21-5 205660-27-1, DNA (human gene XRCC2 plus
 flanks) 205663-78-1 205706-69-0 205707-12-6 205707-14-8
 205710-56-1 205715-24-8 205716-59-2 205716-89-8, DNA (human clone
 RP1-23K20) 205717-04-0, DNA (human clone RP1-71L16) 205899-35-0, DNA
 (human clone RP5-844F9) 205900-08-9, DNA (human clone GSHB-512P14)
 205900-09-0 205902-20-1 205905-47-1 205918-58-7 205919-81-9
 205921-22-8 205950-09-0 205950-52-3 205954-64-9 205956-98-5
 205968-31-6, DNA (human clone P1.11659) 205968-33-8, DNA (human clone
 475I1) 205968-36-1 206038-54-2, DNA (human clone HRPC890E16)
 206040-15-5 206081-86-9 206084-02-8 206084-06-2 206087-02-7
 206092-31-1 206092-36-6 206100-95-0 206101-23-7 206143-03-5
 206231-79-0 206231-85-8 206232-18-0 206234-54-0 206234-57-3, DNA
 (human clone RT191) 206234-58-4, DNA (human clone 798F12)
 206235-25-8, DNA (human clone 415B5) 206235-27-0, DNA (human clone
 390H2) 206235-37-2 206241-82-9 206250-34-2 206250-37-5
 206251-38-9 206251-64-1 206251-91-4 206323-66-2 206323-73-1
 206323-77-5

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 206324-22-3 206324-25-6 206324-29-0 206393-33-1, DNA (human clone
 RP4-604G5) 206393-36-4 206393-37-5, DNA (human clone 66A7)
 206397-23-1 206512-16-5, DNA (human clone 255A6) 206572-88-5
 206578-64-5 206582-00-5 206583-52-0 206599-38-4 206602-93-9

206612-22-8 206614-10-0 206615-28-3 206630-37-7 206630-54-8
 206630-59-3 206630-65-1 206630-74-2 206630-93-5 206631-02-9
 206631-03-0 206631-09-6 206631-19-8 206632-16-8, DNA (human clone
 RP5-911H5) 206684-65-3 206685-71-4, DNA (human clone RP1-273N12)
 206685-74-7 206685-96-3, DNA (human clone GSHB-184P14) 206686-43-3
 206687-21-0 206710-76-1 206713-57-7 206735-15-1 206803-55-6
 206804-74-2 206808-76-6 206821-01-4 206912-03-0 206912-04-1
 206912-06-3, DNA (human clone hRPC.1028-K-7) 206912-07-4, DNA (human
 clone hRPC1107-A-17) 206912-56-3 206914-19-4 206914-96-7
 206959-54-8 206971-42-8 207065-26-7 207065-27-8 207067-38-7
 207086-77-9 207086-81-5 207142-91-4 207146-12-1 207217-19-4
 207217-67-2, DNA (human clone 264,M,20) 207247-77-6 207255-74-1, DNA
 (human clone 170m10) 207271-07-6 207271-90-7 207272-06-8
 207317-97-3, DNA (human clone RP3-430A16) 207334-86-9 207355-08-6,
 DNA (human clone RP5-1052M9) 207363-90-4 207369-78-6, DNA (human
 clone 189n23) 207369-82-2 207374-62-7 207544-75-0, DNA (human clone
 363E3) 207544-90-9, DNA (human clone GSHB-358P8) 207544-92-1
 207584-06-3 207584-68-7 207590-59-8 207705-49-5, DNA (human clone
 CTA-27603) 207722-42-7 207755-17-7, DNA (human clone RP3-406A7)
 207808-69-3 207837-96-5, DNA (human clone BWXD501) 207842-27-1
 207873-40-3 207889-04-1 207889-27-8, DNA (human clone T1040-119B8f-2)
 207889-33-6, DNA (human clone T1866-f90A8f-1) 207889-34-7
 207889-42-7, DNA (human clone T1866-f90A8f-10) 207890-68-4
 207891-57-4 207894-08-4 207936-70-7, DNA (human clone hRPC.1171-I-10)
 207937-11-9 207941-98-8 207943-98-4 207944-56-7, DNA (human clone
 RP1-45I4) 207944-57-8 208075-87-0 208083-93-6 208136-45-2
 208140-80-1 208141-73-5 208206-56-8 208216-31-3 208225-42-7
 208227-66-1 208227-77-4, DNA (human clone RP4-758L10) 208230-30-2
 208236-46-8 208303-79-1 208354-34-1, DNA (human clone 632A8)
 208388-49-2 208504-91-0, DNA (human clone RT286) 208504-97-6, DNA
 (human clone hCIT.117-K-16) 208544-41-6, DNA (human clone 316H7)
 208544-77-8, DNA (human clone RPC11-388A16) 208544-97-2, DNA (human
 clone CIT-HSP-311e8) 208544-99-4, DNA (human clone hRPC.1050-D-4)
 208546-79-6 208546-95-6, DNA (human clone 173m17) 208575-37-5
 208575-67-1 208607-47-0 208609-55-6 208611-47-6 208682-09-1
 208683-05-0 208686-00-4 208690-41-9 208736-97-4 208955-88-8
 208957-03-3, DNA (human clone RPC11-228P16) 209096-69-5, DNA (human
 clone hCIT.69-H-8) 209107-30-2 209107-65-3 209134-73-6
 209140-22-7 209148-97-0, DNA (human clone RP6-220J16) 209149-00-8,
 DNA (human clone RP3-525L6) 209149-01-9, DNA (human clone RP4-616B8
 cDNA) 209225-77-4, 24: PN: W00153836 TABLE: 3-5 claimed DNA
 209296-54-8, DNA (human cell line HAT109 cDNA) 209312-80-1 209365-38-8
 209365-41-3, DNA (human clone CTA-352J5) 209365-47-9 209365-53-7, DNA
 (human clone CTA-315H11) 209365-54-8, DNA (human clone RG313A17)
 209365-58-2, DNA (human clone CTA-298G8) 209365-60-6, DNA (human clone
 CTA-271G13) 209365-66-2 209365-71-9, DNA (human clone RG161A02)
 209365-72-0 209365-73-1, DNA (human clone RG140B11) 209365-84-4
 209365-85-5, DNA (human clone CTB-52H6) 209365-96-8 209366-00-7
 209366-01-8 209366-05-2 209366-07-4, DNA (human clone RP11-353P23)
 209366-08-5 209366-11-0 209366-20-1 209366-22-3 209366-28-9
 209366-37-0, DNA (human clone RP5-1185I7) 209366-40-5, DNA (human clone
 RP5-1173I20) 209366-42-7, DNA (human clone RP5-1165K10) 209366-44-9
 209366-45-0, DNA (human clone RP5-1159O4) 209366-58-5, DNA (human clone
 RP5-1121E10) 209366-59-6, DNA (human clone RP5-1119N5) 209366-67-6,
 DNA (human clone GS1-421I3) 209366-69-8, DNA (human clone GS1-293C5)
 209366-87-0 209366-92-7, DNA (human clone RP5-1019E5) 209366-99-4
 209367-01-1, DNA (human clone RP5-979P20) 209367-04-4 209367-07-7,
 DNA (human clone RP5-953F6) 209367-24-8 209367-29-3, DNA (human clone
 DJ0876A24) 209367-30-6 209367-34-0, DNA (human clone RP5-855D21)
 209367-38-4 209367-52-2, DNA (human clone RP4-800G7) 209367-58-8, DNA
 (human clone RP4-778K6) 209367-59-9, DNA (human clone RP4-771P4)
 209367-64-6, DNA (human clone RP4-754G14) 209367-66-8 209367-77-1,
 DNA (human clone RP4-728D4) 209367-79-3, DNA (human clone RP4-607J23)
 209367-81-7, DNA (human clone RP4-593H12) 209367-85-1, DNA (human clone
 DJ0555N02) 209367-88-4 209367-99-7 209368-04-7 209368-07-0, DNA
 (human clone 277F10) 209368-08-1, DNA (human clone 267D11)

209368-41-2, DNA (human clone RP4-691F11) 209368-42-3, DNA (human clone RP4-687K1) 209368-46-7, DNA (human clone RP4-673M15) 209368-54-7, DNA (human clone RP4-647C14) 209368-58-1, DNA (human clone RP4-609N19) 209561-45-5 209569-99-3 209575-59-7 209582-27-4 209662-79-3 209755-54-4 209761-67-1 209768-69-4, DNA (human clone RP1-91J24) 209769-21-1, DNA (human clone RP4-777O23) 209769-22-2, DNA (human clone RP4-537P9) 209770-93-4, DNA (human clone RP5-905M6) 209779-36-2 209811-81-4 209815-05-4 209894-91-7 209928-18-7, DNA (human clone RP3-452M16) 209928-84-7 209934-21-4 209942-94-9 209949-66-6 209950-10-7 209950-42-5 210002-31-6 210084-01-8 210085-58-8, DNA (human clone B153K6)

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT 210085-62-4 210086-21-8, DNA (human clone RP4-655N24) 210092-58-3 210152-48-0 210183-25-8 210263-16-4 210264-25-8 210270-18-1 210272-51-8 210280-89-0 210281-24-6 210316-29-3 210317-72-9 210385-74-3 210386-71-3, DNA (human clone RP5-1189B24) 210386-74-6, DNA (human clone RP3-422G23) 210387-29-4, DNA (human clone RT70) 210388-20-8, DNA (human clone P1 737H5) 210446-71-2 210448-31-0 210448-77-4 210449-83-5 210449-88-0 210449-91-5 210449-97-1 210449-99-3 210450-02-5 210452-65-6, DNA (human clone RP3-329E20) 210453-49-9 210510-05-7 210525-27-2, DNA (human clone 96-4B) 210525-68-1, DNA (human clone CTA-324D18) 210526-16-2 210526-20-8 210526-21-9 210526-22-0, DAN (human gene STK13 plus flanks) 210526-25-3 210526-26-4 210668-95-4 210669-05-9 210716-25-9 210717-54-7 210719-51-0 210722-37-5 210724-00-8 210851-67-5 211070-70-1 211153-21-8 211153-75-2 211153-77-4 211153-84-3 211153-90-1 211153-93-4 211154-00-6 211154-09-5 211154-13-1 211154-19-7 211155-05-4 211159-79-4 211166-21-1 211166-26-6 211166-39-1 211166-53-9 211168-97-7 211168-99-9 211169-00-5 211169-01-6 211169-04-9 211169-66-3 211203-61-1 211260-40-1 211260-41-2 211260-44-5 211260-78-5 211278-39-6, GenBank AC005318 211292-14-7 211394-88-6 211397-34-1 211397-35-2, DNA (human clone hRPK.640-I-15) 211462-47-4 211462-50-9, DNA (human clone hRPK.147-L-13) 211554-88-0 211592-99-3 211611-19-7 211838-75-4 211856-58-5, DNA (human clone 2H2) 211856-66-5 211856-69-8, DNA (human clone 119j3 fragment) 211877-84-8, DNA (human clone 194j18) 211877-86-0 211877-89-3 211877-92-8, DNA (human clone 352A12) 211878-24-9 211878-32-9 211878-82-9 211879-16-2 211879-42-4 211882-71-2 211884-66-1, DNA (human clone IMAGE:178805 cDNA) 211884-74-1 211967-10-1, DNA (human clone RP5-1137M13) 212217-77-1 212217-94-2 212218-36-5 212229-94-2 212345-58-9, DNA (human clone RP3-341E18) 212345-87-4 212350-86-2 212355-15-2 212357-27-2 212358-37-7 212359-34-7 212367-37-8 212368-83-7 212405-19-1 212412-97-0 212525-62-7 212542-49-9 212593-67-4 212596-33-3 212597-61-0 212600-91-4 212604-36-9 212664-34-1, DNA (human clone RP1-191N21) 212664-37-4, DNA (human clone RP3-409O10) 212664-53-4 212667-73-7 212669-44-8 212670-17-2 212670-66-1 212686-32-3, DNA (human clone 14951) 212686-35-6, DNA (human clone hRPK.1096-G-20) 212718-64-4 212718-68-8 212718-72-4 212723-36-9 212733-91-0 212739-45-2 212796-96-8 212805-60-2 212806-46-7 212807-78-8 212812-02-7, DNA (human clone RP4-703H14) 212812-07-2 212812-08-3 212812-12-9 212816-87-0 212819-95-9 212820-82-1 212858-00-9 212858-88-3 212861-18-2 212864-64-7 212878-11-0 212878-39-2 212878-68-7 212880-82-5 212884-18-9 212886-63-0 212889-61-7 212916-91-1 212917-86-7 212920-84-8 212925-93-4 212933-62-5 212946-72-0 212949-21-8 213172-57-7 213173-92-3 213213-69-5 213214-22-3 213214-27-8 213291-88-4, DNA (human clone B200N5) 213293-76-6, DNA (human clone RP5-1021I20) 213311-87-6 213378-73-5 213514-68-2, DNA (human clone RP4-662N3) 213516-28-0, DNA (human clone RP4-701O16) 214108-98-2 214109-21-4, DNA (human clone IMAGE:175500

cDNA) 214111-44-1, DNA (human clone IMAGE:289989 cDNA) 214112-22-8, DNA (human clone IMAGE:310097 cDNA) 214112-23-9, DNA (human clone IMAGE:310408 cDNA) 214112-61-5 214112-64-8, DNA (human clone IMAGE:325606 cDNA) 214112-88-6, DNA (human clone IMAGE:340966 cDNA) 214112-90-0, DNA (human clone IMAGE:341228 cDNA) 214113-83-4, DNA (human clone IMAGE:344462 cDNA) 214113-91-4, DNA (human clone IMAGE:344867 cDNA) 214114-32-6, DNA (human clone IMAGE:345882 cDNA) 214114-42-8, DNA (human clone IMAGE:346281 cDNA) 214115-19-2, DNA (human clone IMAGE:347554 cDNA) 214155-22-3, DNA (human clone IMAGE:357191 cDNA) 214155-65-4, DNA (human clone IMAGE:359036 cDNA) 214155-72-3, DNA (human clone IMAGE:359137 cDNA) 214155-78-9 214156-01-1, DNA (human clone RP1-197L1) 214157-99-0, DNA (human clone hRPK.271-K-11) 214456-84-5 214456-99-2, DNA (human clone 141E2) 214513-64-1 214514-73-5 214514-93-9 214733-16-1 215060-81-4, DNA (human clone IMAGE:206650 cDNA) 215061-42-0, DNA (human clone IMAGE:322796 cDNA) 215061-69-1, DNA (human clone IMAGE:346133 cDNA) 215061-80-6 215061-98-6 215093-38-2 215210-92-7, DNA (human clone 114k9) 215210-93-8, DNA (human clone P1 LBL#8) 215210-99-4 215211-02-2 215212-73-0, DNA (human clone 249h5) 215212-75-2 215400-71-8 215400-72-9, DNA (human clone RP5-1093I16) 215400-74-1, DNA (human clone RP4-577P23) 215827-49-9 215831-93-9 215832-18-1 215832-98-7 215834-09-6 215836-65-0 215837-79-9 215847-98-6 215852-12-3 215884-59-6 215885-60-2 215899-19-7

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT 215902-63-9 215902-75-3 215904-12-4 216123-27-2, GenBank AB017335 216125-85-8, DNA (human clone RP3-462023) 216125-86-9, DNA (human clone RP3-465N24) 216126-87-3 216126-88-4, DNA (human clone RP1-171N11) 216126-92-0, DNA (human clone RP1-126A5) 216127-46-7 216130-39-1 216130-48-2 216130-49-3, DNA (human clone hRPK.243-K-12) 216140-37-3 216141-78-5 216175-68-7 216175-89-2, DNA (human clone RP1-184J9) 216180-05-1 216195-79-8 216296-13-8 216296-16-1 216296-21-8 216296-23-0 216296-30-9 216296-40-1 216296-60-5 216296-75-2 216296-86-5 216296-96-7 216296-98-9 216297-00-6 216297-09-5 216430-72-7 216430-82-9 216430-83-0 216567-98-5 216654-04-5 216764-54-4 216917-49-6 216926-95-3 216926-96-4 216945-89-0 217048-06-1 217050-06-1 217052-90-9, DNA (human clone RP5-1119D9) 217053-00-4 217053-08-2, DNA (human clone RP3-460J8) 217053-11-7, DNA (human clone RP4-545L17) 217053-14-0, DNA (human clone RP4-620E11) 217053-19-5 217053-30-0 217053-35-5, DNA (human clone RP5-963K23) 217053-81-1, DNA (human clone hRPK.178-C-3) 217061-87-5 217116-00-2 217120-74-6 217120-75-7, DNA (human cell line Hep3B) 217120-95-1 217121-02-3, DNA (human clone LA16-360B4) 217121-03-4, DNA (human clone LA16-371H6) 217121-07-8, DNA (human clone RP3-410I8) 217124-22-6 217125-65-0 217126-06-2 217130-16-0 217131-01-6 217132-72-4 217135-91-6 217137-59-2 217227-23-1 217229-45-3 217240-47-6 217245-41-5 217332-85-9 217345-29-4 217357-55-6 217357-89-6 217511-75-6, DNA (human clone RP1-298J15) 217511-81-4, DNA (human clone RP1-51J12) 217515-67-8 217516-53-5 217516-66-0 217532-33-7 217533-58-9 217534-68-4 217536-88-4 217537-87-6 217544-56-4 217579-22-1, DNA (human clone 34j15) 217580-78-4, DNA (human clone C0315N08) 217581-41-4 217586-87-3 217590-81-3 217594-14-4 217828-70-1 217828-73-4 217828-74-5 217828-86-9, DNA (human clone hRPK.62-F-10) 217846-54-3 217938-79-9 218016-74-1 218028-28-5 218029-76-6 218050-39-6 218054-94-5 218056-09-8 218094-17-8 218095-95-5 218097-30-4 218097-89-3 218101-76-9 218103-69-6 218110-76-0 218111-67-2 218121-70-1 218169-89-2 218175-75-8 218193-65-8 218195-15-4 218247-04-2 218247-74-6 218251-21-9 218315-42-5 218321-10-9 218323-83-2 218326-17-1 218328-02-0 218348-33-5 218350-76-6 218427-22-6, DNA (human clone hRPK.259-G-18) 218427-23-7, DNA (human clone hRPK.269-G-24) 218472-60-7 218574-47-1,

DNA (human clone hRPK.481-C-4) 218574-48-2 218574-49-3 218584-42-0
 218589-75-4 218686-82-9 218763-31-6 218763-65-6 218854-04-7
 218866-00-3 218877-47-5 218879-33-5 218880-29-6 218882-90-7
 218883-13-7 218994-53-7 218998-24-4 218998-28-8 219101-27-6
 219102-52-0, DNA (human clone RP1-55C23) 219116-64-0 219258-29-4
 219268-56-1 219273-65-1 219274-57-4 219277-58-4 219283-09-7
 219286-15-4 219295-49-5 219332-58-8 219337-54-9 219354-50-4
 219358-08-4 219369-35-4 219380-46-8 219381-44-9 219385-29-2
 219386-67-1 219388-54-2 219388-55-3, DNA (human clone RPCI5-751E10)
 219392-86-6 219405-86-4 219412-38-1 219513-78-7 219587-73-2
 219588-17-7 219628-21-4 219628-33-8 219805-84-2 219805-85-3
 219805-86-4 219805-87-5 219805-90-0 220008-06-0 220188-32-9
 220263-27-4 220279-59-4 220367-22-6 220500-09-4 220500-28-7
 220500-32-3 220500-34-5 220500-48-1 220500-51-6 220500-54-9
 220500-55-0 220500-56-1 220500-58-3 220500-64-1 220500-66-3
 220500-69-6 220500-77-6 220500-83-4 220500-87-8 220563-47-3
 220660-85-5 221069-89-2 221118-50-9 221294-25-3 221369-33-1
 221403-02-7 221403-11-8 221406-56-0, DNA (human clone RP1-287G14)
 221407-00-7 221407-22-3 221407-81-4 221411-68-3 221428-07-5, DNA
 (human clone RP1-27K12) 221431-33-0, DNA (human clone 192 cDNA)
 221431-37-4, DNA (human clone 308 cDNA) 221431-45-4, DNA (human clone
 628 cDNA) 221431-46-5, DNA (human clone 638 cDNA) 221433-03-0
 221436-76-6 221581-80-2 221592-50-3 221599-42-4 221599-84-4
 221606-15-1

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 221608-97-5 221703-48-6 221704-73-0, DNA (human clone hRPK.215-P-18)
 221719-13-7 221722-27-6 221728-43-4, DNA (human clone RP1-279I9)
 221728-45-6, DNA (human clone RP3-322I12) 221728-48-9 221729-22-2
 221729-25-5, DNA (human clone YR-29 cDNA) 221731-10-8 221732-55-4
 221732-65-6 221733-05-7 221733-34-2 221737-78-6 221742-93-4
 221749-92-4 221753-82-8 221754-65-0 221757-95-5 221769-54-6
 221770-41-8 221772-96-9 221780-81-0 221780-85-4 221780-93-4, DNA
 (human clone hRPK.651-L-9) 221784-10-7 221799-48-0 221815-22-1
 221828-13-3 221828-37-1 221828-68-8 221829-78-3 221838-07-9
 221850-65-3 221851-70-3 221852-62-6 221968-80-5 222016-47-9
 222067-59-6, DNA (human clone RP11-400O10) 222067-72-3, DNA (human
 clone GS1-114I9) 222067-73-4 222067-76-7 222067-82-5, DNA (human
 clone RP5-981O7) 222067-87-0 222067-89-2, DNA (human clone RP5-850I1
) 222067-90-5, DNA (human clone RP5-820A21) 222067-97-2
 222068-00-0, DNA (human clone RP4-622E21) 222069-14-9 222070-39-5
 222072-70-0 222077-70-5 222081-69-8 222083-09-2 222084-45-9
 222090-09-7 222097-19-0 222098-14-8 222100-15-4 222104-97-4
 222105-05-7 222111-02-6 222113-45-3 222127-77-7 222127-94-8
 222135-51-5 222192-99-6, DNA (human clone RP5-953A4) 222205-30-3
 222207-02-5 222207-07-0 222207-09-2, DNA (human clone RPCI1-96H9)
 222207-11-6 222210-34-6 222216-24-2 222218-01-1 222223-97-4
 222235-13-4 222236-27-3 222242-74-2 222243-87-0 222246-90-4
 222342-96-3 222447-17-8, DNA (human clone RP1-273F20) 222447-20-3
 222447-21-4 222464-17-7 222464-25-7 222470-68-0 222472-77-7
 222480-08-2 222483-21-8 222486-11-5 222495-05-8 222525-86-2
 222526-53-6 222526-54-7 222526-70-7 222565-19-7, DNA (human clone
 Pac 9c13) 222565-35-7 222566-51-0 222672-99-3, DNA (human clone
 RPCI3-305I20) 222673-27-0, DNA (human clone CIT-B-470f8) 222673-37-2
 222673-39-4, DNA (human clone CIT-B-393i15) 222673-50-9 222673-51-0,
 DNA (human clone hRPK.421-E-14) 222706-21-0, DNA (human clone
 RP6-198C21) 222706-56-1 222706-69-6 222754-81-6 222760-05-6
 222766-71-4 222769-78-0 222776-66-1 222783-49-5 222795-14-4
 222818-83-9 222822-45-9 222822-46-0 222822-48-2 222822-51-7
 222822-54-0 222822-55-1, GenBank AB020868 222822-69-7 222822-70-0,
 DNA (human clone RPCI11-319E16) 222822-71-1, DNA (human clone

RPCI5-1154L15) 222822-72-2, DNA (human clone hRPK.15-A-1)
 222823-50-9 222824-73-9, DNA (human clone CTA-215D11) 222826-42-8
 222831-42-7 222837-14-1 222866-63-9 222993-18-2, DNA (human gene
 ASH2L protein cDNA) 223172-36-9, DNA (human gene EPFP1 fragment)
 223212-02-0, DNA (human clone RP5-1103G7) 223212-35-9, DNA (human clone
 C0287J14) 223212-41-7 223242-10-2 223242-11-3 223349-57-3
 223657-02-1 223657-04-3 223766-62-9 223897-14-1, DNA (human clone
 hRPK.692-E-18) 223898-99-5 223899-30-7 223899-31-8 223899-34-1,
 DNA (human clone hRPK.11-A-1) 223901-27-7, DNA (human clone IMAGE
 286356) 223932-62-5 223986-01-4 223986-27-4 223999-15-3
 224010-29-1 224011-08-9 224027-22-9 224075-61-0 224077-36-5
 224077-69-4 224080-73-3 224080-85-7 224091-16-1 224097-72-7
 224100-40-7 224102-51-6 224102-78-7 224105-18-4 224125-03-5
 224125-24-0 224133-88-4 224137-13-7 224137-44-4 224151-50-2
 224155-77-5 224195-49-7 224200-83-3 224208-48-4 224217-77-0
 224244-60-4 224244-89-7 224250-05-9 224255-04-3 224255-07-6
 224255-10-1 224257-77-6 224272-30-4 224327-57-5 224329-45-7
 224350-60-1, DNA (human cell line LNCaP cDNA) 224369-87-3 224370-99-4
 224374-29-2 224375-80-8 224390-57-2 224395-90-8 224408-35-9
 224420-55-7 224458-68-8 224467-90-7 224472-68-8 224482-03-5, DNA
 (human clone hRPK.17-A-1) 224506-97-2 224651-95-0 224662-52-6
 224704-29-4, DNA (human clone IMAGE:1013575 cDNA) 224709-19-7
 224710-60-5 224717-52-6 224718-53-0 224735-32-4 224738-11-8
 224740-16-3 224873-19-2, DNA (human cell line HeLa) 224874-52-6
 224874-92-4, DNA (human clone RP5-892G5) 224874-94-6, DNA (human clone
 RP5-839B19) 224895-26-5 224937-27-3 224937-51-3 225001-92-3
 225009-45-0 225011-72-3 225136-58-3, DNA (human clone RP5-1054C24)
 225137-12-2, DNA (human clone RP11-525G7) 225256-35-9 225260-61-7
 225261-76-7 225297-72-3

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 225312-45-8 225336-24-3 225393-98-6 225394-23-0, DNA (human clone
 C0367I21) 225394-26-3, DNA (human clone RP11-85O21) 225394-27-4
 225394-34-3, DNA (human clone RP11-343N14) 225394-41-2 225395-43-7
 225395-58-4, DNA (human clone RP11-166O4) 225395-61-9, DNA (human clone
 RP4-802G15) 225395-63-1 225401-59-2 225402-19-7, DNA (human clone
 BAC 206f3 gene ASH2L) 225403-62-3, DNA (human clone hRPC.1029-K-10)
 225407-23-8, DNA (human clone hRPK.35-A-1) 225408-63-9, DNA (human
 clone CIT-B-459F4) 225409-62-1, DNA (human clone RPCI11-144O23)
 225409-68-7, DNA (human clone RPCI3-461F17) 225409-71-2 225414-14-2,
 DNA (human cell line NCR-G3 cDNA) 225414-17-5 225414-22-2, DNA (human
 clone CIT-B-26L23) 225414-30-2 225415-22-5 225418-32-6, DNA (human
 clone bac172k1) 225418-42-8, DNA (human clone RPCI3-474D1)
 225420-70-2, DNA (human clone hRPK.376-P-6) 225421-70-5, DNA (human
 clone RPCI11-259O18) 225421-83-0 225427-83-8 225432-07-5
 225434-63-9, DNA (human clone PAC 270M7) 225434-74-2 225435-66-5, DNA
 (human cell line NB4 cDNA) 225436-28-2 225438-94-8, DNA (human clone
 BAC 201G24) 225438-98-2 225439-23-6, DNA (human clone RP11-160K17)
 225439-37-2, DNA (human clone RP5-909F12) 225439-54-3 225439-66-7,
 DNA (human clone RP11-327N17) 225439-69-0 225439-75-8, DNA (human
 clone RP11-22N19) 225439-78-1, DNA (human clone RP5-855F16)
 225441-77-0 225446-80-0 225446-90-2, DNA (human clone 25191 cDNA)
 225447-00-7, DNA (human clone 24952 cDNA) 225447-13-2 225447-19-8, DNA
 (human clone 25061 cDNA) 225447-23-4, DNA (human clone 24901 cDNA)
 225447-56-3 225447-80-3 225447-98-3, DNA (human clone 24856 cDNA)
 225447-99-4 225448-04-4 225448-09-9 225448-11-3 225448-21-5, DNA
 (human clone hRPK.355-O-1) 225448-28-2, DNA (human clone C0310G15)
 225450-41-9 225453-53-2, DNA (human clone hRPK.166-P-13) 225453-84-9
 225453-92-9 225453-95-2 225453-99-6 225454-09-1 225456-55-3, DNA
 (human clone PAC 126N20) 225456-71-3, DNA (human clone GS1-98E2)
 225458-11-7, DNA (human clone RP1-164F3) 225458-15-1 225458-16-2, DNA

(human clone RP4-657E11) 225459-09-6 225464-28-8, DNA (human clone
 RP5-1002M8) 225464-32-4, DNA (human clone RP4-785G19) 225464-38-0,
 DNA (human clone RP4-550H1) 225469-79-4 225470-62-2, DNA (human clone
 RP6-24A23) 225470-70-2, DNA (human clone RP4-718J7) 225470-76-8, DNA
 (human clone LLNLP704M17648Q13) 225473-83-6 225473-86-9
 225473-92-7, DNA (human clone RP1-73H22) 225474-22-6 225475-05-8, DNA
 (human clone DKFZp564C093 cDNA) 225475-30-9, DNA (human clone
 DKFZp564K143 cDNA) 225475-32-1, DNA (human clone DKFZp564M113 cDNA)
 225475-39-8 225476-07-3, DNA (human clone DKFZp586F0219 cDNA)
 225476-22-2 225476-26-6, DNA (human clone DKFZp586A0722 cDNA)
 225476-36-8, DNA (human clone DKFZp586F0922 cDNA) 225478-42-2, DNA
 (human gene KLK4 plus flanks) 225479-17-4 225479-38-9 225497-32-5
 225498-94-2 225499-14-9 225532-15-0 225532-38-7, DNA (human clone
 CIT-B-320G13) 225532-44-5, DNA (human clone RP11-320N7) 225532-47-8,
 DNA (human clone RPCI-11-54H19) 225532-48-9, DNA (human clone
 RPCI-11-520B23) 225532-49-0, DNA (human clone RPCI-11-480G7)
 225532-58-1, DNA (human clone RP11-166B2) 225532-59-2 225538-77-2,
 DNA (human clone RP11-454P5) 225538-78-3, DNA (human clone RP11-407F2)
 225538-91-0, DNA (human clone RP11-83A12) 225547-27-3 225547-32-0,
 DNA (human clone RP4-773A18) 225553-37-7, DNA (human clone RP1-68D15)
 225553-38-8 225556-48-9, DNA (human isolate RomB1) 225556-49-0, DNA
 (human isolate RomB2) 225556-56-9, DNA (human isolate RomB11)
 225559-43-3, DNA (human clone RP4-570L12) 225559-65-9 225559-85-3
 225573-36-4 225573-39-7 225575-74-6 225577-15-1, DNA (human clone
 RP11-74G24) 225577-19-5, DNA (human clone b48) 225577-20-8, DNA
 (human clone b293) 225577-21-9 225585-16-0 225589-57-1
 225590-18-1, DNA (human clone RP1-99E18) 225590-24-9 225590-53-4
 225590-55-6 225597-42-2, DNA (human clone RP11-451J3) 225597-45-5
 225597-51-3, DNA (human clone RP11-325F22) 225598-74-3 225598-75-4
 225598-78-7 225598-92-5 225599-01-9 225599-09-7 225599-18-8
 225599-24-6 225599-25-7 225599-30-4 225599-31-5 225599-32-6
 225599-34-8 225599-40-6, GenBank AF077052 225599-95-1 225601-85-4,
 DNA (human clone RP4-686C3) 225604-06-8, DNA (human clone RPCI11-283I3
) 225608-08-2 225608-09-3, DNA (human cell line HeLa) 225612-25-9
 225623-28-9, DNA (human clone RP5-863C7) 225630-68-2 225630-73-9, DNA
 (human clone R-1012A1) 225630-78-4 225634-42-4 225634-90-2, DNA
 (human clone IMAGE:76196 cDNA) 225635-24-5, DNA (human clone
 IMAGE:191714 cDNA) 225636-27-1, DNA (human clone cCI11-280 gene RPL27A)
 225639-29-2 225639-34-9 225639-38-3 225639-39-4, DNA (human clone
 RPCI11-277E18) 225639-43-0 225639-62-3, DNA (human clone B1L1C6)
 225639-63-4 225639-66-7, DNA (human clone RP3-392M17) 225639-67-8,
 DNA (human clone RP3-468K18) 225670-64-4 225671-09-0, DNA (human
 clone hRPK.67-A-1) 225674-63-5 225674-97-5, DNA (human clone
 RP4-565E6) 225680-01-3, DNA (human clone HAW100 cDNA) 225681-29-8,
 DNA (human clone RPCI11-473N11) 225690-85-7 225690-89-1
 225690-92-6, DNA (human clone R-862P13) 225691-52-1, DNA (human clone
 RP4-813O16) 225692-17-1 225695-80-7 225697-33-6 225699-51-4, DNA
 (human clone RPCI11-513P18) 225699-52-5 225699-54-7, DNA (human clone
 CTB-10G5) 225707-11-9, DNA (human clone R-973N13) 225707-13-1, DNA
 (human clone R-857B24) 225711-66-0, DNA (human clone RPCIP704C216Q2)
 225715-15-1 225717-38-4 225717-67-9, DNA (human clone DKFZp586E1422
 cDNA) 225717-73-7, DNA (human clone DKFZp564O0582 cDNA) 225717-83-9,
 DNA (human clone DKFZp564G2022 cDNA) 225717-98-6, DNA (human clone
 DKFZp564P0823 cDNA) 225718-00-3, DNA (human clone DKFZp564A222 cDNA)
 225718-03-6, DNA (human clone DKFZp564A042 cDNA) 225718-21-8
 225718-41-2, DNA (human clone DKFZp564C1969 cDNA) 225718-42-3, DNA
 (human clone DKFZp564D016 cDNA) 225718-44-5, DNA (human clone
 DKFZp566C0324 cDNA) 225718-52-5 225718-85-4, DNA (human clone
 DKFZp566K1246 cDNA) 225719-28-8 225719-84-6 225723-46-6
 225723-51-3 225723-53-5 225723-76-2 225723-82-0, DNA (human clone
 DKFZp586G1923 cDNA) 225724-90-3 225731-60-2, DNA (human isolate 4)
 225732-85-4, DNA (human clone RP3-486I3) 225733-02-8, DNA (human clone
 RP4-657D16 cDNA) 225734-03-2, DNA (human clone DKFZp564E0582 cDNA)
 225734-10-1, DNA (human clone DKFZp564M2223 cDNA) 225734-23-6
 225734-56-5, DNA (human clone RP11-449G16) 225740-38-5, DNA (human
 clone snt1 cDNA) 225747-60-4 225747-66-0 225747-91-1 225747-94-4

225748-00-5 225748-05-0 225748-20-9 225748-28-7 225748-34-5
 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 225748-37-8 225748-38-9 225748-43-6 225748-45-8 225748-46-9
 225748-48-1 225748-52-7 225748-62-9 225748-64-1 225748-65-2
 225749-01-9 225749-21-3, DNA (human clone b563b9) 225750-07-2
 225754-61-0 225771-93-7 225772-71-4 225776-71-6, DNA (human clone
 RP11-15J24) 225885-07-4 225888-08-4 225890-82-4 225898-68-0
 225898-91-9 225905-67-9 225915-02-6, DNA (human clone CIT-B-471f3)
 226031-42-1 226036-32-4 226058-01-1, DNA (human clone RP1-198I9)
 226058-12-4, DNA (human clone RPCI11-1038A11) 226058-50-0, DNA (human
 clone RP11-395L14) 226059-34-3 226059-43-4 226060-60-2
 226061-29-6 226062-80-2 226062-81-3 226062-82-4 226062-85-7
 226062-86-8 226062-87-9 226062-89-1 226063-04-3 226063-09-8
 226063-65-6 226063-69-0, DNA (human clone 344N5) 226149-87-7
 226205-37-4 226205-47-6 226205-49-8 226205-93-2 226206-38-8,
 GenBank AF150089 226208-05-5 226208-07-7 226208-09-9 226378-81-0
 226453-47-0 226455-77-2 226464-28-4 226535-14-4, DNA (human clone
 RP1-72A23) 226535-15-5, DNA (human clone RP5-823F3) 226536-94-3,
 GenBank AF092128 226536-96-5 226537-01-5 226643-91-0 226658-16-8
 226683-33-6 226784-20-9 227048-56-8 227053-19-2 227053-52-3, DNA
 (human clone DKFZp564E1962 cDNA) 227053-56-7, DNA (human clone
 DKFZp564G2362 cDNA) 227053-57-8, DNA (human clone DKFZp564G0462 cDNA)
 227053-61-4 227053-62-5 227053-70-5 227053-75-0 227053-82-9, DNA
 (human clone DKFZp586G1822 cDNA) 227054-07-1, DNA (human clone
 DKFZp434I143 cDNA) 227054-11-7, DNA (human clone DKFZp434L013 cDNA)
 227054-16-2, DNA (human clone DKFZp434N093 cDNA) 227054-50-4, DNA (human
 clone DKFZp434K171 cDNA) 227054-58-2 227054-65-1, DNA (human clone
 DKFZp434B142 cDNA) 227055-51-8 227055-54-1 227055-80-3, DNA (human
 clone RP1-101K10) 227059-21-4 227064-56-4 227067-47-2
 227067-56-3, DNA (human clone RP11-29A1) 227072-63-1 227072-79-9
 227072-81-3 227073-32-7 227075-70-9, DNA (human clone XX-189m5)
 227076-03-1, DNA (human clone NH0373F14) 227114-67-2 227117-05-7
 227118-36-7 227120-70-9 227447-24-7 227447-33-8 227447-36-1
 227447-47-4 227498-26-2 227511-66-2 227513-24-8 227514-19-4
 227540-11-6 227593-59-1 227593-69-3 227593-77-3, DNA (human clone
 RP1-298J18) 227741-94-8 227742-88-3, DNA (human clone GS1-304P7)
 227744-11-8, DNA (human clone CTB-177N7) 227744-25-4, DNA (human clone
 RPCI11-436A20) 227744-32-3 227860-49-3 227875-33-4 227878-97-9
 227880-33-3 228039-04-1 228056-36-8 228056-49-3 228062-80-4
 228071-30-5 228084-80-8 228241-78-9, DNA (human clone BAC 2175M1)
 228543-62-2, GenBank AF047431 228592-02-7 228635-43-6 228690-72-0
 228690-75-3, DNA (human cell line NB4 cDNA) 228690-80-0 228823-95-8
 228994-05-6 228996-94-9, DNA (human clone RP11-73N1) 229199-28-4
 229302-57-2, DNA (human clone bac41i21) 229302-58-3 229305-16-2
 229305-17-3 229305-18-4 229305-24-2, DNA (human clone CITB-187P1)
 229305-25-3, DNA (human clone RPCI11-180M15) 229379-33-3 229380-20-5
 229391-75-7 229438-61-3 229440-76-0 229445-21-0 229445-24-3
 229453-16-1 229456-46-6 229459-66-9 229461-23-8 229501-26-2
 229503-27-9 229566-62-5 229578-59-0 229579-85-5 229585-64-2
 229593-62-8 229594-87-0 229606-27-3 229846-16-6 229847-66-9
 229857-86-7 229860-84-8 229862-55-9 229863-08-5 230074-62-1
 230161-88-3 230163-06-1 230274-78-9 230274-82-5 230278-33-8
 230281-65-9, DNA (human clone CITB-243A6) 230281-75-1, DNA (human clone
 RP11-576F1) 230327-70-5 230333-52-5 230343-29-0 230419-93-9
 230424-93-8 230434-00-1 230597-76-9 230603-65-3 230605-21-7
 230607-33-7 230609-52-6, DNA (human clone RP11-95H11) 230654-63-4
 230661-29-7 230802-99-0 230810-55-6 230942-79-7, DNA (human clone
 RP5-842G6) 230943-98-3, DNA (human gene FRG1) 230946-32-4
 230946-78-8 230946-96-0 230946-97-1 230995-95-6 230999-80-1
 231000-01-4 231000-92-3 231009-25-9 231010-53-0 231015-72-8

231022-51-8 231033-48-0 231033-97-9 231037-01-7 231041-24-0
 231047-33-9 231047-57-7 231140-15-1 231262-63-8 231262-91-2
 231268-31-8 231268-57-8 231268-59-0 231268-76-1 231268-81-8
 231271-03-7, DNA (human clone LLNLF-162A4) 231271-91-3, DNA (human
 clone CTD-2228J24) 231274-95-6, DNA (human clone CTC-566I14)
 231275-33-5, DNA (human clone CTC-500L4) 231275-80-2, DNA (human clone
 CTC-436P18) 231443-82-6 231447-47-5 231449-78-8 231456-99-8
 231505-20-7

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 231510-02-4 231511-93-6 231512-99-5 231520-97-1 231528-55-5
 231531-86-5 231534-37-5 231535-61-8 231544-68-6 231552-97-9
 231553-49-4 231555-41-2 231567-77-4 231605-45-1 231784-80-8
 231786-14-4 231801-17-5 232221-29-3 232237-48-8, GenBank E15239
 232311-35-2 232366-82-4 232372-44-0 232387-15-4 232468-33-6
 232584-14-4 232697-03-9 232717-75-8 232871-38-4 232872-79-6
 232877-38-2 232910-46-2, DNA (human clone R-873E2) 232910-47-3, DNA
 (human clone R-898B23) 232910-65-5, DNA (human clone RP5-839B4)
 232912-18-4 233005-50-0 233006-16-1 233013-67-7 233025-28-0
 233032-77-4 233034-62-3 233040-33-0 233042-51-8 233057-71-1
 233058-15-6 233064-23-8 233064-95-4 233066-08-5 233185-46-1
 233195-89-6 233218-93-4 233224-65-2 233231-62-4 233240-13-6
 233251-27-9 233443-91-9 233446-76-9 233464-11-4 233581-89-0, DNA
 (human clone RP11-558P14) 233653-20-8 233653-52-6, DNA (human clone
 RP11-17I6) 233660-23-6 233744-02-0 233994-82-6 234027-69-1
 234042-97-8 234070-76-9 234071-47-7 234419-25-1, DNA (human clone
 RP4-534K7) 234423-76-8 234750-16-4, DNA (human clone GS1-120K12)
 234750-40-4, DNA (human clone CTD-2317F5) 234847-33-7 235327-29-4
 235328-62-8 235346-26-6 235354-98-0 235357-61-6 235357-79-6
 235358-65-3 235365-00-1 235404-56-5 235409-25-3, DNA (human gene
 GBDR1 cDNA plus flanks) 235412-28-9, DNA (human protein NFAR-2 cDNA)
 235413-52-2 235539-52-3 235558-43-7 235559-09-8 235569-83-2
 235586-45-5 236074-01-4 236092-75-4 236128-07-7 236131-89-8
 236136-56-4 236606-71-6 236610-52-9 236644-32-9 237377-85-4
 237710-52-0 237725-90-5, DNA (human clone DKFZp586L0724 cDNA)
 237726-00-0 237726-02-2, DNA (human clone DKFZp566D211 cDNA)
 237726-10-2, DNA (human clone DKFZp566D143 cDNA) 237726-11-3, DNA (human
 clone DKFZp566M063 cDNA) 237726-19-1, DNA (human clone DKFZp586I2022
 cDNA) 237726-25-9, DNA (human clone DKFZp586P1922 cDNA) 237726-87-3,
 DNA (human clone DKFZp586F0221 cDNA) 237733-40-3, DNA (human clone BAC
 clone djn085o06) 237999-72-3 237999-75-6 238005-85-1, DNA (human
 clone RP11-83M12) 238153-91-8 238186-75-9 238212-00-5 238215-40-2
 238216-63-2 238221-94-8 238227-20-8 238503-95-2 238522-68-4
 238553-63-4 238628-36-9 238629-08-8 238631-01-1 238631-40-8
 238631-42-0 238637-00-8 238639-43-5 238643-32-8 238643-47-5
 238644-57-0 238648-70-9 238649-16-6 238654-89-2 238659-50-2
 238666-39-2 238667-11-3 238670-91-2 238686-77-6 238692-12-1
 238716-94-4 238809-86-4 238810-81-6 238817-43-1 238822-55-4
 238828-89-2 238849-03-1 238889-91-3 238935-04-1 238959-11-0
 239063-93-5 239434-66-3 239435-37-1, DNA (human clone RP4-687F11)
 239435-39-3, DNA (human clone RP4-803J11) 239778-81-5 239879-26-6
 239890-52-9 239931-42-1 239963-45-2 239963-86-1 239965-10-7
 239972-44-2 239981-06-7 240027-78-5 240089-13-8 240109-58-4, DNA
 (human clone B291N6) 240394-92-7, DNA (human clone RP11-13G14)
 240394-98-3 240395-25-9, DNA (human clone RP11-174G6) 240395-67-9,
 DNA (human clone LLNLR-297C12) 240396-56-9, DNA (human clone CTD-2214G1
) 240600-94-6 240624-37-7 240791-59-7, DNA (human clone CTD-2547F10
) 240796-90-1 241118-24-1 241118-30-9, DNA (human clone DKFZp434D156
 cDNA) 241118-42-3, DNA (human clone DKFZp434P106 cDNA) 241118-50-3,
 DNA (human clone DKFZp586C1817 cDNA) 241118-65-0, DNA (human clone
 DKFZp586F1822 cDNA) 241118-85-4, DNA (human clone DKFZp434B061 cDNA)

241118-86-5, DNA (human clone DKFZp434C131 cDNA) 241119-75-5, DNA (human clone DKFZp566F2124 cDNA) 241120-24-1, DNA (human clone DKFZp564I0463 cDNA) 241120-48-9 241120-76-3 241120-90-1, DNA (human clone DKFZp586K0524 cDNA) 241120-94-5 241213-99-0 241308-24-7 241315-22-0 241343-77-1 241379-19-1 241385-64-8 241386-89-0 241464-55-1, DNA (human clone RP11-122L9) 241525-82-6 241589-44-6 241791-30-0, DNA (human clone R-226F19) 241996-96-3 242031-50-1 242037-50-9 242054-28-0 242125-11-7, DNA (human gene HSF4 fragment) 242153-51-1 242155-72-2 242164-21-2 242167-44-8 242276-57-9 242301-92-4 242307-70-6 242446-26-0 242693-16-9 242719-67-1 242786-99-8 242790-60-9 242790-63-2 242829-11-4 242942-44-5 242956-89-4 242987-65-1 242987-84-4 242994-05-4 242995-12-6 242998-78-3 243055-79-0 243071-45-6 243112-29-0, DNA (human clone R-476J6) 243112-68-7 243112-69-8 243114-99-0
 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT 243115-00-6 243115-21-1 243148-90-5 243152-79-6 243156-30-1 243159-65-1 243162-96-1 243165-10-8 243168-66-3 243171-84-8 243182-72-1 243211-03-2 243212-84-2 243252-03-1 243270-86-2 243410-30-2 243417-08-5 243517-12-6 243519-60-0 243566-15-6 243593-88-6 243600-62-6 243611-70-3 243616-40-2 243811-41-8 243877-47-6, DNA (human clone R-73E17) 243877-55-6, DNA (human clone RP1-315G1) 243877-61-4, DNA (human clone 1057B06) 243877-65-8, DNA (human clone 367K01) 243877-88-5 243878-20-8 243878-23-1 243991-99-3 244043-51-4 244046-55-7, DNA (human clone H-NH0514011) 244047-30-1, DNA (human clone CTC-503K11) 244110-46-1, DNA (human clone RP4-585I14) 244110-60-9 244111-36-2, DNA (human clone RP11-606L6) 244162-53-6, DNA (human clone R-356O9) 244375-20-0 244379-88-2 244440-38-8 244441-92-7 244442-14-6 244442-23-7 244442-53-3 244458-59-1 244484-45-5 244501-59-5 244544-61-4 244558-95-0 244560-60-9 244570-22-7 244578-80-1 244579-66-6 244586-57-0 244591-31-9 244592-19-6 244642-14-6 244647-43-6 244659-18-5 244668-15-3 244673-09-4 244680-44-2 244683-99-6 244804-65-7, DNA (human clone R-159L20) 244804-71-5, DNA (human clone R-204K16) 244805-89-8, DNA (human clone RP5-1059L7) 244806-25-5, DNA (human clone RP4-659I19) 244808-92-2, DNA (human clone RP13-212L9) 244809-05-0, DNA (human clone RP1-136O14) 244809-07-2, DNA (human clone RP1-202D23) 244874-07-5 245023-33-0 245034-79-1 245034-81-5 245101-41-1, DNA (human clone DKFZp434G1735 cDNA) 245101-55-7, DNA (human clone DKFZp434O0827 cDNA) 245207-71-0, DNA (human clone DKFZp434P171 cDNA) 245207-93-6, DNA (human clone DKFZp566J2324 cDNA) 245462-39-9 245617-11-2 245781-82-2 245782-60-9 245810-34-8 245810-47-3, DNA (human gene GNG5ps plus flanks) 246053-19-0 246054-04-6, DNA (human gene SPON2 spondin 2 cDNA) 246191-26-4, GenBank AF196779 246431-88-9 246454-93-3 246456-60-0 246464-21-1 246784-84-9 247095-43-8 247181-90-4, DNA (human clone RP5-999L4) 247305-99-3 247315-99-7 247317-04-0 247554-43-4 247560-12-9 247560-17-4 247560-19-6 247560-26-5 247560-32-3 247560-38-9 247560-63-0 247560-73-2 247560-74-3 247560-76-5 247561-04-2 247561-21-3 247561-23-5 247561-24-6 247561-28-0 247561-30-4 247561-35-9 247561-60-0 247561-80-4 247563-61-7 247563-67-3 247895-91-6 247945-94-4 247949-33-3 247961-95-1 248227-38-5 248236-01-3 248400-84-2 248401-40-3 248401-64-1 248402-54-2 248406-12-4 248409-51-0 248411-00-9 248411-32-7 248413-41-4 248417-49-4, DNA (human EST (expressed sequence tag)) 248421-09-2, DNA (human EST (expressed sequence tag)) 248422-03-9 248423-14-5 248425-20-9 248425-28-7 248427-61-4 248569-94-0, DNA (human clone C-2268P10) 248574-49-4, DNA (human clone RP5-1029F21) 248577-80-2 248578-10-1, DNA (human clone DKFZp434G1115 cDNA) 248578-18-9, DNA (human clone DKFZp434M2315 cDNA) 248578-33-8, DNA (human clone DKFZp434C1717 cDNA) 248578-58-7, DNA (human clone DKFZp434J0828 cDNA) 248845-23-0 248848-30-8 248857-43-4

248858-76-6 248860-88-0 248901-85-1 248903-43-7 248904-48-5, DNA
 (human clone R-561B11) 248907-13-3 249345-53-7 249346-02-9
 249357-46-8 249406-49-3 249456-80-2 249458-69-3 249461-58-3
 249461-85-6 249463-67-0 249464-06-0 249478-87-3 249481-54-7
 249593-67-7, DNA (human clone RP11-108L7) 249593-68-8, DNA (human clone
 RP11-291L22) 249594-25-0, DNA (human cell line Jurkat cDNA)
 249596-92-7, DNA (human clone C-2510G9) 249597-62-4 249600-69-9
 249650-15-5, DNA (human clone C-2560C21) 249666-05-5 249666-94-2
 249680-26-0 249684-96-6 249695-78-1 249707-05-9 249766-97-0
 249766-99-2, DNA (human clone 854M03) 249767-00-8 250018-71-4
 250024-76-1 250032-84-9 250453-96-4 250466-19-4 250478-77-4
 250500-20-0, GenBank AF110774 250500-35-7 250500-40-4 250501-61-2
 250502-32-0, DNA (human isolate X-5) 250502-39-7, DNA (human isolate
 X-13) 250503-31-2, DNA (human isolate 13-23) 250905-58-9
 250919-90-5 251037-29-3 251037-94-2, DNA (human clone RP5-869M20)
 251072-98-7, DNA (human clone RP5-1068H6) 251073-14-0, DNA (human clone
 C-2566J3) 251073-31-1, DNA (human clone RP11-107I14) 251082-03-8
 251082-05-0 251082-08-3 251082-11-8 251082-14-1 251082-18-5
 251082-22-1 251082-26-5 251082-33-4, GenBank AF126021 251082-34-5
 251204-01-0 251240-34-3, DNA (human clone R-841O20) 251240-39-8, DNA
 (human clone C-2538G10) 251242-82-7 251244-62-9 251276-26-3
 251282-35-6 251336-50-2 251337-93-6 251399-40-3 251427-48-2
 251517-84-7 251517-95-0, DNA (human clone DKFZp434A1114 cDNA)
 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 251518-26-0, DNA (human clone DKFZp434E109 cDNA) 251518-34-0, DNA (human
 clone DKFZp434O159 cDNA) 251518-81-7, DNA (human clone DKFZp434E0121
 cDNA) 251592-30-0 251599-81-2 251601-15-7 251602-33-2
 251602-95-6 251667-49-9, DNA (human clone RP4-687J17) 251880-71-4,
 DNA (human clone R-667E4) 251882-41-4 251882-60-7
 251884-77-2 251885-95-7 251887-52-2 251891-24-4, DNA (human clone
 RP1-233G16) 252063-90-4 252092-02-7 252124-77-9, DNA (human clone
 FLB2302 cDNA) 252124-82-6 252173-06-1, DNA (human clone FLB7235 cDNA)
 252173-13-0, DNA (human clone FLB7711 cDNA) 252225-80-2 252420-19-2
 252425-71-1 252444-42-1 252635-77-1, 30: PN: WO0153836 TABLE: 3-5
 claimed DNA 252697-18-0 252706-45-9 252713-19-2, DNA (human clone
 RPCI-11-127I20) 252718-71-1 252781-16-1 252820-21-6
 252820-33-0 252828-37-8, DNA (human clone R-391B7) 252833-71-9
 252833-78-6 252884-43-8, DNA (human clone HQ0692) 252888-43-0
 252922-38-6, DNA (human clone R-588D7) 252957-85-0, DNA (human clone
 RP11-904M10) 252994-02-8 252994-05-1 252994-13-1 252994-27-7, DNA
 (human clone 24J14) 253028-53-4 253048-51-0 253051-12-6
 253054-96-5 253060-38-7 253064-84-5 253065-04-2 253070-69-8
 253090-93-6 253097-45-9 253098-14-5 253115-03-6, DNA (human cell
 line WAV17 clone Q2F5) 253165-23-0 253232-81-4 253241-67-7
 253242-35-2 253258-70-7, DNA (human clone BAC 139I22) 253263-51-3
 253502-11-3, DNA (human cell line bulk cDNA) 253929-62-3, DNA (human
 clone C-2246N19) 254120-38-2 254130-30-8 254154-30-8 254154-40-0
 254154-43-3 254154-60-4, DNA (human clone DKFZp434C1714 cDNA)
 254155-10-7, DNA (human clone DKFZp434I1716 cDNA) 254155-54-9, DNA
 (human clone DKFZp434H0872 cDNA) 254156-18-8, DNA (human clone
 DKFZp434M0326 cDNA) 254156-35-9, DNA (human clone DKFZp434J052 cDNA)
 254156-70-2, DNA (human clone DKFZp761M2324 cDNA) 254156-75-7, DNA
 (human clone DKFZp434P182 cDNA) 254156-86-0, DNA (human clone
 DKFZp434J0428 cDNA) 254156-90-6, DNA (human clone DKFZp761G179 cDNA)
 254157-30-7, DNA (human clone DKFZp434E1030 cDNA) 254157-38-5, DNA
 (human clone DKFZp434O1230 cDNA) 254157-51-2, DNA (human clone
 DKFZp434K1323 cDNA) 254157-56-7, DNA (human clone DKFZp761A051 cDNA)
 254157-68-1 254157-82-9, DNA (human clone DKFZp434A1518 cDNA)
 254157-94-3, DNA (human clone DKFZp434D0818 cDNA) 254158-06-0, DNA
 (human clone DKFZp434P1019 cDNA) 254158-07-1, DNA (human clone

DKFZp434P2119 cDNA) 254158-17-3, DNA (human clone DKFZp434E0620 cDNA)
 254158-41-3, DNA (human clone DKFZp586I0521 cDNA) 254159-13-2, DNA
 (human clone DKFZp434E1212 cDNA) 254159-14-3, DNA (human clone
 DKFZp434I0812 cDNA) 254417-56-6, DNA (human clone R-102C24)
 254653-11-7 254718-04-2 254718-97-3, DNA (human clone CBCCCC09 cDNA)
 254719-02-3, DNA (human clone CBCCIF11 cDNA) 254719-23-8, DNA (human
 clone CBFASE03 cDNA) 254719-34-1, DNA (human clone CBFBN02 cDNA)
 254719-38-5, DNA (human clone CBFQ02 cDNA) 254719-41-0, DNA (human
 clone CBLABB10 cDNA) 254719-61-4, DNA (human clone CBNACC01 cDNA)
 254719-76-1 254719-85-2 254720-13-3 254720-15-5 254720-28-0
 254720-30-4 254720-34-8 254720-39-3 254720-49-5 254720-52-0
 254720-58-6 254720-61-1 254945-03-4 254946-81-1 254950-97-5
 254951-07-0, DNA (human clone FLB4718) 254951-17-2, DNA (human clone
 FLB9737) 254951-18-3 254953-99-6 255088-50-7 255091-51-1
 255119-29-0 255119-55-2 255129-65-8 255131-13-6 255139-39-0
 255162-75-5 255168-77-5 255169-96-1 255244-02-1 255267-15-3
 255283-48-8 255283-62-6 255290-15-4 255296-88-9 255349-79-2
 255349-81-6, DNA (human clone 21B42C4) 255402-82-5 255437-77-5
 255452-22-3 255473-53-1 255634-87-8 255640-33-6 255640-97-2
 255641-30-6 255671-65-9 255939-45-8 255942-84-8 256183-69-4
 256194-26-0 256202-22-9 256207-50-8 256315-83-0, DNA (human clone
 B738P18) 256315-84-1, DNA (human clone B812P3) 256315-85-2, DNA
 (human clone B880L11) 256316-15-1 256357-37-6 256360-38-0, 64: PN:
 WO0153836 TABLE: 3-5 claimed DNA 256360-51-7 256551-24-3 256591-42-1
 256592-24-2 256594-37-3 256599-02-7 256601-21-5 256615-01-7
 256615-02-8, GenBank AF224669 256617-49-9 256617-67-1, DNA (human
 clone DKFZp761F152 cDNA) 256617-86-4, DNA (human clone DKFZp761D0223
 cDNA) 256617-90-0, DNA (human clone DKFZp761N0123 cDNA) 256618-27-6,
 DNA (human clone DKFZp434A0312 cDNA) 256618-41-4, DNA (human clone
 DKFZp586P1424 cDNA) 256621-90-6, DNA (human clone ADKA03432 cDNA)
 256621-95-1, DNA (human clone ADSE00529 cDNA) 256622-00-1, DNA (human
 clone ADSE01233 cDNA) 256622-07-8, DNA (human clone ADSE01923 cDNA)
 256622-21-6, DNA (human clone COL00424 cDNA) 256622-24-9, DNA (human
 clone COL00548 cDNA) 256622-40-9, DNA (human clone COL01383 cDNA)
 256622-55-6, DNA (human clone COL02766 cDNA) 256622-58-9, DNA (human
 clone COL03057 cDNA) 256622-79-4, DNA (human clone COL04648 cDNA)
 256623-43-5, DNA (human clone COL09448 cDNA) 256623-80-0, DNA (human
 clone COLF1210 cDNA) 256623-93-5, DNA (human clone COLF2014 cDNA)
 256624-63-2 256624-75-6 256624-90-5 256624-91-6 256625-20-4
 256625-37-3 256625-67-9, DNA (human clone KAIA4517 cDNA) 256625-72-6,
 DNA (human clone KAIA4699 cDNA) 256625-86-2 256625-98-6 256626-06-9
 256626-11-6 256626-25-2 256626-34-3 256626-42-3 256626-46-7
 256626-58-1 256626-79-6 256626-98-9 256627-13-1 256627-20-0
 256627-32-4 256627-43-7 256627-57-3, DNA (human clone REC00607 cDNA)
 256627-87-9 256627-92-6 256627-96-0 256628-27-0 256628-39-4
 256628-41-8, DNA (human clone KAIA804 cDNA) 256628-93-0, DNA (human
 clone HUV00275 cDNA) 256628-97-4 256629-11-5 256629-17-1
 256629-24-0 256629-28-4 256629-37-5 256629-62-6 256629-72-8, DNA
 (human clone COL00343 cDNA) 256629-90-0, DNA (human clone ADSE01435
 cDNA) 256629-98-8 256630-28-1, DNA (human clone ADKA01706 cDNA)
 256630-38-3

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES
 (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 256667-45-5 256668-50-5 256673-25-3 256673-51-5 256676-44-5
 256678-69-0 256681-67-1 256687-99-7 256689-86-8 256900-93-3,
 Protein (human clone HEMBA1000817) 256901-17-4 256901-33-4, Protein
 (human clone HEMBA1001579) 256901-35-6 256901-36-7 256901-61-8,
 Protein (human clone HEMBA1002458) 256901-93-6, Protein (human clone
 HEMBA1003033) 256902-08-6, Protein (human clone HEMBA1003286)
 256902-63-3, Protein (human clone HEMBA1004850) 256902-69-9
 256902-90-6, Protein (human clone HEMBB1000037) 256902-93-9

256902-95-1, Protein (human clone HEMBB1000226) 256903-07-8, Protein (human clone HEMBB1000631) 256903-56-7, Protein (human clone NT2RM1000257) 256903-65-8 256903-94-3, Protein (human clone NT2RM2000624) 256904-09-3, Protein (human clone NT2RM2000984) 256904-23-1, Protein (human clone NT2RM2001243) 256904-39-9, Protein (human clone NT2RM2001950) 256904-87-7 256905-15-4, Protein (human clone NT2RP1000959) 256905-16-5, Protein (human clone NT2RP1000966) 256905-23-4, Protein (human clone NT2RP1001466) 256905-32-5, Protein (human clone NT2RP2000007) 256905-40-5, Protein (human clone NT2RP2000091) 256905-56-3, Protein (human clone NT2RP2000270) 256905-77-8 256905-89-2, Protein (human clone NT2RP2000892) 256905-97-2 256906-10-2, Protein (human clone NT2RP2001721) 256906-15-7, Protein (human clone NT2RP2002270) 256906-32-8, Protein (human clone NT2RP2002986) 256906-43-1 256906-50-0 256906-53-3, Protein (human clone NT2RP2004389) 256906-54-4, Protein (human clone NT2RP2004392) 256906-55-5 256906-71-5 256906-91-9 256906-95-3, Protein (human clone NT2RP2005635) 256907-12-7, Protein (human clone NT2RP2005804) 256907-31-0, Protein (human clone NT2RP2006237) 256907-38-7 256907-66-1, Protein (human clone NT2RP3000759) 256907-73-0, Protein (human clone NT2RP3000869) 256907-78-5, Protein (human clone NT2RP3000994) 256908-09-5 256908-16-4, Protein (human clone NT2RP3004480) 256908-58-4, Protein (human clone NT2RP4000614) 256908-91-5, Protein (human clone NT2RP4001117) 256908-92-6 256908-93-7, Protein (human clone NT2RP4001138) 256909-19-0, Protein (human clone NT2RP4001524) 256909-20-3, Protein (human clone NT2RP4001547) 256909-34-9, Protein (human clone NT2RP4001679) 256909-49-6 256909-57-6, Protein (human clone NT2RP4002791) 256909-64-5, Protein (human clone NT2RP5003522) 256909-66-7, Protein (human clone NT2RP5003534) 256909-82-7, Protein (human clone OVARC1000326) 256910-57-3 256910-79-9 256910-80-2 256911-04-3 256911-63-4 256912-04-6 256912-33-1 256912-38-6 256912-48-8 256912-74-0 256913-02-7 256913-04-9 256913-71-0 256913-92-5 257083-51-5 257094-47-6 257104-27-1 257132-66-4 257150-11-1 257256-69-2, DNA (human clone RP11-636L7) 257323-33-4 257585-88-9 257586-14-4 257586-22-4 257586-41-7, DNA (human clone CBFAC07 cDNA) 257586-46-2 257586-60-0 257592-82-8 257963-22-7 257995-46-3 258391-70-7 258401-66-0 258466-26-1 258489-14-4, DNA (human gene GSR plus flanks) 258489-15-5 258803-21-3 258804-22-7 259066-91-6 259071-47-1, DNA (human clone B649M24) 259071-50-6, DNA (human clone B783C3) 259244-10-5, GenBank AB004064 259444-22-9 259451-13-3 259459-41-1 259478-10-9 259478-14-3 259478-27-8 259478-33-6 259478-37-0 259478-77-8 259478-83-6 259478-87-0 259479-19-1 259479-20-4 259495-65-3 259499-12-2 259548-90-8 259566-47-7 259579-06-1 259642-97-2 367831-40-1, DNA (human clone B812E1)

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT 140284-66-8 151875-72-8 171716-06-6

251882-60-7 252718-71-1

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

RN 140284-66-8 HCAPLUS

CN 755: PN: WO0153836 TABLE: 3-5 claimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 151875-72-8 HCAPLUS

CN DNA (human clone TL27 androgen-induced cDNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 171716-06-6 HCAPLUS

CN DNA (human HT-1080 cell clone HP00269 transforming growth factor- β -like protein cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 251882-60-7 HCAPLUS

CN DNA (human gene TGFBR3 transforming growth factor β receptor type III 851-amino acid isoform cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 252718-71-1 HCAPLUS

CN 466: PN: WO0153836 TABLE: 3-5 claimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 10 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:716749 HCAPLUS

DN 135:268336

ED Entered STN: 02 Oct 2001

TI Differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer

IN Schlegel, Robert; Endege, Wilson; Monahan, John E.

PA Millennium Predictive Medicine, Inc., USA

SO PCT Int. Appl., 975 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM G01N033-574

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 9, 13, 14, 63

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001053836 | A2 | 20010726 | WO 2001-XB2318 | 20010124 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | WO 2001053836 | A2 | 20010726 | WO 2001-US2318 | 20010124 |
| | WO 2001053836 | A3 | 20020606 | | |
| | WO 2001053836 | C2 | 20021107 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | US 2000-178525P | P | 20000124 | | |
| | US 2000-183245P | P | 20000217 | | |
| | US 2000-190139P | P | 20000316 | | |
| | US 2000-208126P | P | 20000531 | | |
| | US 2000-219705P | P | 20000718 | | |
| | US 2000-255160P | P | 20001213 | | |
| | WO 2001-US2318 | A | 20010124 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|------------------------------------|
| WO 2001053836 | ICM | G01N033-574 |
| WO 2001053836 | ECLA | G01N033/574C14 |

AB This invention relates to newly discovered correlations between expression of certain nucleic acid markers and the cancerous state of human prostate cells. The levels of expression of individual markers and combinations of markers described herein correlates with the presence of prostate cancer or a pre-malignant condition in a patient. Methods are provided for detecting the presence of prostate cancer in a sample, the absence of prostate cancer in a sample, the stage of a prostate cancer, the metastatic potential of a prostate cancer, the indolence or aggressiveness of the cancer, and other characteristics of prostate cancer that are relevant to prevention, diagnosis, characterization and therapy of prostate cancer in a patient. Thousands of differentially-expressed cDNA markers are identified in subtracted cDNA libraries and by transcript profiling. [This abstract record is the third of four records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

ST tumor assocd protein cDNA prostate cancer; diagnosis prostate cancer tumor assocd protein cDNA; antitumor agent prostate tumor assocd protein cDNA

IT Carcinogens
(assessment of test compound potential; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Diagnosis
(cancer; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Blood analysis
Computer application
Drug screening
Immunoassay
Nucleic acid amplification (method)
Nucleic acid hybridization
Test kits
Tumor markers
Urine analysis
cDNA sequences
(differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT cDNA
mRNA
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Antibodies
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Antisense oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Hybridoma
(for antibody production; differentially expressed nucleic acids encoding

tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Androgens
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (markers with sensitivity to; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Prostate gland
(neoplasm, inhibitors; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Prostate gland
(neoplasm; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Antitumor agents
(prostate gland; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Lymph
Semen
(sample anal. in; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Proteins, specific or class
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(secretory; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT Proteins, specific or class
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(tumor-associated; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT 108598-54-5, DNA (human clone 9-110 amyloid A4 glycoprotein cDNA)
115490-23-8, DNA (human clone pKK-Cat250 catalase cDNA minus stop codon)
115536-82-8 115536-85-1 117443-36-4, DNA (human fibroblast proteoglycanase cDNA) 118103-70-1 121630-81-7 124586-01-2
126466-74-8, DNA (human clone LP211 lipocortin I cDNA plus flanks)
127314-95-8, DNA (human clone 16 gene rac1 protein cDNA) 127547-90-4,
DNA (human lymphokine MCP 1 cDNA plus flanks) 132702-51-3, DNA (human clone R10/R16 annexin VII cDNA plus flanks) 133924-59-1, DNA (human annexin II cDNA plus flanks) 134010-88-1 134376-28-6 134497-66-8,
DNA (human clone λ hg22 calmodulin pseudogene CAMII- ψ 2 plus flanks) 134687-68-6 134851-46-0 134944-80-2 135113-71-2
135231-53-7 135373-53-4 135433-70-4 135542-32-4 135622-19-4
135639-93-9 135668-14-3 135750-36-6, DNA (human clone pADE2H1 protein cDNA plus flanks) 136046-25-8 136462-43-6, DNA (human clone 5 antigen CD 59 cDNA plus flanks) 137925-72-5, DNA (human proteinase C5-subunit cDNA plus flanks) 137925-73-6, DNA (human proteinase C8-subunit cDNA plus flanks) 138016-40-7, DNA (human steroid 27-monooxygenase cDNA plus flanks) 138546-05-1 138575-76-5 138929-19-8, DNA (human clone pH9 gene 1-8U coding region plus flanks) 139045-35-5 139075-24-4
139460-39-2 139802-90-7 139802-91-8 139803-27-3 139803-65-9,
GenBank M37400 139803-71-7 139803-78-4 139803-81-9, GenBank X05606
139803-91-1, GenBank X02596 139803-94-4 139804-18-5, GenBank J05480
139804-20-9 139804-46-9, GenBank X04407 139804-47-0, GenBank K03002
139804-75-4 139804-76-5 139805-28-0, GenBank M15887 139805-85-9
139805-99-5 139806-03-4 139806-22-7 139806-48-7 139806-67-0
139806-77-2 139806-81-8 139807-03-7, GenBank X05345 139807-12-8

139808-38-1 139808-43-8 139808-44-9 139808-50-7 139808-52-9
 139808-63-2, DNA (human annexin I cDNA plus flanks) 139808-64-3, GenBank
 J02959 139808-72-3 139809-09-9 139809-47-5 139809-48-6
 139809-56-6, DNA (human neuroleukin cDNA plus flanks) 139809-63-5
 139809-74-8, GenBank M21897 139810-16-5, GenBank M23725 139810-21-2
 139810-66-5, GenBank M11949 139810-71-2 139810-92-7 139811-30-6
 139811-35-1, GenBank J04615 139811-53-3, GenBank M20030 139811-54-4
 139812-18-3 139812-77-4, GenBank J02966 139812-88-7, DNA (human
 ubiquitin cDNA plus flanks) 139815-83-1 139825-06-2, GenBank J04443
 139826-80-5 139835-76-0, GenBank M61831 139836-20-7 139836-36-5
 139837-00-6 139840-22-5, DNA (human γ -actin cDNA plus flanks)
 139840-53-2 139841-10-4, DNA (human protein p68 gene plus flanks)
 139844-12-5 139844-61-4, GenBank M68840 139845-79-7 139846-38-1
 139847-33-9, GenBank X07270 139848-16-1 139848-18-3 139848-33-2
 139851-14-2, DNA (human clone HHCC29 EST (expressed sequence tag)
 EST00071) 139852-99-6 139854-25-4 139854-89-0 139856-46-5
 139857-62-8 139859-64-6 139860-40-5, GenBank M80335 139861-97-5
 139862-32-1 139866-58-3 139867-54-2 139946-78-4 140014-82-0
 140025-49-6, GenBank J04137 140025-59-8 140025-65-6, GenBank M55265
 140025-83-8 140025-85-0, GenBank M17081 140025-93-0 140026-23-9
 140026-24-0, GenBank M59305 140026-28-4, GenBank J04205 140026-42-2
 140026-47-7, GenBank M20260 140026-51-3 140026-60-4 140026-67-1
 140026-95-5 140027-08-3 140027-16-3, GenBank J04478 140027-39-0
 140027-40-3 140027-79-8 140027-94-7, GenBank M29550 140027-95-8
 140028-06-4 140028-08-6, GenBank J02871 140028-13-3, GenBank M27691
 140028-18-8 140028-23-5, GenBank M30448 140028-30-4 140028-72-4,
 GenBank M60527 140028-78-0 140028-86-0 140028-87-1, GenBank X04571
 140028-93-9 140028-99-5 140029-03-4 140029-05-6 140029-07-8
 140029-48-7 140029-50-1, GenBank X04325 140029-51-2 140029-52-3
 140029-63-6 140029-74-9 140029-86-3 140029-87-4 140030-12-2
 140030-23-5, GenBank X04697 140030-55-3 140030-60-0 140030-69-9,
 GenBank X12433 140030-77-9 140030-92-8 140030-93-9 140031-20-5,
 GenBank M22414 140031-21-6 140031-40-9 140031-50-1 140031-76-1
 140031-85-2, GenBank M30938 140031-94-3 140032-00-4 140032-05-9
 140032-31-1, GenBank D90228 140032-38-8, GenBank J04031 140032-57-1,
 GenBank M15470 140032-90-2 140033-01-8 140033-36-9 140033-37-0
 140033-61-0 140033-67-6, GenBank M21895 140033-68-7, GenBank M21896
 140033-76-7, GenBank M24902 140033-77-8 140033-82-5 140033-83-6
 140033-85-8 140033-89-2 140033-90-5 140033-94-9 140033-97-2
 140034-00-0 140034-03-3, DNA (human gelsolin fragment cDNA)
 140034-05-5 140034-08-8 140034-14-6, GenBank M34181 140034-26-0
 140034-30-6 140034-41-9, GenBank M22803 140034-51-1 140034-55-5
 140034-65-7 140034-69-1 140034-84-0 140034-99-7 140035-01-4
 140035-06-9 140035-08-1 140035-21-8 140035-47-8 140035-51-4
 140035-80-9, GenBank M13231 140035-86-5, GenBank M16768 140035-88-7,
 GenBank M16804 140035-94-5 140035-97-8 140036-08-4 140036-18-6
 140036-24-4 140036-36-8 140036-49-3, DNA (human α -tubulin cDNA)
 140036-58-4, GenBank X15653 140036-62-0 140036-66-4, GenBank AX138824
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 140036-72-2, GenBank J03518 140036-74-4 140048-79-9 140048-87-9
 140049-44-1 140050-06-2 140050-69-7 140051-42-9 140063-26-9,
 GenBank M61832 140064-33-1 140066-41-7, GenBank M60255 140066-87-1
 140067-35-2 140067-47-6, DNA (human clone pAH12 cDNA) 140067-54-5
 140068-65-1 140069-94-9, GenBank X52174 140069-99-4 140070-33-3
 140072-62-4 140072-69-1 140072-70-4 140073-35-4, GenBank M69104
 140073-38-7 140076-95-5, DNA (human gene ARNT cDNA plus flanks)
 140078-92-8 140079-00-1, DNA (human clone GRH-Mev10 cDNA) 140079-02-3
 140079-04-5 140079-10-3 140079-11-4 140079-26-1 140079-28-3
 140083-15-4, GenBank M64788 140084-64-6, DNA (human cyclin C cDNA plus
 flanks) 140084-91-9 140085-57-0 140087-32-7 140089-68-5
 140090-83-1 140093-94-3 140094-60-6 140097-39-8 140098-29-9
 140098-53-9 140101-97-9 140102-97-2 140103-04-4 140103-05-5

140108-98-1 140109-64-4 140109-65-5 140110-18-5 140263-91-8
 140263-93-0 140274-21-1 140274-26-6, GenBank X02544 140274-41-5
 140274-52-8 140274-74-4, GenBank M13692 140274-93-7, GenBank J04794
 140274-96-0 140274-97-1, GenBank M22324 140275-12-3, GenBank M25077
 140275-61-2 140275-64-5 140275-79-2 140276-06-8, GenBank J03507
 140276-24-0 140276-52-4, GenBank M10941 140276-80-8, GenBank M20776
 140276-83-1 140276-84-2 140276-85-3, GenBank M19961 140277-18-5
 140277-19-6, GenBank M22976 140277-21-0 140277-27-6 140277-28-7
 140277-72-1 140277-86-7 140277-99-2, GenBank M11119 140278-21-3,
 GenBank J02876 140278-28-0, GenBank M12670 140278-35-9 140278-36-0
 140278-48-4 140278-50-8, GenBank M24355 140278-76-8 140278-77-9
 140278-87-1, GenBank AX278686 140279-26-1 140279-70-5, GenBank M31630
 140279-84-1, GenBank X03473 140279-85-2 140279-94-3, GenBank M11887
 140279-97-6 140280-03-1 140280-05-3 140280-23-5 140280-28-0
 140281-58-9 140282-24-2 140282-49-1 140282-76-4, GenBank M27937
 140282-88-8 140283-31-4 140283-47-2, GenBank M16942 140283-57-4,
 GenBank M27689 140283-61-0 140283-67-6, GenBank K00409 140283-68-7
 140283-71-2, GenBank M36647 140283-76-7 140284-11-3, GenBank M22919
 140284-15-7 140284-28-2 140284-33-9, GenBank M16650 140284-37-3
 140284-54-4 140284-73-7 140284-81-7, GenBank X04741 140285-03-6
 140285-14-9 140285-63-8 140286-02-8, GenBank M34081 140286-05-1
 140286-06-2 140286-11-9 140286-66-4 140286-74-4, GenBank M15885
 140286-76-6 140287-16-7, DNA (human clone p-gamma-1 cDNA) 140287-17-8
 140287-63-4 140287-65-6 140287-66-7 140287-68-9 140287-71-4
 140287-93-0, GenBank M12125 140288-07-9, GenBank M14326 140288-10-4
 140288-22-8 140288-37-5 140288-38-6, GenBank M11548 140303-68-0
 140305-62-0 140305-64-2 140306-07-6, GenBank M28211 140317-73-3
 140318-19-0, GenBank M61866 140320-63-4 140324-70-5 140324-71-6
 140327-28-2, GenBank X53777 140330-69-4 140332-48-5 140336-55-6
 140337-45-7 140341-42-0 140341-43-1 140344-34-9 140347-92-8, DNA
 (human clone UIII moesin cDNA plus flanks) 140347-94-0 140351-58-2
 140352-77-8, GenBank X17567 140352-85-8 140352-86-9, GenBank M86492
 140354-72-9 140356-87-2 140357-48-8 140357-70-6 140358-35-6
 140358-46-9 140359-85-9 140505-98-2 140506-79-2, GenBank M31511
 140507-57-9 140507-98-8 140508-48-1 140510-02-7, GenBank M27544
 140511-31-5, GenBank M26324 140511-87-1 140512-58-9, GenBank J00200
 140512-93-2 140513-16-2 140513-90-2 140513-91-3 140514-01-8
 140514-50-7 140514-53-0, GenBank M34055 140514-93-8 140514-94-9,
 GenBank M15661 140515-31-7 140515-39-5, GenBank M10906 140515-40-8,
 GenBank J03870 140515-72-6, GenBank X04503 140517-12-0, DNA (human
 thymosin β 4 plus flanks) 140517-54-0, GenBank X13482 140517-58-4
 140538-33-6, GenBank M23419 140538-83-6 140540-32-5 140557-18-2, RNA
 (human 7L1 repetitive fragment) 140557-25-1 140559-42-8 140563-72-0
 140585-82-6 140586-34-1 140588-06-3 140596-46-9 140598-39-6,
 GenBank X59352 140598-70-5 140722-48-1 140737-78-6 140740-01-8,
 GenBank M34175 140740-06-3, GenBank X07429 140740-24-5 140740-31-4
 140740-36-9 140740-51-8, GenBank J03779 140741-77-1, GenBank J04444
 140741-78-2 140742-06-9, GenBank J05211 140742-23-0 140742-50-3
 140742-82-1 140742-95-6, GenBank M14335 140743-26-6 140743-83-5,
 GenBank M20681 140744-16-7 140744-24-7, DNA (human gene HPS90B plus
 flanks) 140744-36-1 140745-09-1 140747-21-3 140748-27-2, GenBank
 M21574 140752-50-7

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 140752-65-4 140774-52-3, GenBank M24543 140775-47-9 140790-03-0
 140791-01-1 140791-16-8 140794-04-3, DNA (human liver gene IGF-I plus
 flanks) 140794-34-9 140794-51-0 140801-66-7 140804-22-4, GenBank
 M64572 140806-08-2 140812-22-2 140812-67-5 140813-79-2
 140815-95-8 140817-19-2 140817-77-2, GenBank D90359 140825-16-7
 140826-30-8 140827-00-5, GenBank X52022 140827-06-1 140827-43-6
 140828-26-8 140828-27-9, DNA (human desmoplakin I cDNA plus 5'-flank)
 140828-29-1 140830-46-2 140830-81-5 140952-08-5 140960-48-1, DNA
 (human clone LRP 1-9 cDNA) 140968-66-7 140991-44-2 140996-05-0

140999-51-5 141000-80-8 141004-90-2 141005-78-9, DNA (human clone
 Ht31 enzyme-anchoring protein fragment-specifying) 141006-05-5
 141006-27-1 141009-57-6 141010-30-2 141015-35-2, DNA (human
 β -actin cDNA plus flanks) 141015-40-9 141015-66-9, GenBank X63753
 141162-79-0 141162-81-4 141163-59-9 141163-81-7 141165-10-8
 141370-75-4 141373-09-3 141373-86-6 141490-77-9 141609-39-4
 141640-70-2, DNA (human clone pACT2 α 1-chymotrypsin
 inhibitor-specifying plus flanks) 141657-44-5 141878-47-9
 141961-85-5, DNA (human glycoprotein IIIb cDNA plus flanks) 142099-66-9
 142101-47-1 142158-29-0 142318-55-6 142361-67-9 142432-45-9, DNA
 (human retin cDNA plus flanks) 142433-05-4 142433-07-6 142455-82-1
 142552-26-9 142553-00-2, DNA (human FKBP 25 receptor cDNA plus flanks)
 142553-83-1 142579-00-8 142579-28-0 142579-42-8, DNA (human cell
 line Hela cDNA) 142693-00-3 142694-23-3 142694-25-5 142694-33-5
 142768-14-7 142789-02-4, GenBank X57500 142830-35-1 142862-63-3
 142862-66-6 142862-71-3 142883-21-4 142915-77-3, GenBank Z11241
 142916-16-3, GenBank Z11338 142931-65-5 142964-74-7, GenBank Z11227
 142964-87-2 143001-94-9 143001-98-3 143003-25-2 143024-81-1
 143025-36-9 143025-44-9 143178-19-2, DNA (human proteinase subunit
 ζ cDNA plus flanks) 143190-78-7 143342-11-4 143368-89-2, DNA
 (human clone hEc10 cadherin E cDNA plus flanks) 143368-99-4
 143386-62-3 143461-87-4 143506-52-9 143506-53-0 143506-78-9
 143524-98-5 143580-81-8 143608-33-7 143695-07-2 143695-26-5
 143744-73-4 143829-54-3 143845-86-7 143967-85-5 144531-33-9
 144531-43-1 144531-49-7 144531-98-6, DNA (human lactoylglutathione
 lyase cDNA plus flanks) 144560-33-8 144560-34-9 144560-35-0
 144560-45-2 144560-47-4 144592-20-1 144713-92-8, DNA (human clone
 λ KB3 basigin cDNA plus flanks) 144755-29-3 144755-35-1
 144915-64-0, DNA (human IN157 cell utrophin cDNA) 145043-70-5
 145093-29-4, GenBank S66196 145171-94-4 145257-45-0 145257-46-1
 145258-24-8 145280-55-3 145280-68-8 145281-48-7 145347-70-2
 145405-48-7 145495-43-8, GenBank L07261 145530-29-6 145647-25-2, DNA
 (human histone H 1 gene plus flanks) 145677-16-3 145709-28-0
 145710-46-9 145710-47-0 145711-52-0 145735-34-8 145885-54-7
 145885-71-8 145906-71-4 145971-89-7 145971-93-3 145973-37-1,
 GenBank L08238 145974-12-5 145974-15-8 145975-20-8 145975-45-7
 146001-73-2, DNA (human cadherin E cDNA plus flanks) 146002-78-0,
 GenBank L01439 146003-70-5 146068-55-5 146170-03-8 146170-11-8
 146193-39-7 146193-40-0, DNA (human clone plac-1 calnexin cDNA plus
 flanks) 146193-97-7 146592-52-1 146737-03-3 146990-56-9
 147191-06-8 147191-33-1 147191-60-4 147270-81-3 147351-38-0
 147371-77-5 147401-67-0 147401-89-6 147431-97-8 147457-14-5, DNA
 (Trypanosoma brucei strain 427 microtubule-associated protein
 fragment-specifying) 147535-23-7 147617-99-0 147618-09-5
 147668-92-6, GenBank Z19471 147692-64-6 147692-72-6, GenBank Z17864
 147773-07-7 147825-15-8, DNA (human antigen tum- cDNA plus flanks)
 147825-32-9 147942-02-7 148086-82-2 148087-87-0 148106-77-8
 148107-95-3 148107-96-4 148108-31-0, GenBank X02875 148108-37-6
 148141-28-0 148141-73-5, GenBank X12660 148142-00-1 148142-53-4
 148142-59-0, GenBank D12981 148142-62-5 148210-74-6 148212-02-6
 148212-43-5, DNA (human gene MUC6 mucin 169-amino acid fragment-specifying
 plus 3'-flank) 148232-68-2 148233-84-5, GenBank L09749 148281-97-4,
 GenBank M94654 148284-09-7 148284-80-4, DNA (human intestinal trefoil
 factor cDNA plus flanks) 148311-39-1 148311-88-0 148363-09-1
 148363-15-9 148391-57-5 148449-41-6 148450-36-6 148450-37-7
 148450-38-8 148450-41-3 148450-43-5 148450-44-6 148450-45-7
 148450-46-8 148450-48-0 148450-49-1 148450-51-5 148450-52-6
 148450-53-7 148450-58-2 148450-60-6 148450-64-0 148450-65-1
 148488-47-5 148488-48-6 148512-85-0
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 148541-88-2, RNA (Trimyema archaeal symbiont) 148611-72-7 148636-88-8
 148636-91-3 148662-00-4 148664-96-4 148783-33-9 148784-15-0

148784-16-1 148803-00-3 148803-16-1 148803-23-0, GenBank Z18956
 148921-64-6, DNA (human EST02752 cDNA clone HFBCA56) 148923-06-2, DNA
 (human EST02894 cDNA clone HFBCM46) 148954-05-6 148954-93-2
 148985-94-8, DNA (human clone HFBD18 EST (expressed sequence tag)
 EST03437) 148986-81-6, DNA (human clone HFBD43 EST (expressed sequence
 tag) EST03524) 149079-24-3, DNA (human EST04463 cDNA clone HFBDV34)
 149120-56-9, DNA (human clone SP25 testican cDNA plus flanks)
 149134-76-9, DNA (human EST04814 cDNA clone HFBEA96) 149135-35-3, DNA
 (human EST04873 cDNA clone HFBE82) 149137-47-3, DNA (human clone
 HFBEF11 EST (expressed sequence tag) EST05085) 149215-30-5 149241-27-0
 149278-15-9 149278-16-0 149291-53-2 149448-34-0, DNA (human cystatin
 B cDNA) 149449-93-4 149450-76-0 149482-88-2 149483-33-0
 149583-17-5 149583-59-5 149584-59-8 149616-69-3 149618-14-4
 149619-96-5 149644-17-7 149738-26-1 149766-00-7, DNA (human
 phosphoprotein MPP2 C-terminal fragment-specifying plus 3'-flank)
 149768-40-1, GenBank X71810 149768-93-4 149800-06-6, GenBank D16217
 149870-97-3, DNA (human gene AF-4 protein isoform cDNA plus flanks)
 149974-83-4 150052-32-7, DNA (human clone pHG-7 ribosome protein L 7
 cDNA plus 3'-flank) 150090-65-6 150220-18-1 150246-86-9
 150247-58-8 150249-62-0 150249-65-3, DNA (human dematin cDNA plus
 flanks) 150250-03-6 150250-05-8 150278-77-6 150326-54-8
 150326-96-8 150353-59-6 150383-62-3 150419-82-2 150420-80-7, DNA
 (human clone CTG-B33 cDNA fragment) 150421-21-9 150421-31-1, DNA
 (human protein kinase C isoenzyme ζ cDNA) 150425-79-9, GenBank
 Z22968 150426-74-7, DNA (human clone pBJ1- β ARK2 β -adrenergic
 receptor kinase 2 cDNA) 150471-65-1 150471-66-2 150472-52-9
 150490-72-5 150574-81-5 150733-77-0 150735-23-2 150735-27-6
 150820-40-9 150838-25-8 150886-88-7 150911-17-4, GenBank Z25224
 150944-68-6 151119-03-8 151119-52-7 151146-70-2 151148-95-7
 151209-77-7 151242-55-6 151243-52-6 151246-55-8 151246-85-4
 151317-98-5 151318-98-8, DNA (human secretory protein P1.B cDNA plus
 flanks) 151376-78-2 151398-98-0 151399-06-3 151430-35-2
 151494-17-6 151494-22-3 151494-23-4 151494-35-8 151497-11-9
 151497-26-6 151522-34-8 151526-14-6 151548-43-5 151569-56-1
 151576-53-3 151580-05-1 151581-02-1 151608-80-9 151610-43-4
 151610-44-5 151611-25-5 151634-49-0 151634-94-5, GenBank D21243
 151635-20-0 151660-75-2 151788-70-4 151973-87-4 152002-66-9
 152023-02-4 152054-72-3 152057-23-3 152079-16-8 152112-29-3
 152281-40-8 152282-48-9 152282-49-0 152282-50-3 152282-51-4
 152282-55-8, DNA (human clone PO2ST9 cDNA) 152282-63-8 152282-66-1
 152283-37-9 152283-47-1 152283-56-2 152283-57-3 152283-58-4
 152313-99-0 152314-68-6, DNA (human gene Mpv17 plus flanks)
 152315-76-9 152345-16-9 152347-86-9 152372-05-9 152394-92-8
 152395-06-7 152410-93-0 152439-56-0 152470-02-5 152472-33-8
 152472-34-9 152585-37-0 152649-94-0 152652-54-5 152652-57-8
 152850-96-9 152851-65-5 152852-80-7 152853-54-8 152854-05-2
 153017-28-8 153055-18-6 153055-56-2 153055-57-3 153056-13-4
 153057-40-0 153057-49-9 153057-51-3 153057-95-5 153058-76-5
 153224-49-8 153317-26-1 153317-28-3 153384-52-2 153418-26-9
 153419-65-9 153420-53-2 153454-22-9 153518-48-0 153518-64-0
 153593-05-6 153608-67-4 153636-19-2 153663-93-5 153664-55-2
 153792-67-7 153792-68-8 153793-53-4, DNA (human clone ftp-3)
 153793-54-5 153961-36-5 153961-87-6 153961-89-8 153962-35-7
 153962-36-8 153962-48-2 153964-23-9 153964-34-2 154209-78-6
 154209-79-7 154245-85-9 154246-97-6 154251-45-3 154297-37-7
 154332-69-1 154432-32-3 154448-28-9 154449-46-4 154449-47-5
 154449-84-0 154451-29-3 154684-45-4 154685-98-0 154687-60-2
 154768-38-4 154898-18-7 154980-08-2 154980-76-4 154980-77-5
 154980-79-7 154980-80-0 154980-81-1 154980-82-2 154980-84-4
 155285-16-8 155458-62-1 155460-51-8 155462-24-1 155483-27-5
 155548-49-5 155571-92-9 155609-98-6 155610-59-6 155712-76-8
 155715-41-6 155748-05-3 156104-30-2 156195-91-4 156196-12-2

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,

assessment, prevention, and therapy of human prostate cancer)

IT 156225-32-0 156225-90-0 156225-91-1 156225-92-2 156252-09-4
 156252-11-8 156316-14-2 156552-53-3 156552-83-9 156552-86-2
 156552-87-3 156552-88-4 156552-89-5 156552-90-8 156552-92-0
 156552-95-3 156584-36-0 156613-26-2 156650-88-3 156651-39-7
 156675-00-2 156677-28-0 156678-89-6 156678-95-4 156709-73-8
 156711-18-1, GenBank D32051 156712-28-6 156827-77-9 156851-58-0
 156887-92-2 156890-57-2 156931-99-6 157084-40-7 157112-37-3
 157114-36-8 157114-38-0 157151-65-0 157153-51-0 157317-36-7
 157317-37-8 157344-67-7 157344-70-2 157417-98-6, GenBank L35249
 157417-99-7 157655-15-7 157779-21-0 158004-65-0, DNA (human
 oviductin cDNA plus flanks) 158024-12-5 158056-56-5 158058-56-1
 158105-90-9, DNA (human clone 58 protein cDNA) 158106-03-7 158106-05-9
 158106-95-7 158126-22-8 158126-99-9, GenBank D38037 158127-68-5
 158160-16-8 158245-35-3 158278-78-5 158336-52-8 158339-25-4
 158339-26-5 158339-27-6 158339-28-7 158339-29-8 158339-48-1
 158339-59-4 158409-75-7 158410-41-4 158411-27-9 158411-33-7
 158448-23-8 158448-63-6 158450-64-7 158479-67-5 158643-36-8
 158644-01-0 158645-17-1 158645-18-2 158709-32-1 158761-51-4
 158762-06-2 158763-36-1, GenBank L29296 158763-37-2 158764-13-7
 158764-15-9 158764-16-0 158765-57-2 158765-61-8 158765-62-9
 158765-63-0 158765-64-1 158827-27-1 158910-01-1 158928-91-7
 158929-86-3 158929-88-5 158935-14-9 159069-29-1 159127-27-2
 159200-54-1 159200-90-5 159232-15-2 159409-46-8 159447-26-4
 159629-90-0 159744-11-3 159913-43-6 159960-85-7 160020-16-6
 160021-95-4 160043-37-8 160043-79-8 160044-67-7 160074-18-0
 160074-54-4 160075-33-2 160075-34-3 160075-38-7 160075-39-8
 160075-41-2 160075-44-5 160075-46-7 160075-91-2 160075-92-3
 160077-28-1 160100-66-3 160119-87-9 160162-81-2 160162-85-6
 160164-65-8 160164-71-6 160165-00-4 160165-22-0 160165-41-3
 160165-86-6 160181-57-7 160182-11-6 160220-16-6 160263-66-1
 160263-67-2 160301-38-2 160364-88-5 160396-26-9 160396-28-1
 160396-76-9 160397-44-4 160610-52-6, DNA (human gene OXA1Hs cDNA plus
 flanks) 160898-31-7 160930-46-1 160933-00-6 160933-01-7
 160933-02-8 160933-03-9 160933-04-0 160934-19-0 160935-23-9
 161045-87-0, DNA (human gene XH2 plus flanks) 161046-40-8 161046-63-5,
 GenBank U09716 161046-66-8 161048-09-5 161049-54-3 161050-07-3
 161071-03-0 161101-56-0 161133-41-1, GenBank T28083 161208-24-8,
 GenBank T28638 161211-60-5, GenBank T28974 161273-39-8 161273-81-0
 161274-01-7 161339-32-8, GenBank T29959 161379-81-3, GenBank T30604
 161381-21-1, GenBank T30677 161381-47-1, GenBank T30767 161413-50-9
 161472-57-7, GenBank T31772 161505-77-7, GenBank T32212 161542-28-5,
 GenBank T32930 161652-22-8, GenBank T34459 161655-24-9, GenBank T34760
 161702-85-8, GenBank T35276 161784-48-1 161850-15-3 161899-06-5
 161933-67-1 161937-87-7 162114-49-0 162158-26-1 162158-75-0,
 GenBank D45021 162352-95-6, DNA (human hevin cDNA plus flanks)
 162383-51-9 162485-30-5 162487-93-6 162528-77-0 162619-59-2
 162622-89-1 162624-47-7 162625-89-0 162670-89-5 162672-81-3
 162674-21-7 162675-14-1 162724-84-7 162724-85-8 162726-16-1
 162726-45-6 162766-62-3 162766-63-4 162766-95-2 162769-10-0
 162771-38-2 162775-37-3 162799-03-3 162801-44-7 162801-71-0
 162805-21-2 162807-51-4 162832-36-2 162834-47-1 162837-75-4
 162838-24-6 162840-54-2 162841-34-1 162861-31-6 162861-40-7
 162865-20-5 162865-95-4 162865-98-7 162866-73-1 162905-83-1
 162906-18-5 162911-02-6 162943-19-3 162944-06-1
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 162945-53-1 162945-66-6 162947-51-5 162948-96-1 162985-37-7
 162985-95-7 162986-60-9 162989-61-9 163024-18-8 163028-70-4
 163051-06-7 163051-33-0 163053-12-1 163055-06-9 163056-23-3
 163056-30-2 163057-62-3 163091-89-2 163094-48-2 163094-52-8
 163099-50-1 163100-42-3 163101-17-5 163137-92-6 163139-26-2
 163141-12-6 163141-68-2 163141-78-4 163142-99-2 163143-90-6

163144-79-4 163145-57-1 163145-69-5 163146-05-2 163146-86-9
 163146-98-3 163147-05-5 163171-82-2 163173-21-5 163176-31-6
 163177-03-5 163178-52-7 163179-04-2 163180-02-7 163197-33-9
 163198-20-7 163198-41-2 163199-36-8 163199-68-6 163200-22-4
 163200-76-8 163201-11-4 163202-00-4 163202-45-7 163243-11-6,
 GenBank D30921 163249-82-9 163282-93-7 163323-00-0 163370-65-8
 163372-66-5 163373-44-2 163375-65-3 163375-69-7 163375-78-8
 163378-54-9 163406-38-0 163407-77-0 163408-32-0 163408-50-2
 163413-79-4 163414-43-5 163414-44-6 163416-98-6 163417-22-9
 163417-29-6 163418-20-0 163418-31-3 163467-59-2 163476-26-4
 163501-06-2 163544-38-5 163566-41-4 163567-52-0 163569-46-8
 163573-79-3 163576-07-6 163576-20-3 163577-27-3 163578-67-4
 163578-83-4 163578-88-9 163602-53-7 163603-32-5 163605-49-0
 163607-66-7 163608-83-1 163609-22-1 163609-94-7 163610-52-4
 163635-42-5 163636-88-2 163637-14-7 163638-54-8 163639-34-7
 163639-78-9 163643-62-7 163644-03-9 163644-25-5 163644-26-6
 163645-08-7 163645-91-8 163646-66-0 163647-04-9 163689-61-0
 163692-88-4 163693-74-1 163740-82-7 163744-45-4 163744-61-4
 163746-16-5 163746-95-0 163747-40-8 163783-64-0 163783-72-0
 163787-76-6 163787-92-6 163791-56-8 163792-23-2 163792-66-3
 163793-79-1 163794-41-0 163816-47-5 163820-89-1 163821-20-3
 163821-21-4 163822-65-9 163823-45-8 163824-92-8 163825-76-1
 163829-70-7 163863-62-5 163865-89-2 163905-29-1 163906-11-4
 163906-20-5 163907-18-4 163907-27-5 163907-61-7 163907-80-0
 163908-41-6 163908-73-4 163910-79-0 163911-06-6 163938-27-0
 163941-51-3 163942-01-6 163942-12-9 163942-38-9 163942-90-3
 163943-59-7 163944-10-3 163944-47-6 163945-37-7 163946-03-0
 163949-49-3 163952-85-0 163987-79-9 163990-23-6 163990-56-5
 163991-55-7 163992-38-9 163995-06-0 163996-85-8 163997-14-6
 163997-24-8 163998-59-2 164000-33-3 164000-43-5 164056-24-0
 164085-32-9 164085-78-3 164088-67-9 164089-41-2 164091-14-9
 164097-12-5 164098-60-6 164126-92-5 164127-06-4 164128-04-5
 164128-08-9 164129-41-3 164130-37-4 164132-33-6 164133-59-9
 164133-71-5 164133-72-6 164135-99-3 164136-00-9 164137-95-5
 164141-81-5 164142-02-3 164143-69-5 164187-29-5 164191-18-8
 164191-54-2 164191-85-9 164194-60-9 164196-79-6 164197-20-0
 164198-21-4 164198-89-4 164246-19-9 164247-33-0 164271-53-8
 164271-56-1 164273-29-4 164273-97-6 164275-00-7 164275-21-2
 164275-33-6 164278-91-5 164282-69-3 164283-33-4 164285-06-7
 164286-51-5 164286-83-3 164303-74-6 164306-42-7 164307-18-0
 164307-21-5 164307-24-8 164309-24-4 164312-86-1 164314-94-7
 164315-46-2 164318-30-3 164318-61-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 164318-65-4 164319-83-9 164319-97-5 164321-50-0 164321-67-9
 164367-45-7 164368-23-4 164369-38-4 164381-66-2 164419-30-1
 164419-87-8 164422-42-8 164425-66-5 164426-15-7 164428-91-5
 164429-46-3 164430-05-1 164430-41-5 164431-86-1 164432-39-7
 164438-28-2 164440-56-6 164447-98-7 164448-10-6 164452-02-2
 164452-27-1 164474-65-1 164475-98-3 164477-10-5 164478-49-3,
 GenBank L40326 164484-52-0 164486-69-5 164489-60-5 164490-24-8
 164493-25-8 164494-48-8 164496-05-3 164500-08-7 164569-50-0
 164570-42-7 164572-25-2 164572-58-1 164574-07-6 164574-87-2
 164600-32-2 164601-23-4 164602-32-8 164605-45-2 164612-61-7
 164618-04-6 164622-91-7 164623-16-9 164626-18-0, GenBank F01327
 164636-31-1, GenBank F01265 164637-60-9 164676-62-4 164679-51-0
 164681-26-9 164703-15-5 164704-20-5 164706-16-5 164710-19-4
 164741-30-4 164742-81-8 164744-59-6 164744-68-7 164745-00-0
 164745-21-5 164746-98-9 164754-68-1 164756-96-1 164760-60-5
 164762-17-8 164764-10-7 164766-58-9 164767-86-6 164770-40-5
 164770-97-2 164775-62-6 164775-81-9 164779-20-8 164779-44-6
 164806-46-6 164811-12-5 164817-37-2 164817-55-4 164820-87-5
 164820-96-6 164821-70-9 164822-84-8 164823-41-0 164823-60-3

| | | | | |
|-------------|-------------|--------------|-----------------------------------|-------------|
| 164843-57-6 | 164867-84-9 | 164868-98-8 | 164869-83-4 | 164878-35-7 |
| 164880-34-6 | 164882-82-0 | 164886-59-3 | 164897-04-5 | 164902-14-1 |
| 164902-44-7 | 164903-22-4 | 164904-38-5 | 164909-30-2 | 164938-65-2 |
| 164938-76-5 | 164939-82-6 | 164941-22-4 | 164941-29-1 | 164942-97-6 |
| 164944-17-6 | 164944-24-5 | 164945-28-2 | 164945-76-0 | 164946-14-9 |
| 164947-27-7 | 164950-67-8 | 164951-76-2, | DNA (human clone 5G3 3'-end cDNA) | |
| 164952-47-0 | 164952-59-4 | 164952-71-0, | DNA (human clone HPEPT1 cDNA) | |
| 164954-10-3 | 164964-70-9 | 164964-82-3 | 164964-83-4 | 164966-49-8 |
| 164967-70-8 | 164970-44-9 | 164971-15-7 | 164971-21-5 | 164971-39-5 |
| 164992-92-1 | 164993-00-4 | 164993-03-7 | 164995-28-2 | 164995-98-6 |
| 164997-96-0 | 164998-25-8 | 164998-89-4 | 164999-13-7 | 165002-44-8 |
| 165002-48-2 | 165008-74-2 | 165009-97-2 | 165012-01-1 | 165012-89-5 |
| 165013-17-2 | 165014-47-1 | 165016-69-3 | 165022-15-1 | 165022-54-8 |
| 165022-65-1 | 165022-72-0 | 165023-48-3 | 165023-90-5 | 165024-17-9 |
| 165024-72-6 | 165024-82-8 | 165024-92-0 | 165026-68-6 | 165026-72-2 |
| 165026-86-8 | 165028-48-8 | 165028-60-4 | 165029-13-0 | 165029-18-5 |
| 165029-28-7 | 165077-62-3 | 165078-75-1 | 165080-08-0 | 165080-63-7 |
| 165081-43-6 | 165084-24-2 | 165085-59-6 | 165085-63-2 | 165085-77-8 |
| 165087-87-6 | 165089-43-0 | 165092-14-8 | 165093-22-1 | 165094-29-1 |
| 165096-82-2 | 165097-25-6 | 165097-41-6 | 165098-79-3 | 165136-98-1 |
| 165139-40-2 | 165142-10-9 | 165142-35-8 | 165142-82-5 | 165146-33-8 |
| 165146-34-9 | 165148-40-3 | 165150-37-8 | 165150-48-1 | 165156-67-2 |
| 165157-75-5 | 165157-84-6 | 165158-26-9 | 165158-83-8 | 165159-69-3 |
| 165162-37-8 | 165163-30-4 | 165164-53-4 | 165165-22-0 | 165165-34-4 |
| 165165-44-6 | 165165-45-7 | 165165-46-8 | 165165-57-1 | 165165-75-3 |
| 165169-33-5 | 165199-69-9 | 165211-59-6 | 165211-80-3 | 165212-44-2 |
| 165212-92-0 | 165213-12-7 | 165213-62-7 | 165214-64-2 | 165217-35-6 |
| 165219-53-4 | 165222-98-0 | 165224-84-0 | 165224-89-5 | 165225-13-8 |
| 165228-52-4 | 165229-70-9 | 165229-78-7 | 165230-33-1 | 165231-01-6 |
| 165236-43-1 | 165236-94-2 | 165237-49-0 | 165240-46-0 | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

| | | | | |
|----|-------------|--------------|-------------------------------|----------------------------------|
| IT | 165240-77-7 | 165244-09-7 | 165244-63-3, | DNA (human clone SAH 406-3 cDNA) |
| | 165297-93-8 | 165298-19-1 | 165298-80-6 | 165299-93-4 |
| | 165302-23-8 | 165302-39-6 | 165302-65-1 | 165300-30-1 |
| | 165342-35-8 | 165345-64-2 | 165346-38-3 | 165339-85-5 |
| | 165349-72-4 | 165352-29-4 | 165355-46-4 | 165342-23-4 |
| | 165361-75-1 | 165363-62-2 | 165363-81-5 | 165347-39-7 |
| | | | | 165347-83-1 |
| | | | | 165360-32-7 |
| | | | | 165360-65-6 |
| | | | | 165364-38-5 |
| | | | | 165365-11-7, |
| | | | | DNA |
| | | | | (human cell line Jurkat cDNA) |
| | | | | 165415-39-4 |
| | | | | 165418-38-2 |
| | | | | 165421-26-1 |
| | 165422-13-9 | 165428-30-8 | 165430-37-5 | 165433-75-0 |
| | 165437-26-3 | 165437-74-1 | 165437-76-3 | 165435-26-7 |
| | 165442-02-4 | 165443-39-0 | 165469-66-9 | 165440-32-4 |
| | 165470-72-4 | 165471-09-0 | 165473-40-5 | 165441-85-0 |
| | 165477-11-2 | 165480-52-4 | 165481-92-5 | 165470-14-4 |
| | 165485-38-1 | 165485-75-6 | 165486-73-7 | 165470-25-7 |
| | 165491-18-9 | 165495-89-6 | 165496-24-2 | 165473-54-1 |
| | 165497-45-0 | 165499-56-9, | DNA (human clone hJNKK1 cDNA) | 165476-01-7 |
| | 165503-58-2 | 165504-27-8 | 165505-77-1 | 165484-75-3 |
| | 165508-03-2 | 165509-55-7 | 165511-46-6 | 165488-34-6 |
| | 165515-77-5 | 165515-87-7 | 165516-66-5 | 165496-58-2 |
| | 165518-20-7 | 165519-47-1 | 165520-21-8 | 165496-81-1 |
| | 165520-86-5 | 165561-90-0 | 165562-19-6 | 165499-56-9, |
| | 165562-95-8 | 165562-96-9 | 165563-40-6 | DNA (human clone hJNKK1 cDNA) |
| | 165563-97-3 | 165564-51-2 | 165565-43-5 | 165503-38-8 |
| | 165567-98-6 | 165570-68-3 | 165571-17-5 | 165507-08-4 |
| | 165572-83-8 | 165573-78-4 | 165573-99-9 | 165507-50-6 |
| | 165575-44-0 | 165576-10-3 | 165576-23-8 | 165511-88-6 |
| | 165578-07-4 | 165578-54-1 | 165580-45-0 | 165511-88-6 |
| | 165623-48-3 | 165625-90-1 | 165626-24-4 | 165517-72-6 |
| | 165630-60-4 | 165630-64-8 | 165632-21-3 | 165517-76-0 |
| | 165633-28-3 | 165634-20-8 | 165636-09-9 | 165520-48-9 |
| | 165638-11-9 | 165638-47-1 | 165638-61-9 | 165520-53-6 |
| | 165640-14-2 | 165640-41-5 | 165640-58-4 | 165520-87-8 |
| | | | | 165562-22-1 |
| | | | | 165562-87-8 |
| | | | | 165562-94-0 |
| | | | | 165563-66-6 |
| | | | | 165563-94-9 |
| | | | | 165567-33-9 |
| | | | | 165572-44-1 |
| | | | | 165572-73-6 |
| | | | | 165574-19-6 |
| | | | | 165574-55-0 |
| | | | | 165576-35-2 |
| | | | | 165577-55-9 |
| | | | | 165581-48-6 |
| | | | | 165583-52-8 |
| | | | | 165626-67-5 |
| | | | | 165629-79-8 |
| | | | | 165632-37-1 |
| | | | | 165632-59-7 |
| | | | | 165637-68-3 |
| | | | | 165637-98-9 |
| | | | | 165638-78-8 |
| | | | | 165639-63-4 |
| | | | | 165641-01-0 |
| | | | | 165641-09-8 |

| | | | | |
|-------------|-------------|-------------|-------------|-------------|
| 165642-24-0 | 165642-72-8 | 165642-95-5 | 165643-31-2 | 165644-67-7 |
| 165644-83-7 | 165645-49-8 | 165645-86-3 | 165645-97-6 | 165646-06-0 |
| 165647-10-9 | 165647-30-3 | 165647-63-2 | 165647-82-5 | 165647-97-2 |
| 165649-63-8 | 165649-81-0 | 165649-94-5 | 165651-82-1 | 165652-41-5 |
| 165652-48-2 | 165653-38-3 | 165653-43-0 | 165654-32-0 | 165654-62-6 |
| 165655-64-1 | 165655-92-5 | 165656-58-6 | 165656-86-0 | 165690-24-4 |
| 165691-15-6 | 165691-52-1 | 165691-65-6 | 165691-98-5 | 165692-06-8 |
| 165692-95-5 | 165693-42-5 | 165694-02-0 | 165694-15-5 | 165694-31-5 |
| 165694-37-1 | 165694-75-7 | 165694-94-0 | 165695-15-8 | 165695-18-1 |
| 165696-14-0 | 165696-97-9 | 165697-92-7 | 165697-96-1 | 165698-22-6 |
| 165698-35-1 | 165698-70-4 | 165699-27-4 | 165699-70-7 | 165701-18-8 |
| 165701-48-4 | 165701-95-1 | 165702-86-3 | 165703-26-4 | 165703-64-0 |
| 165708-83-8 | 165708-95-2 | 165709-31-9 | 165709-34-2 | 165712-26-5 |
| 165716-31-4 | 165717-25-9 | 165717-47-5 | 165717-68-0 | 165719-62-0 |
| 165719-63-1 | 165755-95-3 | 165756-60-5 | 165756-86-5 | 165757-13-1 |
| 165757-30-2 | 165764-20-5 | 165764-43-2 | 165767-49-7 | 165768-10-5 |
| 165768-81-0 | 165771-51-7 | 165776-64-7 | 165777-21-9 | 165778-31-4 |
| 165778-33-6 | 165781-43-1 | 165781-46-4 | | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

| | | | | | |
|----|--------------|------------------------------------|-------------|-------------|-------------|
| IT | 165781-69-1 | 165782-62-7 | 165782-99-0 | 165783-51-7 | 165784-02-1 |
| | 165784-38-3 | 165784-41-8 | 165788-11-4 | 165789-84-4 | 165791-74-2 |
| | 165794-02-5 | 165794-59-2 | 165794-82-1 | 165797-71-7 | 165797-87-5 |
| | 165798-07-2 | 165799-43-9 | 165799-68-8 | 165799-80-4 | 165826-96-0 |
| | 165827-30-5 | 165828-20-6 | 165828-49-9 | 165828-54-6 | 165829-31-2 |
| | 165830-51-3 | 165831-79-8 | 165831-86-7 | 165832-26-8 | 165833-29-4 |
| | 165833-96-5 | 165833-99-8 | 165834-02-6 | 165834-03-7 | 165837-01-4 |
| | 165838-40-4 | 165838-44-8 | 165838-57-3 | 165839-38-3 | 165839-54-3 |
| | 165840-43-7 | 165840-77-7 | 165841-00-9 | 165841-03-2 | 165841-08-7 |
| | 165841-10-1 | 165842-15-9 | 165843-86-7 | 165845-60-3 | 165846-01-5 |
| | 165846-26-4 | 165846-57-1 | 165846-63-9 | 165847-04-1 | 165847-31-4 |
| | 165848-23-7 | 165849-23-0 | 165850-37-3 | 165850-38-4 | 165852-58-4 |
| | 165852-66-4 | 165852-94-8 | 165853-34-9 | 165854-46-6 | 165854-50-2 |
| | 165855-15-2 | 165855-25-4 | 165856-49-5 | 165857-58-9 | 165859-13-2 |
| | 165859-33-6 | 165859-37-0 | 165859-90-5 | 165860-80-0 | 165860-84-4 |
| | 165860-89-9 | 165866-44-4 | 165867-21-0 | 165869-39-6 | 165869-47-6 |
| | 165870-44-0 | 165870-63-3 | 165907-49-3 | 165908-63-4 | 165909-68-2 |
| | 165910-38-3 | 165910-47-4 | 165911-19-3 | 165911-45-5 | 165911-51-3 |
| | 165911-68-2 | 165913-97-3 | 165916-95-0 | 165917-08-8 | 165917-17-9 |
| | 165918-40-1 | 165918-83-2 | 165918-97-8 | 165919-13-1 | 165919-20-0 |
| | 165919-28-8 | 165919-41-5 | 165919-49-3 | 165939-95-7 | 165940-62-5 |
| | 165941-66-2 | 165941-69-5 | 165941-89-9 | 165942-01-8 | 165942-51-8 |
| | 165968-91-2 | 165969-63-1 | 165971-01-7 | 165971-43-7 | 165971-46-0 |
| | 165971-82-4 | 165973-16-0 | 165974-24-3 | 165974-33-4 | 165974-56-1 |
| | 165975-37-1 | 165975-61-1 | 165975-66-6 | 165975-67-7 | 165978-24-5 |
| | 165979-15-7 | 165979-87-3 | 165982-92-3 | 165983-00-6 | 165983-04-0 |
| | 165983-09-5 | 165983-18-6 | 165984-34-9 | 165985-33-1 | 165985-36-4 |
| | 165985-68-2 | 165985-82-0 | 165986-60-7 | 165987-13-3 | 165987-76-8 |
| | 165987-83-7 | 165989-59-3 | 165989-61-7 | 165989-82-2 | 165990-23-8 |
| | 165991-43-5 | 165991-88-8 | 165993-21-5 | 165993-67-9 | 165993-81-7 |
| | 165994-10-5 | 165994-81-0 | 165994-86-5 | 165995-15-3 | 166000-07-3 |
| | 166000-14-2 | 166002-18-2 | 166004-60-0 | 166005-53-4 | 166005-73-8 |
| | 166007-74-5 | 166007-91-6 | 166008-14-6 | 166008-37-3 | 166009-90-1 |
| | 166009-92-3 | 166013-64-5 | 166015-88-9 | 166019-19-8 | 166050-72-2 |
| | 166052-61-5 | 166055-01-2 | 166055-51-2 | 166068-24-2 | 166068-67-3 |
| | 166069-43-8 | 166069-62-1 | 166070-23-1 | 166072-99-7 | 166077-83-4 |
| | 166079-41-0 | 166080-07-5 | 166080-78-0 | 166081-19-2 | 166083-26-7 |
| | 166120-24-7, | DNA (human gene TAF2H plus flanks) | | | 166125-12-8 |
| | 166126-49-4 | 166128-21-8 | 166131-49-3 | 166138-24-5 | 166139-64-6 |
| | 166140-58-5 | 166141-38-4 | 166141-74-8 | 166141-80-6 | 166141-83-9 |
| | 166143-56-2 | 166144-33-8 | 166145-10-4 | 166148-10-3 | 166148-38-5 |
| | 166148-79-4 | 166148-89-6 | 166149-15-1 | 166149-24-2 | 166149-25-3 |
| | 166152-35-8 | 166153-64-6 | 166155-75-5 | 166156-33-8 | 166156-71-4 |

| | | | | |
|-------------|-------------|-------------|-------------|-------------|
| 166158-59-4 | 166160-94-7 | 166198-88-5 | 166204-14-4 | 166206-02-6 |
| 166206-33-3 | 166207-17-6 | 166208-17-9 | 166209-37-6 | 166209-67-2 |
| 166211-76-3 | 166212-87-9 | 166217-24-9 | 166217-44-3 | 166217-94-3 |
| 166220-29-7 | 166223-97-8 | 166224-59-5 | 166224-73-3 | 166225-58-7 |
| 166227-18-5 | 166228-38-2 | 166285-66-1 | 166290-29-5 | 166290-32-0 |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 166290-94-4 | 166291-00-5 | 166291-28-7 | 166293-37-4 | 166295-79-0 |
| | 166299-82-7 | 166299-83-8 | 166341-39-5 | 166343-45-9 | 166344-81-6 |
| | 166345-46-6 | 166345-75-1 | 166350-13-6 | 166357-25-1 | 166357-42-2 |
| | 166360-57-2 | 166360-82-3 | 166361-05-3 | 166362-23-8 | 166415-21-0 |
| | 166415-39-0 | 166415-83-4 | 166416-91-7 | 166420-94-6 | 166421-56-3 |
| | 166423-57-0 | 166453-71-0 | 166457-16-5 | 166459-26-3 | 166493-71-6 |
| | 166493-89-6 | 166494-85-5 | 166495-27-8 | 166497-14-9 | 166498-03-9 |
| | 166500-67-0 | 166506-97-4 | 166507-07-9 | 166507-72-8 | 166510-83-4 |
| | 166511-58-6 | 166512-85-2 | 166513-72-0 | 166548-62-5 | 166548-85-2 |
| | 166552-19-8 | 166552-72-3 | 166553-25-9 | 166553-85-1 | 166555-04-0 |
| | 166555-76-6 | 166555-77-7 | 166556-40-7 | 166556-53-2 | 166556-54-3 |
| | 166558-96-9 | 166560-71-0 | 166561-83-7 | 166564-92-7 | 166567-82-4 |
| | 166569-96-6 | 166571-59-1 | 166572-03-8 | 166573-72-4 | 166577-01-1 |
| | 166580-87-6 | 166581-10-8 | 166604-48-4 | 166606-78-6 | 166607-54-1 |
| | 166608-78-2 | 166609-60-5 | 166609-61-6 | 166610-59-9 | 166611-90-1 |
| | 166612-45-9 | 166612-93-7 | 166613-13-4 | 166613-58-7 | 166613-65-6 |
| | 166613-82-7 | 166613-91-8 | 166614-32-0 | 166615-54-9 | 166616-79-1 |
| | 166617-02-3 | 166617-43-2 | 166617-62-5 | 166618-61-7 | 166618-99-1 |
| | 166619-66-5 | 166619-69-8 | 166621-19-8 | 166622-15-7 | 166625-11-2 |
| | 166631-64-7 | 166631-78-3 | 166632-60-6 | 166632-87-7 | 166633-37-0 |
| | 166633-64-3 | 166634-38-4 | 166634-54-4 | 166634-71-5 | 166636-41-5 |
| | 166636-61-9 | 166636-68-6 | 166637-55-4 | 166637-86-1 | 166637-92-9 |
| | 166638-04-6 | 166638-26-2 | 166638-39-7 | 166638-42-2 | 166638-65-9 |
| | 166639-69-6 | 166640-29-5 | 166640-40-0 | 166640-64-8 | 166640-94-4 |
| | 166641-06-1 | 166641-43-6 | 166641-68-5 | 166641-73-2 | 166642-03-1 |
| | 166643-09-0 | 166643-20-5 | 166643-76-1 | 166644-08-2 | 166644-16-2 |
| | 166644-66-2 | 166644-72-0 | 166645-61-0 | 166645-76-7 | 166647-73-0 |
| | 166647-85-4 | 166648-60-8 | 166648-86-8 | 166649-91-8 | 166649-93-0 |
| | 166650-18-6 | 166650-37-9 | 166650-62-0 | 166651-26-9 | 166651-80-5 |
| | 166651-84-9 | 166652-03-5 | 166652-10-4 | 166652-40-0 | 166652-41-1 |
| | 166652-55-7 | 166652-72-8 | 166652-80-8 | 166653-12-9 | 166653-16-3 |
| | 166653-17-4 | 166653-51-6 | 166674-17-5 | 166674-33-5 | 166674-53-9 |
| | 166674-56-2 | 166675-67-8 | 166675-69-0 | 166676-29-5 | 166676-38-6 |
| | 166676-54-6 | 166677-07-2 | 166677-80-1 | 166677-86-7 | 166678-89-3 |
| | 166679-66-9 | 166679-83-0 | 166680-00-8 | 166680-10-0 | 166681-15-8 |
| | 166681-54-5 | 166682-03-7 | 166682-58-2 | 166682-73-1 | 166682-85-5 |
| | 166682-93-5 | 166684-99-7 | 166685-98-9 | 166686-55-1 | 166687-41-8 |
| | 166688-53-5 | 166688-64-8 | 166689-00-5 | 166689-52-7 | 166689-54-9 |
| | 166689-82-3 | 166690-14-8 | 166692-78-0 | 166693-03-4 | 166693-12-5 |
| | 166693-31-8 | 166694-12-8 | 166694-51-5 | 166694-76-4 | 166695-60-9 |
| | 166697-41-2 | 166697-49-0 | 166701-45-7 | 166702-03-0 | 166702-30-3 |
| | 166705-61-9 | 166706-28-1 | 166706-60-1 | 166709-10-0 | 166709-60-0 |
| | 166711-13-3 | 166713-11-7 | 166716-70-7 | 166721-85-3 | 166722-21-0 |
| | 166722-85-6 | 166722-95-8 | 166723-21-3 | 166723-45-1 | 166724-31-8 |
| | 166724-72-7 | 166725-93-5 | 166726-35-8 | 166726-39-2 | 166727-19-1 |
| | 166727-35-1 | 166728-76-3 | 166728-77-4 | 166728-82-1 | 166728-97-8 |
| | 166728-99-0 | 166729-17-5 | 166729-18-6 | 166730-04-7 | 166731-32-4 |
| | 166731-48-2 | 166775-50-4 | | | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

| | | | | | |
|----|-------------|-------------|-------------|-----------------------------|-------------|
| IT | 166776-22-3 | 166778-17-2 | 166778-32-1 | 166778-33-2 | 166836-92-6 |
| | 166839-38-9 | 166841-24-3 | 166841-26-5 | 166845-04-1, GenBank M95627 | |
| | 166845-77-8 | 166846-14-6 | 166846-15-7 | 166857-78-9 | 166857-95-0 |

| | | | | |
|-------------|-------------|-------------|-------------|-------------|
| 166858-56-6 | 166859-99-0 | 166860-28-2 | 166860-59-9 | 166860-89-5 |
| 166861-07-0 | 166861-21-8 | 166861-59-2 | 166862-58-4 | 166862-78-8 |
| 166862-94-8 | 166863-77-0 | 166863-95-2 | 166864-26-2 | 166864-51-3 |
| 166866-19-9 | 166867-72-7 | 166868-74-2 | 166868-82-2 | 166868-86-6 |
| 166869-52-9 | 166869-97-2 | 166870-19-5 | 166870-29-7 | 166870-56-0 |
| 166870-60-6 | 166908-55-0 | 166908-57-2 | 166908-68-5 | 166908-74-3 |
| 166909-05-3 | 166909-07-5 | 166909-20-2 | 166909-29-1 | 166910-01-6 |
| 166910-03-8 | 166910-54-9 | 166914-09-6 | 166914-10-9 | 166914-19-8 |
| 166914-57-4 | 166915-46-4 | 166916-12-7 | 166916-16-1 | 166916-19-4 |
| 166917-12-0 | 166917-18-6 | 166918-24-7 | 166919-10-4 | 166919-18-2 |
| 166919-22-8 | 166920-54-3 | 166921-14-8 | 166921-39-7 | 166922-03-8 |
| 166922-20-9 | 166922-28-7 | 166923-06-4 | 166923-10-0 | 166923-13-3 |
| 166928-44-5 | 166928-50-3 | 166933-27-3 | 166933-28-4 | 166933-29-5 |
| 167001-80-1 | 167004-29-7 | 167034-57-3 | 167035-11-2 | 167039-18-1 |
| 167042-89-9 | 167044-73-7 | 167047-68-9 | 167047-87-2 | 167050-11-5 |
| 167061-81-6 | 167068-57-7 | 167072-82-4 | 167118-50-5 | 167122-68-1 |
| 167127-04-0 | 167131-32-0 | 167132-93-6 | 167133-93-9 | 167135-54-8 |
| 167136-11-0 | 167177-51-7 | 167185-37-7 | 167186-51-8 | 167186-64-3 |
| 167188-27-4 | 167188-90-1 | 167189-00-6 | 167189-38-0 | 167192-90-7 |
| 167196-25-0 | 167196-45-4 | 167197-13-9 | 167197-95-7 | 167200-75-1 |
| 167205-99-4 | 167206-37-3 | 167229-65-4 | 167234-44-8 | 167237-53-8 |
| 167238-87-1 | 167252-27-9 | 167334-32-9 | 167334-58-9 | 167334-92-1 |
| 167335-11-7 | 167338-91-2 | 167341-11-9 | 167341-51-7 | 167344-53-8 |
| 167346-12-5 | 167347-82-2 | 167348-08-5 | 167348-09-6 | 167348-12-1 |
| 167349-12-4 | 167349-53-3 | 167435-38-3 | 167437-31-2 | 167441-58-9 |
| 167441-63-6 | 167443-21-2 | 167443-29-0 | 167443-88-1 | 167443-89-2 |
| 167444-39-5 | 167445-23-0 | 167445-27-4 | 167445-64-9 | 167446-51-7 |
| 167447-13-4 | 167447-55-4 | 167447-82-7 | 167447-97-4 | 167448-06-8 |
| 167448-27-3 | 167449-10-7 | 167449-75-4 | 167450-21-7 | 167450-45-5 |
| 167450-88-6 | 167451-18-5 | 167451-42-5 | 167451-49-2 | 167454-64-0 |
| 167455-76-7 | 167455-78-9 | 167456-40-8 | 167456-45-3 | 167458-04-0 |
| 167459-26-9 | 167459-32-7 | 167459-50-9 | 167459-53-2 | 167459-54-3 |
| 167459-66-7 | 167461-43-0 | 167464-42-8 | 167505-11-5 | 167505-26-2 |
| 167507-37-1 | 167511-29-7 | 167512-72-3 | 167513-65-7 | 167513-84-0 |
| 167514-82-1 | 167515-91-5 | 167519-02-0 | 167520-09-4 | 167520-73-2 |
| 167522-56-7 | 167529-61-5 | 167531-55-7 | 167571-71-3 | 167572-76-1 |
| 167577-66-4 | 167578-94-1 | 167581-57-9 | 167583-33-7 | 167583-82-6 |
| 167583-91-7 | 167583-99-5 | 167584-00-1 | 167584-11-4 | 167584-40-9 |
| 167584-52-3 | 167584-72-7 | 167584-97-6 | 167586-81-4 | 167586-92-7 |
| 167586-93-8 | 167588-10-5 | 167588-39-8 | 167590-93-4 | 167591-16-4 |
| 167592-69-0 | 167597-64-0 | 167661-22-5 | 167664-98-4 | 167665-11-4 |
| 167667-12-1 | 167668-51-1 | 167669-10-5 | 167669-37-6 | 167671-18-3 |
| 167671-50-3 | 167672-01-7 | 167711-87-7 | 167712-38-1 | 167712-48-3 |
| 167712-52-9 | 167712-94-9 | 167714-04-7 | 167714-17-2 | 167714-28-5 |
| 167718-07-2 | 167737-30-6 | 167738-25-2 | | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

| | | | | | |
|----|----------------|----------------|----------------|----------------|----------------|
| IT | 167739-67-5 | 167747-13-9 | 167749-47-5 | 167791-71-1 | 167791-94-8 |
| | 167793-94-4 | 167796-21-6 | 167804-81-1 | 167806-00-0 | 167809-69-0 |
| | 167809-90-7 | 167812-38-6 | 167816-32-2 | 167876-18-8 | 167876-27-9 |
| | 167876-38-2 | 167876-41-7 | 167877-49-8 | 167878-05-9 | 167880-10-6 |
| | 167880-40-2 | 167880-81-1 | 167880-86-6 | 167881-26-7 | 167882-13-5 |
| | 167908-10-3 | 167908-99-8 | 167909-64-0 | 167910-45-4 | 167910-48-7 |
| | 167922-53-4 | 167924-96-1 | 167924-98-3 | 167926-86-5 | 167927-79-9 |
| | 167927-93-7 | 167928-79-2 | 167932-64-1 | 168146-81-4 | 168218-78-8 |
| | 168218-82-4 | 168218-97-1 | 168219-12-3 | 168219-23-6 | 168220-17-5 |
| | 168220-58-4 | 168221-61-2 | 168221-81-6 | 168222-11-5 | 168222-68-2 |
| | 168223-08-3 | 168224-39-3 | 168224-45-1 | 168225-14-7 | 168226-90-2 |
| | 168227-94-9 | 168312-33-2 | 168314-92-9 | 168349-08-4 | GenBank D52802 |
| | 168356-01-2 | GenBank D53496 | 168364-66-7 | GenBank D54335 | 168372-50-7 |
| | 168384-38-1 | 168386-81-0 | GenBank D50977 | 168437-00-1 | GenBank D55565 |
| | 168437-62-5 | 168437-65-8 | 168439-03-0 | GenBank D60110 | 168447-40-3 |
| | GenBank D60970 | 168450-88-2 | GenBank D61285 | 168458-43-3 | 168515-01-3 |

168516-55-0 168517-07-5 168517-68-8 168517-97-3 168518-81-8
 168520-46-5 168521-22-0 168522-70-1 168522-72-3 168522-87-0
 168523-02-2 168523-10-2 168528-00-5, GenBank D58694 168532-98-7
 168570-51-2 168570-86-3 168575-44-8 168577-29-5 168578-29-8
 168589-84-2, GenBank D56420 168603-21-2 168604-41-9 168657-85-0
 168662-18-8 168665-87-0 168744-50-1 168745-39-9 168745-77-5
 168745-87-7 168746-59-6 168747-28-2 168789-22-8 168789-30-8
 168789-95-5 168792-95-8 168793-16-6 168793-27-9 168793-45-1
 168795-44-6 168796-89-2 168797-10-2 168797-86-2 168799-93-7
 168807-83-8 168808-22-8 168808-39-7 168852-18-4 168854-17-9
 168856-95-9 168857-02-1 168857-93-0 168858-08-0 168859-23-2
 168859-39-0 168862-47-3 168862-56-4 168864-48-0 168868-56-2
 168869-08-7 168869-30-5 168871-66-7 168872-36-4 168874-48-4
 168874-69-9 168874-94-0 168876-61-7 168877-37-0 168877-80-3, DNA
 (human cell line HL-60 cDNA) 168881-66-1, DNA (human clone cosmid
 CRI-JC2015) 168882-72-2 168884-90-0 168925-07-3 168927-88-6
 168927-90-0 168929-73-5 168932-82-9 168933-57-1 168935-40-8
 168940-19-0 168941-08-0 168941-09-1 168941-30-8 168942-23-2
 168944-92-1 168945-75-3 168948-78-5 168950-02-5 168952-02-1
 168952-18-9 168953-19-3 168953-67-1 168954-29-8 168954-54-9
 168955-01-9 168955-72-4 168957-00-4 168987-37-9 168988-22-5
 168988-79-2 168995-17-3 168997-16-8 169003-42-3 169003-96-7
 169006-16-0 169007-40-3 169007-92-5 169008-26-8 169011-71-6
 169011-86-3 169011-99-8 169013-46-1 169016-49-3 169016-80-2
 169017-01-0 169018-26-2 169023-07-8 169023-13-6 169023-25-0
 169023-26-1 169023-36-3 169074-79-7 169075-13-2, DNA (human clone
 plck13-1 cDNA) 169078-55-1 169078-63-1 169078-68-6 169079-03-2
 169079-76-9 169084-01-9 169089-43-4 169342-27-2 169342-32-9
 169343-89-9 169343-93-5 169344-11-0 169344-64-3 169344-65-4
 169347-11-9 169348-14-5 169349-14-8 169349-77-3 169351-86-4
 169355-78-6 169358-63-8 169358-71-8 169359-00-6 169360-82-1
 169398-82-7 169402-36-2 169402-51-1 169403-53-6 169407-82-3
 169408-34-8 169412-60-6 169413-43-8 169416-25-5 169417-59-8
 169420-89-7 169421-00-5 169422-41-7 169422-80-4 169425-77-8
 169428-45-9 169429-91-8 169431-77-0 169431-96-3
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)
 IT 169481-01-0 169481-35-0 169483-82-3 169487-18-7 169487-66-5
 169489-59-2 169492-11-9 169568-24-5 169569-33-9 169570-75-6
 169572-24-1 169574-48-5 169576-31-2 169579-84-4 169579-85-5
 169582-39-2 169582-53-0 169583-33-9 169583-58-8 169586-24-7
 169630-83-5 169633-60-7 169635-34-1 169635-70-5 169639-75-2
 169643-78-1 169646-12-2 169646-25-7 169649-92-7 169652-22-6
 169653-35-4 169654-78-8 169655-84-9 169656-20-6 169656-23-9
 169711-70-0 169712-61-2 169716-24-9 169717-06-0 169717-07-1
 169725-15-9 169732-76-7 169733-40-8 169794-90-5 169923-67-5, DNA
 (human clone 115e1) 170048-96-1 170051-92-0 170076-24-1
 170076-48-9 170076-80-9 170077-86-8 170134-17-5 170174-24-0
 170174-52-4 170176-83-7 170179-23-4 170181-60-9 170182-65-7
 170184-32-4 170185-66-7 170187-20-9 170187-32-3 170192-03-7
 170195-83-2 170195-97-8 170198-12-6 170200-92-7 170201-54-4
 170202-60-5 170204-80-5 170205-02-4 170205-27-3 170252-25-2
 170252-93-4 170253-49-3 170256-23-2 170257-05-3 170257-07-5
 170259-06-0 170259-39-9 170259-97-9 170262-19-8 170314-41-7
 170315-38-5 170315-86-3 170318-73-7 170318-98-6 170319-40-1
 170322-32-4 170324-15-9 170339-82-9 170340-93-9 170342-75-3
 170343-86-9 170387-32-3 170404-42-9 170405-37-5 170406-84-5
 170409-77-5 170409-98-0 170410-06-7 170413-40-8 170413-77-1
 170413-78-2 170417-21-7 170417-60-4 170475-23-7 170475-89-5
 170476-69-4 170477-12-0 170516-84-4 170517-01-8 170517-69-8
 170518-01-1 170518-74-8 170522-08-4 170522-98-2 170524-50-2
 170525-60-7 170529-19-8 170530-64-0 170531-70-1 170537-56-1
 170537-67-4 170538-42-8 170539-44-3 170539-89-6 170540-51-9

170543-03-0 170546-14-2 170548-28-4 170549-66-3 170551-35-6,
 GenBank U38654 170591-95-4 170592-01-5 170592-05-9 170596-97-1
 170597-74-7 170598-08-0 170598-19-3 170600-38-1 170600-91-6
 170602-72-9 170602-75-2 170607-78-0 170609-08-2 170614-94-5
 170615-97-1 170616-02-1 170616-46-3 170616-56-5 170664-54-7
 170665-61-9 170666-98-5 170667-92-2 170668-03-8 170668-44-7
 170668-71-0 170676-51-4 170677-40-4 170755-99-4 170758-12-0
 170760-96-0 170763-16-3 170763-58-3 170763-63-0 170764-50-8
 170766-35-5 170768-50-0 170769-41-2 170769-73-0 170771-81-0
 170771-82-1 170772-64-2 170775-71-0 170812-11-0 170813-29-3
 170813-85-1 170813-90-8 170816-65-6, DNA (human clone B9 cDNA)
 170820-38-9 170820-98-1 170822-29-4 170826-49-0 170827-17-5
 170829-43-3 170829-44-4 170829-89-7 170830-24-7 170836-22-3
 170896-92-1 170906-80-6 171024-93-4 171025-00-6 171025-36-8
 171026-55-4 171027-24-0 171027-94-4 171119-85-0 171130-93-1
 171138-14-0 171139-06-3 171139-45-0 171139-85-8 171143-20-7
 171145-17-8 171145-18-9 171145-36-1 171148-58-6 171151-92-1
 171152-61-7 171166-37-3 171166-94-2 171167-50-3 171168-88-0
 171169-42-9 171175-13-6 171206-73-8 171207-20-8 171207-85-5
 171207-94-6 171208-40-5 171209-20-4 171209-59-9 171210-92-7
 171213-71-1 171214-38-3 171224-85-4 171225-68-6 171299-64-2
 171300-30-4 171300-79-1 171301-17-0 171301-88-5 171303-15-4
 171304-48-6 171305-05-8

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 171305-45-6 171306-51-7 171307-32-7 171394-92-6 171395-90-7
 171395-95-2 171396-69-3 171440-91-8 171440-93-0 171441-68-2
 171444-71-6 171445-07-1 171448-15-0, DNA (human clone 73f, 73d cDNA)
 171449-27-7 171449-38-0 171451-08-4 171451-47-1 171451-94-8
 171452-45-2 171453-15-9 171453-19-3 171454-08-3 171455-59-7
 171455-63-3 171528-35-1 171528-59-9 171529-23-0 171529-64-9
 171529-93-4 171530-63-5 171530-85-1 171539-44-9, GenBank U40671
 171630-35-6 171630-41-4 171630-95-8 171631-41-7 171633-83-3
 171633-90-2 171634-93-8 171635-66-8 171635-70-4 171637-94-8
 171638-20-3 171638-31-6 171640-02-1 171695-35-5 171695-94-6
 171696-06-3 171696-12-1 171696-74-5 171697-30-6 171697-40-8
 171699-53-9 171699-93-7 171700-14-4 171700-84-8 171702-87-7
 171703-74-5 171704-77-1 171704-96-4 171705-56-9 171705-78-5
 171706-14-2 171706-42-6 171706-76-6 171707-68-9 171708-74-0
 171709-63-0 171709-69-6 171712-77-9 171716-06-6 171748-04-2
 171748-27-9 171748-37-1 171749-79-4 171749-81-8 171750-21-3
 171750-92-8 171751-01-2 171785-60-7 171787-18-1 171788-10-6
 171788-13-9 171788-99-1 171789-30-3 171789-62-1 171789-66-5
 171790-63-9 171790-67-3 171793-05-8 171793-53-6 171793-62-7
 171794-17-5 171830-82-3 171831-72-4 171832-46-5 171832-79-4
 171833-19-5 171835-37-3 171840-12-3 171845-13-9, DNA (human cell
 line KG-1 cDNA) 171845-16-2 171845-21-9, DNA (human cell line KG-1
 cDNA) 171845-24-2, DNA (human cell line KG-1 cDNA) 171845-25-3
 171845-27-5 171845-29-7 171845-30-0 171845-31-1, DNA (human cell
 line KG-1 cDNA) 171845-32-2, DNA (human cell line KG-1 cDNA)
 171845-33-3 171845-34-4 171845-40-2 171870-36-3 172009-02-8
 172013-50-2 172013-52-4 172013-56-8 172013-59-1 172013-61-5
 172013-65-9 172013-66-0 172014-14-1 172014-18-5 172014-19-6
 172022-55-8 172022-66-1 172047-21-1 172047-55-1 172047-83-5
 172048-67-8 172050-18-9 172051-79-5 172055-85-5 172056-06-3
 172056-46-1 172056-92-7 172058-84-3 172059-33-5 172059-50-6
 172060-80-9 172061-51-7 172061-93-7 172063-22-8 172064-75-4
 172064-97-0 172065-76-8 172066-17-0 172068-23-4 172068-86-9
 172069-07-7 172069-48-6 172070-18-7 172070-75-6 172071-59-9
 172071-78-2 172072-77-4 172073-43-7 172106-15-9 172108-13-3
 172109-45-4 172109-82-9 172109-98-7 172110-70-2 172110-88-2
 172111-45-4 172112-25-3 172112-33-3 172114-20-4 172114-82-8
 172115-76-3 172116-17-5 172116-20-0 172116-69-7 172117-92-9

172118-53-5 172120-32-0 172120-79-5 172123-01-2 172123-27-2
 172124-31-1 172127-30-9 172127-90-1 172129-85-0 172130-21-1
 172130-95-9 172131-11-2 172134-39-3 172135-68-1 172137-43-8, 9:
 PN: WO0021995 PAGE: 25 unclaimed DNA 172142-18-6 172184-90-6
 172185-34-1, DNA (human cell line BL41/B95-8 cDNA) 172185-89-6
 172188-63-5 172190-28-2 172190-68-0 172190-91-9 172191-25-2
 172191-78-5 172192-64-2 172196-82-6 172197-23-8 172231-19-5
 172232-43-8 172232-84-7 172233-36-2 172234-94-5 172235-24-4
 172236-11-2 172236-24-7 172236-28-1 172236-84-9 172236-99-6
 172237-93-3 172237-95-5 172238-20-9 172238-74-3 172239-93-9
 172240-30-1 172240-69-6 172241-83-7 172242-49-8 172242-57-8
 172243-15-1 172243-26-4 172244-08-5 172244-17-6 172244-36-9
 172244-41-6 172248-46-3 172382-25-1 172382-36-4 172384-57-5
 172385-23-8 172385-62-5 172386-12-8

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 172387-80-3 172387-87-0 172388-04-4 172388-45-3 172388-62-4
 172390-07-7 172390-08-8 172390-31-7 172390-60-2 172391-44-5
 172392-27-7 172394-11-5 172394-62-6 172394-69-3 172395-14-1
 172395-21-0 172396-87-1 172397-45-4 172398-46-8 172431-74-2
 172433-48-6 172434-34-3 172434-35-4 172434-45-6 172435-10-8
 172435-47-1 172435-55-1 172435-74-4 172436-55-4 172437-39-7
 172438-98-1 172441-14-4 172441-38-2 172441-80-4 172442-11-4
 172443-00-4 172443-45-7 172443-56-0 172444-49-4 172445-63-5
 172550-09-3 172550-72-0 172551-58-5 172551-81-4 172552-43-1
 172552-84-0 172555-57-6 172556-25-1 172556-28-4 172556-57-9
 172556-76-2 172556-78-4 172557-53-8 172558-00-8 172561-02-3
 172562-22-0 172562-41-3 172563-12-1 172563-36-9 172565-05-8
 172565-96-7 172566-21-1 172566-40-4 172566-55-1 172567-41-8
 172568-23-9 172569-66-3 172570-60-4 172571-22-1 172571-35-6
 172574-97-9 172575-27-8 172577-00-3 172577-01-4 172637-25-1
 172706-19-3 172707-89-0 172708-89-3 172709-00-1 172713-23-4
 172714-87-3 172715-97-8 172718-53-5 172719-73-2 172761-31-8
 172763-55-2 172764-39-5 172765-40-1 172766-00-6 172767-14-5
 172769-21-0 172769-37-8 172770-56-8 172770-82-0 172771-91-4
 172772-78-0 172772-90-6 172772-91-7 172773-15-8 172808-48-9
 172808-80-9 172812-14-5 172813-04-6 172813-05-7 172816-58-9
 172818-36-9 172855-17-3 172855-58-2 172855-91-3 172856-36-9
 172860-20-7 172860-46-7 172866-18-1 172866-48-7 172961-28-3,
 GenBank U43604 173003-48-0 173017-75-9 173078-60-9 173124-62-4
 173131-22-1 173134-29-7, GenBank D81855 173225-57-5 173225-82-6
 173229-08-8 173236-03-8 173236-74-3 173237-15-5 173237-30-4
 173295-62-0 173486-77-6, DNA (human clone I-14 cDNA) 173487-92-8
 173491-62-8 173494-99-0 173495-69-7 173496-24-7 173496-55-4
 173497-03-5 173498-83-4 173503-59-8 173504-02-4 173509-94-9
 173511-78-9 173512-14-6 173512-64-6 173513-66-1 173514-27-7
 173514-31-3 173514-63-1 173514-94-8 173515-32-7 173516-27-3
 173516-33-1 173516-59-1 173517-11-8 173517-27-6 173517-35-6
 173517-79-8 173518-44-0 173518-62-2 173518-64-4 173520-23-5
 173560-80-0 173561-05-2 173561-47-2 173562-15-7 173562-38-4
 173563-02-5 173563-50-3 173563-61-6 173563-63-8 173563-70-7
 173564-03-9 173564-06-2 173564-22-2 173566-37-5 173566-39-7
 173566-49-9 173566-80-8 173567-11-8 173567-60-7 173569-51-2
 173569-61-4 173570-87-1 173570-92-8 173571-81-8 173571-94-3
 173573-03-0 173573-15-4 173574-47-5 173574-56-6 173574-58-8
 173575-08-1 173575-62-7 173575-71-8 173576-12-0 173577-31-6
 173577-65-6 173577-82-7 173578-56-8 173579-26-5 173579-37-8
 173579-63-0 173579-66-3 173579-78-7 173579-87-8 173580-04-6
 173580-14-8 173581-10-7 173582-84-8 173616-74-5 173620-07-0
 173621-58-4 173622-89-4 173623-24-0 173623-28-4 173623-40-0
 173623-82-0 173623-92-2 173624-01-6 173624-19-6 173624-34-5
 173624-35-6 173624-50-5 173624-60-7 173624-66-3 173624-71-0
 173624-90-3 173625-17-7 173625-39-3 173625-47-3 173626-13-6

173626-32-9 173626-64-7 173627-02-6 173628-12-1 173628-64-3
173629-05-5

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

IT 173629-15-7 173629-22-6 173629-41-9 173629-70-4 173629-84-0
173629-89-5 173630-88-1 173631-35-1 173631-46-4 173631-50-0
173632-38-7 173632-87-6 173633-43-7 173634-09-8 173634-87-2
173636-05-0 173637-78-0 173637-93-9 173638-24-9 173638-31-8
173638-49-8 173639-26-4 173640-35-2 173640-53-4 173641-60-6
173641-83-3 173642-78-9 173643-35-1 173643-80-6 173644-85-4
173645-17-5 173645-18-6 173645-46-0 173646-34-9 173646-36-1
173647-36-4 173648-41-4 173649-81-5 173649-83-7 173650-21-0
173650-35-6 173650-44-7 173650-83-4 173651-37-1 173696-48-5
173696-66-7 173697-44-4 173699-61-1 173700-69-1 173702-18-6
173702-80-2 173703-25-8 173704-21-7 173704-66-0 173705-12-9
173706-78-0 173707-30-7 173708-89-9 173715-06-5, GenBank U47674
173716-11-5 173742-21-7 173742-94-4 173744-22-4 173744-51-9
173751-14-9 173793-58-3 173795-18-1, 6: PN: US6066617 SEQID: 8
unclaimed DNA 173796-48-0 173796-68-4 173799-48-9 173801-40-6
173801-48-4 173802-24-9 173804-03-0 173805-27-1 173805-41-9
173807-16-4 173807-71-1 173808-00-9 173808-12-3 173808-96-3
173809-40-0 173810-81-6 173812-06-1 173814-82-9 173817-46-4
173817-85-1 173818-24-1 173818-46-7 173818-70-7 173819-42-6
173819-50-6 173819-89-1 173822-40-7 173822-90-7 173824-72-1
173824-80-1 173824-90-3 173825-30-4 173825-34-8 173825-73-5,
GenBank U39657 173826-67-0 173826-73-8 173827-31-1 173869-95-9
173891-45-7 174025-16-2 174025-60-6 174025-92-4 174025-99-1
174026-63-2 174026-79-0 174026-99-4 174027-36-2 174027-37-3
174027-45-3 174027-53-3 174027-63-5 174028-08-1 174028-12-7
174028-46-7 174028-55-8 174028-99-0 174029-25-5 174031-51-7
174031-76-6 174031-95-9 174032-13-4 174032-16-7 174032-30-5
174032-95-2 174033-13-7 174033-32-0 174033-44-4 174033-79-5
174034-22-1 174035-43-9 174036-03-4 174036-22-7 174037-36-6
174038-51-8 174038-63-2 174038-81-4 174039-92-0 174040-16-5
174040-58-5 174040-95-0 174041-76-0 174041-93-1 174042-17-2
174042-33-2 174042-56-9 174042-97-8 174044-37-2 174044-40-7
174048-28-3 174048-40-9 174049-57-1 174050-25-0 174050-46-5
174050-52-3 174050-66-9 174051-55-9 174052-11-0 174052-23-4
174052-45-0 174052-63-2 174052-89-2 174053-40-8 174054-36-5
174055-12-0 174055-18-6 174055-36-8 174058-78-7 174100-68-6
174105-81-8, DNA (human STS (sequence tag site)) 174171-46-1
174232-93-0 174234-28-7 174234-75-4 174234-78-7 174234-82-3
174235-01-9 174235-21-3 174235-46-2 174236-21-6 174236-89-6
174236-91-0 174237-35-5 174237-96-8 174239-14-6 174239-22-6
174240-65-4 174240-75-6 174240-78-9 174242-41-2 174242-66-1
174242-98-9 174243-80-2 174244-50-9 174245-09-1 174246-15-2
174249-11-7 174249-12-8 174249-60-6 174251-03-7 174251-07-1
174251-73-1 174252-02-9 174252-31-4 174253-44-2 174286-64-7, DNA
(human cell line G2 cDNA) 174286-67-0, GenBank M98026 174286-68-1, DNA
(human cell line HeLa cDNA) 174286-82-9 174294-99-6 174297-66-6
174373-16-1 174373-82-1 174374-92-6 174376-02-4 174376-34-2
174378-43-9 174379-13-6 174379-83-0 174381-94-3 174383-95-0
174384-09-9 174384-10-2 174384-39-5 174385-64-9 174385-86-5
174396-39-5 174425-01-5 174426-14-3 174426-63-2 174432-44-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

IT 174433-12-6 174433-96-6 174434-09-4 174434-86-7 174436-96-5
174441-96-4 174441-98-6 174441-99-7 174442-00-3 174445-41-1
174446-33-4 174447-54-2 174450-06-7 174596-23-7 174917-09-0
174917-30-7 174917-42-1 174917-88-5 174918-10-6 174918-55-9

174918-66-2 174920-50-4 174922-40-8 174922-89-5 174925-14-5
 174926-49-9 174926-57-9 174926-67-1 174926-79-5 174928-44-0
 174929-36-3 174930-36-0 174931-16-9 174932-15-1 174935-60-5
 174936-90-4 174938-70-6 174940-09-1 174942-22-4 174942-28-0
 174943-05-6 174956-93-5 175003-49-3 175005-14-8 175007-85-9
 175036-17-6 175038-33-2 175038-64-9 175041-57-3 175041-66-4
 175043-77-3 175049-75-9 175050-01-8 175052-41-2 175053-00-6
 175054-41-8 175054-84-9 175057-86-0 175058-12-5 175058-19-2
 175058-21-6 175060-63-6 175062-03-0 175068-38-9 175100-31-9
 175101-40-3 175101-86-7 175107-63-8, GenBank U36188 175120-05-5
 175120-19-1 175120-58-8 175121-41-2 175124-00-2 175124-28-4
 175124-66-0 175125-15-2 175125-20-9 175129-84-7 175130-04-8
 175130-85-5 175179-44-9 175179-57-4 175179-89-2 175180-03-7
 175185-21-4 175189-51-2 175190-55-3 175190-69-9 175196-86-8
 175196-91-5, GenBank A26595 175197-01-0, GenBank A29216 175300-96-6
 175302-92-8, DNA (human clone CD46 CY4 cDNA) 175303-39-6 175303-46-5
 175383-98-9 175384-49-3 175452-49-0 175491-49-3 175491-72-2
 175492-02-1 175492-16-7 175492-30-5 175492-92-9 175493-19-3
 175493-26-2 175495-65-5 175497-15-1 175498-83-6 175498-88-1
 175499-03-3 175500-51-3 175501-04-9 175501-60-7 175501-69-6
 175502-47-3 175503-00-1 175503-06-7 175506-41-9 175508-33-5
 175508-43-7 175508-75-5 175511-20-3 175511-26-9 175511-95-2
 175513-29-8 175515-03-4 175515-16-9 175516-64-0 175517-56-3
 175518-92-0 175568-35-1 175572-65-3 175573-29-2 175574-35-3
 175576-48-4 175576-77-9 175578-99-1 175579-18-7 175579-63-2
 175579-97-2 175618-50-5 175618-69-6 175619-71-3 175620-49-2
 175620-85-6 175623-54-8 175628-43-0 175629-77-3 175630-54-3
 175630-67-8 175632-75-4 175637-27-1 175638-52-5 175642-11-2
 175669-37-1 175741-15-8 175741-76-1 175742-30-0 175744-01-1
 175744-30-6 175749-59-4 175752-41-7 175752-93-9 175754-94-6
 175755-71-2 175755-89-2 175755-96-1 175757-20-7 175758-51-7
 175760-98-2 175762-24-0 175762-46-6 175764-27-9 175764-48-4
 175764-88-2 175765-56-7 175765-74-9 175767-71-2 175767-94-9
 175773-18-9 175773-59-8 175802-88-7 175803-29-9 175806-43-6
 175809-34-4 175809-61-7 175811-60-6 175813-21-5 175813-25-9
 175813-73-7 175813-92-0 175816-21-4 175817-20-6 175826-12-7
 175827-06-2 175829-38-6 175929-39-2 175929-59-6 175930-55-9
 175931-74-5 175933-72-9 175958-98-2 176078-92-5 176079-04-2
 176079-14-4 176079-69-9 176079-83-7 176080-21-0 176080-85-6
 176083-00-4 176083-12-8 176121-62-3 176122-58-0 176122-96-6
 176154-64-6 176157-34-9 176157-40-7 176157-54-3 176182-64-2
 176184-73-9 176188-04-8 176188-39-9 176188-41-3 176188-76-4
 176195-16-7 176195-27-0 176195-28-1 176267-71-3 176273-14-6
 176276-57-6, GenBank W21894 176280-25-4, GenBank W22330 176293-33-7
 176294-31-8 176295-77-5 176297-29-3 176333-67-8
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 176337-02-3 176337-25-0 176339-83-6 176341-05-2 176341-56-3
 176341-96-1 176342-06-6 176349-40-9 176353-68-7, DNA (Lechenaultia
 heteromera) 176354-23-7, DNA (Verreauxia reinwardtii) 176356-23-3,
 GenBank W26780 176359-33-4, GenBank W26008 176359-58-3, GenBank W25970
 176363-70-5, GenBank W27182 176364-84-4, GenBank W27229 176365-18-7
 176394-84-6, GenBank W26372 176395-94-1, GenBank W26413 176397-45-8,
 GenBank W27484 176397-64-1, GenBank W27440 176398-42-8, GenBank W27526
 176403-35-3, GenBank W27890 176403-88-6, GenBank W27968 176409-11-3,
 GenBank W28466 176410-89-2, GenBank W28596 176411-74-8, DNA (human EST
 (expressed sequence tag)) 176413-69-7, GenBank W28867 176414-39-4,
 GenBank W28994 176460-20-1 176461-89-5 176462-06-9 176464-29-2
 176465-24-0 176466-12-9 176467-45-1 176470-83-0 176471-74-2
 176473-76-0 176474-93-4 176476-40-7 176476-65-6 176477-07-9
 176480-46-9 176482-24-9 176482-72-7 176482-73-8 176574-24-6
 176575-26-1 176576-09-3 176603-70-6 176604-14-1 176604-29-8
 176604-65-2 176604-90-3 176605-14-4 176605-99-5 176606-69-2

176606-81-8 176608-00-7 176609-73-7 176609-86-2 176610-42-7
 176610-43-8 176614-68-9 176618-45-4 176618-64-7 176620-45-4
 176621-12-8 176621-37-7 176621-55-9 176624-11-6 176624-95-6
 176625-40-4 176626-74-7 176628-00-5 176630-37-8 176630-95-8
 176668-73-8, DNA (Avena sativa cell line PEWI cDNA) 176668-75-0, DNA
 (human clone XX-65019) 176740-61-7 176800-78-5, DNA (human
 plakophilin 2 cDNA fragment) 176807-90-2 176833-85-5 176863-44-8
 176864-18-9 176864-90-7 176866-06-1 176878-77-6 176879-97-3
 176880-15-2 176880-22-1 176880-68-5 176881-15-5 176882-33-0
 176882-68-1 176883-42-4 176883-84-4 176884-05-2 176884-51-8
 176884-84-7 176887-05-1 176888-89-4 176890-36-1 176891-99-9
 176925-44-3 176929-00-3 176929-25-2 176929-40-1 176932-57-3
 176933-17-8 176935-07-2 176935-16-3 176936-04-2 176936-68-8
 176937-57-8, DNA (human clone GHc-389H8 cDNA) 176983-84-9 176984-22-8
 176984-64-8 176993-46-7 176993-76-3 176994-01-7 176996-22-8
 177013-20-6 177118-65-9 177119-90-3 177121-59-4 177121-83-4
 177124-15-1 177124-98-0 177129-72-5 177250-19-0 177250-27-0
 177253-38-2 177253-45-1 177254-73-8 177290-36-7 177291-38-2
 177299-34-2 177300-25-3 177300-48-0 177303-80-9 177304-59-5,
 GenBank U54831 177308-93-9 177369-64-1 177370-21-7 177372-32-6
 177373-91-0 177374-13-9 177375-22-3 177377-45-6 177379-30-5
 177379-83-8 177392-80-2 177393-04-3 177393-96-3 177395-32-3
 177398-26-4 177398-81-1 177400-86-1 177401-22-8 177402-48-1
 177444-24-5 177449-87-5 177451-37-5 177451-54-6 177452-64-1
 177453-32-6 177458-74-1 177459-04-0 177459-34-6 177460-77-4
 177515-08-1 177525-61-0, GenBank U28811 177526-23-7 177527-68-3
 177527-80-9 177530-13-1 177589-29-6 177589-84-3, GenBank L78669
 177624-34-9 177629-44-6 177631-79-7 177633-51-1 177634-25-2
 177634-93-4 177635-65-3 177636-56-5 177668-52-9 177668-84-7
 177670-78-9 177671-33-9 177671-57-7 177674-83-8 177674-97-4
 177676-29-8 177676-51-6 177677-46-2 177678-19-2 177679-14-0
 177679-22-0 177679-64-0 177680-25-0 177680-54-5 177799-99-4
 177803-26-8 177804-17-0 177804-20-5 177804-47-6 177804-54-5
 177804-96-5 177805-19-5 177805-64-0 177806-19-8 177806-24-5
 177806-32-5 177808-60-5 177808-97-8 177809-47-1 177809-87-9
 177809-99-3 177810-44-5 177810-66-1 177811-88-0 177812-27-0
 177812-49-6 177813-08-0 177814-12-9 177815-40-6 177816-43-2
 177817-00-4 177818-28-9 177819-01-1 177820-16-5 177820-50-7
 177820-68-7 177820-78-9 177820-83-6

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 177820-89-2 177821-14-6 177821-58-8 177823-39-1, DNA (human protein
 FX cDNA plus flanks) 177826-93-6 177828-36-3 177829-09-3
 177829-62-8 177832-37-0 177832-64-3 177832-95-0 177833-04-4
 177833-38-4 177833-71-5 177834-12-7 177834-32-1 177834-71-8
 177861-15-3 177861-44-8 177862-32-7 177875-49-9 177875-50-2
 177876-33-4 177877-45-1 177877-67-7 177880-40-9 177917-26-9
 177920-68-2 177925-62-1 177926-58-8 177997-74-9 177998-36-6
 177999-08-5 177999-50-7 177999-85-8 178000-99-2 178001-98-4
 178002-76-1 178004-41-6 178005-02-2 178005-28-2 178012-40-3
 178013-06-4 178013-11-1 178013-12-2 178013-18-8 178013-65-5
 178013-67-7 178013-71-3 178014-55-6 178014-87-4 178015-24-2
 178015-91-3 178018-98-9 178020-00-3 178022-36-1 178022-71-4
 178023-86-4 178089-88-8 178090-22-7 178090-77-2 178091-43-5
 178092-38-1 178092-60-9 178092-64-3 178093-01-1 178093-93-1
 178129-34-5 178129-80-1 178130-46-6 178130-91-1 178130-94-4
 178131-28-7 178132-09-7 178133-04-5 178133-08-9 178133-38-5
 178134-07-1 178134-23-1 178134-26-4 178135-04-1 178135-30-3
 178136-11-3 178148-70-4 178186-18-0 178189-12-3 178189-34-9
 178189-66-7 178189-94-1 178190-27-7 178191-49-6 178196-56-0
 178197-90-5 178218-73-0 178219-46-0 178221-49-3 178222-21-4
 178222-57-6 178223-79-5 178223-91-1 178223-94-4 178224-23-2
 178224-69-6 178280-21-2 178280-58-5 178282-79-6 178283-40-4

178283-46-0 178283-75-5 178283-88-0 178284-17-8 178284-60-1
 178284-95-2 178285-40-0 178286-09-4 178286-62-9 178294-32-1,
 GenBank U46691 178336-25-9 178336-26-0 178336-67-9 178336-87-3
 178337-63-8 178338-52-8 178338-73-3 178338-74-4 178339-44-1
 178341-51-0 178342-00-2 178342-27-3 178342-52-4 178356-40-6, DNA
 (human gene S3111125 cDNA) 178410-24-7 178656-79-6 178658-98-5
 178662-69-6, DNA (Vigna unguiculata cDNA) 178664-19-2 178664-23-8, DNA
 (human isolate VL4 cDNA) 178705-30-1 178706-65-5 178708-30-0
 178708-55-9 178711-89-2 178712-15-7 178712-30-6 178713-01-4
 178713-81-0 178714-54-0 178714-82-4 178715-09-8 178715-35-0
 178715-41-8 178715-49-6 178716-07-9 178717-98-1 178718-09-7
 178719-37-4 178721-08-9 178721-35-2 178722-43-5 178724-27-1
 178724-79-3 178725-10-5 178728-75-1 178728-93-3 178729-17-4
 178729-53-8 178729-96-9 178730-88-6 178731-12-9 178733-42-1
 178734-09-3 178768-32-6 178772-40-2 178773-59-6 178773-64-3
 178777-70-3 178780-53-5 178780-54-6 178780-79-5 178780-86-4
 178781-24-3 178781-26-5 178781-34-5 178781-75-4 178781-77-6
 178782-48-4 178782-55-3 178846-64-5 178847-33-1 178847-41-1,
 GenBank U53328 178923-06-3 179132-35-5 179138-36-4 179203-49-7
 179203-54-4 179205-14-2 179205-56-2 179206-51-0 179207-42-2
 179212-03-4 179212-12-5 179212-96-5 179214-56-3 179214-83-6
 179215-31-7 179216-16-1 179216-94-5 179217-44-8 179217-65-3
 179218-52-1 179218-98-5 179218-99-6 179220-59-8 179220-62-3
 179222-43-6 179308-30-6 179308-31-7 179379-14-7 179443-32-4
 179444-19-0, GenBank C02739 179446-46-9, GenBank C02912 179448-64-7,
 GenBank C03130 179506-44-6, GenBank C04057 179509-63-8, GenBank C04376
 179514-97-7, GenBank C04910 179515-12-9, GenBank C04925 179596-33-9
 179708-61-3 179725-95-2 179968-98-0 179970-01-5 179973-29-6
 179980-05-3 180009-42-1, GenBank X95677 180018-02-4 180107-10-2
 180109-13-1

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 180169-10-2 180173-07-3 180225-00-7 180231-79-2 180235-59-0
 180237-81-4 180245-59-4 180245-61-8 180245-65-2 180245-66-3
 180245-68-5 180245-71-0 180245-72-1 180245-78-7 180245-79-8
 180246-36-0 180310-15-0 180360-78-5 180362-24-7 180426-57-7, DNA
 (human cell line 5583-S cDNA) 180454-13-1 180454-60-8 180458-52-0
 180550-56-5 180563-66-0 180564-33-4 180565-37-1 180567-67-3
 180568-20-1 180604-87-9, GenBank U43899 180664-28-2 180669-84-5
 180671-00-5 180671-04-9 180672-37-1 180687-12-1 180703-28-0
 180703-67-7 180711-38-0 180754-66-9 180769-38-4 180769-44-2
 181015-10-1 181087-20-7 181090-07-3 181092-59-1 181099-67-2
 181105-01-1 181105-43-1 181110-00-9, DNA (human protein
 Snu246p-specifying) 181110-09-8 181160-07-6 181160-77-0
 181164-80-7 181167-70-4 181169-04-0 181204-51-3 181204-52-4
 181204-54-6 181205-17-4 181249-89-8 181253-42-9 181254-91-1
 181255-15-2 181383-62-0 181505-76-0, GenBank U66197 181545-35-7
 181556-97-8 181559-25-1 181598-15-2 181616-79-5 181671-78-3
 181678-93-3 181687-25-2 181692-15-9 181726-48-7 181735-40-0
 181735-43-3 181735-98-8 181738-42-1 181738-89-6 181739-59-3
 181740-02-3 181744-94-5 181754-00-7 181754-47-2 181795-01-7
 181860-89-9 181904-20-1 181913-78-0 181913-87-1 181914-96-5
 181922-68-9, DNA (human cell line HeLa cDNA) 181922-75-8 181922-95-2,
 DNA (human clone cos43) 182093-73-8 182095-00-7 182111-39-3
 182114-12-1, DNA (human clone TSA303 cDNA) 182179-71-1 182179-72-2
 182179-74-4 182273-34-3 182331-04-0 182332-13-4 182339-52-2
 182341-99-7 182375-16-2 182381-30-2 182387-31-1 182389-12-4
 182391-00-0 182391-40-8 182394-25-8 182397-59-7 182398-88-5
 182399-00-4 182455-35-2, GenBank U72398 182540-25-6 182643-64-7
 182732-17-8 182734-73-2 182736-04-5 182762-18-1 182762-19-2
 182762-26-1 182766-68-3 182766-71-8 182781-67-5 182782-51-0
 182785-92-8 182788-48-3 182859-55-8 182860-21-5 182860-33-9
 182862-08-4, DNA (human clone c86) 182939-77-1 182943-17-5

182996-35-6 183080-64-0 183080-66-2 183080-67-3 183080-69-5
 183084-08-4 183094-52-2 183096-21-1 183096-72-2 183100-20-1
 183100-30-3 183100-31-4 183100-33-6 183100-34-7 183100-35-8
 183100-38-1 183100-41-6 183100-43-8 183100-44-9 183100-46-1
 183100-51-8 183100-53-0 183100-55-2 183100-58-5 183100-59-6
 183102-73-0 183192-89-4 183265-08-9 183265-56-7, DNA (human clone
 119127 cDNA) 183336-48-3 183363-29-3 183390-82-1 183391-21-1
 183391-25-5, DNA (human clone 68a1) 183391-39-1 183391-46-0
 183458-80-2 183462-39-7 183469-23-0 183470-20-4, GenBank U77456
 183576-00-3 183576-31-0, GenBank U77720 183640-84-8 183645-72-9
 183651-06-1 183686-04-6 183701-97-5 183712-81-4 183712-90-5
 183713-17-9 183750-26-7 183759-78-6 183760-86-3 183761-33-3
 183762-11-0 183769-10-0 183769-15-5 183770-60-7 183771-17-7
 183775-86-2 183780-23-6 183818-64-6, GenBank D63861 183824-55-7
 183829-25-6 183832-08-8 183845-39-8 183845-82-1 183973-67-3,
 GenBank U68536 183974-50-7 183976-77-4 183976-81-0 183979-91-1
 183982-49-2 183983-91-7 183984-04-5 183984-10-3 183984-23-8
 183984-28-3 183984-52-3 183984-54-5 184054-23-7 184078-63-5
 184080-41-9 184184-50-7 184189-10-4 184199-72-2 184204-41-9
 184205-99-0 184209-21-0 184209-87-8 184214-41-3 184217-04-7
 184217-38-7 184218-62-0 184251-69-2 184257-90-7 184267-05-8,
 GenBank U80040 184327-04-6 184332-49-8
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)
 IT 184341-47-7 184342-41-4 184382-28-3 184383-15-1 184385-55-5
 184389-35-3 184393-76-8 184403-81-4 184438-37-7 184440-44-6
 184502-10-1 184506-83-0 184508-70-1 184512-32-1, DNA (human clone
 cSRL30h11) 184513-21-1 184517-37-1 184517-70-2 184540-77-0
 184547-94-2 184565-93-3 184565-95-5 184566-02-7 184566-12-9
 184566-16-3, DNA (human clone hCDO-1 cDNA) 184571-17-3 184613-06-7
 184672-62-6 184723-28-2, GenBank U72937 184807-46-3 184807-58-7
 184807-80-5 184818-86-8 184861-07-2 184862-12-2 184864-22-0
 184932-46-5 184932-97-6 184940-44-1, DNA (human gene HOXB13)
 184940-83-8 184974-95-6 184974-97-8 184974-98-9 185083-77-6
 185128-20-5 185128-50-1 185162-78-1 185164-13-0 185166-48-7
 185174-92-9 185175-51-3 185182-29-0 185182-31-4 185185-47-1
 185240-74-8 185269-85-6 185272-54-2 185282-74-0 185358-57-0
 185367-05-9 185370-06-3 185370-80-3 185372-60-5 185373-39-1
 185471-65-2 185478-83-5 185478-88-0 185481-55-4 185648-16-2
 185655-67-8 185665-54-7 185666-53-9 185708-23-0 185717-80-0
 185770-54-1 185770-92-7 185772-87-6, DNA (human clone RP1-230G1)
 185773-62-0, DNA (human gene SML1 exon 1 plus flanks) 185782-68-7
 185862-19-5 185872-81-5 185925-34-2 185925-44-4, DNA (human clone
 DJ527C21) 185935-80-2 185938-38-9 185938-48-1 185940-99-2
 186007-74-9, DNA (human cell line IMR-32 cDNA) 186015-71-4 186016-07-9
 186017-40-3 186017-57-2 186152-99-8 186167-88-4 186169-43-7
 186220-58-6 186233-96-5 186445-46-5 186445-47-6 186445-79-4
 186445-96-5 186473-74-5 186560-50-9 186620-28-0 186624-03-3
 186628-37-5 186637-52-5 186679-66-3 186816-96-6 186858-68-4
 186859-68-7 186861-96-1 186870-46-2 186872-42-4 186874-03-3
 186878-71-7 186999-95-1 187000-70-0 187000-72-2 187004-91-7
 187125-48-0, DNA (human clone RP1-271G9) 187125-50-4, DNA (human clone
 RP1-50A13) 187130-33-2 187132-48-5 187139-65-7 187201-93-0
 187204-11-1 187261-20-7 187261-86-5 187285-60-5 187313-50-4,
 GenBank AA247773 187352-01-8, GenBank U81001 187352-29-0 187352-72-3
 187354-45-6 187381-64-2 187437-67-8 187437-87-2 187438-92-2
 187439-73-2 187446-83-9 187502-45-0 187505-44-8 187509-60-0
 187557-27-3 187558-06-1 187567-17-5 187640-56-8 187640-94-4
 187764-79-0 187767-37-9 187790-71-2 187790-86-9, GenBank X76771
 187821-54-1 187824-40-4, GenBank U90339 187958-71-0, DNA (human clone
 pDJ1173a5) 188089-54-5 188089-57-8, DNA (human clone 23907 cDNA)
 188089-59-0, DNA (human clone 23722 cDNA) 188089-65-8 188089-66-9
 188090-50-8, DNA (human clone 23667 and 23775 cDNA) 188101-70-4, GenBank

X99802 188161-37-7 188163-65-7 188164-96-7 188208-15-3
 188218-09-9 188226-27-9 188235-27-0 188238-42-8 188274-11-5
 188274-94-4 188283-13-8 188284-23-3 188288-23-5 188315-24-4
 188326-59-2 188334-17-0 188336-85-8 188460-06-2 188464-53-1
 188470-69-1 189089-11-0, GenBank U82535 189203-64-3 189285-74-3
 189356-92-1 189410-82-0 189417-47-8 189424-01-9 189465-18-7,
 GenBank AB002559 189467-20-7 189478-16-8 189612-11-1 189677-14-3
 189723-13-5 189723-30-6 189732-09-0 189741-65-9 189743-40-6
 189743-42-8 189773-73-7 189774-00-3 189776-20-3 189788-61-2
 189840-57-1 189841-80-3 189867-58-1 189869-38-3 189914-78-1
 189920-70-5 189920-95-4 189923-01-1 189923-03-3 189923-04-4
 190036-60-3 190119-30-3 190147-84-3 190147-86-5 190161-87-6
 190162-33-5 190162-66-4 190164-47-7 190179-94-3 190179-96-5
 190180-16-6 190180-21-3 190416-92-3, DNA (human clone 176H7)
 190416-96-7 190473-31-5 190496-51-6, DNA (human clone 113F3)
 190501-82-7 190545-40-5, DNA (human clone 3 karyopherin β 3 cDNA)
 190555-38-5 190557-43-8 190558-01-1 190558-21-5 190558-49-7
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)
 IT 190614-70-1 190625-66-2 190640-93-8 190648-22-7 190681-48-2
 190699-44-6 190738-31-9 190742-67-7, DNA (human clone cosmid LK1023)
 190742-69-9, GenBank AF002996 190821-23-9 190880-82-1 190989-57-2
 190993-47-6 191047-85-5 191075-85-1 191119-46-7 191128-89-9
 191141-59-0 191141-77-2 191143-22-3 191147-77-0 191148-41-1
 191149-51-6 191150-74-0 191199-00-5 191207-75-7 191211-09-3
 191261-27-5 191292-12-3 191313-13-0 191318-48-6 191378-92-4
 191396-28-8 191431-44-4 191452-45-6 191456-71-0 191516-85-5
 191562-91-1, GenBank AA325370 191564-15-5, GenBank AA325474
 191573-86-1, GenBank AA326465 191573-87-2, GenBank AA326466
 191624-10-9, GenBank AA328435 191631-66-0, GenBank AA329233
 191647-67-3, GenBank AA330793 191691-64-2, GenBank AA332288
 191700-09-1, GenBank AA333116 191758-97-1, GenBank AA335696
 191760-47-1, DNA (human EST (expressed sequence tag)) 191769-75-2,
 GenBank AA336878 191775-27-6, GenBank AA337404 191779-21-2, GenBank
 AA337798 191812-59-6, GenBank AA338634 191822-68-1, GenBank AA339622
 191882-13-0 191899-22-6, GenBank AA343749 192019-48-0, GenBank
 AA349886 192020-45-4, GenBank AA349983 192032-84-1, GenBank AA351222
 192085-70-4, GenBank AA352688 192090-49-6, GenBank AA353179
 192097-83-9, GenBank AA353913 192117-40-1 192143-25-2 192143-26-3
 192143-32-1 192143-43-4 192143-46-7 192143-56-9 192143-61-6
 192143-69-4 192143-79-6 192143-84-3 192143-85-4 192143-89-8
 192143-97-8 192144-00-6 192144-06-2 192144-07-3 192144-09-5
 192144-13-1 192144-14-2 192144-19-7 192144-95-9 192146-00-2,
 GenBank AA355954 192146-02-4 192148-21-3, GenBank AA356182
 192148-34-8 192176-08-2, GenBank AA358978 192232-89-6, GenBank
 AA359611 192234-52-9, GenBank AA359735 192287-18-6, GenBank AA364033
 192334-61-5, GenBank U89436 192341-15-4, GenBank AA367068 192351-57-8,
 GenBank AA368087 192368-22-2, GenBank AA369721 192392-34-0
 192400-41-2, GenBank AA370428 192410-32-5, GenBank AA371420
 192415-40-0, GenBank AA371957 192422-35-8, GenBank AA372674
 192489-75-1 192497-49-7 192498-38-7 192501-84-1 192543-39-8,
 GenBank AA378378 192548-19-9, GenBank AA378849 192563-37-4
 192688-88-3, GenBank AA386348 192690-50-9, GenBank E00195 192695-23-1
 192730-01-1 192732-83-5, GenBank E01500 192733-79-2 192734-33-1,
 GenBank E01787 192734-74-0 192736-32-6, GenBank E02135 192739-54-1,
 GenBank E02823 192844-00-1 192955-32-1 193031-20-8 193043-75-3
 193055-27-5 193103-70-7 193108-81-5 193134-69-9, DNA (human clone
 RP1-179M20) 193164-35-1 193166-97-1 193177-65-0 193178-45-9
 193179-00-9 193239-15-5 193240-86-7 193247-57-3 193256-53-0
 193264-18-5 193324-46-8 193324-67-3 193324-99-1 193365-74-1,
 GenBank AA294883 193381-45-2, GenBank AA296484 193430-57-8, DNA (human
 EST (expressed sequence tag)) 193446-36-5, GenBank AA299346
 193458-14-9, GenBank AA300574 193460-20-7, DNA (human EST (expressed

sequence tag)) 193462-83-8, DNA (human importin- α 6 cDNA plus
flanks) 193491-56-4, GenBank AA301138 193494-57-4, GenBank AA301439
193506-18-2, GenBank AA302601 193516-74-4 193568-31-9, GenBank
AA304899 193568-36-4 193569-13-0 193571-25-4 193574-57-1
193575-00-7 193577-94-5, GenBank AA305862 193578-05-1, GenBank
AA305873 193581-58-7, GenBank AA306226 193583-96-9, GenBank AA306444
193584-43-9, GenBank AA306511 193585-26-1, GenBank AA306594
193585-55-6, GenBank AA306623 193586-41-3, GenBank AA306709
193586-66-2, DNA (human EST (expressed sequence tag)) 193587-78-9,
GenBank AA306846 193588-49-7, GenBank AA306917 193588-93-1
193588-98-6 193589-92-3 193592-01-7 193592-59-5 193592-64-2
193597-11-4 193598-10-6 193598-64-0 193641-08-6 193642-49-8
193647-46-0 193655-74-2 193657-59-9, GenBank AA310059 193660-06-9,
GenBank AA310330 193671-60-2, GenBank AA311461 193672-00-3, GenBank
AA311501 193672-55-8 193705-89-4, GenBank AA311933 193711-45-4,
GenBank AA312489 193713-81-4 193714-10-2, GenBank AA312778
193715-32-1, GenBank AA312886 193720-29-5 193721-45-8 193725-50-7
193728-01-7 193729-45-2 193731-75-8 193733-58-3 193733-68-5
193735-02-3 193737-08-5 193771-95-8 193772-78-0 193773-05-6
193777-88-7 193778-54-0 193782-81-9 193783-61-8 193784-04-2
193784-25-7 193784-43-9 193785-51-2 193786-73-1 193790-51-1,
GenBank AA317246 193800-41-8, GenBank AA318236 193801-39-7, GenBank
AA318266 193926-57-7, GenBank AA323846 193932-93-3 193938-63-5
194002-54-5, DNA (human cell line JEG-3 cDNA) 194004-78-9 194080-50-7
194136-95-3 194182-01-9 194247-74-0 194250-33-4 194382-88-2
194384-78-6 194407-63-1 194431-08-8 194431-09-9 194444-73-0
194465-77-5 194531-04-9 194562-07-7 194562-41-9, DNA (human clone
297N7) 194630-75-6 194706-63-3, GenBank AJ000332 194711-70-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

IT 194745-99-8 194749-47-8 194750-84-0 194756-19-9 194771-50-1
194780-79-5 194817-57-7 194832-54-7 194832-58-1 195016-28-5
195038-28-9, GenBank A36460 195124-79-9 195243-12-0 195268-50-9
195268-56-5, GenBank U80743 195398-64-2, DNA (human clone
alpha-est218/52C1 cDNA) 195398-70-0 195398-72-2, DNA (human clone iota
cDNA) 195412-62-5, DNA (human clone LA16-444G9) 195432-09-8
195461-89-3 195463-94-6 195548-97-1 195580-30-4 195633-14-8
195748-38-0 195751-54-3 195770-27-5 195784-86-2 195792-18-8, DNA
(human clone RP1-138B7) 195811-32-6 195901-38-3 195908-64-6
195926-48-8 195935-95-6 196014-17-2 196016-81-6 196016-82-7
196016-83-8 196021-77-9 196035-90-2 196056-56-1 196056-58-3
196056-64-1, DNA (human clone 46a9) 196056-68-5 196151-56-1
196384-22-2, DNA (human decysin cDNA plus flanks) 196527-20-5
196535-52-1 196596-11-9 196678-52-1 196694-80-1 196726-92-8
196825-42-0 196968-94-2 197040-79-2 197061-33-9, DNA (human clone
hCIT529I10) 197065-79-5 197116-77-1 197118-87-9 197128-78-2
197199-60-3 197256-49-8 197336-94-0 197416-34-5 197424-52-5
197624-85-4 197627-28-4 197627-33-1 197629-16-6 197682-31-8
197683-32-2 197737-80-7 197738-81-1 197827-57-9 197867-27-9
198056-06-3 198056-21-2 198122-48-4, GenBank U75330 198123-05-6
198157-08-3 198464-40-3 198508-16-6 198522-37-1 198535-54-5
198540-82-8 198587-52-9 198622-30-9 198718-82-0, GenBank U65090
198733-19-6 198734-24-6 198816-67-0 198817-03-7 198841-61-1
199030-93-8 199058-55-4 199068-40-1 199149-09-2 199150-17-9, DNA
(human clone HA6353 cDNA) 199152-60-8, DNA (human clone cosmid V4G7)
199153-80-5 199159-42-7 199208-93-0 199239-59-3 199319-97-6,
GenBank AF025999 199376-83-5, DNA (human clone RP1-9E21 cDNA)
199399-33-2 199409-65-9 199424-99-2 199432-16-1, GenBank AF026548
199490-76-1 199490-77-2 199640-25-0 199648-03-8 199723-28-9
199770-87-1, GenBank D50369 199770-88-2 199770-89-3 199770-95-1, DNA
(human clone HRPC905N1) 199899-69-9 199909-11-0 199914-63-1
199955-73-2 200024-87-9 200047-60-5, DNA (human clone HCIT268N12)
200146-73-2 200160-57-2, DNA (human gene UbC(8u) plus flanks)

200165-34-0 200245-25-6 200326-96-1, DNA (human clone HuCE21 cDNA)
 200466-15-5 200468-75-3 200475-42-9 200475-46-3 200475-47-4
 200516-29-6 200516-30-9, DNA (human clone HG0891 cDNA) 200586-23-8
 200588-43-8 200593-47-1 200593-56-2, DNA (human clone 23623 cDNA)
 200593-57-3, DNA (human clone 23837 cDNA) 200596-74-3, DNA (human cell
 line HeLa cDNA) 200597-32-6 200597-63-3 200762-10-3, DNA (human
 clone HG0286 cDNA) 200762-15-8 200762-23-8 200762-31-8 200771-02-4
 200771-04-6 200892-59-7 200895-33-6 201097-01-0 201120-98-1, DNA
 (human clone RP1-11703) 201247-98-5 201250-54-6 201255-48-3
 201263-08-3 201264-35-9 201333-87-1 201374-08-5 201385-39-9
 201439-71-6 201444-36-2, DNA (human clone hCIT.123-J-14) 201457-06-9
 201501-83-9 201562-03-0 201713-56-6 201776-98-9 201898-70-6
 201901-59-9, DNA (human clone HRP1169K15) 201951-81-7 201959-42-4
 201962-72-3 201980-73-6 202088-07-1, GenBank U58855 202091-24-5
 202109-52-2 202113-02-8 202166-21-0 202253-87-0 202254-56-6,
 GenBank Y16132 202497-27-6 202549-42-6 202569-58-2 202573-86-2
 202609-72-1 202631-42-3 202633-80-5 202634-37-5 202639-01-8,
 GenBank AF040966 202639-55-2 202704-98-1 202774-34-3, DNA (human
 clone 23701 cDNA) 202775-65-3 202775-67-5 202838-02-6 202838-33-3
 202839-33-6 202840-37-7, DNA (human clone No.1 cDNA) 202840-49-1
 202883-07-6 202943-54-2 202950-29-6 203029-14-5 203041-82-1
 203106-52-9 203145-45-3 203164-22-1 203224-75-3, DNA (human clone
 CTB-158017) 203224-79-7 203227-42-3 203232-79-5, DNA (human clone
 HCIT305D20) 203241-89-8, DNA (human cell line FOB-cells cDNA)
 203269-67-4 203282-46-6 203291-47-8 203299-71-2 203609-93-2
 203843-79-2 203848-80-0 203848-83-3 204023-71-2 204023-75-6
 204024-99-7 204033-80-7 204093-54-9 204094-18-8 204181-94-2
 204209-94-9 204216-15-9 204314-80-7 204371-80-2 204372-92-9
 204410-81-1 204421-18-1, DNA (human clone cgtm1)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 204484-54-8 204531-07-7 204539-10-6 204558-23-6 204620-23-5
 204629-88-9 204629-93-6 204664-47-1 204664-66-4 204664-81-3, DNA
 (human clone RP1-147M19) 204670-89-3 204682-83-7 204685-64-3,
 GenBank AC004228 204828-54-6, DNA (human clone 399H11) 204830-38-6,
 DNA (human clone HCIT542B22) 204870-20-2, DNA (human clone RPC11-316M24
) 204884-40-2 204890-00-6 204890-53-9 204896-12-8 204896-42-4
 205278-88-2 205284-85-1 205286-77-7 205290-88-6, DNA (human clone
 278C19) 205291-39-0 205343-02-8, GenBank AF051782 205482-62-8
 205546-60-7 205602-38-6 205603-43-6 205606-14-0 205665-97-0
 205669-97-2 205670-77-5 205716-93-4, DNA (human clone RP3-323P24)
 205804-34-8 205861-71-8 205904-57-0 205947-42-8 205950-64-7
 205968-31-6, DNA (human clone P1.11659) 205968-62-3, DNA (human cell
 line HepG2 cDNA) 206038-53-1 206095-56-9, DNA (human clone 1076B9)
 206223-43-0 206225-39-0 206225-90-3 206231-79-0 206232-03-3
 206232-06-6 206232-11-3 206232-18-0 206324-15-4 206324-22-3
 206324-27-8 206324-70-1 206324-81-4 206393-33-1, DNA (human clone
 RP4-604G5) 206393-38-6 206570-62-9 206578-64-5 206581-52-4
 206601-71-0 206614-10-0 206617-71-2 206623-03-2 206630-23-1,
 GenBank U94788 206630-26-4 206630-40-2 206630-41-3 206630-50-4
 206630-67-3 206630-98-0 206631-03-0 206631-05-2 206631-09-6
 206631-20-1 206631-21-2 206631-23-4 206631-29-0 206685-74-7
 206686-43-3 206689-92-1 206736-47-2 206789-41-5 206905-50-2
 206912-03-0 206912-70-1 207079-67-2 207146-11-0 207151-73-3
 207210-80-8 207543-94-0 207835-64-1 207835-80-1 207872-59-1
 207889-42-7, DNA (human clone T1866-f90A8f-10) 207943-98-4
 207944-67-0 207969-73-1, DNA (human gene NDUFV1 plus flanks)
 208029-58-7, DNA (human cell line HeLa cDNA) 208030-91-5, DNA (human
 clone hRPC.1164-O-3) 208033-71-0 208146-96-7 208206-56-8
 208221-53-8 208227-62-7 208227-90-1 208232-65-9 208417-08-7
 208474-86-6 208504-24-9 208504-97-6, DNA (human clone hCIT.117-K-16)
 208544-97-2, DNA (human clone CIT-HSP-311e8) 208544-99-4, DNA (human
 clone hRPC.1050-D-4) 208546-24-1 208554-67-0 208564-52-7

208571-97-5 208572-48-9 208608-04-2, DNA (human gene EXLM1 plus
flanks) 208638-52-2 208751-92-2 208957-03-3, DNA (human clone
RPC11-228P16) 209096-06-0 209149-01-9, DNA (human clone RP4-616B8
cDNA) 209149-32-6 209267-69-6 209296-54-8, DNA (human cell line
HAT109 cDNA) 209365-38-8 209365-54-8, DNA (human clone RG313A17)
209365-61-7, DNA (human clone CTA-270D13) 209365-71-9, DNA (human clone
RG161A02) 209365-84-4 209366-00-7 209366-01-8 209366-05-2
209366-10-9, DNA (human clone LLCos-150F1) 209366-30-3 209366-61-0,
DNA (human clone RP5-1107K15) 209367-04-4 209367-49-7, DNA (human
clone RP4-808A1) 209367-60-2 209367-85-1, DNA (human clone DJ0555N02
) 209367-97-5, DNA (human clone RP1-172A13) 209367-99-7
209368-08-1, DNA (human clone 267D11) 209368-43-4, DNA (human clone
RP4-685A2) 209368-46-7, DNA (human clone RP4-673M15) 209558-81-6
209571-82-4 209579-91-9 209629-03-8 209718-72-9 209770-43-4, DNA
(human gene NIT1 plus flanks) 209775-37-1 209876-51-7 209891-22-5
209928-17-6 209945-73-3 209949-53-1 210085-59-9, DNA (human clone
CTB-163K11) 210251-19-7 210278-92-5 210445-32-2 210446-69-8
210448-77-4 210453-54-6, DNA (human clone BAC 319C17) 210493-73-5,
DNA (human clone RP3-414A15) 210526-16-2 210669-05-9 210671-83-3
210716-40-8 210851-67-5 211063-72-8 211153-65-0 211153-70-7
211153-72-9 211153-87-6 211153-93-4 211153-96-7 211153-99-0
211154-19-7 211154-39-1 211155-01-0 211166-39-1 211167-22-5
211168-98-8 211169-03-8 211169-13-0 211271-88-4 211274-83-8
211278-39-6, GenBank AC005318 211370-71-7 211397-34-1 211397-35-2,
DNA (human clone hRPK.640-I-15) 211403-03-1 211611-07-3
211719-17-4, GenBank G39840 211856-56-3 211856-69-8, DNA (human clone
119j3) 211877-86-0 211878-37-4 211878-83-0 211879-07-1
211879-38-8 211879-39-9 211879-42-4 211879-46-8 211882-75-6
212105-41-4 212217-88-4 212217-99-7 212218-01-4 212218-16-1
212218-36-5 212218-41-2 212368-82-6 212400-73-2 212411-40-0
212539-84-9 212593-01-6 212603-05-9 212673-18-2 212718-64-4
212718-72-4 212723-36-9 212741-48-5 212742-70-6 212749-67-2
212827-69-5 212867-41-9 212876-78-3 212889-61-7 212936-28-2
212945-88-5

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

IT 212951-28-5 213076-46-1 213076-52-9 213171-16-5 213172-06-6
213292-97-8, GenBank AC005516 213292-99-0 213293-77-7, DNA (human
clone RP5-919J22) 213311-83-2 213311-85-4, DNA (human clone
hRPK.215-E-13) 213452-48-3 213515-85-6 213516-21-3, DNA (human
clone NH0332L11) 213516-28-0, DNA (human clone RP4-701O16)
214112-88-6, DNA (human clone IMAGE:340966 cDNA) 214113-34-5, DNA (human
clone IMAGE:343631 cDNA) 214114-60-0, DNA (human clone IMAGE:346551
cDNA) 214157-96-7 214397-28-1 214397-34-9 214516-30-0
214728-64-0 215061-16-8, DNA (human clone IMAGE:262231 cDNA)
215061-69-1, DNA (human clone IMAGE:346133 cDNA) 215093-24-6
215210-93-8, DNA (human clone P1 LBL#8) 215293-94-0, DNA (human
dysferlin cDNA plus flanks) 215400-72-9, DNA (human clone RP5-1093I16)
215825-72-2 215838-06-5 215898-96-7 216122-54-2 216123-27-2,
GenBank AB017335 216126-87-3 216127-46-7 216130-47-1, DNA (human
clone hRPK.63-A-1) 216132-06-8 216296-11-6 216296-37-6
216296-46-7 216296-58-1 216296-71-8 216296-72-9 216296-80-9
216296-87-6 216296-91-2 216296-98-9 216297-03-9 216297-06-2
216297-09-5 216430-72-7 216430-78-3 216480-11-4, DNA (human clone
GS1-234F24) 216909-95-4 216930-66-4 216954-98-2 217053-29-7
217053-35-5, DNA (human clone RP5-963K23) 217056-53-6 217121-11-4
217224-78-7 217224-81-2 217230-41-6 217243-05-5 217332-81-5
217332-85-9 217353-42-9 217360-54-8 217431-02-2 217511-78-9, DNA
(human clone RP1-34B21 cDNA) 217531-14-1 217543-66-3 217579-22-1,
DNA (human clone 34j15) 217580-78-4, DNA (human clone C0315N08)
217580-82-0 217593-07-2 217593-39-0 217828-70-1 217870-85-4,
GenBank A58331 217939-07-6 218046-53-8 218053-56-6 218110-73-7
218190-08-0 218241-11-3 218250-83-0 218250-86-3 218318-19-5

218328-93-9 218349-23-6 218427-23-7, DNA (human clone hRPK.269-G-24)
 218428-97-8 218560-03-3 218564-07-9 218581-54-5 218686-72-7
 218686-82-9 218724-34-6 218763-62-3 218763-64-5 219101-14-1
 219101-27-6 219101-31-2 219258-45-4, DNA (human clone hRPK.294-J-22)
 219338-35-9 219379-07-4 219388-54-2 219388-55-3, DNA (human clone
 RPCI5-751E10) 219389-07-8 219411-84-4 219513-58-3 219513-78-7
 219587-46-9 219628-68-9, GenBank AF090426 219728-53-7 219805-82-0
 219900-39-7 220054-86-4 220093-35-6 220220-69-9, GenBank G41778
 220263-15-0 220499-90-1 220500-03-8 220500-17-4 220500-31-2
 220500-34-5 220500-38-9 220500-46-9 220500-51-6 220500-64-1
 220500-69-6 220500-70-9 220500-85-6 220500-86-7 220500-90-3
 220500-93-6 220793-87-3, Protein (human gene fln29) 221075-71-4
 221210-38-4 221294-28-6 221369-33-1 221431-35-2, DNA (human clone
 203 cDNA) 221433-03-0 221443-45-4 221585-82-6 221588-58-5
 221729-91-5 221736-77-2 221741-24-8 221741-41-9 221764-86-9
 221780-81-0 221780-85-4 221783-07-9 221790-37-0, DNA (human clone
 hRPK.299-G-24) 221823-37-6 221837-90-7 221843-00-1 221851-81-6
 221968-80-5 222067-57-4, DNA (human clone RP11-505D17) 222067-59-6,
 DNA (human clone RP11-400O10) 222067-73-4 222078-93-5 222088-23-5
 222096-50-6 222116-16-7 222118-20-9 222127-20-0 222203-57-8
 222203-71-6 222207-02-5 222217-49-4 222218-08-8 222218-51-1
 222238-65-5 222248-65-9 222342-96-3 222355-25-1, DNA (human clone
 254f11) 222447-20-3 222447-22-5, DNA (human clone RP1-50024 cDNA)
 222460-10-8 222525-83-9 222525-91-9 222525-96-4 222525-98-6
 222526-06-9 222526-11-6 222526-41-2 222526-45-6 222526-51-4
 222672-99-3, DNA (human clone RPCI3-305I20) 222706-60-7 222706-74-3
 222772-77-2 222822-61-9 222837-14-1 223092-84-0 223211-24-3
 223213-46-5, DNA (human clone hRPK.202-H-3) 223242-10-2 223656-87-9
 223683-68-9 223843-49-0 223899-30-7 223899-33-0, DNA (human clone
 RPCI5-1157M23) 223901-04-0, DNA (human clone BAC 501I4) 223987-49-3
 223998-02-5 224004-73-3 224028-85-7 224074-20-8 224091-77-4
 224093-29-2 224101-24-0 224115-12-2 224122-71-8 224154-87-4
 224206-64-8 224213-63-2 224219-44-7 224224-94-6 224241-48-9
 224253-14-9 224255-07-6 224280-37-9 224289-56-9, GenBank U33460
 224290-39-5 224290-65-7, GenBank U42404 224290-72-6 224326-88-9,
 GenBank U48857 224327-91-7 224329-09-3, GenBank U67058 224329-45-7
 224339-01-9 224339-40-6, GenBank U92544 224353-45-1, DNA (human clone
 EHB3 cDNA)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 224359-64-2, GenBank AF036536 224363-21-7 224368-08-5, DNA (human cell
 line MCF-7 cDNA) 224369-63-5, GenBank U78516 224375-07-9 224386-06-5
 224386-22-5 224416-91-5 224461-50-1 224482-03-5, DNA (human clone
 hRPK.17-A-1) 224698-05-9, GenBank AB012922 224891-99-0 225254-61-5
 225280-20-6 225287-60-5 225313-54-2 225315-88-8 225392-87-0, DNA
 (human clone hRPC.56-K-13) 225394-27-4 225395-43-7 225395-58-4, DNA
 (human clone RP11-166O4) 225395-60-8, DNA (human clone RP5-847G17)
 225396-43-0 225403-62-3, DNA (human clone hRPC.1029-K-10)
 225404-02-4, DNA (human gene ABPL cDNA) 225409-68-7, DNA (human clone
 RPCI3-461F17) 225414-14-2, DNA (human cell line NCR-G3 cDNA)
 225426-19-7 225428-39-7 225435-67-6 225439-23-6, DNA (human clone
 RP11-160K17) 225439-67-8, DNA (human clone RP11-298H3) 225439-85-0,
 DNA (human clone RP1-29I24) 225446-69-5, GenBank AF126246 225446-84-4
 225447-39-2, DNA (human clone 24906 cDNA) 225447-44-9, DNA (human clone
 25022 cDNA) 225447-62-1 225447-68-7, DNA (human clone 24945 cDNA)
 225454-03-5 225455-20-9 225456-49-5 225456-51-9, DNA (human gene
 RBM8 cDNA) 225464-38-0, DNA (human clone RP4-550H1) 225468-59-7, DNA
 (human clone RP3-475N16) 225470-06-4, DNA (human clone RP5-1100E15)
 225472-86-6 225473-42-7 225473-80-3 225474-86-2 225475-90-1, DNA
 (human clone DKFZp586B0918 cDNA) 225479-17-4 225479-38-9
 225479-39-0, DNA (human cell line FCCM-9 cDNA) 225494-81-5 225497-32-5
 225498-97-5 225539-24-2 225542-00-7, GenBank U81002 225547-20-6, DNA
 (human clone RP3-346G2) 225547-30-8, DNA (human clone RP5-836N17)

225555-39-5 225559-43-3, DNA (human clone RP4-570L12) 225559-53-5,
DNA (human clone RP1-180E22) 225572-48-5 225572-57-6 225574-66-3
225582-45-6 225582-52-5, DNA (human clone RPCI-11-488J11) 225589-57-1
225590-56-7 225597-42-2, DNA (human clone RP11-451J3) 225597-54-6,
DNA (human clone RP11-158I21) 225598-76-5 225598-82-3 225599-01-9
225599-24-6 225599-30-4 225600-04-4 225601-01-4 225601-84-3, DNA
(human clone RP1-247C2) 225601-85-4, DNA (human clone RP4-686C3)
225611-39-2, DNA (human cell line A549) 225634-43-5 225635-22-3, DNA
(human clone IMAGE:191661 cDNA) 225674-97-5, DNA (human clone RP4-565E6
) 225689-70-3 225691-46-3 225691-96-3 225692-17-1 225694-06-4,
DNA (human gene SGT1 cDNA) 225695-31-8, GenBank AF148513 225709-11-5,
GenBank AF134803 225711-71-7, GenBank AF078671 225714-97-6, DNA (human
clone RPCI11-390D8) 225717-24-8 225717-52-2, DNA (human clone
DKFZp586I1419 cDNA) 225717-56-6, DNA (human clone DKFZp586C201 cDNA)
225717-82-8, DNA (human clone DKFZp564F0522 cDNA) 225718-45-6, DNA
(human clone DKFZp566C0424 cDNA) 225719-08-4, DNA (human clone
DKFZp586K091 cDNA) 225719-49-3 225719-78-8, DNA (human clone
DKFZp586F2323 cDNA) 225723-52-4 225726-90-9 225732-66-1, GenBank
AL049801 225732-86-5, DNA (human clone RP4-570F3) 225734-13-4
225734-26-9, DNA (human clone DKFZp586K1720 cDNA) 225734-59-8, DNA
(human clone RP11-355F16) 225737-27-9 225745-19-7 225745-62-0
225747-58-0 225747-64-8 225747-67-1 225747-70-6 225747-85-3
225748-00-5 225748-05-0 225748-20-9 225748-28-7 225748-45-8
225748-61-8 225748-63-0 225749-03-1, DNA (human clone RP11-7F17)
225765-83-3, DNA (human clone RP1-12G14) 225771-93-7 225777-43-5, DNA
(human gene SMVT plus flanks) 225778-30-3, GenBank AF141870
225885-03-0 225888-26-6, DNA (human clone RP1-293L8) 225889-34-9
225893-75-4, GenBank AL078611 225900-17-4 225911-11-5, DNA (human
clone GS1-180i23) 225915-02-6, DNA (human clone CIT-B-471f3)
225915-04-8, DNA (human clone 678g6) 226031-49-8 226058-50-0, DNA
(human clone RP11-395L14) 226059-80-9 226061-13-8 226204-33-7
226205-49-8 226206-36-6 226208-03-3 226208-05-5 226208-07-7
226456-18-4 226535-91-7, DNA (human clone R-388G3) 226537-02-6,
GenBank AF092136 226642-97-3 226684-03-3 226685-70-7 226773-85-9
226838-82-0 226874-06-2 227045-03-6 227048-47-7, GenBank AF147787
227053-52-3, DNA (human clone DKFZp564E1962 cDNA) 227054-27-5
227054-29-7, DNA (human clone DKFZp434K114 cDNA) 227054-44-6, DNA (human
clone DKFZp434G231 cDNA) 227063-19-6, GenBank AF072933 227067-44-9
227069-34-3 227069-35-4 227072-65-3, DNA (human cell line Jurkat cDNA)
227072-80-2 227072-81-3 227109-95-7 227113-37-3 227114-95-6
227132-52-7 227174-18-7 227174-30-3, DNA (human cell line 1973/10-4
cDNA) 227248-59-1 227446-94-8 227447-31-6 227447-32-7
227502-40-1 227538-94-5 227592-55-4, DNA (human clone DKFZp586C1223
cDNA) 227592-65-6 227592-67-8, DNA (human clone DKFZp586K2123 cDNA)
227741-94-8 227742-19-0, DNA (human clone RP4-659F15) 227868-60-2
227880-31-1 228070-18-6 228082-96-0 228083-90-7 228130-70-9
228241-74-5, DNA (human clone RPCI11-469J4) 228543-40-6 228543-62-2,
GenBank AF047431 228634-77-3 228635-90-3 228686-91-7 228690-70-8
228690-72-0 228690-79-7 228690-88-8 228690-91-3, GenBank AF078866
228691-22-3 228691-23-4 228693-03-6, DNA (human gene POLE1 exons
36-38) 228814-62-8 228992-85-6 228993-34-8, DNA (human gene ESX plus
flanks) 229223-08-9 229304-66-9 229305-28-6 229305-31-1, DNA
(human clone RPCI11-263C16) 229394-58-5 229424-47-9 229432-42-2
229586-52-1 229838-45-3 229839-28-5 229846-65-5 230164-52-0
230273-42-4 230276-33-2 230332-86-2 230598-97-7 230650-63-2
230807-92-8 230808-55-6 230946-91-5 230946-95-9 230946-96-0
230946-97-1 230946-98-2 231004-48-1 231009-68-0 231135-14-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
tumor-associated proteins, kits, and methods for identification,
assessment, prevention, and therapy of human prostate cancer)

IT 231142-40-8 231262-16-1 231267-95-1 231268-08-9 231268-41-0
231268-42-1 231268-46-5 231268-55-6 231268-58-9 231268-59-0
231268-64-7 231268-69-2 231268-73-8 231268-75-0 231268-81-8
231268-82-9 231268-83-0 231270-96-5, DNA (human clone LLNLF-24D8)

231320-62-0 231445-35-5 231449-50-6 231453-32-0 231503-69-8
 231516-45-3 231602-86-1, GenBank AJ245416 231605-45-1 232196-17-7
 232205-27-5 232237-48-8, GenBank E15239 232240-35-6, GenBank E15695
 232252-14-1, GenBank E17361 232290-49-2 232291-22-4 232296-16-1
 232300-10-6 232305-82-7 232358-10-0 232367-05-4 232584-12-2, DNA
 (human gene NPC1 exons 22-24) 232584-14-4 232710-79-1 232911-90-9
 232911-95-4 233183-82-9 233196-87-7 233238-22-7 233445-72-2
 233744-02-0 233986-25-9 234008-54-9 234419-25-1, DNA (human clone
 RP4-534K7) 234556-50-4 234560-37-3 235212-29-0 235347-10-1
 235354-46-8 235548-39-7 235559-42-9 235561-93-0 235562-21-7
 235569-97-8 235571-47-8 235571-58-1 236067-05-3 236079-72-4
 236092-78-7 236604-83-4 236612-85-4 236625-54-0 236627-01-3
 236728-64-6 237053-55-3 237710-10-0 237725-56-3, DNA (human clone
 DKFZp564L0716 cDNA) 237725-97-2, DNA (human clone DKFZp564P0562 cDNA)
 237726-65-7, DNA (human clone DKFZp434C211 cDNA) 238004-62-1
 238059-53-5 238145-30-7, GenBank AI795827 238159-23-4 238188-94-8
 238497-86-4 238515-63-4 238526-29-9 238544-21-3 238627-73-1
 238629-88-4 238631-42-0 238639-57-1 238644-47-8 238657-70-0
 238661-04-6 238667-75-9 238668-00-3 238679-77-1 238688-90-9
 238689-55-9 238690-00-1 238692-41-6 238694-38-7 238697-55-7
 238698-85-6 238724-99-7 238725-49-0 238810-74-7 238820-20-7
 238838-99-8 238839-35-5 238840-69-2 238840-70-5 238841-06-0
 238841-39-9 238850-87-8 238877-70-8 238884-89-4 238973-49-4
 239424-70-5 239434-66-3 239931-74-9 240029-22-5 240034-22-4
 240042-44-8 240572-38-7 240575-27-3 240577-62-2 240604-87-9
 240611-39-6 240615-96-7 241118-29-6, DNA (human clone DKFZp434D146
 cDNA) 241118-62-7, DNA (human clone DKFZp434D111 cDNA) 241118-86-5,
 DNA (human clone DKFZp434C131 cDNA) 241119-13-1, DNA (human clone
 DKFZp434D2135 cDNA) 241119-40-4, DNA (human clone DKFZp434G152 cDNA)
 241119-95-9 241119-96-0, DNA (human clone DKFZp434F2021 cDNA)
 241120-02-5, DNA (human clone DKFZp434H018 cDNA) 241120-17-2, DNA (human
 clone DKFZp564C1563 cDNA) 241120-32-1, DNA (human clone DKFZp564N0763
 cDNA) 241234-21-9 241278-63-7 241337-60-0 241369-69-7
 241389-02-6 241557-69-7 241791-30-0, DNA (human clone R-226F19)
 242021-78-9 242294-77-5 242318-76-9 242447-21-8 242686-38-0
 242686-93-7 242790-56-3, GenBank AP000493 242790-64-3, GenBank
 AP000501 242930-66-1 243051-86-7 243054-14-0 243079-53-0
 243112-34-7, DNA (human clone RP5-914N13) 243112-45-0 243115-03-9
 243115-47-1, GenBank AB025580 243270-86-2 243271-17-2 243412-96-6
 243595-73-5 243596-62-5 243606-26-0 243615-27-2 243616-81-1
 243617-27-8 243622-89-1 243623-74-7 243878-20-8 243886-32-0
 244044-87-9, GenBank AW062837 244046-51-3, DNA (human clone RP11-525K18
) 244162-53-6, DNA (human clone R-35609) 244375-19-7 244430-43-1
 244453-67-6 244456-22-2 244555-39-3 244588-59-8 244810-93-3
 244877-38-1, DNA (human clone C-3035D6) 245026-82-8 245034-81-5
 245100-79-2, GenBank A80239 245373-05-1 245696-87-1 245698-81-1,
 GenBank AB018357 245809-55-6 245810-34-8 246053-19-0 246190-39-6
 246190-40-9, GenBank AF191340 246191-26-4, GenBank AF196779
 246431-34-5 246444-19-9 246778-60-9 247315-99-7 247317-04-0
 247552-60-9 247554-43-4 247560-21-0 247560-32-3 247560-34-5
 247560-39-0 247560-63-0 247560-67-4 247560-74-3 247560-79-8
 247560-82-3 247560-83-4 247560-88-9 247561-05-3 247561-12-2
 247561-24-6 247561-27-9 247561-32-6 247561-67-7 247893-56-7
 247897-17-2 247950-72-7 247952-40-5 247958-41-4 247960-13-0
 247960-26-5 247967-32-4 247970-25-8 248403-83-0, GenBank AI064910
 248411-41-8, GenBank AI114692 248414-93-9, GenBank AI133074
 248415-07-8, GenBank AI133088 248416-93-5, GenBank AI133274
 248418-45-3, GenBank AI133426 248425-51-6, DNA (human EST (expressed
 sequence tag))

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding
 tumor-associated proteins, kits, and methods for identification,
 assessment, prevention, and therapy of human prostate cancer)

IT 248571-44-0, GenBank AF192968 248577-96-0, DNA (human clone DKFZp434N181
 cDNA) 248578-22-5, DNA (human clone DKFZp434A2417 cDNA) 248578-42-9

248900-07-4 248900-16-5, DNA (human clone b461k10) 249333-47-9,
 GenBank AW175627 249354-26-5, DNA (human EST (expressed sequence tag))
 249355-67-7, GenBank AW178072 249413-28-3 249414-14-0 249459-84-5
 249461-83-4 249498-80-4 249593-67-7, DNA (human clone RP11-108L7)
 249680-14-6 249767-00-8 249940-35-0 249982-62-5 249997-06-6
 250023-76-8 250024-16-9 250500-06-2, DNA (human clone RP11-483F11)
 250500-33-5, GenBank AF113129 250501-61-2 251037-29-3 251069-35-9,
 DNA (human clone FLB3017 cDNA) 251082-33-4, GenBank AF126021
 251200-76-7 251219-30-4 251234-25-0 251236-65-4 251240-39-8, DNA
 (human clone C-2538G10) 251383-46-7 251386-04-6 251386-21-7
 251386-38-6 251387-64-1 251387-88-9 251401-60-2 251401-95-3
 251419-50-8 251427-69-7 251427-70-0 251517-84-7 251517-95-0, DNA
 (human clone DKFZp434A1114 cDNA) 251518-24-8, DNA (human clone
 DKFZp434A219 cDNA) 251518-30-6, DNA (human clone DKFZp434J039 cDNA)
 251518-57-7, DNA (human clone DKFZp434L0117 cDNA) 251590-28-0
 251591-48-7 251599-72-1 251600-43-8 251601-86-2 251602-55-8
 251602-71-8 251605-37-5 251605-90-0 251606-09-4 251607-49-5
 251608-47-6 251880-71-4, DNA (human clone R-667E4) 252063-91-5,
 GenBank AP000010 252087-62-0 252124-85-9, DNA (human clone FLB9112
 cDNA) 252169-50-9, GenBank AF052504 252172-28-4 252225-22-2
 252225-80-2 252227-30-8 252415-17-1 252437-52-8 252452-42-9
 252483-16-2 252634-75-6, DNA (human isolate Japanese) 252686-12-7,
 GenBank S39329 252693-25-7 252713-01-2 252715-62-1, DNA (human cell
 line TSUPr1 cDNA) 252775-67-0, GenBank S94541 252777-50-7, GenBank
 S60099 252777-72-3, GenBank S60710 252784-46-6, GenBank S64650
 252789-79-0, GenBank S67815 252790-01-5 252790-34-4, GenBank S69022
 252792-65-7 252795-45-2 252804-67-4, GenBank S75755 252807-21-9,
 GenBank S76756 252810-12-1 252819-74-2 252884-23-4, DNA (human clone
 HQ0457 cDNA) 252922-37-5 252923-01-6, DNA (human protein T-P gene plus
 flanks) 252994-24-4 253047-77-7 253047-78-8 253050-40-7
 253065-27-9 253068-47-2 253085-03-9 253248-19-0 253502-00-0
 254122-64-0 254123-73-4 254154-30-8 254154-54-6, DNA (human clone
 DKFZp434K1013 cDNA) 254155-02-7, DNA (human clone DKFZp434H247 cDNA)
 254155-37-8, DNA (human clone DKFZp434A0172 cDNA) 254156-18-8, DNA
 (human clone DKFZp434M0326 cDNA) 254156-20-2, DNA (human clone
 DKFZp434H202 cDNA) 254156-34-8, DNA (human clone DKFZp434M162 cDNA)
 254157-20-5 254158-04-8, DNA (human clone DKFZp434O1519 cDNA)
 254158-12-8, DNA (human clone DKFZp434B1620 cDNA) 254158-28-6, DNA
 (human clone DKFZp434M0519 cDNA) 254158-59-3, DNA (human clone
 DKFZp434H1210 cDNA) 254158-72-0, DNA (human clone DKFZp434G0310 cDNA)
 254159-34-7, DNA (human clone DKFZp434M075 cDNA) 254680-38-1
 254685-73-9 254718-84-8, DNA (human clone CBAJD12 cDNA) 254719-30-7,
 DNA (human clone CBFBBF03 cDNA) 254719-61-4, DNA (human clone CBNACC01
 cDNA) 254719-68-1, DNA (human clone CBNBDE02 cDNA) 254720-07-5
 254720-34-8 254720-40-6 254720-42-8 254720-60-0 254720-79-1
 254723-04-1, GenBank AF199596 254844-83-2, GenBank AF052059
 254942-71-7 254951-19-4 255089-94-2, GenBank AW360965 255090-30-3,
 GenBank AW361001 255091-32-8, GenBank AW361103 255097-40-6, GenBank
 AW361711 255109-63-8, GenBank AW362982 255115-41-4, GenBank AW363561
 255127-15-2, GenBank AW364827 255128-31-5, GenBank AW364748
 255130-64-4, GenBank AW365085 255138-31-9, GenBank AW365852
 255161-94-5, GenBank AW368293 255163-60-1, GenBank AW368461
 255232-91-8, GenBank AW375589 255246-84-5, GenBank AW376917
 255275-58-2, GenBank AW379827 255289-57-7, GenBank AW381227
 255289-78-2, GenBank AW381248 255312-34-6, GenBank AW383599
 255318-02-6, GenBank AW384101 255325-29-2, GenBank AW384915
 255328-05-3, GenBank AW385192 255329-35-2, GenBank AW385322
 255329-41-0, GenBank AW385328 255349-79-2 255349-81-6, DNA (human
 clone 21B42C4) 255357-47-2 255422-98-1, GenBank AW388939
 255456-84-9, GenBank AW392421 255463-58-2, GenBank AW393095
 255634-49-2 255636-70-5 255642-10-5 255656-65-6 255670-97-4
 255687-39-9 255744-84-4 255746-33-9 255935-29-6 255937-81-6
 255942-20-2 255942-26-8 256186-05-7, DNA (human clone R-356A6)
 256194-09-9 256207-50-8 256212-95-0 256213-27-1, GenBank AF220417
 256315-84-1, DNA (human clone B812P3) 256316-19-5, DNA (human protein
 kinase MINK-1 cDNA) 256354-01-5 256355-88-1 256357-37-6

256615-02-8, GenBank AF224669 256622-28-3, DNA (human clone COL00683 cDNA) 256623-33-3, DNA (human clone COL08740 cDNA) 256623-53-7, DNA (human clone COL09863 cDNA) 256623-93-5, DNA (human clone COLF2014 cDNA) 256624-00-7, DNA (human clone COLF4858 cDNA) 256624-32-5 256624-56-3 256624-58-5 256624-70-1 256624-73-4 256625-29-3 256625-33-9 256625-43-1 256625-45-3 256625-70-4 256625-79-3 256626-08-1 256626-46-7 256626-70-7 256626-77-4 256627-15-3 256627-16-4 256627-30-2 256627-32-4 256627-67-5 256628-02-1 256628-23-6 256628-36-1 256628-41-8, DNA (human clone KAIA804 cDNA) 256628-86-1, DNA (human clone KAIA1223 cDNA) 256629-11-5 256629-12-6 256629-17-1 256629-29-5 256629-31-9 256629-71-7, DNA (human clone COL01292 cDNA) 256630-31-6, DNA (human clone ADKA01414 cDNA) 256899-87-3, GenBank AF198444 256901-48-1, Protein (human clone HEMBA1002125) 256901-84-5, Protein (human clone HEMBA1002863) 256901-92-5, Protein (human clone HEMBA1002997) 256902-92-8, Protein (human clone HEMBB1000119) 256903-14-7, Protein (human clone HEMBB1000763) 256903-25-0, Protein (human clone HEMBB1000975) 256903-86-3, Protein (human clone NT2RM2000522) 256903-90-9, Protein (human clone NT2RM2000577) 256904-64-0, Protein (human clone NT2RM4000395) 256904-66-2, Protein (human clone NT2RM4000457) 256904-71-9, Protein (human clone NT2RM4000520)

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

IT 256904-79-7, Protein (human clone NT2RP1000101) 256904-83-3, Protein (human clone NT2RP1000163) 256904-90-2, Protein (human clone NT2RP1000333) 256904-94-6, Protein (human clone NT2RP1000416) 256905-15-4, Protein (human clone NT2RP1000959) 256905-32-5, Protein (human clone NT2RP2000007) 256905-46-1, Protein (human clone NT2RP2000153) 256905-65-4, Protein (human clone NT2RP2000412) 256905-66-5, Protein (human clone NT2RP2000414) 256905-68-7, Protein (human clone NT2RP2000438) 256905-89-2, Protein (human clone NT2RP2000892) 256905-94-9, Protein (human clone NT2RP2000985) 256905-97-2 256906-12-4, Protein (human clone NT2RP2001969) 256906-38-4, Protein (human clone NT2RP2003265) 256906-80-6 256906-94-2, Protein (human clone NT2RP2005622) 256907-10-5, Protein (human clone NT2RP2005773) 256907-23-0, Protein (human clone NT2RP2006071) 256907-41-2 256907-67-2 256908-03-9, Protein (human clone NT2RP3001472) 256908-15-3, Protein (human clone NT2RP3004466) 256908-29-9, Protein (human clone NT2RP4000111) 256908-38-0, Protein (human clone NT2RP4000290) 256908-77-7 256908-92-6 256908-93-7, Protein (human clone NT2RP4001138) 256909-02-1, Protein (human clone NT2RP4001274) 256909-16-7, Protein (human clone NT2RP4001498) 256909-18-9 256909-27-0, Protein (human clone NT2RP4001575) 256909-43-0, Protein (human clone NT2RP4001896) 256909-77-0, Protein (human clone OVARC1000209) 256910-31-3 256910-54-0 256911-41-8 256911-64-5 256912-21-7 256912-53-5 256912-62-6 256912-96-6 256913-38-9 256913-67-4 256914-17-7 257145-66-7 257586-12-2 257586-14-4 257586-36-0 257586-45-1 257965-49-4 257971-90-7 257977-73-4 257978-04-4 257978-21-5 257978-32-8 257978-52-2 258090-56-1, GenBank AW498895 258250-91-8 258440-09-4 258491-40-6, GenBank AF227218 259279-54-4 259322-52-6, GenBank AJ275986 259459-41-1 259477-85-5 259478-13-2 259478-18-7 259478-31-4 259478-45-0 259478-53-0 259478-54-1 259478-67-6 259478-71-2 259478-77-8 259478-89-2 259479-14-6 259479-17-9 259479-34-0 259565-51-0, GenBank AW578462 259566-71-7, GenBank AW578582 259605-86-2, GenBank AW582604 259694-31-0, GenBank AW583629 267208-83-3 325444-55-1 355841-13-3, GenBank AB007510 362010-09-1, GenBank J59253 362010-10-4, GenBank P00809 362010-11-5, GenBank P00884

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; differentially expressed nucleic acids encoding tumor-associated proteins, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer)

L70 ANSWER 11 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:618207 HCAPLUS
 DN 135:190398
 ED Entered STN: 24 Aug 2001
 TI Nucleic acid markers useful for the identification, assessment, prevention
 and therapy of human cancers
 IN Roth, Frederick P.; Van Huffel, Christophe; White, James V.; Shyjan,
 Andrew W.
 PA Millennium Predictive Medicine, Inc., USA
 SO PCT Int. Appl., 126 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12Q001-68
 CC 1-6 (Pharmacology)

Section cross-reference(s): 3, 13, 14

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|--------------|
| PI | WO 2001061048 | A2 | 20010823 | WO 2001-US5263 | 20010216 <-- |
| | WO 2001061048 | A3 | 20030123 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2002051978 | A1 | 20020502 | US 2001-788100 | 20010216 <-- |
| PRAI | US 2000-183312P | P | 20000217 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES | |
|---------------|-------|------------------------------------|-----|
| WO 2001061048 | ICM | C12Q001-68 | |
| WO 2001061048 | ECLA | C12Q001/68M6B; G01N033/574 | <-- |
| US 2002051978 | NCL | 435/006.000; 435/007.230 | |
| | ECLA | C12Q001/68M6B; G01N033/574 | <-- |

AB The present invention is directed to the identification of markers that can be used to determine the sensitivity of cancer cells to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. Nucleic acid arrays were used to determine the level of expression of sequences (genes) found in 60 different solid tumor cancer cell lines selected from the NCI 60 cancer cell line series. Expression anal. was used to identify markers associated with sensitivity to certain chemotherapeutic agents.

ST tumor assocd protein cDNA sequence human; cancer marker nucleic acid diagnosis therapy

IT Diagnosis

(cancer; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)

IT Antitumor agents

DNA sequences

Drug screening

Immunoassay

Protein sequences

Tumor markers

cDNA sequences

(nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)

IT Antibodies

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(nucleic acid markers useful for the identification, assessment,

- prevention and therapy of human cancers)
- IT Proteins, specific or class
 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (tumor-associated; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)
- IT 81031-47-2, Histone H 4 (*Xenopus laevis*) 92480-15-4, Blood platelet-derived growth factor (human clone pSM-1 precursor reduced)
 94218-75-4, Interleukin 2 (human clone pTG853 protein moiety reduced)
 97599-20-7, Interleukin 1 β (human clone pIL-1-14 precursor reduced)
 98616-16-1, Protein CRBP (human clone 1 precursor reduced) 99149-50-5, Lymphotoxin (human clone λ XB13 precursor protein moiety)
 100984-77-8, Colony-stimulating factor (human clone pBRG-4 precursor protein moiety reduced) 102055-68-5 107121-03-9, Glycoprotein (human clone λ HDR10/ λ HDR5/ λ HDR104 gene mdrl protein moiety reduced) 107217-06-1, Protein (human clone pLY30 gene lyn reduced)
 110734-64-0, Lipocortin II (cattle small subunit reduced) 112023-99-1 112024-77-8, Humoral hypercalcemic factor (human clone BRF.61 precursor)
 112972-84-6 113690-62-3, Protein (human mitochondria-encoded hinge precursor reduced) 114514-06-6, Protein (mouse clone F9-104/F9-12/C3H-82 guanine nucleotide-binding gene ypt1 reduced) 114767-57-6 115190-24-4, Protein MRP8 (human clone λ MRP8-3) 116411-80-4, RNA formation factor AP 1 (human clone hcJ2/hcJ1 gene c-jun reduced) 116765-76-5, Protein (human clone 9 gene rhoC reduced) 117312-64-8, Thymosin β 10 (human precursor) 117871-30-4 117910-55-1 119331-85-0, Glycoprotein IGF-BP I (human clone p19 precursor protein moiety reduced) 120796-71-6, Troponin C (human slow skeletal muscle clone TC1 reduced) 121939-61-5, Phosphoprotein p 53 (human clone RP7/RP3 protein moiety reduced)
 122544-35-8, RNA formation factor AP 2 (human clone AP2-9 reduced)
 123515-87-7, Phospholipase A2 (human clone λ SPLA2cDNA-4 precursor reduced) 124586-56-7 125008-34-6 126236-73-5, Glycophosphoprotein P (human clone pSVB1/pSVM113/pSVC6/pSVA4/pSVS13/pSVTH21 gene mdrl protein moiety reduced) 126880-89-5, Protein SNAP 25 (mouse clone p8.52/p8.51 synaptosome-associated reduced) 127497-35-2, Protein nck (human clone drop6 reduced) 128338-85-2, Antigen HLA-DR-BON (human clone HLA-DRB1*BON β -chain precursor protein moiety reduced) 129039-74-3
 129818-36-6, Integrin (human clone 5.1 β 5-subunit precursor protein moiety reduced) 130067-70-8, Lamin B (human clone pLAM-2 protein moiety reduced) 130704-02-8, Phosphoprotein ABP (human clone 1/4/10/5/3 280-kilodalton subunit protein moiety reduced) 133105-90-5, Protein HSP 27 (human clone 16-7) 133135-21-4, Protein (human clone pcD2h19 gene XPAC reduced) 133423-89-9, Cofilin (human placenta protein moiety reduced) 133925-44-7, Antigen CD 53 (human protein moiety reduced)
 133925-94-7, Protein S 3 (human clone p54-2 ribosome reduced)
 134116-73-7, Laminin (human clone C43/T3/E1/E61/D6/F8/E34/J4 B2-subunit precursor protein moiety reduced) 135527-82-1, Protein ARF 6 (human clone 65S/80 reduced) 135930-84-6 136253-20-8, Protein (human norepinephrine-transporting reduced) 141176-86-5, Protein G (human clone 19A/5B/22H guanine nucleotide-binding α 16-subunit reduced)
 141513-90-8, Protein S 18 (rat clone pRS18-1 ribosome) 143068-03-5
 143295-71-0 143298-35-5 144131-77-1, Moesin (human clone UIII reduced)
 144592-22-3, Antigen TA 4 (human clone pcSCC-2/ λ SCC-1)
 144713-90-6, Calreticulin (human clone Ro38-1 precursor protein moiety reduced) 144905-66-8, RNA formation factor TFIIE (human clone p2EYC α -subunit reduced) 145111-28-0, Sialoglycoprotein ZAG (human clone ZN133 precursor protein moiety reduced) 146150-83-6, RNA formation factor (human gene PBX2 reduced) 146151-12-4, Protein P 2 (human clone A2h myelin basic precursor reduced) 146590-16-1, Receptor (human clone 8rr.20 reduced) 146833-80-9, Calmodulin (rat clone NGB1) 146990-20-7, RNA formation factor Id 2 (human clone pgId-9 reduced) 147279-30-9, RNA formation factor Id (human gene HLH1R21 reduced) 147338-66-7, Lectin L 14 (human gene LGALS2 lactose-binding isoform II subunit reduced)
 147415-79-0 147416-17-9 147571-82-2 147855-41-2, RNA formation factor PSF (human clone A isoform reduced) 148348-50-9 148412-71-9, Protein MCP (human U937 cell macrophage capping deblocked reduced)

148591-61-1, Keratin 2 (human clone pEK2 reduced) 148711-08-4, Laminin (human clone L52/L7/L15/L26 B2t-subunit 1111-amino acid isoform precursor reduced) 148846-85-9 148883-01-6 148883-58-3, Protein (human clone pag gene pag proliferation-associated reduced) 148996-73-0, Protein (human clone pART4 actin-related reduced) 149224-72-6 149407-69-2 150226-92-9, Protein (human clone pAS2 gene CIP1 Cdk-interacting reduced) 150287-67-5 150790-79-7, Protein (human clone IT10C3 tetracycline transporter-like reduced) 150875-21-1 151184-61-1 151185-67-0, Protein OSF 2 (human clone pKOT133 osteoblast-specific precursor reduced) 151185-93-2, Protein p 48 (human clone RbAp48 retinoblastoma-binding reduced) 151187-32-5, Glycoprotein gp 39 (human precursor reduced) 151688-76-5, Protein P1.B (human secretory precursor reduced) 152445-88-0, Drebrin E (human clone gDbh13 reduced) 153421-80-8, Protein (human gene CELL carboxyl esterase-like reduced) 153551-11-2 154610-41-0 154768-88-4 154947-97-4 155578-13-5 156287-52-4 156288-41-4 156289-14-4 156533-34-5 156716-45-9 157298-15-2 157909-59-6 158652-74-5 158935-67-2 159521-93-4 159868-92-5 160339-92-4 160405-20-9 160405-24-3 160576-52-3 161736-58-9, Protein (human 233-amino acid) 163480-85-1 164639-46-7, Protein (human KG-1 cell 462-amino acid) 164639-51-4 165944-83-2 166027-32-3, Calcizzarin (human clone 0133) 166872-22-6 169239-28-5 169535-11-9 169936-62-3 170084-46-5 170346-11-9 170559-28-1 170560-36-8 171041-31-9 171404-08-3 171546-45-5 172279-45-7 172313-88-1 172346-52-0 172452-60-7 172728-17-5 172728-51-7 173014-66-9, Protein (human gene DD96) 173245-88-0 173330-63-7 173833-93-7 173968-89-3 174395-38-1 174722-65-7 175864-30-9 175960-13-1, Protein (human clone SFA-1 gene SFA-1) 176025-28-8 176836-08-1 177403-71-3 177530-30-2, Nexin SNX 1 (human reduced) 177699-09-1 178304-71-7 178360-55-9 179005-92-6, Protein (human cell KG-1 gene KIAA0196) 179158-58-8 180190-22-1 183213-21-0, Semaphorin (human gene CD100 precursor) 183816-66-2, Glycoprotein M6 (human clone GEN-409C07) 184922-59-6 185403-55-8 185530-01-2 185767-10-6 186325-05-3 186361-81-9 188040-72-4 188450-58-0 188551-47-5 188856-92-0 188900-53-0 189122-06-3 189642-72-6, Nuclear factor I (human isoform B3) 189704-53-8 190795-15-4, Importin- α (human gene QIP1 reduced) 193907-81-2 194499-92-8 194616-43-8 196524-09-1 201099-55-0 202150-49-0 210977-30-3 213259-99-5 219482-54-9 219577-85-2 220128-70-1 231617-72-4 253145-55-0 253145-56-1 296817-77-1 301457-16-9, Protein S 100 (human heart isoform A2) 301457-61-4 301549-45-1 333802-92-9 336908-52-2 349711-18-8, Dynactin (human C-terminal fragment) 355485-60-8, Autoantigen p542 (human clone p542) 355485-61-9 355485-62-0, Vinculin (human gene VCL) 355485-66-4 355485-67-5 355485-74-4 355485-79-9 355485-82-4, Tropomyosin (human WI-38 cell isoform) 355485-83-5 355485-84-6, Villin (human) 355485-85-7 355485-86-8 355485-87-9 355485-88-0 355485-89-1 355485-90-4 355485-91-5 355485-92-6 355485-93-7 355485-94-8 355485-95-9, Protein p120 (human KYN-1 cell) 355485-96-0, Protein (human clone 169 gene XE169) 355485-97-1 355485-98-2, Protein (human KG-1 cell gene HA1652) 355486-00-9, Host cell factor (human gene HCF-1) 355486-04-3, Protein (human KG-1 cell gene ha3611) 355486-05-4, Protein (human KG-1 cell gene KIAA0092) 355486-06-5, Protein (human clone apM2 gene apM2) 355486-12-3, Dopamine D4 receptor (human) 355486-13-4 355486-14-5 355486-15-6 355486-16-7 355486-17-8, Epoxidase, squalene (human clone 39H11) 355486-18-9, Protein (human KG-1 cell gene KIAA0141) 355486-19-0, Protein (human gene KIAA0223) 355486-21-4 355486-22-5 355486-25-8 355486-26-9 355486-27-0, Protein R31240-2 (human 5HL2-B cell) 355486-28-1

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)

IT 355486-29-2 355486-30-5 355486-31-6 355804-48-7 355804-51-2
355804-54-5 355804-55-6 355884-52-5 355884-62-7

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,

unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)

IT 50-44-2, 6-Mercaptopurine 51-21-8 55-86-7, Nitrogen mustard 55-98-1, Busulfan 59-05-2, Methotrexate 127-07-1, Hydroxyurea 143-67-9, Vinblastine sulfate 147-94-4, AraC 148-82-3, Melphalan 154-93-8, BCNU 305-03-3, Chlorambucil 1605-68-1D, Taxane, compds. 2068-78-2, Vincristine sulfate 7440-06-4D, Platinum, compds., biological studies 11056-06-7, Bleomycin 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 29767-20-2, Teniposide 33069-62-4, Taxol 33419-42-0, Etoposide 41575-94-4, Carboplatin 53910-25-1 65271-80-9, Mitoxantrone 123948-87-8, Topotecan

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)

IT 123515-33-3 134946-10-4, GenBank M25296 135113-71-2, GenBank D00860 135527-45-6, GenBank M57763 135889-42-8, GenBank M63167 136252-70-5, GenBank M65105 137700-53-9, GenBank M38591 137925-72-5, DNA (human proteinase C5-subunit cDNA plus flanks) 139803-20-6, GenBank J05017 139808-70-1, GenBank D00102 139808-72-3 139808-82-5, GenBank M29447 139825-36-8, GenBank M22898 139852-98-5, GenBank M59216 139858-91-6, GenBank M80333 140026-30-8 140027-50-5, GenBank M37033 140027-95-8 140028-12-2, GenBank X07438 140028-22-4 140029-58-9, GenBank X03656 140031-65-8, GenBank J04474 140032-26-4, GenBank M19045 140033-61-0, GenBank J02923 140034-69-1 140036-63-1, GenBank X12901 140061-68-3, GenBank M60756 140064-67-1, GenBank M63888 140072-67-9, GenBank X52730 140079-21-6, DNA (human protein nck cDNA plus flanks) 140083-83-6, GenBank M63904 140087-41-8, GenBank M64445 140098-52-8, GenBank X59842 140276-18-2, DNA (human calmodulin cDNA plus flanks) 140279-54-5, GenBank J05459 140281-70-5, GenBank M22005 140282-11-7, GenBank J04111 140282-39-9, GenBank M55210 140283-84-7, GenBank M21005 140284-32-8, GenBank M29927 140285-61-6, GenBank M24351 140285-76-3, GenBank M11433 140306-05-4, GenBank M28209 140321-18-2, GenBank M33600 140323-40-6, GenBank X55715 140327-22-6, GenBank X53002 140332-12-3, DNA (human HPB-MLT cell clone 4.10 integrin $\alpha 4$ cDNA plus flanks) 140338-28-9, GenBank M74093 140347-92-8, GenBank M69066 140356-91-8, GenBank X59766 140358-35-6, GenBank M82882 140505-48-2, GenBank M21904 140509-47-3 140576-33-6, GenBank X56411 140740-31-4, GenBank K02765 140744-82-7, GenBank X04500 140745-77-3, GenBank Y00062 140746-15-2 140747-54-2, GenBank M22092 140748-64-7, GenBank M27903 140752-26-7, GenBank M37984 140752-50-7 140794-36-1, GenBank X53416 140801-95-2, GenBank X53586 140806-34-4, GenBank M74587 140824-28-8, GenBank M87860 140959-95-1, GenBank M21934 141003-67-0, GenBank X63468 141878-47-9, GenBank M94345 142318-65-8, GenBank X56494 142788-08-7, DNA (human lamin B cDNA plus flanks) 143386-43-0, GenBank M99061 143695-04-9, GenBank Z14978 143990-12-9, GenBank M98539 144592-20-1, GenBank S66896 145258-24-8, GenBank M88279 145280-65-5, GenBank Z15009 145280-70-2, GenBank X69150 145710-88-9, GenBank L07615 145975-85-5, GenBank D12775 146193-98-8, GenBank L10343 147270-81-3, GenBank X69111 147401-39-6, GenBank X68242 147855-39-8, GenBank X70944 148107-95-3, GenBank X59405 148142-53-4, GenBank D10924 148426-48-6, GenBank D14533 148450-48-0 148450-53-7, GenBank D13641 148450-58-2, GenBank D13643 148450-69-5 148636-88-8, GenBank X71129 148664-96-4, GenBank X67951 148784-57-0, GenBank X68830 148803-04-7, GenBank X70070 149483-70-5, GenBank D12620 150003-52-4, GenBank L11669 150052-36-1, GenBank L10717 150091-13-7, GenBank D13720 150220-18-1, GenBank D14446 150354-87-3, GenBank X71973 150472-78-9, GenBank X74262 150472-84-7, GenBank D13665 150733-35-0, GenBank L19760 151522-34-8, GenBank L25081 151548-79-7, GenBank L14813 151549-93-8, GenBank L25616 151609-93-7 151634-95-6, GenBank D21267 152078-80-3, GenBank D13413 152079-54-4, GenBank Z23090 152283-49-3 152439-56-0 153377-77-6, GenBank D17530 153518-48-0, GenBank L25270 154245-84-8, GenBank D13891 154245-85-9, GenBank D25328 154528-98-0, GenBank Z29064 154862-18-7, GenBank X74614 155119-04-3, GenBank X77197 155153-67-6, GenBank D29992 155283-52-6, GenBank D16181 155462-23-0 155570-90-4, GenBank U09582 155748-20-2, GenBank U04636

156223-93-7, GenBank L27071 156552-87-3 156552-95-3 156827-71-3,
 GenBank D32129 156850-12-3, GenBank U11292 157779-77-6, GenBank X79510
 158026-00-7, GenBank X79198 158643-78-8, GenBank U09178 158764-16-0
 158827-27-1, GenBank D38583 158929-86-3, GenBank U12465 158929-88-5,
 GenBank U13991 159200-55-2, GenBank D26599 159317-28-9, GenBank X81422
 160074-18-0, GenBank U10439 160075-39-8 160075-43-4 160183-38-0,
 GenBank X79857 161273-32-1, GenBank S54005 162158-69-2, GenBank Z46389
 162487-92-5, GenBank L38696 162620-62-4, GenBank T40653 162626-73-5,
 GenBank T46888 162768-00-5, GenBank T49423 162770-24-3, GenBank T49637
 162798-51-8, GenBank T50077 162802-40-6, GenBank T50500 162834-58-4,
 GenBank T51240 162837-38-9, GenBank T51571 162837-41-4, GenBank T51574
 162838-20-2, GenBank T51613 162842-26-4, GenBank T52015 162864-44-0,
 GenBank T52624 162905-90-0, GenBank T53396 162945-29-1, GenBank T54341
 163028-53-3, GenBank T56750 163053-33-6, GenBank T57630 163056-11-9,
 GenBank T57882 163144-05-6, GenBank T59939 163196-66-5, GenBank T61632
 163201-06-7, GenBank T62067 163373-91-9, GenBank T62878 163378-51-6,
 GenBank Z29093 163607-12-3, GenBank T65562 163743-27-9, GenBank T67689
 163746-24-5, GenBank T67986 163826-56-0, GenBank T70595 163907-20-8,
 GenBank T71001 163939-98-8, GenBank T71764 164000-43-5, GenBank R06716
 164133-73-7, GenBank R00285 164141-99-5, GenBank R01157 164198-83-8,
 GenBank T99380 164275-73-4, GenBank R07164 164280-82-4, GenBank R07708
 164312-34-9, GenBank R09532 164478-52-8, GenBank L40357 164499-00-7,
 GenBank T79849 164608-87-1, GenBank L40557 164773-98-2, GenBank T87873
 164807-92-5, GenBank T89676 164813-96-1, GenBank T90280 164835-51-2,
 GenBank T92451 164842-51-7, GenBank T93094 164874-34-4, GenBank T96325
 164874-62-8, GenBank T96364 164879-97-4, GenBank T96942 164883-17-4,
 GenBank T93284 164901-45-5, GenBank T95052 164952-59-4, GenBank U21049
 164952-68-5, GenBank U21909 164953-09-7, GenBank D49547 164954-16-9,
 GenBank L40904 165024-18-0, GenBank R15814 165024-78-2, GenBank R15876
 165081-26-5, GenBank R16659 165144-42-3, GenBank U17886 165213-53-6,
 GenBank R22197 165360-59-8, GenBank R28281 165425-44-5, GenBank R32120
 165438-88-0, GenBank R33465 165563-72-4, GenBank R39044 165643-01-6,
 GenBank R43023 165654-41-1, GenBank R44057 165757-30-2,
 GenBank D37965 165768-16-1, GenBank R47985 165781-23-7, GenBank R49416
 165792-06-3, GenBank R50499 165834-31-1, GenBank R52117 165834-65-1,
 GenBank R52151 165837-91-2, GenBank R52477 165919-12-0, GenBank R56869
 165942-35-8, GenBank R59181 165971-42-6, GenBank R59617 165977-68-4,
 GenBank R60181 165979-44-2, GenBank R60357 166210-18-0, GenBank R72819
 166210-45-3, GenBank R72846 166212-51-7, GenBank R73052 166357-88-6,
 GenBank Z24727 166419-16-5, GenBank R80612 166513-61-7, GenBank H01408
 166553-77-1, GenBank H02031 166556-04-3, GenBank H02258 166564-07-4,
 GenBank H03061 166567-88-0, GenBank H03442

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
 study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; nucleic acid markers useful for the
 identification, assessment, prevention and therapy of human
 cancers)

IT 166576-57-4, GenBank H04311 166608-99-7, GenBank H05285 166609-35-4,
 GenBank H05300 166612-72-2, GenBank H05672 166633-88-1, GenBank H08144
 166634-00-0, GenBank H08156 166636-37-9, GenBank H08393 166638-57-9,
 GenBank H08613 166639-95-8, GenBank H08751 166647-86-5, GenBank H09542
 166652-92-2, GenBank H10048 166685-69-4, GenBank H11347 166703-55-5,
 GenBank H13133 166704-16-1, GenBank H13194 166723-32-6, GenBank H15167
 166846-15-7, GenBank D45370 166866-65-5, GenBank H17409 166872-20-4,
 GenBank U33052 167128-26-9, GenBank H44953 167133-20-2, GenBank H45474
 167196-75-0, GenBank H48100 167229-77-8, GenBank D44497 167347-74-2,
 GenBank H20709 167431-27-8, GenBank H21532 167442-83-3, GenBank H22688
 167444-36-2, GenBank H22821 167446-81-3, GenBank H23079 167451-38-9,
 GenBank H23544 167458-62-0, GenBank H24250 167459-47-4, GenBank H24310
 167518-02-7, GenBank H26185 167527-84-6, GenBank H27202 167573-16-2,
 GenBank H28131 167665-32-9, GenBank H38231 167714-11-6, GenBank L40395
 168310-20-1, GenBank U25657 168662-18-8, GenBank U24704 168857-78-1,
 GenBank R98454 168933-24-2, GenBank H49870 168935-68-0, GenBank H50114
 168993-68-8, GenBank H52992 168996-46-1, GenBank H53270 169016-97-1,
 GenBank H54676 169023-26-1, GenBank U31383 169078-81-3, GenBank H55933

169424-67-3, GenBank H61452 169434-13-3, GenBank H62365 169489-04-7,
 GenBank H63361 169645-70-9, GenBank H67901 169645-98-1, GenBank H67849
 169715-41-7, GenBank U22312 169717-06-0, GenBank U37689 169725-04-6,
 GenBank L38932 169791-77-9, GenBank Z48923 170184-14-2, GenBank H70924
 170189-78-3, GenBank H71488 170257-51-9, GenBank H74007 170319-40-1,
 GenBank X91257 170402-96-7, GenBank X87237 170405-42-2, GenBank H77302
 170479-75-1, GenBank H79341 170525-77-6, GenBank H80342 170559-29-2,
 GenBank S78798 170592-05-9, GenBank D43682 170611-47-9, GenBank U38980
 170896-92-1, GenBank D49490 171445-82-2, GenBank D50312 171449-34-6,
 GenBank X86691 171845-29-7 172012-63-4, GenBank X89109 172047-21-1,
 GenBank D49489 172177-77-4, GenBank U30185 172713-23-4, GenBank U33818
 172866-48-7, GenBank X95325 173005-07-7, GenBank U44755 173487-92-8,
 GenBank U46751 174054-33-2, GenBank U23430 174058-47-0, GenBank X90840
 174127-98-1, GenBank D50810 174170-20-8, GenBank D50495 174253-22-6,
 GenBank U43753 174440-90-5, GenBank U47054 174441-98-6 174442-00-3
 175111-69-0, GenBank U45285 175958-96-0, GenBank D29963 176145-76-9,
 GenBank U53225 176365-16-5, GenBank D78129 176936-68-8, GenBank D78014
 177013-59-1 178197-91-6, GenBank D84424 178294-33-2 178300-52-2,
 GenBank X98178 178664-19-2, GenBank X98801 180245-70-9, GenBank D86976
 180488-53-3, GenBank D87258 180568-13-2, GenBank U62801 181110-09-8,
 GenBank D79205 181254-91-1, GenBank Y08134 181613-87-6, GenBank Z80787
 183049-81-2, GenBank D49958 183080-26-4, GenBank U60800 183100-51-8,
 GenBank D87462 183100-53-0, GenBank D87464 183264-99-5, GenBank D63160
 183265-12-5, GenBank D88146 183265-93-2, GenBank AC000061 184343-22-4,
 GenBank X97267 184382-28-3, GenBank D89667 184974-98-9, GenBank D87438
 185083-24-3, GenBank Y08265 185655-99-6, GenBank D86640 185924-64-5,
 GenBank U51586 185928-32-9, GenBank U78525 186070-22-4, GenBank D83017
 186363-59-7, GenBank U73843 186445-46-5, GenBank U74612 186786-31-2,
 GenBank Y09561 187005-83-0, GenBank D86043 187821-66-5, GenBank
 AD000092 188221-38-7, GenBank U70862 188275-31-2, GenBank Y10871
 188288-23-5, GenBank X98507 189123-41-9, GenBank U73379 189465-14-3,
 GenBank AB002533 189775-65-3, GenBank AB003177 189923-62-4, GenBank
 Y07755 190180-33-7, GenBank AC002073 190496-22-1, GenBank AB003698
 190743-43-2, GenBank Y08374 194004-77-8, GenBank X99728 194711-70-1,
 GenBank AF002020 195016-31-0 195425-74-2, GenBank AF012270
 195792-59-7, GenBank AC002486 196481-29-5, GenBank AJ001487
 252699-69-7, GenBank S58733 252807-36-6, GenBank S76942 252809-26-0,
 GenBank S77356

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
 study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; nucleic acid markers useful for the
 identification, assessment, prevention and therapy of human cancers)

IT 260242-78-2, 1: PN: WO0011218 PAGE: 38 unclaimed DNA

RL: PRP (Properties)

(unclaimed sequence; nucleic acid markers useful for the
 identification, assessment, prevention and therapy of human cancers)

IT 92480-15-4, Blood platelet-derived growth factor (human clone
 pSM-1 precursor reduced) 165944-83-2 355485-87-9

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
 unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
 study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; nucleic acid markers useful for the
 identification, assessment, prevention and therapy of human
 cancers)

RN 92480-15-4 HCAPLUS

CN Blood platelet-derived growth factor (human clone pSM-1 precursor reduced)
 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 165944-83-2 HCAPLUS

CN Protein (human tumor suppressor gene PRLTS) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355485-87-9 HCAPLUS

CN Complement C 3 (human clone pC3.[11,49,59] gene C3) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 140028-22-4 140740-31-4, GenBank K02765
165757-30-2, GenBank D37965

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(nucleotide sequence; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)

RN 140028-22-4 HCAPLUS

CN DNA (human clone pSM-1 gene c-sis platelet-derived growth factor cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 140740-31-4 HCAPLUS

CN DNA (human clone WO0118542_SEQID_2492 ovary tumor-associated protein cDNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 165757-30-2 HCAPLUS

CN DNA (human blood platelet-derived growth factor β -like tumor suppressor protein cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 12 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:489619 HCAPLUS

DN 135:71268

ED Entered STN: 06 Jul 2001

TI Use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation

IN Orum, Henrik; Koch, Troel; Skouv, Jan; Jakobsen, Mogen Havsteen

PA Exiqon A/S, Den.

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N015-11

ICS A61K031-712; C07H021-00; A61P029-00; A61P035-00

CC 1-6 (Pharmacology)

Section cross-reference(s): 3

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|--------------|
| PI | WO 2001048190 | A2 | 20010705 | WO 2000-IB2043 | 20001222 <-- |
| | WO 2001048190 | A3 | 20020510 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2395320 | AA | 20010705 | CA 2000-2395320 | 20001222 <-- |
| | US 2002068709 | A1 | 20020606 | US 2000-747913 | 20001222 <-- |
| | EP 1240322 | A2 | 20020918 | EP 2000-990866 | 20001222 <-- |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | JP 2003524637 | T2 | 20030819 | JP 2001-548703 | 20001222 <-- |
| PRAI | US 1999-171873P | P | 19991223 | <-- | |
| | WO 2000-IB2043 | W | 20001222 | <-- | |

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

```

-----
WO 2001048190   ICM   C12N015-11
                  ICS   A61K031-712; C07H021-00; A61P029-00; A61P035-00
WO 2001048190   ECLA   C07H021/00C4; C12N015/11B; C12N015/11B7      <--
US 2002068709   NCL    514/044.000; 435/455.000
                  ECLA   C07H021/00C4; C12N015/11B; C12N015/11B7      <--
AB   The invention relates to therapeutic applications of LNA-modified
      oligonucleotides. In particular, the invention provides methods for
      treatment of undesired cell growth as well as treatment of inflammatory
      related diseases and disorders. Preferably, administration of an
      LNA-modified oligonucleotide modulates expression of a targeted gene
      associated with the undesired cell growth or an inflammatory related disease
      or disorder. Thus, the peritoneal cells of rats injected i.p. with
      LNA-containing oligonucleotides directed to FcεR1α mRNA produced
      less FcεR1α and released less histamine than did rats given
      unmodified oligonucleotides.
ST   locked nucleic acid oligonucleotide antitumor antiinflammatory
IT   Antigens
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (4F2 antigen, gene for, inhibition of expression of; use of locked
          nucleic acid-modified oligonucleotides for treatment of cancer and
          inflammation)
IT   Platelet-derived growth factors
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (A chain, gene for, inhibition of expression of; use of locked nucleic
          acid-modified oligonucleotides for treatment of cancer and
          inflammation)
IT   Immunoglobulins
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (A1, gene for, modulation of expression of; use of locked nucleic
          acid-modified oligonucleotides for treatment of cancer and
          inflammation)
IT   Immunoglobulins
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (A2, gene for, modulation of expression of; use of locked nucleic
          acid-modified oligonucleotides for treatment of cancer and
          inflammation)
IT   Platelet-derived growth factors
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (AA, gene for, inhibition of expression of; use of locked nucleic
          acid-modified oligonucleotides for treatment of cancer and
          inflammation)
IT   Platelet-derived growth factors
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (AB, gene for, inhibition of expression of; use of locked nucleic
          acid-modified oligonucleotides for treatment of cancer and
          inflammation)
IT   Chemokines
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (ABCD-1, gene for, inhibition of expression of; use of locked nucleic
          acid-modified oligonucleotides for treatment of cancer and
          inflammation)
IT   Gene, animal
      RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
          BSU (Biological study, unclassified); BIOL (Biological study); PROC
          (Process)
          (ABL1, inhibition of expression of; use of locked nucleic acid-modified
          oligonucleotides for treatment of cancer and inflammation)
IT   Gene, animal
      RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
          BSU (Biological study, unclassified); BIOL (Biological study); PROC
          (Process)
          (ABL2, inhibition of expression of; use of locked nucleic acid-modified
          oligonucleotides for treatment of cancer and inflammation)
IT   Gene, animal
      RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

```

BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ABR, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ADAM11, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ADAMTS-1, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(AKT1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(AKT2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AMAC-1, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(APC, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ARAF1, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ARAF2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(AREG, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ARHA, inhibition of expression of; use of locked nucleic acid-modified

- oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ARHB, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ARHC, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (AT, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (AXL, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (B cell-attracting chemokine 1, gene for, inhibition of expression of;
 use of locked nucleic acid-modified oligonucleotides for treatment of
 cancer and inflammation)
- IT Platelet-derived growth factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (B chain, gene for, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BAD, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BAG1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BAI1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BAK, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BAK1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BAP1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BARD1, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BAX, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Platelet-derived growth factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (BB, gene for, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Cell adhesion molecules
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (BB-1, gene for, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BCL2, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BCL2A1, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BCL3, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BCL5, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BCL6, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BCNS, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BCR, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BCS, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BL, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BLYM, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BM11, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BMYC, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BRAF, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BRCA1, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BRCA2, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (BRCD1, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Complement receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (C5a, gene for, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and

inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CALCR, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CASP1, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CASP13, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CASP2, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CASP3, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CASP4, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CASP5, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CASP6, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CBL, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CCF18, gene for, inhibition of expression of; use of locked nucleic

acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNA1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNA2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNB1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNB2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNC, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCND1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCND2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCND3, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNE1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNE2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNF, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNG1, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNG2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNH, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNK, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNT1, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CCNT2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD100, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD101, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD103, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD104, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD105, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD107, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD109, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD11, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD110, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD111, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD112, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD113, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD114, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD115, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD116, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD117, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD118, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD119, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD120, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD121, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD124, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD126, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD127, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD129, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD130, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD132, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD133, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD134, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD24, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(CD27, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD33, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD37, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD39, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD41, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD42, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD47, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD48, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD49, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD52, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD53, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD57, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD6, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD63, gene for, inhibition of expression of; use of locked nucleic

acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD65, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD66, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD67, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD70, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD72, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD73, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD77, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD79, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD83, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD85, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD87, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD89, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD9, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

- inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD90, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD91, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD93, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD94, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD96, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD97, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD99, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDC23, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDC25A, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDC25C, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDC2L1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDC2L2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDC34, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDH1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDH5, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDH7, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDK10, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDK2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDK3, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDK4, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDK5, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CDK6, inhibition of expression of; use of locked nucleic acid-modified

oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDK7, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDK8, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDK9, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKL1, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKL2, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKN1A, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKN1B, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKN1C, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKN2A, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKN2B, inhibition of expression of; use of locked nucleic

acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKN2C, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKN2D, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDKN3, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (CDL4, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDw108, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDw12, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDw123, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDw125, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDw128, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDw131, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CDw17, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (CDw60, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDw75, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDw76, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDw78, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDw84, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CDw92, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CHES1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(COT, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CREB1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CREBBP, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CRK, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CRKL, inhibition of expression of; use of locked nucleic acid-modified

- oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CSF1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CSF1R, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CSF2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CSF2RA, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CSF2RB, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CSF2RY, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(CSF3R, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCR1, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCR2, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCR3, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXCR4, gene for, inhibition of expression of; use of locked nucleic

- acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR5, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CX3CR, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (D, gene for, modulation of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (D10S170, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (DAP, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (DAP3, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (DAPK1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (DBCCR1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (DCC, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (DDX6, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (E, gene for, modulation of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

inflammation)

IT Cadherins
Selectins
Selectins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E-, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E2F1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E2F4, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E4F1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EBI-1, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(EGF, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(EGFR, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(EIF4E, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(EIF4EBP1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(EIP3S2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(EIP3S6, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ELE1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ELK1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ELK3, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ELK4, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(EMP1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(EMS1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ENA-78, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(EPHA1, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(EPHA3, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(ERBAL2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and

inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ERBB2, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ERBB3, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ERBB4, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ERG, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ERPL1, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ESR1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ESR2, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ESRRA, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ESRRB, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ESRRG, inhibition of expression of; use of locked nucleic

acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study) (EST, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (ETS1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (ETS2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (ETV3, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (ETV4, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (ETV6, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (EVI1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (EWSR1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (FAT, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (FER, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(FES, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGD1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGF1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGF10, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGF11, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGF12, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGF13, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGF14, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGF16, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGF17, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC

(Process)
 (FGF18, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGF19, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGF2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGF3, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGF4, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGF5, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGF6, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGF7, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGF8, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGF9, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (FGFR1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGFR2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGFR3, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGFR4, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FGR, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FKHL1, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FLI1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FLT1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FMS, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FOS, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FOSB, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FOSL1, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FOSL2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FPS, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(FYN, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(G, gene for, modulation of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(GADD45A, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(GLI, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(GLI2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(GLI3, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GRO/MGSA, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(GRO1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal

- RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(GRO2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(GRO3, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HCAM, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HCC-1, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HCC-4, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(HCK, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(HGF, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(HKR3, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HNK-1, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(HOXA11, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(HOXA10, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC

(Process)
(HOXB2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(HPC1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HPCA-2, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(HRAS, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(HSPA9, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(I-309, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(I-TAC, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ICAM-1 (intercellular adhesion mol. 1), gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ICAM-2 (intercellular adhesion mol. 2), gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ICAM-3 (intercellular adhesion mol. 3), gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(IFNB1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(IFNG, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(IFNGR1, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(IFNGR2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(IRF4, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgA1, gene for, modulation of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgA2, gene for, modulation of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgD, gene for, modulation of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgE type I, gene for, modulation of expression of; use of locked
nucleic acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgE type II, gene for, inhibition of expression of; use of locked
nucleic acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgE, gene for, modulation of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG type I, gene for, inhibition of expression of; use of locked
nucleic acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG type II, gene for, inhibition of expression of; use of locked
nucleic acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG type III, gene for, inhibition of expression of; use of locked
nucleic acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Immunoglobulin receptors

- RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG, gene for, modulation of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgM, gene for, modulation of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(JUN, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(JUNB, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(JUND, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(KAI1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(KIT, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(KRAS2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Selectins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(L-, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Proteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LAP TGF- β 1, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LARC, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(LCK, inhibition of expression of; use of locked nucleic acid-modified

- oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (LCN1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (LCN2, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (LCO, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (LCP1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (LCP2, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LIX, gene for, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LKN-1, gene for, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LMC, gene for, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Oligonucleotides
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (LNA-containing; use of locked nucleic acid-modified oligonucleotides for
 treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (LP5A, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (LTA, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(LTB, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(LTK, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(LYN, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(M, gene for, modulation of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(M1S1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(M4S1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(M6P2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAD, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MADH4, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAF, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAFG, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAFK, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAP2K1, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAP2K4, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAP2K6, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAP3K14, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAP3K7, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAP3K8, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAPKAPK3, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAS1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MAX, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MCAF/MCP-1, gene for, inhibition of expression of; use of locked
nucleic acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MCC, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MCF2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Glycoproteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MCP (membrane cofactor protein), gene for, inhibition of expression
of; use of locked nucleic acid-modified oligonucleotides for treatment
of cancer and inflammation)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MDC (macrophage-derived chemokine), gene for, inhibition of expression
of; use of locked nucleic acid-modified oligonucleotides for treatment
of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MDM2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MDR1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MDR2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MEL, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MEN1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(MET, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)

(MGR2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MLH1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MMP1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MMP2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MMP3, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MMP9, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MNAT1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MOS, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MPL, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MSH2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(MYB, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (MYBL1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (MYBL2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (MYCL1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (MYCN, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Cadherins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (N-, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Cell adhesion molecules
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (N-CAM, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (N-ras, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NAP-2, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (NBL1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (NCC-4, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (NF1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);

BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NF2, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NFKB2, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NKTR, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NOS2A, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NOS2B, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NOS2C, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NOS3, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NOTCH4, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NOV, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(NRG1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC

(Process)
 (NRG2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (NTRK1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Cell adhesion molecules
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Ng-CAM, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ODC1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Selectins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (P-, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (PACE, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (PAI1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (PAI2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PARC, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (PCNA, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (PDGFA, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC

(Process)
(PDGFB, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PDGFB, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PDGFRB, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PECAM-1, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PIM1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PLAT, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PLAU, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PLAUR, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PLG, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PMS1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PMS2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(PPARA, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(PPARBP, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(PPARG, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(PTCH, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(PVT1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(RAF1, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(RALA, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(RALB, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(RARA, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(RARB, inhibition of expression of; use of locked nucleic acid-modified
oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC

(Process)
 (RARG, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (RASA1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (RBL1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (RBBP6, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (REL, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (RELA, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (REQ, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (RET, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (RMYC, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (ROS1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (RRAS, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines

- RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SCYB9, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SDF-1 (stromal-derived factor-1), gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(SEA, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(SET, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(SKI, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(SKIL, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SLC, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(SMARCB1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(SPI1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(SPINK1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(SRC, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(SSEA-1 (stage-specific embryonic antigen 1), gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)

(ST5, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(STCP-1, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)

(SUPT3H, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)

(SUPT5H, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)

(SUPT6H, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)

(TAF2A, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)

(TAF2H, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal

RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)

(TAL1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Proteins, specific or class

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(TAPA-1 (target of antiproliferative antibody, 1), gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(TARC, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TECK, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(TF, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Proteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TGF- β bpI, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(THPO, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(THRA, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(THRB, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(TIAM1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(TIM, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(TIMP1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(TIMP2, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC
(Process)
(TM4SF1, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and

inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (TNF, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (TP53, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (TP53BP2, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (TP73, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (VAV1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (VAV2, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Cell adhesion molecules
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (VCAM-1, gene for, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (VDR, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (VEGF, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (VGF, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (VHL, inhibition of expression of; use of locked nucleic acid-modified

- oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (WNT1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (WNT2, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (WNT5A, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (WT1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (YES1, inhibition of expression of; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antigens CD11, gene for, inhibition of expression of; use of locked
 nucleic acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antigens CD11a, gene for, inhibition of expression of; use of locked
 nucleic acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antigens CD11b, gene for, inhibition of expression of; use of locked
 nucleic acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antigens CD11c, gene for, inhibition of expression of; use of locked
 nucleic acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Antitumor agents
 (brain; use of locked nucleic acid-modified oligonucleotides for
 treatment of cancer and inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)
 (c-myc, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)
- IT Gene, animal
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
 BSU (Biological study, unclassified); BIOL (Biological study); PROC
 (Process)

(c-sis, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Intestine, neoplasm
(colon, inhibitors; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Antitumor agents
(colon; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Gene
(expression, inhibition of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT Glycoproteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene KAI1, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

IT CD1 (antigen)
CD14 (antigen)
CD19 (antigen)
CD2 (antigen)
CD20 (antigen)
CD22 (antigen)
CD26 (antigen)
CD28 (antigen)
CD3 (antigen)
CD30 (antigen)
CD34 (antigen)
CD36 (antigen)
CD38 (antigen)
CD4 (antigen)
CD40 (antigen)
CD44 (antigen)
CD45 (antigen)
CD45RO (antigen)
CD5 (antigen)
CD56 (antigen)
CD59 (antigen)
CD68 (antigen)
CD69 (antigen)
CD7 (antigen)
CD8 (antigen)
CD80 (antigen)
CD86 (antigen)
Cadherins
Eotaxin
Fas antigen
Granulocyte colony-stimulating factor receptors
Insulin-like growth factor I receptors
Interleukin 10
Interleukin 11
Interleukin 12
Interleukin 13
Interleukin 15
Interleukin 16
Interleukin 17
Interleukin 18
Interleukin 1 α
Interleukin 1 β
Interleukin 2
Interleukin 3
Interleukin 4
Interleukin 4 receptors
Interleukin 5
Interleukin 6
Interleukin 6 receptors

Interleukin 7
 Interleukin 7 receptors
 Interleukin 8
 Interleukin 9
 Invariant chain (class II antigen)
 LFA-3 (antigen)
 Leukosialin
 Macrophage inflammatory protein 1 α
 Macrophage inflammatory protein 1 β
 Platelet-derived growth factors
 RANTES (chemokine)
 TCR $\alpha\beta$ (receptor)
 TCR $\gamma\delta$ (receptor)
 Transferrin receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene for, inhibition of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT DNA repair
 Signal transduction, biological
 (gene for, modulation of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT CD antigens
 Cell adhesion molecules
 Chemokine receptors
 Chemokines
 Immunoglobulin receptors
 Immunoglobulins
 Interleukin receptors
 Interleukins
 Multidrug resistance proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene for, modulation of expression of; use of locked nucleic
 acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT Liver, neoplasm
 (hepatoma, inhibitors; use of locked nucleic acid-modified
 oligonucleotides for treatment of cancer and inflammation)

IT Antitumor agents
 (hepatoma; use of locked nucleic acid-modified oligonucleotides for
 treatment of cancer and inflammation)

IT Brain, neoplasm
 Lung, neoplasm
 Ovary, neoplasm
 Stomach, neoplasm
 Testis, neoplasm
 (inhibitors; use of locked nucleic acid-modified oligonucleotides for
 treatment of cancer and inflammation)

IT CD antigens
 Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (integrin $\alpha 7$, gene for, inhibition of expression of; use of
 locked nucleic acid-modified oligonucleotides for treatment of cancer
 and inflammation)

IT CD antigens
 Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (integrin $\beta 5$, gene for, inhibition of expression of; use of locked
 nucleic acid-modified oligonucleotides for treatment of cancer and
 inflammation)

IT CD antigens
 Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (integrin $\beta 7$, gene for, inhibition of expression of; use of locked
 nucleic acid-modified oligonucleotides for treatment of cancer and

- inflammation)
- IT Interleukin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interleukin 10 receptors, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interleukin 11, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interleukin 13, α -chain, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin 1 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interleukin 1 α , gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interleukin 9, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Proteins, specific or class
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(latent TGF- β 1, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antitumor agents
(leukemia; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antitumor agents
(lung; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Lymphokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lymphotactins, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Prostate gland
(neoplasm, inhibitors; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(oncogene, inhibition of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antitumor agents
(ovary; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin 12
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p40 subunit, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin 12
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p70 subunit, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antitumor agents
(prostate gland; use of locked nucleic acid-modified oligonucleotides

- for treatment of cancer and inflammation)
- IT Antitumor agents
(small intestine; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Intestine, neoplasm
(small, inhibitors; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antitumor agents
(stomach; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Antitumor agents
(testis; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tumor suppressor, modulation of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Complement receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type 1, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Complement receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type 2, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin 1 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type I, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin 1 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type II, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Anti-inflammatory agents
Antitumor agents
(use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin 8 receptors
Platelet-derived growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α , gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α -, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin 2 receptors
Interleukin 3 receptors
Interleukin 5 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α -chain, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
($\alpha 8$, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and

- inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α IEL, gene for, inhibition of expression of; use of locked
nucleic acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α IIB, gene for, inhibition of expression of; use of locked
nucleic acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α v, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 1, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 2, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 3, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 4, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 5, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 6, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β chemokine receptor CCR1, gene for, inhibition of expression of;
use of locked nucleic acid-modified oligonucleotides for treatment of
cancer and inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β chemokine receptor CCR2, gene for, inhibition of expression of;
use of locked nucleic acid-modified oligonucleotides for treatment of
cancer and inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β chemokine receptor CCR3, gene for, inhibition of expression of;
use of locked nucleic acid-modified oligonucleotides for treatment of
cancer and inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β chemokine receptor CCR4, gene for, inhibition of expression of;
use of locked nucleic acid-modified oligonucleotides for treatment of
cancer and inflammation)

- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β chemokine receptor CCR5, gene for, inhibition of expression of;
use of locked nucleic acid-modified oligonucleotides for treatment of
cancer and inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β chemokine receptor CCR6, gene for, inhibition of expression of;
use of locked nucleic acid-modified oligonucleotides for treatment of
cancer and inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β chemokine receptor CCR7, gene for, inhibition of expression of;
use of locked nucleic acid-modified oligonucleotides for treatment of
cancer and inflammation)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β chemokine receptor CCR8, gene for, inhibition of expression of;
use of locked nucleic acid-modified oligonucleotides for treatment of
cancer and inflammation)
- IT Interleukin 8 receptors
Platelet-derived growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β , gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β -, gene for, inhibition of expression of; use of
locked nucleic acid-modified oligonucleotides for treatment of cancer
and inflammation)
- IT Interleukin 2 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β -chain, gene for, inhibition of expression of; use of locked
nucleic acid-modified oligonucleotides for treatment of cancer and
inflammation)
- IT Transforming growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β -transforming growth factor type II, gene for, inhibition of
expression of; use of locked nucleic acid-modified oligonucleotides for
treatment of cancer and inflammation)
- IT Transforming growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β -transforming growth factor, type III, gene for, inhibition of
expression of; use of locked nucleic acid-modified oligonucleotides for
treatment of cancer and inflammation)
- IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 1-, gene for, inhibition of expression of; use of
locked nucleic acid-modified oligonucleotides for treatment of cancer
and inflammation)
- IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 2-, gene for, inhibition of expression of; use of
locked nucleic acid-modified oligonucleotides for treatment of cancer
and inflammation)
- IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 3-, gene for, inhibition of expression of; use of
locked nucleic acid-modified oligonucleotides for treatment of cancer
and inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 8, gene for, inhibition of expression of; use of locked nucleic
acid-modified oligonucleotides for treatment of cancer and
inflammation)

- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 1, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 2, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 3, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 4, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 5, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 6, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ IP-10, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ , gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT Interleukin 2 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ -chain, gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT 346505-50-8P 346505-51-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(anti-Fc ϵ R1 α LNA oligonucleotide; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT 9054-63-1, Aminopeptidase, microsomal 67763-96-6, IGF-1 67763-97-7, IGF-2 82707-54-8, Neprilysin 83869-56-1, GM-CSF 98603-84-0, Sialyl-Lewis X 99085-47-9, Complement decay-accelerating factor 143011-72-7, G-CSF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene for, inhibition of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)
- IT 141907-41-7, Matrix metalloproteinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene for, modulation of expression of; use of locked nucleic acid-modified oligonucleotides for treatment of cancer and inflammation)

L70 ANSWER 13 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:472523 HCAPLUS
 DN 135:66255
 ED Entered STN: 29 Jun 2001
 TI Liquid composition of a biodegradable block copolymer for drug delivery system
 IN Seo, Min-hyo; Choi, In-ja
 PA Samyang Corp., S. Korea
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K047-30
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 37

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|--------------|
| PI | WO 2001045742 | A1 | 20010628 | WO 2000-KR1508 | 20001221 <-- |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | KR 2001063314 | A | 20010709 | KR 1999-60349 | 19991222 <-- |
| | CA 2395077 | AA | 20010628 | CA 2000-2395077 | 20001221 <-- |
| | EP 1244471 | A1 | 20021002 | EP 2000-989005 | 20001221 <-- |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | JP 2003517886 | T2 | 20030603 | JP 2001-546681 | 20001221 <-- |
| | JP 3614820 | B2 | 20050126 | | |
| | AU 779713 | B2 | 20050210 | AU 2001-25550 | 20001221 <-- |
| | US 2003082234 | A1 | 20030501 | US 2002-169012 | 20020622 <-- |
| PRAI | KR 1999-60349 | A | 19991222 | <-- | |
| | WO 2000-KR1508 | W | 20001221 | <-- | |

CLASS

| | PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|----|--|-------|--|
| | WO 2001045742 | ICM | A61K047-30 |
| | WO 2001045742 | ECLA | A61K009/00M4; A61K047/10; A61K047/32; A61K047/34 <-- |
| | US 2003082234 | NCL | 424/486.000; 514/012.000 |
| | | ECLA | A61K009/00M4; A61K047/10; A61K047/32; A61K047/34 <-- |
| AB | The present invention relates to a liquid polymeric composition capable of forming a physiol. active substance-containing implant when it is injected into a living body and a method of preparation. The composition comprises a water-soluble biocompatible liquid polyethylene glycol derivative, a biodegradable block copolymer which is insol. in water but soluble in the water-soluble biocompatible liquid polyethylene glycol derivative and a physiol. active substance. Thus, a triblock copolymer was prepared from lactide-1,4-dioxanone and PEG. Piroxicam 150, the above biodegradable block copolymer 400, diacetyl polyethylene glycol 420, and gelatin 30 mg were dissolved in a 50% aqueous HOAc solution and the drug-containing liquid polymeric composition was filtered and the organic solvent was removed. | | |
| ST | polyester polyoxyalkylene block liq drug delivery prepn | | |
| IT | Polyoxyalkylenes, biological studies | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkyl ethers; liquid composition of biodegradable block copolymer for drug delivery system) | | |
| IT | Polymers, biological studies | | |
| | RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (biodegradable, block; liquid composition of biodegradable block copolymer for | | |

drug delivery system)

IT Drug delivery systems
(implants; liquid composition of biodegradable block copolymer for drug delivery system)

IT Anti-inflammatory agents
Antibacterial agents
Antitumor agents
Solvents
Surfactants
Vaccines
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Gonadotropin-releasing hormone receptor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Polyoxyalkylenes, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Albumins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Bone morphogenetic proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Carbohydrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Gelatins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Interleukin 2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Platelet-derived growth factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Proteins, general, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Salts, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Tumor necrosis factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT Drug delivery systems
(liqs.; liquid composition of biodegradable block copolymer for drug delivery system)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; liquid composition of biodegradable block copolymer for drug delivery system)

IT Polyoxyalkylenes, biological studies
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyester-, block, triblock; liquid composition of biodegradable block copolymer for drug delivery system)

IT Polyesters, biological studies
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(polyoxyalkylene-, block, triblock; liquid composition of biodegradable block copolymer for drug delivery system)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α ; liquid composition of biodegradable block copolymer for drug delivery system)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β ; liquid composition of biodegradable block copolymer for drug delivery system)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ ; liquid composition of biodegradable block copolymer for drug delivery system)

IT 64-17-5, Ethanol, uses 64-19-7, Acetic acid, uses 67-63-0, Isopropanol, uses 67-64-1, Acetone, uses 75-05-8, Acetonitrile, uses 123-91-1, Dioxane, uses 127-19-5, Dimethylacetamide
RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PROC (Process); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT 25322-68-3, Polyethylene glycol
RL: RCT (Reactant); RACT (Reactant or reagent)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT 24991-55-7P 27252-83-1P 37684-51-8P 346407-45-2P 346407-46-3P 346407-47-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(liquid composition of biodegradable block copolymer for drug delivery system)

IT 50-70-4, Sorbitol, biological studies 50-76-0, Actinomycin-D 50-78-2, Aspirin 50-99-7, Glucose, biological studies 51-21-8, 5-Fluorouracil 53-86-1, Indomethacin 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 59-01-8, Kanamycin 59-05-2, Methotrexate 59-23-4, Galactose, biological studies 60-54-8, Tetracycline 63-42-3, Lactose 69-53-4, Ampicillin 69-65-8, Mannitol 87-79-6, Sorbose 87-99-0, Xylitol 99-20-7, Trehalose 103-90-2, Acetaminophen 114-07-8, Erythromycin 151-21-3, Sodium dodecylsulfate, biological studies 471-34-1, Calcium carbonate, biological studies 557-34-6, Zinc acetate 564-25-0, Doxycycline 1066-17-7, colistin 1309-42-8, Magnesium hydroxide 1314-13-2, Zinc oxide, biological studies 1403-66-3, Gentamycin 1404-00-8, Mitomycin 1404-04-2, Neomycin 1404-90-6, Vancomycin 1405-87-4, bacitracin 1406-05-9, Penicillin 1407-47-2, angiotensin 3486-35-9, Zinc carbonate 5104-49-4, Flurbiprofen 6990-06-3, Fusidic acid 7446-70-0, Aluminum chloride, biological studies 7542-37-2, Paromomycin 7646-85-7, Zinc chloride, biological studies 7647-14-5, Sodium chloride, biological studies 7786-30-3, Magnesium chloride, biological studies 9001-63-2, Lysozyme 9002-72-6, Somatotropin 9003-39-8, Polyvinylpyrrolidone 9004-10-8, insulin; biological studies 9004-32-4, Sodium carboxymethyl cellulose 9004-54-0, Dextran, biological studies 9004-61-9, Hyaluronic acid 9007-12-9, calcitonin 9007-92-5, glucagon, biological studies 9012-76-4, Chitosan 9034-39-3, growth hormone releasing factor 9034-40-6, LHRH 9061-61-4, nerve growth factor 10043-52-4, Calcium chloride, biological studies 10118-90-8, Minocycline 11056-06-7, Bleomycin 11096-26-7, erythropoietin 11111-12-9, Cephalosporin 12619-70-4, Cyclodextrin 13614-98-7, Minocycline hydrochloride 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15687-27-1, Ibuprofen 16039-53-5, Zinc lactate 20830-81-3, Daunorubicin 21645-51-2, Aluminum hydroxide, biological studies 22071-15-4, Ketoprofen 22204-53-1, Naproxen 23155-02-4, Phosphomycin 23214-92-8, Doxorubicin 24305-27-9, thyrotropin releasing hormone 25316-40-9, Adriamycin 25322-68-3D, alkyl ethers 25496-72-4, Glyceryl monooleate 29679-58-1, Fenoprofen 31566-31-1, Glyceryl monostearate 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 34493-98-6, Dibekacin 36322-90-4, Piroxicam 37517-28-5, Amikacin 40828-46-4, Suprofen 41575-94-4, Carboplatin 51110-01-1, somatostatin 52093-21-7, Micronomicin 53994-73-3, Cephaclor 58957-92-9, Idarubicin

59804-37-4, Tenoxicam 59995-64-1, Thienamycin 60118-07-2, endorphin
 62229-50-9, EGF 63527-52-6 64221-86-9, Imipenem 68767-14-6,
 Loxoprofen 74011-58-8, Enoxacin 81627-83-0, M-CSF 82419-36-1,
 Ofloxacin 85721-33-1, Ciprofloxacin 86090-08-6, angiostatin
 100986-85-4, Levofloxacin 106392-12-5, Poloxamer 114977-28-5, Taxotere
 126467-48-9, porcine growth hormone 143011-72-7, GCSF 187888-07-9,
 endostatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (liquid composition of biodegradable block copolymer for drug
 delivery system)

IT 168399-10-8P 205371-73-9P 207986-05-8P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (triblock; liquid composition of biodegradable block copolymer for drug
 delivery system)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Atrix Laboratories; WO 9527481 A1 1995 HCAPLUS
- (2) Atrix Laboratories; WO 9621427 A1 1996 HCAPLUS
- (3) Takaok; J Hard Tissue Biol 1996, V5(2), P133 HCAPLUS
- (4) Zhongren Science & Technology Co; CN 1208616 A 1999 HCAPLUS

IT 103-90-2, Acetaminophen

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (liquid composition of biodegradable block copolymer for drug
 delivery system)

RN 103-90-2 HCAPLUS

CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L70 ANSWER 14 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:435369 HCAPLUS

DN 135:56914

ED Entered STN: 15 Jun 2001

TI Nucleic acid compositions, kits, and methods for identification,
 assessment, prevention, and therapy of human cervical cancer

IN Schlegel, Robert; Deeds, James; Berger, Allison; Zhao, Xumei

PA Millennium Predictive Medicine, Inc., USA

SO PCT Int. Appl., 436 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM G01N033-574

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 14, 63

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2001042792 | A2 | 20010614 | WO 2000-US33311 | 20001208 |
| WO 2001042792 | A3 | 20020131 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002009724 | A1 | 20020124 | US 2000-732560 | 20001208 |

| | | |
|----------------------|---|----------|
| PRAI US 1999-169811P | P | 19991208 |
| US 1999-171330P | P | 19991221 |
| US 2000-189113P | P | 20000314 |
| US 2000-193943P | P | 20000331 |
| US 2000-203772P | P | 20000512 |
| US 2000-210820P | P | 20000609 |
| US 2000-220113P | P | 20000721 |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|---|--|
| WO 2001042792 | ICM | G01N033-574 |
| WO 2001042792 | ECLA | C07K014/47A34; G01N033/50D2D2; G01N033/574C2 |
| US 2002009724 | NCL | 435/006.000; 435/007.230; 530/388.800; 435/070.210; 435/344.000 |
| | ECLA | C07K014/47A34; G01N033/50D2D2; G01N033/574C2 |
| AB | The invention relates to nucleic acid compns., kits, and methods for detecting, characterizing, preventing, and treating cervical cancers. A variety of markers (7280 different GenBank Accession Nos.) are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of cervical cancer. | |
| ST | cervical cancer gene expression diagnosis therapy; sequence cervical cancer gene expression human | |
| IT | Hybridoma (antibody production by; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer) | |
| IT | Carcinogens (assessing potential activity of; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer) | |
| IT | Diagnosis (cancer; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer) | |
| IT | Uterus, neoplasm (cervix, inhibitors; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer) | |
| IT | Antitumor agents Uterus, neoplasm (cervix; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer) | |
| IT | Human papillomavirus (model system; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer) | |
| IT | Drug screening Nucleic acid amplification (method) Nucleic acid hybridization Test kits Tumor markers cDNA sequences (nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer) | |
| IT | cDNA mRNA RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence) (nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer) | |
| IT | Antibodies RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer) | |
| IT | Gene, animal | |

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

IT Proteins, specific or class

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)

(secretory; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 345277-95-4 | 345277-96-5 | 345277-97-6 | 345277-98-7 | 345277-99-8 |
| | 345278-00-4 | 345278-01-5 | 345278-02-6 | 345278-03-7 | 345278-04-8 |
| | 345278-05-9 | 345278-06-0 | 345278-07-1 | 345278-08-2 | 345278-09-3 |
| | 345278-10-6 | 345278-11-7 | 345278-12-8 | 345278-13-9 | 345278-14-0 |
| | 345278-15-1 | 345278-16-2 | 345278-17-3 | 345278-18-4 | 345278-19-5 |
| | 345278-20-8 | 345278-21-9 | 345278-22-0 | 345278-23-1 | 345278-24-2 |
| | 345278-25-3 | 345278-26-4 | 345278-27-5 | 345278-28-6 | 345278-29-7 |
| | 345278-30-0 | 345278-31-1 | 345278-32-2 | 345278-33-3 | 345278-34-4 |
| | 345278-35-5 | 345278-36-6 | 345278-37-7 | 345278-38-8 | 345278-39-9 |
| | 345278-40-2 | 345278-41-3 | 345278-42-4 | 345278-43-5 | 345278-44-6 |
| | 345278-45-7 | 345278-46-8 | 345278-47-9 | 345278-48-0 | 345278-49-1 |
| | 345278-50-4 | 345278-51-5 | 345278-52-6 | 345278-53-7 | 345278-54-8 |
| | 345278-55-9 | 345278-56-0 | 345278-57-1 | 345278-58-2 | 345278-59-3 |
| | 345278-60-6 | 345278-61-7 | 345278-62-8 | 345278-63-9 | 345278-64-0 |
| | 345278-65-1 | 345278-66-2 | 345278-67-3 | 345278-68-4 | 345278-69-5 |
| | 345278-70-8 | 345278-71-9 | 345278-72-0 | 345278-73-1 | 345278-74-2 |
| | 345278-75-3 | 345278-76-4 | 345278-77-5 | 345278-78-6 | 345278-79-7 |
| | 345278-80-0 | 345278-81-1 | 345278-82-2 | 345278-83-3 | 345278-84-4 |
| | 345278-85-5 | 345278-86-6 | 345278-87-7 | 345278-88-8 | 345278-89-9 |
| | 345278-90-2 | 345278-91-3 | 345278-92-4 | 345278-93-5 | 345278-94-6 |
| | 345278-95-7 | 345278-96-8 | 345278-97-9 | 345278-98-0 | 345278-99-1 |
| | 345279-00-7 | 345279-01-8 | 345279-02-9 | 345279-03-0 | 345279-04-1 |
| | 345279-05-2 | 345279-06-3 | 345279-07-4 | 345279-08-5 | 345279-09-6 |
| | 345279-10-9 | 345279-11-0 | 345279-12-1 | 345279-13-2 | 345279-14-3 |
| | 345279-15-4 | 345279-16-5 | 345279-17-6 | 345279-33-6 | |

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

| | | | | | |
|----|-------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| IT | 113148-43-9, GenBank E07643 | 115536-85-1, GenBank E01954 | 117443-36-4, GenBank J03209 | 126466-74-8, GenBank E01979 | 127314-95-8, GenBank M29870 |
| | 129552-67-6, GenBank AF025998 | 132050-58-9, GenBank E02516 | 133924-59-1, GenBank D00017 | 134010-88-1, GenBank E02628 | 135231-53-7, GenBank E01915 |
| | 135622-19-4, GenBank M55618 | 135668-14-3, GenBank X14420 | 137748-89-1, GenBank M63438 | 137925-73-6, GenBank E03414 | 138575-76-5, GenBank M63573 |
| | 138929-19-8, GenBank X57352 | 139802-74-7, GenBank K01396 | 139802-90-7, GenBank X13839 | 139802-91-8, GenBank J05192 | 139803-55-7, GenBank X00570 |
| | 139803-94-4, GenBank M22590 | 139804-72-1, GenBank X05231 | 139804-73-2, GenBank M11718 | 139804-75-4, GenBank X13238 | 139805-31-5, GenBank J02645 |
| | 139805-84-8, GenBank K00799 | 139805-85-9, GenBank M10905 | 139805-99-5, GenBank M55543 | 139806-03-4, GenBank J04162 | 139806-77-2, GenBank M11353 |
| | 139806-81-8, GenBank X02457 | 139806-96-5, GenBank K00422 | 139807-63-9, GenBank M34455 | 139807-68-4, GenBank M22009 | 139807-71-9, GenBank M29467 |
| | 139807-72-0, GenBank M29469 | 139808-03-0, GenBank X02990 | 139808-44-9, GenBank Y00503 | 139808-63-2, GenBank X05908 | 139808-65-4, GenBank M25280 |
| | 139808-72-3, GenBank M16038 | 139809-09-9, GenBank X00497 | 139809-47-5, GenBank M22918 | 139809-48-6, GenBank M22920 | 139810-21-2, GenBank M22382 |
| | 139810-40-5, GenBank M11948 | 139810-41-6, GenBank J03223 | 139811-30-6, GenBank M25756 | 139811-50-0, GenBank M19888 | 139811-62-4, GenBank D00068 |
| | 139812-50-3, GenBank M20259 | 139812-88-7, GenBank M26880 | 139817-38-2, GenBank X00650 | 139820-03-4, GenBank X00620 | 139836-36-5, GenBank M61715 |
| | 139836-78-5, GenBank M63488 | 139837-39-1, GenBank M62896 | 139837-40-4, GenBank M62898 | 139840-22-5, GenBank X04098 | 139840-53-2, GenBank X57766 |
| | 139841-10-4, GenBank X15729 | 139843-98-4, GenBank X53331 | 139844-02-3, | | |

GenBank X54304 139844-09-0, GenBank X52966 139844-12-5, GenBank X16940
139848-33-2, GenBank X17206 139852-00-9, GenBank M74019 139854-89-0,
GenBank X57351 139857-62-8, GenBank X54473 139864-81-6, GenBank M85677
139866-58-3, GenBank M69181 139866-86-7, GenBank M87068 140020-85-5,
GenBank X05656 140025-54-3, GenBank M36501 140025-83-8, GenBank M29872
140025-93-0, GenBank M11560 140026-06-8, GenBank J03804 140026-22-8,
GenBank K02215 140026-29-5, GenBank M18216 140026-60-4, GenBank X01630
140027-05-0, GenBank M17017 140027-08-3, GenBank J04080 140027-26-5,
GenBank J03037 140027-39-0, GenBank X12451 140027-50-5, GenBank M37033
140027-60-7, GenBank M29540 140027-79-8, GenBank M17517 140028-00-8,
GenBank X06700 140028-27-9, GenBank M14219 140028-31-5, GenBank M14221
140028-98-4, GenBank J03745 140028-99-5, GenBank M14328 140029-07-8,
GenBank M17254 140029-48-7, GenBank X13425 140029-51-2, GenBank M55542
140029-63-6, GenBank J03248 140029-65-8, GenBank M20867 140029-74-9,
GenBank M31159 140030-24-6, GenBank Y00291 140030-60-0, GenBank M16342
140030-82-6, GenBank J03048 140030-92-8, GenBank J03171 140030-93-9,
GenBank J03143 140031-08-9, GenBank M28696 140031-21-6, GenBank M24594
140031-39-6, GenBank M29696 140031-40-9, GenBank J04208 140031-50-1,
GenBank J05633 140031-51-2, GenBank M35198 140031-76-1, GenBank X07695
140032-25-3, GenBank J03801 140033-36-9, GenBank J03934 140033-45-0,
GenBank M12267 140033-50-7, GenBank X13694 140033-61-0, GenBank J02923
140033-89-2, GenBank J03575 140033-94-9, GenBank J03503 140033-97-2,
GenBank M26066 140033-99-4, GenBank J02814 140034-00-0, GenBank L00160
140034-03-3, GenBank X04412 140034-05-5, GenBank M31606 140034-30-6,
GenBank Y00345 140034-65-7, GenBank J03802 140034-90-8, GenBank J05249
140034-99-7, GenBank Y00282 140035-06-9, GenBank X06747 140035-08-1,
GenBank M29064 140035-21-8, GenBank J03015 140035-47-8, GenBank J03040
140035-51-4, GenBank X07820 140035-95-6, GenBank M11507 140036-15-3,
GenBank J03358 140036-24-4, GenBank M27504 140036-36-8, GenBank X15187
140036-49-3, GenBank K00558 140036-74-4, GenBank J03827 140036-77-7,
GenBank M30608 140048-79-9, GenBank J02853 140050-06-2, GenBank M24630
140064-16-0, GenBank M31165 140064-33-1, GenBank M63180 140064-70-6,
GenBank M55150 140066-85-9, GenBank M65209 140066-87-1, GenBank M65217
140069-11-0, GenBank X16850 140070-33-3, GenBank X06409 140079-00-1,
GenBank X15722 140079-11-4, GenBank X15949 140087-32-7, GenBank M73547
140095-38-1, GenBank M74775 140098-29-9, GenBank M85038 140098-53-9,
GenBank X59841 140101-97-9, GenBank M63838 140108-81-2, GenBank M87789
140109-62-2, GenBank X63629 140263-93-0, GenBank M22538 140274-21-1,
GenBank J04164 140274-41-5, GenBank X00351 140275-61-2, GenBank D00099
140275-68-9, GenBank M37104 140275-79-2, GenBank M20471 140275-97-4,
GenBank M13656 140276-23-9, GenBank X07549 140277-27-6, GenBank Y00052
140277-28-7, GenBank M15796 140277-72-1, GenBank M29548 140278-35-9,
GenBank M11147 140278-36-0, GenBank M10119 140278-59-7, GenBank X07979
140278-69-9, GenBank M14354 140278-70-2, GenBank M14539 140278-73-5,
GenBank M35543 140278-74-6, GenBank X01677 140278-77-9, GenBank J02642
140278-78-0, GenBank X01111 140280-03-1, GenBank X12597 140281-58-9,
GenBank X02422 140281-67-0, GenBank J03909 140282-23-1, GenBank M19723
140283-31-4, GenBank J00194 140283-32-5, GenBank J00196 140283-34-7,
GenBank K01171 140283-61-0, GenBank K01144 140283-64-3, GenBank X00457
140283-76-7, GenBank M31212 140285-59-2, GenBank J03580 140285-63-8,
GenBank M34668 140285-76-3, GenBank M11433 140286-05-1, GenBank X12791
140286-06-2, GenBank M36072 140286-11-9, GenBank J03537 140286-77-7,
GenBank X05232 140287-65-6, GenBank M19308 140287-71-4, GenBank M10036
140287-96-3, GenBank M19715 140288-37-5, GenBank M25246 140305-80-2,
GenBank M27635 140317-18-6, GenBank M60333 140317-19-7, GenBank M60334
140320-63-4, GenBank M64241 140321-21-7, GenBank M16957 140324-71-6,
GenBank D00039 140336-55-6, GenBank X56998 140336-89-6, GenBank M62189
140337-45-7, GenBank M60457 140347-92-8, GenBank M69066 140351-09-3,
GenBank M83248 140353-62-4, GenBank M77945 140358-29-8, GenBank M81844
140358-71-0, GenBank M87790 140359-85-9, GenBank X60111 140505-98-2,
GenBank X04470 140506-62-3, GenBank V00567 140507-04-6, GenBank X05360
140507-78-4, GenBank X13923 140507-98-8, GenBank M14200 140508-45-8,
GenBank M33195 140508-48-1, GenBank M12938 140509-90-6, GenBank X02490
140510-80-1, GenBank M11937 140511-86-0, GenBank X07362 140511-87-1,
GenBank M58549 140513-90-2, GenBank M17885 140513-91-3, GenBank M17886
140514-50-7, GenBank X07819 140514-93-8, GenBank X06617 140517-12-0,

GenBank M17733 140557-25-1, GenBank V00594 140559-28-0, GenBank X01213
 140559-42-8, GenBank M24194 140563-72-0, GenBank X56999 140566-50-3,
 GenBank X55885 140598-70-5, GenBank M81757 140610-83-9, GenBank M77693
 140737-79-7, GenBank M11313 140740-24-5, GenBank J03464

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 140740-31-4, GenBank K02765 140742-82-1, GenBank X02761 140744-36-1,
 GenBank X02530 140747-21-3, GenBank J03528 140775-47-9, GenBank M26663
 140798-22-7, GenBank X56160 140800-76-6, GenBank X14787 140801-95-2,
 GenBank X53586 140813-79-2, GenBank M74558 140815-95-8, GenBank M76729
 140828-27-9, GenBank M77830 140829-97-6, GenBank Z11773 140830-46-2,
 GenBank M90104 140956-66-7, GenBank M28424 140996-05-0, GenBank X62534
 140999-62-8, GenBank M83772 141000-81-9, GenBank D00760 141004-41-3,
 GenBank M77233 141009-56-5, GenBank M90809 141015-35-2, GenBank X63432
 141015-55-6, GenBank Z11894 141015-56-7, GenBank Z11890 141760-71-6,
 GenBank M65292 142097-47-0, GenBank M86609 142099-71-6, GenBank M73713
 142101-47-1, GenBank M83653 142101-96-0, GenBank M88468 142101-98-2,
 GenBank D11094 142318-55-6, GenBank X65923 142433-04-3, GenBank X57809
 142433-07-6, GenBank X57812 142433-17-8, GenBank X57824 142455-80-9,
 GenBank X59706 142455-82-1, GenBank X62744 142552-26-9, GenBank M96803
 142579-00-8, GenBank M87339 142694-33-5, GenBank M87284 142862-63-3,
 GenBank X55654 143001-94-9, GenBank X64707 143001-98-3, GenBank D12676
 143002-00-0, GenBank D01059 143003-25-2, GenBank M84443 143003-28-5,
 GenBank M95929 143024-81-1, GenBank M97856 143025-36-9, GenBank D90373
 143342-11-4, GenBank M93651 143369-00-0, GenBank X65614 143404-03-9,
 GenBank S87759 143524-46-3, GenBank M93426 143525-26-2, GenBank X67325
 143695-18-5, GenBank L01411 143695-19-6, GenBank L01413 143744-73-4,
 GenBank X54941 143854-78-8, GenBank X00756 144531-33-9, GenBank L05425
 144532-37-6, GenBank L03146 144532-43-4, GenBank L03152 144532-47-8,
 GenBank L03156 144532-53-6, GenBank L03162 144532-59-2, GenBank L03168
 144560-37-2, GenBank L05095 144560-38-3, GenBank L05096 144592-20-1,
 GenBank E03814 145009-01-4, GenBank Z16598 145257-44-9, GenBank L06145
 145258-16-8, GenBank L03203 145347-70-2, GenBank S74678 145421-89-2,
 GenBank E05213 145496-42-0, GenBank X63071 145620-69-5, GenBank X54137
 145709-28-0, GenBank L07515 145710-47-0, GenBank L07633 145711-52-0,
 GenBank L07540 145791-81-7, GenBank S42404 145906-54-3, GenBank X52426
 145906-62-3, GenBank X53296 145971-93-3, GenBank L08441 145974-00-1,
 GenBank L01279 145975-20-8, GenBank L02426 146737-04-4, GenBank D90453
 147270-81-3, GenBank X69111 147476-29-7, GenBank Z17621 147565-04-6,
 GenBank AR003350 147639-77-8, GenBank Z19171 147692-87-3, GenBank
 Z17355 147748-50-3, GenBank X59417 147825-15-8, GenBank X56932
 147825-60-3, GenBank M93425 148061-48-7, GenBank X55999 148086-64-0,
 GenBank X04236 148107-30-6, GenBank X58082 148107-40-8, GenBank X58092
 148107-49-7, GenBank Z18325 148107-61-3, GenBank X56510 148108-35-4,
 GenBank X01405 148108-37-6, GenBank X01742 148142-00-1, GenBank X67698
 148142-01-2, GenBank X69151 148311-88-0, GenBank L11566 148363-09-1,
 GenBank L06070 148391-57-5, GenBank L12168 148392-85-2, GenBank L07393
 148450-36-6, GenBank D14657 148450-55-9, GenBank D13639 148450-60-6,
 GenBank D13630 148635-70-5, GenBank Z20504 148664-96-4, GenBank X67951
 148782-97-2, GenBank D11428 149102-60-3, GenBank T06718 149135-48-8,
 GenBank T06997 149215-30-5, GenBank D13988 149449-93-4, GenBank L15702
 149450-76-0, GenBank L16510 149584-07-6, GenBank T08377 149737-30-4,
 GenBank X70476 149768-93-4, GenBank S59049 150220-18-1, GenBank D14446
 150246-86-9, GenBank X71087 150247-58-8, GenBank Z22658 150382-86-8,
 GenBank M38267 150383-62-3, GenBank L19597 150421-21-9, GenBank L19956
 150471-65-1, GenBank L09159 150472-83-6, GenBank D13666 150472-84-7,
 GenBank D13665 150489-52-4, GenBank L13923 150735-23-2, GenBank L13799
 150838-28-1, GenBank L22157 150886-88-7, GenBank L22569 150912-86-0,
 GenBank T10557 150944-63-1, GenBank L19908 151043-36-6, GenBank T10942
 151116-64-2, GenBank L20463 151118-67-1, GenBank Z24575 151118-88-6,
 GenBank Z24596 151119-08-3, GenBank Z24616 151119-21-0, GenBank Z24588
 151119-56-1, GenBank Z24636 151119-60-7, GenBank Z24640 151119-81-2,
 GenBank Z24659 151241-78-0, GenBank L12110 151243-52-6, GenBank X64875

151375-58-5, GenBank U02032 151376-78-2, GenBank D17554 151497-26-6, GenBank U02493 151579-21-4, GenBank T12814 151658-57-0, GenBank L25259 151904-14-2, GenBank T12940 151973-87-4, GenBank D13866 152054-71-2, GenBank D23661 152112-49-7, GenBank L12535 152282-50-3, GenBank D21262 152282-55-8, GenBank D25274 152282-62-7, GenBank D17793 152283-09-5, GenBank L23808 152348-09-9, GenBank U03891 152410-93-0, GenBank L27211 152471-70-0, GenBank D26125 152473-31-9, GenBank X72964 152514-50-6, GenBank X72467 152514-61-9, GenBank X72452 153056-13-4, GenBank X75593 153057-95-5, GenBank X73902 153100-38-0, GenBank U04313 153317-30-7, GenBank L11700 153420-53-2, GenBank X75861 153592-41-7, GenBank S68288 153593-05-6, GenBank S69272 153637-89-9, GenBank D15050 153793-53-4, GenBank U01923 153794-03-7, GenBank U04735 153961-36-5, GenBank U07151 153962-36-8, GenBank X78136 154209-78-6, GenBank U05875 154246-97-6, GenBank L29158 154251-45-3, GenBank X77548 154513-61-8, GenBank U07550 154680-64-5, GenBank U07516 154688-57-0, GenBank U07431 154768-38-4, GenBank E06721 154834-94-3, GenBank D26443 154946-33-5, GenBank X78947 154980-76-4, GenBank D29640 154980-77-5, GenBank D29641 154980-83-3, GenBank D29956 155152-96-8, GenBank U09196 155285-16-8, GenBank D30655 155286-15-0, GenBank T18696 155484-34-7, GenBank Z33597 155571-21-4, GenBank L33179 155610-76-7, GenBank X79234 155744-60-8, GenBank X75185 156196-12-2, GenBank U10117 156504-60-8, GenBank T22417 156504-61-9, GenBank T22418 156584-36-0, GenBank U10485 156613-26-2, GenBank D16562 156614-21-0, GenBank X60146 156650-88-3, GenBank L20941 156653-55-3, GenBank U09278 156709-73-8, GenBank U08815 156712-27-5, GenBank X74330 156887-92-2, GenBank U09813 156887-94-4, GenBank U10550 157114-38-0, GenBank D21092 157114-69-7, GenBank X75308 157153-70-3, GenBank E07218 157268-45-6, GenBank T17422 157711-87-0, GenBank S71381 157934-18-4, GenBank L35594 158005-22-2, GenBank U12170 158022-65-2, GenBank L33801 158127-68-5, GenBank D26129 158187-36-1, GenBank T24606 158245-35-3, GenBank X81109 158336-52-8, GenBank U07919 158339-25-4, GenBank U14967 158339-26-5, GenBank U14968 158339-28-7, GenBank U14970 158339-59-4, GenBank U14966 158374-37-9, GenBank X81817 158411-21-3, GenBank L34155 158411-33-7, GenBank D28473 158448-35-2, GenBank U13369 158682-33-8, GenBank X82018 158764-13-7, GenBank D14710 158909-63-8, GenBank Z46347 158928-76-8, GenBank U13738 159200-54-1, GenBank D26598 159200-55-2, GenBank D26599 159200-90-5, GenBank D26600 159230-82-7, GenBank Z42302 159445-30-4, GenBank D30658 159743-52-9, GenBank L32748 159840-47-8, GenBank Z43536 159913-43-6, GenBank D50487 159962-53-5, GenBank Z45184

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

IT 160020-43-9, GenBank Z46622 160020-49-5, GenBank Z46606 160021-95-4, GenBank D21254 160021-97-6, GenBank D42073 160043-37-8, GenBank U16850 160074-18-0, GenBank U10439 160121-23-3, GenBank L33854 160122-18-9, GenBank L37368 160162-90-3, GenBank D16985 160163-71-3, GenBank D17174 160164-48-7, GenBank D17032 160164-65-8, GenBank D17039 160166-16-5, GenBank D16947 160263-66-1, GenBank U15008 160327-88-8, GenBank T12310 160330-65-4, GenBank T19594 160364-88-5, GenBank S70290 160368-78-5, GenBank T20087 160396-13-4, GenBank T18962 160396-69-0, GenBank T19018 160438-85-7, GenBank T19291 160474-32-8, GenBank T27413 160492-74-0, GenBank A21187 160493-50-5, GenBank A21185 160610-52-6, GenBank X80695 160613-47-8, GenBank S74681 161046-14-6, GenBank U13665 161050-07-3, GenBank U14394 161071-02-9, GenBank U16306 161102-35-8, GenBank L38562 161102-38-1, GenBank L34600 161103-64-6, GenBank T27579 161274-01-7, GenBank D38524 161340-72-3, GenBank T30099 161378-13-8, GenBank T30369 161570-50-9, GenBank T33345 161571-06-8, GenBank T33406 161624-66-4, GenBank T34178 161752-36-9, GenBank T36122 161818-28-6, GenBank S73813 161850-13-1, GenBank E08291 161850-14-2, GenBank E08292 161850-15-3, GenBank E08293 161850-16-4, GenBank E08294 161933-58-0, GenBank T37405 162027-34-1, GenBank T38698 162027-36-3, GenBank T38700 162030-19-5, GenBank U14187 162197-47-9, GenBank L39061 162390-03-6, GenBank T44091 162451-02-7, GenBank T46131 162525-76-0, GenBank U18728 162561-82-2, GenBank Z47552 162617-52-9, GenBank T40311 162672-81-3, GenBank T47520 162673-02-1, GenBank T47541 162674-35-3, GenBank T47693 162724-35-8,

GenBank T48366 162769-82-6, GenBank T49651 162769-88-2, GenBank T49657
 162770-83-4, GenBank T49712 162771-38-2, GenBank T49801 162775-37-3,
 GenBank E08663 162806-02-2, GenBank T50828 162859-72-5, GenBank T52152
 162867-26-7, GenBank T52893 162909-68-4, GenBank T53773 162911-85-5,
 GenBank T53990 162949-60-2, GenBank T54750 162986-60-9, GenBank T55728
 162986-96-1, GenBank T55770 163048-05-3, GenBank T57069 163049-38-5,
 GenBank T57235 163051-44-3, GenBank T57441 163054-81-7, GenBank T57778
 163055-06-9, GenBank T57803 163102-31-6, GenBank T59256 163143-04-2,
 GenBank T59798 163143-90-6, GenBank T59873 163145-29-7, GenBank T60048
 163170-63-6, GenBank T60482 163175-07-3, GenBank T60926 163176-59-8,
 GenBank T61078 163180-37-8, GenBank T61456 163199-65-3, GenBank T61896
 163200-84-8, GenBank T62048 163202-45-7, GenBank T62179 163245-97-4,
 GenBank D31249 163246-93-3, GenBank D31345 163249-73-8, GenBank D45421
 163369-78-6, GenBank T62491 163371-27-5, GenBank T62627 163376-63-4,
 GenBank T63201 163376-89-4, GenBank T63171 163408-32-0, GenBank T63324
 163410-39-7, GenBank T63587 163415-93-8, GenBank T64048 163417-70-7,
 GenBank T64262 163576-07-6, GenBank F07635 163599-50-6, GenBank T64837
 163600-27-9, GenBank T64887 163601-00-1, GenBank T64880 163601-55-6,
 GenBank T64956 163601-83-0, GenBank T65058 163605-58-1, GenBank T65407
 163609-83-4, GenBank T65833 163643-54-7, GenBank T66824 163644-24-4,
 GenBank T66814 163644-26-6, GenBank T66816 163645-08-7, GenBank T66936
 163646-66-0, GenBank T67053 163689-67-6, GenBank T67271 163782-00-1,
 GenBank T68321 163782-12-5, GenBank T68333 163785-53-3, GenBank T68645
 163787-90-4, GenBank T68892 163789-99-9, GenBank T69073 163794-32-9,
 GenBank T69468 163816-57-7, GenBank T69603 163821-21-4, GenBank T70123
 163821-87-2, GenBank T70109 163824-52-0, GenBank T70398 163824-91-7,
 GenBank T70437 163825-95-4, GenBank T70541 163865-89-2, GenBank D49396
 163905-29-1, GenBank T70810 163906-20-5, GenBank T70901 163909-28-2,
 GenBank T71209 163909-91-9, GenBank T71272 163911-79-3, GenBank T71460
 163937-90-4, GenBank T71578 163940-53-2, GenBank T71841 163944-47-6,
 GenBank T72235 163944-71-6, GenBank T72259 163987-79-9, GenBank R05416
 163997-55-5, GenBank R06392 163999-17-5, GenBank R06566 163999-26-6,
 GenBank R06575 163999-92-6, GenBank R06653 164000-32-2, GenBank R06705
 164000-36-6, GenBank R06709 164000-70-8, GenBank R06675 164087-45-0,
 GenBank R01515 164088-67-9, GenBank R01637 164089-12-7, GenBank R01682
 164089-34-3, GenBank R01732 164096-73-5, GenBank R02480 164099-69-8,
 GenBank R02739 164100-31-6, GenBank R02801 164127-06-4, GenBank T99617
 164133-59-9, GenBank R00275 164133-71-5, GenBank R00283 164134-11-6,
 GenBank R00323 164134-82-1, GenBank R00425 164137-94-4, GenBank R00706
 164141-81-5, GenBank R01139 164143-33-3, GenBank R01323 164143-44-6,
 GenBank R01279 164188-84-5, GenBank T98414 164189-21-3, GenBank T98394
 164189-76-8, GenBank T98506 164191-15-5, GenBank T98612 164191-85-9,
 GenBank T98628 164192-40-9, GenBank T98719 164195-46-4, GenBank T99043
 164195-58-8, GenBank T99055 164196-17-2, GenBank T99176 164196-23-0,
 GenBank T99105 164197-73-3, GenBank T99312 164198-21-4, GenBank T99280
 164270-52-4, GenBank X85160 164272-85-9, GenBank R06900 164275-58-5,
 GenBank R07141 164275-76-7, GenBank R07167 164277-42-3, GenBank R07295
 164279-65-6, GenBank R07560 164302-72-1, GenBank R08561 164305-40-2,
 GenBank R08769 164308-07-0, GenBank R09062 164312-63-4, GenBank R09561
 164313-45-5, GenBank R09602 164315-41-7, GenBank R09724 164315-42-8,
 GenBank R09725 164318-30-3, GenBank R09980 164318-61-0, GenBank R10011
 164320-02-9, GenBank R10159 164320-17-6, GenBank R10103 164321-50-0,
 GenBank R10284 164321-58-8, GenBank R10292 164370-82-5, GenBank R10662
 164416-96-0, GenBank T72691 164425-47-2, GenBank T73614 164431-23-6,
 GenBank T74141 164433-05-0, GenBank T74284 164434-01-9, GenBank T74394
 164438-28-2, GenBank T74846 164440-25-9, GenBank T75041 164449-17-6,
 GenBank T77100 164451-34-7, GenBank T77308 164452-67-9, GenBank T77499
 164473-80-7, GenBank T77595 164476-02-2, GenBank T77733 164477-51-4,
 GenBank T77893 164489-60-5, GenBank T78909 164501-12-6, GenBank T80061
 164501-83-1, GenBank T80132 164502-83-4, GenBank T80232 164507-25-9,
 GenBank U21128 164572-58-1, GenBank T81140 164574-07-6, GenBank T81289
 164574-56-5, GenBank T81338 164600-59-3, GenBank T81514 164602-24-8,
 GenBank T81658 164604-36-8, GenBank T81891 164606-29-5, GenBank T82022
 164616-04-0, GenBank F11839 164625-38-1, GenBank F00559 164688-14-6,
 GenBank F13527 164696-53-1, GenBank T82907 164698-28-6, GenBank T83117
 164702-61-8, GenBank T83550 164703-15-5, GenBank T83657 164703-68-8,

GenBank T83630 164707-08-8, GenBank T83997 164711-59-5, GenBank T84472
 164745-00-0, GenBank T84975 164747-43-7, GenBank T85249 164765-15-5,
 GenBank T86983 164765-42-8, GenBank T87010 164768-66-5, GenBank T87341
 164779-54-8, GenBank T89094 164811-12-5, GenBank T89996 164811-90-9,
 GenBank T90074 164813-52-9, GenBank T90236 164814-71-5, GenBank T90355
 164814-79-3, GenBank T90363 164814-91-9, GenBank T90375

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 164816-76-6, GenBank T90560 164820-36-4, GenBank T90920 164821-55-0,
 GenBank T91039 164823-60-3, GenBank T91244 164827-60-5, GenBank T91644
 164831-37-2, GenBank T92021 164865-72-9, GenBank T95504 164867-23-6,
 GenBank T95689 164867-64-5, GenBank T95650 164868-54-6, GenBank T95748
 164876-60-2, GenBank T96522 164876-95-3, GenBank T96601 164878-05-1,
 GenBank T96688 164878-35-7, GenBank T96718 164878-66-4, GenBank T96804
 164879-43-0, GenBank T96832 164880-56-2, GenBank T96935 164880-80-2,
 GenBank T96986 164882-82-0, GenBank T97170 164887-21-2, GenBank T93627
 164891-90-1, GenBank T94055 164900-67-8, GenBank T94974 164901-45-5,
 GenBank T95052 164901-88-6, GenBank T95113 164903-22-4, GenBank T95274
 164904-51-2, GenBank T95333 164939-82-6, GenBank T97457 164943-71-9,
 GenBank T97782 164943-95-7, GenBank T97868 164946-77-4, GenBank T98151
 164947-08-4, GenBank T98182 164951-75-1, GenBank U21911 164951-82-0,
 GenBank Z47727 164953-82-6, GenBank L40736 164954-10-3, GenBank L38951
 164964-31-2, GenBank R10896 164964-52-7, GenBank R10917 164965-82-6,
 GenBank R11047 164970-63-2, GenBank R11529 164971-70-4, GenBank R11636
 164993-03-7, GenBank R11888 164995-90-8, GenBank R12175 165002-57-3,
 GenBank R12817 165002-65-3, GenBank R12825 165006-83-7, GenBank R13243
 165008-21-9, GenBank R13381 165009-57-4, GenBank R13517 165009-59-6,
 GenBank R13519 165009-86-9, GenBank R13546 165009-97-2, GenBank R13557
 165009-98-3, GenBank R13558 165013-64-9, GenBank R13925 165014-83-5,
 GenBank R14044 165016-69-3, GenBank R14230 165017-14-1, GenBank R14275
 165018-82-6, GenBank R14443 165019-35-2, GenBank R14496 165020-69-9,
 GenBank R16069 165021-34-1, GenBank R16134 165021-37-4, GenBank R16137
 165021-47-6, GenBank R15708 165021-79-4, GenBank R16006 165022-76-4,
 GenBank R16157 165023-82-5, GenBank R15443 165024-35-1, GenBank R15832
 165025-22-9, GenBank R15922 165028-92-2, GenBank R14663 165031-37-8,
 GenBank R14908 165032-10-0, GenBank R14981 165076-41-5, GenBank R15357
 165078-34-2, GenBank R16367 165079-91-4, GenBank R16524 165080-10-4,
 GenBank R16543 165080-14-8, GenBank R16547 165080-70-6, GenBank R16603
 165082-00-8, GenBank R16733 165084-24-2, GenBank R16957 165085-59-6,
 GenBank R17092 165086-24-8, GenBank R17157 165086-32-8, GenBank R17165
 165086-47-5, GenBank R17180 165087-91-2, GenBank R17324 165088-04-0,
 GenBank R17337 165088-61-9, GenBank R17394 165091-09-8, GenBank R17642
 165091-20-3, GenBank R17667 165091-70-3, GenBank R17717 165091-75-8,
 GenBank R17722 165091-98-5, GenBank R17731 165092-78-4, GenBank R17811
 165138-83-0, GenBank R19158 165140-35-2, GenBank R19314 165140-94-3,
 GenBank R19337 165142-54-1, GenBank R19529 165151-29-1, GenBank T26540
 165156-79-6, GenBank R19773 165158-62-3, GenBank R19956 165158-83-8,
 GenBank R19977 165161-33-1, GenBank R20227 165162-98-1, GenBank R20392
 165163-22-4, GenBank R20416 165165-54-8, GenBank R20648 165199-69-9,
 GenBank R20813 165202-92-6, GenBank R21136 165206-67-7, GenBank R21511
 165213-11-6, GenBank R22155 165213-95-6, GenBank R22239 165214-64-2,
 GenBank R22308 165219-53-4, GenBank R22748 165223-26-7, GenBank R23083
 165224-33-9, GenBank R23190 165225-13-8, GenBank R23270 165226-51-7,
 GenBank R23408 165227-26-9, GenBank R23483 165229-81-2, GenBank R23738
 165234-29-7, GenBank R24186 165236-93-1, GenBank R24450 165237-73-0,
 GenBank R24530 165238-34-6, GenBank R24591 165241-23-6, GenBank R24880
 165242-17-1, GenBank R24974 165296-50-4, GenBank R25234 165298-05-5,
 GenBank R25389 165298-14-6, GenBank R25398 165300-68-5, GenBank R25652
 165304-05-2, GenBank R25989 165341-23-1, GenBank R26344 165341-96-8,
 GenBank R26417 165342-35-8, GenBank R26456 165343-05-5, GenBank R26526
 165343-47-5, GenBank R26531 165345-11-9, GenBank R26732 165345-23-3,
 GenBank R26744 165345-82-4, GenBank R26803 165346-71-4, GenBank R26892
 165346-98-5, GenBank R26919 165347-39-7, GenBank R26960 165347-56-8,

GenBank R26977 165352-36-3, GenBank R27457 165361-78-4, GenBank R28400
 165412-23-7, GenBank R30849 165418-11-1, GenBank R31386 165418-38-2,
 GenBank R31413 165420-50-8, GenBank R31625 165421-26-1, GenBank R31701
 165421-83-0, GenBank R31758 165425-02-5, GenBank R32078 165426-72-2,
 GenBank R32248 165428-29-5, GenBank R32405 165428-64-8, GenBank R32440
 165433-82-9, GenBank R32959 165435-75-6, GenBank R33152 165437-78-5,
 GenBank R33355 165438-24-4, GenBank R33401 165439-00-9, GenBank R33477
 165440-65-3, GenBank R33642 165441-43-0, GenBank R33720 165441-86-1,
 GenBank R33763 165469-66-9, GenBank R34225 165470-14-4, GenBank R34273
 165470-55-3, GenBank R34314 165472-36-6, GenBank U09623 165473-54-1,
 GenBank L38486 165475-40-1, GenBank R34382 165477-24-7, GenBank R34566
 165477-25-8, GenBank R34567 165477-42-9, GenBank R34584 165478-83-1,
 GenBank R34725 165483-97-6, GenBank R35230 165484-75-3, GenBank R35283
 165486-87-3, GenBank R35500 165491-23-6, GenBank R35948 165492-16-0,
 GenBank R36081 165493-08-3, GenBank R36207 165493-62-9, GenBank R36144
 165505-37-3, GenBank R37093 165505-77-1, GenBank R37224 165506-22-9,
 GenBank R37165 165509-47-7, GenBank R37511 165511-46-6, GenBank R37738
 165511-99-9, GenBank R37791 165512-14-1, GenBank R37876 165512-60-7,
 GenBank R37817 165517-14-6, GenBank R38306 165520-27-4, GenBank R38619
 165520-53-6, GenBank R38645 165521-08-4, GenBank R38685 165521-26-6,
 GenBank R38703 165562-53-8, GenBank R38899 165562-71-0, GenBank R38917
 165563-00-8, GenBank R38995 165563-34-8, GenBank R38946 165563-39-3,
 GenBank R38951 165563-54-2, GenBank R38966 165564-51-2, GenBank R39111
 165565-91-3, GenBank R39239 165566-05-2, GenBank R39258 165571-21-1,
 GenBank R39769 165572-43-0, GenBank R39861 165574-19-6, GenBank R40057
 165575-44-0, GenBank R40105 165576-07-8, GenBank R40228 165576-10-3,
 GenBank R40231 165576-35-2, GenBank R40176 165578-22-3, GenBank R40449
 165578-54-1, GenBank R40481 165580-31-4, GenBank R40649 165583-00-6,
 GenBank R40918 165583-28-8, GenBank R40946 165625-51-4, GenBank R41294
 165632-21-3, GenBank R41943 165632-46-2, GenBank R41981 165632-63-3,
 GenBank R41998 165632-98-4, GenBank R41965 165633-28-3, GenBank R42061
 165634-00-4, GenBank R42168 165634-06-0, GenBank R42174 165634-60-6,
 GenBank R42182 165635-95-0, GenBank R42317 165639-92-9, GenBank R42714
 165640-59-5, GenBank R42781 165642-12-6, GenBank R42934 165642-95-5,
 GenBank R43017 165643-04-9, GenBank R43026 165643-71-0, GenBank R43093
 165644-67-7, GenBank R43189 165645-28-3, GenBank R43250 165646-01-5,
 GenBank R43323 165647-49-4, GenBank R43471 165649-63-8, GenBank R43535
 165651-16-1, GenBank R43713 165651-37-6, GenBank R43734 165651-58-1,
 GenBank R43755 165652-41-5, GenBank R43798 165654-61-5, GenBank R44077
 165690-05-1, GenBank R44327 165690-24-4, GenBank R44346

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 165694-02-0, GenBank R44741 165694-80-4, GenBank R44739 165696-97-9,
 GenBank R44985 165697-20-1, GenBank R45008 165697-34-7, GenBank R45056
 165697-89-2, GenBank R45111 165697-94-9, GenBank R45116 165699-18-3,
 GenBank R45255 165699-70-7, GenBank R45292 165699-99-0, GenBank R45321
 165700-36-7, GenBank R45358 165700-83-4, GenBank R45367 165702-90-9,
 GenBank R45636 165703-26-4, GenBank R45672 165708-94-1, GenBank R45963
 165709-07-9, GenBank R45976 165709-31-9, GenBank R46000 165717-25-9,
 GenBank R46794 165719-62-0, GenBank X85372 165719-63-1, GenBank X85373
 165764-43-2, GenBank U25789 165768-10-5, GenBank R47979 165771-34-6,
 GenBank R48303 165773-08-0, GenBank R48477 165776-75-0, GenBank R48844
 165778-31-4, GenBank R49124 165778-51-8, GenBank R49144 165781-66-8,
 GenBank R49459 165782-75-2, GenBank R49568 165782-94-5, GenBank R49587
 165794-68-3, GenBank R50761 165795-77-7, GenBank R50870 165797-22-8,
 GenBank R51015 165797-28-4, GenBank R51021 165799-49-5, GenBank R51242
 165826-68-6, GenBank R51354 165826-96-0, GenBank R51382 165828-07-9,
 GenBank R51493 165832-60-0, GenBank R51946 165833-44-3, GenBank R52030
 165833-51-2, GenBank R52037 165834-75-3, GenBank R52161 165839-11-2,
 GenBank R52597 165839-96-3, GenBank R52682 165842-15-9, GenBank R52901
 165846-38-8, GenBank R53323 165846-66-2, GenBank R53351 165851-91-2,
 GenBank R53928 165851-93-4, GenBank R53930 165852-19-7, GenBank R53889
 165852-57-3, GenBank R53942 165853-33-8, GenBank R54035 165853-47-4,

GenBank R54049 165854-75-1, GenBank R54160 165855-69-6, GenBank R54249
165857-97-6, GenBank R54444 165858-17-3, GenBank R54559 165858-52-6,
GenBank R54541 165859-33-6, GenBank R54590 165859-35-8, GenBank R54592
165861-29-0, GenBank R54610 165864-17-5, GenBank R54779 165864-53-9,
GenBank R55150 165864-76-6, GenBank R55140 165865-90-7, GenBank R55105
165866-62-6, GenBank R55185 165869-96-5, GenBank R55490 165870-63-3,
GenBank R55619 165870-70-2, GenBank R55626 165907-46-0, GenBank R55747
165910-35-0, GenBank R56043 165911-68-2, GenBank R56123 165916-14-3,
GenBank R56562 165916-96-1, GenBank R56643 165917-08-8, GenBank R56604
165917-57-7, GenBank R56738 165941-23-1, GenBank R59135 165941-69-5,
GenBank R59087 165968-91-2, GenBank R59304 165969-65-3, GenBank R59371
165971-88-0, GenBank R59562 165972-89-4, GenBank R59681 165973-16-0,
GenBank R59722 165974-11-8, GenBank R59833 165976-61-4, GenBank R60094
165982-92-3, GenBank R60705 165983-04-0, GenBank R60717 165983-17-5,
GenBank R60730 165983-94-8, GenBank R60807 165986-54-9, GenBank R61067
165986-60-7, GenBank R61073 165987-50-8, GenBank R61163 165987-74-6,
GenBank R61187 165988-84-1, GenBank R61297 165989-59-3, GenBank R61372
165991-88-8, GenBank R61601 165992-49-4, GenBank R61662 165993-66-8,
GenBank R61779 165993-79-3, GenBank R61845 165994-86-5, GenBank R61871
165999-32-6, GenBank R62242 166000-06-2, GenBank R62288 166002-08-0,
GenBank R62460 166002-76-2, GenBank R62603 166002-77-3, GenBank R62604
166003-34-5, GenBank R62612 166008-12-4, GenBank R63104 166008-37-3,
GenBank R63129 166008-45-3, GenBank R63137 166012-09-5, GenBank R63515
166012-37-9, GenBank R63543 166014-53-5, GenBank R63747 166015-08-3,
GenBank R63790 166015-76-5, GenBank R63811 166016-06-4, GenBank R63841
166016-34-8, GenBank R63900 166017-22-7, GenBank R64004 166026-05-7,
GenBank S75295 166050-92-6, GenBank R64251 166055-01-2, GenBank R64693
166055-77-2, GenBank R64716 166066-59-7, GenBank R65798 166068-54-8,
GenBank R65993 166069-17-6, GenBank R66056 166071-23-4, GenBank R66262
166071-29-0, GenBank R66268 166071-71-2, GenBank R66310 166072-99-7,
GenBank R66438 166074-01-7, GenBank R66540 166074-94-8, GenBank R66633
166077-24-3, GenBank R66863 166077-82-3, GenBank R66922 166081-43-2,
GenBank R67283 166123-31-5, GenBank R68091 166123-90-6, GenBank R68150
166125-84-4, GenBank R68344 166127-79-3, GenBank R68539 166128-21-8,
GenBank R68581 166128-74-1, GenBank R68634 166129-09-5, GenBank R68669
166130-43-4, GenBank R68803 166130-45-6, GenBank R68805 166133-57-9,
GenBank R69117 166134-76-5, GenBank R69236 166135-47-3, GenBank R69307
166138-07-4, GenBank R69567 166138-62-1, GenBank R69622 166139-11-3,
GenBank R69671 166140-38-1, GenBank R69798 166140-93-8, GenBank R69853
166145-58-0, GenBank R70318 166148-38-5, GenBank R70598 166148-89-6,
GenBank R70649 166148-98-7, GenBank R70658 166151-07-1, GenBank R70867
166151-65-1, GenBank R70925 166153-91-9, GenBank R71151 166156-31-6,
GenBank R71391 166156-80-5, GenBank R71440 166158-67-4, GenBank R71627
166198-88-5, GenBank R71689 166202-74-0, GenBank R72075 166204-42-8,
GenBank R72243 166204-43-9, GenBank R72244 166208-87-3, GenBank R72688
166211-12-7, GenBank R72913 166215-89-0, GenBank R73354 166222-88-4,
GenBank R74004 166225-66-7, GenBank R74253 166226-27-3, GenBank R74357
166227-35-6, GenBank R74415 166291-10-7, GenBank R76263 166292-34-8,
GenBank R76394 166293-58-9, GenBank R76544 166295-46-1, GenBank R76749
166299-01-0, GenBank R77104 166300-23-8, GenBank R77226 166344-91-8,
GenBank R77864 166349-14-0, GenBank R78287 166357-21-7, GenBank X87446
166357-50-2, GenBank X87455 166359-72-4, GenBank R78490 166359-75-7,
GenBank R78465 166359-79-1, GenBank R78469 166359-96-2, GenBank R78498
166360-14-1, GenBank R78516 166360-46-9, GenBank R78548 166360-83-4,
GenBank R78585 166360-89-0, GenBank R78591 166360-95-8, GenBank R78597
166362-22-7, GenBank R78724 166364-69-8, GenBank R78971 166365-80-6,
GenBank R79082 166416-26-8, GenBank R80322 166422-94-2, GenBank R80990
166457-15-4, GenBank R81830 166506-88-3, GenBank H00733 166507-11-5,
GenBank H00756 166507-79-5, GenBank H00824 166511-17-7, GenBank H01164
166513-03-7, GenBank H01350 166549-56-0, GenBank H01610 166551-34-4,
GenBank H01788 166552-72-3, GenBank H01926 166553-85-1, GenBank H02039
166555-76-6, GenBank H02230 166556-53-2, GenBank H02307 166561-70-2,
GenBank H02824 166561-83-7, GenBank H02837 166561-94-0, GenBank H02848
166577-01-1, GenBank H04382 166578-39-8, GenBank H04493 166581-10-8,
GenBank H04757 166604-88-2, GenBank H04810 166605-40-9, GenBank H04891
166605-96-5, GenBank H05039 166607-27-8, GenBank H05057 166607-54-1,

GenBank H05140 166611-60-5, GenBank H05552 166612-07-3, GenBank H05580
 166613-91-8, GenBank H05777 166614-92-2, GenBank H05875 166615-76-5,
 GenBank H05934 166618-85-5, GenBank H06273 166619-66-5, GenBank H06377
 166619-69-8, GenBank H06380 166621-27-8, GenBank H06580 166623-38-7,
 GenBank H06675 166626-23-9, GenBank H07025 166627-22-1, GenBank H07071
 166632-73-1, GenBank H08029 166633-63-2, GenBank H08119 166636-76-6,
 GenBank H08432 166637-22-5, GenBank H08478 166637-92-9, GenBank H08548
 166638-04-6, GenBank H08560 166638-05-7, GenBank H08561
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 166638-08-0, GenBank H08564 166638-39-7, GenBank H08595 166639-74-3,
 GenBank H08730 166644-89-9, GenBank H09245 166645-79-0, GenBank H09335
 166645-87-0, GenBank H09343 166646-36-2, GenBank H09392 166646-71-5,
 GenBank H09427 166646-99-7, GenBank H09455 166647-05-8, GenBank H09461
 166648-44-8, GenBank H09600 166648-58-4, GenBank H09614 166648-80-2,
 GenBank H09636 166651-58-7, GenBank H09914 166651-83-8, GenBank H09939
 166652-54-6, GenBank H10010 166653-42-5, GenBank H10098 166653-44-7,
 GenBank H10100 166675-81-6, GenBank H10356 166679-83-0, GenBank H10761
 166680-00-8, GenBank H10778 166682-25-3, GenBank H11003 166682-58-2,
 GenBank H11036 166683-49-4, GenBank H11127 166683-52-9, GenBank H11130
 166683-73-4, GenBank H11151 166685-42-3, GenBank H11320 166686-75-5,
 GenBank H11453 166686-76-6, GenBank H11454 166686-89-1, GenBank H11467
 166687-84-9, GenBank H11562 166690-30-8, GenBank H11808 166690-60-4,
 GenBank H11838 166693-27-2, GenBank H12105 166694-12-8, GenBank H12190
 166694-76-4, GenBank H12254 166695-12-1, GenBank H12290 166700-67-0,
 GenBank H12845 166701-68-4, GenBank H12946 166702-94-9, GenBank H13072
 166705-22-2, GenBank H13300 166707-99-9, GenBank H13577 166713-11-7,
 GenBank H14057 166716-57-0, GenBank H14433 166719-45-5, GenBank H14723
 166720-12-3, GenBank H14810 166722-22-1, GenBank H14986 166722-49-2,
 GenBank H15084 166722-59-4, GenBank H15094 166723-21-3, GenBank H15099
 166723-52-0, GenBank H15111 166724-35-2, GenBank H15215 166725-47-9,
 GenBank H15274 166726-12-1, GenBank H15385 166726-38-1, GenBank H15416
 166726-90-5, GenBank H15446 166727-46-4, GenBank H15560 166728-19-4,
 GenBank H15597 166728-98-9, GenBank H15676 166728-99-0, GenBank H15677
 166731-35-7, GenBank H15913 166731-72-2, GenBank H15950 166732-37-2,
 GenBank H16015 166732-73-6, GenBank H16051 166777-79-3, GenBank H16401
 166836-92-6, GenBank U27143 166839-71-0, GenBank U27460 166845-77-8,
 GenBank D38073 166845-84-7, GenBank D55671 166848-08-4, GenBank Z47087
 166848-15-3, GenBank Z30570 166849-24-7, GenBank X86772 166858-93-1,
 GenBank H16637 166859-60-5, GenBank H16704 166860-02-2, GenBank H16746
 166860-07-7, GenBank H16751 166860-45-3, GenBank H16789 166861-59-2,
 GenBank H16903 166862-53-9, GenBank H16997 166862-59-5, GenBank H17003
 166863-03-2, GenBank H17047 166863-36-1, GenBank H17080 166863-77-0,
 GenBank H17121 166864-14-8, GenBank H17158 166864-40-0, GenBank H17184
 166864-95-5, GenBank H17239 166865-91-4, GenBank H17335 166866-20-2,
 GenBank H17364 166866-68-8, GenBank H17412 166867-68-1, GenBank H17512
 166868-06-0, GenBank H17550 166868-71-9, GenBank H17615 166869-87-0,
 GenBank H17731 166870-60-6, GenBank H17804 166872-20-4, GenBank S75548
 166908-46-9, GenBank H17860 166908-69-6, GenBank H17883 166913-21-9,
 GenBank H18335 166915-17-9, GenBank H18531 166917-01-7, GenBank H18715
 166917-02-8, GenBank H18716 166919-99-9, GenBank H19013 166920-09-8,
 GenBank H19023 166920-12-3, GenBank H19026 166921-88-6, GenBank H19202
 166922-15-2, GenBank H19229 166922-25-4, GenBank H19239 166926-46-1,
 GenBank U25804 167001-80-1, GenBank H39560 167035-42-9, GenBank H39991
 167038-91-7, GenBank H40323 167041-55-6, GenBank H40604 167044-18-0,
 GenBank H40880 167045-20-7, GenBank H40964 167047-16-7, GenBank H41165
 167061-81-6, GenBank H42679 167062-46-6, GenBank H42664 167062-73-9,
 GenBank H42722 167118-69-6, GenBank H44051 167127-00-6, GenBank H44784
 167127-96-0, GenBank H45003 167132-44-7, GenBank H45390 167134-11-4,
 GenBank H45568 167136-11-0, GenBank H45810 167173-97-9, GenBank H45841
 167175-57-7, GenBank H46041 167181-56-8, GenBank H46553 167189-33-5,
 GenBank H47358 167189-72-2, GenBank H47397 167192-02-1, GenBank H47627
 167196-97-6, GenBank H48122 167200-75-1, GenBank U19769 167206-37-3,

GenBank U28249 167232-50-0, GenBank R83213 167236-47-7, GenBank R83610
 167237-95-8, GenBank R83758 167238-38-2, GenBank R83836 167239-51-2,
 GenBank R83880 167334-24-9, GenBank H19359 167334-36-3, GenBank H19371
 167335-87-7, GenBank H19522 167337-32-8, GenBank H19667 167337-51-1,
 GenBank H19686 167339-18-6, GenBank H19853 167347-17-3, GenBank H20652
 167349-37-3, GenBank H20872 167349-73-7, GenBank H20908 167353-10-8,
 GenBank H21245 167431-35-8, GenBank H21540 167434-87-9, GenBank H21892
 167435-38-3, GenBank H21943 167436-83-1, GenBank H22088 167439-41-0,
 GenBank H22346 167440-76-8, GenBank H22481 167442-93-5, GenBank H22698
 167442-94-6, GenBank H22699 167443-91-6, GenBank H22856 167445-12-7,
 GenBank H22917 167446-51-7, GenBank H23049 167446-99-3, GenBank H23123
 167447-68-9, GenBank H23170 167447-71-4, GenBank H23173 167448-50-2,
 GenBank H23255 167448-68-2, GenBank H23315 167448-77-3, GenBank H23324
 167448-82-0, GenBank H23329 167448-98-8, GenBank H23265 167449-54-9,
 GenBank H23349 167455-43-8, GenBank H23979 167455-78-9, GenBank H23985
 167456-55-5, GenBank H24126 167456-88-4, GenBank H24105 167456-91-9,
 GenBank H24108 167459-28-1, GenBank H24352 167462-59-1, GenBank H24688
 167512-25-6, GenBank H25625 167515-15-3, GenBank H25972 167526-45-6,
 GenBank H27048 167532-28-7, GenBank H27646 167572-76-1, GenBank H28091
 167573-04-8, GenBank H28119 167574-41-6, GenBank H28256 167583-91-7,
 GenBank H29207 167584-10-3, GenBank H29226 167584-34-1, GenBank H29250
 167584-52-3, GenBank H29268 167584-77-2, GenBank H29295 167585-57-1,
 GenBank H29432 167586-70-1, GenBank H29484 167588-53-6, GenBank H29678
 167589-04-0, GenBank H29718 167600-63-7, GenBank H30877 167660-20-0,
 GenBank H37774 167661-37-2, GenBank H37832 167662-52-4, GenBank H37989
 167664-98-4, GenBank H38263 167665-41-0, GenBank H38240 167668-09-9,
 GenBank H38522 167670-61-3, GenBank H38804 167671-18-3, GenBank H38848
 167671-34-3, GenBank H38864 167674-15-9, GenBank H39115 167675-08-3,
 GenBank H39221 167712-48-3, GenBank U14603 167712-52-9, GenBank U17714
 167745-42-8, GenBank R85090 167746-35-2, GenBank R85213 167782-68-5,
 GenBank R85342 167783-43-9, GenBank R85387 167784-93-2, GenBank R85537
 167789-50-6, GenBank R86035 167792-34-9, GenBank R86305 167795-40-6,
 GenBank R86721 167803-73-8, GenBank R87650 167809-15-6, GenBank R88192
 167809-65-6, GenBank R88242 167879-47-2, GenBank R89224 167879-83-6,
 GenBank R89260 167908-14-7, GenBank R89615 167922-48-7, GenBank R90930
 167922-53-4, GenBank R90934 167925-42-0, GenBank R91266 167928-90-7,
 GenBank R91577 167929-22-8, GenBank R91686 167929-25-1, GenBank R91689
 167932-27-6, GenBank R91986 167932-67-4, GenBank R91953 168146-82-5,
 GenBank X81696 168218-38-0, GenBank R92123 168220-17-5, GenBank R92281
 168221-78-1, GenBank R92452 168223-09-4, GenBank R92602 168223-16-3,
 GenBank R92609 168224-39-3, GenBank R92806 168225-48-7, GenBank R92852
 168226-90-2, GenBank R92994 168345-20-8, GenBank D52414

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 168371-92-4, GenBank D55094 168372-50-7, GenBank D55192 168512-87-6,
 GenBank X84373 168516-55-0, GenBank R93124 168518-23-8, GenBank R93255
 168520-73-8, GenBank R93542 168520-82-9, GenBank R93551 168521-52-6,
 GenBank R93621 168522-49-4, GenBank R93715 168523-26-0, GenBank R93783
 168528-25-4, GenBank D58753 168532-98-7, GenBank D63874 168576-84-9,
 GenBank R94456 168576-87-2, GenBank R94542 168585-99-7, GenBank D56120
 168590-43-0, GenBank D56406 168593-98-4, GenBank R94947 168604-41-9,
 GenBank D45198 168744-50-1, GenBank R95684 168744-57-8, GenBank R95691
 168744-97-6, GenBank R95731 168745-06-0, GenBank R95740 168745-15-1,
 GenBank R95749 168745-44-6, GenBank R95778 168790-15-6, GenBank R96240
 168790-65-6, GenBank R96290 168793-34-8, GenBank R96568 168793-45-1,
 GenBank R96579 168793-50-8, GenBank R96527 168793-75-7, GenBank R96552
 168794-44-3, GenBank R96668 168797-10-2, GenBank R96941 168799-65-3,
 GenBank R97233 168799-87-9, GenBank R97220 168802-77-5, GenBank R97502
 168806-11-9, GenBank R97836 168806-21-1, GenBank R97846 168810-17-1,
 GenBank R98242 168813-25-0, GenBank S78569 168858-06-8, GenBank R98485
 168858-53-5, GenBank R98532 168859-23-2, GenBank R98407 168859-52-7,
 GenBank R98623 168860-01-3, GenBank R98592 168862-56-4, GenBank R98851
 168863-08-9, GenBank R98903 168864-97-9, GenBank R99092 168871-69-0,

GenBank R99758 168872-36-4, GenBank R99831 168876-61-7, GenBank H48472
 168877-37-0, GenBank U14750 168884-46-6, GenBank H48677 168884-78-4,
 GenBank H48661 168884-99-9, GenBank H48706 168926-69-0, GenBank H49263
 168927-48-8, GenBank H49289 168932-05-6, GenBank H49751 168932-82-9,
 GenBank H49828 168935-48-6, GenBank H50094 168935-61-3, GenBank H50107
 168939-53-5, GenBank H50500 168940-75-8, GenBank H50622 168941-09-1,
 GenBank H50656 168942-92-5, GenBank H50839 168945-03-7, GenBank H51050
 168945-53-7, GenBank H51100 168949-14-2, GenBank H51461 168951-58-4,
 GenBank H51705 168987-29-9, GenBank H52353 168987-66-4, GenBank H52390
 168990-48-5, GenBank H52672 168994-49-8, GenBank H53073 168996-51-8,
 GenBank H53275 169002-93-1, GenBank H53915 169003-99-0, GenBank H54023
 169004-69-7, GenBank H54093 169006-61-5, GenBank H54285 169011-71-6,
 GenBank U32989 169016-49-3, GenBank H54628 169016-50-6, GenBank H54629
 169016-81-3, GenBank H54660 169017-57-6, GenBank H54577 169018-26-2,
 GenBank H54752 169023-07-8, GenBank U33760 169075-13-2, GenBank L47647
 169075-17-6, GenBank L47574 169078-02-8, GenBank H55854 169078-57-3,
 GenBank H55909 169082-92-2, GenBank H56344 169082-96-6, GenBank H56348
 169085-42-1, GenBank H56594 169089-43-4, GenBank U24105 169109-76-6,
 GenBank S79895 169146-74-1, GenBank X87212 169345-09-9, GenBank H57180
 169346-39-8, GenBank H57310 169352-16-3, GenBank H57887 169354-47-6,
 GenBank H58118 169354-48-7, GenBank H58119 169355-78-6, GenBank H58234
 169358-40-1, GenBank H58452 169359-74-4, GenBank H58645 169360-88-7,
 GenBank H58708 169399-20-6, GenBank H58872 169399-21-7, GenBank H58873
 169402-51-1, GenBank H59203 169402-78-2, GenBank H59230 169403-07-0,
 GenBank H59259 169406-17-1, GenBank H59618 169408-28-0, GenBank H59725
 169410-86-0, GenBank H60038 169412-23-1, GenBank H60175 169413-94-9,
 GenBank H60321 169422-90-6, GenBank H61242 169422-91-7, GenBank H61243
 169424-79-7, GenBank H61464 169427-46-7, GenBank H61698 169429-02-1,
 GenBank H61835 169430-27-7, GenBank H61979 169430-57-3, GenBank H62009
 169431-51-0, GenBank H62103 169434-35-9, GenBank H62387 169483-44-7,
 GenBank H62801 169484-37-1, GenBank H62894 169485-28-3, GenBank H62985
 169490-15-7, GenBank H63472 169492-49-3, GenBank H63706 169567-82-2,
 GenBank H63826 169569-57-7, GenBank H63976 169571-03-3, GenBank H64147
 169581-78-6, GenBank H65261 169583-58-8, GenBank H65395 169585-02-8,
 GenBank H65595 169589-62-2, GenBank H66030 169590-02-7, GenBank H66070
 169590-23-2, GenBank H66023 169638-43-1, GenBank H67188 169639-65-0,
 GenBank H67282 169639-75-2, GenBank H67292 169647-89-6, GenBank H68107
 169649-88-1, GenBank H68308 169650-83-3, GenBank H68403 169651-70-1,
 GenBank H68509 169653-90-1, GenBank H68664 169654-42-6, GenBank H68952
 169656-20-6, GenBank H68845 169657-33-4, GenBank H69143 169657-46-9,
 GenBank H69156 169732-76-7, GenBank D45248 169733-40-8, GenBank D37991
 169791-55-3, GenBank X89589 170048-96-1, GenBank U36764 170074-29-0,
 GenBank H69334 170077-03-9, GenBank H69608 170077-78-8, GenBank H69683
 170131-28-9, GenBank H69785 170135-17-8, GenBank H70140 170175-85-6,
 GenBank H70394 170182-64-6, GenBank H70774 170191-93-2, GenBank H71703
 170192-03-7, GenBank H71713 170193-38-1, GenBank H71848 170196-03-9,
 GenBank H72113 170196-09-5, GenBank H72119 170199-68-5, GenBank H72474
 170203-59-5, GenBank H72917 170203-60-8, GenBank H72918 170252-93-4,
 GenBank H73590 170253-59-5, GenBank H73816 170253-60-8, GenBank H73817
 170254-08-7, GenBank H73866 170255-23-9, GenBank H73914 170258-39-6,
 GenBank H73727 170259-06-0, GenBank H74086 170260-81-8, GenBank H73265
 170262-18-7, GenBank H74264 170318-73-7, GenBank X87176 170319-40-1,
 GenBank X91257 170324-15-9, GenBank U37519 170339-52-3, GenBank H75569
 170341-01-2, GenBank H75703 170403-89-1, GenBank X85545 170408-44-3,
 GenBank H77641 170410-06-7, GenBank H77766 170417-27-3, GenBank H78484
 170417-80-8, GenBank H78537 170477-22-2, GenBank H79088 170517-04-1,
 GenBank H79469 170517-69-8, GenBank H79534 170517-94-9, GenBank H79559
 170518-64-6, GenBank H79629 170522-98-2, GenBank H80063 170523-38-3,
 GenBank H80103 170528-89-9, GenBank H80655 170529-18-7, GenBank H80684
 170529-19-8, GenBank H80685 170529-83-6, GenBank H80749 170530-15-1,
 GenBank H80804 170531-97-2, GenBank H81009 170534-67-5, GenBank H81199
 170534-68-6, GenBank H81200 170534-98-2, GenBank H81331 170536-37-5,
 GenBank H81359 170541-49-8, GenBank H81938 170547-61-2, GenBank H82536
 170591-94-3, GenBank D78151 170591-98-7, GenBank D59253 170593-70-1,
 GenBank H82848 170593-89-2, GenBank H82891 170594-14-6, GenBank H82974
 170595-38-7, GenBank H83067 170596-60-8, GenBank H83178 170597-07-6,

GenBank H83225 170606-69-6, GenBank H84153 170607-02-0, GenBank H84211
 170607-45-1, GenBank H84229 170609-50-4, GenBank H84480 170666-09-8,
 GenBank H85272 170668-82-3, GenBank H85475 170672-00-1, GenBank U39050
 170676-51-4, GenBank U39360 170713-95-8, GenBank L49054 170764-48-4,
 GenBank H86642 170766-67-3, GenBank H86876 170768-50-0, GenBank H87106
 170773-29-2, GenBank H87536 170774-96-6, GenBank H87703 170823-47-9,
 GenBank H88734 171026-36-1, GenBank H89637 171027-87-5, GenBank H89788
 171123-33-4, GenBank H90219 171126-59-3, GenBank H90577 171128-00-0,
 GenBank H90718 171128-49-7, GenBank H90767 171136-55-3, GenBank U27467
 171138-45-7, GenBank H91614 171140-40-2, GenBank H91776
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 171141-02-9, GenBank H91845 171145-36-1, GenBank H92234 171146-58-0,
 GenBank H92372 171152-61-7, GenBank D49387 171166-93-1, GenBank X87843
 171168-25-5, GenBank H92758 171169-20-3, GenBank H92853 171206-06-7,
 GenBank H93149 171206-18-1, GenBank H93216 171207-05-9, GenBank H93249
 171207-92-4, GenBank H93393 171208-32-5, GenBank H93373 171208-79-0,
 GenBank H93463 171209-20-4, GenBank H93424 171209-59-9, GenBank H93552
 171209-94-2, GenBank H93482 171211-34-0, GenBank H93692 171221-38-8,
 GenBank H93832 171300-35-9, GenBank H94487 171301-88-5, GenBank H94617
 171304-75-9, GenBank H94897 171305-07-0, GenBank H94929 171306-01-7,
 GenBank H95038 171309-13-0, GenBank H95342 171309-95-8, GenBank H95424
 171394-22-2, GenBank H95465 171394-86-8, GenBank H95529 171395-95-2,
 GenBank H95638 171396-69-3, GenBank H95712 171440-71-4, GenBank H95956
 171440-74-7, GenBank H95959 171440-75-8, GenBank H95960 171442-10-7,
 GenBank H96095 171443-50-8, GenBank H96235 171444-04-5, GenBank H96289
 171445-07-1, GenBank H96392 171445-31-1, GenBank H96416 171449-27-7,
 GenBank X87241 171451-08-4, GenBank H96527 171453-02-4, GenBank H96630
 171453-15-9, GenBank H96643 171453-26-2, GenBank H96654 171453-32-0,
 GenBank H96660 171453-45-5, GenBank H96673 171453-82-0, GenBank H96712
 171454-08-3, GenBank H96738 171454-49-2, GenBank H96834 171630-35-6,
 GenBank H97508 171631-85-9, GenBank H97597 171634-74-5, GenBank H97861
 171634-81-4, GenBank H97868 171634-93-8, GenBank H97880 171635-15-7,
 GenBank H97970 171637-91-5, GenBank H98215 171694-34-1, GenBank H98534
 171695-16-2, GenBank H98636 171696-60-9, GenBank H98742 171697-30-6,
 GenBank H98812 171698-56-9, GenBank H98963 171699-05-1, GenBank H98987
 171699-53-9, GenBank H99035 171699-93-7, GenBank H99075 171701-19-2,
 GenBank H99170 171701-69-2, GenBank H99257 171702-38-8, GenBank H99362
 171703-29-0, GenBank H99415 171704-96-4, GenBank H99586 171706-44-8,
 GenBank H99768 171707-71-4, GenBank H99816 171708-73-9, GenBank H99996
 171708-74-0, GenBank H99997 171708-79-5, GenBank N20003 171748-27-9,
 GenBank N20328 171749-74-9, GenBank N20475 171749-79-4, GenBank N20480
 171786-89-3, GenBank N20960 171787-18-1, GenBank N20989 171788-08-2,
 GenBank N21079 171789-62-1, GenBank N21233 171790-42-4, GenBank N21313
 171791-36-9, GenBank N21407 171791-99-4, GenBank N21470 171793-05-8,
 GenBank N21576 171793-50-3, GenBank N21621 171793-62-7, GenBank N21633
 171840-12-3, GenBank U41060 171841-83-1, GenBank S79639 171870-36-3,
 GenBank U36336 171886-66-1, GenBank L36983 171886-69-4, GenBank X84958
 172013-17-1, GenBank U41514 172013-75-1, GenBank U41569 172047-21-1,
 GenBank D49489 172049-64-8, GenBank N22897 172049-68-2, GenBank N22901
 172049-80-8, GenBank N22913 172053-83-7, GenBank N23340 172054-30-7,
 GenBank N23390 172055-70-8, GenBank N23530 172056-00-7, GenBank N23599
 172056-06-3, GenBank N23605 172056-32-5, GenBank N23578 172057-94-2,
 GenBank N23756 172059-45-9, GenBank N23877 172060-34-3, GenBank N23996
 172060-84-3, GenBank N24046 172061-93-7, GenBank N24155 172063-19-3,
 GenBank N24281 172064-39-0, GenBank N24401 172064-75-4, GenBank N24437
 172066-47-6, GenBank N24609 172068-43-8, GenBank N24805 172069-06-6,
 GenBank N24868 172071-83-9, GenBank N25150 172072-41-2, GenBank N25204
 172104-18-6, GenBank S78085 172106-41-1, GenBank N25578 172109-82-9,
 GenBank N25920 172110-07-5, GenBank N25945 172111-45-4, GenBank N26083
 172112-25-3, GenBank N26163 172112-33-3, GenBank N26171 172117-92-9,
 GenBank N26769 172119-38-9, GenBank N26928 172122-12-2, GenBank N27118
 172122-52-0, GenBank N27159 172129-31-6, GenBank N27799 172129-34-9,

GenBank N27802 172130-02-8, GenBank N27916 172191-51-4, GenBank N28391
 172192-66-4, GenBank N28524 172192-78-8, GenBank N28536 172194-46-6,
 GenBank N28729 172195-24-3, GenBank N28754 172198-93-5, GenBank N29133
 172234-13-8, GenBank N29763 172235-61-9, GenBank N29825 172239-00-8,
 GenBank N30205 172239-60-0, GenBank N30256 172240-13-0, GenBank N30348
 172242-40-9, GenBank N30553 172242-44-3, GenBank N30557 172242-60-3,
 GenBank N30573 172242-69-2, GenBank N30517 172243-85-5, GenBank N30728
 172244-04-1, GenBank N30747 172244-08-5, GenBank N30751 172244-17-6,
 GenBank N30680 172244-36-9, GenBank N30699 172244-50-7, GenBank N30713
 172249-73-9, GenBank X89750 172379-30-5, GenBank N30959 172379-47-4,
 GenBank N30976 172382-16-0, GenBank N31292 172382-66-0, GenBank N31283
 172384-11-1, GenBank N31459 172387-85-8, GenBank N31806 172388-18-0,
 GenBank N31866 172389-42-3, GenBank N32019 172390-21-5, GenBank N32085
 172390-61-3, GenBank N32045 172392-02-8, GenBank N32201 172392-27-7,
 GenBank N32226 172393-31-6, GenBank N32396 172394-83-1, GenBank N32556
 172397-88-5, GenBank N32909 172397-91-0, GenBank N32912 172398-49-1,
 GenBank N32907 172431-21-9, GenBank N32949 172431-74-2, GenBank N33041
 172431-87-7, GenBank N33054 172431-96-8, GenBank N33063 172432-09-6,
 GenBank N33012 172440-23-2, GenBank N33851 172440-70-9, GenBank N33900
 172442-24-9, GenBank N34055 172550-49-1, GenBank N34362 172551-49-4,
 GenBank N34426 172551-51-8, GenBank N34429 172555-60-1, GenBank N34827
 172555-72-5, GenBank N34839 172556-66-0, GenBank N34933 172556-76-2,
 GenBank N34943 172556-99-9, GenBank N34966 172557-71-0, GenBank N35038
 172559-20-5, GenBank N35187 172559-92-1, GenBank N35259 172562-02-6,
 GenBank N35469 172562-26-4, GenBank N35493 172563-79-0, GenBank N35646
 172566-78-8, GenBank N35945 172567-73-6, GenBank N36040 172568-01-3,
 GenBank N36068 172569-07-2, GenBank N36174 172569-65-2, GenBank N36232
 172570-12-6, GenBank N36279 172572-39-3, GenBank N36506 172573-21-6,
 GenBank N36588 172574-37-7, GenBank N36704 172574-78-6, GenBank N36745
 172575-86-9, GenBank N36853 172706-19-3, GenBank N39426 172707-76-5,
 GenBank N39577 172713-23-4, GenBank U33818 172714-96-4, GenBank N38891
 172715-65-0, GenBank N38960 172716-68-6, GenBank N39063 172717-89-4,
 GenBank N39161 172718-20-6, GenBank N39280 172760-52-0, GenBank N39749
 172762-75-3, GenBank N39937 172763-55-2, GenBank N40017 172763-61-0,
 GenBank N40023 172764-78-2, GenBank N40140 172765-08-1, GenBank N40170
 172765-18-3, GenBank N40180 172765-26-3, GenBank N40188 172768-34-2,
 GenBank N40495 172769-21-0, GenBank N40582 172770-18-2, GenBank N40679
 172772-28-0, GenBank N40889 172772-58-6, GenBank N40919 172773-07-8,
 GenBank N40968 172773-36-3, GenBank N40997 172773-91-0, GenBank N41052
 172810-39-8, GenBank N41577 172811-07-3, GenBank N41645 172812-09-8,
 GenBank N41768 172812-46-3, GenBank N41842 172813-04-6, GenBank N41826
 172815-07-5, GenBank N42045 172815-24-6, GenBank N42062 172818-36-9,
 GenBank U37283 172857-43-1, GenBank N42469 172857-74-8, GenBank N42500
 172859-11-9, GenBank N42665 172860-94-5, GenBank N42826

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 172861-19-7, GenBank N42801 172866-18-1, GenBank D50525 173003-48-0,
 GenBank U41371 173017-61-3, GenBank D50310 173139-74-7, GenBank D79157
 173140-07-3, GenBank D79190 173224-00-5, GenBank N43819 173224-37-8,
 GenBank N43856 173225-57-5, GenBank N43976 173226-82-9, GenBank N44101
 173227-22-0, GenBank N44141 173228-59-6, GenBank N44278 173228-77-8,
 GenBank N44296 173237-77-9, GenBank D82223 173237-99-5, GenBank D82427
 173489-58-2, GenBank N44490 173490-92-1, GenBank N44673 173492-38-1,
 GenBank N44764 173492-64-3, GenBank N44907 173493-26-0, GenBank N44889
 173495-07-3, GenBank N45091 173495-30-2, GenBank N45114 173495-47-1,
 GenBank N45131 173495-54-0, GenBank N45138 173497-32-0, GenBank N45313
 173498-62-9, GenBank N45441 173499-63-3, GenBank N45525 173499-71-3,
 GenBank N45616 173501-51-4, GenBank N45732 173504-69-3, GenBank N46050
 173507-18-1, GenBank N46299 173507-43-2, GenBank N46324 173511-78-9,
 GenBank N46759 173512-15-7, GenBank N46796 173512-23-7, GenBank N46804
 173512-91-9, GenBank N46872 173513-07-0, GenBank N46888 173515-32-7,
 GenBank N47113 173517-21-0, GenBank N47302 173517-30-1, GenBank N47311
 173517-35-6, GenBank N47316 173517-81-2, GenBank N47362 173518-07-5,

GenBank N47388 173518-63-3, GenBank N47444 173518-88-2, GenBank N47469 173561-76-7,
173520-23-5, GenBank N47604 173560-79-7, GenBank N47690 173562-10-2, GenBank N47785
GenBank N47813 173561-98-3, GenBank N47773 173562-10-2, GenBank N47924 173564-03-9,
173562-58-8, GenBank N47922 173562-60-2, GenBank N48027 173564-75-5, GenBank N48089
GenBank N48075 173564-57-3, GenBank N48261 173566-39-7, GenBank N48259 173566-71-7,
173566-37-5, GenBank N48293 173567-10-7, GenBank N48252 173568-27-9, GenBank N48458
173571-28-3, GenBank N48751 173572-01-5, GenBank N48816 173574-70-4,
GenBank N49121 173575-08-1, GenBank N49079 173575-19-4, GenBank N49138
173576-20-0, GenBank N49269 173578-23-9, GenBank N49377 173578-63-7,
GenBank N49478 173580-04-6, GenBank N49619 173580-14-8, GenBank N49629
173580-50-2, GenBank N49665 173581-36-7, GenBank N49751 173582-68-8,
GenBank N49883 173582-84-8, GenBank N49899 173616-68-7, GenBank N50073
173616-74-5, GenBank N50079 173617-06-6, GenBank N50152 173618-56-9,
GenBank N50301 173618-97-8, GenBank N50262 173619-90-4, GenBank N50375
173621-51-7, GenBank N50556 173621-98-2, GenBank N50603 173622-06-5,
GenBank N50611 173623-17-1, GenBank N50675 173623-33-1, GenBank N50738
173624-41-4, GenBank N50834 173625-39-3, GenBank N50904 173626-06-7,
GenBank N50976 173626-32-9, GenBank N51002 173628-12-1, GenBank N51226
173628-91-6, GenBank N51325 173629-22-6, GenBank N51297 173629-60-2,
GenBank N51386 173629-89-5, GenBank N51362 173630-04-1, GenBank N51401
173631-73-7, GenBank N51521 173632-80-9, GenBank N51702 173633-43-7,
GenBank N51740 173633-55-1, GenBank N51752 173634-41-8, GenBank N51837
173634-63-4, GenBank N51859 173634-87-2, GenBank N51883 173636-36-7,
GenBank N52018 173637-04-2, GenBank N52073 173638-24-9, GenBank N52151
173638-31-8, GenBank N52158 173639-13-9, GenBank N52337 173639-49-1,
GenBank N52373 173641-78-6, GenBank N52549 173642-18-7, GenBank N52615
173644-33-2, GenBank N52810 173645-17-5, GenBank N52875 173645-18-6,
GenBank N52876 173645-25-5, GenBank N52883 173645-53-9, GenBank N52980
173645-91-5, GenBank N52938 173646-27-0, GenBank N53024 173647-36-4,
GenBank N53133 173647-75-1, GenBank N53172 173648-41-4, GenBank N53214
173649-55-3, GenBank N53352 173652-21-6, GenBank N53641 173652-24-9,
GenBank N53644 173696-76-9, GenBank N53906 173697-95-5, GenBank N54061
173699-28-0, GenBank N54221 173700-07-7, GenBank N54344 173700-76-0,
GenBank N54333 173702-18-6, GenBank N54512 173702-69-7, GenBank N54540
173703-50-9, GenBank N54672 173704-09-1, GenBank N54751 173704-66-0,
GenBank N54728 173704-98-8, GenBank N54774 173705-54-9, GenBank N54848
173706-31-5, GenBank N54925 173714-58-4, GenBank N54994 173742-24-0,
GenBank N55269 173756-14-4, GenBank U28488 173756-52-0, GenBank U48251
173759-46-1, GenBank N56639 173794-79-1, GenBank N56836 173795-01-2,
GenBank N56858 173795-66-9, GenBank N56888 173799-36-5, GenBank N57241
173801-48-4, GenBank N57483 173802-12-5, GenBank N57594 173802-24-9,
GenBank N57526 173802-28-3, GenBank N57530 173802-52-3, GenBank N57554
173802-55-6, GenBank N57557 173803-39-9, GenBank N57659 173804-03-0,
GenBank N57722 173804-04-1, GenBank N57723 173805-34-0, GenBank N57865
173805-75-9, GenBank N57906 173806-63-8, GenBank N57993 173806-99-0,
GenBank N58035 173807-29-9, GenBank N58065 173812-22-1, GenBank N58494
173815-63-9, GenBank N58936 173816-94-9, GenBank N59030 173818-26-3,
GenBank N59138 173818-70-7, GenBank N59206 173819-45-9, GenBank N59281
173819-83-5, GenBank N59289 173820-41-2, GenBank N59377 173821-46-0,
GenBank N59482 173821-50-6, GenBank N59486 173822-42-9, GenBank N59534
173823-81-9, GenBank N59716 173824-99-2, GenBank N59835 174025-41-3,
GenBank N62157 174026-41-6, GenBank N62213 174026-97-2, GenBank N62269
174027-53-3, GenBank N62301 174027-70-4, GenBank N62339 174028-11-6,
GenBank N62375 174028-54-7, GenBank N62402 174028-55-8, GenBank N62403
174029-41-5, GenBank N62514 174031-39-1, GenBank N62684 174031-81-3,
GenBank N62731 174032-11-2, GenBank N62761 174033-32-0, GenBank N62924
174034-43-6, GenBank N62969 174035-28-0, GenBank N63102 174039-50-0,
GenBank N63425 174039-65-7, GenBank N63516 174039-78-2, GenBank N63529
174040-53-0, GenBank N63604 174040-72-3, GenBank N63623 174041-93-1,
GenBank N63744 174042-56-9, GenBank N63807 174043-89-1, GenBank N63940
174043-98-2, GenBank N63949 174044-37-2, GenBank N63988 174044-45-2,
GenBank N63996 174044-73-6, GenBank N64024 174046-24-3, GenBank N64175
174048-23-8, GenBank N64374 174048-54-5, GenBank N64405 174051-86-6,
GenBank N64737 174051-90-2, GenBank N64741 174052-11-0, GenBank N64762
174052-29-0, GenBank N64780 174052-30-3, GenBank N64781 174052-66-5,

GenBank N64817 174053-11-3, GenBank N64862 174055-36-8, GenBank U41515
 174169-32-5, GenBank U27768 174234-11-8, GenBank N66068 174235-20-2,
 GenBank N66177 174236-21-6, GenBank N66278 174236-97-6, GenBank N66354
 174241-18-0, GenBank N66777 174243-75-5, GenBank N67034 174243-79-9,
 GenBank N67038 174248-28-3, GenBank N67487 174251-63-9, GenBank N67822
 174286-68-1, GenBank D14041 174369-19-8, GenBank N68001 174371-65-4,
 GenBank N68247 174373-16-1, GenBank N68399 174373-25-2, GenBank N68408
 174376-02-4, GenBank N68686 174376-34-2, GenBank N68719 174381-19-2,
 GenBank N69204 174381-94-3, GenBank N69283 174383-95-0, GenBank N69491
 174386-04-0, GenBank N69694 174425-95-7, GenBank N69913 174426-84-7,
 GenBank N70059 174429-80-2, GenBank N70382 174430-71-8, GenBank N70411
 174433-61-5, GenBank N70759 174436-00-1, GenBank N71015

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 174436-13-6, GenBank N70948 174436-53-4, GenBank N71028 174436-96-5,
 GenBank N71080 174437-25-3, GenBank N71055 174442-56-9, GenBank N71484
 174445-41-1, GenBank N71769 174445-54-6, GenBank N71782 174445-68-2,
 GenBank N71796 174918-10-6, GenBank N72215 174918-51-5, GenBank N72259
 174918-57-1, GenBank N72265 174920-42-4, GenBank N72450 174923-79-6,
 GenBank N72800 174925-10-1, GenBank N72918 174925-34-9, GenBank N72878
 174925-35-0, GenBank N72879 174927-40-3, GenBank N73130 174928-34-8,
 GenBank N73242 174930-61-1, GenBank N73448 174930-93-9, GenBank N73429
 174931-24-9, GenBank N73571 174931-26-1, GenBank N73499 174931-63-6,
 GenBank N73536 174931-77-2, GenBank N73550 174932-42-4, GenBank N73611
 174932-94-6, GenBank N73703 174934-34-0, GenBank N73827 174934-43-1,
 GenBank N73836 174934-50-0, GenBank N73843 174935-82-1, GenBank N73975
 174936-90-4, GenBank N74131 174937-24-7, GenBank N74085 174937-95-2,
 GenBank N74189 174938-39-7, GenBank N74236 174939-02-7, GenBank N74340
 174939-55-0, GenBank N74313 174940-07-9, GenBank N74390 174941-30-1,
 GenBank N74524 174943-74-9, GenBank N74762 175009-31-1, GenBank L47125
 175034-89-6, GenBank N77415 175036-17-6, GenBank N77514 175038-57-0,
 GenBank N77772 175043-94-4, GenBank N78357 175044-44-7, GenBank N78327
 175048-81-4, GenBank N78843 175049-46-4, GenBank N78828 175049-74-8,
 GenBank N78902 175052-03-6, GenBank N79142 175053-75-5, GenBank N79301
 175054-10-1, GenBank N79336 175058-12-5, GenBank N79738 175058-19-2,
 GenBank N79745 175059-84-4, GenBank N79910 175061-88-8, GenBank N80114
 175063-68-0, GenBank N80294 175065-73-3, GenBank N80499 175098-30-3,
 GenBank N80848 175100-75-1, GenBank N81093 175120-19-1, GenBank N74956
 175121-14-9, GenBank N75028 175121-41-2, GenBank N75055 175121-94-5,
 GenBank N75122 175122-05-1, GenBank N75133 175123-24-7, GenBank N75239
 175125-11-8, GenBank N75464 175128-01-5, GenBank N75745 175129-84-7,
 GenBank N75947 175179-53-0, GenBank N76097 175180-60-6, GenBank N76192
 175180-61-7, GenBank N76193 175183-84-3, GenBank N76567 175188-10-0,
 GenBank N77034 175188-62-2, GenBank N77006 175189-05-6, GenBank N77080
 175189-55-6, GenBank N77138 175190-46-2, GenBank N77229 175302-92-8,
 GenBank D84105 175303-39-6, GenBank U51920 175303-85-2, GenBank U51478
 175304-35-5, GenBank N81261 175307-20-7, GenBank N81611 175490-82-1,
 GenBank N91677 175492-02-1, GenBank N91797 175492-92-9, GenBank N91887
 175493-05-7, GenBank N91900 175493-26-2, GenBank N91921 175493-57-9,
 GenBank N91952 175493-67-1, GenBank N91962 175494-21-0, GenBank N92016
 175495-93-9, GenBank N92188 175495-98-4, GenBank N92193 175496-59-0,
 GenBank N92254 175497-85-5, GenBank N92380 175498-74-5, GenBank N92469
 175500-51-3, GenBank N92646 175503-29-4, GenBank N92924 175506-41-9,
 GenBank N93236 175508-08-4, GenBank N93403 175508-43-7, GenBank N93438
 175512-99-9, GenBank N93894 175513-46-9, GenBank N93941 175516-14-0,
 GenBank N94209 175516-35-5, GenBank N94230 175516-67-3, GenBank N94262
 175518-09-9, GenBank N94404 175518-29-3, GenBank N94424 175518-93-1,
 GenBank N94488 175567-68-7, GenBank N99217 175567-87-0, GenBank N99256
 175572-07-3, GenBank N94758 175574-39-7, GenBank N95011 175575-74-3,
 GenBank N95138 175575-80-1, GenBank N95144 175577-22-7, GenBank N95322
 175579-16-5, GenBank N95433 175579-18-7, GenBank N95435 175581-18-7,
 GenBank N95680 175582-16-8, GenBank N95761 175617-72-8, GenBank N98412
 175620-83-4, GenBank N98591 175625-06-6, GenBank N99168 175626-06-9,

GenBank N99356 175626-74-1, GenBank N99391 175627-28-8, GenBank N99372
 175628-91-8, GenBank N99582 175630-67-8, GenBank N99711 175636-50-7,
 GenBank W00390 175637-57-7, GenBank W00491 175740-76-8, GenBank W00856
 175741-15-8, GenBank W00895 175744-01-1, GenBank W01113 175746-00-6,
 GenBank W01340 175746-30-2, GenBank W01197 175746-97-1, GenBank W01458
 175747-86-1, GenBank W01501 175749-52-7, GenBank W01713 175750-50-2,
 GenBank W01830 175751-93-6, GenBank W01974 175755-71-2, GenBank W02333
 175759-19-0, GenBank W02702 175762-35-3, GenBank W03018 175764-48-4,
 GenBank W03191 175765-85-2, GenBank W03482 175766-10-6, GenBank W03488
 175766-33-3, GenBank W03373 175767-71-2, GenBank W03687 175773-22-5,
 GenBank W04244 175773-80-5, GenBank W04496 175802-93-4, GenBank W04385
 175803-19-7, GenBank W04411 175806-21-0, GenBank W04713 175806-50-5,
 GenBank W04674 175806-72-1, GenBank W04744 175808-36-3, GenBank W04928
 175813-25-9, GenBank W05406 175814-44-5, GenBank W05514 175815-57-3,
 GenBank W05607 175817-54-6, GenBank W05834 175827-06-2, GenBank U50079
 175829-40-0, GenBank L43821 175928-48-0, GenBank W07043 175928-64-0,
 GenBank W07068 175936-60-4, GenBank W07798 176078-66-3, GenBank W15150
 176079-80-4, GenBank W15274 176080-35-6, GenBank W15339 176082-48-7,
 GenBank W15521 176120-16-4, GenBank W16596 176121-53-2, GenBank W16715
 176121-62-3, GenBank W16724 176182-64-2, GenBank W20458 176184-73-9,
 GenBank W19519 176186-88-2, GenBank W19646 176195-28-1, GenBank X97065
 176267-10-0, GenBank W21572 176267-44-0, GenBank W21597 176267-47-3,
 GenBank W21015 176267-79-1, GenBank W21055 176268-45-4, GenBank W21081
 176269-98-0, GenBank W21107 176269-99-1, GenBank W21108 176270-93-2,
 GenBank W21213 176272-07-4, GenBank W21317 176272-90-5, GenBank W21390
 176285-58-8, GenBank W22929 176289-02-4, GenBank W23214 176294-30-7,
 GenBank W23757 176294-84-1, GenBank W23819 176294-89-6, GenBank W23598
 176295-89-9, GenBank W23937 176330-56-6, GenBank W23834 176332-81-3,
 GenBank W24279 176332-85-7, GenBank W24147 176336-32-6, GenBank W24499
 176337-15-8, GenBank W24628 176338-71-9, GenBank W24886 176341-96-1,
 GenBank W25202 176347-80-1, GenBank W24833 176353-68-7, GenBank X87388
 176362-35-9, GenBank W27126 176365-18-7, GenBank D50420 176396-60-4,
 GenBank W26401 176404-81-2, GenBank W28005 176411-74-8, GenBank W28729
 176461-08-8, GenBank W30772 176464-43-0, GenBank W31088 176466-02-7,
 GenBank W31245 176469-88-8, GenBank W31683 176472-11-0, GenBank W31757
 176475-08-4, GenBank W32135 176475-72-2, GenBank W32227 176476-94-1,
 GenBank W32096 176477-07-9, GenBank W32408 176480-32-3, GenBank W32715
 176482-24-9, GenBank D49372 176551-86-3, GenBank W32947 176553-03-0,
 GenBank W33012 176554-56-6, GenBank W33021 176573-78-7, GenBank W35166
 176574-46-2, GenBank W35256 176603-27-3, GenBank W37280 176604-14-1,
 GenBank W37112 176604-71-0, GenBank W37424 176604-89-0, GenBank W37305
 176605-14-4, GenBank W37447 176605-67-7, GenBank W37375 176606-31-8,
 GenBank W37573 176607-66-2, GenBank W37634 176607-77-5, GenBank W37683
 176608-66-5, GenBank W37689 176609-00-0, GenBank W37833 176610-27-8,
 GenBank W37763 176610-59-6, GenBank W37993 176616-39-0, GenBank W38391
 176616-86-7, GenBank W38600 176617-43-9, GenBank W37075

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 176618-45-4, GenBank W38679 176620-22-7, GenBank W38890 176623-56-6,
 GenBank W39160 176626-29-2, GenBank W39443 176629-71-3, GenBank U44772
 176630-37-8, GenBank U50939 176808-79-0, GenBank W40404 176811-35-1,
 GenBank W40516 176832-03-4, GenBank W42450 176832-21-6, GenBank W42459
 176832-34-1, GenBank W42512 176832-59-0, GenBank W42556 176863-44-8,
 GenBank W42812 176879-04-2, GenBank W44701 176880-05-0, GenBank W44860
 176880-62-9, GenBank W45008 176882-10-3, GenBank W45098 176886-80-9,
 GenBank W45572 176887-91-5, GenBank W45690 176888-44-1, GenBank W45588
 176890-36-1, GenBank W44508 176921-74-7, GenBank W46155 176922-31-9,
 GenBank W46341 176924-18-8, GenBank W46488 176925-42-1, GenBank W46575
 176925-97-6, GenBank W46667 176926-09-3, GenBank W46679 176928-45-3,
 GenBank W46964 176929-00-3, GenBank W46900 176929-17-2, GenBank W46977
 176930-00-0, GenBank W47101 176930-56-6, GenBank W47073 176930-60-2,
 GenBank W47077 176931-08-1, GenBank W47156 176931-72-9, GenBank W47230
 176931-94-5, GenBank W47184 176932-55-1, GenBank W47115 176932-56-2,

GenBank W47363 176932-76-6, GenBank W47324 176932-94-8, GenBank W47361
 176933-23-6, GenBank W47260 176934-33-1, GenBank W47454 176934-93-3,
 GenBank W47416 176935-92-5, GenBank W47641 176983-95-2, GenBank W48685
 176984-22-8, GenBank W48762 176984-43-3, GenBank W48793 176984-88-6,
 GenBank W48852 176985-76-5, GenBank W48619 177119-34-5, GenBank W52085
 177119-99-2, GenBank W52186 177120-54-6, GenBank W52272 177121-47-0,
 GenBank W52248 177121-62-9, GenBank W52378 177122-55-3, GenBank W52627
 177124-64-0, GenBank W52669 177124-97-9, GenBank W51794 177125-16-5,
 GenBank W51909 177125-81-4, GenBank W53029 177126-41-9, GenBank W51760
 177126-60-2, GenBank W52104 177129-19-0, GenBank W52773 177248-74-7,
 GenBank W55924 177249-05-7, GenBank W55967 177250-31-6, GenBank W56081
 177252-06-1, GenBank W56189 177289-55-3, GenBank W56334 177289-98-4,
 GenBank W56634 177290-63-0, GenBank W56597 177291-31-5, GenBank W56753
 177291-49-5, GenBank W56771 177291-70-2, GenBank W56793 177309-00-1,
 GenBank Z68926 177309-02-3, GenBank Z68928 177309-03-4, GenBank Z68929
 177309-14-7, GenBank Z68940 177309-65-8, GenBank Z69025 177371-44-7,
 GenBank W57698 177372-48-4, GenBank W58028 177372-63-3, GenBank W58092
 177392-80-2, GenBank W60015 177398-26-4, GenBank W60565 177398-81-1,
 GenBank W60414 177399-46-1, GenBank W60701 177399-79-0, GenBank W60718
 177400-61-2, GenBank W60820 177400-86-1, GenBank W60845 177452-64-1,
 GenBank W63776 177513-54-1, GenBank W65460 177514-42-0, GenBank W65409
 177515-10-5, GenBank W65294 177526-29-3, GenBank U54711 177527-46-7,
 GenBank U57693 177527-68-3, GenBank U57847 177527-90-1, GenBank D45915
 177527-92-3, GenBank X95747 177527-93-4, GenBank X95748 177527-94-5,
 GenBank X95749 177623-49-3, GenBank W67174 177624-07-6, GenBank W67330
 177633-79-3, GenBank W68261 177633-83-9, GenBank W68265 177634-24-1,
 GenBank W68219 177634-25-2, GenBank W68220 177636-48-5, GenBank W68511
 177643-43-5, GenBank L77567 177668-82-5, GenBank W69211 177670-77-8,
 GenBank W69184 177671-45-3, GenBank W69472 177672-26-3, GenBank W69544
 177673-38-0, GenBank W69668 177675-53-5, GenBank W69814 177675-69-3,
 GenBank W69878 177676-24-3, GenBank W69953 177676-28-7, GenBank W69648
 177676-51-6, GenBank W69960 177677-37-1, GenBank W70065 177680-54-5,
 GenBank W70343 177804-95-4, GenBank W72436 177805-38-8, GenBank W72005
 177806-18-7, GenBank W72665 177806-32-5, GenBank W72679 177807-83-9,
 GenBank W72201 177808-59-2, GenBank W72748 177809-24-4, GenBank W72815
 177810-29-6, GenBank W72293 177810-44-5, GenBank W72798 177811-77-7,
 GenBank W72909 177813-54-6, GenBank W73087 177814-59-4, GenBank W73172
 177818-32-5, GenBank W73527 177820-77-8, GenBank W73587 177821-58-8,
 GenBank W73748 177826-86-7, GenBank U59288 177826-92-5, GenBank U60115
 177829-09-3, GenBank W74133 177832-61-0, GenBank W74359 177861-20-0,
 GenBank W74701 177875-23-9, GenBank W75957 177875-93-3, GenBank W75938
 177877-12-2, GenBank W76286 177877-26-8, GenBank W76300 177877-46-2,
 GenBank W76320 177877-84-8, GenBank W76368 177879-12-8, GenBank W76278
 177880-22-7, GenBank W76584 177920-45-5, GenBank W78156 177926-37-3,
 GenBank W78754 177926-56-6, GenBank W78773 177928-48-2, GenBank W78794
 177928-59-5, GenBank W78928 177997-74-9, GenBank W79647 177998-16-2,
 GenBank W79382 177998-72-0, GenBank W79731 178002-03-4, GenBank W79345
 178002-64-7, GenBank W79283 178010-86-1, GenBank W81135 178013-12-2,
 GenBank W81118 178013-65-5, GenBank W80611 178014-53-4, GenBank W80739
 178020-27-4, GenBank W81662 178020-38-7, GenBank W81214 178021-14-2,
 GenBank W81668 178023-47-7, GenBank W81371 178023-59-1, GenBank W81576
 178023-90-0, GenBank W81617 178024-24-3, GenBank W81506 178089-22-0,
 GenBank W84366 178089-26-4, GenBank W84370 178091-43-5, GenBank W84627
 178092-12-1, GenBank W84690 178093-74-8, GenBank W84584 178093-77-1,
 GenBank W84808 178094-00-3, GenBank W84820 178129-80-1, GenBank W86378
 178130-64-8, GenBank W85781 178130-91-1, GenBank W85878 178131-28-7,
 GenBank W85697 178133-68-1, GenBank W85847 178135-68-7, GenBank W86335
 178135-93-8, GenBank W86360 178136-11-3, GenBank W86214 178136-32-8,
 GenBank W86391 178148-70-4, GenBank U43701 178186-36-2, GenBank W86445
 178188-55-1, GenBank W86523 178189-66-7, GenBank W86832 178189-94-1,
 GenBank W86860 178190-09-5, GenBank W86875 178190-27-7, GenBank W86823
 178190-91-5, GenBank W86947 178196-56-0, GenBank U56255 178219-62-0,
 GenBank W87384 178220-36-5, GenBank W87541 178222-60-1, GenBank W87713
 178223-30-8, GenBank W87752 178223-94-4, GenBank W87826 178280-75-6,
 GenBank W89066 178281-76-0, GenBank W88967 178281-82-8, GenBank W88497
 178282-16-1, GenBank W88571 178282-56-9, GenBank W88587 178284-86-1,

GenBank W88884 178285-93-3, GenBank W88681 178299-74-6, GenBank X98327
 178335-29-0, GenBank W90002 178337-50-3, GenBank W90211 178337-63-8,
 GenBank W90224 178338-41-5, GenBank W90506 178338-52-8, GenBank W90164
 178338-73-3, GenBank W90519 178339-37-2, GenBank W90522 178339-44-1,
 GenBank W90529 178340-23-3, GenBank W90175 178341-40-7, GenBank W90353
 178341-84-9, GenBank W90659 178342-35-3, GenBank W90740 178342-52-4,
 GenBank W90323 178343-08-3, GenBank W90793 178343-30-1, GenBank W90693
 178644-86-5, GenBank C00568 178652-38-5, GenBank C01283 178658-07-6,
 GenBank X98717 178660-29-2, GenBank Z74615 178660-30-5, GenBank Z74616
 178663-74-6, GenBank X99062 178706-42-8, GenBank W92775 178706-46-2,
 GenBank W92779 178706-79-1, GenBank W92812 178708-12-8, GenBank W92946
 178708-29-7, GenBank W92963 178708-30-0, GenBank W92964 178709-53-0,
 GenBank W93067 178709-89-2, GenBank W93113 178710-30-0, GenBank W93163
 178710-45-7, GenBank W93178 178710-55-9, GenBank W93188

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 178710-98-0, GenBank W93212 178712-18-0, GenBank W93382 178712-63-5,
 GenBank W93407 178713-88-7, GenBank W93592 178715-41-8, GenBank W93709
 178716-25-1, GenBank W93568 178717-98-1, GenBank W94009 178719-13-6,
 GenBank W94063 178719-81-8, GenBank W94165 178723-21-2, GenBank W94460
 178723-87-0, GenBank W94401 178725-35-4, GenBank W94714 178728-28-4,
 GenBank W94994 178728-59-1, GenBank W95016 178728-92-2, GenBank W95000
 178729-75-4, GenBank W91879 178729-94-7, GenBank W91888 178733-37-4,
 GenBank W92258 178767-50-5, GenBank W92399 178772-40-2, GenBank W95279
 178776-22-2, GenBank W95594 178777-41-8, GenBank W95801 178777-70-3,
 GenBank W95757 178781-52-7, GenBank W96146 178781-72-1, GenBank W96184
 178783-15-8, GenBank W96325 178785-35-8, GenBank W96506 178836-11-8,
 GenBank U62891 178846-64-5, GenBank W99251 178847-33-1, GenBank U37230
 178857-10-8, GenBank C02426 179130-60-0, GenBank N86077 179140-67-1,
 GenBank N87113 179199-36-1, GenBank N89240 179200-13-6, GenBank N89307
 179204-63-8, GenBank N89812 179205-56-2, GenBank N89861 179208-13-0,
 GenBank N90104 179211-97-3, GenBank N90508 179213-11-7, GenBank N90598
 179213-21-9, GenBank N90608 179214-21-2, GenBank N90744 179214-85-8,
 GenBank N90808 179215-31-7, GenBank N90882 179218-52-1, GenBank N91175
 179220-22-5, GenBank N91307 179220-59-8, GenBank N91382 179221-52-4,
 GenBank N91475 179222-59-4, GenBank N91582 179224-98-7, GenBank
 AA002132 179225-23-1, GenBank AA002258 179225-38-8, GenBank AA001611
 179228-64-9, GenBank AA001870 179228-93-4, GenBank AA001749
 179229-43-7, GenBank AA001835 179230-03-6, GenBank AA001815
 179268-90-7, GenBank AA002125 179288-81-4, GenBank AA005087
 179289-35-1, GenBank AA005063 179289-77-1, GenBank AA005124
 179292-33-2, GenBank AA004489 179293-17-5, GenBank AA004632
 179293-23-3, GenBank AA004638 179293-33-5, GenBank AA004648
 179293-94-8, GenBank AA004664 179294-01-0, GenBank AA004671
 179294-19-0, GenBank AA004689 179294-51-0, GenBank AA004806
 179294-57-6, GenBank AA004832 179299-64-0, GenBank AA004975
 179308-31-7, GenBank D78275 179345-26-7, GenBank W99328 179361-92-3,
 GenBank AA001449 179362-82-4, GenBank AA001536 179363-24-7, GenBank
 AA001567 179363-88-3, GenBank AA001431 179364-30-8, GenBank AA000998
 179365-98-1, GenBank AA001227 179366-25-7, GenBank AA001222
 179378-39-3, GenBank U57091 179503-01-6, GenBank AA007419 179503-87-8,
 GenBank AA007515 179504-70-2, GenBank AA007588 179504-88-2, GenBank
 AA007606 179505-01-2, GenBank AA007619 179505-05-6, GenBank AA007623
 179505-35-2, GenBank AA007581 179505-43-2, GenBank AA007641
 179505-51-2, GenBank AA007663 179563-39-4, GenBank AA011057
 179563-62-3, GenBank AA011228 179563-93-0, GenBank AA011259
 179564-34-2, GenBank AA011215 179564-35-3, GenBank AA011281
 179564-61-5, GenBank AA011307 179565-71-0, GenBank AA011367
 179565-80-1, GenBank AA011427 179567-51-2, GenBank AA011607
 179568-07-1, GenBank AA011593 179568-38-8, GenBank AA011685
 179581-70-5, GenBank AA009763 179581-77-2, GenBank AA009770
 179581-80-7, GenBank AA009773 179581-97-6, GenBank AA009809
 179582-38-8, GenBank AA009455 179583-53-0, GenBank AA009608

179583-71-2, GenBank AA009627 179583-88-1, GenBank AA009755
179584-12-4, GenBank AA009433 179586-97-1, GenBank AA010065
179587-31-6, GenBank AA010079 179588-09-1, GenBank AA010158
179588-19-3, GenBank AA010188 179589-35-6, GenBank AA010305
179589-70-9, GenBank AA010250 179589-91-4, GenBank AA010351
179591-20-9, GenBank AA010421 179592-35-9, GenBank AA010605
179592-38-2, GenBank AA010608 179593-66-9, GenBank AA010715
179593-79-4, GenBank AA010748 179593-91-0, GenBank AA010760
179594-65-1, GenBank AA010805 179595-63-2, GenBank AA010932
179596-05-5, GenBank AA010954 179596-93-1, GenBank AA011061
179597-27-4, GenBank AA011095 179643-43-7, GenBank AA012866
179643-76-6, GenBank AA012939 179649-07-1, GenBank AA013198
179649-19-5, GenBank AA013357 179699-25-3, GenBank AA015663
179699-77-5, GenBank AA015658 179700-98-2, GenBank AA015891
179701-84-9, GenBank AA015850 179702-87-5, GenBank AA015959
179704-61-1, GenBank AA016000 179705-24-9, GenBank AA016234
179717-78-3, GenBank AA017066 179719-67-6, GenBank AA016980
179719-95-0, GenBank AA017133 179723-44-5, GenBank AA017620
179723-62-7, GenBank AA017417 179724-47-1, GenBank AA017698
179727-22-1, GenBank L78132 179771-30-3, GenBank AA018229 179773-62-7,
GenBank AA018437 179773-74-1, GenBank AA018449 179774-41-5, GenBank
AA018338 179776-06-8, GenBank AA018671 179776-11-5, GenBank AA018676
179777-81-2, GenBank AA019482 179780-41-7, GenBank AA018979
179784-30-6, GenBank AA019203 179785-53-6, GenBank AA019591
179787-26-9, GenBank AA019774 179837-57-1, GenBank AA020878
179837-63-9, GenBank AA020911 179837-85-5, GenBank AA021013
179838-30-3, GenBank AA020855 179840-13-2, GenBank AA021212
179842-29-6, GenBank AA021463 179844-52-1, GenBank AA021181
179844-55-4, GenBank AA021194 179854-47-8, GenBank AA023022
179854-78-5, GenBank AA022466 179854-92-3, GenBank AA022480
179857-05-7, GenBank AA022684 179858-00-5, GenBank AA022788
179858-43-6, GenBank AA022886 179858-97-0, GenBank AA022838
179859-22-4, GenBank AA022937 179963-26-9, GenBank AA025291
179963-72-5, GenBank AA024389 179964-49-9, GenBank AA024401
179967-61-4, GenBank AA024799 179968-77-5, GenBank AA024932
179969-12-1, GenBank AA024968 179970-01-5, GenBank AA025057
179970-44-6, GenBank AA025082 179973-99-0, GenBank AA025432
179976-02-4, GenBank AA025715 179977-06-1, GenBank AA025884
179977-21-0, GenBank AA025898 180010-07-5, GenBank AA027264
180010-61-1, GenBank AA026170 180011-38-5, GenBank AA026332
180016-13-1, GenBank AA027233 180016-19-7, GenBank AA027239
180017-04-3, GenBank AA026215 180017-12-3, GenBank AA026102
180017-61-2, GenBank AA026682 180021-65-2, GenBank AA027091
180021-91-4, GenBank AA027098 180098-42-4, GenBank AA028145
180099-76-7, GenBank AA028164 180112-63-4, GenBank AA029754
180112-74-7, GenBank AA029838 180114-52-7, GenBank AA029963
180115-17-7, GenBank AA028921 180115-54-2, GenBank AA030055
180117-58-2, GenBank AA029146 180118-18-7, GenBank AA029107
180121-62-4, GenBank AA029490 180122-06-9, GenBank AA029522
180122-34-3, GenBank AA029597 180123-05-1, GenBank AA029676
180190-58-3, GenBank S82470 180218-17-1, GenBank AA031284 180220-45-5,
GenBank AA031513 180220-97-7, GenBank AA031575 180221-32-3, GenBank
AA031602 180222-77-9, GenBank AA031745 180222-96-2, GenBank AA031764
180225-64-3, GenBank AA032023 180227-48-9, GenBank AA032198
180227-55-8, GenBank AA032205 180227-61-6, GenBank AA032221
180236-62-8, GenBank C06300 180360-89-8, GenBank AA033532 180361-35-7,
GenBank AA033590 180362-42-9, GenBank AA033742 180363-55-7, GenBank
AA033832 180365-40-6, GenBank AA033986 180367-23-1, GenBank AA034222
180367-76-4, GenBank AA034213 180368-26-7, GenBank AA034103
180380-49-8, GenBank AA035095 180380-93-2, GenBank AA035208
180382-61-0, GenBank AA035703 180443-94-1, GenBank AA036683
180444-08-0, GenBank AA036697 180446-36-0, GenBank AA036881
180453-34-3, GenBank R29720 180454-16-4, GenBank AA037138 180454-23-3,
GenBank AA037145 180455-24-7, GenBank AA037170
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

IT 180455-26-9, GenBank AA037172 180455-83-8, GenBank AA037208
 180455-93-0, GenBank AA037254 180456-05-7, GenBank AA037284
 180456-30-8, GenBank AA037290 180456-55-7, GenBank AA037399
 180458-47-3, GenBank AA037359 180458-77-9, GenBank AA037518
 180487-02-9, GenBank AA037788 180487-14-3, GenBank AA037809
 180541-08-6, GenBank AA039354 180543-75-3, GenBank AA039639
 180544-99-4, GenBank AA039762 180545-99-7, GenBank AA039857
 180549-24-0, GenBank AA040170 180549-76-2, GenBank AA040242
 180550-79-2, GenBank AA040344 180551-21-7, GenBank AA040332
 180554-77-2, GenBank AA040741 180554-88-5, GenBank AA040617
 180559-31-3, GenBank AA041241 180561-26-6, GenBank AA041445
 180562-29-2, GenBank AA041520 180567-67-3, GenBank U61397 180654-15-3,
 GenBank AA043167 180657-20-9, GenBank AA043416 180661-11-4, GenBank
 AA043806 180662-65-1, GenBank AA044004 180662-79-7, GenBank AA043951
 180664-24-8, GenBank AA044118 180664-54-4, GenBank AA044205
 180665-74-1, GenBank AA044307 180667-71-4, GenBank AA042864
 180667-83-8, GenBank AA044379 180668-96-6, GenBank AA042990
 180687-12-1, GenBank D50405 180702-10-7, GenBank AA044656 180703-41-7,
 GenBank AA044769 180704-24-9, GenBank AA044869 180704-40-9, GenBank
 AA044885 180704-43-2, GenBank AA044888 180707-45-3, GenBank AA045192
 180707-49-7, GenBank AA045196 180707-85-1, GenBank AA045230
 180708-30-9, GenBank AA045214 180708-93-4, GenBank AA045340
 180709-06-2, GenBank AA045074 180709-17-5, GenBank AA045345
 180709-46-0, GenBank AA045393 180709-57-3, GenBank AA045404
 180709-85-7, GenBank AA045385 180710-95-6, GenBank AA045508
 180711-16-4, GenBank AA045529 180750-18-9, GenBank AA046582
 180750-40-7, GenBank AA046622 180750-46-3, GenBank AA046628
 180751-75-1, GenBank AA046704 180752-19-6, GenBank AA046785
 180752-24-3, GenBank AA046790 180755-36-6, GenBank AA047099
 180755-53-7, GenBank AA047134 180757-59-9, GenBank AA047338
 180758-71-8, GenBank AA045606 180760-02-5, GenBank AA047436
 180760-64-9, GenBank AA047499 180761-14-2, GenBank AA045664
 180765-27-9, GenBank AA046116 180766-14-7, GenBank AA045993
 180768-07-4, GenBank AA046360 180805-94-1, GenBank AA047606
 180806-17-1, GenBank AA047803 180884-11-1, GenBank U50534 180886-37-7,
 GenBank Z75668 181087-73-0, GenBank AA053484 181088-70-0, GenBank
 AA053071 181091-26-9, GenBank AA053265 181091-88-3, GenBank AA053665
 181093-95-8, GenBank AA053860 181094-24-6, GenBank AA053909
 181097-45-0, GenBank AA054169 181098-43-1, GenBank AA054277
 181099-04-7, GenBank AA054341 181099-26-3, GenBank AA054358
 181100-13-0, GenBank AA054406 181101-17-7, GenBank AA054582
 181102-03-4, GenBank AA054602 181102-38-5, GenBank AA054701
 181102-68-1, GenBank AA054771 181104-10-9, GenBank AA053288
 181157-60-8, GenBank AA055326 181157-73-3, GenBank AA055349
 181157-92-6, GenBank AA055368 181158-13-4, GenBank AA055439
 181158-95-2, GenBank AA055523 181159-24-0, GenBank AA055485
 181160-37-2, GenBank AA055637 181162-03-8, GenBank AA055768
 181162-79-8, GenBank AA055880 181163-45-1, GenBank AA055945
 181164-13-6, GenBank AA056013 181164-77-2, GenBank AA056096
 181164-95-4, GenBank AA056057 181164-98-7, GenBank AA056060
 181166-43-8, GenBank AA056231 181167-29-3, GenBank AA056334
 181167-93-1, GenBank AA056381 181168-43-4, GenBank AA056474
 181168-60-5, GenBank AA056509 181168-77-4, GenBank AA056453
 181169-48-2, GenBank AA056588 181170-58-1, GenBank AA056608
 181194-08-1, GenBank AA057153 181197-26-2, GenBank AA057264
 181198-41-4, GenBank AA057378 181198-57-2, GenBank AA057366
 181198-91-4, GenBank AA057426 181244-02-0, GenBank AA058323
 181244-42-8, GenBank AA058453 181244-61-1, GenBank AA058456
 181246-09-3, GenBank AA058597 181247-32-5, GenBank AA058708
 181248-33-9, GenBank AA058818 181249-30-9, GenBank AA058899
 181321-84-6, GenBank AA059347 181387-97-3, GenBank AA062802
 181388-83-0, GenBank AA063398 181391-38-8, GenBank AA062957
 181391-58-2, GenBank AA063467 181408-42-4, GenBank AA064945

181450-53-3, GenBank Y08247 181667-11-8, GenBank AA069135 181672-69-5,
 GenBank AA069549 181688-53-9, GenBank AA071255 181688-81-3, GenBank
 AA071235 181690-96-0, GenBank AA071501 181695-05-6, GenBank U62589
 181729-12-4, GenBank C17474 181732-82-1, GenBank C17916 181743-30-6,
 GenBank C18921 181743-38-4, GenBank C18929 181754-47-2, GenBank U60975
 181897-71-2, GenBank AA074241 181898-23-7, GenBank AA074258
 181901-72-4, GenBank AA074650 181905-43-1, GenBank AA075029
 181906-15-0, GenBank AA075085 181906-97-8, GenBank AA075184
 181909-94-4, GenBank AA075422 181910-44-1, GenBank AA075531
 181911-45-5, GenBank AA075632 181911-48-8, GenBank AA075635
 181912-96-9, GenBank AA075781 181913-91-7, GenBank AA075682
 181916-46-1, GenBank AA076135 181917-04-4, GenBank AA076191
 181920-34-3, GenBank AA076461 181921-88-0, GenBank AA076645
 181922-68-9, GenBank U70322 182095-91-6, GenBank AA078778 182179-71-1,
 GenBank D87666 182179-74-4, GenBank D87735 182340-41-6, GenBank C21459
 182342-45-6, GenBank U66691 182375-18-4, GenBank AA081043 182375-26-4,
 GenBank AA081068 182376-05-2, GenBank AA081149 182376-11-0, GenBank
 AA081223 182377-19-1, GenBank AA081355 182377-78-2, GenBank AA081234
 182379-44-8, GenBank AA080889 182382-02-1, GenBank AA081600
 182383-09-1, GenBank AA081711 182384-11-8, GenBank AA081795
 182384-68-5, GenBank AA081817 182387-58-2, GenBank AA082142
 182388-40-5, GenBank AA082241 182389-26-0, GenBank AA082314
 182389-98-6, GenBank AA082348 182391-20-4, GenBank AA082499
 182391-64-6, GenBank AA082304 182392-32-1, GenBank AA082572
 182392-83-2, GenBank AA082523 182393-30-2, GenBank AA082747
 182396-16-3, GenBank AA083032 182397-65-5, GenBank AA083207
 182398-24-9, GenBank AA083228 182399-44-6, GenBank AA083345
 182402-43-3, GenBank AA083645 182404-77-9, GenBank AA083740
 182445-02-9, GenBank AA084560 182449-74-7, GenBank AA084984
 182451-08-7, GenBank AA085104 182452-72-8, GenBank AA085319
 182456-60-6, GenBank AA085435 182457-15-4, GenBank AA085512
 182457-72-3, GenBank AA085538 182459-66-1, GenBank AA086333
 182462-46-0, GenBank AA085759 182463-26-9, GenBank AA085872
 182463-62-3, GenBank AA085824 182463-67-8, GenBank AA085810
 182537-36-6, GenBank AA088914 182537-56-0, GenBank AA088177
 182538-30-3, GenBank AA088197 182539-05-5, GenBank AA088326
 182539-29-3, GenBank AA088359 182540-36-9, GenBank AA088457
 182541-07-7, GenBank AA088544 182541-27-1, GenBank AA088564
 182542-34-3, GenBank AA088655 182543-19-7, GenBank AA088740
 182543-37-9, GenBank AA088758 182543-49-3, GenBank AA088779
 182543-53-9, GenBank AA088783 182585-96-2, GenBank AA090857
 182586-80-7, GenBank AA091050 182594-12-3, GenBank AA089897
 182595-08-0, GenBank AA089985 182596-13-0, GenBank AA090106
 182597-87-1, GenBank AA090243 182598-16-9, GenBank AA090264
 182598-84-1, GenBank AA091398 182599-74-2, GenBank AA091496
 182600-63-1, GenBank AA092002 182601-96-3, GenBank AA092185
 182610-79-3, GenBank AA091555 182611-71-8, GenBank AA091687
 182613-19-0, GenBank AA091771 182640-90-0, GenBank AA093071
 182649-27-0, GenBank AA093842 182656-52-6, GenBank AA094496
 182662-46-0, GenBank AA095065 182665-88-9, GenBank AA095443
 182671-07-4, GenBank AA095962 182729-60-8, GenBank AA098929
 182731-43-7, GenBank AA099083 182732-04-3, GenBank AA099236

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 182732-17-8, GenBank AA098867 182732-89-4, GenBank AA099251
 182733-00-2, GenBank AA099262 182733-61-5, GenBank AA099288
 182733-74-0, GenBank AA101861 182734-34-5, GenBank AA099169
 182734-89-0, GenBank AA101919 182734-98-1, GenBank AA098997
 182736-16-9, GenBank AA099515 182736-23-8, GenBank AA099522
 182736-29-4, GenBank AA099033 182737-56-0, GenBank AA099568
 182737-78-6, GenBank AA101964 182737-99-1, GenBank AA099554
 182738-71-2, GenBank AA099631 182762-19-2, GenBank X98263 182762-26-1,
 GenBank X99920 182765-13-5, GenBank AA099819 182766-49-0, GenBank

AA099910 182768-11-2, GenBank AA100037 182769-75-1, GenBank AA100168
182773-17-7, GenBank AA100340 182775-19-5, GenBank AA100612
182775-48-0, GenBank AA100440 182775-69-5, GenBank AA100657
182776-15-4, GenBank AA100671 182776-63-2, GenBank AA100738
182778-10-5, GenBank AA100799 182778-23-0, GenBank AA100852
182784-24-3, GenBank AA102591 182784-77-6, GenBank AA101243
182785-39-3, GenBank AA102646 182785-68-8, GenBank AA101173
182785-80-4, GenBank AA102670 182786-23-8, GenBank AA101291
182786-28-3, GenBank AA101296 182788-26-7, GenBank AA100531
182789-40-8, GenBank AA102738 182790-72-3, GenBank AA101561
182790-73-4, GenBank AA101562 182848-68-6, GenBank Y09022 182860-33-9,
GenBank D78611 182862-09-5, GenBank AC000048 183081-26-7, GenBank
AA112748 183082-37-3, GenBank AA111855 183082-38-4, GenBank AA111856
183085-81-6, GenBank AA112936 183086-69-3, GenBank AA112172
183088-52-0, GenBank AA112288 183100-28-9, GenBank D87434 183100-59-6,
GenBank D87742 183103-06-2, GenBank X98505 183215-38-5, GenBank
AA113788 183217-91-6, GenBank AA114086 183219-48-9, GenBank AA114226
183330-45-2, GenBank AA114879 183333-07-5, GenBank AA115592
183333-69-9, GenBank AA115076 183334-62-5, GenBank AA115558
183334-90-9, GenBank AA115244 183335-43-5, GenBank AA115284
183335-95-7, GenBank AA115336 183336-84-7, GenBank AA115310
183336-97-2, GenBank AA115399 183337-59-9, GenBank AA115716
183340-22-9, GenBank AA115838 183340-62-7, GenBank AA115983
183340-83-2, GenBank AA116004 183341-38-0, GenBank AA116060
183452-22-4, GenBank AA120794 183453-64-7, GenBank AA122021
183454-20-8, GenBank AA120880 183456-12-4, GenBank AA120962
183457-21-8, GenBank AA122269 183457-24-1, GenBank AA122272
183458-45-9, GenBank AA122237 183460-83-5, GenBank AA122401
183461-08-7, GenBank AA121266 183461-54-3, GenBank AA121249
183463-72-1, GenBank AA121428 183464-38-2, GenBank AA121581
183465-54-5, GenBank AA121632 183465-81-8, GenBank AA121743
183466-09-3, GenBank AA121753 183466-17-3, GenBank AA121778
183470-03-3, GenBank U77054 183630-71-9, GenBank AA127805 183631-39-2,
GenBank AA127783 183632-32-8, GenBank AA127962 183632-35-1, GenBank
AA127965 183635-15-6, GenBank AA125917 183635-92-9, GenBank AA126599
183636-68-2, GenBank AA127075 183636-86-4, GenBank AA127221
183637-10-7, GenBank AA125790 183637-12-9, GenBank AA125792
183637-27-6, GenBank AA125915 183637-95-8, GenBank AA126195
183638-39-3, GenBank AA127058 183638-76-8, GenBank AA126259
183644-29-3, GenBank AA125927 183644-79-3, GenBank AA125988
183645-98-9, GenBank AA126115 183649-03-8, GenBank AA126493
183650-72-8, GenBank AA126755 183650-98-8, GenBank AA126817
183651-02-7, GenBank AA126821 183651-59-4, GenBank AA126951
183651-66-3, GenBank AA126958 183652-10-0, GenBank AA126911
183652-64-4, GenBank AA127116 183655-21-2, GenBank AA127419
183685-93-0, GenBank AA128518 183687-22-1, GenBank AA128743
183688-09-7, GenBank AA128984 183689-87-4, GenBank AA129170
183690-07-5, GenBank AA129223 183691-51-2, GenBank AA129310
183691-53-4, GenBank AA129312 183693-35-8, GenBank AA129552
183694-20-4, GenBank AA129783 183695-59-2, GenBank AA129932
183698-47-7, GenBank AA128508 183699-10-7, GenBank AA129861
183699-89-0, GenBank AA133194 183700-07-4, GenBank AA133212
183700-35-8, GenBank AA128607 183702-59-2, GenBank AA133273
183702-83-2, GenBank AA133277 183703-94-8, GenBank AA133375
183705-37-5, GenBank AA133547 183707-06-4, GenBank AA133721
183707-34-8, GenBank AA133692 183708-06-7, GenBank AA133778
183708-16-9, GenBank AA133796 183709-11-7, GenBank AA130016
183709-59-3, GenBank AA130028 183711-25-3, GenBank AA134036
183711-63-9, GenBank AA130141 183712-91-6, GenBank AA130221
183716-00-9, GenBank AA130262 183717-26-2, GenBank AA130347
183750-28-9, GenBank AA130522 183750-51-8, GenBank AA134283
183752-61-6, GenBank AA130596 183753-68-6, GenBank AA130541
183753-74-4, GenBank AA130547 183753-86-8, GenBank AA130652
183754-39-4, GenBank AA130626 183757-62-2, GenBank AA130827
183759-82-2, GenBank AA131231 183760-59-0, GenBank AA131358
183760-94-3, GenBank AA131315 183761-56-0, GenBank AA131299

183761-84-4, GenBank AA131421 183762-21-2, GenBank AA131506
 183763-36-2, GenBank AA131526 183763-84-0, GenBank AA131707
 183765-53-9, GenBank AA131673 183766-86-1, GenBank AA131908
 183768-09-4, GenBank AA132065 183768-32-3, GenBank AA132090
 183769-74-6, GenBank AA132195 183770-62-9, GenBank AA132330
 183771-41-7, GenBank AA132250 183774-10-9, GenBank AA132677
 183774-91-6, GenBank AA132580 183775-90-8, GenBank AA132889
 183777-46-0, GenBank AA132987 183782-14-1, GenBank AA134871
 183783-44-0, GenBank AA134862 183783-80-4, GenBank AA134813
 183784-12-5, GenBank AA134595 183784-46-5, GenBank AA134576
 183821-38-7, GenBank AA134919 183828-24-2, GenBank AA135695
 183829-28-9, GenBank AA135748 183829-42-7, GenBank AA135813
 183830-03-7, GenBank AA135929 183831-17-6, GenBank AA137266
 183831-77-8, GenBank AA135504 183832-23-7, GenBank AA135919
 183833-63-8, GenBank AA135914 183835-02-1, GenBank AA136155
 183837-70-9, GenBank AA136442 183837-75-4, GenBank AA136447
 183839-82-9, GenBank AA136532 183840-12-2, GenBank AA136707
 183840-96-2, GenBank AA136750 183841-02-3, GenBank AA136756
 183842-87-7, GenBank AA136796 183843-46-1, GenBank AA136964
 183843-63-2, GenBank AA137000 183844-34-0, GenBank AA136983
 183844-65-7, GenBank AA137144 183845-10-5, GenBank AA137109
 183845-82-1, GenBank U63743 183976-81-0, GenBank X94754 183984-08-9,
 GenBank U79258 184076-75-3, GenBank AA142842 184076-85-5, GenBank
 AA142865 184076-89-9, GenBank AA142869 184076-94-6, GenBank AA142952
 184077-08-5, GenBank AA142966 184078-31-7, GenBank AA142923
 184080-26-0, GenBank AA143286 184081-57-0, GenBank AA143201
 184082-48-2, GenBank AA143471 184084-95-5, GenBank AA143726
 184140-81-6, GenBank AA146968 184140-96-3, GenBank AA147032
 184144-56-7, GenBank AA147361 184146-18-7, GenBank AA147454
 184146-57-4, GenBank AA147552 184146-98-3, GenBank AA147654
 184184-25-6, GenBank AA147523 184184-60-9, GenBank AA147833
 184189-02-4, GenBank AA148199 184191-11-5, GenBank AA149360
 184198-81-0, GenBank AA148915 184199-23-3, GenBank AA149082
 184199-69-7, GenBank AA151210 184199-73-3, GenBank AA151214
 184200-19-9, GenBank AA151244 184201-05-6, GenBank AA149065
 184204-36-2, GenBank AA149309 184204-75-9, GenBank AA149415
 184205-44-5, GenBank AA151486 184207-15-6, GenBank AA149509
 184209-90-3, GenBank AA149640 184212-21-3, GenBank AA151775
 184214-83-3, GenBank AA149854 184216-16-8, GenBank AA149842
 184216-96-4, GenBank AA149994 184217-31-0, GenBank AA152165
 184217-51-4, GenBank AA149882 184217-66-1, GenBank AA149968
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 184252-28-6, GenBank AA150161 184253-35-8, GenBank AA152204
 184253-57-4, GenBank AA148508 184253-61-0, GenBank AA152258
 184254-34-0, GenBank AA148548 184254-58-8, GenBank AA148573
 184254-91-9, GenBank AA148793 184256-60-8, GenBank AA150263
 184258-05-7, GenBank AA150416 184258-42-2, GenBank AA150298
 184258-45-5, GenBank AA150301 184258-77-3, GenBank AA150487
 184258-95-5, GenBank AA150505 184258-97-7, GenBank AA150507
 184260-26-2, GenBank AA150638 184260-50-2, GenBank AA150662
 184260-53-5, GenBank AA150665 184263-05-6, GenBank AA150918
 184263-89-6, GenBank AA151002 184263-90-9, GenBank AA151003
 184321-20-8, GenBank AA155695 184322-13-2, GenBank AA155787
 184323-62-4, GenBank AA155913 184324-42-3, GenBank AA155942
 184326-62-3, GenBank AA156235 184329-06-4, GenBank AA156356
 184330-64-1, GenBank AA156632 184331-62-2, GenBank AA156674
 184332-06-7, GenBank AA156782 184332-08-9, GenBank AA156784
 184332-17-0, GenBank AA156793 184332-25-0, GenBank AA156801
 184333-90-2, GenBank AA156901 184334-06-3, GenBank AA156982
 184334-32-5, GenBank AA156964 184335-22-6, GenBank AA157089
 184335-65-7, GenBank AA157150 184336-81-0, GenBank AA157266
 184338-86-1, GenBank AA157472 184340-47-4, GenBank AA157632

184341-75-1, GenBank AA157743 184386-55-8, GenBank AA157889
184389-27-3, GenBank AA158169 184390-17-8, GenBank AA158258
184390-53-2, GenBank AA158217 184391-52-4, GenBank AA158345
184397-54-4, GenBank AA159015 184400-34-8, GenBank AA159259
184400-38-2, GenBank AA159272 184400-95-1, GenBank AA159356
184402-37-7, GenBank AA159826 184405-52-5, GenBank AA159654
184410-90-0, GenBank AA159552 184438-89-9, GenBank AA159669
184439-08-5, GenBank AA159688 184442-93-1, GenBank AA160484
184444-33-5, GenBank AA160606 184445-77-0, GenBank AA160812
184497-99-2, GenBank AA165051 184498-54-2, GenBank AA165313
184500-66-1, GenBank AA164582 184507-85-5, GenBank AA165410
184540-62-3, GenBank AA167814 184540-65-6, GenBank AA167817
184540-96-3, GenBank AA167654 184542-82-3, GenBank AA166739
184546-03-0, GenBank AA167113 184546-96-1, GenBank AA167223
184547-26-0, GenBank AA167129 184548-54-7, GenBank AA167381
184566-96-9, GenBank AA169159 184568-02-3, GenBank AA169154
184568-79-4, GenBank AA169340 184569-15-1, GenBank AA169547
184569-32-2, GenBank AA169564 184571-47-9, GenBank AA169487
184572-05-2, GenBank AA169645 184572-95-0, GenBank AA169418
184573-57-7, GenBank AA169392 184574-05-8, GenBank AA169449
184611-03-8, GenBank AA171463 184611-95-8, GenBank AA171510
184613-87-4, GenBank AA171706 184615-86-9, GenBank AA171899
184619-25-8, GenBank AA172293 184619-52-1, GenBank AA172370
184620-30-2, GenBank AA172400 184663-07-8, GenBank AA173381
184663-15-8, GenBank AA173408 184665-68-7, GenBank AA173657
184665-83-6, GenBank AA173610 184668-20-0, GenBank AA173910
184668-76-6, GenBank AA173948 184669-18-9, GenBank AA174008
184670-22-2, GenBank AA174102 184670-26-6, GenBank AA174106
184671-52-1, GenBank AA173042 184671-55-4, GenBank AA173153
184671-77-0, GenBank AA173184 184723-19-1, GenBank D67031 184743-13-3,
GenBank AA176220 184745-78-6, GenBank AA176483 184748-12-7, GenBank
AA176764 184809-31-2, GenBank AA179554 184813-28-3, GenBank AA180100
184813-53-4, GenBank AA180124 184814-92-4, GenBank AA180262
184926-12-3, GenBank AA181023 184926-36-1, GenBank AA180949
184927-52-4, GenBank AA181085 184929-30-4, GenBank AA181201
184929-87-1, GenBank AA181314 184930-35-6, GenBank AA181413
184931-01-9, GenBank AA181455 184932-07-8, GenBank AA181580
185084-51-9, GenBank X95073 185128-25-0, GenBank Z83843 185128-49-8,
GenBank U82258 185160-37-6, GenBank AA188162 185161-93-7, GenBank
AA187379 185162-18-9, GenBank AA187405 185164-13-0, GenBank AA187428
185164-23-2, GenBank AA187505 185164-93-6, GenBank AA187610
185165-13-3, GenBank AA187719 185166-95-4, GenBank AA187875
185167-56-0, GenBank AA187933 185168-34-7, GenBank AA187966
185168-39-2, GenBank AA187971 185168-73-4, GenBank AA188063
185170-59-6, GenBank AA188203 185171-02-2, GenBank AA187982
185172-12-7, GenBank AA186426 185172-31-0, GenBank AA186485
185173-39-1, GenBank AA186477 185173-44-8, GenBank AA186399
185173-51-7, GenBank AA186406 185177-85-9, GenBank AA187014
185178-77-2, GenBank AA186939 185178-87-4, GenBank AA187073
185179-49-1, GenBank AA187030 185179-62-8, GenBank AA188256
185181-97-9, GenBank AA188527 185182-61-0, GenBank AA188591
185184-50-3, GenBank AA188761 185184-61-6, GenBank AA188789
185186-53-2, GenBank AA188921 185186-70-3, GenBank AA189000
185188-02-7, GenBank AA189106 185231-25-8, GenBank D49743 185236-11-7,
GenBank AB000220 185264-94-2, GenBank AA190747 185266-10-8, GenBank
AA190789 185266-79-9, GenBank AA190764 185267-30-5, GenBank AA190773
185268-22-8, GenBank AA190941 185269-58-3, GenBank AA190993
185270-94-4, GenBank AA191071 185271-17-4, GenBank AA190587
185271-42-5, GenBank AA190629 185274-47-9, GenBank AA191422
185275-38-1, GenBank AA191476 185275-81-4, GenBank AA191464
185276-16-8, GenBank AA191512 185276-20-4, GenBank AA191516
185282-74-0, GenBank X97324 185286-26-4, GenBank AA192527 185286-40-2,
GenBank AA192547 185290-45-3, GenBank AA192268 185290-91-9, GenBank
AA192816 185291-86-5, GenBank AA192903 185292-02-8, GenBank AA192935
185294-20-6, GenBank AA193156 185296-21-3, GenBank AA193351
185297-99-8, GenBank AA193340 185326-50-5, GenBank AA193486

185362-45-2, GenBank AA194517 185365-26-8, GenBank AA194819
 185365-73-5, GenBank AA194876 185366-10-3, GenBank AA194646
 185366-29-4, GenBank AA194830 185366-32-9, GenBank AA194833
 185367-03-7, GenBank AA194894 185367-52-6, GenBank AA194966
 185368-05-2, GenBank AA195088 185368-50-7, GenBank AA195113
 185369-50-0, GenBank AA194973 185370-20-1, GenBank AA195273
 185371-60-2, GenBank AA195420 185371-78-2, GenBank AA195387
 185372-17-2, GenBank AA195398 185372-23-0, GenBank AA195463
 185372-30-9, GenBank AA195470 185373-83-5, GenBank AA195647
 185374-35-0, GenBank AA195696 185469-35-6, GenBank AA196003
 185475-19-8, GenBank AA196633 185478-61-9, GenBank AA196962
 185497-19-2, GenBank AA197344 185498-86-6, GenBank AA195946
 185498-96-8, GenBank AA195956 185581-88-8, GenBank AA199717
 185583-95-3, GenBank AA199836 185584-14-9, GenBank AA199891
 185645-28-7, GenBank AA203134 185647-47-6, GenBank AA203379
 185649-83-6, GenBank AA203561 185655-67-8, GenBank U65785 185665-62-7,
 GenBank AA205854 185665-83-2, GenBank AA206991 185665-84-3, GenBank
 AA205860 185704-97-6, GenBank AA206267 185705-24-2, GenBank AA206277
 185706-50-7, GenBank AA206220 185707-68-0, GenBank AA206527
 185708-22-9, GenBank AA206582 185711-39-1, GenBank AA206848
 185712-86-1, GenBank AA207014 185713-42-2, GenBank AA207131
 185715-71-3, GenBank AA207185 185716-49-8, GenBank AA207267
 185717-17-3, GenBank AA207224 185721-26-0, GenBank AA205253
 185724-23-6, GenBank AA205565 185724-43-0, GenBank AA205539
 185725-66-0, GenBank AA205654 185725-78-4, GenBank AA205625
 185726-16-3, GenBank AA205722 185770-54-1, GenBank U51990 185784-99-0,
 GenBank AA209524 185785-04-0, GenBank AA209529 185785-06-2, GenBank
 AA209531 185861-83-0, GenBank AA210760 185863-28-9, GenBank AA210891
 185869-31-2, GenBank AA211509 185870-77-3, GenBank AA211703
 185889-93-4, GenBank AA213429

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human cervical
cancer)

IT 185892-22-2, GenBank AA213816 185922-77-4, GenBank AA214548
 185922-88-7, GenBank AA214559 185928-76-1, GenBank U84581 185936-05-4,
 GenBank AA215363 185940-04-9, GenBank AA215724 185975-85-3, GenBank
 AA216192 185976-45-8, GenBank AA216238 185977-19-9, GenBank AA216202
 186015-07-6, GenBank AA216670 186017-40-3, GenBank D87127 186070-10-0,
 GenBank AB000450 186070-23-5, GenBank D83018 186170-47-8, GenBank
 AA218820 186174-02-7, GenBank AA219100 186227-95-2, GenBank U85429
 186285-30-3, GenBank U86602 186287-01-4, GenBank AA220979 186287-60-5,
 GenBank AA221029 186364-73-8, GenBank X96401 186478-04-6, GenBank
 AA223779 186478-36-4, GenBank AA223828 186481-49-2, GenBank AA224124
 186482-94-0, GenBank AA224269 186563-01-9, GenBank AA225256
 186564-55-6, GenBank AA225348 186564-87-4, GenBank AA225436
 186565-23-1, GenBank AA225515 186565-36-6, GenBank AA225528
 186566-24-5, GenBank AA225601 186566-94-9, GenBank AA225644
 186573-77-3, GenBank AA226337 186574-40-3, GenBank AA226380
 186576-32-9, GenBank AA226546 186577-40-2, GenBank AA226672
 186580-68-7, GenBank Y11251 186620-23-5, GenBank AA226732 186626-89-1,
 GenBank AA227366 186628-23-9, GenBank AA227594 186628-80-8, GenBank
 AA227579 186635-30-3, GenBank AA228284 186636-25-9, GenBank AA228389
 186716-18-7, GenBank AA229467 186716-93-8, GenBank AA228697
 186718-36-5, GenBank AA229419 186719-08-4, GenBank AA229611
 186719-16-4, GenBank AA229619 186720-63-8, GenBank AA228935
 186722-36-1, GenBank AA229777 186723-46-6, GenBank AA229047
 186724-31-2, GenBank AA229087 186726-23-8, GenBank AA229951
 186728-18-7, GenBank AA230173 186849-86-5, GenBank AA233959
 186850-85-1, GenBank AA232379 186851-32-1, GenBank AA232345
 186854-68-2, GenBank AA232172 186855-82-3, GenBank AA232645
 186856-44-0, GenBank AA232691 186857-04-5, GenBank AA232626
 186857-08-9, GenBank AA232710 186863-01-4, GenBank AA233376
 186865-01-0, GenBank AA233643 186865-79-2, GenBank AA233646
 186866-23-9, GenBank AA233418 186870-55-3, GenBank AA234982

186871-76-1, GenBank AA235007 186872-69-5, GenBank AA234138
186876-15-3, GenBank AA236444 186881-06-1, GenBank AA234732
186882-45-1, GenBank AA234824 186882-61-1, GenBank AA234933
186882-94-0, GenBank AA234671 186920-89-8, GenBank AA235347
186921-12-0, GenBank AA235370 186921-79-9, GenBank AA235430
186926-16-9, GenBank AA235805 186928-27-8, GenBank AA236085
186929-49-7, GenBank AA236689 186931-80-6, GenBank AA236840
186999-54-2, GenBank U66661 187005-83-0, GenBank D86043 187132-18-9,
GenBank D86955 187132-48-5, GenBank U91321 187194-43-0, GenBank
AA242913 187197-50-8, GenBank AA243241 187198-94-3, GenBank AA243346
187202-76-2, GenBank AA243499 187203-17-4, GenBank AA243799
187204-42-8, GenBank AA243990 187204-48-4, GenBank AA243828
187205-61-4, GenBank AA244162 187206-54-8, GenBank AA244240
187208-38-4, GenBank AA244377 187304-21-8, GenBank AA248319
187312-08-9, GenBank AA249154 187312-68-1, GenBank AA248658
187313-24-2, GenBank AA249195 187313-81-1, GenBank AA248706
187316-87-6, GenBank AA249421 187317-12-0, GenBank AA248791
187363-41-3, GenBank AA252968 187364-49-4, GenBank AA253098
187366-90-1, GenBank AA253340 187369-40-0, GenBank AA250730
187370-10-1, GenBank AA253448 187373-95-1, GenBank AA251178
187373-99-5, GenBank AA251182 187375-48-0, GenBank AA251338
187377-11-3, GenBank AA251303 187377-13-5, GenBank AA251305
187379-48-2, GenBank AA251758 187380-27-4, GenBank AA251800
187381-23-3, GenBank AA251927 187381-76-6, GenBank AA252014
187502-52-9, GenBank AA256802 187502-73-4, GenBank AA256824
187503-72-6, GenBank AA256863 187504-50-3, GenBank AA256849
187508-77-6, GenBank AA255900 187509-49-5, GenBank AA256108
187509-98-4, GenBank AA256157 187510-92-5, GenBank AA256235
187511-18-8, GenBank AA256330 187511-23-5, GenBank AA256335
187512-70-5, GenBank AA256461 187519-87-5, GenBank AA255740
187560-25-4, GenBank AA258725 187560-72-1, GenBank AA258735
187566-00-3, GenBank AA257992 187566-65-0, GenBank AA258057
187568-05-4, GenBank AA258104 187568-35-0, GenBank AA259207
187637-19-0, GenBank AA261831 187640-81-9, GenBank AA261990
187644-26-4, GenBank AA262799 187645-56-3, GenBank AA262211
187645-86-9, GenBank AA262168 187647-73-0, GenBank AA262988
187791-14-6, GenBank U90878 187958-47-0, GenBank U91618 188089-57-8,
GenBank U90907 188089-59-0, GenBank U90909 188160-04-5, GenBank
AA278550 188160-63-6, GenBank AA278512 188160-96-5, GenBank AA278536
188162-72-3, GenBank AA278789 188162-98-3, GenBank AA278660
188163-31-7, GenBank AA278240 188163-90-8, GenBank AA278759
188165-78-8, GenBank AA278921 188166-71-4, GenBank AA279072
188167-13-7, GenBank AA279100 188167-46-6, GenBank AA279150
188167-72-8, GenBank AA279097 188168-34-5, GenBank AA279172
188170-70-9, GenBank AA279396 188170-78-7, GenBank AA279422
188170-82-3, GenBank AA279426 188171-10-0, GenBank AA279466
188207-46-7, GenBank AA279657 188213-11-8, GenBank AA278401
188215-22-7, GenBank AA280203 188215-27-2, GenBank AA280208
188216-27-5, GenBank AA280288 188216-34-4, GenBank AA280279
188221-37-6, GenBank U68566 188223-63-4, GenBank U86782 188232-60-2,
GenBank AA280676 188236-40-0, GenBank AA281030 188237-42-5, GenBank
AA280931 188239-92-1, GenBank AA281412 188268-68-0, GenBank AA281626
188270-61-3, GenBank AA281743 188270-62-4, GenBank AA281744
188272-47-1, GenBank AA280577 188276-49-5, GenBank AA282206
188276-73-5, GenBank AA282230 188277-09-0, GenBank AA282202
188277-67-0, GenBank AA282159 188280-37-7, GenBank AA282594
188281-65-4, GenBank AA282712 188282-86-2, GenBank AA282707
188283-37-6, GenBank AA282895 188284-43-7, GenBank AA282983
188286-33-1, GenBank AA283172 188314-60-5, GenBank AA284551
188314-75-2, GenBank AA284584 188315-41-5, GenBank AA284668
188316-04-3, GenBank AA284866 188316-69-0, GenBank AA284982
188316-84-9, GenBank AA284934 188316-98-5, GenBank AA284955
188317-78-4, GenBank AA283629 188318-27-6, GenBank AA285095
188322-20-5, GenBank AA283932 188322-56-7, GenBank AA283950
188322-63-6, GenBank AA283961 188322-82-9, GenBank AA283983
188323-91-3, GenBank AA284067 188325-85-1, GenBank AA284334

188327-91-5, GenBank AA284464 188328-98-5, GenBank U60061 188337-46-4,
 GenBank AA285258 188340-50-3, GenBank AC000386 188453-48-7, GenBank
 AA287310 188456-32-8, GenBank AA287741 188461-25-8, GenBank AA286908
 188461-77-0, GenBank AA287969 188463-39-0, GenBank AA287122
 188464-00-8, GenBank AA287004 188464-10-0, GenBank AA287184
 188464-13-3, GenBank AA287187 189123-41-9, GenBank U73379 189236-80-4,
 GenBank U59808 189356-92-1, GenBank D88153 189402-51-5, GenBank
 AA290737 189405-49-0, GenBank AA290630 189408-07-9, GenBank AA291163
 189408-27-3, GenBank AA291183 189408-62-6, GenBank AA291227
 189409-73-2, GenBank AA291144 189410-60-4, GenBank AA291407
 189411-48-1, GenBank AA291513 189411-62-9, GenBank AA291484
 189412-11-1, GenBank AA291577 189413-51-2, GenBank AA291715
 189414-52-6, GenBank AA291690 189415-97-2, GenBank AA291772
 189416-53-3, GenBank AA292019 189417-88-7, GenBank AA292153
 189418-09-5, GenBank AA292031 189418-85-7, GenBank AA292047
 189419-20-3, GenBank AA292283 189419-48-5, GenBank AA292191
 189420-19-7, GenBank AA292226 189423-26-5, GenBank AA292676

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 189424-98-4, GenBank AA457728 189425-62-5, GenBank AA292993
 189427-47-2, GenBank AA293515 189428-93-1, GenBank AA293570
 189430-32-8, GenBank AA293286 189430-46-4, GenBank AA293300
 189431-65-0, GenBank AA293727 189433-96-3, GenBank AA293819
 189434-94-4, GenBank AA293782 189434-96-6, GenBank AA293784
 189435-03-8, GenBank AA292823 189435-06-1, GenBank AA292871
 189465-34-7, GenBank AB002804 189598-75-2, GenBank AA393214
 189605-66-1, GenBank AA393869 189605-71-8, GenBank AA393892
 189607-86-1, GenBank AA394106 189609-77-6, GenBank AA394152
 189609-86-7, GenBank AA394299 189609-90-3, GenBank AA394303
 189612-11-1, GenBank U94586 189706-89-6, GenBank AA398854 189708-38-1,
 GenBank AA397813 189710-02-9, GenBank AA397906 189711-72-6, GenBank
 AA398246 189711-88-4, GenBank AA398262 189712-78-5, GenBank AA398352
 189713-73-3, GenBank AA398384 189714-09-8, GenBank AA398482
 189714-46-3, GenBank AA398458 189715-25-1, GenBank AA398581
 189723-88-4, GenBank AA399218 189724-16-1, GenBank AA399264
 189724-71-8, GenBank AA399317 189724-74-1, GenBank AA399320
 189724-80-9, GenBank AA399326 189729-52-0, GenBank AA401304
 189729-83-7, GenBank AA401370 189730-50-5, GenBank AA401437
 189730-54-9, GenBank AA401441 189733-15-1, GenBank AA400090
 189733-35-5, GenBank AA400128 189735-47-5, GenBank AA400262
 189735-77-1, GenBank AA400292 189737-29-9, GenBank AA400391
 189737-31-3, GenBank AA400393 189737-51-7, GenBank AA400476
 189739-27-3, GenBank AA400592 189772-18-7, GenBank AA401111
 189773-45-3, GenBank AA401224 189773-57-7, GenBank AA401236
 189773-96-4, GenBank AA401257 189774-39-8, GenBank AA401275
 189775-07-3, GenBank U92018 189776-21-4, GenBank AA403048 189776-27-0,
 GenBank AA403072 189781-33-7, GenBank AA402159 189782-20-5, GenBank
 AA402298 189782-73-8, GenBank AA402352 189784-88-1, GenBank AA402724
 189785-56-6, GenBank AA402796 189786-40-1, GenBank AA402879
 189786-58-1, GenBank AA402915 189788-59-8, GenBank AA402011
 189788-92-9, GenBank AA402247 189790-10-1, GenBank AA403061
 189791-83-1, GenBank AA401693 189793-05-3, GenBank AA402435
 189803-66-5, GenBank U94855 189834-68-2, GenBank AA404656 189834-96-6,
 GenBank AA404692 189835-68-5, GenBank AA404646 189836-07-5, GenBank
 AA404225 189836-21-3, GenBank AA404239 189836-33-7, GenBank AA404269
 189836-50-8, GenBank AA404286 189836-52-0, GenBank AA404288
 189836-57-5, GenBank AA404293 189836-96-2, GenBank AA404346
 189837-06-7, GenBank AA404356 189838-30-0, GenBank AA404486
 189839-31-4, GenBank AA404564 189868-02-8, GenBank F22810 189901-95-9,
 GenBank AA405631 189902-00-9, GenBank AA405636 189902-24-7, GenBank
 AA405587 189902-42-9, GenBank AA405624 189902-70-3, GenBank AA404988
 189902-90-7, GenBank AA405008 189904-51-6, GenBank AA405443
 189906-38-5, GenBank AA405208 189906-57-8, GenBank AA405227

189906-88-5, GenBank AA405362 189907-23-1, GenBank AA405415
 189907-62-8, GenBank AA405690 189908-03-0, GenBank AA405748
 189908-06-3, GenBank AA405751 189908-57-4, GenBank AA405804
 189909-23-7, GenBank AA405869 189910-42-7, GenBank AA405989
 189910-71-2, GenBank AA406019 189911-13-5, GenBank AA406061
 189911-59-9, GenBank AA405984 189912-54-7, GenBank AA406205
 189912-86-5, GenBank AA406192 189912-97-8, GenBank AA406113
 189912-99-0, GenBank AA406115 189913-63-1, GenBank AA406311
 189913-89-1, GenBank AA406320 189914-14-5, GenBank AA406363
 189914-23-6, GenBank AA406372 189914-64-5, GenBank AA406395
 189914-81-6, GenBank AA406428 189915-02-4, GenBank AA406449
 189915-09-1, GenBank AA406456 189915-56-8, GenBank AA406505
 189916-12-9, GenBank AA406551 189916-36-7, GenBank AA406575
 189916-41-4, GenBank AA406580 189923-05-5, GenBank U90552 189964-98-5,
 GenBank AA411204 189965-19-3, GenBank AA411234 189966-68-5, GenBank
 AA411392 189967-16-6, GenBank AA411440 189967-28-0, GenBank AA411452
 189969-09-3, GenBank AA410206 189969-95-7, GenBank AA410293
 189970-00-1, GenBank AA410298 189970-12-5, GenBank AA410310
 189970-32-9, GenBank AA411556 189970-57-8, GenBank AA411655
 189970-76-1, GenBank AA411674 189972-74-5, GenBank AA410429
 189973-41-9, GenBank AA410496 189973-87-3, GenBank AA410480
 189973-95-3, GenBank AA410488 189974-12-7, GenBank AA410567
 189975-42-6, GenBank AA410680 190027-55-5, GenBank AA411107
 190029-80-2, GenBank AA411876 190033-13-7, GenBank AA412193
 190033-31-9, GenBank AA412229 190033-39-7, GenBank AA412237
 190033-86-4, GenBank AA412284 190037-42-4, GenBank AA412632
 190058-74-3, GenBank AA423940 190117-00-1, GenBank AA417097
 190118-30-0, GenBank AA417227 190119-83-6, GenBank AA417380
 190119-87-0, GenBank AA417384 190120-35-5, GenBank AA416552
 190144-43-5, GenBank AA416733 190144-46-8, GenBank AA416736
 190144-96-8, GenBank AA416767 190145-14-3, GenBank AA416785
 190145-50-7, GenBank AA416816 190145-77-8, GenBank AA416843
 190151-13-4, GenBank AA418999 190152-39-7, GenBank AA419064
 190152-72-8, GenBank AA419192 190153-33-4, GenBank AA419251
 190154-22-4, GenBank AA419164 190156-70-8, GenBank AA419582
 190157-10-9, GenBank AA419614 190157-25-6, GenBank AA419602
 190157-71-2, GenBank AA417592 190157-74-5, GenBank AA417595
 190158-47-5, GenBank AA417659 190158-71-5, GenBank AA417683
 190159-14-9, GenBank AA417744 190159-56-9, GenBank AA417803
 190159-58-1, GenBank AA417805 190159-70-7, GenBank AA417737
 190160-69-1, GenBank AA417900 190161-00-3, GenBank AA417912
 190161-08-1, GenBank AA417920 190161-09-2, GenBank AA417921
 190161-21-8, GenBank AA417933 190161-34-3, GenBank AA417946
 190161-44-5, GenBank AA417956 190162-19-7, GenBank AA418021
 190162-47-1, GenBank AA418077 190162-67-5, GenBank AA418097
 190163-14-5, GenBank AA418144 190163-71-4, GenBank AA418119
 190163-88-3, GenBank AA418200 190164-09-1, GenBank AA418221
 190165-01-6, GenBank AA418304 190165-20-9, GenBank AA418322
 190165-99-2, GenBank AA418383 190166-58-6, GenBank AA418442
 190166-75-7, GenBank AA418507 190167-01-2, GenBank AA418523
 190167-71-6, GenBank AA418610 190167-88-5, GenBank AA418510
 190168-32-2, GenBank AA418644 190168-58-2, GenBank AA418670
 190169-61-0, GenBank AA418782 190169-78-9, GenBank AA418808
 190169-81-4, GenBank AA418811 190169-91-6, GenBank AA418821
 190170-34-4, GenBank AA418846 190170-88-8, GenBank AA418900
 190171-20-1, GenBank AA418922 190171-30-3, GenBank AA418951
 190171-34-7, GenBank AA418955 190171-38-1, GenBank AA418959
 190171-72-3, GenBank AA418984 190171-76-7, GenBank AA418988
 190180-20-2, GenBank D86227 190181-07-8, GenBank AA420462 190212-36-3,
 GenBank AA420491 190213-10-6, GenBank AA420625 190214-64-3, GenBank
 AA420758 190427-02-2, GenBank AA420992 190427-86-2, GenBank AA421584
 190427-87-3, GenBank AA421023 190427-94-2, GenBank AA421030
 190428-00-3, GenBank AA420982 190429-15-3, GenBank AA421213
 190429-57-3, GenBank AA421258 190469-98-8, GenBank AA421171
 190470-77-0, GenBank AA421242 190471-17-1, GenBank AA421420
 190471-78-4, GenBank AA421481 190472-30-1, GenBank AA421533

190473-09-7, GenBank AA421595 190473-71-3, GenBank AA421682
 190474-42-1, GenBank AA421754 190474-72-7, GenBank AA421603
 190476-75-6, GenBank AA421845 190476-80-3, GenBank AA421850
 190477-61-3, GenBank AA422057 190496-86-7, GenBank AA424706
 190497-76-8, GenBank AA423867 190499-58-2, GenBank AA424102
 190501-58-7, GenBank AA424293

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 190501-82-7, GenBank AA424317 190502-34-2, GenBank AA424352
 190502-51-3, GenBank AA424395 190503-06-1, GenBank AA424441
 190503-60-7, GenBank AA424504 190504-29-1, GenBank AA424564
 190504-43-9, GenBank AA424578 190544-76-4, GenBank AA424653
 190544-80-0, GenBank AA424657 190544-94-6, GenBank AA424680
 190544-98-0, GenBank AA424684 190545-08-5, GenBank AA424632
 190553-35-6, GenBank AA425175 190553-68-5, GenBank AA425208
 190553-78-7, GenBank AA425236 190553-91-4, GenBank AA425249
 190554-65-5, GenBank AA425323 190555-24-9, GenBank AA425400
 190555-33-0, GenBank AA425382 190555-43-2, GenBank AA425419
 190555-64-7, GenBank AA425395 190555-92-1, GenBank AA425485
 190555-97-6, GenBank AA425411 190556-09-3, GenBank AA425475
 190556-25-3, GenBank AA425500 190556-64-0, GenBank AA425556
 190556-70-8, GenBank AA425562 190556-87-7, GenBank AA425465
 190556-89-9, GenBank AA425467 190557-12-1, GenBank AA425551
 190557-14-3, GenBank AA425553 190557-29-0, GenBank AA425587
 190557-47-2, GenBank AA425641 190558-45-3, GenBank AA425757
 190558-75-9, GenBank AA425879 190559-04-7, GenBank AA426048
 190559-11-6, GenBank AA426019 190559-21-8, GenBank AA426065
 190559-99-0, GenBank AA426341 190560-14-6, GenBank AA426374
 190561-12-7, GenBank AA426499 190561-35-4, GenBank AA426495
 190562-10-8, GenBank AA426586 190562-12-0, GenBank AA426588
 190562-44-8, GenBank AA424744 190562-58-4, GenBank AA424767
 190563-32-7, GenBank AA424796 190563-86-1, GenBank AA424913
 190564-06-8, GenBank AA424950 190564-51-3, GenBank AA425014
 190564-84-2, GenBank AA425047 190565-05-0, GenBank AA424984
 190565-40-3, GenBank AA425102 190565-89-0, GenBank AA425352
 190567-15-8, GenBank AA425120 190567-78-3, GenBank AA425139
 190568-25-3, GenBank AA425545 190568-39-9, GenBank AA425160
 190569-86-9, GenBank AA426216 190569-90-5, GenBank AA425861
 190571-27-8, GenBank AA426227 190614-70-1, GenBank U96915 190621-96-6,
 GenBank AA428229 190622-58-3, GenBank AA428341 190625-09-3, GenBank
 AA428836 190627-07-7, GenBank AA429076 190627-42-0, GenBank AA429171
 190628-77-4, GenBank AA429326 190629-70-0, GenBank AA430351
 190631-30-2, GenBank AA430497 190631-37-9, GenBank AA430504
 190631-58-4, GenBank AA430540 190631-70-0, GenBank AA430552
 190631-75-5, GenBank AA430573 190631-77-7, GenBank AA430575 190632-55-
 4, GenBank AA430639 190632-64-5, GenBank AA430665 190632-91-8, GenBank
 AA430675 190634-13-0, GenBank AA427447 190634-47-0, GenBank AA427433
 190634-93-6, GenBank AA427619 190635-25-7, GenBank AA427667
 190635-72-4, GenBank AA427690 190636-46-5, GenBank AA427789
 190636-49-8, GenBank AA427792 190636-91-0, GenBank AA427815
 190636-97-6, GenBank AA427858 190637-20-8, GenBank AA427899
 190637-65-1, GenBank AA427970 190637-95-7, GenBank AA428044
 190638-08-5, GenBank AA428074 190638-17-6, GenBank AA428099
 190638-27-8, GenBank AA428117 190638-54-1, GenBank AA428136
 190639-00-0, GenBank AA428240 190639-60-2, GenBank AA429307
 190639-81-7, GenBank AA429422 190642-60-5, GenBank AA428250
 190642-70-7, GenBank AA428418 190642-73-0, GenBank AA428421
 190642-83-2, GenBank AA430687 190644-00-9, GenBank AA427782
 190645-07-9, GenBank AA428454 190645-08-0, GenBank AA428455
 190681-86-8, GenBank AA429937 190681-95-9, GenBank AA429980
 190682-04-3, GenBank AA429989 190682-46-3, GenBank AA430032
 190682-54-3, GenBank AA430040 190682-83-8, GenBank AA429944
 190682-84-9, GenBank AA429945 190683-60-4, GenBank AA430010

190683-69-3, GenBank AA430092 190683-70-6, GenBank AA430093
 190683-85-3, GenBank AA430172 190684-18-5, GenBank AA430205
 190684-81-2, GenBank AA430241 190695-69-3, GenBank AA431201
 190695-78-4, GenBank AA431210 190697-76-8, GenBank AA431408
 190698-06-7, GenBank AA431438 190701-01-0, GenBank AA431734
 190701-08-7, GenBank AA431741 190701-16-7, GenBank AA431749
 190701-40-7, GenBank AA431773 190701-63-4, GenBank AA431796
 190701-84-9, GenBank AA431817 190702-35-3, GenBank AA431868
 190703-33-4, GenBank AA431967 190703-52-7, GenBank AA431986
 190703-96-9, GenBank AA432030 190704-28-0, GenBank AA432062
 190704-40-6, GenBank AA432074 190704-41-7, GenBank AA432075
 190704-66-6, GenBank AA432100 190704-74-6, GenBank AA432108
 190741-67-4, GenBank Y13247 190820-76-9, GenBank AA433818 190822-26-5,
 GenBank AA433968 190823-46-2, GenBank AA434088 190823-48-4, GenBank
 AA434090 190824-02-3, GenBank AA434144 190824-18-1, GenBank AA434160
 190826-56-3, GenBank AA434402 190826-74-5, GenBank AA434420
 190827-08-8, GenBank AA434454 190827-41-9, GenBank AA434487
 190827-51-1, GenBank AA434497 190827-56-6, GenBank AA434502
 190828-12-7, GenBank AA434558 190870-58-7, GenBank AA435877
 190870-92-9, GenBank AA435948 190870-94-1, GenBank AA435950
 190871-48-8, GenBank AA436031 190872-14-1, GenBank AA436097
 190872-45-8, GenBank AA436158 190872-89-0, GenBank AA436128
 190873-23-5, GenBank AA436233 190874-17-0, GenBank AA436325
 190874-41-0, GenBank AA436269 190874-62-5, GenBank AA436290
 190875-00-4, GenBank AA436384 190875-72-0, GenBank AA436456
 190875-95-7, GenBank AA436479 190876-90-5, GenBank AA436574
 190877-11-3, GenBank AA436595 190877-27-1, GenBank AA436611
 190878-54-7, GenBank AA436738 190880-43-4, GenBank AA436927
 190880-59-2, GenBank AA436943 190882-06-5, GenBank AA437090
 190882-09-8, GenBank AA437093 190882-40-7, GenBank AA437124
 190884-71-0, GenBank AA437355 190884-85-6, GenBank AA437370
 190920-80-0, GenBank U60337 190950-99-3, GenBank AA458549 190951-01-0,
 GenBank AA458551 190951-29-2, GenBank AA458578 190987-03-2, GenBank
 AA442043 190988-34-2, GenBank AA442174 190988-66-0, GenBank AA442206
 190989-47-0, GenBank AA442287 190989-50-5, GenBank AA442290
 190990-12-6, GenBank AA442352 190990-30-8, GenBank AA442370
 190993-52-3, GenBank AA442692 190993-55-6, GenBank AA442695
 191005-01-3, GenBank AA442853 191005-84-2, GenBank AA442936
 191006-24-3, GenBank AA442976 191006-52-7, GenBank AA443004
 191006-87-8, GenBank AA443039 191007-11-1, GenBank AA443063
 191009-34-4, GenBank AA443286 191010-77-2, GenBank AA443429
 191012-48-3, GenBank AA443602 191049-01-1, GenBank AA443690
 191049-13-5, GenBank AA443702 191050-97-2, GenBank AA443853
 191051-15-7, GenBank AA443903 191051-32-8, GenBank AA443920
 191051-40-8, GenBank AA443971 191052-11-6, GenBank AA443936
 191052-71-8, GenBank AA444066 191052-76-3, GenBank AA444071
 191052-91-2, GenBank AA444020 191053-06-2, GenBank AA444129
 191055-86-4, GenBank AA444386 191071-53-1, GenBank AA446016
 191074-99-4, GenBank AA446344 191076-22-9, GenBank AA446428
 191076-99-0, GenBank AA446505 191078-67-8, GenBank AA446675
 191078-74-7, GenBank AA446682 191079-08-0, GenBank AA446716
 191079-74-0, GenBank AA446782 191079-84-2, GenBank AA446792
 191080-11-2, GenBank AA446819 191080-18-9, GenBank AA446826
 191080-73-6, GenBank AA446881 191080-77-0, GenBank AA446885
 191080-93-0, GenBank AA446901 191080-99-6, GenBank AA446907
 191081-71-7, GenBank AA446979 191081-72-8, GenBank AA446980
 191082-10-7, GenBank AA447018 191082-19-6, GenBank AA447027
 191117-09-6, GenBank AA447232 191120-24-8, GenBank AA447453 191120-30-
 6, GenBank AA447459 191120-84-0, GenBank AA447486 191121-00-3, GenBank
 AA447502 191121-01-4, GenBank AA447503 191121-02-5, GenBank AA447504
 191121-20-7, GenBank AA447522 191121-23-0, GenBank AA447525
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

| | | | | | | |
|----|--------------|---------|----------|--------------|---------|----------|
| IT | 191121-63-8, | GenBank | AA447610 | 191122-00-6, | GenBank | AA447574 |
| | 191122-77-7, | GenBank | AA447679 | 191122-86-8, | GenBank | AA447688 |
| | 191123-20-3, | GenBank | AA447780 | 191123-21-4, | GenBank | AA447781 |
| | 191123-22-5, | GenBank | AA447782 | 191123-61-2, | GenBank | AA447773 |
| | 191123-75-8, | GenBank | AA447729 | 191123-94-1, | GenBank | AA447797 |
| | 191123-95-2, | GenBank | AA447798 | 191124-07-9, | GenBank | AA447810 |
| | 191124-54-6, | GenBank | AA447835 | 191124-88-6, | GenBank | AA447947 |
| | 191124-89-7, | GenBank | AA447948 | 191125-16-3, | GenBank | AA447896 |
| | 191126-12-2, | GenBank | AA448015 | 191126-30-4, | GenBank | AA448033 |
| | 191126-64-4, | GenBank | AA448110 | 191126-92-8, | GenBank | AA448074 |
| | 191127-49-8, | GenBank | AA448126 | 191127-63-6, | GenBank | AA448140 |
| | 191127-80-7, | GenBank | AA448157 | 191127-84-1, | GenBank | AA448161 |
| | 191128-54-8, | GenBank | AA448257 | 191128-67-3, | GenBank | AA448270 |
| | 191128-74-2, | GenBank | AA448277 | 191128-86-6, | GenBank | AA448289 |
| | 191130-12-8, | GenBank | AA448400 | 191130-14-0, | GenBank | AA448402 |
| | 191130-59-3, | GenBank | AA448464 | 191131-52-9, | GenBank | AA448526 |
| | 191131-95-0, | GenBank | AA448599 | 191132-11-3, | GenBank | AA448615 |
| | 191132-42-0, | GenBank | AA448646 | 191132-60-2, | GenBank | AA448664 |
| | 191133-07-0, | GenBank | AA448735 | 191133-27-4, | GenBank | AA448755 |
| | 191133-52-5, | GenBank | AA448729 | 191133-56-9, | GenBank | AA448760 |
| | 191133-57-0, | GenBank | AA448761 | 191136-75-1, | GenBank | AA449429 |
| | 191136-87-5, | GenBank | AA449289 | 191137-20-9, | GenBank | AA449394 |
| | 191137-45-8, | GenBank | AA449419 | 191137-80-1, | GenBank | AA450333 |
| | 191137-83-4, | GenBank | AA450336 | 191137-97-0, | GenBank | AA450350 |
| | 191138-18-8, | GenBank | AA449459 | 191139-13-6, | GenBank | AA448967 |
| | 191139-31-8, | GenBank | AA449037 | 191139-32-9, | GenBank | AA449038 |
| | 191139-82-9, | GenBank | AA449008 | 191139-94-3, | GenBank | AA449120 |
| | 191140-08-6, | GenBank | AA449054 | 191140-21-3, | GenBank | AA449067 |
| | 191141-07-8, | GenBank | AA449332 | 191141-09-0, | GenBank | AA449334 |
| | 191141-11-4, | GenBank | AA449336 | 191141-32-9, | GenBank | AA449357 |
| | 191141-57-8, | GenBank | AA449481 | 191141-66-9, | GenBank | AA449490 |
| | 191141-92-1, | GenBank | AA449516 | 191142-06-0, | GenBank | AA449530 |
| | 191142-65-1, | GenBank | AA449621 | 191143-05-2, | GenBank | AA449590 |
| | 191143-08-5, | GenBank | AA449593 | 191143-64-3, | GenBank | AA449688 |
| | 191143-79-0, | GenBank | AA449703 | 191144-28-2, | GenBank | AA449742 |
| | 191144-94-2, | GenBank | AA449862 | 191145-33-2, | GenBank | AA449821 |
| | 191146-62-0, | GenBank | AA450009 | 191148-64-8, | GenBank | AA450189 |
| | 191149-02-7, | GenBank | AA450227 | 191149-39-0, | GenBank | AA450264 |
| | 191149-69-6, | GenBank | AA450294 | 191187-94-7, | GenBank | AA451609 |
| | 191188-18-8, | GenBank | AA451633 | 191189-82-9, | GenBank | AA451767 |
| | 191190-16-6, | GenBank | AA451811 | 191190-22-4, | GenBank | AA451817 |
| | 191190-56-4, | GenBank | AA451851 | 191190-96-2, | GenBank | AA451886 |
| | 191190-98-4, | GenBank | AA451888 | 191191-02-3, | GenBank | AA451892 |
| | 191191-05-6, | GenBank | AA451895 | 191191-13-6, | GenBank | AA451903 |
| | 191191-14-7, | GenBank | AA451904 | 191191-79-4, | GenBank | AA451969 |
| | 191191-88-5, | GenBank | AA451978 | 191192-02-6, | GenBank | AA451992 |
| | 191192-87-7, | GenBank | AA452058 | 191192-89-9, | GenBank | AA452060 |
| | 191193-20-1, | GenBank | AA452091 | 191193-72-3, | GenBank | AA452193 |
| | 191194-62-4, | GenBank | AA452250 | 191194-68-0, | GenBank | AA452256 |
| | 191194-90-8, | GenBank | AA452278 | 191195-02-5, | GenBank | AA452317 |
| | 191195-21-8, | GenBank | AA452336 | 191195-30-9, | GenBank | AA452345 |
| | 191195-31-0, | GenBank | AA452346 | 191195-33-2, | GenBank | AA452348 |
| | 191195-42-3, | GenBank | AA452357 | 191195-75-2, | GenBank | AA452371 |
| | 191196-08-4, | GenBank | AA452404 | 191196-79-9, | GenBank | AA452497 |
| | 191197-98-5, | GenBank | AA452566 | 191198-23-9, | GenBank | AA452627 |
| | 191198-48-8, | GenBank | AA452652 | 191199-36-7, | GenBank | AA452752 |
| | 191199-99-2, | GenBank | AA452822 | 191200-01-8, | GenBank | AA452824 |
| | 191200-25-6, | GenBank | AA452802 | 191201-65-7, | GenBank | AA452955 |
| | 191201-73-7, | GenBank | AA452963 | 191201-76-0, | GenBank | AA452966 |
| | 191201-78-2, | GenBank | AA452968 | 191202-25-2, | GenBank | AA453015 |
| | 191202-37-6, | GenBank | AA453027 | 191202-38-7, | GenBank | AA453028 |
| | 191202-42-3, | GenBank | AA453032 | 191202-93-4, | GenBank | AA453105 |
| | 191203-86-8, | GenBank | AA453176 | 191203-91-5, | GenBank | AA453181 |
| | 191204-64-5, | GenBank | AA453287 | 191204-70-3, | GenBank | AA453293 |
| | 191205-45-5, | GenBank | AA453335 | 191205-51-3, | GenBank | AA453341 |
| | 191205-57-9, | GenBank | AA453347 | 191205-69-3, | GenBank | AA453359 |

| | |
|-------------------------------|-------------------------------|
| 191206-37-8, GenBank AA453477 | 191206-38-9, GenBank AA453478 |
| 191206-58-3, GenBank AA453418 | 191206-75-4, GenBank AA453435 |
| 191207-26-8, GenBank AA453495 | 191207-58-6, GenBank AA453527 |
| 191207-87-1, GenBank AA453577 | 191208-76-1, GenBank AA453675 |
| 191209-00-4, GenBank AA453712 | 191209-04-8, GenBank AA453677 |
| 191209-21-9, GenBank AA453694 | 191209-38-8, GenBank AA453728 |
| 191209-40-2, GenBank AA453730 | 191209-65-1, GenBank AA453755 |
| 191209-84-4, GenBank AA453774 | 191210-00-1, GenBank AA453790 |
| 191210-15-8, GenBank AA453872 | 191210-30-7, GenBank AA453823 |
| 191210-39-6, GenBank AA453832 | 191210-46-5, GenBank AA453839 |
| 191210-66-9, GenBank AA453859 | 191210-70-5, GenBank AA453863 |
| 191210-90-9, GenBank AA453816 | 191211-26-4, GenBank AA453916 |
| 191237-49-7, GenBank AA453942 | 191237-66-8, GenBank AA453982 |
| 191237-83-9, GenBank AA453999 | 191237-88-4, GenBank AA454004 |
| 191237-92-0, GenBank AA454008 | 191238-00-3, GenBank AA454016 |
| 191238-09-2, GenBank AA454033 | 191238-56-9, GenBank AA454080 |
| 191238-74-1, GenBank AA454098 | 191239-33-5, GenBank AA454149 |
| 191239-58-4, GenBank AA454174 | 191239-82-4, GenBank AA454227 |
| 191243-60-4, GenBank AA456778 | 191244-56-1, GenBank AA454579 |
| 191245-14-4, GenBank AA454566 | 191245-46-2, GenBank AA454611 |
| 191246-03-4, GenBank AA454668 | 191246-88-5, GenBank AA454753 |
| 191247-11-7, GenBank AA454820 | 191247-24-2, GenBank AA454776 |
| 191247-97-9, GenBank AA454862 | 191248-14-3, GenBank AA454879 |
| 191248-15-4, GenBank AA454880 | 191248-49-4, GenBank AA454978 |
| 191248-72-3, GenBank AA454921 | 191248-83-6, GenBank AA454932 |
| 191249-00-0, GenBank AA454949 | 191249-36-2, GenBank AA454989 |
| 191249-57-7, GenBank AA455010 | 191249-60-2, GenBank AA455013 |
| 191249-87-3, GenBank AA455040 | 191249-89-5, GenBank AA455042 |
| 191249-90-8, GenBank AA455043 | 191250-52-9, GenBank AA455133 |
| 191250-60-9, GenBank AA455087 | 191250-84-7, GenBank AA455168 |
| 191251-16-8, GenBank AA455150 | 191251-29-3, GenBank AA455163 |
| 191251-30-6, GenBank AA455164 | 191251-44-2, GenBank AA455210 |
| 191251-56-6, GenBank AA455222 | 191251-71-5, GenBank AA455280 |
| 191252-13-8, GenBank AA455262 | 191252-29-6, GenBank AA455235 |
| 191253-16-4, GenBank AA455382 | 191254-03-2, GenBank AA455396 |
| 191254-30-5, GenBank AA455496 | 191254-65-6, GenBank AA455510 |
| 191254-74-7, GenBank AA455519 | 191254-95-2, GenBank AA455566 |
| 191255-14-8, GenBank AA455585 | 191255-17-1, GenBank AA455588 |
| 191255-26-2, GenBank AA455597 | 191255-63-7, GenBank AA455554 |
| 191255-93-3, GenBank AA455693 | 191256-06-1, GenBank AA455706 |
| 191256-15-2, GenBank AA455644 | 191257-39-3, GenBank AA455846 |
| 191258-12-5, GenBank AA455878 | 191258-78-3, GenBank AA455944 |
| 191258-89-6, GenBank AA455984 | 191259-06-0, GenBank AA456001 |
| 191259-19-5, GenBank AA456014 | 191259-27-5, GenBank AA456023 |
| 191259-54-8, GenBank AA455969 | 191259-58-2, GenBank AA455973 |
| 191259-61-7, GenBank AA455976 | 191259-68-4, GenBank AA456035 |
| 191259-95-7, GenBank AA456062 | 191260-18-1, GenBank AA456109 |
| 191260-29-4, GenBank AA456077 | 191260-79-4, GenBank AA456370 |
| 191260-85-2, GenBank AA456376 | 191261-27-5, GenBank AA456454 |
| 191261-28-6, GenBank AA456455 | 191261-58-2, GenBank AA456437 |
| 191261-67-3, GenBank AA456446 | 191261-75-3, GenBank AA456394 |
| 191261-81-1, GenBank AA456400 | 191261-84-4, GenBank AA456403 |
| 191262-07-4, GenBank AA456510 | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

| | |
|----------------------------------|-------------------------------|
| IT 191263-06-6, GenBank AA456585 | 191263-29-3, GenBank AA456608 |
| 191263-37-3, GenBank AA456616 | 191264-13-8, GenBank AA456664 |
| 191265-46-0, GenBank AA456184 | 191265-54-0, GenBank AA456192 |
| 191266-03-2, GenBank AA456161 | 191266-22-5, GenBank AA456271 |
| 191266-40-7, GenBank AA456289 | 191266-54-3, GenBank AA456303 |
| 191266-67-8, GenBank AA456254 | 191266-78-1, GenBank AA456265 |
| 191266-87-2, GenBank AA456321 | 191266-91-8, GenBank AA456325 |
| 191266-94-1, GenBank AA456818 | 191266-97-4, GenBank AA456821 |

| | |
|-------------------------------|-------------------------------|
| 191267-09-1, GenBank AA456833 | 191267-54-6, GenBank AA456878 |
| 191267-62-6, GenBank AA456886 | 191268-59-4, GenBank AA457042 |
| 191269-26-8, GenBank AA457051 | 191269-57-5, GenBank AA457082 |
| 191269-67-7, GenBank AA457092 | 191269-83-7, GenBank AA457108 |
| 191269-93-9, GenBank AA457118 | 191270-07-2, GenBank AA457152 |
| 191270-73-2, GenBank AA457138 | 191270-86-7, GenBank AA458491 |
| 191271-15-5, GenBank AA457247 | 191271-72-4, GenBank AA458501 |
| 191271-73-5, GenBank AA458502 | 191271-74-6, GenBank AA458503 |
| 191271-80-4, GenBank AA458509 | 191271-87-1, GenBank AA458516 |
| 191271-99-5, GenBank AA458528 | 191293-48-8, GenBank AA457501 |
| 191313-22-1, GenBank AA458622 | 191313-27-6, GenBank AA458627 |
| 191313-37-8, GenBank AA458637 | 191313-53-8, GenBank AA458653 |
| 191314-57-5, GenBank AA458838 | 191315-00-1, GenBank AA458801 |
| 191315-54-5, GenBank AA458884 | 191316-28-6, GenBank AA458943 |
| 191316-76-4, GenBank AA458994 | 191316-78-6, GenBank AA458996 |
| 191317-26-7, GenBank AA459045 | 191317-81-4, GenBank AA459100 |
| 191317-87-0, GenBank AA459106 | 191318-13-5, GenBank AA459132 |
| 191318-29-3, GenBank AA459148 | 191318-61-3, GenBank AA459180 |
| 191319-08-1, GenBank AA459227 | 191319-63-8, GenBank AA459282 |
| 191319-73-0, GenBank AA459292 | 191320-48-6, GenBank AA459368 |
| 191320-73-7, GenBank AA459393 | 191320-90-8, GenBank AA459410 |
| 191321-70-7, GenBank AA459491 | 191321-85-4, GenBank AA459507 |
| 191322-20-0, GenBank AA459542 | 191322-92-6, GenBank AA459614 |
| 191322-98-2, GenBank AA459621 | 191323-04-3, GenBank AA459627 |
| 191323-09-8, GenBank AA459632 | 191323-21-4, GenBank AA459645 |
| 191323-39-4, GenBank AA459663 | 191323-78-1, GenBank AA459702 |
| 191324-03-5, GenBank AA459727 | 191324-19-3, GenBank AA459743 |
| 191325-56-1, GenBank AA459880 | 191362-85-3, GenBank AA460012 |
| 191363-67-4, GenBank AA460074 | 191363-71-0, GenBank AA460078 |
| 191364-44-0, GenBank AA460239 | 191364-59-7, GenBank AA460254 |
| 191364-63-3, GenBank AA460258 | 191364-74-6, GenBank AA460310 |
| 191365-43-2, GenBank AA460299 | 191365-76-1, GenBank AA460432 |
| 191365-82-9, GenBank AA460438 | 191366-24-2, GenBank AA460480 |
| 191366-40-2, GenBank AA461403 | 191366-66-2, GenBank AA461456 |
| 191366-80-0, GenBank AA461390 | 191367-13-2, GenBank AA461460 |
| 191367-20-1, GenBank AA461467 | 191367-39-2, GenBank AA461486 |
| 191367-45-0, GenBank AA461492 | 191367-62-1, GenBank AA461509 |
| 191367-92-7, GenBank AA461583 | 191368-25-9, GenBank AA461616 |
| 191368-46-4, GenBank AA461574 | 191368-48-6, GenBank AA461576 |
| 191369-00-3, GenBank AA460149 | 191369-12-7, GenBank AA460115 |
| 191370-02-2, GenBank AA460514 | 191370-08-8, GenBank AA460520 |
| 191370-30-6, GenBank AA460369 | 191370-73-7, GenBank AA460529 |
| 191371-34-3, GenBank AA460651 | 191371-78-5, GenBank AA460669 |
| 191372-15-3, GenBank AA460732 | 191373-14-5, GenBank AA460805 |
| 191373-40-7, GenBank AA460831 | 191373-47-4, GenBank AA460838 |
| 191373-63-4, GenBank AA460893 | 191373-70-3, GenBank AA460900 |
| 191373-94-1, GenBank AA460847 | 191374-06-8, GenBank AA460859 |
| 191374-19-3, GenBank AA460872 | 191374-55-7, GenBank AA460946 |
| 191374-66-0, GenBank AA460957 | 191374-72-8, GenBank AA460963 |
| 191376-02-0, GenBank AA461132 | 191376-06-4, GenBank AA461136 |
| 191376-34-8, GenBank AA461084 | 191376-42-8, GenBank AA461092 |
| 191376-70-2, GenBank AA461120 | 191377-57-8, GenBank AA461254 |
| 191378-07-1, GenBank AA461304 | 191394-46-4, GenBank AA463220 |
| 191394-50-0, GenBank AA463224 | 191395-25-2, GenBank AA463275 |
| 191395-78-5, GenBank AA463248 | 191396-40-4, GenBank AA463323 |
| 191397-17-8, GenBank AA463446 | 191397-24-7, GenBank AA463453 |
| 191397-25-8, GenBank AA463454 | 191434-66-9, GenBank AA463492 |
| 191434-72-7, GenBank AA463498 | 191434-82-9, GenBank AA463458 |
| 191434-84-1, GenBank AA463460 | 191434-87-4, GenBank AA463463 |
| 191435-55-9, GenBank AA463568 | 191435-93-5, GenBank AA463661 |
| 191436-37-0, GenBank AA463625 | 191437-56-6, GenBank AA463788 |
| 191437-57-7, GenBank AA463789 | 191437-61-3, GenBank AA463793 |
| 191437-65-7, GenBank AA463797 | 191437-98-6, GenBank AA463830 |
| 191438-05-8, GenBank AA463837 | 191439-23-3, GenBank AA464018 |
| 191439-36-8, GenBank AA463964 | 191440-00-3, GenBank AA464062 |
| 191440-15-0, GenBank AA464095 | 191441-10-8, GenBank AA464147 |

191441-24-4, GenBank AA464152 191441-70-0, GenBank AA464236
 191441-71-1, GenBank AA464237 191442-01-0, GenBank AA464210
 191442-68-9, GenBank AA464305 191442-92-9, GenBank AA464329
 191443-05-7, GenBank AA464342 191443-11-5, GenBank AA464354
 191443-15-9, GenBank AA464358 191444-92-5, GenBank AA464529
 191445-12-2, GenBank AA464542 191445-26-8, GenBank AA464557
 191445-37-1, GenBank AA464568 191445-38-2, GenBank AA464569
 191445-46-2, GenBank AA464612 191445-54-2, GenBank AA464622
 191445-55-3, GenBank AA464623 191445-62-2, GenBank AA464630
 191445-79-1, GenBank AA464593 191445-81-5, GenBank AA464595
 191445-87-1, GenBank AA464601 191446-40-9, GenBank AA464729
 191446-79-4, GenBank AA464688 191446-80-7, GenBank AA464689
 191446-82-9, GenBank AA464691 191446-91-0, GenBank AA464700
 191446-95-4, GenBank AA464704 191446-99-8, GenBank AA464708
 191447-01-5, GenBank AA464710 191447-02-6, GenBank AA464711
 191447-50-4, GenBank AA464824 191449-51-1, GenBank AA465049
 191453-45-9, GenBank AA465720 191453-48-2, GenBank AA465723
 191454-18-9, GenBank AA465148 191454-98-5, GenBank AA465228
 191455-26-2, GenBank AA465256 191455-28-4, GenBank AA465258
 191455-39-7, GenBank AA465269 191455-56-8, GenBank AA465286
 191456-44-7, GenBank AA465374 191456-93-6, GenBank AA465424
 191457-13-3, GenBank AA465444 191458-10-3, GenBank AA465541
 191458-15-8, GenBank AA465546 191458-61-4, GenBank AA465593
 191458-66-9, GenBank AA465598 191458-84-1, GenBank AA465616
 191459-22-0, GenBank AA465654 191503-47-6, GenBank AA467729
 191504-50-4, GenBank AA467769 191508-90-4, GenBank AA468236
 191509-65-6, GenBank AA468308 191517-56-3, GenBank AA469048
 191518-20-4, GenBank AA469207 191518-59-9, GenBank AA469166 191579-03-0, GenBank AA326982 191581-35-8, GenBank AA327247 191583-56-9, GenBank AA327455 191585-12-3, GenBank AA327592 191621-60-0, GenBank AA328185
 191623-27-5, GenBank AA328352 191624-18-7, GenBank AA328443
 191634-76-1, GenBank AA329529 191637-10-2, GenBank AA329754
 191638-89-8, GenBank AA329927 191690-38-7, GenBank AA332143
 191691-50-6, GenBank AA332250 191692-92-9, GenBank AA332410
 191693-30-8, GenBank AA332470 191695-24-6, GenBank AA332593
 191696-01-2, GenBank AA332672 191696-54-5, GenBank AA332772
 191702-40-6, GenBank AA333358 191702-72-4, GenBank AA333390
 191705-44-9, GenBank AA333694 191706-78-2, GenBank AA333796
 191714-74-6, GenBank AA334592 191715-38-5, GenBank AA334656
 191716-16-2, GenBank AA334734 191752-16-6, GenBank AA335086
 191754-25-3, GenBank AA335356 191756-14-6, GenBank AA335527
 191760-47-1, GenBank AA335862 191763-92-5, GenBank AA336273
 191767-93-8, GenBank AA336690 191769-25-2, GenBank AA336815
 191772-12-0, GenBank AA337085 191776-83-7, GenBank AA337617
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

IT 191813-86-2, GenBank AA338761 191834-73-8, GenBank AA340767
 191836-95-0, GenBank AA340989 191838-94-5, GenBank AA341183
 191843-99-9, GenBank AA341693 191897-85-5, GenBank AA343612
 191904-13-9, GenBank AA344287 191905-47-2, GenBank AA344350
 191912-68-2, GenBank AA345096 191943-68-7, GenBank AA345486
 191944-10-2, GenBank AA345528 191946-39-1, GenBank AA345757
 191954-13-9, GenBank AA346556 191961-18-9, GenBank AA347236
 191973-58-7, GenBank AA348472 191973-68-9, GenBank AA348482
 192010-08-5, GenBank AA348945 192010-50-7, GenBank AA348987
 192016-33-4, GenBank AA349571 192018-43-2, GenBank AA349781
 192027-81-9, GenBank AA350719 192037-54-0, GenBank AA351686
 192041-78-4, GenBank AA352116 192084-58-5, GenBank AA352567
 192087-58-4, GenBank AA352888 192089-09-1, GenBank AA353039
 192102-61-7, GenBank AA354391 192114-53-7, GenBank AA355584
 192117-11-6, GenBank AA355867 192117-40-1, GenBank Y09188 192143-63-8, GenBank AB002330 192143-90-1, GenBank AB002357 192144-14-2, GenBank AB002382 192151-75-0, GenBank AA356575 192154-45-3, GenBank AA356815

192156-61-9, GenBank AA357031 192161-51-6, GenBank AA357538
192163-20-5, GenBank AA357671 192167-79-6, GenBank AA358176
192232-84-1, GenBank AA359492 192239-87-5, GenBank AA360254
192241-74-0, GenBank AA360441 192242-47-0, GenBank AA360514
192243-76-8, GenBank AA360607 192244-37-4, GenBank AA360704
192246-69-8, GenBank AA360936 192248-00-3, GenBank AA361063
192265-62-6, GenBank AA362771 192277-32-0, GenBank AA363047
192282-66-9, GenBank AA363581 192293-09-7, GenBank AA364646
192295-41-3, GenBank AA364833 192310-85-3, GenBank U91919 192347-55-0,
GenBank AA367685 192356-16-4, GenBank AA368546 192368-62-0, GenBank
AA369836 192402-57-6, GenBank AA370644 192418-72-7, GenBank AA372230
192424-95-6, GenBank AA372927 192427-16-0, GenBank AA373141
192475-05-1, GenBank AA374161 192475-38-0, GenBank AA374198
192475-73-3, GenBank AA374233 192477-65-9, GenBank AA374376
192481-90-6, GenBank AA374890 192485-23-7, GenBank AA375184
192488-79-2, GenBank AA375478 192489-33-1, GenBank AA375594
192490-56-5, GenBank AA375717 192491-76-2, GenBank AA375867
192492-04-9, GenBank AA375815 192492-72-1, GenBank AA375933
192493-35-9, GenBank AA376034 192494-82-9, GenBank AA376143
192497-32-8, GenBank AA376424 192502-11-7, GenBank AA376837
192532-35-7, GenBank AA377265 192532-89-1, GenBank AA377319
192534-01-3, GenBank AA377431 192545-57-6, GenBank AA378617
192558-37-5, GenBank AA379901 192562-30-4, GenBank AA380293
192594-75-5, GenBank AA380819 192595-92-9, GenBank AA380936
192598-51-9, GenBank AA381196 192615-71-7, GenBank AA382938
192617-53-1, GenBank AA383074 192618-31-8, GenBank AA383177
192666-35-6, GenBank AA384095 192670-47-6, GenBank AA384518
192671-87-7, GenBank AA384671 192686-59-2, GenBank AA386075
192690-52-1, GenBank E00199 192730-93-1, GenBank E01198 192733-66-7,
GenBank E01630 192733-79-2, GenBank E01650 192734-74-0, GenBank E01888
192735-22-1, GenBank E01972 192792-30-6, GenBank E07165 192797-82-3,
GenBank U95367 192798-63-3, GenBank AF000148 192843-04-2, GenBank
AA469968 192843-39-3, GenBank AA470003 192843-84-8, GenBank AA470051
192853-52-4, GenBank AA471017 192854-38-9, GenBank AF003594
192854-82-3, GenBank AF003521 192859-96-4, GenBank AA471246
192951-51-2, GenBank AA476494 192952-33-3, GenBank AA476576
192952-42-4, GenBank AA476585 192952-61-7, GenBank AA476604
192956-16-4, GenBank AA476961 192956-63-1, GenBank AA477008 192956-98-
2, GenBank AA477044 192957-19-0, GenBank AA477065 192957-88-3, GenBank
AA478982 192958-94-4, GenBank AA479566 192959-74-3, GenBank AA479646
192961-20-9, GenBank AA479795 192961-82-3, GenBank AA479857
192962-05-3, GenBank AA477082 192962-88-2, GenBank AA477165
192963-69-2, GenBank AA477297 192964-99-1, GenBank AA477428
192966-98-6, GenBank AA477628 192983-10-1, GenBank Z75331 192983-61-2,
GenBank AA479906 192983-68-9, GenBank AA479913 192983-75-8, GenBank
AA479920 192984-18-2, GenBank AA476234 192984-24-0, GenBank AA476240
192984-37-5, GenBank AA476253 192984-56-8, GenBank AA476272
192984-69-3, GenBank AA476285 192986-22-4, GenBank AA476438
192986-44-0, GenBank AA476460 193030-73-8, GenBank AA478043
193031-81-1, GenBank AA478258 193031-91-3, GenBank AA478268
193032-02-9, GenBank AA478279 193032-82-5, GenBank AA478331
193034-28-5, GenBank AA478473 193034-35-4, GenBank AA478481
193035-18-6, GenBank AA478585 193035-37-9, GenBank AA478524
193035-55-1, GenBank AA478542 193035-99-3, GenBank AA478645
193036-13-4, GenBank AA478659 193036-24-7, GenBank AA478670
193036-55-4, GenBank AA478747 193036-94-1, GenBank AA478717
193036-96-3, GenBank AA478719 193036-98-5, GenBank AA478721
193037-67-1, GenBank AA478812 193038-08-3, GenBank AA478880
193038-64-1, GenBank AA478866 193038-73-2, GenBank AA478875
193039-39-3, GenBank AA479063 193041-26-8, GenBank AA479259
193041-39-3, GenBank AA479272 193041-43-9, GenBank AA479276
193041-51-9, GenBank AA479284 193041-75-7, GenBank AA479308
193041-88-2, GenBank AA479243 193042-38-5, GenBank AA479398
193042-71-6, GenBank AA479351 193043-04-8, GenBank AA479453
193043-33-3, GenBank AA479402 193043-79-7, GenBank AA479503
193044-24-5, GenBank AA479954 193044-48-3, GenBank AA479978

| | |
|-------------------------------|-------------------------------|
| 193044-67-6, GenBank AA479997 | 193044-82-5, GenBank AA480012 |
| 193049-39-7, GenBank AA480529 | 193056-21-2, GenBank AA481927 |
| 193056-64-3, GenBank AA481944 | 193058-62-7, GenBank AA482110 |
| 193058-69-4, GenBank AA482117 | 193059-87-9, GenBank AA482294 |
| 193060-70-7, GenBank AA482377 | 193104-11-9, GenBank AA480828 |
| 193104-13-1, GenBank AA480830 | 193104-27-7, GenBank AA480844 |
| 193104-34-6, GenBank AA480851 | 193104-63-1, GenBank AA480880 |
| 193105-10-1, GenBank AA480979 | 193105-81-6, GenBank AA481052 |
| 193105-87-2, GenBank AA481058 | 193106-03-5, GenBank AA480994 |
| 193106-53-5, GenBank AA481100 | 193106-80-8, GenBank AA481069 |
| 193106-87-5, GenBank AA481076 | 193107-57-2, GenBank AA481177 |
| 193108-37-1, GenBank AA481269 | 193108-51-9, GenBank AA481283 |
| 193109-17-0, GenBank AA481349 | 193109-80-7, GenBank AA481397 |
| 193110-20-2, GenBank AA481464 | 193110-37-1, GenBank AA481438 |
| 193111-25-0, GenBank AA481540 | 193111-48-7, GenBank AA481597 |
| 193111-69-2, GenBank AA481618 | 193112-09-3, GenBank AA481578 |
| 193112-96-8, GenBank AA481759 | 193113-66-5, GenBank AA481718 |
| 193116-29-9, GenBank AA482741 | 193117-31-6, GenBank AA482855 |
| 193123-04-5, GenBank AA483460 | 193132-88-6, GenBank AA484409 |
| 193161-82-9, GenBank AA485036 | 193163-20-1, GenBank AA485080 |
| 193163-23-4, GenBank AA485141 | 193164-83-9, GenBank AA485303 |
| 193164-90-8, GenBank AA485310 | 193166-21-1, GenBank AA485449 |
| 193166-25-5, GenBank AA485453 | 193166-26-6, GenBank AA485454 |
| 193166-30-2, GenBank AA485458 | 193166-44-8, GenBank AA485467 |
| 193166-72-2, GenBank AA485495 | 193166-89-1, GenBank AA485512 |
| 193167-05-4, GenBank AA485528 | 193167-97-4, GenBank AA485608 |
| 193167-98-5, GenBank AA485609 | 193168-25-1, GenBank AA485648 |
| 193168-75-1, GenBank AA485677 | 193169-10-7, GenBank AA485734 |
| 193169-49-2, GenBank AA485773 | 193169-80-1, GenBank AA485810 |
| 193170-23-9, GenBank AA485853 | 193170-93-3, GenBank AA485877 |
| 193171-12-9, GenBank AA485896 | 193171-25-4, GenBank AA486362 |
| 193171-30-1, GenBank AA486367 | 193171-55-0, GenBank AA487767 |
| 193171-85-6, GenBank AA487797 | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

| | |
|----------------------------------|-------------------------------|
| IT 193172-00-8, GenBank AA487812 | 193172-66-6, GenBank AA487845 |
| 193174-58-2, GenBank AA488070 | 193175-61-0, GenBank AA488181 |
| 193175-65-4, GenBank AA488185 | 193176-17-9, GenBank AA488230 |
| 193176-25-9, GenBank AA488238 | 193176-41-9, GenBank AA488289 |
| 193176-88-4, GenBank AA488340 | 193177-47-8, GenBank AA488297 |
| 193178-11-9, GenBank AA488413 | 193178-49-3, GenBank AA488517 |
| 193178-72-2, GenBank AA488460 | 193178-78-8, GenBank AA488466 |
| 193180-84-6, GenBank AA485983 | 193181-02-1, GenBank AA485913 |
| 193181-73-6, GenBank AA486001 | 193181-89-4, GenBank AA486017 |
| 193182-02-4, GenBank AA486055 | 193182-36-4, GenBank AA486041 |
| 193182-57-9, GenBank AA486085 | 193183-10-7, GenBank AA486138 |
| 193183-27-6, GenBank AA486195 | 193183-39-0, GenBank AA486207 |
| 193183-76-5, GenBank AA486175 | 193184-13-3, GenBank AA486261 |
| 193184-35-9, GenBank AA486283 | 193184-37-1, GenBank AA486230 |
| 193184-72-4, GenBank AA486300 | 193185-01-2, GenBank AA486402 |
| 193185-06-7, GenBank AA486407 | 193185-24-9, GenBank AA486312 |
| 193185-35-2, GenBank AA486375 | 193185-39-6, GenBank AA486379 |
| 193185-64-7, GenBank AA486455 | 193185-69-2, GenBank AA486460 |
| 193185-80-7, GenBank AA486471 | 193186-71-9, GenBank AA486538 |
| 193187-35-8, GenBank AA486612 | 193188-08-8, GenBank AA486728 |
| 193188-11-3, GenBank AA486731 | 193188-65-7, GenBank AA486746 |
| 193188-66-8, GenBank AA486747 | 193188-87-3, GenBank AA486805 |
| 193189-09-2, GenBank AA486827 | 193189-44-5, GenBank AA486796 |
| 193189-57-0, GenBank AA486838 | 193190-34-0, GenBank AA486849 |
| 193192-64-2, GenBank AA487121 | 193192-85-7, GenBank AA487202 |
| 193192-96-0, GenBank AA487213 | 193192-98-2, GenBank AA487215 |
| 193193-01-0, GenBank AA487218 | 193193-46-3, GenBank AA487191 |
| 193193-64-5, GenBank AA487252 | 193229-64-0, GenBank AA487480 |

| | |
|-------------------------------|-------------------------------|
| 193229-67-3, GenBank AA487483 | 193230-36-3, GenBank AA487552 |
| 193230-41-0, GenBank AA487557 | 193230-44-3, GenBank AA487560 |
| 193230-92-1, GenBank AA487608 | 193231-16-2, GenBank AA487632 |
| 193231-18-4, GenBank AA487634 | 193231-21-9, GenBank AA487637 |
| 193231-35-5, GenBank AA487651 | 193231-58-2, GenBank AA487674 |
| 193233-95-3, GenBank AF006305 | 193235-19-7, GenBank AA488721 |
| 193235-33-5, GenBank AA488735 | 193235-63-1, GenBank AA488765 |
| 193235-95-9, GenBank AA488797 | 193236-23-6, GenBank AA488825 |
| 193236-82-7, GenBank AA488884 | 193236-83-8, GenBank AA488885 |
| 193236-87-2, GenBank AA488889 | 193236-96-3, GenBank AA488898 |
| 193237-68-2, GenBank AA488970 | 193237-98-8, GenBank AA489000 |
| 193238-05-0, GenBank AA489007 | 193238-21-0, GenBank AA489023 |
| 193238-78-7, GenBank AA489080 | 193239-09-7, GenBank AA489111 |
| 193239-36-0, GenBank AA489138 | 193239-97-3, GenBank AA489199 |
| 193239-98-4, GenBank AA489200 | 193240-30-1, GenBank AA489232 |
| 193240-59-4, GenBank AA489261 | 193240-63-0, GenBank AA489265 |
| 193240-95-8, GenBank AA489297 | 193241-07-5, GenBank AA489309 |
| 193241-09-7, GenBank AA489311 | 193241-74-6, GenBank AA489343 |
| 193244-03-0, GenBank AA489606 | 193244-05-2, GenBank AA489608 |
| 193244-08-5, GenBank AA489611 | 193244-33-6, GenBank AA489636 |
| 193244-45-0, GenBank AA489648 | 193244-61-0, GenBank AA489664 |
| 193244-93-8, GenBank AA489696 | 193244-96-1, GenBank AA489699 |
| 193245-04-4, GenBank AA489707 | 193245-35-1, GenBank AA489738 |
| 193245-40-8, GenBank AA489743 | 193245-69-1, GenBank AA490192 |
| 193246-09-2, GenBank AA490232 | 193246-31-0, GenBank AA490263 |
| 193246-35-4, GenBank AA490267 | 193247-20-0, GenBank AA490352 |
| 193247-56-2, GenBank AA490388 | 193248-31-6, GenBank AA490463 |
| 193248-51-0, GenBank AA490483 | 193248-54-3, GenBank AA490486 |
| 193248-62-3, GenBank AA490494 | 193248-77-0, GenBank AA490509 |
| 193248-89-4, GenBank AA490521 | 193249-15-9, GenBank AA490547 |
| 193249-29-5, GenBank AA490561 | 193249-77-3, GenBank AA490609 |
| 193249-79-5, GenBank AA490611 | 193249-85-3, GenBank AA490617 |
| 193249-95-5, GenBank AA490627 | 193250-03-2, GenBank AA490635 |
| 193250-41-8, GenBank AA490673 | 193250-48-5, GenBank AA490680 |
| 193250-52-1, GenBank AA490684 | 193250-99-6, GenBank AA490731 |
| 193251-65-9, GenBank AA490798 | 193251-72-8, GenBank AA490805 |
| 193251-92-2, GenBank AA490825 | 193252-13-0, GenBank AA490846 |
| 193252-67-4, GenBank AA490900 | 193252-70-9, GenBank AA490903 |
| 193252-78-7, GenBank AA490911 | 193253-26-8, GenBank AA490959 |
| 193253-52-0, GenBank AA490985 | 193253-56-4, GenBank AA490989 |
| 193255-58-2, GenBank AA491191 | 193255-75-3, GenBank AA491208 |
| 193255-81-1, GenBank AA491247 | 193255-90-2, GenBank AA491256 |
| 193256-05-2, GenBank AA491271 | 193256-26-7, GenBank AA491292 |
| 193257-71-5, GenBank AA491395 | 193259-16-4, GenBank AA489847 |
| 193259-73-3, GenBank AA489904 | 193260-13-8, GenBank AA489944 |
| 193262-41-8, GenBank AA490172 | 193301-02-9, GenBank AA492143 |
| 193302-31-7, GenBank AA492272 | 193312-84-4, GenBank AA493138 |
| 193316-98-2, GenBank AA493532 | 193324-30-0, GenBank AA494295 |
| 193367-75-8, GenBank AA295093 | 193370-02-4, GenBank AA295311 |
| 193371-30-1, GenBank AA295396 | 193374-77-5, GenBank AA295786 |
| 193374-88-8, GenBank AA295797 | 193374-95-7, GenBank AA295804 |
| 193376-31-7, GenBank AA295941 | 193376-86-2, GenBank AA295996 |
| 193377-64-9, GenBank AA296074 | 193382-71-7, GenBank AA296582 |
| 193383-29-8, GenBank AA296640 | 193384-57-5, GenBank AA296775 |
| 193385-35-2, GenBank AA296846 | 193385-60-3, GenBank AA296871 |
| 193386-46-8, GenBank AA296929 | 193390-21-5, GenBank AA297323 |
| 193390-25-9, GenBank AA297327 | 193390-26-0, GenBank AA297328 |
| 193391-48-9, GenBank AA297432 | 193431-73-1, GenBank AA297883 |
| 193431-76-4, GenBank AA297886 | 193433-40-8, GenBank AA298050 |
| 193433-75-9, GenBank AA298085 | 193435-84-6, GenBank AA298282 |
| 193437-80-8, GenBank AA298447 | 193438-36-7, GenBank AA298576 |
| 193438-83-4, GenBank AA298593 | 193439-38-2, GenBank AA298648 |
| 193440-87-8, GenBank AA298773 | 193443-79-7, GenBank AA299067 |
| 193446-58-1, GenBank AA299360 | 193453-55-3, GenBank AA300065 |
| 193457-43-1, GenBank AA300491 | 193459-29-9, GenBank AA300651 |
| 193460-03-6, GenBank AA300711 | 193460-24-1, GenBank AA300732 |

| | |
|-------------------------------|-------------------------------|
| 193463-07-9, GenBank AA300994 | 193490-80-1, GenBank AA301062 |
| 193493-80-0, GenBank AA301343 | 193496-91-2, GenBank AA301676 |
| 193498-44-1, GenBank AA301789 | 193498-80-5, GenBank AA301863 |
| 193498-81-6, GenBank AA301864 | 193499-27-3, GenBank AA301910 |
| 193500-63-9, GenBank AA302028 | 193504-74-4, GenBank AA302457 |
| 193504-90-4, GenBank AA302473 | 193509-21-6, GenBank AA302919 |
| 193511-02-3, GenBank AA303085 | 193517-26-9, GenBank AA303709 |
| 193518-13-7, GenBank AA303796 | 193519-67-4, GenBank AA303950 |
| 193520-45-5, GenBank AA304028 | 193520-60-4, GenBank AA304043 |
| 193566-66-4, GenBank AA304730 | 193568-67-1, GenBank AA304935 |
| 193568-93-3, GenBank AA304961 | 193572-63-3, GenBank AA305331 |
| 193573-49-8, GenBank AA305417 | 193574-26-4, GenBank AA305494 |
| 193579-29-2, GenBank AA305997 | 193580-11-9, GenBank AA306079 |
| 193580-78-8, GenBank AA306146 | 193581-64-5, GenBank AA306232 |
| 193584-18-8, GenBank AA306486 | 193584-20-2, GenBank AA306488 |
| 193585-52-3, GenBank AA306620 | 193586-66-2, GenBank AA306734 |
| 193587-95-0, GenBank AA306863 | 193588-15-7, GenBank AA306883 |
| 193588-19-1, GenBank AA306887 | 193589-90-1, GenBank AA307058 |
| 193590-02-2, GenBank AA307070 | 193593-81-6, GenBank AA307449 |
| 193596-32-6, GenBank AA307700 | 193597-49-8, GenBank AA307818 |
| 193598-09-3, GenBank AA307875 | 193638-10-7, GenBank AA308049 |
| 193639-22-4, GenBank AA308274 | 193639-88-2, GenBank AA308215 |
| 193646-59-2, GenBank AA309002 | 193656-28-9, GenBank AA309928 |
| 193656-29-0, GenBank AA309929 | 193657-32-8, GenBank AA310030 |
| 193659-96-0, GenBank AA310320 | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
identification, assessment, prevention, and therapy of human cervical
cancer)

| | |
|----------------------------------|-------------------------------|
| IT 193665-12-2, GenBank AA310838 | 193667-22-0, GenBank AA311023 |
| 193668-41-6, GenBank AA311139 | 193669-26-0, GenBank AA311227 |
| 193703-57-0, GenBank AA311701 | 193705-25-8, GenBank AA311869 |
| 193705-52-1, GenBank AA311896 | 193705-61-2, GenBank AA311905 |
| 193711-68-1, GenBank AA312550 | 193711-92-1, GenBank AA312574 |
| 193712-11-7, GenBank AA312513 | 193717-04-3, GenBank AA313048 |
| 193717-87-2, GenBank AA313131 | 193719-26-5, GenBank AA313277 |
| 193722-06-4, GenBank AA313552 | 193722-58-6, GenBank AA313603 |
| 193722-62-2, GenBank AA313607 | 193723-49-8, GenBank AA313668 |
| 193723-92-1, GenBank AA313775 | 193724-65-1, GenBank AA313794 |
| 193728-37-9, GenBank AA314119 | 193729-89-4, GenBank AA314286 |
| 193730-31-3, GenBank AA314378 | 193732-58-0, GenBank AA314654 |
| 193732-63-7, GenBank AA314659 | 193733-25-4, GenBank AA314674 |
| 193736-15-1, GenBank AA314920 | 193769-13-0, GenBank AA315072 |
| 193771-32-3, GenBank AA315317 | 193772-16-6, GenBank AA315426 |
| 193774-79-7, GenBank AA315627 | 193778-41-5, GenBank AA316016 |
| 193778-79-9, GenBank AA316055 | 193778-95-9, GenBank AA316071 |
| 193779-42-9, GenBank AA316153 | 193783-12-9, GenBank AA316502 |
| 193788-91-9, GenBank AA317092 | 193791-61-6, GenBank AA317329 |
| 193792-01-7, GenBank AA317411 | 193792-93-7, GenBank AA317477 |
| 193793-75-8, GenBank AA317551 | 193797-92-1, GenBank AA317976 |
| 193801-48-8, GenBank AA318377 | 193847-47-1, GenBank AA318591 |
| 193847-84-6, GenBank AA318628 | 193848-18-9, GenBank AA318662 |
| 193848-92-9, GenBank AA318737 | 193858-19-4, GenBank AA319664 |
| 193858-81-0, GenBank AA319726 | 193859-53-9, GenBank AA319798 |
| 193873-99-3, GenBank AA321244 | 193908-63-3, GenBank AA322115 |
| 193913-82-5, GenBank AA322537 | 193917-77-0, GenBank AA322966 |
| 193931-15-6, GenBank AA495734 | 193931-71-4, GenBank AA495790 |
| 193931-85-0, GenBank AA495804 | 193931-99-6, GenBank AA495818 |
| 193932-00-2, GenBank AA495819 | 193932-40-0, GenBank AA495859 |
| 193932-74-0, GenBank AA495893 | 193932-79-5, GenBank AA495898 |
| 193932-85-3, GenBank AA495904 | 193933-16-3, GenBank AA495935 |
| 193934-39-3, GenBank AA496058 | 193934-64-4, GenBank AA496083 |
| 193934-66-6, GenBank AA496085 | 193934-68-8, GenBank AA496087 |
| 193934-78-0, GenBank AA496097 | 193934-86-0, GenBank AA496105 |
| 193935-13-6, GenBank AA496133 | 193937-09-6, GenBank AA496329 |

193937-51-8, GenBank AA496373 193937-86-9, GenBank AA496409
 193940-05-5, GenBank AA496628 193940-27-1, GenBank AA496650
 193940-41-9, GenBank AA496664 193941-60-5, GenBank AA496784
 193941-68-3, GenBank AA496792 193941-77-4, GenBank AA496801
 193942-12-0, GenBank AA496836 193943-25-8, GenBank AA496949
 193943-69-0, GenBank AA496993 193943-75-8, GenBank AA496999
 193943-78-1, GenBank AA497002 193982-55-7, GenBank AA497093
 193982-71-7, GenBank AA497109 193982-73-9, GenBank AA497111 193982-81-
 9, GenBank AA497119 193982-84-2, GenBank AA497122 193982-85-3, GenBank
 AA497123 194082-86-5, GenBank AA501657 194110-83-3, GenBank AA502292
 194115-94-1, GenBank AA502836 194118-93-9, GenBank AA503078
 194119-09-0, GenBank AA503208 194123-50-7, GenBank AA503607
 194127-03-2, GenBank AA503870 194133-01-2, GenBank AF001862
 194135-21-2, GenBank AA504095 194135-46-1, GenBank AA504120
 194135-54-1, GenBank AA504128 194136-30-6, GenBank AA504204
 194136-58-8, GenBank AA504232 194136-65-7, GenBank AA504239
 194136-88-4, GenBank AA504262 194136-91-9, GenBank AA504265
 194136-92-0, GenBank AA504266 194136-98-6, GenBank AA504272
 194137-09-2, GenBank AA504283 194137-53-6, GenBank AA504327
 194137-77-4, GenBank AA504351 194137-80-9, GenBank AA504354
 194138-15-3, GenBank AA504389 194139-69-0, GenBank AA504492
 194169-31-8, GenBank AA504556 194170-10-0, GenBank AA504631
 194170-30-4, GenBank AA504590 194170-71-3, GenBank AA504719
 194171-33-0, GenBank AA504707 194171-63-6, GenBank AA504752
 194172-09-3, GenBank AA504798 194172-30-0, GenBank AA504844
 194172-98-0, GenBank AA504832 194174-64-6, GenBank AA505117
 194175-36-5, GenBank AA505063 194175-61-6, GenBank AA505150
 194175-73-0, GenBank AA505162 194180-02-4, GenBank AA505615
 194180-19-3, GenBank AA505632 194201-19-9, GenBank AA507382
 194201-31-5, GenBank AA507394 194201-42-8, GenBank AA507405
 194203-63-9, GenBank AA507626 194249-26-8, GenBank AA507911
 194258-76-9, GenBank AA508736 194334-93-5, GenBank AA512975
 194376-26-6, GenBank AA513848 194376-41-5, GenBank AA513783
 194376-68-6, GenBank AA513869 194382-31-5, GenBank AF007217
 194393-73-2, GenBank AA515132 194465-77-5, GenBank U67171 194511-16-5,
 GenBank AA520999 194511-32-5, GenBank AA521015 194512-09-9, GenBank
 AA521093 194512-19-1, GenBank AA521103 194513-63-8, GenBank AA521247
 194513-65-0, GenBank AA521249 194513-74-1, GenBank AA521292
 194514-13-1, GenBank AA521297 194514-16-4, GenBank AA521300
 194514-33-5, GenBank AA521370 194514-42-6, GenBank AA521346
 194514-44-8, GenBank AA521348 194514-76-6, GenBank AA521327
 194515-04-3, GenBank AA521411 194515-22-5, GenBank AA521384
 194515-32-7, GenBank AA521394 194515-55-4, GenBank AA521439
 194529-49-2, GenBank AA522693 194556-07-5, GenBank U90441 194557-10-3,
 GenBank AA523094 194560-43-5, GenBank AA523399 194568-21-3, GenBank
 AA524064 194574-81-7, GenBank AA524726 194577-85-0, GenBank AA525031
 194590-11-9, GenBank AA525960 194624-44-7, GenBank AA526745
 194627-64-0, GenBank AA527072 194629-15-7, GenBank AA527216
 194629-92-0, GenBank AA527293 194638-72-7, GenBank AA528173
 194711-89-2, GenBank AB004066 194748-15-7, GenBank AA532398
 194749-18-3, GenBank AA532501 194750-75-9, GenBank AA532664
 194752-08-4, GenBank AA532956 194753-26-9, GenBank AA533037
 194754-05-7, GenBank AA533146 194755-42-5, GenBank AA533283
 194759-49-4, GenBank AA533770 194764-10-8, GenBank AA534231
 194764-73-3, GenBank AA532734 194770-61-1, GenBank AA534645
 194772-42-4, GenBank AA534826 194772-58-2, GenBank AA534842
 194780-37-5, GenBank AA535621 194820-87-6, GenBank AA536175
 194832-59-2, GenBank AF006088 195243-12-0, GenBank Y13936 195268-50-9,
 GenBank U80735 195285-79-1, GenBank AA545745 195285-95-1, GenBank
 AA545771 195398-76-6, GenBank AF001893 195432-03-2, GenBank D87367
 195474-04-5, GenBank AA548870 195474-23-8, GenBank AA548889
 195474-66-9, GenBank AA548849 195493-74-4, GenBank AA550845
 195498-72-7, GenBank AA551344 195499-19-5, GenBank AA551391
 195544-68-4, GenBank AA552077 195548-39-1, GenBank AA552449
 195553-65-2, GenBank AA552974 195561-42-3, GenBank AA553751
 195567-60-3, GenBank AA554373 195568-93-5, GenBank AA554506

195570-12-8, GenBank AA554630 195572-95-3, GenBank AA554914
 195590-25-1, GenBank AA557264 195593-36-3, GenBank AA557575
 195635-40-6, GenBank AA558585 195636-25-0, GenBank AA558670
 195699-51-5, GenBank AA564555 195699-99-1, GenBank AA564604
 195743-94-3, GenBank AA565099 195746-27-1, GenBank AA565334
 195747-89-8, GenBank AA565499 195751-21-4, GenBank AA565834
 195766-67-7, GenBank AF005654 195770-40-2, GenBank AC002456
 195786-88-0, GenBank AA568922 195789-22-1, GenBank AA569156
 195791-37-8, GenBank AB006679 195903-78-7, GenBank AA573737
 195906-00-4, GenBank AA573959 195934-70-4, GenBank AA576764
 195938-21-7, GenBank AA577071 195943-59-0, GenBank AA577613
 196016-81-6, GenBank U54558 196016-83-8, GenBank U54562 196021-77-9,
 GenBank AF002715 196026-35-4, GenBank AF015767 196034-41-0, GenBank
 AA581035 196038-30-9, GenBank AA581425 196045-81-5, GenBank AA582588
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 196048-44-9, GenBank AA582853 196048-46-1, GenBank AA582855
 196053-14-2, GenBank AA582006 196056-67-4, GenBank U70734 196160-40-4,
 GenBank AA584921 196388-85-9, GenBank AA585327 196389-98-7, GenBank
 AA585440 196419-43-9, GenBank AF015283 196450-44-9, GenBank D84488
 196529-76-7, GenBank AA586687 196535-66-7, GenBank AA587278
 196536-67-1, GenBank AA587379 196570-37-3, GenBank AF017418
 196596-11-9, GenBank U68140 196626-33-2, GenBank AA588189 196631-84-2,
 GenBank AA587754 196637-14-6, GenBank AA588729 196683-77-9, GenBank
 AJ001348 196687-24-8, GenBank AA593834 196687-54-4, GenBank AA593864
 196733-67-2, GenBank AA595238 196735-99-6, GenBank AA595471
 196740-58-6, GenBank AA595937 196968-94-2, GenBank D88674 196973-80-5,
 GenBank AF019225 197040-79-2, GenBank D37766 197061-34-0, GenBank
 AA598982 197062-07-0, GenBank AA598996 197062-24-1, GenBank AA598470
 197062-41-2, GenBank AA598515 197062-52-5, GenBank AA598526
 197062-57-0, GenBank AA598487 197062-75-2, GenBank AA598505
 197062-78-5, GenBank AA598508 197062-92-3, GenBank AA598582
 197063-11-9, GenBank AA598601 197063-19-7, GenBank AA598533
 197063-24-4, GenBank AA598538 197063-51-7, GenBank AA598561
 197063-57-3, GenBank AA598567 197063-65-3, GenBank AA598635
 197063-70-0, GenBank AA598640 197063-81-3, GenBank AA598652
 197063-82-4, GenBank AA598653 197063-90-4, GenBank AA598615
 197063-96-0, GenBank AA598621 197064-19-0, GenBank AA598668
 197064-36-1, GenBank AA598970 197064-40-7, GenBank AA598974
 197065-73-9, GenBank AA598758 197066-15-2, GenBank AA598776
 197066-33-4, GenBank AA598794 197104-41-9, GenBank AA598796
 197105-14-9, GenBank AA598817 197105-28-5, GenBank AA598887
 197105-63-8, GenBank AA598918 197106-12-0, GenBank AA599068
 197106-88-0, GenBank AA599092 197106-90-4, GenBank AA599094
 197107-44-1, GenBank AA599120 197108-25-1, GenBank AA599187
 197108-90-0, GenBank AA599251 197109-08-3, GenBank AA599311
 197111-26-5, GenBank AA599495 197112-21-3, GenBank AA599574
 197113-12-5, GenBank AA599717 197113-26-1, GenBank AA599768
 197114-51-5, GenBank AA599857 197117-84-3, GenBank AA600192
 197118-30-2, GenBank AA600217 197118-77-7, GenBank AA600214
 197124-69-9, GenBank AA600853 197135-21-0, GenBank AA601970
 197138-26-4, GenBank AA601946 197139-22-3, GenBank AA602217
 197184-60-4, GenBank AA602257 197202-62-3, GenBank AF017688
 197280-73-2, GenBank AB007191 197330-87-3, GenBank AA604210
 197415-36-4, GenBank AA608514 197415-77-3, GenBank AA608555
 197415-78-4, GenBank AA608556 197415-80-8, GenBank AA608558
 197418-11-4, GenBank AA608730 197419-02-6, GenBank AA608852
 197419-06-0, GenBank AA608856 197419-20-8, GenBank AA608870
 197419-42-4, GenBank AA608923 197421-99-1, GenBank AA609161
 197422-27-8, GenBank AA609189 197423-02-2, GenBank AA609216
 197423-27-1, GenBank AA609284 197424-79-6, GenBank AA609363
 197424-80-9, GenBank AA609364 197424-81-0, GenBank AA609365
 197425-15-3, GenBank AA609454 197425-98-2, GenBank AA609556

197428-62-9, GenBank AA609783 197429-08-6, GenBank AA609904
 197429-97-3, GenBank AA610000 197430-56-1, GenBank AA610016
 197469-70-8, GenBank AA610476 197475-62-0, GenBank AF000152
 197627-12-6, GenBank AF019214 197669-68-4, GenBank AA612919
 197677-96-6, GenBank AA612632 197687-11-9, GenBank AA613834
 197687-75-5, GenBank AA613908 197689-20-6, GenBank AA614033
 197692-58-3, GenBank AA613803 197694-89-6, GenBank AA614529
 197734-28-4, GenBank AA614729 197763-44-3, GenBank AA617655
 197815-49-9, GenBank AA618477 197816-22-1, GenBank AA618549
 198352-46-4, GenBank Y12653 198382-35-3, GenBank AA621761 198383-90-3,
 GenBank AA620407 198383-97-0, GenBank AA620415 198384-83-7, GenBank
 AA620477 198384-91-7, GenBank AA620485 198385-38-5, GenBank AA620528
 198385-72-7, GenBank AA620591 198385-78-3, GenBank AA620597
 198385-86-3, GenBank AA620608 198385-87-4, GenBank AA620609
 198385-89-6, GenBank AA620611 198386-52-6, GenBank AA620669
 198386-90-2, GenBank AA620709 198386-98-0, GenBank AA620757
 198387-64-3, GenBank AA620783 198388-81-7, GenBank AA620862
 198389-13-8, GenBank AA620995 198389-87-6, GenBank AA621031
 198391-13-8, GenBank AA621132 198391-93-4, GenBank AA621184
 198392-11-9, GenBank AA621202 198392-76-6, GenBank AA621291
 198393-20-3, GenBank AA621339 198393-99-6, GenBank AA621478
 198397-56-7, GenBank AA621725 198399-30-3, GenBank AA622011
 198464-40-3, GenBank AF027302 198509-36-3, GenBank AA625387
 198511-60-3, GenBank AA625487 198511-75-0, GenBank AA625567
 198512-36-6, GenBank AA625628 198512-42-4, GenBank AA625634
 198512-59-3, GenBank AA625651 198512-61-7, GenBank AA625653 198512-70-
 8, GenBank AA625662 198512-74-2, GenBank AA625666 198513-73-4, GenBank
 AA625765 198513-96-1, GenBank AA625788 198515-30-9, GenBank AA625922
 198515-85-4, GenBank AA625977 198515-99-0, GenBank AA625991
 198516-03-9, GenBank AA625995 198516-32-4, GenBank AA626024
 198517-86-1, GenBank AA626178 198518-48-8, GenBank AA626240
 198518-63-7, GenBank AA626255 198521-15-2, GenBank AA626507
 198523-06-7, GenBank AA626698 198524-53-7, GenBank AA626845
 198528-67-5, GenBank AA627554 198536-99-1, GenBank AA627916
 198538-11-3, GenBank AA628232 198538-87-3, GenBank AA628230
 198540-53-3, GenBank AA628462 198593-39-4, GenBank AA629189
 198594-10-4, GenBank AA629262 198594-81-9, GenBank AA629357
 198733-19-6, GenBank AF016266 198734-06-4, GenBank AF015926
 198753-54-7, GenBank Y08685 198841-61-1, GenBank U96759 198848-05-4,
 GenBank AA629692 198849-75-1, GenBank AA629862 198850-65-6, GenBank
 AA630017 198851-39-7, GenBank AA630104 198851-99-9, GenBank AA630084
 198855-79-7, GenBank AA630449 198857-64-6, GenBank AA630628
 198858-07-0, GenBank AA630734 198858-74-1, GenBank AA630771
 198859-03-9, GenBank AA630800 198862-63-4, GenBank AA631152
 199029-58-8, GenBank AB008109 199030-31-4, GenBank AA633433
 199044-48-9, GenBank AA633549 199044-55-8, GenBank AA633556
 199044-76-3, GenBank AA633577 199044-86-5, GenBank AA633658
 199046-46-3, GenBank AA633747 199047-41-1, GenBank AA633901
 199048-57-2, GenBank AA633954 199048-91-4, GenBank AA633993
 199049-04-2, GenBank AA634006 199049-26-8, GenBank AA634028
 199050-25-4, GenBank AA634103 199050-31-2, GenBank AA634109
 199050-43-6, GenBank AA634175 199052-08-9, GenBank AA634371
 199052-48-7, GenBank AA634360 199053-25-3, GenBank AA634427
 199053-32-2, GenBank AA634434 199057-73-3, GenBank AA634876
 199148-98-6, GenBank AF022913 199149-09-2, GenBank AF026292
 199159-29-0, GenBank AA640687 199160-62-8, GenBank AA640827
 199209-13-7, GenBank AA641959 199219-78-8, GenBank AA643026
 199223-61-5, GenBank AA643416 199227-27-5, GenBank AA643835
 199228-82-5, GenBank AA643953 199230-61-0, GenBank AA644088
 199230-73-4, GenBank AA644128 199231-41-9, GenBank AA644211
 199231-44-2, GenBank AA644214 199233-79-9, GenBank AA644448
 199236-02-7, GenBank AA644657 199237-60-0, GenBank AF000381
 199308-74-2, GenBank AA648474 199311-90-5, GenBank AA648790
 199347-82-5, GenBank AA649507 199359-89-2, GenBank AF026692
 199517-13-0, GenBank AA653775 199550-21-5, GenBank AA654660
 199552-17-5, GenBank AA654827 199553-53-2, GenBank AA654953

199553-59-8, GenBank AA654959 199620-66-1, GenBank AA657788
 199626-66-9, GenBank AA658330 199626-78-3, GenBank AA658374
 199630-90-5, GenBank AA658821

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 199634-65-6, GenBank AA659162 199634-80-5, GenBank AA659202
 199640-12-5, GenBank AA659680 199769-36-3, GenBank AF027292
 199770-88-2, GenBank D50371 199901-37-6, GenBank AF029914 199901-77-4,
 GenBank AF031385 199913-61-6, GenBank AA662538 199951-12-7, GenBank
 AA663188 199958-26-4, GenBank AA663941 199959-15-4, GenBank AA663981
 199959-17-6, GenBank AA663983 199959-20-1, GenBank AA663986
 199959-38-1, GenBank AA664004 199959-74-5, GenBank AA664040
 199960-13-9, GenBank AA664067 199960-47-9, GenBank AA664101
 199961-02-9, GenBank AA664179 199961-18-7, GenBank AA664195
 199963-49-0, GenBank AA664406 200023-47-8, GenBank AF026939
 200044-65-1, GenBank AA666348 200048-22-2, GenBank AF027158
 200086-01-7, GenBank AA668301 200087-72-5, GenBank AA668470
 200162-02-3, GenBank AA668531 200166-33-2, GenBank AA668928
 200167-73-3, GenBank AA669136 200170-15-6, GenBank AA669329
 200170-45-2, GenBank AA669359 200171-65-9, GenBank AA669526
 200171-75-1, GenBank AA669536 200174-34-1, GenBank AA669758
 200175-52-6, GenBank AA669832 200175-81-1, GenBank AA669952
 200178-80-9, GenBank AA670200 200180-11-6, GenBank AA670330
 200180-35-4, GenBank AA670355 200180-37-6, GenBank AA670357
 200180-88-7, GenBank AA670408 200245-25-6, GenBank AJ002955
 200385-49-5, GenBank AF033095 200474-72-2, GenBank AA680244
 200475-32-7, GenBank AB007885 200475-39-4, GenBank AB007892
 200516-43-4, GenBank AB007949 200518-75-8, GenBank AF020351
 200522-68-5, GenBank AA680335 200525-01-5, GenBank AA680052
 200525-19-5, GenBank AA680070 200525-78-6, GenBank AA680186
 200527-44-2, GenBank AA676225 200528-98-9, GenBank AA676458
 200529-71-1, GenBank AA676460 200529-77-7, GenBank AA676466
 200529-82-4, GenBank AA676470 200530-64-9, GenBank AA676590
 200531-00-6, GenBank AA676625 200533-15-9, GenBank AA676840
 200534-29-8, GenBank AA676955 200534-31-2, GenBank AA676957
 200534-35-6, GenBank AA676961 200534-44-7, GenBank AA676970
 200534-72-1, GenBank AA676998 200534-90-3, GenBank AA677016
 200534-99-2, GenBank AA677025 200535-44-0, GenBank AA677070
 200535-51-9, GenBank AA677077 200536-57-8, GenBank AA677183
 200536-74-9, GenBank AA677200 200537-74-2, GenBank AA677300
 200537-91-3, GenBank AA677317 200538-77-8, GenBank AA677403
 200539-78-2, GenBank AA677504 200540-08-5, GenBank AA677534
 200541-60-2, GenBank AA677687 200541-79-3, GenBank AA677706
 200542-57-0, GenBank AA677784 200543-36-8, GenBank AA677863
 200543-43-7, GenBank AA677870 200543-97-1, GenBank AA677924
 200544-20-3, GenBank AA677947 200544-82-7, GenBank AA678009
 200544-94-1, GenBank AA678021 200544-97-4, GenBank AA678024
 200545-38-6, GenBank AA678065 200545-45-5, GenBank AA678072
 200545-65-9, GenBank AA678092 200546-33-4, GenBank AA678160
 200546-49-2, GenBank AA678176 200546-51-6, GenBank AA678178
 200548-60-3, GenBank AA678388 200580-83-2, GenBank AA678829
 200582-50-9, GenBank AA679000 200584-04-9, GenBank AA679177
 200585-09-7, GenBank AA679286 200585-52-0, GenBank AA679352
 200585-97-3, GenBank AA679314 200587-87-7, GenBank AA679565
 200588-24-5, GenBank AA679602 200590-12-1, GenBank AA679801
 200593-47-1, GenBank AF035286 200593-50-6, GenBank AF035289
 200593-94-8, GenBank AF035304 200594-01-0, GenBank AF035313
 200594-05-4, GenBank AF035309 200594-44-1, GenBank AF035320
 200594-53-2, GenBank AF035582 200597-28-0, GenBank AB007878
 200598-58-9, GenBank AB009282 200762-08-9, GenBank AB007916
 200769-53-5, GenBank AF035811 200769-59-1, GenBank AF035784
 200771-28-4, GenBank AA682910 200772-43-6, GenBank AA683050
 200772-83-4, GenBank AA683077 200772-91-4, GenBank AA683085

| | |
|-------------------------------|-------------------------------|
| 200773-10-0, GenBank AA683117 | 200776-77-8, GenBank AA682244 |
| 200777-57-7, GenBank AA682779 | 200777-58-8, GenBank AA682780 |
| 200778-10-5, GenBank AA682848 | 200778-14-9, GenBank AA682851 |
| 200779-39-1, GenBank AA682321 | 200779-63-1, GenBank AA682381 |
| 200779-68-6, GenBank AA682386 | 200779-81-3, GenBank AA682399 |
| 200780-96-7, GenBank AA682514 | 200781-03-9, GenBank AA682521 |
| 200781-27-7, GenBank AA682545 | 200781-81-3, GenBank AA682599 |
| 200782-06-5, GenBank AA682624 | 200782-08-7, GenBank AA682626 |
| 200782-24-7, GenBank AA682642 | 200784-19-6, GenBank AA683520 |
| 200784-67-4, GenBank AA683568 | 200784-77-6, GenBank AA683578 |
| 200784-78-7, GenBank AA683581 | 200894-64-0, GenBank AA687426 |
| 200924-71-6, GenBank AB001636 | 201119-88-2, GenBank AF031647 |
| 201120-93-6, GenBank AL020990 | 201248-71-7, GenBank AA694005 |
| 201368-23-2, GenBank AA699390 | 201368-58-3, GenBank AA699427 |
| 201369-70-2, GenBank AA699770 | 201370-61-8, GenBank AA699878 |
| 201371-56-4, GenBank AA699908 | 201372-05-6, GenBank AA700005 |
| 201372-48-7, GenBank AA700048 | 201372-54-5, GenBank AA700054 |
| 201375-40-8, GenBank AA700322 | 201377-56-2, GenBank AA700556 |
| 201378-41-8, GenBank AA699496 | 201379-83-1, GenBank AA699644 |
| 201380-88-3, GenBank AA700736 | 201381-89-7, GenBank AA700758 |
| 201382-02-7, GenBank AA700764 | 201382-19-6, GenBank AA700859 |
| 201382-36-7, GenBank AA700876 | 201382-39-0, GenBank AA700879 |
| 201382-72-1, GenBank AA700832 | 201382-78-7, GenBank AA700838 |
| 201383-63-3, GenBank AA700904 | 201384-45-4, GenBank AA700997 |
| 201386-41-6, GenBank AA701242 | 201387-52-2, GenBank AA701351 |
| 201387-54-4, GenBank AA701353 | 201388-26-3, GenBank AA701455 |
| 201388-28-5, GenBank AA701457 | 201388-53-6, GenBank AA701379 |
| 201390-11-6, GenBank AA701545 | 201390-81-0, GenBank AA701640 |
| 201390-93-4, GenBank AA701652 | 201390-96-7, GenBank AA701655 |
| 201391-74-4, GenBank AA701860 | 201391-77-7, GenBank AA701863 |
| 201392-82-7, GenBank AA701978 | 201392-85-0, GenBank AA701981 |
| 201393-23-9, GenBank AA701996 | 201394-99-2, GenBank AA702185 |
| 201396-17-0, GenBank AA702304 | 201398-65-4, GenBank AA702567 |
| 201399-31-7, GenBank AA702639 | 201400-20-6, GenBank AA702740 |
| 201401-02-7, GenBank AA702758 | 201401-25-4, GenBank AA702781 |
| 201429-00-7, GenBank AA702973 | 201430-50-4, GenBank AA703141 |
| 201431-34-7, GenBank AA703250 | 201431-75-6, GenBank AA703216 |
| 201438-79-1, GenBank AF034176 | 201440-32-6, GenBank AF038404 |
| 201441-20-5, GenBank AF016371 | 201445-45-6, GenBank AA703384 |
| 201445-68-3, GenBank AA703449 | 201445-79-6, GenBank AA703460 |
| 201445-80-9, GenBank AA703392 | 201446-46-0, GenBank AA703496 |
| 201449-40-3, GenBank AA703779 | 201452-25-7, GenBank AA704064 |
| 201453-96-5, GenBank AA704230 | 201454-99-1, GenBank AA704323 |
| 201455-06-3, GenBank AA704330 | 201455-22-3, GenBank AA704370 |
| 201455-61-0, GenBank AA704421 | 201455-86-9, GenBank AA704401 |
| 201456-22-6, GenBank AA704483 | 201456-67-9, GenBank AA704448 |
| 201456-97-5, GenBank AA704524 | 201457-76-3, GenBank AA704615 |
| 201460-98-2, GenBank AA704965 | 201462-41-1, GenBank AA705077 |
| 201493-58-5, GenBank AA705112 | 201494-71-5, GenBank AA705225 |
| 201494-83-9, GenBank AA705237 | 201496-69-7, GenBank AA705423 |
| 201499-32-3, GenBank AA705686 | 201499-38-9, GenBank AA705692 |
| 201502-68-3, GenBank AA706022 | 201504-72-5, GenBank AA706226 |
| 201505-90-0, GenBank AA706344 | 201508-22-7, GenBank AA706577 |
| 201511-07-1, GenBank AA706901 | 201512-12-1, GenBank AA706968 |
| 201512-18-7, GenBank AA706974 | 201512-48-3, GenBank AA707004 |
| 201513-30-6, GenBank AA707086 | 201514-29-6, GenBank AA707185 |
| 201514-43-4, GenBank AA707199 | 201515-64-2, GenBank AA707321 |
| 201517-92-2, GenBank AA707550 | 201518-74-3, GenBank AA707633 |
| 201518-91-4, GenBank AA707650 | 201519-00-8, GenBank AA707659 |
| 201519-02-0, GenBank AA707661 | 201520-88-9, GenBank AA707847 |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

IT 201520-94-7, GenBank AA707853 201524-01-8, GenBank AA708161

201525-41-9, GenBank AA708301 201525-57-7, GenBank AA708317
201525-68-0, GenBank AA708329 201526-77-4, GenBank AA708440
201527-47-1, GenBank AA708508 201559-99-1, GenBank AA708798
201561-17-3, GenBank AA708916 201562-37-0, GenBank AA709036
201562-45-0, GenBank AA709044 201562-82-5, GenBank AA709092
201563-14-6, GenBank AA709124 201564-82-1, GenBank AA709305
201566-22-5, GenBank AA709410 201566-26-9, GenBank AA709414
201713-64-6, GenBank AB009284 201721-64-4, GenBank AA713610
201761-98-0, GenBank AA714933 201779-71-7, GenBank AA716710
201834-18-6, GenBank AA718910 201838-61-1, GenBank AA719354
201842-70-8, GenBank AA719764 201843-50-7, GenBank AA719844
201844-45-3, GenBank AA719940 201913-45-3, GenBank AA721611
201926-32-1, GenBank AF017257 201952-35-4, GenBank AJ000519
201959-24-2, GenBank AA722437 201964-99-0, GenBank AA723013
202019-93-0, GenBank AA724380 202031-34-3, GenBank AA725561
202098-12-2, GenBank AA729088 202104-50-5, GenBank AA729743
202113-02-8, GenBank Y11435 202150-77-4, GenBank AA730776 202157-75-3,
GenBank AA731867 202163-15-3, GenBank AA732587 202172-65-4, GenBank
AA732811 202172-66-5, GenBank AA732812 202173-27-1, GenBank AA732873
202173-71-5, GenBank AA732917 202174-37-6, GenBank AA732983
202174-57-0, GenBank AA733003 202174-76-3, GenBank AA733022
202174-92-3, GenBank AA733038 202174-94-5, GenBank AA733040
202175-54-0, GenBank AA733100 202176-49-6, GenBank AA733195
202176-57-6, GenBank AA733203 202250-44-0, GenBank AJ001382
202253-85-8, GenBank Y14736 202253-86-9, GenBank Y14737 202253-87-0,
GenBank Y14738 202300-01-4, GenBank AA737128 202313-24-4, GenBank
AA738004 202315-61-5, GenBank AA738240 202431-59-2, GenBank AA740372
202434-72-8, GenBank AA740727 202437-59-0, GenBank AA740952
202442-56-6, GenBank AA741408 202518-02-3, GenBank AA744762
202552-62-3, GenBank AA743800 202612-56-4, GenBank AA747442
202622-74-0, GenBank AA748435 202704-98-1, GenBank AF022229
202880-45-3, GenBank AA757170 202882-25-5, GenBank AA757351
202882-91-5, GenBank AA757417 202883-38-3, GenBank AA757464
202884-82-0, GenBank AA757608 202885-77-6, GenBank AA757674
202886-30-4, GenBank AA757731 202886-31-5, GenBank AA757732
202888-23-1, GenBank AA757932 202891-32-5, GenBank AA758257
202892-22-6, GenBank AA758349 202892-82-8, GenBank AA758429
202899-23-8, GenBank AA759046 202942-83-4, GenBank AF006259
202943-54-2, GenBank Y12860 202947-04-4, GenBank AA760715 203027-75-2,
GenBank AF043294 203030-99-3, GenBank AA764736 203041-40-1, GenBank
AA765775 203085-30-7, GenBank AA767648 203085-82-9, GenBank AA767779
203097-65-8, GenBank AA768667 203098-94-6, GenBank AA768847
203102-34-5, GenBank AA769168 203102-77-6, GenBank AA769195
203106-73-4, GenBank AA769595 203144-24-5, GenBank AA770613
203145-44-2, GenBank AF025438 203166-85-2, GenBank AA773083
203170-14-3, GenBank AA773398 203170-19-8, GenBank AA773335
203216-46-0, GenBank AA773856 203217-64-5, GenBank AA774247
203218-77-3, GenBank AA772816 203223-82-9, GenBank AF030234
203230-44-8, GenBank AL021683 203232-26-2, GenBank AF035360
203232-88-6, GenBank AB010710 203239-09-2, GenBank AF044333
203269-28-7, GenBank AC004099 203281-39-4, GenBank AA774665
203282-05-7, GenBank AA774638 203283-61-8, GenBank AA774843
203284-26-8, GenBank AA774876 203285-93-2, GenBank AA775030
203286-89-9, GenBank AA775257 203286-91-3, GenBank AA775259
203287-10-9, GenBank AA775241 203287-71-2, GenBank AA775270
203288-32-8, GenBank AA775290 203288-49-7, GenBank AA775423
203288-56-6, GenBank AA775355 203288-79-3, GenBank AA775378
203288-98-6, GenBank AA775397 203289-02-5, GenBank AA775415
203289-32-1, GenBank AA775431 203289-59-2, GenBank AA775447
203291-38-7, GenBank AA775616 203292-03-9, GenBank AA775721
203292-29-9, GenBank AA775738 203292-82-4, GenBank AA775763
203293-45-2, GenBank AA775839 203293-63-4, GenBank AA775857
203293-71-4, GenBank AA775865 203293-78-1, GenBank AA775872
203294-01-3, GenBank AA775828 203294-04-6, GenBank AA775831
203295-38-9, GenBank AA775987 203295-74-3, GenBank AA776087
203297-52-3, GenBank AA776294 203345-44-2, GenBank AA776794

203346-69-4, GenBank AA776942 203347-47-1, GenBank AA777002
 203347-59-5, GenBank AA777014 203348-54-3, GenBank AA777102
 203348-94-1, GenBank AA777187 203348-99-6, GenBank AA777192
 203351-61-5, GenBank AA777435 203351-80-8, GenBank AA777384
 203352-49-2, GenBank AA777477 203353-73-5, GenBank AA777488
 203353-78-0, GenBank AA777493 203354-71-6, GenBank AA777605
 203357-24-8, GenBank AA777915 203357-27-1, GenBank AA777917
 203357-43-1, GenBank AA777928 203358-79-6, GenBank AA778098
 203363-10-4, GenBank AA778560 203363-11-5, GenBank AA778561
 203363-90-0, GenBank AA778645 203364-66-3, GenBank AA778675
 203365-15-5, GenBank AA778771 203366-18-1, GenBank AA778874
 203369-09-9, GenBank AA779165 203369-61-3, GenBank AA779217
 203371-45-3, GenBank AA779401 203372-23-0, GenBank AA779480
 203376-08-3, GenBank AA779865 203376-35-6, GenBank AA779892
 203376-92-5, GenBank AA779949 203413-57-4, GenBank AA781074
 203415-55-8, GenBank AA781207 203426-88-4, GenBank AA782337
 203430-01-7, GenBank AA782679 203544-74-5, GenBank AA788641
 203545-90-8, GenBank AA788738 203548-17-8, GenBank AA788970
 203609-99-8, GenBank U82761 203848-80-0, GenBank AF047181 204024-99-7,
 GenBank AF044588 204025-39-8, GenBank AA807586 204039-10-1, GenBank
 AA806060 204041-71-4, GenBank AA806294 204042-45-5, GenBank AA806371
 204051-87-6, GenBank AA804750 204101-44-0, GenBank AA808946
 204103-30-0, GenBank AA809199 204105-09-9, GenBank AA809396
 204148-95-8, GenBank AA810675 204164-56-7, GenBank AA812236
 204184-03-2, GenBank AF001945 204214-92-6, GenBank AA814719
 204221-86-3, GenBank AA815407 204372-88-3, GenBank AJ223812
 204408-35-5, GenBank U91942 204412-29-3, GenBank AF046001 204421-81-8,
 GenBank AB011079 204431-17-4, GenBank AA835885 204467-69-6, GenBank
 AA825931 204471-63-6, GenBank AA826294 204471-78-3, GenBank AA826309
 204473-16-5, GenBank AA827350 204484-54-8, GenBank AA826906
 204488-06-2, GenBank AA827228 204531-35-1, GenBank AA829295
 204554-92-7, GenBank AA831659 204557-85-7, GenBank AA831959
 204563-22-4, GenBank U64898 204614-07-3, GenBank AA834301 204620-47-3,
 GenBank AA833773 204627-30-5, GenBank AA835460 204628-47-7, GenBank
 AF045229 204632-25-7, GenBank AA836663 204632-46-2, GenBank AA836535
 204661-15-4, GenBank AF029669 204679-04-9, GenBank AA838640
 204679-45-8, GenBank AA837819 204682-38-2, GenBank AA838112
 204721-42-6, GenBank AA838691 204722-02-1, GenBank AA838670
 204884-40-2, GenBank AF047472 204884-41-3, GenBank AF047473
 204889-69-0, GenBank AA843176 204892-05-7, GenBank AA843404
 204892-08-0, GenBank AA843407 204898-58-8, GenBank AA844124
 204901-81-5, GenBank AA844447 204937-39-3, GenBank AA844864
 204940-52-3, GenBank AA845178 204948-15-2, GenBank AA846308
 204950-77-6, GenBank AA846523 204953-37-7, GenBank AA846794
 204953-58-2, GenBank AA846735 204955-65-7, GenBank AA845432
 204956-27-4, GenBank AA845455 204964-85-2, GenBank AA847557
 205169-05-7, GenBank AA852328 205200-20-0, GenBank AA852527
 205229-91-0, GenBank AA856556 205268-89-9, GenBank AA857015
 205269-64-3, GenBank AA857101

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 205269-99-4, GenBank AA857093 205270-66-2, GenBank AA857163
 205271-81-4, GenBank AA857212 205273-35-4, GenBank AA857437
 205274-08-4, GenBank AA857478 205274-26-6, GenBank AA857496
 205276-08-0, GenBank AA857735 205276-69-3, GenBank AA857716
 205291-30-1, GenBank AC004381 205342-48-9, GenBank AF049140
 205403-50-5, GenBank AA861590 205404-45-1, GenBank AA861631
 205410-51-1, GenBank AA861951 205413-05-4, GenBank AA862240
 205414-70-6, GenBank AA862371 205415-81-2, GenBank AA862434
 205419-55-2, GenBank AA862813 205422-21-5, GenBank AA863086
 205422-90-8, GenBank AA863149 205424-09-5, GenBank AA863314
 205424-35-7, GenBank AA863365 205424-79-9, GenBank AA863383
 205425-54-3, GenBank AA863469 205467-04-5, GenBank AA865437

| | | |
|-------------------------------|-------------------------------|-------------------------------|
| 205467-17-0, GenBank AA865450 | 205467-36-3, GenBank AA865469 | |
| 205469-95-0, GenBank AA865729 | 205471-44-9, GenBank AA865878 | |
| 205473-78-5, GenBank AA866113 | 205474-25-5, GenBank AA866160 | |
| 205475-28-1, GenBank AA864226 | 205477-80-1, GenBank AA864479 | |
| 205478-25-7, GenBank AA864524 | 205480-04-2, GenBank AA864704 | |
| 205570-85-0, GenBank AA868008 | 205575-91-3, GenBank AA872010 | |
| 205603-18-5, GenBank AF036331 | 205608-20-4, GenBank AA868929 | |
| 205662-45-9, GenBank AA872057 | 205664-76-2, GenBank AA872323 | |
| 205664-92-2, GenBank AA872336 | 205665-08-3, GenBank AA872436 | |
| 205665-59-4, GenBank AA872402 | 205665-77-6, GenBank AA872420 | |
| 205668-34-4, GenBank AA872817 | 205670-66-2, GenBank AA873060 | |
| 205671-42-7, GenBank AA873056 | 205706-70-3, GenBank AF011920 | |
| 205707-38-6, GenBank AA873159 | 205709-30-4, GenBank AA873355 | |
| 205710-29-8, GenBank AA873459 | 205711-02-0, GenBank AA873564 | |
| 205711-16-6, GenBank AA873578 | 205712-05-6, GenBank AA873604 | |
| 205715-24-8, GenBank AF052578 | 205850-18-6, GenBank AF049688 | |
| 205900-69-2, GenBank AF053304 | 205905-53-9, GenBank AA876039 | |
| 205906-13-4, GenBank AA876021 | 205909-98-4, GenBank AA875893 | |
| 205910-68-5, GenBank AA875933 | 205920-30-5, GenBank AA877166 | |
| 205946-43-6, GenBank AA877255 | 205947-68-8, GenBank AA877479 | |
| 205949-08-2, GenBank AA877618 | 205950-90-9, GenBank AA877815 | |
| 205953-22-6, GenBank AA878048 | 205956-24-7, GenBank AA878391 | |
| 205961-54-2, GenBank AA878880 | 205961-82-6, GenBank AA878899 | |
| 205962-16-9, GenBank AA878933 | 206040-86-0, GenBank AA883400 | |
| 206081-08-5, GenBank AA884545 | 206081-85-8, GenBank AA884622 | |
| 206083-19-4, GenBank AA885210 | 206084-19-7, GenBank AA885311 | |
| 206085-41-8, GenBank AA885433 | 206088-98-4, GenBank AA884886 | |
| 206089-09-0, GenBank AA884897 | 206092-12-8, GenBank AF035933 | |
| 206103-67-5, GenBank AA886322 | 206147-21-9, GenBank AA887673 | |
| 206148-78-9, GenBank AA887751 | 206152-35-4, GenBank AA888148 | |
| 206152-69-4, GenBank AA888182 | 206153-50-6, GenBank AA888290 | |
| 206219-69-4, GenBank AF053233 | 206221-54-7, GenBank AF054838 | |
| 206225-39-0, GenBank AF032456 | 206231-42-7, GenBank AF055033 | |
| 206231-79-0, GenBank AF054990 | 206232-04-4, GenBank AF055015 | |
| 206232-17-9, GenBank AF055028 | 206233-34-3, GenBank AJ004954 | |
| 206233-35-4, GenBank AJ004955 | 206233-36-5, GenBank AJ004956 | |
| 206248-63-7, GenBank AA890180 | 206248-80-8, GenBank AA890136 | |
| 206253-78-3, GenBank AA890663 | 206323-03-7, GenBank AF054663 | |
| 206324-70-1, GenBank Y10351 | 206395-37-1, GenBank AA894557 | 206395-48-4, GenBank AA894577 |
| 206396-06-7, GenBank AA894627 | 206396-65-8, GenBank AA894687 | 206399-05-5, GenBank AA894927 |
| 206572-23-8, GenBank AA902264 | 206585-87-7, GenBank AA903708 | 206591-34-6, GenBank AA904239 |
| 206592-61-2, GenBank AA904362 | 206602-34-8, GenBank AA905314 | 206603-32-9, GenBank AA905491 |
| 206604-92-2, GenBank AA907403 | 206614-10-0, GenBank AF037448 | 206630-54-8, GenBank AB011100 |
| 206631-13-2, GenBank AB011159 | 206631-18-7, GenBank AB011164 | 206631-27-8, GenBank AB011173 |
| 206631-23-4, GenBank AB011169 | 206695-12-7, GenBank AA908982 | 206704-94-1, GenBank AA910100 |
| 206631-35-8, GenBank AB011181 | 206729-42-2, GenBank AA912466 | 206792-62-3, GenBank AA916325 |
| 206696-74-4, GenBank AA909144 | 206793-57-9, GenBank AA916420 | 206808-44-8, GenBank AA917350 |
| 206723-42-4, GenBank AA911900 | 206826-41-7, GenBank AA919102 | 206914-28-5, GenBank AC004594 |
| 206732-75-4, GenBank AA912796 | 206914-28-5, GenBank AC004594 | 206951-74-8, GenBank AA922029 |
| 206793-50-2, GenBank AA916413 | 206958-69-2, GenBank AA922691 | 207078-81-7, GenBank AA928656 |
| 206802-91-7, GenBank AF056717 | 207156-64-7, GenBank AA933074 | 207217-66-1, GenBank AC004616 |
| 206815-47-6, GenBank AA918023 | 207262-21-3, GenBank AA934755 | 207326-61-2, GenBank AA936768 |
| 206912-70-1, GenBank AF058392 | 207326-92-9, GenBank AA936799 | 207334-60-9, GenBank AA937381 |
| 206950-63-2, GenBank AA921913 | 207550-92-3, GenBank AA947751 | 207579-37-1, GenBank AA948207 |
| 206955-62-6, GenBank AA922376 | | |
| 206958-77-2, GenBank AA922700 | | |
| 207156-38-5, GenBank AA933048 | | |
| 207160-34-7, GenBank AA932598 | | |
| 207251-86-3, GenBank AF020043 | | |
| 207271-38-3, GenBank AA935727 | | |
| 207326-76-9, GenBank AA936783 | | |
| 207331-87-1, GenBank AA937108 | | |
| 207545-07-1, GenBank AF060567 | | |
| 207577-88-6, GenBank AA948058 | | |

207587-78-8, GenBank AA946908 207667-93-4, GenBank AC004664
 207707-23-1, GenBank AA953714 207722-22-3, GenBank AA954443
 207903-55-7, GenBank AA962240 207944-59-0, GenBank AL023577
 208030-89-1, GenBank AC004699 208030-91-5, GenBank AC004703
 208069-80-1, GenBank AA968896 208076-91-9, GenBank AA969601
 208089-31-0, GenBank AA970732 208134-23-0, GenBank AA972350
 208134-28-5, GenBank AA972355 208143-68-4, GenBank AA973461
 208205-77-0, GenBank AF064092 208208-55-3, GenBank AA976525
 208210-11-1, GenBank AA974971 208218-25-1, GenBank AA975786
 208227-89-8, GenBank AF065388 208230-31-3, GenBank AL023655
 208232-67-1, GenBank AA976655 208323-30-2, GenBank AF013759
 208326-87-8, GenBank AF000670 208386-09-8, GenBank AA983252
 208386-23-6, GenBank AA983267 208428-52-8, GenBank AA985228
 208506-21-2, GenBank AA989355 208552-04-9, GenBank AF026381
 208554-32-9, GenBank AF039701 208557-54-4, GenBank AF062165
 208562-13-4, GenBank AA987866 208564-82-3, GenBank AA988136
 208567-88-8, GenBank AA989185 208608-04-2, GenBank AB006651
 208635-11-4, GenBank AA991239 208640-35-1, GenBank AA992138
 208672-73-5, GenBank AA992733 208680-25-5, GenBank AA992486
 208681-56-5, GenBank AA992596 208694-70-6, GenBank AA994106
 208699-79-0, GenBank AA994689 208702-35-6, GenBank AA994997
 208704-46-5, GenBank AA995086 208751-92-2, GenBank D89937 208825-67-6,
 GenBank AA999712 208886-61-7, GenBank AA999953 208889-79-6, GenBank
 AI000271 208957-14-6, GenBank AF068836 209151-53-1, GenBank Y17392
 209300-32-3, GenBank AI004415 209302-77-2, GenBank AI004650
 209305-39-5, GenBank AI004915 209305-56-6, GenBank AI004930
 209309-56-8, GenBank AI005330 209365-97-9, GenBank AC005045
 209512-55-0, GenBank AI014649 209556-79-6, GenBank AI015589
 209565-67-3, GenBank AI016477 209567-78-2, GenBank AI016688
 209573-30-8, GenBank AI017240 209578-54-1, GenBank AI017778
 209581-27-1, GenBank AI018038 209585-87-5, GenBank AI018321
 209629-69-6, GenBank AI018613 209662-79-3, GenBank AF028832
 209707-83-5, GenBank AI023265 209718-83-2, GenBank AI022220
 209720-55-8, GenBank AI023341 209754-01-8, GenBank AI025120
 209754-81-4, GenBank AI025259 209770-70-7, GenBank AF069765
 209774-45-8, GenBank AI026942 209776-63-6, GenBank AI027161
 209779-67-9, GenBank AI027465 209811-93-8, GenBank AI028127
 209813-61-6, GenBank AI028295 209815-77-0, GenBank AI028512
 209820-61-1, GenBank AI026819 209823-38-1, GenBank AI027887
 209878-20-6, GenBank AI031682

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 209880-53-5, GenBank AI031950 209891-23-6, GenBank AF071594
 209938-86-3, GenBank AI033304 209942-94-9, GenBank AI033712
 210003-38-6, GenBank Y08982 210084-01-8, GenBank AC005180 210086-21-8,
 GenBank AC005193 210251-68-6, GenBank AI037879 210263-76-6, GenBank
 AI039087 210268-97-6, GenBank AI039609 210273-35-1, GenBank AI040048
 210310-04-6, GenBank AI041067 210311-14-1, GenBank AI041124
 210312-58-6, GenBank AI041309 210386-71-3, GenBank AL030996
 210386-74-6, GenBank AL031003 210449-79-9, GenBank AF070626
 210450-02-5, GenBank AF070649 210452-72-5, GenBank AJ006266
 210507-76-9, GenBank AF069904 210523-71-0, GenBank AJ004913
 210526-37-7, GenBank AI046024 210569-86-1, GenBank AR015927
 210669-05-9, GenBank AF042166 210670-35-2, GenBank AI051245
 210675-02-8, GenBank AI051775 210721-64-5, GenBank AI052525
 211025-68-2, GenBank AF059611 211062-65-6, GenBank AF075587
 211063-73-9, GenBank AJ228139 211070-28-9, GenBank AI053702
 211153-72-9, GenBank AB014542 211153-73-0, GenBank AB014543
 211154-01-7, GenBank AB014571 211154-07-3, GenBank AB014577
 211154-17-5, GenBank AB014587 211155-02-1, GenBank AB014598
 211155-04-3, GenBank AB014599 211167-09-8, GenBank AI056411
 211197-44-3, GenBank AI057064 211260-38-7, GenBank AF038952
 211275-24-0, GenBank AF047433 211397-31-8, GenBank AF054175

211397-44-3, GenBank AF054186 211856-60-9, GenBank AC005345
211878-25-0, GenBank AF052093 211878-26-1, GenBank AF052094
211878-55-6, GenBank AF052124 211882-43-8, GenBank AF049672
212105-41-4, GenBank Y16241 212217-93-1, GenBank AF070555 212217-94-2,
GenBank AF070556 212217-99-7, GenBank AF070561 212218-00-3, GenBank
AF070562 212218-34-3, GenBank AF070596 212218-47-8, GenBank AF070609
212366-14-8, GenBank AI075033 212367-01-6, GenBank AI075172
212403-50-4, GenBank AI075782 212536-39-5, GenBank AI077905
212536-69-1, GenBank AI077939 212543-27-6, GenBank AI078595
212590-07-3, GenBank AI079233 212595-42-1, GenBank AI079730
212596-48-0, GenBank AI079874 212602-84-1, GenBank AI080476
212670-70-7, GenBank AI081540 212722-29-7, GenBank AF081192
212738-35-7, GenBank AI084459 212796-15-1, GenBank AI085948
212802-92-1, GenBank AI086608 212804-81-4, GenBank AI086797
212810-64-5, GenBank AI087367 212812-11-8, GenBank AL031296
212815-95-7, GenBank AI087805 212826-80-7, GenBank AI088809
212859-58-0, GenBank AI089452 212863-05-3, GenBank AI089794
212867-19-1, GenBank AI090240 212873-35-3, GenBank AI090872
212873-95-5, GenBank AI090889 212884-07-6, GenBank AI091910
212924-07-7, GenBank AI093207 212932-41-7, GenBank AI094099
213171-16-5, GenBank AF049910 213173-60-5, GenBank AI097642
213220-31-6, GenBank AI097213 213291-90-8, GenBank AF061741
213452-46-1, GenBank AB012190 213510-40-8, GenBank Y17941 213946-62-4,
GenBank AB006746 214110-56-2, GenBank AF086002 214110-57-3, GenBank
AF086003 214111-70-3, GenBank AF086116 214111-74-7, GenBank AF086120
214112-15-9, GenBank AF086161 214112-37-5, GenBank AF086183
214112-59-1, GenBank AF086205 214113-76-5, GenBank AF086322
214113-84-5, GenBank AF086330 214113-90-3, GenBank AF086336
214114-62-2, GenBank AF086408 214115-00-1, GenBank AF086446
214155-01-8, GenBank AF086545 214155-16-5, GenBank AF086484
214155-78-9, GenBank AJ010069 214325-82-3, GenBank AF062346
214472-53-4, GenBank AF115345 214730-80-0, GenBank AI123672
215462-86-5, GenBank AB004304 215819-67-3, GenBank AF053641
215840-95-2, GenBank AI126345 215844-68-1, GenBank AI126722
215847-46-4, GenBank AI127013 215852-07-6, GenBank AI127441
215852-79-2, GenBank AI127556 215884-73-4, GenBank AI127879
215886-30-9, GenBank AI128031 215902-89-9, GenBank AI129664
216178-32-4, GenBank AI131218 216181-41-8, GenBank AI131549
216274-41-8, GenBank G52838 216295-54-4, GenBank AF069668 216296-76-3,
GenBank AB018320 216296-87-6, GenBank AB018331 216296-90-1, GenBank
AB018334 216322-07-5, GenBank AC005682 216567-75-8, GenBank AB015234
216654-09-0, GenBank AB004852 216923-40-9, GenBank AI139036
216931-04-3, GenBank AI139802 216934-47-3, GenBank AF091627
216940-10-2, GenBank AI140455 216943-56-5, GenBank AI140804
216943-58-7, GenBank AI140806 216954-36-8, GenBank AI141893
217049-37-1, GenBank AI142105 217049-70-2, GenBank AI142138
217052-95-4, GenBank AL031584 217056-03-6, GenBank AI142384
217056-66-1, GenBank AI142427 217125-28-5, GenBank AI143147
217125-84-3, GenBank AI143203 217131-84-5, GenBank AI143806
217240-99-8, GenBank AI147899 217244-50-3, GenBank AI148251
217511-74-5, GenBank AL031775 217580-82-0, GenBank AF057160
217583-20-5, GenBank AI167324 217954-35-3, GenBank AF063613
218026-83-6, GenBank AI184475 218029-93-7, GenBank AI184787
218031-00-6, GenBank AI184894 218032-70-3, GenBank AI185064
218038-46-1, GenBank AI185641 218042-50-3, GenBank AI186047
218043-42-6, GenBank AI186139 218087-80-0, GenBank AB012910
218094-24-7, GenBank AI187822 218099-35-5, GenBank AI188333
218105-57-8, GenBank AI188956 218109-79-6, GenBank AI189381
218109-84-3, GenBank AI189386 218128-72-4, GenBank AJ005766
218183-63-2, GenBank AI192724 218186-16-4, GenBank AI192979
218197-04-7, GenBank AI194068 218247-16-6, GenBank AI198824
218257-84-2, GenBank AI199897 218267-96-0, GenBank AI205584
218268-54-3, GenBank AJ223183 218323-64-9, GenBank AI202683
218333-24-5, GenBank AI203647 218346-90-8, GenBank AF023259
218348-33-5, GenBank AF070523 218374-15-3, GenBank AI207168
218375-69-0, GenBank AI207324 218427-65-7, GenBank AF095288

218427-66-8, GenBank AF095289 218556-42-4, GenBank AJ012077
 218556-43-5, GenBank AJ012078 218561-60-5, GenBank AI214206
 218570-59-3, GenBank AI215107 218573-56-9, GenBank AF060228
 218687-04-8, GenBank AI216969 218687-08-2, GenBank AI216973
 218687-13-9, GenBank AI216978 218687-21-9, GenBank AI216986
 218687-23-1, GenBank AI216988 218687-38-8, GenBank AI217003
 218763-64-5, GenBank AF077367 218851-05-9, GenBank AI219585
 218860-84-5, GenBank AI220569 218872-93-6, GenBank AI221783
 218878-19-4, GenBank AI222310 218995-35-8, GenBank AI225126
 219258-47-6, GenBank AC005919 219277-82-4, GenBank AI241236
 219281-43-3, GenBank AI241597 219370-94-2, GenBank AI247571
 219383-38-7, GenBank AI248817 219408-12-5, GenBank AI251337
 219411-88-8, GenBank AI251743 219513-57-2, GenBank AF072810
 219658-34-1, GenBank AF045941 219728-81-1, GenBank U87791 219731-16-5,
 GenBank AB018080 219805-83-1, GenBank AF044955 220092-79-5, GenBank
 AF086904 220153-32-2, GenBank Y16961 220500-09-4, GenBank AB020637
 220500-34-5, GenBank AB020662 220500-37-8, GenBank AB020665
 220500-52-7, GenBank AB020680 220500-64-1, GenBank AB020692
 220710-71-4, GenBank AF101051 221174-66-9, GenBank AF082888
 221294-25-3, GenBank AF075242 221396-05-0, GenBank AI252283
 221399-20-8, GenBank AI252627 221407-22-3, GenBank AI253436
 221407-40-5, GenBank AI253288 221407-44-9, GenBank AI253292
 221407-52-9, GenBank AI253300 221407-81-4, GenBank AI253330
 221407-86-9, GenBank AI253335 221407-87-0, GenBank AI253336
 221407-88-1, GenBank AI253337 221407-98-3, GenBank AI253347
 221408-30-6, GenBank AI253379 221408-39-5, GenBank AI253388
 221431-38-5, GenBank AF091076 221701-22-0, GenBank AB013924
 221702-48-3, GenBank AB015051 221712-48-7, GenBank AI265770
 221727-66-8, GenBank AF042331 221729-25-5, GenBank AJ012409

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

IT 221729-53-9, GenBank AI267182 221729-56-2, GenBank AI267185
 221729-91-5, GenBank AI267162 221730-13-8, GenBank AI267254
 221730-81-0, GenBank AI267282 221730-84-3, GenBank AI267285
 221730-88-7, GenBank AI267289 221731-06-2, GenBank AI267307
 221731-18-6, GenBank AI267351 221731-33-5, GenBank AI267316
 221731-78-8, GenBank AI267379 221732-12-3, GenBank AI267414
 221732-38-3, GenBank AI267515 221732-88-3, GenBank AI267454
 221733-57-9, GenBank AI267521 221733-68-2, GenBank AI267532
 221734-11-8, GenBank AI267658 221734-24-3, GenBank AI267664
 221736-01-2, GenBank AI267838 221741-49-7, GenBank AI268345
 221742-55-8, GenBank AI268430 221743-12-0, GenBank AI268550
 221761-79-1, GenBank AI270350 221780-80-9, GenBank AB019563
 221780-82-1, GenBank AB019565 221780-85-4, GenBank AB019568
 221783-07-9, GenBank D83197 221816-73-5, GenBank AI274773 221820-72-0,
 GenBank AI275175 221822-50-0, GenBank AI275379 221848-49-3, GenBank
 AI277995 222080-58-2, GenBank AI279790 222083-89-8, GenBank AI280125
 222090-92-8, GenBank AI280830 222096-51-7, GenBank AI281395
 222100-68-7, GenBank AI281815 222129-91-1, GenBank AI284792
 222132-92-5, GenBank AI285111 222203-76-1, GenBank AL034349
 222210-15-3, GenBank AI288285 222239-72-7, GenBank AI291206
 222240-56-4, GenBank AI291282 222245-72-9, GenBank AI291800
 222447-88-3, GenBank AI298000 222454-54-8, GenBank AI298334
 222456-16-8, GenBank AI298496 222461-58-7, GenBank AI299124
 222466-51-5, GenBank AI299928 222475-73-2, GenBank AI300852
 222476-68-8, GenBank AI300947 222480-43-5, GenBank AI301329
 222525-83-9, GenBank AB023137 222525-92-0, GenBank AB023146
 222526-55-8, GenBank AB023209 222526-70-7, GenBank AB023224
 222526-75-2, GenBank AB023229 222563-98-6, GenBank AJ010442
 222564-00-3, GenBank AJ010444 222564-02-5, GenBank AJ010446
 222565-34-6, GenBank AF070672 222565-36-8, GenBank AF070674
 222752-01-4, GenBank AI304857 222760-19-2, GenBank AI306478
 222768-09-4, GenBank AI305745 222779-50-2, GenBank AI307515

222779-92-2, GenBank AI307557 222780-02-1, GenBank AI307569
 222797-17-3, GenBank AI309334 222824-73-9, GenBank AL034417
 222826-52-0, GenBank AL034430 222828-72-0, GenBank AI312092
 222831-11-0, GenBank AI312353 223097-36-7, GenBank AF103415
 223097-69-6, GenBank AF103559 223097-74-3, GenBank AF103564
 223097-82-3, GenBank AF103572 223099-54-5, GenBank AF103436
 223100-57-0, GenBank AF034607 223211-24-3, GenBank AF054284
 223212-35-9, GenBank AC006230 223349-57-3, GenBank AB021288
 223568-28-3, GenBank AF097725 223609-79-8, GenBank AB005548
 223656-93-7, GenBank AJ001634 223764-80-5, GenBank AF102826
 223899-03-4, GenBank AB021654 223981-96-2, GenBank AI332560
 223985-85-1, GenBank AI332952 224001-08-5, GenBank AI334450
 224009-97-6, GenBank AI335426 224017-91-8, GenBank AI336224
 224071-11-8, GenBank AI338972 224086-25-3, GenBank AI340510
 224086-75-3, GenBank AI340563 224087-57-4, GenBank AI340653
 224091-77-4, GenBank AI341138 224110-60-5, GenBank AI342937
 224118-70-1, GenBank AI343764 224120-72-3, GenBank AI343970
 224121-21-5, GenBank AI344026 224121-87-3, GenBank AI344101
 224131-90-2, GenBank AI345143 224136-44-1, GenBank AI345608
 224140-26-5, GenBank AI346017 224149-93-3, GenBank AI346994
 224196-86-5, GenBank AI347602 224212-01-5, GenBank AI349166
 224214-56-6, GenBank AI349430 224217-13-4, GenBank AI349698
 224244-73-9, GenBank AI352510 224245-37-8, GenBank AI352575
 224279-12-3, GenBank AI355149 224290-50-0, GenBank U41850 224290-68-0,
 GenBank U42457 224290-69-1, GenBank U42458 224290-71-5, GenBank U42593
 224290-72-6, GenBank U42594 224327-91-7, GenBank U61083 224327-92-8,
 GenBank U61084 224330-85-2, GenBank U73522 224336-63-4, GenBank U87564
 224336-77-0, GenBank U87954 224341-22-4, GenBank U97251 224353-42-8,
 GenBank AF015041 224363-49-9, GenBank AF044221 224368-08-5, GenBank
 AF063308 224384-57-0, GenBank AI357416 224385-12-0, GenBank AI357472
 224389-58-6, GenBank AI357921 224402-84-0, GenBank AI359254
 224423-73-8, GenBank AF125182 224504-92-1, GenBank AI366015
 224508-47-8, GenBank AI366374 224508-49-0, GenBank AI366376
 224508-54-7, GenBank AI366381 224656-10-4, GenBank AI367288
 224709-37-9, GenBank AC006322 224714-08-3, GenBank AI368587
 224719-89-5, GenBank AI369186 224873-17-0, GenBank AF091263
 224882-07-9, GenBank AI372834 225007-55-6, GenBank AI375712
 225008-76-4, GenBank AI375834 225010-45-7, GenBank AI376003
 225258-91-3, GenBank AI376751 225259-65-4, GenBank AI376825
 225289-38-3, GenBank AI379830 225396-80-5, GenBank U60067 225396-81-6,
 GenBank U60068 225404-72-8, GenBank AB015907 225424-68-0, GenBank
 AF051099 225426-19-7, GenBank AF068235 225426-42-6, GenBank AF069601
 225429-32-3, GenBank AF097874 225435-66-5, GenBank AF061737
 225436-28-2, GenBank AF081282 225438-71-1, GenBank AF125507
 225438-98-2, GenBank AC006960 225445-78-3, GenBank AF100737
 225446-81-1, GenBank AF131739 225447-33-6, GenBank AF131791
 225447-44-9, GenBank AF131802 225447-90-5, GenBank AF131848
 225447-98-3, GenBank AF131856 225453-90-7, GenBank AF070650
 225453-97-4, GenBank AF070657 225453-99-6, GenBank AF070659
 225454-01-3, GenBank AF070661 225454-04-6, GenBank AF070664
 225454-09-1, GenBank AF070669 225458-22-0, GenBank AJ132694
 225468-62-2, GenBank AJ010901 225468-63-3, GenBank AJ011007
 225468-85-9, GenBank Y17957 225469-80-7, GenBank AJ131720 225474-92-0,
 GenBank AL049229 225475-15-0, GenBank AL049260 225475-76-3, GenBank
 AL049346 225475-90-1, GenBank AL049367 225475-95-6, GenBank AL049381
 225532-47-8, GenBank AC007227 225538-80-7, GenBank AC007250
 225539-27-5, GenBank AF079566 225567-31-7, GenBank AF109196
 225575-72-4, GenBank AB019392 225576-60-3, GenBank AB011472
 225581-68-0, GenBank AB017019 225590-18-1, GenBank AL049694
 225590-24-9, GenBank AL049696 225590-53-4, GenBank AF077200
 225590-55-6, GenBank AF077202 225590-60-3, GenBank AF077207
 225597-43-3, GenBank AC007392 225598-88-9, GenBank AF132952
 225598-95-8, GenBank AF132959 225599-18-8, GenBank AF077030
 225599-30-4, GenBank AF077042 225599-31-5, GenBank AF077043
 225599-33-7, GenBank AF077045 225599-88-2, GenBank AF121856
 225609-77-8, GenBank AP000131 225633-58-9, GenBank AF127918

| | |
|-------------------------------|-------------------------------|
| 225634-43-5, GenBank AF147331 | 225634-48-0, GenBank AF147336 |
| 225634-79-7, GenBank AF147367 | 225635-22-3, GenBank AF147410 |
| 225635-24-5, GenBank AF147412 | 225679-30-1, GenBank AF114263 |
| 225679-32-3, GenBank AF113887 | 225680-01-3, GenBank AF116910 |
| 225691-47-4, GenBank AL049824 | 225707-41-5, GenBank AJ236552 |
| 225713-15-5, GenBank AF124440 | 225717-24-8, GenBank AL050011 |
| 225717-30-6, GenBank AL050022 | 225717-57-7, GenBank AL050120 |
| 225717-59-9, GenBank AL050137 | 225717-79-3, GenBank AL049940 |
| 225718-04-7, GenBank AL049969 | 225718-33-2, GenBank AL049999 |
| 225718-37-6, GenBank AL050003 | 225719-41-5, GenBank AL050179 |
| 225723-40-0, GenBank AL050255 | 225723-75-1, GenBank AL050272 |
| 225723-81-9, GenBank AL050289 | 225723-82-0, GenBank AL050290 |
| 225726-88-5, GenBank AF067168 | 225733-95-9, GenBank AL050353 |
| 225734-01-0, GenBank AL050380 | 225734-06-5, GenBank AL050386 |
| 225746-23-6, GenBank AF145316 | 225747-66-0, GenBank AF151807 |
| 225747-85-3, GenBank AF151826 | 225747-99-9, GenBank AF151840 |
| 225748-02-7, GenBank AF151843 | 225748-27-6, GenBank AF151868 |
| 225748-55-0, GenBank AF151896 | |

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

| | |
|----------------------------------|-------------------------------|
| IT 225748-64-1, GenBank AF151905 | 225748-67-4, GenBank AF151908 |
| 225748-69-6, GenBank AF152097 | 225770-92-3, GenBank AB020981 |
| 225885-07-4, GenBank AF144755 | 225892-80-8, GenBank AF153201 |
| 225894-50-8, GenBank AJ241361 | 225894-52-0, GenBank AJ241363 |
| 225906-21-8, GenBank AF144103 | 225949-79-1, GenBank AI391187 |
| 226027-91-4, GenBank AI392908 | 226027-95-8, GenBank AI392912 |
| 226063-04-3, GenBank AB028624 | 226063-82-7, GenBank AC007880 |
| 226144-32-7, GenBank AI399801 | 226163-95-7, GenBank AI401777 |
| 226204-35-9, GenBank AF083248 | 226208-07-7, GenBank AF085359 |
| 226208-08-8, GenBank AF085360 | 226208-35-1, GenBank AF093535 |
| 226435-28-5, GenBank AI418469 | 226440-43-3, GenBank AI418993 |
| 226443-95-4, GenBank AI419347 | 226449-20-3, GenBank AI419877 |
| 226455-77-2, GenBank AI420543 | 226467-43-2, GenBank AI421720 |
| 226497-75-2, GenBank AI424788 | 226537-60-6, GenBank AF100741 |
| 226539-28-2, GenBank AB024313 | 226605-42-1, GenBank AI431290 |
| 226605-70-5, GenBank AI431318 | 226621-36-9, GenBank AI432942 |
| 226623-51-4, GenBank AI433157 | 226634-37-3, GenBank AI434250 |
| 226646-11-3, GenBank AI435429 | 226647-27-4, GenBank AI435548 |
| 226683-91-6, GenBank AI439408 | 226686-84-6, GenBank AI439702 |
| 226690-22-8, GenBank AI440063 | 226840-71-7, GenBank AI453252 |
| 226845-05-2, GenBank AI453689 | 227041-78-3, GenBank AI457107 |
| 227048-56-8, GenBank AF153608 | 227048-57-9, GenBank AF153609 |
| 227049-92-5, GenBank AF084457 | 227053-70-5, GenBank AL080097 |
| 227053-72-7, GenBank AL080099 | 227053-75-0, GenBank AL080102 |
| 227054-22-0, GenBank AL080150 | 227054-57-1, GenBank AL080185 |
| 227054-64-0, GenBank AL080192 | 227055-47-2, GenBank AJ238098 |
| 227072-63-1, GenBank AF111713 | 227072-79-9, GenBank AF050638 |
| 227072-81-3, GenBank AF044956 | 227114-15-0, GenBank AI458677 |
| 227273-50-9, GenBank AB022651 | 227273-52-1, GenBank AB022653 |
| 227273-53-2, GenBank AB022654 | 227273-55-4, GenBank AB022656 |
| 227447-32-7, GenBank AF100756 | 227515-73-3, GenBank AI469754 |
| 227520-25-4, GenBank AI470208 | 227525-02-2, GenBank AI470686 |
| 227592-38-3, GenBank AL096713 | 227592-43-0, GenBank AL096719 |
| 227744-18-5, GenBank AF075601 | 227869-85-4, GenBank AI479200 |
| 227872-58-4, GenBank AI479476 | 227877-71-6, GenBank AI479992 |
| 228052-18-4, GenBank AI499245 | 228065-19-8, GenBank AI500553 |
| 228069-01-0, GenBank AI491915 | 228082-24-4, GenBank AI493269 |
| 228125-26-6, GenBank AI493487 | 228595-95-7, GenBank AI521639 |
| 228613-96-5, GenBank AI523444 | 228637-79-4, GenBank AI525843 |
| 228690-70-8, GenBank AF078845 | 228690-73-1, GenBank AF078848 |
| 228690-75-3, GenBank AF078850 | 228690-80-0, GenBank AF078855 |
| 228690-83-3, GenBank AF078858 | 228690-87-7, GenBank AF078862 |
| 228690-88-8, GenBank AF078863 | 228691-23-4, GenBank AF107406 |

228694-10-8, GenBank AF138300 228801-23-8, GenBank AI537494
 228803-45-0, GenBank AI537716 228815-38-1, GenBank AI538918
 228822-57-9, GenBank AI539641 228848-99-5, GenBank AL096857
 228849-00-1, GenBank AL096858 228926-33-8, GenBank AI547125
 229221-41-4, GenBank AI557059 229302-99-2, GenBank AJ388655
 229377-63-3, GenBank AI559274 229380-05-6, GenBank AI559516
 229380-75-0, GenBank AI559586 229435-64-7, GenBank AI565043
 229445-98-1, GenBank AI566084 229517-06-0, GenBank G48728 229567-88-8,
 GenBank AI568741 229575-61-5, GenBank AI569519 229585-48-2, GenBank
 AI570510 229590-55-0, GenBank AI571021 229592-20-5, GenBank AI571186
 229606-40-0, GenBank AI572613 229607-78-7, GenBank AI572752
 229608-78-0, GenBank AI572852 229651-18-7, GenBank AI573140
 229855-17-8, GenBank AI581958 229876-60-2, GenBank AI584139
 230076-28-5, GenBank AI589040 230085-70-8, GenBank AI589993
 230088-03-6, GenBank AI590227 230088-20-7, GenBank AI590244
 230095-48-4, GenBank AI590981 230275-21-5, GenBank AI608975
 230277-77-7, GenBank AJ132502 230280-12-3, GenBank AF146018
 230327-77-2, GenBank AI610369 230340-26-8, GenBank AI611676
 230351-94-7, GenBank AI612885 230595-41-2, GenBank AI623627
 230601-60-2, GenBank AI624249 230604-24-7, GenBank AI624515
 230605-93-3, GenBank AC008249 230660-46-5, GenBank AI625736
 230802-96-7, GenBank AI627852 230807-50-8, GenBank AI628312
 230983-24-1, GenBank AI630330 230983-83-2, GenBank AI630389
 230995-02-5, GenBank AI631515 231004-49-2, GenBank AI632471
 231005-12-2, GenBank AI632536 231005-20-2, GenBank AI632544
 231008-41-6, GenBank AI632869 231036-63-8, GenBank AI635718
 231042-50-5, GenBank AI636308 231138-57-1, GenBank AI638172
 231268-56-7, GenBank AB029000 231268-61-4, GenBank AB029005
 231446-05-2, GenBank AL047434 231448-42-3, GenBank AL048446
 231449-36-8, GenBank AL048540 231451-60-8, GenBank AL047334
 231452-01-0, GenBank AL047758 231452-18-9, GenBank AL047775
 231454-09-4, GenBank AL048846 231455-25-7, GenBank AL048962
 231456-21-6, GenBank AL049058 231460-67-6, GenBank AL047980
 231461-31-7, GenBank AL048044 231461-43-1, GenBank AL048056
 231508-91-1, GenBank AI651114 231511-08-3, GenBank AI651336
 231526-12-8, GenBank AI652855 231537-49-8, GenBank AI654007
 231602-85-0, GenBank AJ237946 231605-09-7, GenBank AF158255
 231605-45-1, GenBank AF168956 232199-22-3, GenBank F24734 232208-28-5,
 GenBank F25640 232326-52-2, GenBank F30835 232375-18-7, GenBank F35702
 232393-19-0, GenBank F37503 232403-69-9, GenBank AI668664 232403-99-5,
 GenBank AI668694 232718-37-5, GenBank AI673251 232869-94-2, GenBank
 AI674170 232889-26-8, GenBank AI676122 232889-81-5, GenBank AI676178
 232911-90-9, GenBank AL109788 232915-52-5, GenBank AF127035
 233005-69-1, GenBank AI677829 233007-62-0, GenBank AI678023
 233046-26-9, GenBank AI681916 233046-63-4, GenBank AI681953
 233058-91-8, GenBank AI683193 233061-29-5, GenBank AI683431
 233179-64-1, GenBank AI684170 233193-81-2, GenBank AI685608
 233206-95-6, GenBank AI686949 233230-56-3, GenBank AI689321
 233240-88-5, GenBank AI690344 233244-60-5, GenBank AI690721
 233247-18-2, GenBank AF110647 233251-27-9, GenBank AF156965
 233252-31-8, GenBank AF172398 233441-09-3, GenBank AI692191
 233443-31-7, GenBank AI692405 233446-17-8, GenBank AI692703
 233450-57-2, GenBank AI693146 233458-32-7, GenBank AI693922
 233459-72-8, GenBank AI694064 233459-93-3, GenBank AI694087
 233743-86-7, GenBank AF176642 233990-83-5, GenBank AI695403
 234007-19-3, GenBank AI697049 234017-79-9, GenBank AI698120
 234026-44-9, GenBank AI698989 234047-59-7, GenBank AI701122
 234056-40-7, GenBank AI702016 234166-23-5, GenBank AI707589
 234173-57-0, GenBank AI708331 234179-97-6, GenBank AI708983
 234535-04-7, GenBank AI718099 234537-49-6, GenBank AI718421
 234547-32-1, GenBank AI719420 234564-55-7, GenBank AI721164
 234821-37-5, GenBank AI732618 234821-56-8, GenBank AI732637
 234822-64-1, GenBank AI732747 234823-00-8, GenBank AI732783
 234835-91-7, GenBank AI734101 234836-83-0, GenBank AI734197
 234837-24-2, GenBank AI734238 235213-87-3, GenBank AI738828
 235215-28-8, GenBank AI738971 235320-03-3, GenBank AI740459

235320-78-2, GenBank AI740534 235322-06-2, GenBank AI740662
 235339-94-3, GenBank AI742461 235357-87-6, GenBank AI744264
 235542-82-2, GenBank AI749547 235550-66-0, GenBank AI750332
 235554-03-7, GenBank AI750669 235554-16-2, GenBank AI750682
 235556-13-5, GenBank AI750879 235558-39-1, GenBank AI751017
 235558-68-6, GenBank AI751046 235561-62-3, GenBank AI751428
 235569-86-5, GenBank AI752253 235569-87-6, GenBank AI752254
 235576-46-2, GenBank AI752913 235576-90-6, GenBank AI752957

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; nucleic acid compns., kits, and methods for
 identification, assessment, prevention, and therapy of human cervical
 cancer)

| | | |
|----|-------------------------------|-------------------------------|
| IT | 235576-91-7, GenBank AI752958 | 235578-13-9, GenBank AI753080 |
| | 235583-56-9, GenBank AI753623 | 235584-00-6, GenBank AI753667 |
| | 235584-41-5, GenBank AI753708 | 235587-00-5, GenBank AI753968 |
| | 235588-34-8, GenBank AI754104 | 235591-60-3, GenBank AI754431 |
| | 235591-92-1, GenBank AI754463 | 235598-45-5, GenBank AI755118 |
| | 235598-71-7, GenBank AI755144 | 235600-09-6, GenBank AI755283 |
| | 236070-25-0, GenBank AI760367 | 236074-27-4, GenBank AI760770 |
| | 236075-65-3, GenBank AI760908 | 236130-19-1, GenBank AI762707 |
| | 236608-07-4, GenBank AI765826 | 236616-83-4, GenBank AI766705 |
| | 236623-61-3, GenBank AI767296 | 236636-61-6, GenBank AI768688 |
| | 236642-59-4, GenBank AI769287 | 236729-42-3, GenBank AF179212 |
| | 237377-85-4, GenBank AF083441 | 237703-73-0, GenBank AI791364 |
| | 237725-66-5, GenBank AL110153 | 237725-74-5, GenBank AL110161 |
| | 238154-14-8, GenBank AI796711 | 238154-95-5, GenBank AI796793 |
| | 238173-66-5, GenBank AI798680 | 238515-71-4, GenBank AI807806 |
| | 238531-32-3, GenBank AI809369 | 238539-49-6, GenBank AI810190 |
| | 238552-87-9, GenBank AI811548 | 238554-56-8, GenBank AI811719 |
| | 238626-42-1, GenBank AL035835 | 238626-81-8, GenBank AL035875 |
| | 238627-29-7, GenBank AL035924 | 238628-03-0, GenBank AL036003 |
| | 238628-23-4, GenBank AL036026 | 238629-49-7, GenBank AL036165 |
| | 238629-82-8, GenBank AL036211 | 238633-52-8, GenBank AL036650 |
| | 238634-21-4, GenBank AL036732 | 238636-28-7, GenBank AL036984 |
| | 238637-39-3, GenBank AL037114 | 238637-48-4, GenBank AL037123 |
| | 238644-43-4, GenBank AL037961 | 238644-44-5, GenBank AL037964 |
| | 238648-40-3, GenBank AL038463 | 238649-82-6, GenBank AL038648 |
| | 238657-08-4, GenBank AL039504 | 238659-67-1, GenBank AL039797 |
| | 238662-16-3, GenBank AL040084 | 238681-41-9, GenBank AL041840 |
| | 238691-31-1, GenBank AL042869 | 238692-05-2, GenBank AL042948 |
| | 238693-55-5, GenBank AL043113 | 238694-58-1, GenBank AL043232 |
| | 238698-78-7, GenBank AL043665 | 238701-65-0, GenBank AL079445 |
| | 238722-16-2, GenBank AI814180 | 238809-62-6, GenBank AI815380 |
| | 238810-27-0, GenBank AI815445 | 238812-37-8, GenBank AI815655 |
| | 238817-34-0, GenBank AI816152 | 238831-87-3, GenBank AL044967 |
| | 238835-78-4, GenBank AL045399 | 238836-71-0, GenBank AL045504 |
| | 238843-64-6, GenBank AL046250 | 238849-31-5, GenBank AL046839 |
| | 238854-39-2, GenBank AL079833 | 238855-82-8, GenBank AL079980 |
| | 238876-87-4, GenBank AI818599 | 238905-12-9, GenBank AI821465 |
| | 238910-83-3, GenBank AI822051 | 238911-72-3, GenBank AI822140 |
| | 238932-15-5, GenBank AI823903 | 238942-58-0, GenBank AI824951 |
| | 238957-44-3, GenBank AI826456 | 238966-70-6, GenBank AI827394 |
| | 238978-64-8, GenBank AI828592 | 238987-34-3, GenBank AI829472 |
| | 238991-38-3, GenBank AI829878 | 239877-93-1, GenBank AI857956 |
| | 239878-34-3, GenBank AI857997 | 239901-78-1, GenBank AI860354 |
| | 239904-10-0, GenBank AI860586 | 239906-62-8, GenBank AI860838 |
| | 239916-12-2, GenBank AI861786 | 239919-81-4, GenBank AI862171 |
| | 239926-32-0, GenBank AI862834 | 239938-31-9, GenBank AI864040 |
| | 239965-27-6, GenBank AI866820 | 239965-60-7, GenBank AI866692 |
| | 239966-04-2, GenBank AI866736 | 239969-02-9, GenBank AI867101 |
| | 240087-29-0, GenBank AI878826 | 240087-97-2, GenBank AI878894 |
| | 240575-73-9, GenBank AI884829 | 240616-48-2, GenBank AI888924 |
| | 240630-76-6, GenBank AI890362 | 241119-78-8, GenBank AL117561 |
| | 241120-18-3, GenBank AL117595 | 241120-29-6, GenBank AL117604 |
| | 241120-79-6, GenBank AL117651 | 241220-78-0, GenBank AI912782 |

241326-96-5, GenBank AI923459 241332-10-5, GenBank AI923980
 241344-24-1, GenBank AI925203 241355-11-3, GenBank AI926208
 241363-46-2, GenBank AI927130 241368-92-3, GenBank AI927678
 241518-38-7, GenBank AI932225 241549-20-2, GenBank AI935315
 241552-41-0, GenBank AI935636 241568-90-1, GenBank AI937296
 241796-76-9, GenBank AF182292 242045-15-4, GenBank AI953354
 242160-53-8, GenBank AI962046 242299-43-0, GenBank AI970562
 242319-76-2, GenBank AI972614 242446-99-7, GenBank AF035034
 242672-11-3, GenBank AI978703 242687-02-1, GenBank AI982899
 242721-42-2, GenBank AI986352 242783-70-6, GenBank AI990727
 242924-04-5, GenBank AW001775 242942-31-0, GenBank AW003634
 242975-31-1, GenBank AW006783 243051-03-8, GenBank AW014416
 243115-59-5, GenBank AB026722 243153-67-5, GenBank AW020650
 243169-93-9, GenBank AW022287 243173-95-7, GenBank AW022694
 243181-89-7, GenBank AW023497 243260-39-1, GenBank AW028560
 243267-70-1, GenBank AW029294 243415-76-1, GenBank AW044178 243420-40-8, GenBank AW044647 243618-05-5, GenBank AL120989 243878-27-5, GenBank AL121588 244565-26-2, GenBank AW081741 244920-10-3, GenBank AW105540
 245713-72-8, GenBank AB032768 246052-76-6, GenBank AF103907
 246438-08-4, GenBank AW149311 246467-64-1, GenBank AW152280
 247560-82-3, GenBank AB033026 247561-31-5, GenBank AB033077
 248418-12-4, GenBank AI133393 248578-03-2, GenBank AL133044
 248840-24-6, GenBank AW166315 249465-40-5, GenBank AW188948
 249766-98-1, GenBank AL133244 249844-64-2, GenBank AF176085
 251155-09-6, GenBank AW231122 252063-89-1, GenBank L25851 252108-77-3, GenBank AW265370 252690-93-0, GenBank S47339 252693-35-9, GenBank S50732 252779-73-0, GenBank S62490 252790-01-5, GenBank S68015
 252792-29-3, GenBank S69002 252803-22-8, GenBank S74728 252810-12-1, GenBank S77601 252812-47-8, GenBank S78271 252819-74-2, GenBank S82081
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (nucleotide sequence; nucleic acid compns., kits, and methods for identification, assessment, prevention, and therapy of human cervical cancer)

L70 ANSWER 15 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:338299 HCAPLUS

DN 134:344597

ED Entered STN: 11 May 2001

TI Bone hemostasis treatment with Pluronics

IN Levy, Michael; Wang, Michael Y.; Armstrong, Jonathan Keith; Fisher, Timothy Charles

PA Children's Hospital, USA

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61F002-02

ICS A61F002-28

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|--------------|
| WO 2001032101 | A1 | 20010510 | WO 2000-US29144 | 20001020 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1231869 | A1 | 20020821 | EP 2000-972322 | 20001020 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

IE, SI, LT, LV, FI, RO, MK, CY, AL
 US 2003095945 A1 20030522 US 2002-140015 20020429 <--
 PRAI US 1999-162347P P 19991029 <--
 WO 2000-US29144 W 20001020 <--

CLASS


| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|--|---|
| WO 2001032101 | ICM | A61F002-02 |
| | ICS | A61F002-28 |
| WO 2001032101 | ECLA | A61L024/04+C08L71/02; A61L024/04M+C08L71/02 <-- |
| US 2003095945 | NCL | 424/078.380 |
| | ECLA | A61L024/04+C08L71/02; A61L024/04M+C08L71/02 <-- |
| AB | A method for controlling bleeding from bones, comprises the use of copolymers of oxyethylene and oxypropylene or mixts. to cover the bleeding portions of bones. The copolymers are resorbable by the body, not metabolized, simple to prepare, inexpensive, readily available, and do not interfere with the fusion, osteogenesis, and related tissue healing and repair of the affected bones. | |
| ST | bone hemostasis polyoxyalkylene | |
| IT | Bone morphogenetic proteins RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (1; bone hemostasis with polyoxyethylene-polyoxypropylene block copolymer) | |
| IT | Analgesics Antibiotics Antitumor agents Blood coagulation Bone Hemostatics (bone hemostasis with polyoxyethylene-polyoxypropylene block copolymer) | |
| IT | Polyoxyalkylenes, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bone hemostasis with polyoxyethylene-polyoxypropylene block copolymer) | |
| IT | Bone morphogenetic proteins RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bone morphogenetic protein 2; bone hemostasis with polyoxyethylene-polyoxypropylene block copolymer) | |
| IT | Growth factors, animal RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bone; bone hemostasis with polyoxyethylene-polyoxypropylene block copolymer) | |
| IT | Transforming growth factors RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (β -; bone hemostasis with polyoxyethylene-polyoxypropylene block copolymer) | |
| IT | 106392-12-5, Polyoxyethylene-polyoxypropylene block copolymer RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bone hemostasis with polyoxyethylene-polyoxypropylene block copolymer) | |
| IT | 60-54-8D, Tetracycline, derivs. 69-72-7D, Salicylic acid, derivs. 103-90-2, Acetaminophen 154-93-8, Carmustine 1406-05-9, Penicillin 7414-83-7, Etidronatedisodium 9007-12-9, Calcitonin 11111-12-9, Cephalosporin 13721-01-2D, derivs. 57248-88-1, Pamidronate disodium 82640-04-8, Raloxifene hydrochloride 115436-72-1, Risedronate sodium RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bone hemostasis with polyoxyethylene-polyoxypropylene block copolymer) | |

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Tjia; US 5520923 A 1996

IT 103-90-2, Acetaminophen
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (bone hemostasis with polyoxyethylene-polyoxypropylene block
 copolymer)
 RN 103-90-2 HCAPLUS
 CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L70 ANSWER 16 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:227759 HCAPLUS
 DN 132:262128
 ED Entered STN: 07 Apr 2000
 TI Short peptides which selectively modulate the activity of protein kinases
 IN Ben-Sasson, Shmuel A.
 PA The Children's Medical Center Corporation, USA; Yisum Research
 Development Company of the Hebrew University of Jerusalem
 SO PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12N009-12
 ICS G01N033-68; A61K038-45; A61P035-00; A61P037-00
 CC 7-3 (Enzymes)
 FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|--------------|-----------------|--------------|
| WO 2000018895 | A1 | 20000406 | WO 1999-US22106 | 19990924 <-- |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2343934 | AA | 20000406 | CA 1999-2343934 | 19990924 <-- |
| AU 9960590 | A1 | 20000417 | AU 1999-60590 | 19990924 <-- |
| EP 1115847 | A1 | 20010718 | EP 1999-969737 | 19990924 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2002525382 | T2 | 20020813 | JP 2000-572342 | 19990924 <-- |
| US 2002160478 | A1 | 20021031 | US 2002-38612 | 20020108 <-- |
| US 6723830 | B2 | 20040420 | | |
| PRAI US 1998-161094 | A | 19980925 <-- | | |
| WO 1999-US22106 | W | 19990924 <-- | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|--|
| WO 2000018895 | ICM | C12N009-12 |
| | ICS | G01N033-68; A61K038-45; A61P035-00; A61P037-00 |
| WO 2000018895 | ECLA | C12N009/12B1 <-- |
| US 2002160478 | NCL | 530/317.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000 |
| | ECLA | C12N009/12B1 <-- |

OS MARPAT 132:262128
 AB Peptides which are peptide derivs. of the α D region of a protein kinase can modulate the activity of protein kinases. For example, the

peptide derivs. of the α D region of Jak3 inhibit the proliferation of human endothelial cells and the human prostate cancer cell line PC3 in vitro at concns. as low as 0.3 μ M. Thus, the activity of a protein kinase in a subject can be modulated by administering one or more of these peptides. Also disclosed are methods of identifying a peptide derivative of an α D region of a protein kinase that modulates the activity of the protein kinase.

ST protein kinase inhibition peptide alphaD region

IT Proliferation inhibition

(short peptides which selectively modulate the activity of protein kinases)

IT Peptides, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(short peptides which selectively modulate the activity of protein kinases)

IT Antibodies

RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation); PROC (Process)

(short peptides which selectively modulate the activity of protein kinases)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 263140-37-0 | 263140-38-1 | 263140-39-2 | 263140-40-5 | 263140-41-6 |
| | 263140-42-7 | 263140-43-8 | 263140-44-9 | 263140-45-0 | 263140-46-1 |
| | 263140-47-2 | 263140-48-3 | 263140-49-4 | 263140-50-7 | 263140-51-8 |
| | 263140-52-9 | 263140-53-0 | 263140-54-1 | 263140-55-2 | 263140-56-3 |
| | 263140-57-4 | 263140-58-5 | 263140-59-6 | 263140-60-9 | 263140-61-0 |
| | 263140-62-1 | 263140-63-2 | 263140-64-3 | 263140-65-4 | 263140-66-5 |
| | 263140-67-6 | 263140-68-7 | 263140-69-8 | 263140-70-1 | 263140-71-2 |
| | 263140-72-3 | 263140-73-4 | 263140-74-5 | 263140-75-6 | 263140-76-7 |
| | 263140-77-8 | 263140-78-9 | 263140-79-0 | 263140-80-3 | 263140-81-4 |
| | 263140-82-5 | 263140-83-6 | 263140-84-7 | 263140-85-8 | 263140-86-9 |
| | 263140-87-0 | 263140-88-1 | 263140-89-2 | 263140-90-5 | 263140-91-6 |
| | 263140-92-7 | 263140-93-8 | 263140-94-9 | 263140-95-0 | 263140-96-1 |
| | 263140-97-2 | 263140-98-3 | 263140-99-4 | 263141-00-0 | 263141-01-1 |
| | 263141-02-2 | 263141-03-3 | 263141-04-4 | 263141-05-5 | 263141-06-6 |
| | 263141-07-7 | 263141-08-8 | 263141-09-9 | 263141-10-2 | 263141-11-3 |
| | 263141-12-4 | | | | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(short peptides which selectively modulate the activity of protein kinases)

IT 9026-43-1, Protein kinase 54004-64-7, Protein kinase GRK1 88201-45-0, Insulin receptor kinase 114051-78-4 125149-26-0, Fibroblast growth factor receptor kinase 127407-08-3, G Protein-coupled receptor kinase 136396-12-8, Platelet-derived growth factor receptor β -kinase 137632-06-5, Csk protein kinase 140208-17-9, Gene lyn protein kinase 141349-87-3, Gene fyn protein kinase 141349-89-5 141349-91-9, Gene c-yes protein kinase 141350-03-0 142539-66-0, Activin receptor kinase 144638-77-7, Protein kinase Flt-4 144697-17-6, Gene c-src protein kinase 144941-32-2, Fgr kinase 145539-86-2, Gene hck protein kinase 146702-86-5, Transforming growth factor β receptor II kinase 147171-37-7, Protein kinase β ARK2 147302-47-4, TrkC receptor tyrosine kinase 148047-26-1, Flg receptor tyrosine kinase 148047-29-4, Gene tek protein kinase 149146-03-2, Fibroblast growth factor receptor 3 tyrosine kinase 149146-91-8, TrkB receptor tyrosine kinase 149146-92-9, Trk kinase 149371-16-4, Protein kinase β ARK1 150027-21-7, Blood platelet-derived growth factor α -receptor tyrosine kinase 150316-06-6, Bek receptor kinase 150428-23-2, Cyclin-dependent protein kinase 150977-45-0, Protein kinase Flk-1 152166-53-5, Neurotrophin receptor kinase 152478-56-3, Jak1 kinase 152478-57-4, Jak2 kinase 153190-60-4, Discoidin domain receptor 2 kinase 153190-61-5, Tyk2 kinase 153570-69-5, Fibroblast growth factor receptor 4 tyrosine kinase 153700-57-3, Protein kinase GRK5 157482-36-5, Jak3 kinase 158129-99-8, Protein kinase GRK6 159606-08-3, I κ B Kinase 161052-08-0, Gene Tie protein kinase 161384-16-3, Jak kinase

162032-63-5, Discoidin domain receptor tyrosine kinase 162032-63-5,
Discoidin domain receptor 1 kinase 163441-58-5, Matk protein kinase
173585-04-1, Integrin-linked kinase 175449-81-7, Protein kinase GRK4
179241-73-7, Gene ALK1 protein kinase 181429-78-7, Protein kinase ALK-3
186709-18-2, ALK-5 protein kinase 195329-51-2, Activin receptor-like
kinase 6 213763-56-5, Activin type II receptor kinase 249617-19-4,
Activin-like kinase 2 263554-71-8, Activin type IIa receptor kinase
263554-79-6

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)

(short peptides which selectively modulate the activity of protein
kinases)

| | | | | | |
|----|-------------|-------------|-------------|-------------|-------------|
| IT | 263139-57-7 | 263139-58-8 | 263139-59-9 | 263139-60-2 | 263139-61-3 |
| | 263139-62-4 | 263139-63-5 | 263139-64-6 | 263139-65-7 | 263139-66-8 |
| | 263139-67-9 | 263139-68-0 | 263139-69-1 | 263139-70-4 | 263139-71-5 |
| | 263139-72-6 | 263139-73-7 | 263139-74-8 | 263139-75-9 | 263139-76-0 |
| | 263139-77-1 | 263139-78-2 | 263139-79-3 | 263139-80-6 | 263139-81-7 |
| | 263139-82-8 | 263139-83-9 | 263139-84-0 | 263139-85-1 | 263139-86-2 |
| | 263139-87-3 | 263139-88-4 | 263139-89-5 | 263139-90-8 | 263139-91-9 |
| | 263139-92-0 | 263139-93-1 | 263139-94-2 | 263139-95-3 | 263139-96-4 |
| | 263139-97-5 | 263139-98-6 | 263139-99-7 | 263140-00-7 | 263140-01-8 |
| | 263140-02-9 | 263140-03-0 | 263140-04-1 | 263140-05-2 | 263140-06-3 |
| | 263140-07-4 | 263140-08-5 | 263140-09-6 | 263140-10-9 | 263140-11-0 |
| | 263140-12-1 | 263140-13-2 | 263140-14-3 | 263140-15-4 | 263140-16-5 |
| | 263140-17-6 | 263140-18-7 | 263140-19-8 | 263140-20-1 | 263140-21-2 |
| | 263140-22-3 | 263140-23-4 | 263140-24-5 | 263140-25-6 | 263140-26-7 |
| | 263140-27-8 | 263140-28-9 | 263140-29-0 | 263140-30-3 | 263140-31-4 |
| | 263140-32-5 | 263140-33-6 | 263140-34-7 | 263140-35-8 | 263140-36-9 |
| | 263266-55-3 | 263266-58-6 | 263266-66-6 | 263267-50-1 | 263267-53-4 |
| | 263267-63-6 | 263267-90-9 | 263269-30-3 | 263271-13-2 | 263271-14-3 |
| | 263271-19-8 | 263271-21-2 | 263271-22-3 | 263271-23-4 | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); BIOL (Biological study)

(α D region peptide; short peptides which selectively modulate the
activity of protein kinases)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Kemp, B; WO 9725341 A 1997 HCAPLUS
- (2) Terrapin Tech Inc; WO 9832017 A 1998 HCAPLUS
- (3) Warner Lambert Co; WO 9407913 A 1994 HCAPLUS

IT 136396-12-8, Platelet-derived growth factor receptor β -kinase
146702-86-5, Transforming growth factor β receptor II kinase
150027-21-7, Blood platelet-derived growth factor α -receptor
tyrosine kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)

(short peptides which selectively modulate the activity of protein
kinases)

RN 136396-12-8 HCAPLUS

CN Kinase (phosphorylating), blood platelet-derived growth factor
 β -receptor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 146702-86-5 HCAPLUS

CN Kinase (phosphorylating), β -transforming growth factor type II
receptor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 150027-21-7 HCAPLUS

CN Kinase (phosphorylating), blood platelet-derived growth factor
 α -receptor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 17 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:202240 HCAPLUS

DN 132:329471
 ED Entered STN: 30 Mar 2000
 TI A protein-based therapeutic for human cytomegalovirus infection
 AU Jean, Francois; Thomas, Laurel; Molloy, Sean S.; Liu, Gseping; Jarvis, Michael A.; Nelson, Jay A.; Thomas, Gary
 CS Vollum Institute, and Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Portland, OR, 97201, USA
 SO Proceedings of the National Academy of Sciences of the United States of America (2000), 97(6), 2864-2869
 CODEN: PNASA6; ISSN: 0027-8424
 PB National Academy of Sciences
 DT Journal
 LA English
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 10
 AB Current antiviral strategies target viral gene products. Although initially successful, their severe toxicity and susceptibility to circumvention by the generation of drug-resistant variants limit their usefulness. By contrast, the central role of the host cell serine endoprotease furin in the proteolytic activation of numerous pathogens points to the endoprotease as a strategic target for therapeutics. Herein, we show that the production of infectious human cytomegalovirus is dramatically reduced by exogenous addition of a bioengineered serpin, .alpha.1-PDX. This protein is a potent and selective furin inhibitor (Ki = 0.6 nM) and is 10-fold more effective than currently used antiherpetic agents in cell-culture models. The requirement of furin for the processing of envelope glycoproteins from many pathogenic viruses and for the activation of several bacterial toxins suggests that selective inhibitors of furin have potential as broad-based anti-pathogens.
 ST furin inhibitor alpha1 antitrypsin antipathogenic cytomegalovirus; antiviral CMV serpin alpha1PDX furin inhibitor
 IT Antiviral agents
 Cytomegalovirus
 (a protein-based therapeutic for human cytomegalovirus infection)
 IT Envelope proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (a protein-based therapeutic for human cytomegalovirus infection)
 IT 9001-92-7, Endoprotease 141760-45-4, Furin
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (a protein-based therapeutic for human cytomegalovirus infection)
 IT 9041-92-3
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (serpin; a protein-based therapeutic for human cytomegalovirus infection)
 RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Alford, C; The Human Herpesviruses 1993, P227
 (2) Anderson, E; J Biol Chem 1993, V268, P24887 HCAPLUS
 (3) Barker, A; Chest 1997, V112, P607 HCAPLUS
 (4) Britt, W; Intervirology 1996, V39, P401 HCAPLUS
 (5) Britt, W; J Virol 1992, V66, P6747 HCAPLUS
 (6) Condra, J; Haemophilia 1998, V4, P610 MEDLINE
 (7) Dahlen, J; J Biol Chem 1998, V273, P1851 HCAPLUS
 (8) Garten, W; Biochimie 1994, V76, P217 HCAPLUS
 (9) Gordon, V; Infect Immun 1994, V62, P333 HCAPLUS
 (10) Guo, H; Virology 1990, V174, P217 HCAPLUS
 (11) Hallenberger, S; Nature 1992, V360, P358 HCAPLUS
 (12) Hitt, M; Methods in Molecular Genetics 1995, V7, P13 HCAPLUS
 (13) Jean, F; Proc Natl Acad Sci USA 1998, V95, P7293 HCAPLUS
 (14) Klenk, H; Trends Microbiol 1994, V2, P39 MEDLINE

- (15) Lu, W; J Biol Chem 1993, V268, P14583 HCAPLUS
 (16) Molloy, S; EMBO J 1994, V13, P18 HCAPLUS
 (17) Molloy, S; Trends Cell Biol 1999, V9, P28 HCAPLUS
 (18) Moulard, M; Virus Res 1999, V60, P55 HCAPLUS
 (19) Nagai, Y; Virology 1976, V72, P494 HCAPLUS
 (20) Navarro, D; Virology 1993, V197, P143 HCAPLUS
 (21) Pereira, L; Infect Agents Dis 1994, V3, P9 HCAPLUS
 (22) Steiner, D; Curr Opin Chem Biol 1998, V2, P31 HCAPLUS
 (23) Steinhauer, D; Virology 1999, V258, P1 HCAPLUS
 (24) Subbarao, K; Science 1998, V279, P393 HCAPLUS
 (25) Swierkosz, E; Manual for Clinical Microbiology 1999, P1624
 (26) Van Rompaey, L; Biochem J 1997, V326, P507 HCAPLUS
 (27) van de Loo, J; J Biol Chem 1997, V272, P27116 HCAPLUS
 (28) Vey, M; Virology 1995, V206, P746 HCAPLUS
 (29) Vogelmeier, C; Am J Respir Crit Care Med 1997, V155, P536 MEDLINE
 (30) Volchkov, V; Proc Natl Acad Sci USA 1998, V95, P5762 HCAPLUS
 (31) Watanabe, M; J Virol 1995, V69, P3206 HCAPLUS
 (32) Wentworth, B; Proc Soc Exp Biol Med 1970, V135, P253 MEDLINE
 (33) Xiang, Y; Mol Biol Cell in press 2000

IT 141760-45-4, Furin

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(a protein-based therapeutic for human cytomegalovirus infection)

RN 141760-45-4 HCAPLUS

CN Furin (enzyme) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9041-92-3

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(serpin; a protein-based therapeutic for human cytomegalovirus infection)

RN 9041-92-3 HCAPLUS

CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 18 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:144772 HCAPLUS

DN 132:189689

ED Entered STN: 03 Mar 2000

TI Bioreductive conjugates for drug targeting

IN Adams, Ged; Blake, David; Naughton, Declan; Stratford, Ian

PA Theramark Limited, UK; Adams, Margaret

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K047-48

CC 1-12 (Pharmacology)

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|------|---------------|------|----------|--|--------------|--|
| PI | WO 2000010610 | A2 | 20000302 | WO 1999-GB2606 | 19990819 <-- | |
| | W: | | | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | |
| | RW: | | | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | |
| | AU 9954296 | A1 | 20000314 | AU 1999-54296 | 19990819 <-- | |
| PRAI | GB 1998-18027 | A | 19980819 | | <-- | |

GB 1998-18156 A 19980820 <--
 WO 1999-GB2606 W 19990819 <--

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|--|
| WO 2000010610 | ICM | A61K047-48 |
| WO 2000010610 | ECLA | A61K031/404; A61K031/407; A61K047/48H4 <-- |

OS MARPAT 132:189689

AB The use of a bioreductive conjugate comprised of a noncytotoxic bioreductive moiety having linked thereto at least one therapeutic agent, and salts thereof, is disclosed for the healing of wounds and the treatment of fibrotic disorders, ulcerative colitis, inflammatory bowel disease, epilepsy, cardiovascular reperfusion injury, cerebral reperfusion injury, hypertension, cystic fibrosis, psoriasis, para-psoriasis, peptic ulcers, gastric ulcers, duodenal ulcers, diabetic ulcers dementia, oncol., AIDS, rheumatoid arthritis, diabetes, and ischemia. Various specific conjugates for treating these conditions are also disclosed.

ST bioreductive conjugate drug targeting therapeutic

IT **Transforming growth factors**
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFβ 3; bioreductive conjugates for drug targeting)

IT DNA
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (alkylation; bioreductive conjugates for drug targeting)

IT Psoriasis
 (and para-psoriasis; bioreductive conjugates for drug targeting)

IT Mitosis
 (antimitotics; bioreductive conjugates for drug targeting)

IT Actins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (assembly and organization modulators; bioreductive conjugates for drug targeting)

IT Alkylation
 (biochem.; bioreductive conjugates for drug targeting)

IT Anti-AIDS agents
 Anti-inflammatory agents
 Anti-ischemic agents
 Anticoagulants
 Anticonvulsants
 Antidiabetic agents
 Antihypertensives
 Antirheumatic agents
 Antitumor agents
 Antiulcer agents
 Apoptosis
 Cardiovascular agents
 Cystic fibrosis
 Drug metabolism
 Drug targeting
 Fibrinolytics
 Fibrosis
 Hypoxia, animal
 Immunomodulators
 Immunosuppressants
 Platelet aggregation inhibitors
 Radical scavengers
 Vasodilators
 Wound healing promoters
 (bioreductive conjugates for drug targeting)

IT Interleukin 10
 Interleukin 4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (bioreductive conjugates for drug targeting)

IT Interleukin 1
 Platelet-derived growth factors
 Sex hormones
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (bioreductive conjugates for drug targeting)

IT Ion channel blockers
 (calcium; bioreductive conjugates for drug targeting)

IT Drugs
 (conjugates; bioreductive conjugates for drug targeting)

IT Corticosteroids, biological studies
 Steroids, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (conjugates; bioreductive conjugates for drug targeting)

IT Diabetes mellitus
 (diabetic ulcer; bioreductive conjugates for drug targeting)

IT Cell cycle
 (drugs specific for; bioreductive conjugates for drug targeting)

IT Intestine, disease
 (duodenum, ulcer; bioreductive conjugates for drug targeting)

IT Growth factors, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (growth factor neutralizing agents; bioreductive conjugates for drug targeting)

IT Intestine, disease
 (inflammatory; bioreductive conjugates for drug targeting)

IT Lung, neoplasm
 Lung, neoplasm
 (inhibitors, A549; bioreductive conjugates for drug targeting)

IT Interleukin 6
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; bioreductive conjugates for drug targeting)

IT Reperfusion
 (injury, including cerebral reperfusion injury; bioreductive conjugates for drug targeting)

IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (integrin receptor activation inhibitors; bioreductive conjugates for drug targeting)

IT Antitumor agents
 Antitumor agents
 (lung, A549; bioreductive conjugates for drug targeting)

IT Ulcer
 (peptic; bioreductive conjugates for drug targeting)

IT Stomach, disease
 (ulcer; bioreductive conjugates for drug targeting)

IT Intestine, disease
 (ulcerative colitis; bioreductive conjugates for drug targeting)

IT Proteins, general, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (wound site, growth factor-associated; bioreductive conjugates for drug targeting)

IT Adrenoceptor antagonists
 (β -; bioreductive conjugates for drug targeting)

IT Polysaccharides, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (β -glycans, soluble; bioreductive conjugates for drug targeting)

IT Transforming growth factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β 1-; bioreductive conjugates for drug targeting)

IT Transforming growth factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(β 2-; bioreductive conjugates for drug targeting)

IT Interferons
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (γ ; bioreductive conjugates for drug targeting)

IT 114560-25-7 114560-34-8, EO 8 161518-24-7, RB 94547J
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (bioreductive conjugates for drug targeting)

IT 50-06-6D, Phenobarbitone, conjugates, biological studies 50-24-8D, Prednisolone, conjugates 50-78-2D, Aspirin, conjugates 52-53-9D, Verapamil, conjugates 52-67-5D, Penicillamine, conjugates 53-86-1D, Indomethacin, conjugates 57-41-0D, Phenytoin, conjugates 58-32-2D, Dipyrindamole, conjugates 59-05-2D, Methotrexate, conjugates 66-97-7D, Psoralen, conjugates 89-57-6D, Mesalazine, conjugates 89-57-6D, 5-Aminosalicylic acid, derivs., conjugates 118-42-3D, Hydroxychloroquine, conjugates 305-03-3D, Chlorambucil, conjugates 443-48-1D, Metronidazole, conjugates 446-86-6D, Azathioprine, conjugates 599-79-1D, Sulfasalazine, conjugates 1069-66-5D, Sodium valproate, conjugates 1406-16-2D, Vitamin D, analogs, conjugates 6556-11-2D, Inositol nicotinate, conjugates 12244-57-4D, Myochrysine, conjugates 15307-86-5D, Diclofenac, conjugates 15687-27-1D, Ibuprofen, conjugates 21829-25-4D, Nifedipine, conjugates 22204-53-1D, Naproxen, conjugates 26171-23-3D, Tolmetin, conjugates 29679-58-1D, Fenoprofen, conjugates 38194-50-2D, Sulindac, conjugates 51234-28-7D, Benoxaprofen, conjugates 56180-94-0D, Acarbose, conjugates 59865-13-3D, Cyclosporin A, conjugates 62571-86-2D, Captopril, conjugates 67763-97-7D, Insulin-like growth factor II, conjugates 73590-58-6D, Omeprazole, conjugates 79217-60-0D, Cyclosporin, derivs., conjugates 87333-19-5D, Ramipril, conjugates 87679-37-6D, Trandolapril, conjugates 97240-79-4D, Topiramate, conjugates 103577-45-3D, Lansoprazole, conjugates 113194-81-3, TMK 209 117976-89-3D, Rabeprazole, conjugates 259876-40-9, TMK 210 259876-41-0, TMK 207
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (bioreductive conjugates for drug targeting)

IT 106096-92-8, Acidic fibroblast growth factor 106096-93-9, Basic fibroblast growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (bioreductive conjugates for drug targeting)

IT 9015-82-1, Angiotensin-converting enzyme 9025-82-5, Phosphodiesterase 9036-21-9, Phosphodiesterase IV 9055-65-6, Prostaglandin synthetase 9068-52-4, Phosphodiesterase V 81669-70-7, Metalloprotease 99676-46-7, Kexin 125978-95-2, Nitric oxide synthase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; bioreductive conjugates for drug targeting)

IT 57285-09-3, Inhibin 114949-22-3, Activin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stimulators; bioreductive conjugates for drug targeting)

IT 99676-46-7, Kexin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; bioreductive conjugates for drug targeting)

RN 99676-46-7 HCAPLUS
 CN Kexin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 19 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:659407 HCAPLUS
 DN 131:281544
 ED Entered STN: 15 Oct 1999
 TI Reagents and methods for inhibiting furin protease activity
 IN Jean, Francois; Thomas, Gary
 PA Oregon Health Sciences University, USA
 SO PCT Int. Appl., 109 pp.

CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07K005-11
 ICS C07K014-81; A61K038-07; A61K038-57
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 10

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|--------------|
| WO 9951624 | A1 | 19991014 | WO 1999-US7776 | 19990408 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2327814 | AA | 19991014 | CA 1999-2327814 | 19990408 <-- |
| AU 9934844 | A1 | 19991025 | AU 1999-34844 | 19990408 <-- |
| PRAI US 1998-81034P | P | 19980408 | <-- | |
| WO 1999-US7776 | W | 19990408 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|------------------------------------|
| WO 9951624 | ICM | C07K005-11 |
| | ICS | C07K014-81; A61K038-07; A61K038-57 |
| WO 9951624 | ECLA | C07K005/10B; C07K014/81B1B1 <-- |

AB This invention relates to methods and reagents for inhibiting furin endoprotease activity and specifically for inhibiting furin endoprotease-mediated maturation of bioactive proteins in vivo and in vitro. The invention specifically provides peptides, peptide analogs, peptide derivs. and peptido-, organo- and chemical mimetics of said peptide inhibitors of furin endoprotease activity. Methods for using furin endoprotease inhibition to attenuate or prevent viral protein maturation, and thereby alleviate viral infections, are provided. Also provided are methods for using furin endoprotease inhibition to attenuate or prevent proteolytic processing of bacterial toxins, thereby alleviating bacterial infections methods are also provided to inhibit proteolytic processing biol. active proteins and peptides. The invention also provides pharmaceutically acceptable compns. of therapeutically effective amts. of furin endoprotease inhibitors.

ST furin endoprotease inhibitor bacterial viral infection

IT Glycoproteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(B, cytomegalovirus, maturation of, inhibition of; reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

IT Toxins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(anthrax, activation of, inhibition of; reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

IT Toxins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(bacterial, activation of, inhibition of; reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing)

to alleviating bacterial and viral infections)

IT Toxins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(diphtheria, activation of, inhibition of; reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

IT Toxins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(exotoxin A, Pseudomonas aeruginosa, activation of, inhibition of; reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

IT Antibacterial agents
Antiviral agents
Cytomegalovirus
(reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

IT 141760-45-4, Furin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

IT 246253-03-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ajoy, B; International Journal of Peptide and Protein Research 1995, V46(3/04), P228
- (2) Basak, E; International Journal of Peptide and Protein Research 1994, V44, P253
- (3) Hol; Angewandte Chemie Int Ed 1986, V25(9), P767
- (4) Jean, E; Biochemical Journal 1995, V307(3), P689
- (5) Jean, E; Journal of Biological Chemistry 1995, V270(33), P19225
- (6) Thomas, G; WO 9416073 A 1994 HCAPLUS
- (7) Weinstein, B; Chemistry and Biochemistry of Amino Acids Peptides and Proteins V7, P266

IT 141760-45-4, Furin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

RN 141760-45-4 HCAPLUS

CN Furin (enzyme) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 246253-03-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (reagents and methods for inhibiting furin protease activity to inhibit viral protein maturation and bacterial toxin processing to alleviating bacterial and viral infections)

RN 246253-03-2 HCAPLUS
 CN Peptide, (Arg-Xaa-Xaa-Arg) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 20 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:396712 HCAPLUS
 DN 131:225365
 ED Entered STN: 29 Jun 1999
 TI Design of a protein-based inhibitor for proprotein convertase furin: expression, purification and inhibition of furin substrates in vivo by an epitope-tag recombinant **serpin .alpha.1-PDX/hf**

AU Jean, Francois; Stella, Kori; Lipps, Craig J.; Hicks, James B.; Thomas, Gary
 CS Vollum Institute, Oregon Health Sciences University, Portland, OR, 97201, USA
 SO Peptides: Frontiers of Peptide Science, Proceedings of the American Peptide Symposium, 15th, Nashville, June 14-19, 1997 (1999), Meeting Date 1997, 690-691. Editor(s): Tam, James P.; Kaumaya, Pravin T. P. Publisher: Kluwer, Dordrecht, Neth.
 CODEN: 67UCAR
 DT Conference
 LA English
 CC 7-3 (Enzymes)
 Section cross-reference(s): 1

AB In addition to a large number of endogenous substrates, many pathogens require processing by furin to exert their virulence. Thus, the design of furin-specific inhibitors is an important area of research for the development of novel therapeutics. A furin -directed α 1-antitrypsin variant, α 1-PDX was previously shown to block the processing of several furin substrates including HIV-1 gp160 and measles virus F0. Here, a His- and FLAG-tagged α 1-PDX, α 1-PDX/hf, was constructed and expressed in bacteria in order to provide a means by which to purify rapidly an active recombinant serpin and follow the recombinant protein during purification. Slow tight-binding inhibition of furin by α 1-PDX/hf was demonstrated.

ST furin inhibitor recombinant serpin α 1PDXhf;
 proprotein convertase inhibitor recombinant serpin α 1PDXhf

IT **Antimicrobial agents**
 (design, purification, and inhibition of furin by an epitope-tag recombinant **serpin α 1 -PDX/hf**)

IT 9041-92-3DP, α 1-Antitrypsin, reactive site variant α 1-PDX, His- and FLAG-tagged
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (design, purification, and inhibition of furin by an epitope-tag recombinant **serpin α 1 -PDX/hf**)

IT 141760-45-4, Furin
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (design, purification, and inhibition of furin by an epitope-tag recombinant **serpin α 1**)

-PDX/hf)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anderson, E; J Biol Chem 1993, V268, P24887 HCAPLUS
- (2) Inocencio, N; J Biol Chem 1994, V269, P31831 HCAPLUS
- (3) Molloy, S; EMBO J 1994, V13, P18 HCAPLUS
- (4) Molloy, S; J Biol Chem 1992, V267, P16936
- (5) Steiner, D; J Biol Chem 1992, V267, P23435 HCAPLUS
- (6) Watanabe, M; J Virol 1995, V69, P3206 HCAPLUS

IT 9041-92-3DP, α 1-Antitrypsin, reactive site variant α 1-PDX, His- and FLAG-tagged

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (design, purification, and inhibition of furin by an epitope-tag recombinant serpin α 1 -PDX/hf)

RN 9041-92-3 HCAPLUS

CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 141760-45-4, Furin

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (design, purification, and inhibition of furin by an epitope-tag recombinant serpin α 1 -PDX/hf)

RN 141760-45-4 HCAPLUS

CN Furin (enzyme) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 21 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:785606 HCAPLUS

DN 130:33011

ED Entered STN: 15 Dec 1998

TI P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor

IN Larsen, Glenn R.; Sako, Dianne S.; Chang, Xiao-jia; Veldman, Geertruida M.; Cumming, Dale; Kumar, Ravindra; Shaw, Gray

PA Genetics Institute, Inc., USA

SO U.S., 67 pp., Cont.-in-part of U.S. Ser. No. 316,305.

CODEN: USXXAM

DT Patent

LA English

IC ICM C12N015-12

ICS C12N015-85

INCL 435069100

CC 1-7 (Pharmacology)

Section cross-reference(s): 3, 6, 13, 15

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|--------------|
| PI | US 5843707 | A | 19981201 | US 1995-428734 | 19950425 <-- |
| | CA 2147623 | AA | 19940511 | CA 1993-2147623 | 19931022 <-- |
| | CA 2497857 | AA | 19940511 | CA 1993-2497857 | 19931022 <-- |
| | EP 1396542 | A2 | 20040310 | EP 2003-25430 | 19931022 <-- |
| | EP 1396542 | A3 | 20040506 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE | | | | |
| | US 5827817 | A | 19981027 | US 1995-477254 | 19950607 <-- |
| | US 5840679 | A | 19981124 | US 1995-472576 | 19950607 <-- |
| | US 6277975 | B1 | 20010821 | US 1996-713556 | 19960830 <-- |
| | US 2003018181 | A1 | 20030123 | US 2001-935144 | 20010821 <-- |
| | AU 770883 | B2 | 20040304 | AU 2001-89337 | 20011108 <-- |
| | JP 2004194664 | A2 | 20040715 | JP 2004-8944 | 20040116 <-- |

Search done by Noble Jarrell

| | | | | | |
|------|----|--------------|----|----------|-----|
| PRAI | US | 1992-965662 | B2 | 19921023 | <-- |
| | US | 1993-112608 | B2 | 19930826 | <-- |
| | US | 1994-235398 | B2 | 19940428 | <-- |
| | US | 1994-316305 | A2 | 19940930 | <-- |
| | CA | 1993-2147623 | A3 | 19931022 | <-- |
| | EP | 1994-900380 | A3 | 19931022 | <-- |
| | JP | 1994-511208 | A3 | 19931022 | <-- |
| | WO | 1993-US10168 | W | 19931022 | <-- |
| | US | 1995-428734 | A3 | 19950425 | <-- |
| | US | 1996-713556 | A1 | 19960830 | <-- |
| | AU | 1997-41492 | A3 | 19970829 | <-- |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|-------|--|
| US 5843707 | ICM | C12N015-12 |
| | ICS | C12N015-85 |
| | INCL | 435069100 |
| US 5843707 | NCL | 435/069.100; 435/252.300; 435/254.110; 435/320.100; 435/325.000; 435/358.000; 435/365.000; 536/023.500 |
| | ECLA | C07K014/47A1A; C07K014/705; C07K016/28C; C07K016/28C10; C07K019/00; C12N009/10; C12N009/10D1; C12N009/10D1A; C12N009/64F2C21C |
| EP 1396542 | ECLA | C07K014/47A1A; C07K016/28C10 |
| US 5827817 | NCL | 514/002.000; 435/069.100; 435/069.700; 514/012.000; 530/300.000; 530/326.000; 530/350.000; 530/395.000 |
| | ECLA | C07K014/47A1A; C07K014/705; C07K016/28C; C07K016/28C10; C07K019/00; C12N009/10; C12N009/10D1; C12N009/10D1A; C12N009/64F2C21C |
| US 5840679 | NCL | 514/002.000; 424/401.000; 514/844.000; 514/937.000; 514/944.000; 530/350.000; 530/351.000 |
| | ECLA | C07K014/47A1A; C07K014/705; C07K016/28C; C07K016/28C10; C07K019/00; C12N009/10; C12N009/10D1; C12N009/10D1A; C12N009/64F2C21C |
| US 6277975 | NCL | 536/023.400; 435/069.700; 530/350.000; 530/387.300; 530/395.000; 536/023.100; 536/023.500 |
| | ECLA | C07K014/47A1A; C07K014/705; C07K016/28C; C07K016/28C10; C07K019/00; C12N009/10; C12N009/10D1; C12N009/10D1A; C12N009/64F2C21C |
| US 2003018181 | NCL | 536/023.400; 530/324.000; 514/002.000 |
| | ECLA | C07K014/19; C07K014/47A1A; C07K014/51; C07K014/52; C07K014/54L; C07K014/705; C07K016/28C; C07K016/28C10; C07K019/00; C12N009/10; C12N009/10D1; C12N009/10D1A; C12N009/64F2C21C |
| JP 2004194664 | FTERM | 2G045/AA40; 2G045/BB03; 2G045/BB20; 2G045/CB01; 2G045/DA12; 2G045/DA13; 2G045/DA14; 2G045/DA36; 2G045/FB03; 4B024/AA01; 4B024/BA80; 4B024/CA04; 4B024/DA02; 4B024/DA06; 4B024/EA04; 4B024/GA11; 4B024/HA11; 4B064/AG01; 4B064/CA10; 4B064/CA19; 4B064/CC24; 4B064/DA01; 4B065/AA01X; 4B065/AA57X; 4B065/AA87X; 4B065/AA93Y; 4B065/AB01; 4B065/CA24; 4B065/CA25; 4B065/CA44; 4C084/AA02; 4C084/AA07; 4C084/BA01; 4C084/BA08; 4C084/BA22; 4C084/BA23; 4C084/CA18; 4C084/NA14; 4C084/ZA02; 4C084/ZA36; 4C084/ZA45; 4C084/ZA54; 4C084/ZA59; 4C084/ZA66; 4C084/ZA67; 4C084/ZA68; 4C084/ZA81; 4C084/ZA89; 4C084/ZA96; 4C084/ZB05; 4C084/ZB08; 4C084/ZB11; 4C084/ZB13; 4C084/ZB21; 4C084/ZB26; 4C084/ZC35; 4C084/ZC41; 4C085/AA14; 4C085/BB11; 4C085/CC23; 4C085/EE01 |

AB A novel P-selectin ligand glycoprotein and its amino acid sequence is disclosed. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compns. containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.

ST inflammation inhibitor P selectin glycoprotein ligand; human glycoprotein
PSGL cDNA sequence

IT Selectins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(E-, interaction; P-selectin glycoprotein ligand PSGL sequence and
expression and use as inflammation inhibitor)

IT Immunoglobulins
Immunoglobulins
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(G1, fusion products; P-selectin glycoprotein ligand PSGL sequence and
expression and use as inflammation inhibitor)

IT Anti-inflammatory agents
Molecular cloning
Mutation
(P-selectin glycoprotein ligand PSGL sequence and expression and use as
inflammation inhibitor)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU
(Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); PROC (Process); USES (Uses)
(P-selectin glycoprotein ligand PSGL sequence and expression and use as
inflammation inhibitor)

IT Antibodies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)
(P-selectin glycoprotein ligand PSGL sequence and expression and use as
inflammation inhibitor)

IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU
(Biological use, unclassified); PRP (Properties); THU (Therapeutic use);
BIOL (Biological study); PROC (Process); USES (Uses)
(PSGL-1 (P-selectin glycoprotein ligand-1); P-selectin glycoprotein
ligand PSGL sequence and expression and use as inflammation inhibitor)

IT Leukocyte
(adhesion, in inflammatory disorder; P-selectin glycoprotein ligand
PSGL sequence and expression and use as inflammation inhibitor)

IT cDNA sequences
(for P-selectin glycoprotein ligand PSGL from human)

IT Immunoglobulins
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(fusion products; P-selectin glycoprotein ligand PSGL sequence and
expression and use as inflammation inhibitor)

IT Cell adhesion
Inflammation
(leukocyte adhesion in; P-selectin glycoprotein ligand PSGL sequence
and expression and use as inflammation inhibitor)

IT Cell adhesion
(leukocyte, in inflammatory disorder; P-selectin glycoprotein ligand
PSGL sequence and expression and use as inflammation inhibitor)

IT Animal cell
(mammalian, transgenic; P-selectin glycoprotein ligand PSGL sequence
and expression and use as inflammation inhibitor)

IT Protein sequences
(of P-selectin glycoprotein ligand PSGL of human)

IT 152890-36-3P 157213-92-8P 157213-93-9P 157213-94-0P 157213-95-1P
RL: BPN (Biosynthetic preparation); PRP (Properties); PUR (Purification or
recovery); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(P-selectin glycoprotein ligand PSGL sequence and expression and use as
inflammation inhibitor)

IT 9054-49-3, N-Acetylglucosamine transferase 37277-69-3,
Fucosyltransferase, guanosine diphosphofucose-galactoside α 1-3(4)-
56626-18-7, Fucosyltransferase 141760-45-4, Paired

**basic amino acid cleaving
enzyme**

RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)

(P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 157214-00-1

RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 172418-10-9P 172450-60-1P 172452-81-2P 172452-82-3P

RL: BPN (Biosynthetic preparation); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence of; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 157214-02-3, DNA (human clone pacesol furin cDNA)

RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(amino acid sequence; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 188242-46-8 216664-53-8 216664-54-9 216664-58-3 216664-60-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(inhibition of P-selectin by; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 152281-21-5

RL: PRP (Properties)

(nucleotide sequence of; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 157214-01-2

RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(nucleotide sequence; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; WO 91/06632 1991
- (2) Anon; WO 92/01718 1992 HCAPLUS
- (3) Anon; WO 92/16612 1992 HCAPLUS
- (4) Anon; WO 92/19735 1992 HCAPLUS
- (5) Anon; WO 94/07917 1994 HCAPLUS
- (6) Anon; WO 94/10309 1994 HCAPLUS
- (7) Anon; WO 94/11498 1994 HCAPLUS
- (8) Aruffo; Cell 1991, V67, P35 HCAPLUS
- (9) Bierhuizen; Proc Nat'l Acad Sci USA 1992, V89, P9326 HCAPLUS
- (10) Johnston; Cell 1989, V56, P1033 HCAPLUS
- (11) Larkin; J Biol Chem 1992, V267, P13661 HCAPLUS
- (12) Larsen; J Biol Chem 1992, V267, P11104 HCAPLUS
- (13) Lasky; US 5304640 1994 HCAPLUS
- (14) Maemura; J Biol Chem 1992, V267(34), P24379 HCAPLUS
- (15) Moore; J Biol Chem 1994, V269(37), P23318 HCAPLUS
- (16) Moore; J Cell Biol 1992, V118, P445 HCAPLUS
- (17) Norgard; J Biol Chem 1993, V268, P12764 HCAPLUS
- (18) Picker; Cell 1991, V66, P921 HCAPLUS
- (19) Polley; PNAS USA 1991, V88, P6224 HCAPLUS
- (20) Sako; Cell 1993, V75, P1179 HCAPLUS
- (21) Steininger; Biochem & Biophys Res Comm 1992, V188(2), P760 HCAPLUS
- (22) Zhou; J Cell Biol 1991, V115, P557 HCAPLUS

IT 141760-45-4, Paired basic amino
acid cleaving enzyme

RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

RN 141760-45-4 HCAPLUS
CN Furin (enzyme) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 157214-02-3, DNA (human clone pacesol furin cDNA)
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(amino acid sequence; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

RN 157214-02-3 HCAPLUS
CN DNA (human clone pacesol furin cDNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 22 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:612193 HCAPLUS
DN 129:225725
ED Entered STN: 28 Sep 1998
TI Protease-resistant M-CSF-alpha mutant and its use as immunostimulant in disease therapy
IN Dwarki, Vavarani; Manning, William C.; Koths, Kirston E.
PA Chiron Corporation, USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N015-27
ICS C07K014-53; A61K048-00; A61K038-19
CC 1-7 (Pharmacology)
Section cross-reference(s): 3

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|--------------|
| WO 9839449 | A1 | 19980911 | WO 1998-US4802 | 19980304 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9864588 | A1 | 19980922 | AU 1998-64588 | 19980304 <-- |
| EP 973904 | A1 | 20000126 | EP 1998-910322 | 19980304 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2001517079 | T2 | 20011002 | JP 1998-538924 | 19980304 <-- |
| PRAI US 1997-38583P | P | 19970304 | <-- | |
| WO 1998-US4802 | W | 19980304 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|---|--|
| WO 9839449 | ICM | C12N015-27 |
| | ICS | C07K014-53; A61K048-00; A61K038-19 |
| WO 9839449 | ECLA | A61K038/19B; A61K038/19B+M; C07K014/53 <-- |
| AB | The invention is a method and composition for reducing a population of diseased cells by administration of a gene delivery vehicle capable of expressing an M-CSF α mutant having a decreased capacity to be proteolytically processed and released from a cell membrane. The invention is also a combination of therapeutic agents including gene delivery vehicles | |

expressing M-CSF α or an M-CSF α mutant in combination, for example, either with a soluble M-CSF, an M-CSF α convertase inhibitor, or a gene delivery vehicle expressing prodrug activator such as thymidine kinase followed by administration of the prodrug. Thus, glioma treatment by combination therapy is described. Irradiated glioblastoma cells are transfected with an adeno-associated virus vector encoding Δ 161-165-M-CSF and DNA encoding herpes simplex virus thymidine kinase. The cells are readministered to the patient and an M-CSF convertase inhibitor is injected at the tumor site several hours later. Soluble M-CSF is also administered at the tumor site. Treatment with M-CSF convertase inhibitor and soluble M-CSF is continued periodically and the patient is monitored by MRI. If tumor regression does not occur, ganciclovir may be administered.

- ST CSF1 mutant protease resistant immunostimulant
- IT Alphavirus
 - Retroviral vectors
 - Semliki Forest virus
 - Virus vectors
 - (M-CSF α mutant-encoding; protease-resistant M-CSF α mutant and its use as immunostimulant in disease therapy)
- IT cDNA sequences
 - (for human M-CSF α deletion mutant)
- IT Protein sequences
 - (of human M-CSF α deletion mutant)
- IT **Drug delivery systems**
 - (prodrugs, combination therapy with M-CSF α and; protease-resistant M-CSF α mutant and its use as immunostimulant in disease therapy)
- IT Antitumor agents
 - Immunostimulants
 - (protease-resistant M-CSF α mutant and its use as immunostimulant in disease therapy)
- IT Adeno-associated virus
 - Human adenovirus
 - Human herpesvirus
 - (vector, M-CSF α mutant-encoding; protease-resistant M-CSF α mutant and its use as immunostimulant in disease therapy)
- IT 99283-08-6P, Colony-stimulating factor 1 (human clone pcCSF-17 precursor protein moiety reduced) 212777-85-0P
 - RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (amino acid sequence; protease-resistant M-CSF α mutant and its use as immunostimulant in disease therapy)
- IT 7481-89-2, DdC 30516-87-1, AZT 59277-89-3, Acyclovir 69123-90-6, FIAC 69123-98-4, FIAU 82410-32-0, Ganciclovir
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (combination therapy with M-CSF α and; protease-resistant M-CSF α mutant and its use as immunostimulant in disease therapy)
- IT 9002-06-6, Thymidine kinase 9023-10-3, XMP pyrophosphorylase 9025-05-2, Cytosine deaminase
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (combination therapy with M-CSF α , prodrug and; protease-resistant M-CSF α mutant and its use as immunostimulant in disease therapy)
- IT 112245-02-0, RO 31-4724
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (convertase inhibitor, combination therapy with M-CSF α and; protease-resistant M-CSF α mutant and its use as immunostimulant in disease therapy)
- IT 99676-46-7, Kexin
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (inhibitor, combination therapy with M-CSF α and; protease-resistant M-CSF α mutant and its use as immunostimulant in disease therapy)
- IT 99283-13-3, DNA (human clone pcCSF-17 colony-stimulating factor 1 cDNA) 212777-83-8
 - RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological

study); USES (Uses)
(nucleotide sequence; protease-resistant M-CSF α mutant and its
use as immunostimulant in disease therapy)

IT 81627-83-0, M-CSF
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(protease-resistant M-CSF α mutant and its use as immunostimulant
in disease therapy)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Cetus Corporation; WO 8902746 A 1989 HCAPLUS
(2) Jadus, M; BLOOD 1996, V87(12), P5232 HCAPLUS
(3) Morita, T; BLOOD 1996, V88(3), P955 HCAPLUS
(4) Mullen, C; PHARMACOLOGY AND THERAPEUTICS 1994, V63(2), P199 MEDLINE
(5) Okada, H; GENE THERAPY 1996, V3(11), P957 HCAPLUS
(6) Ping, D; JOURNAL OF BIOLOGICAL CHEMISTRY 1996, V271(27), P16338
(7) The Regents Of The University Of California; WO 9804282 A 1998 HCAPLUS

IT 99676-46-7, Kexin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor, combination therapy with M-CSF α and;
protease-resistant M-CSF α mutant and its use as immunostimulant
in disease therapy)

RN 99676-46-7 HCAPLUS
CN Kexin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 23 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:404607 HCAPLUS
DN 129:170182
ED Entered STN: 02 Jul 1998
TI Alendronate blocks TGF- β 1 stimulated collagen 1 degradation
by human prostate PC-3 ML cells
AU Stearns, Mark E.
CS Department of Pathology, Allegheny University of the Health Sciences,
Philadelphia, PA, 19102-1192, USA
SO Clinical & Experimental Metastasis (1998), 16(4), 332-339
CODEN: CEXMD2; ISSN: 0262-0898
PB Lippincott-Raven Publishers
DT Journal
LA English
CC 1-6 (Pharmacology)
AB We have previously shown that alendronate can prevent human
PC-3 ML tumor cell metastasis to the bone (Wang and
Stearns, 1991, Differentiation, 48, 115-25). In this paper, ELISAs and
Western blots showed that TGF- β 1 stimulated the secretion of a 72 kDa
matrix metalloproteinase 2 (MMP-2) to enhance the solubilization of
radiolabeled collagen 1 by metastatic human prostate PC-
3 ML cells. A potent bisphosphonate compound, alendronate,
inhibited MMP-2 secretion to block solubilization of
collagen 1. Alendronate failed to inhibit MMP-2 activity
directly, but instead appeared to block cellular secretion of
MMP-2. Alendronate failed to inhibit secretion of tissue
inhibitor of metalloproteinase-2 (TIMP-2; the inhibitor
of MMP-2) and the decrease in collagen 1 solubilization observed may occur,
in part, from changes in the molar stoichiometry of TIMP-2 to MMP-2. We
conclude that alendronate may be a potent inhibitor of bone
resorption based on its ability to block MMP-2 secretion by
tumor cells.

ST alendronate prostate cancer bone metastasis proteinase
IT Animal cell line
(PC-3 ML; alendronate blocks TGF- β 1
stimulated collagen 1 degradation by human prostate PC-3
ML cells)

IT Antitumor agents
Antitumor agents
(bone, metastasis; alendronate blocks TGF- β 1 stimulated

- collagen 1 degradation by human prostate PC-3 ML cells)
- IT Bone, neoplasm
Bone, neoplasm
(metastasis, inhibitors; alendronate blocks
TGF- β 1 stimulated collagen 1 degradation by human prostate PC
-3 ML cells)
- IT Prostate gland
(neoplasm; alendronate blocks TGF- β 1 stimulated collagen
1 degradation by human prostate PC-3 ML cells)
- IT Bone
(resorption, inhibitors; alendronate blocks
TGF- β 1 stimulated collagen 1 degradation by human prostate PC
-3 ML cells)
- IT Collagens, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(type I; alendronate blocks TGF- β 1 stimulated collagen 1
degradation by human prostate PC-3 ML cells)
- IT Transforming growth factors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(β 1-; alendronate blocks TGF- β 1
stimulated collagen 1 degradation by human prostate PC-3
ML cells)
- IT 146480-35-5, Matrix metalloproteinase 2
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); BIOL (Biological study);
PROC (Process)
(alendronate blocks TGF- β 1 stimulated collagen 1 degradation
by human prostate PC-3 ML cells)
- IT 66376-36-1, Alendronate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(alendronate blocks TGF- β 1 stimulated collagen 1 degradation
by human prostate PC-3 ML cells)
- IT 124861-55-8, TIMP-2 proteinase inhibitor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(alendronate blocks TGF- β 1 stimulated collagen 1 degradation
by human prostate PC-3 ML cells)

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Attardo-Parrinello, G; Arch Intern Med 1987, V147, P1629 MEDLINE
- (2) Averbuch, S; Cancer 1992, V72, P3443
- (3) Baron, R; Acta Orthop Scand 1995, V266, P66 MEDLINE
- (4) Berrettoni, B; J Bone Joint Surg 1986, V68, P308 MEDLINE
- (5) Bradford, M; Anal Biochem 1976, V72, P248 HCAPLUS
- (6) Canfield, R; J Clin Endocr Metab 1977, V44, P96 MEDLINE
- (7) Carano, A; J Clin Invest 1990, V85, P456 HCAPLUS
- (8) Chambers, T; J Cell Physiol 1987, V132, P441
- (9) Clarke, N; Br J Urol 1992, V69, P64 MEDLINE
- (10) Cleton, F; Bisphosphonates and tumor osteolysis Rec Progr Cancer Res 1989,
V116, P73 MEDLINE
- (11) Denhardt, D; Pharmac Ther 1993, V59, P329 HCAPLUS
- (12) D'Errico, A; Mod Pathol 1991, V4, P239 MEDLINE
- (13) Elomaa, I; Biomed Pharmacother 1988, V42, P111 MEDLINE
- (14) Elte, J; Eur J Cancer Clin Oncol 1986, V22, P493 MEDLINE
- (15) Everts, V; Cell Physiol 1992, V150, P221 HCAPLUS
- (16) Fitton, A; Drugs 1991, V41, P289 HCAPLUS
- (17) Fleisch, H; Bone 1987, V8, P523
- (18) Frijlink, W; Lancet 1979, V1, P799 HCAPLUS
- (19) Guaitani, A; Bone Resorption, Metastasis, and Diphosphonates 1985, P51
- (20) Hall, D; J Bone Min Res 1994, V9, P221 HCAPLUS
- (21) Heath, J; Biochim Biophys Acta 1984, V802, P151 HCAPLUS
- (22) Hewitt, R; Int J Cancer 1991, V49, P666 HCAPLUS

Search done by Noble Jarrell

- (23) Hill, P; Biochem J 1995, V308, P167 HCAPLUS
- (24) Hughes, F; Lab Invest 1991, V64, P617 MEDLINE
- (25) Irimura, T; Int J Cancer 1987, V40, P24 MEDLINE
- (26) Jung, A; Cancer Res 1984, V44, P3007 HCAPLUS
- (27) Laemmli, U; Nature 1970, V227, P680 HCAPLUS
- (28) Levy, A; Cancer Res 1991, V51, P439 HCAPLUS
- (29) Lorenzo, J; Matrix 1992, V12, P282 HCAPLUS
- (30) Manishen, W; Am J Pathol 1986, V123, P39 MEDLINE
- (31) Martin, T; Clinical Endocrinology of Calcium Metabolism 1987, P171
- (32) Meikle, M; J Cell Sci 1992, V103, P1093 HCAPLUS
- (33) Merlini, G; Hematol Oncol 1990, V3, P23
- (34) Monteagudo, C; Am J Pathol 1990, V136, P585 MEDLINE
- (35) Morton, A; Br Med J V297, P772 MEDLINE
- (36) Murphy, G; Biochim Biophys Acta 1985, V831, P49 HCAPLUS
- (37) Nemoto, R; Cancer 1991, V67, P643 HCAPLUS
- (38) Otsuka, K; Eur J Biochem 1984, V145, P123 HCAPLUS
- (39) Rifas, L; J Clin Invest 1989, V84, P686 HCAPLUS
- (40) Rodan, G; J Clin Invest 1996, V97, P2692 HCAPLUS
- (41) Russel, R; Lancet 1974, V1, P894
- (42) Sanchez-Sweatman, P; Bone Metastasis Mechanisms and Pathophysiology 1996, P123
- (43) Shevrin, D; Prostate 1991, V19, P149 HCAPLUS
- (44) Shimizu, H; J Bone Miner Res 1990, V5, P411 MEDLINE
- (45) Smith, R; Lancet 1971, V1, P945 MEDLINE
- (46) Stearns, M; Cancer Res 1993, V53, P878 HCAPLUS
- (47) Stearns, M; Invas Metas 1996, V16, P116 HCAPLUS
- (48) Stearns, M; Oncol Res 1996, V8, P69 MEDLINE
- (49) Thiebaud, D; Eur J Cancer 1991, V27, P37 MEDLINE
- (50) Towbin, H; Proc Natl Acad Sci USA 1979, V76, P4350 HCAPLUS
- (51) van Holten-Verzantvoort, A; Lancet 1987, V11, P983
- (52) van der Stappen, J; Int J Cancer 1990, V45, P1071 MEDLINE
- (53) Wang, M; Differentiation 1991, V48, P115 MEDLINE
- (54) Wang, M; Oncol Res 1996, V8, P303 HCAPLUS

L70 ANSWER 24 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:299996 HCAPLUS

DN 127:13736

ED Entered STN: 12 May 1997

TI Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor- β 1 on programmed cell death through a p53- and IGF-independent mechanism

AU Rajah, Roopmanthy; Valentinis, Barbara; Cohen, Pinchas

CS Dep. Pediatrics, Univ. Pennsylvania, Philadelphia, PA, 19104, USA

SO Journal of Biological Chemistry (1997), 272(18), 12181-12188

CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

CC 2-10 (Mammalian Hormones)

AB Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) is thought to act by sequestering free IGFs or, possibly, act via a novel IGF-independent mechanism. Supporting its role as a primary growth inhibitor, IGFBP-3 production has been shown to be increased by cell growth-inhibitory agents, such as transforming growth factor- β (TGF- β), and the tumor suppressor gene p53. In this paper, we demonstrate, for the first time, a novel function of IGFBP-3 as an apoptosis-inducing agent and show that this action is mediated through an IGF-IGF receptor-independent pathway. In the p53 neg. prostate cancer cell line, PC-3, the addition of recombinant IGFBP-3 resulted in a dose-dependent induction of apoptosis. 125I-IGFBP-3 bound with high affinity to specific proteins in PC-3 cell lysates and plasma membrane preps. These membrane-associated mols. may serve as receptors that mediate the direct effect of IGFBP-3 on apoptosis. In addition, in an IGF receptor-neg. mouse fibroblast cell line, treatment with recombinant IGFBP-3 as well as transfection of the IGFBP-3 gene induced apoptosis, suggesting that neither IGFs nor IGF receptors are

required for this action. Furthermore, treatment with TGF- β 1, a known apoptosis-inducing agent, resulted in the induction of IGFBP-3 expression 6-12 h before the onset of apoptosis. This effect of TGF- β 1 was prevented by cotreatment with IGFBP-3-neutralizing antibodies or IGFBP-3-specific antisense thiolated oligonucleotides. These findings suggest that IGFBP-3 induces apoptosis through a novel pathway independent of either p53 or the IGF-IGF receptor-mediated cell survival pathway and that IGFBP-3 mediates TGF- β 1 induced apoptosis in PC-3 cells.

- ST IGFBP3 apoptosis TGF p53 IGF
 IT Apoptosis
 Cell membrane
 Cell proliferation
 Signal transduction, biological
 (IGF-BP-3 induces apoptosis and mediates TGF- β 1-induced apoptosis through p53- and IGF-independent mechanisms)
 IT p53 (protein)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (IGF-BP-3 induces apoptosis and mediates TGF- β 1-induced apoptosis through p53- and IGF-independent mechanisms)
 IT Insulin-like growth factor receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (IGF-BP-3 induces apoptosis and mediates TGF- β 1-induced apoptosis through p53- and IGF-independent mechanisms)
 IT Insulin-like growth factor-binding proteins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (IGF-BP-3; IGF-BP-3 induces apoptosis and mediates TGF- β 1-induced apoptosis through p53- and IGF-independent mechanisms)
 IT Prostate gland
 (neoplasm; IGF-BP-3 induces apoptosis and mediates TGF- β 1-induced apoptosis through p53- and IGF-independent mechanisms)
 IT Transforming growth factors
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (β 1-; IGF-BP-3 induces apoptosis and mediates TGF- β 1-induced apoptosis through p53- and IGF-independent mechanisms)
 IT 61912-98-9, Insulin-like growth factor
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (IGF-BP-3 induces apoptosis and mediates TGF- β 1-induced apoptosis through p53- and IGF-independent mechanisms)

RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adamo, M; Endocrinology 1992, V131, P1858 HCAPLUS
- (2) Angeloz-Nicoud, P; Endocrinology 1995, V136, P5485 HCAPLUS
- (3) Benito, A; Blood 1996, V87, P3837 HCAPLUS
- (4) Buckbinder, L; Nature 1995, V377, P646 HCAPLUS
- (5) Cohen, P; Acta Endocrinol 1991, V124(Suppl 2), P74
- (6) Cohen, P; Growth Regul 1993, V3, P23 HCAPLUS
- (7) Cohen, P; J Endocrinol 1994, V142, P407 HCAPLUS
- (8) Cohen, P; Mol Endocrinol 1993, V7, P380 HCAPLUS
- (9) Conover, C; Endocrinology 1991, V129, P3259 HCAPLUS
- (10) Conover, C; Endocrinology 1992, V130, P3191 HCAPLUS
- (11) Deckers, C; Exp Cell Res 1993, V208, P362 HCAPLUS
- (12) Estrov, Z; Blood 1995, V86, P4594 HCAPLUS
- (13) Figueroa, J; J Clin Endocrinol Metab 1995, V80, P3476 HCAPLUS
- (14) Friedlander, P; Mol Cell Biol 1996, V16, P4961 HCAPLUS
- (15) Giudice, L; J Clin Endocrinol Metab 1993, V76, P1115 HCAPLUS
- (16) Goldstein, S; Proc Natl Acad Sci U S A 1991, V88, P9680 HCAPLUS
- (17) Gucev, Z; Cancer Res 1996, V56, P1545 HCAPLUS
- (18) Homburg, C; Blood 1995, V85, P532 HCAPLUS
- (19) Huynh, H; J Biol Chem 1996, V271, P1016 HCAPLUS

- (20) Jones, J; Endocr Rev 1995, V16, P3 HCAPLUS
 (21) Kaicer, E; Growth Regul 1993, V3, P180 HCAPLUS
 (22) Klefstrom, J; EMBO J 1994, V13, P5442 HCAPLUS
 (23) Koopman, G; Blood 1994, V84, P1415 HCAPLUS
 (24) Koseki, T; FEBS Lett 1995, V376, P247 HCAPLUS
 (25) Ludwig, R; Mol Cell Biol 1996, V16, P4952 HCAPLUS
 (26) Martin, J; Endocrinology 1992, V131, P1568 HCAPLUS
 (27) Martin, J; Endocrinology 1992, V131, P1703 HCAPLUS
 (28) Moerman, E; Exp Gerontol 1993, V28, P361 HCAPLUS
 (29) Na, S; J Biol Chem 1996, V271, P11209 HCAPLUS
 (30) Oh, Y; J Biol Chem 1994, V268, P14964
 (31) Oh, Y; J Biol Chem 1995, V270, P13589 HCAPLUS
 (32) Peehl, D; World J Urol 1995, V13, P306 MEDLINE
 (33) Perkel, V; J Clin Endocrinol Metab 1990, V71, P533 HCAPLUS
 (34) Planchon, S; Cancer Res 1995, V55, P3706 HCAPLUS
 (35) Rajah, R; Endocrinology 1996, V137, P2676 HCAPLUS
 (36) Resnicoff, M; Cancer Res 1995, V55, P2463
 (37) Rocha, R; J Natl Cancer Inst 1996, V88, P601 HCAPLUS
 (38) Rorke, E; Exp Cell Res 1995, V216, P65 HCAPLUS
 (39) Rosenfeld, R; Acta Pediatrica Suppl 1994, V399, P154 MEDLINE
 (40) Sell, C; Cancer Res 1995, V55, P303 HCAPLUS
 (41) Sell, C; Proc Natl Acad Sci U S A 1993, V90, P11217 HCAPLUS
 (42) Selvakumaran, M; Oncogene 1994, V9, P1791 HCAPLUS
 (43) Stewart, C; J Biol Chem 1996, V271, P11330 HCAPLUS
 (44) Tewari, M; J Biol Chem 1995, V270, P18738 HCAPLUS
 (45) Tewari, M; J Biol Chem 1995, V270, P3255 HCAPLUS
 (46) Troy, C; Proc Natl Acad Sci U S A 1996, V93, P5635 HCAPLUS
 (47) Tsukada, T; Biochem Biophys Res Commun 1995, V210, P1076 HCAPLUS
 (48) Valentinis, B; Mol Endocrinol 1995, V9, P361 HCAPLUS
 (49) Velez-Yanguas, M; J Clin Endocrinol Metab 1996, V81, P93 HCAPLUS
 (50) Vermes, I; J Immunol Methods 1995, V184, P39 HCAPLUS
 (51) Werner, H; Proc Natl Acad Sci U S A 1996, V93, P8318 HCAPLUS
 (52) Yateman, M; J Endocrinol 1993, V137, P151 HCAPLUS

L70 ANSWER 25 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:220655 HCAPLUS

DN 126:208952

ED Entered STN: 05 Apr 1997

TI Prohormone convertase 7: a new prohormone convertase and its possible role in gp160 envelope glycoprotein processing

IN Seidah, Nabil G.; Day, Robert; Chretien, Michel

PA Institut De Recherches Cliniques De Montreal, Can.; Seidah, Nabil G.; Day, Robert; Chretien, Michel

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N015-57

ICS C12N009-64; C07K016-40; G01N033-573; C12N015-11; C12Q001-68; C12N005-10; C12P021-06; C07K014-16; A61K048-00

CC 7-2 (Enzymes)

Section cross-reference(s): 10, 13, 15

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|--|----------|-----------------|--------------|
| PI | WO 9705256 | A2 | 19970213 | WO 1996-CA520 | 19960802 <-- |
| | WO 9705256 | A3 | 19970313 | | |
| | W: | AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE | | | |
| | RW: | KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM | | | |
| | US 5840529 | A | 19981124 | US 1995-545562 | 19951019 <-- |
| | AU 9666089 | A1 | 19970226 | AU 1996-66089 | 19960802 <-- |
| | EP 842280 | A2 | 19980520 | EP 1996-925622 | 19960802 <-- |

Search done by Noble Jarrell

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

| | | | | | |
|------|----------------|----|----------|----------------|--------------|
| | JP 2000502242 | T2 | 20000229 | JP 1997-507056 | 19960802 <-- |
| PRAI | US 1995-510347 | A | 19950802 | <-- | |
| | US 1995-517015 | A | 19950818 | <-- | |
| | US 1995-545562 | A | 19951019 | <-- | |
| | WO 1996-CA520 | W | 19960802 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES | |
|------------|-------|---|-----|
| WO 9705256 | ICM | C12N015-57 | |
| | ICS | C12N009-64; C07K016-40; G01N033-573; C12N015-11; C12Q001-68; C12N005-10; C12P021-06; C07K014-16; A61K048-00 | |
| WO 9705256 | ECLA | C07K014/16D; C12N009/64F2C21C | <-- |
| US 5840529 | NCL | 435/069.100; 435/320.100; 435/325.000; 530/326.000; 530/328.000; 530/350.000; 536/023.200 | |
| | ECLA | C07K014/16D; C12N009/64F2C21C | <-- |

AB A seventh member of the subtilisin-kexin family isolated from rat, which has been named rPC7, is purified and characterized. The rat spleen cDNA has been totally sequenced. A shorter DNA sequence has been obtained for human, which corresponds to a portion of the catalytic region of a human pro-hormone convertase corresponding to the rat pro-hormone convertase. PC7 clearly distinguishes from the other mammalian members of the subtilisin-kexin family. Its tissue distribution is ubiquitous, but its presence is particularly remarkable in lymphoid tissues. It is present in LoVo cells that are able to cleave the HIV gp160 protein into active gp120 and gp41 proteins and that are deficient in other effective pro-hormone convertases known up to date. It is proposed that PC7 is a good candidate as a maturation enzyme responsible for the conversion of HIV gp 160 protein in target CD+4 cells. Therefore, silencing the expression of PC7 would lead to the inhibition of the activation of gp 160.

ST prohormone convertase 7 cDNA rat; gp160 processing prohormone convertase 7
IT Gene, animal

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(cDNA, for prohormone convertase 7 of rat and human; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

IT Nucleic acid hybridization

PCR (polymerase chain reaction)

(for detection of prohormone convertase 7 gene expression; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

IT Primers (nucleic acid)

Probes (nucleic acid)

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(for detection of prohormone convertase 7 gene expression; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

IT Antisense DNA

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(for inhibiting prohormone convertase 7 gene expression; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

IT cDNA sequences

(for prohormone convertase 7 of rat; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

IT Immunoassay

(for prohormone convertase 7; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

IT Envelope proteins

- RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(gp120env, formation from gp160 of; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT Envelope proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gp160env, processing of; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT Envelope proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(gp41env, formation from gp160 of; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT Human immunodeficiency virus
(inhibition of gp160 processing in treatment of infection by; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT AIDS (disease)
(inhibition of gp160 processing in treatment of; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT Liposomes
(nanocerythrosomes, for delivery of antisense DNA for prohormone convertases; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT Gene therapy
(of AIDS and Alzheimer's disease, inhibition of prohormone convertase 7 synthesis in; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT Protein sequences
(of prohormone convertase 7 of rat; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT Alzheimer's disease
(prohormone convertase 7 as diagnostic marker for; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT Antibodies
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(to prohormone convertase 7; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT 187737-14-0 187737-16-2
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence, prohormone convertase 7 peptide; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT 175960-77-7
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
(amino acid sequence; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT 141760-45-4, Furin
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(inhibition of synthesis of, in treatment of Alzheimer's disease; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)
- IT 99676-46-7P, Prohormone convertase

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)

(new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

IT 187951-86-6 187951-87-7

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nucleotide sequence; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

IT 187953-99-7 187954-00-3 187954-01-4 187954-02-5 187954-03-6 187954-04-7

RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(primer and probe for detection of prohormone convertase 7 gene expression; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

IT 141760-45-4, Furin

RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(inhibition of synthesis of, in treatment of Alzheimer's disease; new prohormone convertase isoenzyme 7 and its possible role in gp160 envelope glycoprotein processing)

RN 141760-45-4 HCAPLUS

CN Furin (enzyme) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 26 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:709850 HCAPLUS

DN 125:330629

ED Entered STN: 29 Nov 1996

TI Impact-resistant resin compositions with metallic luster and their moldings

IN Koizumi, Junji; Shichida, Hiroaki; Ito, Katsushi

PA Toyoda Gosei Kk, Japan

SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM C08L053-00

ICS C08L053-00; C08K003-00; C08K005-00; C08L023-16

CC 37-6 (Plastics Manufacture and Processing)

Section cross-reference(s): 38

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|--------------|
| PI | JP 08239549 | A2 | 19960917 | JP 1995-68796 | 19950301 <-- |
| | JP 3417128 | B2 | 20030616 | | |
| PRAI | JP 1995-68796 | | 19950301 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|-------------|-------|--|
| JP 08239549 | ICM | C08L053-00 |
| | ICS | C08L053-00; C08K003-00; C08K005-00; C08L023-16 |


AB Title compns. giving moldings having clear upper layers (thickness $\geq 20 \mu\text{m}$), useful for automobile bumpers, etc., comprise (A) 50-75 parts crystalline ethylene (I)-propylene (II) block copolymer (2-15% I, Rockwell hardness ≥ 85), (B) 25-50 parts I- α -olefin copolymers (80-95% I), (C) 0-30 phr inorg. fillers, and (D) 0.1-10 phr pigments. Thus, a composition comprising I-II block copolymer (4.4% I, Rockwell hardness 98), I-1-butene copolymer (85% I) 33, talc 10, carbon black 0.2, phthalocyanine blue 0.3, benzidine yellow 0.1, TiO₂ 0.2, powdered Al 1.0, and Mg stearate 0.5 part was molded into a plate, which had a 28- μm clear upper layer and showed Izod impact resistance 310 J/m and metallic luster.

- ST impact resistance polyolefin ethylene propylene copolymer; automotive bumper ethylene propylene copolymer polyolefin; metallic luster ethylene propylene copolymer compn
- IT Impact-resistant materials
(impact-resistant metallic-luster moldings containing ethylene-propylene block copolymer and ethylene α -olefin copolymers for automobile bumpers)
- IT Plastics, molded
RL: DEV (Device component use); PRP (Properties); USES (Uses)
(impact-resistant metallic-luster moldings containing ethylene-propylene block copolymer and ethylene α -olefin copolymers for automobile bumpers)
- IT Carbon black, properties
RL: DEV (Device component use); MOA (Modifier or additive use); PRP (Properties); USES (Uses)
(pigments; impact-resistant metallic-luster moldings containing ethylene-propylene block copolymer and ethylene α -olefin copolymers for automobile bumpers)
- IT Automobiles
(bumpers, impact-resistant metallic-luster moldings containing ethylene-propylene block copolymer and ethylene α -olefin copolymers for automobile bumpers)
- IT 14807-96-6, Talc, uses
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(fillers; impact-resistant metallic-luster moldings containing ethylene-propylene block copolymer and ethylene α -olefin copolymers for automobile bumpers)
- IT 9010-79-1, Ethylene-propylene copolymer 25087-34-7, 1-Butene-ethylene copolymer 26221-73-8, Ethylene-1-octene copolymer 106565-43-9, Ethylene-propylene block copolymer
RL: DEV (Device component use); POF (Polymer in formulation); PRP (Properties); USES (Uses)
(impact-resistant metallic-luster moldings containing ethylene-propylene block copolymer and ethylene α -olefin copolymers for automobile bumpers)
- IT 147-14-8, Phthalocyanine blue 6358-85-6, Benzidine yellow 7429-90-5, Aluminum, properties 13463-67-7, Titanium oxide, properties
RL: DEV (Device component use); MOA (Modifier or additive use); PRP (Properties); USES (Uses)
(pigments; impact-resistant metallic-luster moldings containing ethylene-propylene block copolymer and ethylene α -olefin copolymers for automobile bumpers)
- IT 6358-85-6, Benzidine yellow 13463-67-7, Titanium oxide, properties
RL: DEV (Device component use); MOA (Modifier or additive use); PRP (Properties); USES (Uses)
(pigments; impact-resistant metallic-luster moldings containing ethylene-propylene block copolymer and ethylene α -olefin copolymers for automobile bumpers)
- RN 6358-85-6 HCAPLUS
- CN Butanamide, 2,2'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 13463-67-7 HCAPLUS

CN Titanium oxide (TiO₂) (8CI, 9CI) (CA INDEX NAME)



L70 ANSWER 27 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:460684 HCAPLUS

DN 125:104639

ED Entered STN: 03 Aug 1996

TI Protection against peroxynitrite-dependent tyrosine nitration and .
alpha.1-antiproteinase inactivation by some
anti-inflammatory drugs and by the antibiotic tetracycline

AU Whiteman, Matthew; Kaur, Harparkash; Halliwell, Barry

CS Pharmacology Group, King's College London, London, SW3 6LX, UK

SO Annals of the Rheumatic Diseases (1996), 55(6), 383-387

CODEN: ARDIAO; ISSN: 0003-4967

PB BMJ Publishing Group

DT Journal

LA English

CC 1-7 (Pharmacology)

AB To examine in vitro the ability of several drugs to protect against deleterious effects of peroxynitrite, a cytotoxic agent formed by reaction of nitric oxide with superoxide radical, that may be generated in the rheumatoid joint and could cause joint damage. The ability of several drugs to protect against such possible toxic actions of peroxynitrite as inactivation of .alpha.1-antiproteinase and nitration of tyrosine was evaluated. Most non-steroidal anti-inflammatory drugs were moderately (indomethacin, diclofenac, naproxen, tolmetin) or only weakly (sulindac, ibuprofen, aurothioglucose, flurbiprofen, sulfasalazine, salicylate, penicillamine disulfide) effective in preventing tyrosine nitration and .alpha.1-antiproteinase inactivation by peroxynitrite, but 5-aminosalicylate and penicillamine were much more effective, as was the antibiotic tetracycline (but not ampicillin). Phenylbutazone and flufenamic acid protected effectively against tyrosine nitration, but could not be tested in the .alpha.1-antiproteinase system. The analgesic paracetamol was highly protective in both assay systems. Many drugs used in the treatment of rheumatoid arthritis are unlikely to act by scavenging peroxynitrite. The feasibility of peroxynitrite scavenging as a mechanism of penicillamine, 5-aminosalicylate, and paracetamol action in vivo is discussed.

ST peroxynitrite tyrosine alpha1 antiproteinase antiinflammatory tetracycline
IT Inflammation inhibitors

(antirheumatics, protection against peroxynitrite-dependent tyrosine nitration and alpha 1-

antiproteinase inactivation by some anti-inflammatory drugs and by the antibiotic tetracycline)

IT Inflammation inhibitors

(nonsteroidal, protection against peroxynitrite-dependent tyrosine nitration and alpha 1-

antiproteinase inactivation by some anti-inflammatory drugs and by the antibiotic tetracycline)

IT 19059-14-4, Peroxynitrite

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by some anti-inflammatory drugs and by the antibiotic tetracycline)


IT 60-54-8, Tetracycline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)


(protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by

- some anti-inflammatory drugs and by the antibiotic tetracycline)
- IT 50-33-9, Phenylbutazone, biological studies 53-86-1, Indomethacin
69-72-7, biological studies 89-57-6 103-90-2, Paracetamol
530-78-9, Flufenamic acid 599-79-1, Sulfasalazine 5104-49-4,
Flurbiprofen 12192-57-3, Aurothioglucose 15307-86-5, Diclofenac
15687-27-1, Ibuprofen 20902-45-8, Penicillamine disulfide 22204-53-1,
Naproxen 26171-23-3, Tolmetin 38194-50-2, Sulindac
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(protection against peroxynitrite-dependent tyrosine nitration and
 α 1-antiproteinase inactivation by
some anti-inflammatory drugs and by the antibiotic tetracycline)
- IT 60-18-4, Tyrosine, biological studies 9041-92-3, α
1-Antiproteinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(protection against peroxynitrite-dependent tyrosine nitration and
 α 1-antiproteinase inactivation by
some anti-inflammatory drugs and by the antibiotic tetracycline)
- IT 60-54-8, Tetracycline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(protection against peroxynitrite-dependent tyrosine nitration and
 α 1-antiproteinase inactivation by
some anti-inflammatory drugs and by the antibiotic tetracycline)
- RN 60-54-8 HCAPLUS
- CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



- IT 103-90-2, Paracetamol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(protection against peroxynitrite-dependent tyrosine nitration and
 α 1-antiproteinase inactivation by
some anti-inflammatory drugs and by the antibiotic tetracycline)
- RN 103-90-2 HCAPLUS
- CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



- IT 9041-92-3, α 1-Antiproteinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(protection against peroxynitrite-dependent tyrosine nitration and
 α 1-antiproteinase inactivation by

some anti-inflammatory drugs and by the antibiotic tetracycline)
 RN 9041-92-3 HCAPLUS
 CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 28 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1996:397354 HCAPLUS
 DN 125:67789
 ED Entered STN: 11 Jul 1996
 TI Method for the treatment of periodontal disease and a composition
 containing anti-inflammatories and polypeptide growth factors
 IN Aberg, A. K. Gunnar
 PA Sepracor Inc., USA
 SO PCT Int. Appl., 13 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61F002-00
 ICS A61K031-00
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 62

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|--------------|-----------------|--------------|
| PI | WO 9613226 | A1 | 19960509 | WO 1995-US13989 | 19951030 <-- |
| | W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9641375 | A1 | 19960523 | AU 1996-41375 | 19951030 <-- |
| PRAI | US 1994-332532 | A | 19941031 <-- | | |
| | WO 1995-US13989 | W | 19951030 <-- | | |

CLASS

| | PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|----|--|-------|------------------------------------|
| | WO 9613226 | ICM | A61F002-00 |
| | | ICS | A61K031-00 |
| AB | A method for the treatment of periodontitis and a pharmaceutical composition for use in the method are described. The method comprises administering to a mammal afflicted with periodontitis a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide growth factor and an NSAID to regenerate dental tissue in the mammal afflicted with periodontitis and, thereafter, administering to the mammal a therapeutically effective amount of an NSAID to prevent resorption of the newly regenerated dental tissue. The polypeptide growth factor is selected from the group consisting of PDGF, IGF-1, TGF- α , and CDGF and the NSAID is selected from the group consisting of acetaminophen, aspirin, and aryl propionic acids. The formulation can be in the form of toothpastes and mouthwashes. | | |
| ST | periodontitis polypeptide growth factor antiinflammatory dentifrice | | |
| IT | Dentifrices | | |
| | Mouthwashes | | |
| | (anti-inflammatories and polypeptide growth factors for treatment of periodontitis and for prevention of resorption of regenerated dental tissue) | | |
| IT | Inflammation inhibitors | | |
| | (nonsteroidal; anti-inflammatories and polypeptide growth factors for treatment of periodontitis and for prevention of resorption of regenerated dental tissue) | | |
| IT | Animal growth regulators | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | |
| | (blood platelet-derived growth | | |

factors, anti-inflammatories and polypeptide growth factors for treatment of periodontitis and for prevention of resorption of regenerated dental tissue)

IT Periodontium
(disease, periodontitis, anti-inflammatories and polypeptide growth factors for treatment of periodontitis and for prevention of resorption of regenerated dental tissue)


IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α -transforming growth factors, anti-inflammatories and polypeptide growth factors for treatment of periodontitis and for prevention of resorption of regenerated dental tissue)

IT 50-78-2, Aspirin 103-90-2, Acetaminophen 5104-49-4, Flurbiprofen 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 31793-07-4, Pirprofen 31842-01-0, Indoprofen 41340-25-4, Etodolac 52549-17-4, Pranoprofen 53716-49-7, Carprofen 62031-54-3, Cartilage-derived growth factor 67763-96-6, IGF-1 74103-06-3, Ketorolac 82821-47-4, Aminoprofen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatories and polypeptide growth factors for treatment of periodontitis and for prevention of resorption of regenerated dental tissue)

IT 103-90-2, Acetaminophen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatories and polypeptide growth factors for treatment of periodontitis and for prevention of resorption of regenerated dental tissue)

RN 103-90-2 HCAPLUS

CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L70 ANSWER 29 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:155643 HCAPLUS

DN 124:197110

ED Entered STN: 19 Mar 1996

TI Protein 7B2 as an inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases

IN Martens, Gerardus Julianus Maria

PA Stichting Katholieke Univ., Neth.

SO Neth. Appl., 35 pp.
CODEN: NAXXAN

DT Patent

LA Dutch

IC ICM A61K038-55
ICS C12N015-00; C07K014-81; A61K048-00

CC 7-3 (Enzymes)
Section cross-reference(s): 1, 3

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------|------|----------|-----------------|--------------|
| PI NL 9400032 | A | 19950801 | NL 1994-32 | 19940107 <-- |
| PRAI NL 1994-32 | | 19940107 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|---|
| NL 9400032 | ICM | A61K038-55 |
| | ICS | C12N015-00; C07K014-81; A61K048-00 |
| NL 9400032 | ECLA | A61K038/57; C07K014/47A13; C07K014/81B1 <-- |

AB Protein 7B2, previously found in the mammalian pituitary and the digestive

and reproductive tracts, is an inhibitor of prohormone convertase PC2, an enzyme which converts the prohormone forms of insulin, opiomelanocortin, enkephalin, and dynorphin. Protein 7B2 is therefore useful in treatment of various endocrine disorders. Variants of protein 7B2, in which the enzymic specificity is altered by changes in the amino acid sequence, can be used to treat viral infections by inhibiting the enzymic modification of viral proteins required for viral assembly, replication, etc. Thus, human 7B2 cDNA was cloned in prokaryotic expression vector pQE30, expressed in M15 cells, and the protein was purified by affinity chromatog. on an Ni²⁺-NTA-agarose column. This 27-kDa 7B2 protein specifically inhibited PC2 with $K_i = 2$ nM but did not inhibit PC1; 7B2 protein formed a complex with PC2 which coimmunoprecipitated with a monoclonal antibody to 7B2 and protein A-Sepharose.

- ST protein 7B2 inhibition prohormone convertase
; proteinase inhibitor protein 7B2; endocrine disorder treatment
protein 7B2; virucide protein 7B2
- IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(cDNA, protein 7B2, cloning and expression of; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)
- IT Protein sequences
(of protein 7B2 of human; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)
- IT Plasmid and Episome
(pQE30.h7B2, gene for human protein 7B2 on; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)
- IT Proteins, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(precursors, of virus, inhibition of processing of; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)
- IT Acquired immune deficiency syndrome
Molecular association
Virucides and Virustats
(protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)
- IT Animal growth regulators
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)
- IT Pituitary hormones
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(7B2, protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)
- IT Deoxyribonucleic acid sequences
(complementary, for protein 7B2 of human; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)
- IT Endocrine system
(disease, protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)
- IT Blood coagulation
(disorder, protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

IT **Therapeutics**
 (geno-, protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

IT Glycoproteins, specific or class
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (gp160env, precursors, of virus, inhibition of processing of; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

IT Virus, animal
 (human immunodeficiency, protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

IT 118606-90-9DP, Protein 7B2 (human clone λ H6/ λ H7 precursor reduced), amino acid-substituted variants 174179-29-4DP, amino acid-substituted variants 174179-30-7DP, amino acid-substituted variants 174179-31-8DP, amino acid-substituted variants
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

IT 141760-45-4, Furin (enzyme)
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor, protein 7B2 variant as; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

IT 140274-16-4P
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (nucleotide sequence; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

IT 99676-46-7P, Prohormone convertase PC2
 RL: BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
 (protein 7B2 as inhibitor; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

IT 37205-61-1, Proteinase inhibitor
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (protein 7B2 as; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

IT 141760-45-4, Furin (enzyme)
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor, protein 7B2 variant as; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

RN 141760-45-4 HCAPLUS
 CN Furin (enzyme) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 99676-46-7P, Prohormone convertase PC2
 RL: BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
 (protein 7B2 as inhibitor; protein 7B2 as inhibitor of processing proteinases and variants and fragments for treatment of endocrine and viral diseases)

RN 99676-46-7 HCAPLUS

CN Kexin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 30 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:34652 HCAPLUS

DN 124:76521

ED Entered STN: 18 Jan 1996

TI P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor

IN Larsen, Glenn R.; Sako, Dianne S.; Chang, Xiao-Jia; Veldman, Geertruida M.; Cumming, Dale; Kumar, Ravindra; Shaw, Gray D.

PA Genetics Institute, Inc., USA

SO PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N015-12

ICS C12N009-64; C12N015-62; C07K014-705; C12N015-64; C07K014-68;
C12N015-57; A61K038-17; C12N009-10

CC 1-7 (Pharmacology)

Section cross-reference(s): 3, 6, 13, 15

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|--------------|
| PI | WO 9530001 | A2 | 19951109 | WO 1995-US4968 | 19950424 <-- |
| | WO 9530001 | A3 | 19960111 | | |
| | W: AU, CA, JP, MX | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | AU 9523613 | A1 | 19951129 | AU 1995-23613 | 19950424 <-- |
| | AU 770883 | B2 | 20040304 | AU 2001-89337 | 20011108 <-- |
| PRAI | US 1994-235398 | A | 19940428 | <-- | |
| | US 1994-316305 | A | 19940930 | <-- | |
| | WO 1995-US4968 | W | 19950424 | <-- | |
| | AU 1997-41492 | A3 | 19970829 | <-- | |

CLASS

| | PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|----|--|-------|--|
| | WO 9530001 | ICM | C12N015-12 |
| | | ICS | C12N009-64; C12N015-62; C07K014-705; C12N015-64; C07K014-68; C12N015-57; A61K038-17; C12N009-10 |
| | WO 9530001 | ECLA | C07K014/705; C12N009/10D1A; C12N009/10D1 <-- |
| AB | A novel P-selectin ligand glycoprotein and its amino acid sequence is disclosed. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compns. containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed. | | |
| ST | inflammation inhibitor P selectin glycoprotein ligand; human glycoprotein PSGL cDNA sequence | | |
| IT | Deoxyribonucleic acid sequences Genetic vectors Inflammation inhibitors Mutation Protein sequences (P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor) | | |
| IT | Gene, animal RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor) | | |
| IT | Antibodies RL: BUU (Biological use, unclassified); BIOL (Biological study); USES | | |

Search done by Noble Jarrell

(Uses)
(P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT Leukocyte
(adhesion in inflammatory disorder; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT Glycophosphoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E-selectins, P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(P-selectins, P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT Adhesion
(bio-, of leukocyte in inflammatory disorder; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 152890-36-3P 157213-92-8P 157213-93-9P 157213-94-0P 157213-95-1P
RL: BPN (Biosynthetic preparation); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 9054-49-3, N-Acetylglucosamine transferase 37277-69-3, Fucosyltransferase, guanosine diphosphofucose-galactoside α 1-3(4)-56626-18-7, Fucosyltransferase 141760-45-4, Paired basic amino acid cleaving enzyme
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 157214-00-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 172418-09-6P 172418-10-9P 172418-11-0P 172450-60-1P 172452-81-2P 172452-82-3P
RL: BPN (Biosynthetic preparation); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence of; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 152281-21-5
RL: PRP (Properties)
(nucleotide sequence of; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 60-18-4, Tyrosine, biological studies 21820-51-9, Phosphotyrosine
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(position 46, 48, or 51; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 74-79-3, L-Arginine, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(position 65, or 111, or 292; P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

IT 141760-45-4, Paired basic amino acid cleaving enzyme
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process);

USES (Uses)

(P-selectin glycoprotein ligand PSGL sequence and expression and use as inflammation inhibitor)

RN 141760-45-4 HCAPLUS

CN Furin (enzyme) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 31 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:502187 HCAPLUS

DN 122:255627

ED Entered STN: 21 Apr 1995

TI Engineered serine protease inhibitor prevents furin
-catalyzed activation of the fusion glycoprotein and production of
infectious measles virus

AU Watanabe, Michiko; Hirano, Akiko; Stenglein, Stephen; Nelson, Jay; Thomas,
Gary; Wong, Timothy C.

CS Department of Microbiology, University of Washington School of Medicine,
Seattle, WA, 98195, USA

SO Journal of Virology (1995), 69(5), 3206-10

CODEN: JOVIAM; ISSN: 0022-538X

PB American Society for Microbiology

DT Journal

LA English

CC 1-5 (Pharmacology)

Section cross-reference(s): 10

AB We have identified the major cellular endoprotease that activates the
fusion (F) glycoprotein of measles virus (MV) and have engineered a serine
protease inhibitor (serpin) to target the endoprotease and
inhibit the production of infectious MV. The F-protein precursor of
MV was not cleaved efficiently into the mature F protein in human colon
carcinoma cells lacking functional furin, indicating that
furin is the major enzyme responsible for activation of the MV F
protein. A human serpin .alpha.1
-antitrypsin variant was engineered to specifically inhibit
furin. When expressed from a recombinant vaccinia virus in
primate cells infected by MV, the engineered serpin (.
alpha.1-PDX) specifically inhibited
furin-catalyzed cleavage of the F-protein precursor without
affecting synthesis of other MV proteins. We generated human glioma cells
stably expressing α 1-PDX. MV infection in these cells did not
result in syncytia. The infected cells produced all the MV proteins, but
the F-protein precursor remained largely uncleaved. This did not prevent
virus assembly. However, the released virions contained inactive
F-protein precursor rather than mature F protein, and infectious-virus
titers were reduced by 3 to 4 orders of magnitude. These results show
that a mature F protein is not required for the assembly of MV but is
crucial for virus infectivity. The engineered serpin may offer a novel
mol. antiviral approach against MV.

ST infectious measles virus endoprotease serpin; serine protease
inhibitor measles virus infectivity; fusion glycoprotein measles
virus infectivity serpin

IT Virucides and Virustats

(engineered serine protease inhibitor prevents furin
-catalyzed activation of fusion glycoprotein and production of infectious
measles virus)

IT Glycoproteins, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)

(engineered serine protease inhibitor prevents furin
-catalyzed activation of fusion glycoprotein and production of infectious
measles virus)

IT Virus, animal

(measles, engineered serine protease inhibitor prevents
furin-catalyzed activation of fusion glycoprotein and production of
infectious measles virus)

IT 141760-45-4, Furin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(engineered serine protease inhibitor prevents furin
-catalyzed activation of fusion glycoprotein and production of infectious measles virus)

IT 9001-92-7, Endoprotease
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(engineered serine protease inhibitor prevents furin
-catalyzed activation of fusion glycoprotein and production of infectious measles virus)

IT 9041-92-3, α 1-Antitrypsin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(serpin; engineered serine protease inhibitor
prevents furin-catalyzed activation of fusion glycoprotein
and production of infectious measles virus)

IT 141760-45-4, Furin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(engineered serine protease inhibitor prevents furin
-catalyzed activation of fusion glycoprotein and production of infectious measles virus)

RN 141760-45-4 HCAPLUS
CN Furin (enzyme) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9041-92-3, α 1-Antitrypsin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(serpin; engineered serine protease inhibitor
prevents furin-catalyzed activation of fusion glycoprotein
and production of infectious measles virus)

RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 32 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:373643 HCAPLUS
DN 122:158051
ED Entered STN: 24 Feb 1995
TI β -2 Microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor β 1 action
AU Rowley, David R.; Dang, Truong D.; McBride, Lauren; Gerdes, Michael J.; Lu, Bing; Larsen, Melinda
CS Dep. Cell Biology, Baylor College Medicine, Houston, TX, 77030, USA
SO Cancer Research (1995), 55(4), 781-6
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
CC 15-2 (Immunochemistry)
AB Previous studies have identified a Mr 12,000 protein in rat prostatic stromal cell-conditioned medium with growth stimulatory activity to human prostatic carcinoma cells as a direct match with β 2-microglobulin (β 2-m). The present study was conducted to characterize the activities of human β 2-m directly, using com. available, purified human β 2-m. β 2-M was assayed for growth stimulatory activity to human PC-3 prostatic carcinoma cells and rat PS-1 prostatic stromal cells and for antagonistic activity to transforming growth factor β 1 (TGF- β 1)-induced growth inhibitory actions. β 2-M acted to stimulate [3H]thymidine incorporation in PC-3 cells in a linear,

concentration-dependent and saturable manner in serum-free medium. β 2-M stimulated cell proliferation and significantly decreased population doubling times in both PC-3 and PS-1 cell lines. At half-maximal concns. of TGF- β 1 and lower, β 2-m acted in a concentration-dependent, antagonistic manner, acting to stimulate growth-inhibited PC-3 cells to fully neutralize TGF- β 1 activity. In contrast, cells exposed to maximum activity TGF- β 1 concns. were refractory to β 2-m action, regardless of the concentration tested. This represents the first report to demonstrate a growth-stimulatory activity of β 2-m with carcinoma/epithelial cells and to show β 2-m antagonistic activity to TGF- β 1 growth-induced inhibition. β 2-M has been shown previously to associate with hormone/growth factor receptors. Together, these data suggest that β 2-m may play a role in modulating cell proliferation, possibly through modification of ligand/receptor kinetics. Owing to the elevation of both β 2-m and TGF- β 1 in many dysplastic-neoplastic conditions, β 2-m may be relevant to mechanisms of abnormal proliferation disorders and in modulating TGF- β 1 mechanisms of actions.

ST microglobulin transforming growth factor prostate carcinoma

IT Cell proliferation

Mitogens

(β -2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor β 1 action)

IT Prostate gland

(neoplasm, carcinoma, β -2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor β 1 action)

IT Animal growth regulators

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(β 1-transforming growth factors, β -2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor β 1 action)

IT Microglobulins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(β 2-, β -2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor β 1 action)

L70 ANSWER 33 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:364301 HCAPLUS

DN 122:142669

ED Entered STN: 22 Feb 1995

TI Anti-fouling coatings on medical devices

IN Vachon, David

PA Siemens A.-G., Germany

SO Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM A61L027-00

CC 63-7 (Pharmaceuticals)

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------------------------------|------|----------|-----------------|--------------|
| PI | EP 633031 | A1 | 19950111 | EP 1994-304571 | 19940623 <-- |
| | R: CH, DE, DK, FR, GB, IT, LI, NL, SE | | | | |
| | AU 9464864 | A1 | 19950105 | AU 1994-64864 | 19940621 <-- |
| | JP 07024053 | A2 | 19950127 | JP 1994-163075 | 19940622 <-- |
| PRAI | US 1993-82219 | A | 19930624 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|--|
| EP 633031 | ICM | A61L027-00 |
| EP 633031 | ECLA | A61L027/34; A61L027/34+C08L89/00; A61L027/34+C08L71/02 |

AB A coating composition which inhibits the in vivo formation of scar tissue at the surface of a device comprises a biocompatible polymer and an extracellular matrix mol. or fragment thereof. The composition promotes the growth of viable tissue at the site of insertion of the device. For example, a photoderivatized PEG dissolved in water was mixed with an aqueous solution of arg-gly-asg peptide. A pace maker lead electrode was dipped into the above solution and irradiated in UV chamber and this procedure was repeated until the desired coating thickness was achieved.

ST prosthetic implant coating polymer extracellular matrix

IT Extracellular matrix
(anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

IT Collagens, biological studies
Fibronectins
Gelatin, biological studies
Laminins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

IT Laminins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2, anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

IT Proteoglycans, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aggrecans, anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(blood platelet-derived growth factors, anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

IT Prosthetic materials and Prosthetics
(implants, anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

IT Heart
(pacemaker, artificial, electrodes; anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

IT Glycoproteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tenascins, anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

IT Proteoglycans, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(versicans, anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)


IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitronectins, anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

IT 9002-84-0, Poly(tetrafluoroethylene) 9003-05-8 9003-39-8, PVP
25322-68-3 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 99896-85-2 141104-83-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-fouling coatings for implants containing biocompatible polymers and extracellular matrix components and growth factors)

L70 ANSWER 34 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:295611 HCAPLUS
 DN 122:96045
 ED Entered STN: 14 Jan 1995
 TI Promotion of oxidative damage to arachidonic acid and α 1-antiproteinase by anti-inflammatory drugs in the presence of the heme proteins myoglobin and cytochrome c
 AU Evans, Patricia J.; Akanmu, Dola; Halliwell, Barry
 CS Pharm. Group, Univ. London King's College, London, SW3 6LX, UK
 SO Biochemical Pharmacology (1994), 48(12), 2173-9
 CODEN: BCPA6; ISSN: 0006-2952
 PB Elsevier
 DT Journal
 LA English
 CC 1-7 (Pharmacology)
 AB A mixture of myoglobin and hydrogen peroxide (H2O2) causes peroxidn. of arachidonic acid. This peroxidn. is greatly accelerated by adding phenylbutazone, which is effective even in the absence of H2O2. A wide range of other drugs was examined for their ability to exert similar prooxidant effects. The authors found that meclofenamic acid and flufenamic acid stimulated myoglobin-dependent lipid peroxidn., but only in the presence of H2O2. Ascorbic acid inhibited peroxidn. both in the presence and in the absence of these drugs. Phenylbutazone, meclofenamic acid and flufenamic acid could also cause damage to proteins (as measured by inactivation of α 1-antiproteinase) in the presence of myoglobin and H2O2. The mitochondrial protein cytochrome c can also stimulate lipid peroxidn. in the presence of H2O2. Phenylbutazone and meclofenamic acid, but not flufenamic acid, enhanced the peroxidn., which was again inhibited by ascorbic acid. However, only phenylbutazone caused inactivation of α 1-antiproteinase in the presence of cytochrome c and H2O2. Since respiring mitochondria generate superoxide radicals and H2O2, catalysis of lipid peroxidn. and of the formation of drug-derived radicals by cytochrome c could be a mechanism contributing to mitochondrial damage by drugs.
 ST oxidative damage arachidonate antiproteinase antiinflammatory drug; lipid peroxidn antiinflammatory drug
 IT Peroxidation
 (of lipids; promotion of oxidative damage to arachidonic acid and α 1-antiproteinase by anti-inflammatory drugs in presence of heme proteins myoglobin and cytochrome c)
 IT Lipids, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (promoxidn. of; promotion of oxidative damage to arachidonic acid and α 1-antiproteinase by anti-inflammatory drugs in presence of heme proteins myoglobin and cytochrome c)
 IT Inflammation inhibitors
 Mitochondria
 Oxidative stress, biological
 (promotion of oxidative damage to arachidonic acid and α 1-antiproteinase by anti-inflammatory drugs in presence of heme proteins myoglobin and cytochrome c)
 IT Myoglobins
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (promotion of oxidative damage to arachidonic acid and α 1-antiproteinase by anti-inflammatory drugs in presence of heme proteins myoglobin and cytochrome c)
 IT Proteins, biological studies
 Radicals, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (promotion of oxidative damage to arachidonic acid and α

- 1-antiproteinase by anti-inflammatory drugs in presence of heme proteins myoglobin and cytochrome c)
- IT 50-24-8, Prednisolone 50-33-9, Phenylbutazone, biological studies
50-44-2, Mercaptopurine 50-78-2 52-67-5, D-Penicillamine 53-86-1,
Indomethacin 54-05-7, Chloroquine 59-05-2, Methotrexate 83-89-6,
Quinacrine 103-90-2, Paracetamol 118-42-3, Hydroxychloroquine
130-95-0, Quinine 446-86-6, Azothioprine 530-78-9, Flufenamic acid
599-79-1, Sulfasalazine 644-62-2, Meclofenamic acid 15307-86-5,
Diclofenac 20902-45-8, D-Penicillamine disulfide 22204-53-1, Naproxen
26171-23-3, Tolmetin 30516-87-1, 3'-Azido-3'-deoxythymidine
36322-90-4, Piroxicam
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(promotion of oxidative damage to arachidonic acid and α
1-antiproteinase by anti-inflammatory drugs in
presence of heme proteins myoglobin and cytochrome c)
- IT 9007-43-6, Cytochrome c, biological studies
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); BIOL (Biological study);
PROC (Process)
(promotion of oxidative damage to arachidonic acid and α
1-antiproteinase by anti-inflammatory drugs in
presence of heme proteins myoglobin and cytochrome c)
- IT 50-81-7, Ascorbic acid, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(promotion of oxidative damage to arachidonic acid and α
1-antiproteinase by anti-inflammatory drugs in
presence of heme proteins myoglobin and cytochrome c)
- IT 506-32-1, Arachidonic acid 9004-06-2, Elastase 9041-92-3,
 α 1-Antiproteinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(promotion of oxidative damage to arachidonic acid and α
1-antiproteinase by anti-inflammatory drugs in
presence of heme proteins myoglobin and cytochrome c)
- IT 103-90-2, Paracetamol
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(promotion of oxidative damage to arachidonic acid and α
1-antiproteinase by anti-inflammatory drugs in
presence of heme proteins myoglobin and cytochrome c)
- RN 103-90-2 HCAPLUS
CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



- IT 9041-92-3, α 1-Antiproteinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(promotion of oxidative damage to arachidonic acid and α
1-antiproteinase by anti-inflammatory drugs in
presence of heme proteins myoglobin and cytochrome c)
- RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 35 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:678159 HCAPLUS
DN 115:278159
ED Entered STN: 27 Dec 1991
TI Compositions for the inhibition of protein hormone formation and

uses thereof as therapeutics or prophylactics
 IN Kriegler, Michael; Perez, Carl
 PA Cetus Corp., USA
 SO Can. Pat. Appl., 41 pp.
 CODEN: CPXXEB
 DT Patent
 LA English
 IC ICM C12P021-08
 ICS C12N009-00; A61K039-395; A61K037-64; A61K037-48
 CC 16-2 (Fermentation and Bioindustrial Chemistry)
 Section cross-reference(s): 1
 FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | CA 2020700 | AA | 19910217 | CA 1990-2020700 | 19900709 |
| | WO 9102540 | A1 | 19910307 | WO 1990-US3266 | 19900608 |
| | W: AU, JP, NO | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE | | | | |
| | AU 9059400 | A1 | 19910403 | AU 1990-59400 | 19900608 |
| | EP 491878 | A1 | 19920701 | EP 1990-917939 | 19900608 |
| | EP 491878 | B1 | 19970219 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE | | | | |
| | JP 04507044 | T2 | 19921210 | JP 1990-509543 | 19900608 |
| | JP 2930713 | B2 | 19990803 | | |
| | EP 750037 | A2 | 19961227 | EP 1996-202206 | 19900608 |
| | EP 750037 | A3 | 19970115 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE | | | | |
| | AT 148992 | E | 19970315 | AT 1990-917939 | 19900608 |
| | ES 2097766 | T3 | 19970416 | ES 1990-917939 | 19900608 |
| | NO 9200593 | A | 19920319 | NO 1992-593 | 19920214 |
| | NO 304854 | B1 | 19990222 | | |
| | AU 9520474 | A1 | 19951019 | AU 1995-20474 | 19950602 |
| | AU 685609 | B2 | 19980122 | | |
| PRAI | US 1989-395253 | A | 19890816 | | |
| | EP 1990-917939 | A3 | 19900608 | | |
| | WO 1990-US3266 | A | 19900608 | | |

CLASS

| | PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|----|--|-------|---|
| | CA 2020700 | ICM | C12P021-08 |
| | | ICS | C12N009-00; A61K039-395; A61K037-64; A61K037-48 |
| | EP 750037 | ECLA | C12N009/64F2C21 |
| AB | A method for identifying prophylactics or therapeutics for diseases caused by a mature protein hormone that is derived from convertase-cleavage of its prohormone, e.g. the 26-kilodalton (kD) tumor necrosis factor (TNF), is described. Inhibitors of the TNF convertase comprise anti-convertase antibody, synthetic peptide/compound inhibitors, and/or non-cleavable 26-kD TNF muteins. These inhibitors can be used as prophylactics and/or therapeutics for sepsis, AIDS, or autoimmune diseases. Treatment of sepsis in a baboon model using anti-convertase antibody, recombinant TNF muteins, and synthetic peptides as the convertase inhibitors was shown. | | |
| ST | hormone convertase inhibitor AIDS treatment; sepsis treatment hormone convertase inhibitor; autoimmune disease hormone convertase inhibitor; antibody hormone convertase sepsis treatment | | |
| IT | Protein sequences (of tumor necrosis factor mutein, convertase-resistant) | | |
| IT | Sepsis and Septicemia (prophylactics or therapeutics for, inhibitors of hormone convertase as) | | |
| IT | Antibodies RL: BIOL (Biological study) (to hormone convertase, as prophylactics or therapeutics) | | |

IT Animal cell line
(HL-60, tumor necrosis factor precursor of, inhibition of
processing of, in prophylactics and therapeutics identification)

IT Immunodeficiency
(acquired immune deficiency
syndrome, prophylactics or therapeutics for, inhibitors
of hormone convertase as)

IT Inflammation inhibitors
(antiarthritics, inhibitors of hormone convertase
as)

IT Disease
(autoimmune, prophylactics or therapeutics for, inhibitors of
hormone convertase as)

IT Hormones
RL: BIOL (Biological study)
(pro-, conversion to mature hormone of, inhibitors for, as
prophylactics or therapeutics)

IT 137468-82-7 137468-83-8 137468-84-9 137468-85-0 137468-86-1
137468-87-2 137468-88-3 137468-89-4 137468-90-7, 2-157-Tumor
necrosis factor (human reduced) 137468-91-8 137468-92-9 137468-93-0
137468-94-1
RL: BIOL (Biological study)
(amino acid sequence of and expression of gene for)

IT 99676-46-7
RL: BIOL (Biological study)
(hormone production by, inhibition of, in disease prevention or
treatment)

IT 51050-59-0, 3,4-Dichloro-isocoumarin 51798-45-9 136293-02-2
137067-95-9 137067-96-0 137067-97-1
RL: BIOL (Biological study)
(tumor necrosis factor convertase
inhibitor, as prophylactic or therapeutic)

IT 136266-62-1
RL: BIOL (Biological study)
(tumor necrosis factor convertase
inhibitor, as prophylactics or therapeutics)

IT 99676-46-7
RL: BIOL (Biological study)
(hormone production by, inhibition of, in disease prevention or
treatment)

RN 99676-46-7 HCAPLUS

CN Kexin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L70 ANSWER 36 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:654164 HCAPLUS

DN 115:254164

ED Entered STN: 14 Dec 1991

TI [Ala IL-8] as a leukocyte adhesion inhibitor, and its recombinant
production, purification, and activity

IN Gimbrone, Michael A., Jr.; Obin, Martin S.; Baker, Joffre B.; Hebert,
Caroline Alice

PA Brigham and Women's Hospital, USA; Genentech, Inc.

SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07K013-00
ICS A61K037-02; C12P021-02; C07H015-02; C12N005-10; C12N015-24;
C12N015-70

CC 15-5 (Immunochemistry)
Section cross-reference(s): 1, 63

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|-------|-----------------|-------|
| ----- | ---- | ----- | ----- | ----- |

```

PI WO 9108231 A1 19910613 WO 1990-US6918 19901127 <--
    W: AU, CA, JP
    RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
AU 9169523 A1 19910626 AU 1991-69523 19901127 <--
EP 504257 A1 19920923 EP 1991-901110 19901127 <--
    R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL
JP 05503512 T2 19930610 JP 1991-501540 19901127 <--
US 5451399 A 19950919 US 1992-964525 19921019 <--
PRAI US 1989-443131 A 19891129 <--
    WO 1990-US6918 A 19901127 <--

```

CLASS

```

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
-----
WO 9108231 ICM C07K013-00
ICS A61K037-02; C12P021-02; C07H015-02; C12N005-10;
C12N015-24; C12N015-70
US 5451399 NCL 424/085.200; 514/002.000; 514/008.000; 514/012.000;
514/886.000; 530/351.000
ECLA C07K014/54G <--

```

```

AB The title polypeptide [a 77 residue, amino-terminal-extended form of
interleukin-8 (JL-8)] (I) is provided and is a potent modulator of
neutrophil functions. I and related compns. find use as anti-inflammatory
agents and as therapeutics for clin. indications in which damage to
vascular endothelium and other tissues occurs. Also provided are the
amine acid sequence of I, the corresponding nucleotide sequence, and
methods for recombinant production, purification, and pharmaceutical use of I.
Expression of recombinant I/IL-8 in mammalian cells and of a fusion
protein containing I and ubiquitin in Escherichia coli are described, as is
purification of the recombinant proteins produced. The E. coli-expressed
recombinant I, administered to a rabbit in an i.v. bolus, markedly
depressed (by 59-75%) the accumulation of neutrophils into intradermal
sites injected with various proinflammatory agents. In another experiment, I
markedly inhibited adhesion of neutrophils to endothelium exposed to IL-1
for 4-48 h.
ST interleukin 8 analog neutrophil adhesion inhibition; cloning interleukin 8
analog; inflammation inhibitor interleukin 8 analog
IT Escherichia coli
    (DNA encoding [Ala interleukin-8]77 leukocyte adhesion inhibitor
    cloning and expression in)
IT Plasmid and Episome
    (PRK.hg.8k, with DNA of [Ala interleukin-8]77 leukocyte adhesion
    inhibitors)
IT Inflammation inhibitors
    ([Ala interleukin-8]77 as, leukocyte adhesion inhibition in relation
    to)
IT Neutrophil
    ([Ala interleukin-8]77 for protecting endothelial cell from damage by)
IT Leukocyte
    (adhesion of, inhibition of, [Ala interleukin-8]77 for)
IT Anticoagulants and Antithrombotics
    Steroids, biological studies
    RL: BIOL (Biological study)
    (and [Ala interleukin-8]77 leukocyte adhesion inhibitor for
    pharmaceutical for inflammation inhibition)
IT Immunosuppressants
    Thrombolytics
    (and [Ala interleukin-8]77 leukocyte adhesion inhibitor, for therapy)
IT Endothelium
    (cell of, neutrophil damage to, [Ala interleukin-8]77 for protection
    against)
IT Inflammation
    (leukocyte adhesion inhibition at site of, [Ala interleukin-8]77 for)
IT Pharmaceutical dosage forms
    (of [Ala interleukin-8]77 for inflammation inhibition, leukocyte
    adhesion inhibition in relation to)
IT Protein sequences

```

- (of [Ala interleukin-8]77, complete)
- IT Molecular cloning
 - (of [Ala interleukin-8]77, leukocyte adhesion inhibition in relation to)
- IT Deoxyribonucleic acid sequences
 - (of [Ala interleukin-8]77-encoding DNA)
- IT Deoxyribonucleic acids
 - RL: BIOL (Biological study)
 - (recombinant, encoding [Ala interleukin-8]77)
- IT Antibodies
 - RL: BIOL (Biological study)
 - (to neutrophil trafficking, and [Ala interleukin-8]77 leukocyte adhesion inhibitor for pharmaceutical for inflammation inhibitor)
- IT Animal tissue
 - Organ
 - (vascularized, [Ala interleukin-8]77 for protection of, leukocyte adhesion inhibition in relation to)
- IT Plasmid and Episome
 - (with DNA of [Ala interleukin-8]77 leukocyte adhesion inhibitors)
- IT Animal cell line
 - (293, DNA encoding [Ala interleukin-8]77 leukocyte adhesion inhibitor cloning and expression in)
- IT Nucleic acid hybridization
 - (DNA-DNA, probes for, of DNA fragments of [Ala interleukin-8]77 leukocyte adhesion inhibitor)
- IT Toxins
 - RL: BIOL (Biological study)
 - (endo-, bacterial, for [Ala interleukin-8]77 leukocyte adhesion inhibitor induction)
- IT Proteins, specific or class
 - RL: BIOL (Biological study)
 - (fusion products, of [Ala interleukin-8]77 and ubiquitin, leukocyte adhesion inhibition in relation to)
- IT Pharmaceutical dosage forms
 - (injections, of [Ala interleukin-8]77 for inflammation inhibition, leukocyte adhesion inhibition in relation to)
- IT Lymphokines and Cytokines
 - RL: BIOL (Biological study)
 - (interleukin 1, for [Ala interleukin-8]77 leukocyte adhesion inhibitor induction)
- IT Plasmid and Episome
 - (pRK5, with DNA of [Ala interleukin-8]77 leukocyte adhesion inhibitors)
- IT Pharmaceutical dosage forms
 - (sprays, of [Ala interleukin-8]77 for inflammation inhibition, leukocyte adhesion inhibition in relation to)
- IT Pharmaceutical dosage forms
 - (suppositories, of [Ala interleukin-8]77 for inflammation inhibition, leukocyte adhesion inhibition in relation to)
- IT Pharmaceutical dosage forms
 - (topical, of [Ala interleukin-8]77 for inflammation inhibition, leukocyte adhesion inhibition in relation to)
- IT Lymphokines and Cytokines
 - RL: BIOL (Biological study)
 - (tumor necrosis factor, for [Ala interleukin-8]77 leukocyte adhesion inhibitor induction, for inflammation inhibition)
- IT Interferons
 - RL: BIOL (Biological study)
 - (α , and [Ala interleukin-8]77 leukocyte adhesion inhibitor, for therapy)
- IT Interferons
 - RL: BIOL (Biological study)
 - (β , and [Ala interleukin-8]77 leukocyte adhesion inhibitor, for therapy)
- IT Animal growth regulators
 - RL: BIOL (Biological study)
 - (β -transforming growth

factors, and [Ala interleukin-8]77 leukocyte adhesion inhibitor, for therapy)

IT 137467-73-3, 1-53-Interleukin 8 (human clone 3-10C reduced)
RL: BIOL (Biological study)
([Ala interleukin-8]77 leukocyte adhesion inhibitor purification in relation to isolation of)

IT 9005-49-6, Heparin, biological studies 74863-84-6, Argatroban
RL: BIOL (Biological study)
(and [Ala interleukin-8]77 leukocyte adhesion inhibitor for pharmaceutical for inflammation inhibition)

IT 50-78-2, Aspirin 103-90-2 9039-53-6, Urokinase 15687-27-1, Ibuprofen 81669-57-0, Eminase
RL: BIOL (Biological study)
(and [Ala interleukin-8]77 leukocyte adhesion inhibitor, for therapy)

IT 63-68-3, Methionine, biological studies
RL: BIOL (Biological study)
(at fusion protein junction of ubiquitin and [Ala interleukin-8]77)

IT 112487-62-4, Interleukin 8 (human clone 3-10C reduced)
RL: BIOL (Biological study)
(for leukocyte adhesion inhibition and inflammation inhibition)

IT 60267-61-0, Ubiquitin
RL: BIOL (Biological study)
(fusion proteins with [Ala interleukin-8]77, leukocyte adhesion inhibition in relation to)

IT 9004-32-4, Carboxy methyl cellulose 83453-41-2, Mono-S 132823-72-4, Sepharose S
RL: BIOL (Biological study)
(in [Ala interleukin-8]77 leukocyte adhesion inhibitor purification)


IT 114308-91-7, Neutrophil chemotactic factor (human reduced)
RL: BIOL (Biological study)
(inhibition of activity of, proteolysis-resistant analog of [Ala interleukin-8]77 leukocyte adhesion inhibitor for)

IT 137175-77-0, Deoxyribonucleic acid (human clone pRK.hg.8k interleukin 8 precursor-specifying)
RL: PRP (Properties)
(nucleotide sequence of)

IT 105913-11-9, Plasminogen activator
RL: BIOL (Biological study)
(tissue, and [Ala interleukin-8]77 leukocyte adhesion inhibitor, for therapy)

IT 103-90-2
RL: BIOL (Biological study)
(and [Ala interleukin-8]77 leukocyte adhesion inhibitor, for therapy)

RN 103-90-2 HCAPLUS
CN Acetamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L70 ANSWER 37 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:1783 HCAPLUS
DN 114:1783
ED Entered STN: 12 Jan 1991
TI Cloning and expression of transforming growth factor beta 2
IN Purchio, Anthony F.; Madisen, Linda; Webb, Nancy
PA Oncogen, L. P., USA
SO Eur. Pat. Appl., 58 pp.
CODEN: EPXXDW
DT Patent

LA English
 IC ICM C12N015-16
 ICS C12N015-85; C12N005-10; C07K013-00; A61K037-02
 CC 3-4 (Biochemical Genetics)
 Section cross-reference(s): 1, 13, 16

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|--------------|
| PI | EP 376785 | A2 | 19900704 | EP 1989-403480 | 19891214 <-- |
| | EP 376785 | A3 | 19920102 | | |
| | R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | US 5221620 | A | 19930622 | US 1989-446020 | 19891205 <-- |
| | CA 2005459 | AA | 19900616 | CA 1989-2005459 | 19891213 <-- |
| | NO 8905029 | A | 19900618 | NO 1989-5029 | 19891214 <-- |
| | EP 676474 | A1 | 19951011 | EP 1995-104223 | 19891214 <-- |
| | R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | DK 8906383 | A | 19900617 | DK 1989-6383 | 19891215 <-- |
| | AU 8946835 | A1 | 19900621 | AU 1989-46835 | 19891215 <-- |
| | AU 640115 | B2 | 19930819 | | |
| | ZA 8909623 | A | 19900926 | ZA 1989-9623 | 19891215 <-- |
| | CN 1045992 | A | 19901010 | CN 1989-109814 | 19891216 <-- |
| | JP 05056783 | A2 | 19930309 | JP 1989-327054 | 19891216 <-- |
| PRAI | US 1988-285140 | A | 19881216 | <-- | |
| | US 1989-446020 | A | 19891205 | <-- | |
| | US 1987-106752 | B2 | 19871006 | <-- | |
| | US 1988-148267 | B2 | 19880125 | <-- | |
| | US 1988-234065 | B2 | 19880818 | <-- | |
| | EP 1989-403480 | A3 | 19891214 | <-- | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|---|
| EP 376785 | ICM | C12N015-16 |
| | ICS | C12N015-85; C12N005-10; C07K013-00; A61K037-02 |
| US 5221620 | NCL | 435/360.000; 435/069.100; 435/069.500; 435/069.700; 435/235.100; 530/350.000; 536/023.400; 536/023.500; 536/023.510 |
| EP 676474 | ECLA | C07K014/495 |

AB CDNAs encoding transforming growth factor β -2 (TGF- β 2) from human and simian cell lines are cloned in Escherichia coli and expressed in CHO cells. A chimeric gene encoding the precursor and signal sequences of the transforming growth factor β -1 and mature TGF- β 2 is constructed. The human cDNA was cloned a cDNA bank from tamoxifen-stimulated PC-3 cells in λ gt10. Two clones, one encoding an analog with a deletion in the precursor sequence, were recovered. These cDNAs were then used to screen a cDNA bank from BSC40 monkey cells. A chimeric gene encoding the precursor sequences of simian transforming growth factor β -1 and the sequence of mature TGF- β 2 was constructed and expressed in CHO cells using a simian virus 40 promoter to drive expression. Yields of biol. active TGF- β 2 were .apprx.0.4 mg/L (no data). The protein was properly processed posttranslationally. Biol. assays (inhibition of growth of Mv1Lu cells) showed that the recombinant protein had the same specific activity as the natural protein.

ST transforming growth factor cDNA cloning human; simian transforming growth factor beta cDNA

IT Escherichia coli
 (cloning in, of transforming growth factor β -2 cDNAs of human and simian cell lines)

IT Gene and Genetic element, animal
 RL: BIOL (Biological study)
 (for transforming growth factor β -2 of human simian cell lines, cDNA from, cloning in Escherichia coli and expression in CHO cells of)

IT Molecular cloning
 (of transforming growth factor β -2 cDNAs, of human and simian cell lines, in Escherichia coli)

IT Protein sequences

- (of transforming growth factor β -2, of human, complete)
- IT Protein sequences
 - (of transforming growth factor β -2, of monkey , complete)
- IT Neoplasm inhibitors
 - (transforming growth factor β -2 as, cloning and expression of cDNAs for human and simian forms in relation to)
- IT Wound healing
 - (transforming growth factor β -2 for, cloning and expression of cDNAs for human and simian forms in relation to)
- IT Animal cell line
 - (BSC40, transforming growth factor β -2 of, cDNA for, cloning in Escherichia coli)
- IT Animal cell line
 - (CHO, expression in, of cDNAs for human or simian transforming growth factor β -2)
- IT Animal cell line
 - (COS, expression in, of cDNAs for human or simian transforming growth factor β -2)
- IT Animal cell line
 - (PC-3, transforming growth factor β -2 of, cDNA for, cloning in Escherichia coli)
- IT Gene and Genetic element, animal
 - RL: BIOL (Biological study)
 - (chimeric, for simian transforming growth factor β -1 and human transforming growth factor β -2, expression in CHO cells of)
- IT Proteins, specific or class
 - RL: BIOL (Biological study)
 - (fusion products, of simian transforming growth factor β -1 and human transforming growth factor β -2, chimeric gene for, expression in CHO cells of)
- IT Plasmid and Episome
 - (pBSC-40-1, cDNA for transforming growth factor β -2 of monkey on, cloning in Escherichia coli of)
- IT Plasmid and Episome
 - (pBSC-40-16, cDNA for transforming growth factor β -2 of BSC-40 cells on, cloning in Escherichia coli of)
- IT Plasmid and Episome
 - (pPC-14, cDNA for transforming growth factor β -2 of human on, cloning in Escherichia coli of)
- IT Plasmid and Episome
 - (pPC-21, cDNA for transforming growth factor β -2 of human on, cloning in Escherichia coli of)
- IT Plasmid and Episome
 - (pTGF- β 2-414, cDNA for transforming growth factor β 02 of monkey on, expression in BSC-40 cells of)
- IT Plasmid and Episome
 - (psV2/ β 1- β 2/dhfr, chimeric gene for transforming growth factors β 1 and β 2 on, expression in CHO cells of)
- IT Deoxyribonucleic acid sequences
 - (transforming growth factor β 1/ β 2 fusion protein-specifying, of human and monkey, complete)
- IT Animal growth regulators
 - RL: BIOL (Biological study)
 - (β 1-transforming growth factors, fusion products with transforming growth factor β 2, chimeric gene for, expression in CHO cells of)
- IT Deoxyribonucleic acid sequences
 - Deoxyribonucleic acid sequences
 - (β 2-transforming growth factor-specifying, of human, complete)
- IT Deoxyribonucleic acid sequences
 - Deoxyribonucleic acid sequences
 - (β 2-transforming growth factor-specifying, of monkey, complete)
- IT Animal growth regulators
 - RL: BIOL (Biological study)
 - (β 2-transforming growth factors, cDNA for, of human and simian cell lines, cloning in

Escherichia coli and expression in CHO cells of)

IT Animal growth regulators
 RL: BIOL (Biological study)
 (β 2-transforming growth factors, fusion products, with transforming growth factor β -1, chimeric gene for, expression in CHO cells of)

IT 112509-51-0, Transforming growth factor β2 (human PC-3 cell subunit reduced) 115283-57-3 130940-13-5
 RL: PRP (Properties)
 (amino acid sequence of and cloning in Escherichia coli of cDNA for)

IT 130940-14-6
 RL: PRP (Properties)
 (amino acid sequence of and expression in CHO cells of gene for)

IT 115283-40-4, Deoxyribonucleic acid (human clone λPC-21 transforming growth factor β2 messenger RNA-complementary)
 RL: PRP (Properties)
 (nucleotide sequence and cloning in Escherichia coli and expression in CHO cells of)

IT 124541-15-7 130938-83-9
 RL: PRP (Properties); BIOL (Biological study)
 (nucleotide sequence and cloning in Escherichia coli of)

IT 130938-84-0
 RL: PRP (Properties)
 (nucleotide sequence and expression in CHO cells of)

IT 130938-85-1
 RL: PRP (Properties); BIOL (Biological study)
 (nucleotide sequence of)

L70 ANSWER 38 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1989:531650 HCAPLUS
 DN 111:131650
 ED Entered STN: 14 Oct 1989
 TI Isolation and sequencing of transforming growth factor-β2 (TGF-β2) for use as an antineoplastic agent
 IN Marquardt, Hans; Ikeda, Tatsuhiko; Lioubin, Mario N.
 PA Oncogen, USA
 SO Eur. Pat. Appl., 17 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM C12N015-00
 ICS A61K037-00; C12P021-00; C07K007-00
 CC 13-1 (Mammalian Biochemistry)
 Section cross-reference(s): 63

FAN.CNT 7

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|--------------|
| PI | EP 290012 | A1 | 19881109 | EP 1988-107174 | 19880504 <-- |
| | R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | US 5120535 | A | 19920609 | US 1987-46846 | 19870504 <-- |
| | AU 8815391 | A1 | 19881110 | AU 1988-15391 | 19880502 <-- |
| | JP 01034281 | A2 | 19890203 | JP 1988-107734 | 19880502 <-- |
| | US 5618715 | A | 19970408 | US 1993-75199 | 19930610 <-- |
| | US 5451506 | A | 19950919 | US 1993-78707 | 19930616 <-- |
| | US 5428012 | A | 19950627 | US 1993-85279 | 19930701 <-- |
| | US 5907033 | A | 19990525 | US 1996-678922 | 19960712 <-- |
| PRAI | US 1987-46846 | A | 19870504 | <-- | |
| | US 1987-115776 | A | 19871030 | <-- | |
| | US 1985-811235 | B2 | 19851220 | <-- | |
| | US 1986-935283 | B2 | 19861126 | <-- | |
| | US 1987-115139 | B2 | 19871030 | <-- | |
| | US 1988-144574 | B1 | 19880115 | <-- | |
| | US 1989-397676 | B1 | 19891002 | <-- | |
| | US 1989-428195 | B1 | 19891027 | <-- | |
| | US 1990-501824 | B2 | 19900329 | <-- | |
| | US 1991-664191 | B1 | 19910304 | <-- | |

US 1991-689723 B1 19910422 <--
 US 1992-943387 A1 19920910 <--

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|--|--|
| EP 290012 | ICM | C12N015-00 |
| | ICS | A61K037-00; C12P021-00; C07K007-00 |
| US 5120535 | NCL | 424/085.500; 424/085.100; 424/085.400; 514/002.000; 514/021.000 <-- |
| US 5618715 | NCL | 435/325.000; 435/069.100; 435/069.400; 435/320.100; 435/348.000; 435/360.000; 435/364.000; 435/365.100; 530/300.000; 530/351.000; 536/023.100; 536/023.510 <-- |
| | ECLA | C07K014/52 <-- |
| US 5451506 | NCL | 435/007.230; 435/007.100; 435/007.210; 435/960.000; 530/351.000 <-- |
| | ECLA | C07K014/07; C07K014/475; C07K014/495; C07K014/52A1; C07K016/22; C07K016/24; C12N015/62A; C12N015/73 <-- |
| US 5428012 | NCL | 514/012.000; 424/085.100; 424/085.500; 514/021.000; 530/350.000 <-- |
| | ECLA | C07K014/07; C07K014/52A1; C07K016/22; C07K016/24; C12N015/62A; C12N015/73; C07K014/475; C07K014/495 <-- |
| US 5907033 | NCL | 530/388.230; 435/335.000; 435/336.000; 530/388.240 <-- |
| | ECLA | C07K016/24 <-- |
| AB | TGF- β 2 is isolated from medium conditioned by human adenocarcinoma cells, purified, and sequenced. The TGF- β 2 can be used to inhibit proliferation of neoplastic cells. TGF- β 2 was isolated and purified from medium conditioned by tamoxifen-stimulated human prostatic adenocarcinoma PC-3 cells by batch adsorption on methylsilyl controlled-pore glass, gel permeation chromatog. with Bio-Sil TSK-250, and reversed-phase HPLC. PAGE of the purified protein under nonreducing conditions produced a protein with mol. weight 24,000; under reducing conditions, the mol. weight was 13,000. | |
| ST | transforming growth factor purifn; neoplasm inhibitor transforming growth factor | |
| IT | Gene and Genetic element, animal RL: BIOL (Biological study) (for transforming growth factor- β 2, cloning and expression of) | |
| IT | Molecular cloning (of transforming growth factor- β 2 gene) | |
| IT | Neoplasm inhibitors (transforming growth factor- β 2, purification from tumor cell-conditioned medium of) | |
| IT | Antibodies RL: BIOL (Biological study) (monoclonal, to transforming growth factor- β 2) | |
| IT | Animal growth regulators RL: PUR (Purification or recovery); PREP (Preparation) (β 2-transforming growth factors, purification of, from conditioned medium) | |
| IT | 112509-51-0P, Transforming growth factor β 2 (human PC-3 cell subunit reduced) RL: PREP (Preparation) (amino acid sequence and purification from tumor cell-conditioned medium of) | |

=> b home

FILE 'HOME' ENTERED AT 10:25:50 ON 09 JUN 2005

=>